# newdoc_id = 00c862a6402381a8541bcffe843696e059095300
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	this	_	_	_	_	_	_	_	Seg=O
3	study	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	we	_	_	_	_	_	_	_	Seg=O
6	investigated	_	_	_	_	_	_	_	Seg=O
7	turkey	_	_	_	_	_	_	_	Seg=O
8	reovirus	_	_	_	_	_	_	_	Seg=O
9	(	_	_	_	_	_	_	_	Seg=O
10	TReoV	_	_	_	_	_	_	_	Seg=O
11	)	_	_	_	_	_	_	_	Seg=O
12	in	_	_	_	_	_	_	_	Seg=O
13	tissue	_	_	_	_	_	_	_	Seg=O
14	samples	_	_	_	_	_	_	_	Seg=O
15	from	_	_	_	_	_	_	_	Seg=O
16	young	_	_	_	_	_	_	_	Seg=O
17	birds	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	aged	_	_	_	_	_	_	_	Seg=B-seg
20	15	_	_	_	_	_	_	_	Seg=O
21	days	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	RT	_	_	_	_	_	_	_	Seg=B-seg
24	-	_	_	_	_	_	_	_	Seg=O
25	PCR	_	_	_	_	_	_	_	Seg=O
26	for	_	_	_	_	_	_	_	Seg=O
27	TReoV	_	_	_	_	_	_	_	Seg=O
28	detected	_	_	_	_	_	_	_	Seg=O
29	3.3	_	_	_	_	_	_	_	Seg=O
30	%	_	_	_	_	_	_	_	Seg=O
31	positive	_	_	_	_	_	_	_	Seg=O
32	samples	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=B-seg
34	TReoV	_	_	_	_	_	_	_	Seg=O
35	was	_	_	_	_	_	_	_	Seg=O
36	successfully	_	_	_	_	_	_	_	Seg=O
37	isolated	_	_	_	_	_	_	_	Seg=O
38	in	_	_	_	_	_	_	_	Seg=O
39	Vero	_	_	_	_	_	_	_	Seg=O
40	cells	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	Histological	_	_	_	_	_	_	_	Seg=B-seg
43	analysis	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	positive	_	_	_	_	_	_	_	Seg=O
46	bursa	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	Fabricius	_	_	_	_	_	_	_	Seg=O
49	(	_	_	_	_	_	_	_	Seg=O
50	BF	_	_	_	_	_	_	_	Seg=O
51	)	_	_	_	_	_	_	_	Seg=O
52	revealed	_	_	_	_	_	_	_	Seg=O
53	atrophied	_	_	_	_	_	_	_	Seg=O
54	follicles	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=O
56	lymphocyte	_	_	_	_	_	_	_	Seg=O
57	depletion	_	_	_	_	_	_	_	Seg=O
58	.	_	_	_	_	_	_	_	Seg=O
59	The	_	_	_	_	_	_	_	Seg=B-seg
60	number	_	_	_	_	_	_	_	Seg=O
61	of	_	_	_	_	_	_	_	Seg=O
62	CD8	_	_	_	_	_	_	_	Seg=O
63	?	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	CD4	_	_	_	_	_	_	_	Seg=O
66	?	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=O
68	IgM	_	_	_	_	_	_	_	Seg=O
69	?	_	_	_	_	_	_	_	Seg=O
70	cells	_	_	_	_	_	_	_	Seg=O
71	was	_	_	_	_	_	_	_	Seg=O
72	lower	_	_	_	_	_	_	_	Seg=O
73	in	_	_	_	_	_	_	_	Seg=O
74	infected	_	_	_	_	_	_	_	Seg=O
75	BF	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	Phylogenetic	_	_	_	_	_	_	_	Seg=B-seg
78	analysis	_	_	_	_	_	_	_	Seg=O
79	based	_	_	_	_	_	_	_	Seg=B-seg
80	on	_	_	_	_	_	_	_	Seg=O
81	S3	_	_	_	_	_	_	_	Seg=O
82	gene	_	_	_	_	_	_	_	Seg=O
83	showed	_	_	_	_	_	_	_	Seg=B-seg
84	that	_	_	_	_	_	_	_	Seg=B-seg
85	the	_	_	_	_	_	_	_	Seg=O
86	Brazilian	_	_	_	_	_	_	_	Seg=O
87	TReoV	_	_	_	_	_	_	_	Seg=O
88	isolates	_	_	_	_	_	_	_	Seg=O
89	clustered	_	_	_	_	_	_	_	Seg=O
90	in	_	_	_	_	_	_	_	Seg=O
91	a	_	_	_	_	_	_	_	Seg=O
92	single	_	_	_	_	_	_	_	Seg=O
93	group	_	_	_	_	_	_	_	Seg=O
94	with	_	_	_	_	_	_	_	Seg=O
95	98	_	_	_	_	_	_	_	Seg=O
96	-	_	_	_	_	_	_	_	Seg=O
97	100	_	_	_	_	_	_	_	Seg=O
98	%	_	_	_	_	_	_	_	Seg=O
99	similarity	_	_	_	_	_	_	_	Seg=O
100	to	_	_	_	_	_	_	_	Seg=O
101	TReoV	_	_	_	_	_	_	_	Seg=O
102	strains	_	_	_	_	_	_	_	Seg=O
103	circulating	_	_	_	_	_	_	_	Seg=B-seg
104	in	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	United	_	_	_	_	_	_	_	Seg=O
107	States	_	_	_	_	_	_	_	Seg=O
108	.	_	_	_	_	_	_	_	Seg=O
109	This	_	_	_	_	_	_	_	Seg=B-seg
110	is	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	first	_	_	_	_	_	_	_	Seg=O
113	indication	_	_	_	_	_	_	_	Seg=O
114	that	_	_	_	_	_	_	_	Seg=B-seg
115	TReoV	_	_	_	_	_	_	_	Seg=O
116	infection	_	_	_	_	_	_	_	Seg=O
117	may	_	_	_	_	_	_	_	Seg=O
118	be	_	_	_	_	_	_	_	Seg=O
119	a	_	_	_	_	_	_	_	Seg=O
120	contributing	_	_	_	_	_	_	_	Seg=O
121	factor	_	_	_	_	_	_	_	Seg=O
122	to	_	_	_	_	_	_	_	Seg=O
123	immunosuppression	_	_	_	_	_	_	_	Seg=O
124	in	_	_	_	_	_	_	_	Seg=O
125	young	_	_	_	_	_	_	_	Seg=O
126	birds	_	_	_	_	_	_	_	Seg=O
127	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0146a0b36f80ebcb868c7e16fb60c1a9d2afbf83
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	an	_	_	_	_	_	_	_	Seg=O
4	extensive	_	_	_	_	_	_	_	Seg=O
5	review	_	_	_	_	_	_	_	Seg=O
6	on	_	_	_	_	_	_	_	Seg=O
7	epiphytic	_	_	_	_	_	_	_	Seg=O
8	plants	_	_	_	_	_	_	_	Seg=O
9	that	_	_	_	_	_	_	_	Seg=B-seg
10	have	_	_	_	_	_	_	_	Seg=O
11	been	_	_	_	_	_	_	_	Seg=O
12	used	_	_	_	_	_	_	_	Seg=O
13	traditionally	_	_	_	_	_	_	_	Seg=O
14	as	_	_	_	_	_	_	_	Seg=O
15	medicines	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	It	_	_	_	_	_	_	_	Seg=B-seg
18	provides	_	_	_	_	_	_	_	Seg=O
19	information	_	_	_	_	_	_	_	Seg=O
20	on	_	_	_	_	_	_	_	Seg=O
21	185	_	_	_	_	_	_	_	Seg=O
22	epiphytes	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=O
24	their	_	_	_	_	_	_	_	Seg=O
25	traditional	_	_	_	_	_	_	_	Seg=O
26	medicinal	_	_	_	_	_	_	_	Seg=O
27	uses	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	regions	_	_	_	_	_	_	_	Seg=O
30	where	_	_	_	_	_	_	_	Seg=B-seg
31	Indigenous	_	_	_	_	_	_	_	Seg=O
32	people	_	_	_	_	_	_	_	Seg=O
33	use	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	plants	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	parts	_	_	_	_	_	_	_	Seg=B-seg
38	of	_	_	_	_	_	_	_	Seg=O
39	the	_	_	_	_	_	_	_	Seg=O
40	plants	_	_	_	_	_	_	_	Seg=O
41	used	_	_	_	_	_	_	_	Seg=B-seg
42	as	_	_	_	_	_	_	_	Seg=O
43	medicines	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=B-seg
45	their	_	_	_	_	_	_	_	Seg=O
46	preparation	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	their	_	_	_	_	_	_	_	Seg=O
50	reported	_	_	_	_	_	_	_	Seg=O
51	phytochemical	_	_	_	_	_	_	_	Seg=O
52	properties	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=O
54	pharmacological	_	_	_	_	_	_	_	Seg=O
55	properties	_	_	_	_	_	_	_	Seg=O
56	aligned	_	_	_	_	_	_	_	Seg=B-seg
57	with	_	_	_	_	_	_	_	Seg=O
58	their	_	_	_	_	_	_	_	Seg=O
59	traditional	_	_	_	_	_	_	_	Seg=O
60	uses	_	_	_	_	_	_	_	Seg=O
61	.	_	_	_	_	_	_	_	Seg=O
62	These	_	_	_	_	_	_	_	Seg=B-seg
63	epiphytic	_	_	_	_	_	_	_	Seg=O
64	medicinal	_	_	_	_	_	_	_	Seg=O
65	plants	_	_	_	_	_	_	_	Seg=O
66	are	_	_	_	_	_	_	_	Seg=O
67	able	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=O
69	produce	_	_	_	_	_	_	_	Seg=O
70	a	_	_	_	_	_	_	_	Seg=O
71	range	_	_	_	_	_	_	_	Seg=O
72	of	_	_	_	_	_	_	_	Seg=O
73	secondary	_	_	_	_	_	_	_	Seg=O
74	metabolites	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	including	_	_	_	_	_	_	_	Seg=B-seg
77	alkaloids	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=B-seg
80	a	_	_	_	_	_	_	_	Seg=O
81	total	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	842	_	_	_	_	_	_	_	Seg=O
84	phytochemicals	_	_	_	_	_	_	_	Seg=O
85	have	_	_	_	_	_	_	_	Seg=O
86	been	_	_	_	_	_	_	_	Seg=O
87	identified	_	_	_	_	_	_	_	Seg=O
88	to	_	_	_	_	_	_	_	Seg=O
89	date	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O
91	As	_	_	_	_	_	_	_	Seg=B-seg
92	many	_	_	_	_	_	_	_	Seg=O
93	as	_	_	_	_	_	_	_	Seg=O
94	71	_	_	_	_	_	_	_	Seg=O
95	epiphytic	_	_	_	_	_	_	_	Seg=O
96	medicinal	_	_	_	_	_	_	_	Seg=O
97	plants	_	_	_	_	_	_	_	Seg=O
98	were	_	_	_	_	_	_	_	Seg=O
99	studied	_	_	_	_	_	_	_	Seg=O
100	for	_	_	_	_	_	_	_	Seg=O
101	their	_	_	_	_	_	_	_	Seg=O
102	biological	_	_	_	_	_	_	_	Seg=O
103	activities	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	showing	_	_	_	_	_	_	_	Seg=B-seg
106	promising	_	_	_	_	_	_	_	Seg=O
107	pharmacological	_	_	_	_	_	_	_	Seg=O
108	activities	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	including	_	_	_	_	_	_	_	Seg=B-seg
111	as	_	_	_	_	_	_	_	Seg=O
112	anti	_	_	_	_	_	_	_	Seg=O
113	-	_	_	_	_	_	_	_	Seg=O
114	inflammatory	_	_	_	_	_	_	_	Seg=O
115	,	_	_	_	_	_	_	_	Seg=O
116	antimicrobial	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	anticancer	_	_	_	_	_	_	_	Seg=O
120	agents	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	There	_	_	_	_	_	_	_	Seg=B-seg
123	are	_	_	_	_	_	_	_	Seg=O
124	several	_	_	_	_	_	_	_	Seg=O
125	species	_	_	_	_	_	_	_	Seg=O
126	that	_	_	_	_	_	_	_	Seg=B-seg
127	were	_	_	_	_	_	_	_	Seg=O
128	not	_	_	_	_	_	_	_	Seg=O
129	investigated	_	_	_	_	_	_	_	Seg=O
130	for	_	_	_	_	_	_	_	Seg=O
131	their	_	_	_	_	_	_	_	Seg=O
132	activities	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=B-seg
134	are	_	_	_	_	_	_	_	Seg=O
135	worthy	_	_	_	_	_	_	_	Seg=O
136	of	_	_	_	_	_	_	_	Seg=O
137	exploration	_	_	_	_	_	_	_	Seg=O
138	.	_	_	_	_	_	_	_	Seg=O
139	These	_	_	_	_	_	_	_	Seg=B-seg
140	epipythes	_	_	_	_	_	_	_	Seg=O
141	have	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	potential	_	_	_	_	_	_	_	Seg=O
144	to	_	_	_	_	_	_	_	Seg=B-seg
145	furnish	_	_	_	_	_	_	_	Seg=O
146	drug	_	_	_	_	_	_	_	Seg=O
147	lead	_	_	_	_	_	_	_	Seg=O
148	compounds	_	_	_	_	_	_	_	Seg=O
149	,	_	_	_	_	_	_	_	Seg=O
150	especially	_	_	_	_	_	_	_	Seg=B-seg
151	for	_	_	_	_	_	_	_	Seg=O
152	treating	_	_	_	_	_	_	_	Seg=O
153	cancers	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=B-seg
156	thus	_	_	_	_	_	_	_	Seg=O
157	warrant	_	_	_	_	_	_	_	Seg=O
158	indepth	_	_	_	_	_	_	_	Seg=O
159	investigations	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0232f18e7bbf3192e9e34da1c0abe2a20b2ba1e4
1	Herein	_	_	_	_	_	_	_	Seg=B-seg
2	,	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	LASSBio	_	_	_	_	_	_	_	Seg=O
5	Chemical	_	_	_	_	_	_	_	Seg=O
6	Library	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	presented	_	_	_	_	_	_	_	Seg=O
9	as	_	_	_	_	_	_	_	Seg=O
10	a	_	_	_	_	_	_	_	Seg=O
11	valuable	_	_	_	_	_	_	_	Seg=O
12	source	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	compounds	_	_	_	_	_	_	_	Seg=O
15	for	_	_	_	_	_	_	_	Seg=O
16	screening	_	_	_	_	_	_	_	Seg=O
17	to	_	_	_	_	_	_	_	Seg=B-seg
18	identify	_	_	_	_	_	_	_	Seg=O
19	hits	_	_	_	_	_	_	_	Seg=O
20	suitable	_	_	_	_	_	_	_	Seg=O
21	for	_	_	_	_	_	_	_	Seg=O
22	subsequent	_	_	_	_	_	_	_	Seg=O
23	hit	_	_	_	_	_	_	_	Seg=O
24	-	_	_	_	_	_	_	_	Seg=O
25	to	_	_	_	_	_	_	_	Seg=O
26	-	_	_	_	_	_	_	_	Seg=O
27	lead	_	_	_	_	_	_	_	Seg=O
28	optimization	_	_	_	_	_	_	_	Seg=O
29	stages	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	A	_	_	_	_	_	_	_	Seg=B-seg
32	feature	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	LASSBio	_	_	_	_	_	_	_	Seg=O
36	Chemical	_	_	_	_	_	_	_	Seg=O
37	Library	_	_	_	_	_	_	_	Seg=O
38	worth	_	_	_	_	_	_	_	Seg=O
39	highlighting	_	_	_	_	_	_	_	Seg=O
40	is	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	fact	_	_	_	_	_	_	_	Seg=O
43	that	_	_	_	_	_	_	_	Seg=B-seg
44	it	_	_	_	_	_	_	_	Seg=O
45	is	_	_	_	_	_	_	_	Seg=O
46	a	_	_	_	_	_	_	_	Seg=O
47	smart	_	_	_	_	_	_	_	Seg=O
48	library	_	_	_	_	_	_	_	Seg=O
49	designed	_	_	_	_	_	_	_	Seg=B-seg
50	by	_	_	_	_	_	_	_	Seg=O
51	medicinal	_	_	_	_	_	_	_	Seg=O
52	chemists	_	_	_	_	_	_	_	Seg=O
53	with	_	_	_	_	_	_	_	Seg=O
54	pharmacological	_	_	_	_	_	_	_	Seg=O
55	activity	_	_	_	_	_	_	_	Seg=O
56	as	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	main	_	_	_	_	_	_	_	Seg=O
59	priority	_	_	_	_	_	_	_	Seg=O
60	.	_	_	_	_	_	_	_	Seg=O
61	The	_	_	_	_	_	_	_	Seg=B-seg
62	great	_	_	_	_	_	_	_	Seg=O
63	majority	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	compounds	_	_	_	_	_	_	_	Seg=O
67	part	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	this	_	_	_	_	_	_	_	Seg=O
70	library	_	_	_	_	_	_	_	Seg=O
71	have	_	_	_	_	_	_	_	Seg=O
72	shown	_	_	_	_	_	_	_	Seg=O
73	in	_	_	_	_	_	_	_	Seg=O
74	vivo	_	_	_	_	_	_	_	Seg=O
75	activity	_	_	_	_	_	_	_	Seg=O
76	in	_	_	_	_	_	_	_	Seg=O
77	animal	_	_	_	_	_	_	_	Seg=O
78	models	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	which	_	_	_	_	_	_	_	Seg=B-seg
81	is	_	_	_	_	_	_	_	Seg=O
82	an	_	_	_	_	_	_	_	Seg=O
83	indication	_	_	_	_	_	_	_	Seg=O
84	that	_	_	_	_	_	_	_	Seg=B-seg
85	they	_	_	_	_	_	_	_	Seg=O
86	possess	_	_	_	_	_	_	_	Seg=O
87	overall	_	_	_	_	_	_	_	Seg=O
88	favorable	_	_	_	_	_	_	_	Seg=O
89	bioavailability	_	_	_	_	_	_	_	Seg=O
90	properties	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	hence	_	_	_	_	_	_	_	Seg=O
94	,	_	_	_	_	_	_	_	Seg=O
95	adequate	_	_	_	_	_	_	_	Seg=O
96	pharmacokinetic	_	_	_	_	_	_	_	Seg=O
97	profiles	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	This	_	_	_	_	_	_	_	Seg=B-seg
100	,	_	_	_	_	_	_	_	Seg=O
101	in	_	_	_	_	_	_	_	Seg=O
102	turn	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	is	_	_	_	_	_	_	_	Seg=O
105	supported	_	_	_	_	_	_	_	Seg=O
106	by	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	fact	_	_	_	_	_	_	_	Seg=O
109	that	_	_	_	_	_	_	_	Seg=B-seg
110	approximately	_	_	_	_	_	_	_	Seg=O
111	85	_	_	_	_	_	_	_	Seg=O
112	%	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	compounds	_	_	_	_	_	_	_	Seg=O
116	are	_	_	_	_	_	_	_	Seg=O
117	compliant	_	_	_	_	_	_	_	Seg=O
118	with	_	_	_	_	_	_	_	Seg=O
119-120	Lipinski's	_	_	_	_	_	_	_	_
119	Lipinski	_	_	_	_	_	_	_	Seg=O
120	's	_	_	_	_	_	_	_	Seg=O
121	rule	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	five	_	_	_	_	_	_	_	Seg=O
124	and	_	_	_	_	_	_	_	Seg=O
125	ca	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O
127	95	_	_	_	_	_	_	_	Seg=B-seg
128	%	_	_	_	_	_	_	_	Seg=O
129	are	_	_	_	_	_	_	_	Seg=O
130	compliant	_	_	_	_	_	_	_	Seg=O
131	with	_	_	_	_	_	_	_	Seg=O
132-133	Veber's	_	_	_	_	_	_	_	_
132	Veber	_	_	_	_	_	_	_	Seg=O
133	's	_	_	_	_	_	_	_	Seg=O
134	rules	_	_	_	_	_	_	_	Seg=O
135	,	_	_	_	_	_	_	_	Seg=O
136	two	_	_	_	_	_	_	_	Seg=O
137	important	_	_	_	_	_	_	_	Seg=O
138	guidelines	_	_	_	_	_	_	_	Seg=O
139	for	_	_	_	_	_	_	_	Seg=O
140	oral	_	_	_	_	_	_	_	Seg=O
141	bioavailability	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	In	_	_	_	_	_	_	_	Seg=B-seg
144	this	_	_	_	_	_	_	_	Seg=O
145	work	_	_	_	_	_	_	_	Seg=O
146	it	_	_	_	_	_	_	_	Seg=O
147	is	_	_	_	_	_	_	_	Seg=O
148	presented	_	_	_	_	_	_	_	Seg=O
149	a	_	_	_	_	_	_	_	Seg=O
150	virtual	_	_	_	_	_	_	_	Seg=O
151	screening	_	_	_	_	_	_	_	Seg=O
152	methodology	_	_	_	_	_	_	_	Seg=O
153	combining	_	_	_	_	_	_	_	Seg=B-seg
154	a	_	_	_	_	_	_	_	Seg=O
155	pharmacophore	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	based	_	_	_	_	_	_	_	Seg=O
158	model	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	an	_	_	_	_	_	_	_	Seg=O
161	empirical	_	_	_	_	_	_	_	Seg=O
162	Gibbs	_	_	_	_	_	_	_	Seg=O
163	free	_	_	_	_	_	_	_	Seg=O
164	energy	_	_	_	_	_	_	_	Seg=O
165	-	_	_	_	_	_	_	_	Seg=O
166	based	_	_	_	_	_	_	_	Seg=O
167	model	_	_	_	_	_	_	_	Seg=O
168	for	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	ligand	_	_	_	_	_	_	_	Seg=O
171	-	_	_	_	_	_	_	_	Seg=O
172	protein	_	_	_	_	_	_	_	Seg=O
173	interaction	_	_	_	_	_	_	_	Seg=O
174	to	_	_	_	_	_	_	_	Seg=B-seg
175	explore	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	LASSBio	_	_	_	_	_	_	_	Seg=O
178	Chemical	_	_	_	_	_	_	_	Seg=O
179	Library	_	_	_	_	_	_	_	Seg=O
180	as	_	_	_	_	_	_	_	Seg=O
181	a	_	_	_	_	_	_	_	Seg=O
182	source	_	_	_	_	_	_	_	Seg=O
183	of	_	_	_	_	_	_	_	Seg=O
184	new	_	_	_	_	_	_	_	Seg=O
185	hits	_	_	_	_	_	_	_	Seg=O
186	for	_	_	_	_	_	_	_	Seg=O
187	the	_	_	_	_	_	_	_	Seg=O
188	inhibition	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	the	_	_	_	_	_	_	_	Seg=O
191	phosphatidylinositol	_	_	_	_	_	_	_	Seg=O
192	4-kinase	_	_	_	_	_	_	_	Seg=O
193	IIIβ	_	_	_	_	_	_	_	Seg=O
194	(	_	_	_	_	_	_	_	Seg=O
195	PI4KIIIβ	_	_	_	_	_	_	_	Seg=O
196	)	_	_	_	_	_	_	_	Seg=O
197	enzyme	_	_	_	_	_	_	_	Seg=O
198	,	_	_	_	_	_	_	_	Seg=O
199	which	_	_	_	_	_	_	_	Seg=B-seg
200	is	_	_	_	_	_	_	_	Seg=O
201	related	_	_	_	_	_	_	_	Seg=O
202	to	_	_	_	_	_	_	_	Seg=O
203	the	_	_	_	_	_	_	_	Seg=O
204	development	_	_	_	_	_	_	_	Seg=O
205	of	_	_	_	_	_	_	_	Seg=O
206	viral	_	_	_	_	_	_	_	Seg=O
207	infections	_	_	_	_	_	_	_	Seg=O
208	(	_	_	_	_	_	_	_	Seg=B-seg
209	including	_	_	_	_	_	_	_	Seg=O
210	enteroviruses	_	_	_	_	_	_	_	Seg=O
211	,	_	_	_	_	_	_	_	Seg=O
212	SARS	_	_	_	_	_	_	_	Seg=O
213	coronavirus	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	and	_	_	_	_	_	_	_	Seg=O
216	hepatitis	_	_	_	_	_	_	_	Seg=O
217	C	_	_	_	_	_	_	_	Seg=O
218	virus	_	_	_	_	_	_	_	Seg=O
219	)	_	_	_	_	_	_	_	Seg=O
220	,	_	_	_	_	_	_	_	Seg=O
221	cancers	_	_	_	_	_	_	_	Seg=B-seg
222	and	_	_	_	_	_	_	_	Seg=O
223	neurological	_	_	_	_	_	_	_	Seg=O
224	diseases	_	_	_	_	_	_	_	Seg=O
225	.	_	_	_	_	_	_	_	Seg=O
226	The	_	_	_	_	_	_	_	Seg=B-seg
227	approach	_	_	_	_	_	_	_	Seg=O
228	resulted	_	_	_	_	_	_	_	Seg=O
229	in	_	_	_	_	_	_	_	Seg=O
230	the	_	_	_	_	_	_	_	Seg=O
231	identification	_	_	_	_	_	_	_	Seg=O
232	of	_	_	_	_	_	_	_	Seg=O
233	two	_	_	_	_	_	_	_	Seg=O
234	hits	_	_	_	_	_	_	_	Seg=O
235	,	_	_	_	_	_	_	_	Seg=O
236	LASSBio-1799	_	_	_	_	_	_	_	Seg=O
237	(	_	_	_	_	_	_	_	Seg=O
238	7	_	_	_	_	_	_	_	Seg=O
239	)	_	_	_	_	_	_	_	Seg=O
240	and	_	_	_	_	_	_	_	Seg=O
241	LASSBio-1814	_	_	_	_	_	_	_	Seg=O
242	(	_	_	_	_	_	_	_	Seg=O
243	10	_	_	_	_	_	_	_	Seg=O
244	)	_	_	_	_	_	_	_	Seg=O
245	,	_	_	_	_	_	_	_	Seg=O
246	which	_	_	_	_	_	_	_	Seg=B-seg
247	inhibited	_	_	_	_	_	_	_	Seg=O
248	the	_	_	_	_	_	_	_	Seg=O
249	target	_	_	_	_	_	_	_	Seg=O
250	enzyme	_	_	_	_	_	_	_	Seg=O
251	with	_	_	_	_	_	_	_	Seg=O
252	IC	_	_	_	_	_	_	_	Seg=O
253	50	_	_	_	_	_	_	_	Seg=O
254	values	_	_	_	_	_	_	_	Seg=O
255	of	_	_	_	_	_	_	_	Seg=O
256	3.66	_	_	_	_	_	_	_	Seg=O
257	μM	_	_	_	_	_	_	_	Seg=O
258	and	_	_	_	_	_	_	_	Seg=O
259	IC	_	_	_	_	_	_	_	Seg=O
260	50	_	_	_	_	_	_	_	Seg=O
261	and	_	_	_	_	_	_	_	Seg=O
262	6.09	_	_	_	_	_	_	_	Seg=O
263	μM	_	_	_	_	_	_	_	Seg=O
264	,	_	_	_	_	_	_	_	Seg=O
265	respectively	_	_	_	_	_	_	_	Seg=O
266	.	_	_	_	_	_	_	_	Seg=O
267	This	_	_	_	_	_	_	_	Seg=B-seg
268	study	_	_	_	_	_	_	_	Seg=O
269	also	_	_	_	_	_	_	_	Seg=O
270	enabled	_	_	_	_	_	_	_	Seg=O
271	the	_	_	_	_	_	_	_	Seg=O
272	determination	_	_	_	_	_	_	_	Seg=O
273	of	_	_	_	_	_	_	_	Seg=O
274	the	_	_	_	_	_	_	_	Seg=O
275	structural	_	_	_	_	_	_	_	Seg=O
276	requirements	_	_	_	_	_	_	_	Seg=O
277	for	_	_	_	_	_	_	_	Seg=O
278	interactions	_	_	_	_	_	_	_	Seg=O
279	with	_	_	_	_	_	_	_	Seg=O
280	the	_	_	_	_	_	_	_	Seg=O
281	active	_	_	_	_	_	_	_	Seg=O
282	site	_	_	_	_	_	_	_	Seg=O
283	of	_	_	_	_	_	_	_	Seg=O
284	PI4KIIIβ	_	_	_	_	_	_	_	Seg=O
285	,	_	_	_	_	_	_	_	Seg=O
286	demonstrating	_	_	_	_	_	_	_	Seg=B-seg
287	the	_	_	_	_	_	_	_	Seg=O
288	importance	_	_	_	_	_	_	_	Seg=O
289	of	_	_	_	_	_	_	_	Seg=O
290	both	_	_	_	_	_	_	_	Seg=O
291	acceptor	_	_	_	_	_	_	_	Seg=O
292	and	_	_	_	_	_	_	_	Seg=O
293	donor	_	_	_	_	_	_	_	Seg=O
294	hydrogen	_	_	_	_	_	_	_	Seg=O
295	bonding	_	_	_	_	_	_	_	Seg=O
296	groups	_	_	_	_	_	_	_	Seg=O
297	for	_	_	_	_	_	_	_	Seg=B-seg
298	forming	_	_	_	_	_	_	_	Seg=O
299	interactions	_	_	_	_	_	_	_	Seg=O
300	with	_	_	_	_	_	_	_	Seg=O
301	binding	_	_	_	_	_	_	_	Seg=O
302	site	_	_	_	_	_	_	_	Seg=O
303	residues	_	_	_	_	_	_	_	Seg=O
304	Val598	_	_	_	_	_	_	_	Seg=O
305	and	_	_	_	_	_	_	_	Seg=O
306	Lys549	_	_	_	_	_	_	_	Seg=O
307	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 09bdbea1700a3826acc33484ed51e2fa8c23f047
1	Data	_	_	_	_	_	_	_	Seg=B-seg
2	-	_	_	_	_	_	_	_	Seg=O
3	centric	_	_	_	_	_	_	_	Seg=O
4	models	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	COVID-19	_	_	_	_	_	_	_	Seg=O
7	have	_	_	_	_	_	_	_	Seg=O
8	been	_	_	_	_	_	_	_	Seg=O
9	tried	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	but	_	_	_	_	_	_	_	Seg=B-seg
12	have	_	_	_	_	_	_	_	Seg=O
13	certain	_	_	_	_	_	_	_	Seg=O
14	limitations	_	_	_	_	_	_	_	Seg=O
15	.	_	_	_	_	_	_	_	Seg=O
16	In	_	_	_	_	_	_	_	Seg=B-seg
17	this	_	_	_	_	_	_	_	Seg=O
18	work	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	we	_	_	_	_	_	_	_	Seg=O
21	propose	_	_	_	_	_	_	_	Seg=O
22	an	_	_	_	_	_	_	_	Seg=O
23	agent	_	_	_	_	_	_	_	Seg=O
24	-	_	_	_	_	_	_	_	Seg=O
25	based	_	_	_	_	_	_	_	Seg=O
26	model	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	epidemic	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	a	_	_	_	_	_	_	_	Seg=O
32	confined	_	_	_	_	_	_	_	Seg=O
33	space	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	agents	_	_	_	_	_	_	_	Seg=O
36	representing	_	_	_	_	_	_	_	Seg=O
37	humans	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	An	_	_	_	_	_	_	_	Seg=B-seg
40	extension	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	SEIR	_	_	_	_	_	_	_	Seg=O
44	model	_	_	_	_	_	_	_	Seg=O
45	allows	_	_	_	_	_	_	_	Seg=O
46	us	_	_	_	_	_	_	_	Seg=O
47	to	_	_	_	_	_	_	_	Seg=O
48	consider	_	_	_	_	_	_	_	Seg=O
49	the	_	_	_	_	_	_	_	Seg=O
50	difference	_	_	_	_	_	_	_	Seg=O
51	between	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	appearance	_	_	_	_	_	_	_	Seg=O
54	(	_	_	_	_	_	_	_	Seg=O
55	black	_	_	_	_	_	_	_	Seg=O
56	-	_	_	_	_	_	_	_	Seg=O
57	box	_	_	_	_	_	_	_	Seg=O
58	view	_	_	_	_	_	_	_	Seg=O
59	)	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	spread	_	_	_	_	_	_	_	Seg=O
63	of	_	_	_	_	_	_	_	Seg=O
64	disease	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	and	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	real	_	_	_	_	_	_	_	Seg=O
69	situation	_	_	_	_	_	_	_	Seg=O
70	(	_	_	_	_	_	_	_	Seg=O
71	glass	_	_	_	_	_	_	_	Seg=O
72	-	_	_	_	_	_	_	_	Seg=O
73	box	_	_	_	_	_	_	_	Seg=O
74	view	_	_	_	_	_	_	_	Seg=O
75	)	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	Our	_	_	_	_	_	_	_	Seg=B-seg
78	model	_	_	_	_	_	_	_	Seg=O
79	allows	_	_	_	_	_	_	_	Seg=O
80	for	_	_	_	_	_	_	_	Seg=O
81	simulations	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	lockdowns	_	_	_	_	_	_	_	Seg=O
84	,	_	_	_	_	_	_	_	Seg=O
85	social	_	_	_	_	_	_	_	Seg=O
86	distancing	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	personal	_	_	_	_	_	_	_	Seg=O
89	hygiene	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	quarantine	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=O
94	hospitalization	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	with	_	_	_	_	_	_	_	Seg=O
97	further	_	_	_	_	_	_	_	Seg=O
98	considerations	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	different	_	_	_	_	_	_	_	Seg=O
101	parameters	_	_	_	_	_	_	_	Seg=O
102	such	_	_	_	_	_	_	_	Seg=B-seg
103	as	_	_	_	_	_	_	_	Seg=O
104	the	_	_	_	_	_	_	_	Seg=O
105	extent	_	_	_	_	_	_	_	Seg=O
106	to	_	_	_	_	_	_	_	Seg=B-seg
107	which	_	_	_	_	_	_	_	Seg=O
108	hygiene	_	_	_	_	_	_	_	Seg=O
109	and	_	_	_	_	_	_	_	Seg=O
110	social	_	_	_	_	_	_	_	Seg=O
111	distancing	_	_	_	_	_	_	_	Seg=O
112	are	_	_	_	_	_	_	_	Seg=O
113	observed	_	_	_	_	_	_	_	Seg=O
114	in	_	_	_	_	_	_	_	Seg=O
115	a	_	_	_	_	_	_	_	Seg=O
116	population	_	_	_	_	_	_	_	Seg=O
117	.	_	_	_	_	_	_	_	Seg=O
118	Our	_	_	_	_	_	_	_	Seg=B-seg
119	results	_	_	_	_	_	_	_	Seg=O
120	give	_	_	_	_	_	_	_	Seg=O
121	qualitative	_	_	_	_	_	_	_	Seg=O
122	indications	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	effects	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	various	_	_	_	_	_	_	_	Seg=O
128	policies	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	parameters	_	_	_	_	_	_	_	Seg=O
131	;	_	_	_	_	_	_	_	Seg=O
132	for	_	_	_	_	_	_	_	Seg=B-seg
133	instance	_	_	_	_	_	_	_	Seg=O
134	,	_	_	_	_	_	_	_	Seg=O
135	that	_	_	_	_	_	_	_	Seg=O
136	lockdowns	_	_	_	_	_	_	_	Seg=O
137	by	_	_	_	_	_	_	_	Seg=O
138	themselves	_	_	_	_	_	_	_	Seg=O
139	are	_	_	_	_	_	_	_	Seg=O
140	extremely	_	_	_	_	_	_	_	Seg=O
141	unlikely	_	_	_	_	_	_	_	Seg=O
142	to	_	_	_	_	_	_	_	Seg=O
143	bring	_	_	_	_	_	_	_	Seg=O
144	an	_	_	_	_	_	_	_	Seg=O
145	end	_	_	_	_	_	_	_	Seg=O
146	to	_	_	_	_	_	_	_	Seg=O
147	an	_	_	_	_	_	_	_	Seg=O
148	epidemic	_	_	_	_	_	_	_	Seg=O
149	and	_	_	_	_	_	_	_	Seg=B-seg
150	may	_	_	_	_	_	_	_	Seg=O
151	indeed	_	_	_	_	_	_	_	Seg=O
152	make	_	_	_	_	_	_	_	Seg=O
153	things	_	_	_	_	_	_	_	Seg=O
154	worse	_	_	_	_	_	_	_	Seg=O
155	,	_	_	_	_	_	_	_	Seg=O
156	that	_	_	_	_	_	_	_	Seg=B-seg
157	social	_	_	_	_	_	_	_	Seg=O
158	distancing	_	_	_	_	_	_	_	Seg=O
159	matters	_	_	_	_	_	_	_	Seg=O
160	more	_	_	_	_	_	_	_	Seg=O
161	than	_	_	_	_	_	_	_	Seg=O
162	personal	_	_	_	_	_	_	_	Seg=O
163	hygiene	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=B-seg
166	that	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	growth	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	infection	_	_	_	_	_	_	_	Seg=O
171	comes	_	_	_	_	_	_	_	Seg=O
172	down	_	_	_	_	_	_	_	Seg=O
173	significantly	_	_	_	_	_	_	_	Seg=O
174	for	_	_	_	_	_	_	_	Seg=O
175	moderately	_	_	_	_	_	_	_	Seg=O
176	high	_	_	_	_	_	_	_	Seg=O
177	levels	_	_	_	_	_	_	_	Seg=O
178	of	_	_	_	_	_	_	_	Seg=O
179	social	_	_	_	_	_	_	_	Seg=O
180	distancing	_	_	_	_	_	_	_	Seg=O
181	and	_	_	_	_	_	_	_	Seg=O
182	hygiene	_	_	_	_	_	_	_	Seg=O
183	,	_	_	_	_	_	_	_	Seg=O
184	even	_	_	_	_	_	_	_	Seg=O
185	in	_	_	_	_	_	_	_	Seg=O
186	the	_	_	_	_	_	_	_	Seg=O
187	absence	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	herd	_	_	_	_	_	_	_	Seg=O
190	immunity	_	_	_	_	_	_	_	Seg=O
191	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0b362bc7e9278b56c2740ab7bc10e91c036f835a
1	We	_	_	_	_	_	_	_	Seg=B-seg
2	study	_	_	_	_	_	_	_	Seg=O
3	seasonal	_	_	_	_	_	_	_	Seg=O
4	epidemic	_	_	_	_	_	_	_	Seg=O
5	spreading	_	_	_	_	_	_	_	Seg=O
6	in	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	susceptible	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	infected	_	_	_	_	_	_	_	Seg=O
11	-	_	_	_	_	_	_	_	Seg=O
12	removed	_	_	_	_	_	_	_	Seg=O
13	-	_	_	_	_	_	_	_	Seg=O
14	susceptible	_	_	_	_	_	_	_	Seg=O
15	(	_	_	_	_	_	_	_	Seg=O
16	SIRS	_	_	_	_	_	_	_	Seg=O
17	)	_	_	_	_	_	_	_	Seg=O
18	model	_	_	_	_	_	_	_	Seg=O
19	on	_	_	_	_	_	_	_	Seg=O
20	smallworld	_	_	_	_	_	_	_	Seg=O
21	graphs	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	We	_	_	_	_	_	_	_	Seg=B-seg
24	derive	_	_	_	_	_	_	_	Seg=O
25	a	_	_	_	_	_	_	_	Seg=O
26	mean	_	_	_	_	_	_	_	Seg=O
27	-	_	_	_	_	_	_	_	Seg=O
28	field	_	_	_	_	_	_	_	Seg=O
29	description	_	_	_	_	_	_	_	Seg=O
30	that	_	_	_	_	_	_	_	Seg=B-seg
31	accurately	_	_	_	_	_	_	_	Seg=O
32	captures	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	salient	_	_	_	_	_	_	_	Seg=O
35	features	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	model	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	most	_	_	_	_	_	_	_	Seg=O
41	notably	_	_	_	_	_	_	_	Seg=O
42	a	_	_	_	_	_	_	_	Seg=O
43	phase	_	_	_	_	_	_	_	Seg=O
44	transition	_	_	_	_	_	_	_	Seg=O
45	between	_	_	_	_	_	_	_	Seg=O
46	annual	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=O
48	biennial	_	_	_	_	_	_	_	Seg=O
49	outbreaks	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	A	_	_	_	_	_	_	_	Seg=B-seg
52	numerical	_	_	_	_	_	_	_	Seg=O
53	scaling	_	_	_	_	_	_	_	Seg=O
54	analysis	_	_	_	_	_	_	_	Seg=O
55	exhibits	_	_	_	_	_	_	_	Seg=O
56	a	_	_	_	_	_	_	_	Seg=O
57	diverging	_	_	_	_	_	_	_	Seg=O
58	autocorrelation	_	_	_	_	_	_	_	Seg=O
59	time	_	_	_	_	_	_	_	Seg=O
60	in	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	thermodynamic	_	_	_	_	_	_	_	Seg=O
63	limit	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	which	_	_	_	_	_	_	_	Seg=B-seg
66	confirms	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	presence	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	a	_	_	_	_	_	_	_	Seg=O
71	classical	_	_	_	_	_	_	_	Seg=O
72	discrete	_	_	_	_	_	_	_	Seg=O
73	time	_	_	_	_	_	_	_	Seg=O
74	crystalline	_	_	_	_	_	_	_	Seg=O
75	phase	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	We	_	_	_	_	_	_	_	Seg=B-seg
78	derive	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	phase	_	_	_	_	_	_	_	Seg=O
81	diagram	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	model	_	_	_	_	_	_	_	Seg=O
85	both	_	_	_	_	_	_	_	Seg=O
86	from	_	_	_	_	_	_	_	Seg=O
87	mean	_	_	_	_	_	_	_	Seg=O
88	-	_	_	_	_	_	_	_	Seg=O
89	field	_	_	_	_	_	_	_	Seg=O
90	theory	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	from	_	_	_	_	_	_	_	Seg=O
93	numerics	_	_	_	_	_	_	_	Seg=O
94	.	_	_	_	_	_	_	_	Seg=O
95	Our	_	_	_	_	_	_	_	Seg=B-seg
96	work	_	_	_	_	_	_	_	Seg=O
97	offers	_	_	_	_	_	_	_	Seg=O
98	new	_	_	_	_	_	_	_	Seg=O
99	perspectives	_	_	_	_	_	_	_	Seg=O
100	by	_	_	_	_	_	_	_	Seg=B-seg
101	demonstrating	_	_	_	_	_	_	_	Seg=O
102	that	_	_	_	_	_	_	_	Seg=B-seg
103	small	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	worldness	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=O
107	non	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	Markovianity	_	_	_	_	_	_	_	Seg=O
110	can	_	_	_	_	_	_	_	Seg=O
111	stabilize	_	_	_	_	_	_	_	Seg=O
112	a	_	_	_	_	_	_	_	Seg=O
113	classical	_	_	_	_	_	_	_	Seg=O
114	discrete	_	_	_	_	_	_	_	Seg=O
115	time	_	_	_	_	_	_	_	Seg=O
116	crystal	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=B-seg
119	by	_	_	_	_	_	_	_	Seg=O
120	linking	_	_	_	_	_	_	_	Seg=O
121	recent	_	_	_	_	_	_	_	Seg=O
122	efforts	_	_	_	_	_	_	_	Seg=O
123	to	_	_	_	_	_	_	_	Seg=B-seg
124	understand	_	_	_	_	_	_	_	Seg=O
125	such	_	_	_	_	_	_	_	Seg=O
126	dynamical	_	_	_	_	_	_	_	Seg=O
127	phases	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	matter	_	_	_	_	_	_	_	Seg=O
130	to	_	_	_	_	_	_	_	Seg=B-seg
131	the	_	_	_	_	_	_	_	Seg=O
132	century	_	_	_	_	_	_	_	Seg=O
133	-	_	_	_	_	_	_	_	Seg=O
134	old	_	_	_	_	_	_	_	Seg=O
135	problem	_	_	_	_	_	_	_	Seg=O
136	of	_	_	_	_	_	_	_	Seg=O
137	biennial	_	_	_	_	_	_	_	Seg=O
138	epidemics	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0b6936373351a029b06b8784ff8077d755e7ee96
1	Ebola	_	_	_	_	_	_	_	Seg=B-seg
2	virus	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	EBOV	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	,	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	non	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	segmented	_	_	_	_	_	_	_	Seg=O
11	single	_	_	_	_	_	_	_	Seg=O
12	-	_	_	_	_	_	_	_	Seg=O
13	stranded	_	_	_	_	_	_	_	Seg=O
14	RNA	_	_	_	_	_	_	_	Seg=O
15	virus	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	is	_	_	_	_	_	_	_	Seg=O
18	often	_	_	_	_	_	_	_	Seg=O
19	-	_	_	_	_	_	_	_	Seg=O
20	most	_	_	_	_	_	_	_	Seg=O
21	transmitted	_	_	_	_	_	_	_	Seg=O
22	through	_	_	_	_	_	_	_	Seg=O
23	body	_	_	_	_	_	_	_	Seg=O
24	fluids	_	_	_	_	_	_	_	Seg=O
25	like	_	_	_	_	_	_	_	Seg=O
26	sweat	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	tears	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	saliva	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	nasal	_	_	_	_	_	_	_	Seg=O
34	secretions	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	Till	_	_	_	_	_	_	_	Seg=B-seg
37	date	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	there	_	_	_	_	_	_	_	Seg=O
40	is	_	_	_	_	_	_	_	Seg=O
41	no	_	_	_	_	_	_	_	Seg=O
42	licensed	_	_	_	_	_	_	_	Seg=O
43	vaccine	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	EBOV	_	_	_	_	_	_	_	Seg=O
46	is	_	_	_	_	_	_	_	Seg=O
47	available	_	_	_	_	_	_	_	Seg=O
48	in	_	_	_	_	_	_	_	Seg=O
49	the	_	_	_	_	_	_	_	Seg=O
50	market	_	_	_	_	_	_	_	Seg=O
51	;	_	_	_	_	_	_	_	Seg=O
52	however	_	_	_	_	_	_	_	Seg=B-seg
53	,	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	world	_	_	_	_	_	_	_	Seg=O
56	is	_	_	_	_	_	_	_	Seg=O
57	increasingly	_	_	_	_	_	_	_	Seg=O
58	vulnerable	_	_	_	_	_	_	_	Seg=O
59	to	_	_	_	_	_	_	_	Seg=O
60	this	_	_	_	_	_	_	_	Seg=O
61	emerging	_	_	_	_	_	_	_	Seg=O
62	threat	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	Hence	_	_	_	_	_	_	_	Seg=B-seg
65	,	_	_	_	_	_	_	_	Seg=O
66	it	_	_	_	_	_	_	_	Seg=O
67	is	_	_	_	_	_	_	_	Seg=O
68	the	_	_	_	_	_	_	_	Seg=O
69	need	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	time	_	_	_	_	_	_	_	Seg=O
72	to	_	_	_	_	_	_	_	Seg=O
73	develop	_	_	_	_	_	_	_	Seg=O
74	a	_	_	_	_	_	_	_	Seg=O
75	vaccine	_	_	_	_	_	_	_	Seg=O
76	for	_	_	_	_	_	_	_	Seg=O
77	EBOV	_	_	_	_	_	_	_	Seg=O
78	to	_	_	_	_	_	_	_	Seg=B-seg
79	hinder	_	_	_	_	_	_	_	Seg=O
80	its	_	_	_	_	_	_	_	Seg=O
81	dissemination	_	_	_	_	_	_	_	Seg=O
82	.	_	_	_	_	_	_	_	Seg=O
83	The	_	_	_	_	_	_	_	Seg=B-seg
84	current	_	_	_	_	_	_	_	Seg=O
85	study	_	_	_	_	_	_	_	Seg=O
86	has	_	_	_	_	_	_	_	Seg=O
87	been	_	_	_	_	_	_	_	Seg=O
88	designed	_	_	_	_	_	_	_	Seg=O
89	for	_	_	_	_	_	_	_	Seg=O
90	identification	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	characterization	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=O
94	the	_	_	_	_	_	_	_	Seg=O
95	potential	_	_	_	_	_	_	_	Seg=O
96	B	_	_	_	_	_	_	_	Seg=O
97	and	_	_	_	_	_	_	_	Seg=O
98	T	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	cell	_	_	_	_	_	_	_	Seg=O
101	epitopes	_	_	_	_	_	_	_	Seg=O
102	using	_	_	_	_	_	_	_	Seg=B-seg
103	the	_	_	_	_	_	_	_	Seg=O
104	Immuno	_	_	_	_	_	_	_	Seg=O
105	-	_	_	_	_	_	_	_	Seg=O
106	informatics	_	_	_	_	_	_	_	Seg=O
107	tools	_	_	_	_	_	_	_	Seg=O
108	,	_	_	_	_	_	_	_	Seg=O
109	and	_	_	_	_	_	_	_	Seg=B-seg
110	it	_	_	_	_	_	_	_	Seg=O
111	helped	_	_	_	_	_	_	_	Seg=O
112	in	_	_	_	_	_	_	_	Seg=O
113	finding	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	potent	_	_	_	_	_	_	_	Seg=O
116	vaccine	_	_	_	_	_	_	_	Seg=O
117	candidates	_	_	_	_	_	_	_	Seg=O
118	against	_	_	_	_	_	_	_	Seg=O
119	EBOV	_	_	_	_	_	_	_	Seg=O
120	.	_	_	_	_	_	_	_	Seg=O
121	Prediction	_	_	_	_	_	_	_	Seg=B-seg
122	,	_	_	_	_	_	_	_	Seg=O
123	antigenicity	_	_	_	_	_	_	_	Seg=O
124	and	_	_	_	_	_	_	_	Seg=O
125	allergenicity	_	_	_	_	_	_	_	Seg=O
126	testing	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	predicted	_	_	_	_	_	_	_	Seg=O
129	B	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	T	_	_	_	_	_	_	_	Seg=O
132-133	cells'	_	_	_	_	_	_	_	_
132	cells	_	_	_	_	_	_	_	Seg=O
133	'	_	_	_	_	_	_	_	Seg=O
134	epitopes	_	_	_	_	_	_	_	Seg=O
135	was	_	_	_	_	_	_	_	Seg=O
136	done	_	_	_	_	_	_	_	Seg=O
137	as	_	_	_	_	_	_	_	Seg=B-seg
138	well	_	_	_	_	_	_	_	Seg=O
139	to	_	_	_	_	_	_	_	Seg=O
140	identify	_	_	_	_	_	_	_	Seg=O
141	their	_	_	_	_	_	_	_	Seg=O
142	potential	_	_	_	_	_	_	_	Seg=O
143	as	_	_	_	_	_	_	_	Seg=O
144	a	_	_	_	_	_	_	_	Seg=O
145	vaccine	_	_	_	_	_	_	_	Seg=O
146	candidate	_	_	_	_	_	_	_	Seg=O
147	and	_	_	_	_	_	_	_	Seg=B-seg
148	to	_	_	_	_	_	_	_	Seg=O
149	measure	_	_	_	_	_	_	_	Seg=O
150	their	_	_	_	_	_	_	_	Seg=O
151	safety	_	_	_	_	_	_	_	Seg=O
152	level	_	_	_	_	_	_	_	Seg=O
153	respectively	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O
155	Among	_	_	_	_	_	_	_	Seg=B-seg
156	B	_	_	_	_	_	_	_	Seg=O
157	-	_	_	_	_	_	_	_	Seg=O
158	cell	_	_	_	_	_	_	_	Seg=O
159	epitopes	_	_	_	_	_	_	_	Seg=O
160	"	_	_	_	_	_	_	_	Seg=O
161	WIPAGIGVTGVIIA	_	_	_	_	_	_	_	Seg=O
162	"	_	_	_	_	_	_	_	Seg=O
163	showed	_	_	_	_	_	_	_	Seg=O
164	a	_	_	_	_	_	_	_	Seg=O
165	high	_	_	_	_	_	_	_	Seg=O
166	antigenicity	_	_	_	_	_	_	_	Seg=O
167	score	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=B-seg
169	it	_	_	_	_	_	_	_	Seg=O
170	would	_	_	_	_	_	_	_	Seg=O
171	play	_	_	_	_	_	_	_	Seg=O
172	an	_	_	_	_	_	_	_	Seg=O
173	important	_	_	_	_	_	_	_	Seg=O
174	role	_	_	_	_	_	_	_	Seg=O
175	in	_	_	_	_	_	_	_	Seg=B-seg
176	evoking	_	_	_	_	_	_	_	Seg=O
177	the	_	_	_	_	_	_	_	Seg=O
178	immune	_	_	_	_	_	_	_	Seg=O
179	response	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O
181	In	_	_	_	_	_	_	_	Seg=B-seg
182	T	_	_	_	_	_	_	_	Seg=O
183	-	_	_	_	_	_	_	_	Seg=O
184	cell	_	_	_	_	_	_	_	Seg=O
185	epitopes	_	_	_	_	_	_	_	Seg=O
186	,	_	_	_	_	_	_	_	Seg=O
187	peptides	_	_	_	_	_	_	_	Seg=O
188	"	_	_	_	_	_	_	_	Seg=O
189	AIGLAWIPY	_	_	_	_	_	_	_	Seg=O
190	"	_	_	_	_	_	_	_	Seg=O
191	and	_	_	_	_	_	_	_	Seg=O
192	"	_	_	_	_	_	_	_	Seg=O
193	IRGFPRCRY	_	_	_	_	_	_	_	Seg=O
194	"	_	_	_	_	_	_	_	Seg=O
195	presented	_	_	_	_	_	_	_	Seg=O
196	high	_	_	_	_	_	_	_	Seg=O
197	antigenicity	_	_	_	_	_	_	_	Seg=O
198	score	_	_	_	_	_	_	_	Seg=O
199	,	_	_	_	_	_	_	_	Seg=O
200	which	_	_	_	_	_	_	_	Seg=B-seg
201	binds	_	_	_	_	_	_	_	Seg=O
202	to	_	_	_	_	_	_	_	Seg=O
203	MHC	_	_	_	_	_	_	_	Seg=O
204	class	_	_	_	_	_	_	_	Seg=O
205	-	_	_	_	_	_	_	_	Seg=O
206	I	_	_	_	_	_	_	_	Seg=O
207	and	_	_	_	_	_	_	_	Seg=O
208	MHC	_	_	_	_	_	_	_	Seg=O
209	class	_	_	_	_	_	_	_	Seg=O
210	-	_	_	_	_	_	_	_	Seg=O
211	II	_	_	_	_	_	_	_	Seg=O
212	alleles	_	_	_	_	_	_	_	Seg=O
213	respectively	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O
215	All	_	_	_	_	_	_	_	Seg=B-seg
216	predicted	_	_	_	_	_	_	_	Seg=O
217	epitopes	_	_	_	_	_	_	_	Seg=O
218	were	_	_	_	_	_	_	_	Seg=O
219	analyzed	_	_	_	_	_	_	_	Seg=O
220	and	_	_	_	_	_	_	_	Seg=B-seg
221	compared	_	_	_	_	_	_	_	Seg=O
222	with	_	_	_	_	_	_	_	Seg=O
223	already	_	_	_	_	_	_	_	Seg=O
224	reported	_	_	_	_	_	_	_	Seg=O
225	peptides	_	_	_	_	_	_	_	Seg=O
226	carefully	_	_	_	_	_	_	_	Seg=O
227	.	_	_	_	_	_	_	_	Seg=O
228	Comparatively	_	_	_	_	_	_	_	Seg=B-seg
229	,	_	_	_	_	_	_	_	Seg=O
230	Peptides	_	_	_	_	_	_	_	Seg=O
231	predicted	_	_	_	_	_	_	_	Seg=B-seg
232	in	_	_	_	_	_	_	_	Seg=O
233	the	_	_	_	_	_	_	_	Seg=O
234	present	_	_	_	_	_	_	_	Seg=O
235	study	_	_	_	_	_	_	_	Seg=O
236	showed	_	_	_	_	_	_	_	Seg=B-seg
237	more	_	_	_	_	_	_	_	Seg=O
238	immunogenicity	_	_	_	_	_	_	_	Seg=O
239	score	_	_	_	_	_	_	_	Seg=O
240	than	_	_	_	_	_	_	_	Seg=O
241	already	_	_	_	_	_	_	_	Seg=O
242	reported	_	_	_	_	_	_	_	Seg=O
243	peptides	_	_	_	_	_	_	_	Seg=O
244	,	_	_	_	_	_	_	_	Seg=O
245	used	_	_	_	_	_	_	_	Seg=B-seg
246	as	_	_	_	_	_	_	_	Seg=O
247	positive	_	_	_	_	_	_	_	Seg=O
248	control	_	_	_	_	_	_	_	Seg=O
249	,	_	_	_	_	_	_	_	Seg=O
250	and	_	_	_	_	_	_	_	Seg=B-seg
251	are	_	_	_	_	_	_	_	Seg=O
252	more	_	_	_	_	_	_	_	Seg=O
253	immunogenic	_	_	_	_	_	_	_	Seg=O
254	as	_	_	_	_	_	_	_	Seg=B-seg
255	compared	_	_	_	_	_	_	_	Seg=O
256	to	_	_	_	_	_	_	_	Seg=O
257	them	_	_	_	_	_	_	_	Seg=O
258	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0b7581ab8ae5da78a11692b4c7d9399ec6dea283
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	In	_	_	_	_	_	_	_	Seg=B-seg
4	this	_	_	_	_	_	_	_	Seg=O
5	study	_	_	_	_	_	_	_	Seg=O
6	we	_	_	_	_	_	_	_	Seg=O
7	evaluated	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	RespoCheck	_	_	_	_	_	_	_	Seg=O
10	Mycoplasma	_	_	_	_	_	_	_	Seg=O
11	triplex	_	_	_	_	_	_	_	Seg=O
12	real	_	_	_	_	_	_	_	Seg=O
13	-	_	_	_	_	_	_	_	Seg=O
14	time	_	_	_	_	_	_	_	Seg=O
15	PCR	_	_	_	_	_	_	_	Seg=O
16	for	_	_	_	_	_	_	_	Seg=O
17	the	_	_	_	_	_	_	_	Seg=O
18	detection	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	bronchoalveolar	_	_	_	_	_	_	_	Seg=O
21	lavage	_	_	_	_	_	_	_	Seg=O
22	fluid	_	_	_	_	_	_	_	Seg=O
23	(	_	_	_	_	_	_	_	Seg=O
24	BALF	_	_	_	_	_	_	_	Seg=O
25	)	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	Mycoplasma	_	_	_	_	_	_	_	Seg=O
28	(	_	_	_	_	_	_	_	Seg=O
29	M.	_	_	_	_	_	_	_	Seg=O
30	)	_	_	_	_	_	_	_	Seg=O
31	dispar	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	M.	_	_	_	_	_	_	_	Seg=O
34	bovis	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	M.	_	_	_	_	_	_	_	Seg=O
37	bovirhinis	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	all	_	_	_	_	_	_	_	Seg=B-seg
40	three	_	_	_	_	_	_	_	Seg=O
41	associated	_	_	_	_	_	_	_	Seg=O
42	with	_	_	_	_	_	_	_	Seg=O
43	bovine	_	_	_	_	_	_	_	Seg=O
44	respiratory	_	_	_	_	_	_	_	Seg=O
45	disease	_	_	_	_	_	_	_	Seg=O
46	(	_	_	_	_	_	_	_	Seg=O
47	BRD	_	_	_	_	_	_	_	Seg=O
48	)	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	Primers	_	_	_	_	_	_	_	Seg=B-seg
51	and	_	_	_	_	_	_	_	Seg=O
52	probes	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	RespoCheck	_	_	_	_	_	_	_	Seg=O
56	Mycoplasma	_	_	_	_	_	_	_	Seg=O
57	triplex	_	_	_	_	_	_	_	Seg=O
58	real	_	_	_	_	_	_	_	Seg=O
59	-	_	_	_	_	_	_	_	Seg=O
60	time	_	_	_	_	_	_	_	Seg=O
61	PCR	_	_	_	_	_	_	_	Seg=O
62	are	_	_	_	_	_	_	_	Seg=O
63	based	_	_	_	_	_	_	_	Seg=O
64	on	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	V3	_	_	_	_	_	_	_	Seg=O
67	/	_	_	_	_	_	_	_	Seg=O
68	V4	_	_	_	_	_	_	_	Seg=O
69	region	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	16S	_	_	_	_	_	_	_	Seg=O
73	rRNA	_	_	_	_	_	_	_	Seg=O
74	gene	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77	three	_	_	_	_	_	_	_	Seg=O
78	Mycoplasma	_	_	_	_	_	_	_	Seg=O
79	species	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	Results	_	_	_	_	_	_	_	Seg=B-seg
82	:	_	_	_	_	_	_	_	Seg=O
83	The	_	_	_	_	_	_	_	Seg=B-seg
84	analytical	_	_	_	_	_	_	_	Seg=O
85	sensitivity	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	RespoCheck	_	_	_	_	_	_	_	Seg=O
89	triplex	_	_	_	_	_	_	_	Seg=O
90	real	_	_	_	_	_	_	_	Seg=O
91	-	_	_	_	_	_	_	_	Seg=O
92	time	_	_	_	_	_	_	_	Seg=O
93	PCR	_	_	_	_	_	_	_	Seg=O
94	was	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	as	_	_	_	_	_	_	_	Seg=B-seg
97	determined	_	_	_	_	_	_	_	Seg=O
98	by	_	_	_	_	_	_	_	Seg=O
99	spiking	_	_	_	_	_	_	_	Seg=O
100	experiments	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	the	_	_	_	_	_	_	_	Seg=O
103	Mycoplasma	_	_	_	_	_	_	_	Seg=O
104	strains	_	_	_	_	_	_	_	Seg=O
105	in	_	_	_	_	_	_	_	Seg=O
106	Phosphate	_	_	_	_	_	_	_	Seg=O
107	Buffered	_	_	_	_	_	_	_	Seg=O
108	Saline	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	300	_	_	_	_	_	_	_	Seg=B-seg
111	colony	_	_	_	_	_	_	_	Seg=O
112	forming	_	_	_	_	_	_	_	Seg=O
113	units	_	_	_	_	_	_	_	Seg=O
114	(	_	_	_	_	_	_	_	Seg=O
115	cfu)/mL	_	_	_	_	_	_	_	Seg=O
116	for	_	_	_	_	_	_	_	Seg=O
117	M.	_	_	_	_	_	_	_	Seg=O
118	dispar	_	_	_	_	_	_	_	Seg=O
119	,	_	_	_	_	_	_	_	Seg=O
120	and	_	_	_	_	_	_	_	Seg=O
121	30	_	_	_	_	_	_	_	Seg=O
122	cfu	_	_	_	_	_	_	_	Seg=O
123	/	_	_	_	_	_	_	_	Seg=O
124	mL	_	_	_	_	_	_	_	Seg=O
125	for	_	_	_	_	_	_	_	Seg=O
126	M.	_	_	_	_	_	_	_	Seg=O
127	bovis	_	_	_	_	_	_	_	Seg=O
128	or	_	_	_	_	_	_	_	Seg=O
129	M.	_	_	_	_	_	_	_	Seg=O
130	bovirhinis	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O
132	The	_	_	_	_	_	_	_	Seg=B-seg
133	analytical	_	_	_	_	_	_	_	Seg=O
134	sensitivity	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	RespoCheck	_	_	_	_	_	_	_	Seg=O
138	Mycoplasma	_	_	_	_	_	_	_	Seg=O
139	triplex	_	_	_	_	_	_	_	Seg=O
140	real	_	_	_	_	_	_	_	Seg=O
141	-	_	_	_	_	_	_	_	Seg=O
142	time	_	_	_	_	_	_	_	Seg=O
143	PCR	_	_	_	_	_	_	_	Seg=O
144	was	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	as	_	_	_	_	_	_	_	Seg=B-seg
147	determined	_	_	_	_	_	_	_	Seg=O
148	on	_	_	_	_	_	_	_	Seg=O
149	purified	_	_	_	_	_	_	_	Seg=O
150	DNA	_	_	_	_	_	_	_	Seg=O
151	,	_	_	_	_	_	_	_	Seg=O
152	10	_	_	_	_	_	_	_	Seg=B-seg
153	fg	_	_	_	_	_	_	_	Seg=O
154	DNA	_	_	_	_	_	_	_	Seg=O
155	per	_	_	_	_	_	_	_	Seg=O
156	assay	_	_	_	_	_	_	_	Seg=O
157	for	_	_	_	_	_	_	_	Seg=O
158	M.	_	_	_	_	_	_	_	Seg=O
159	dispar	_	_	_	_	_	_	_	Seg=O
160	and	_	_	_	_	_	_	_	Seg=O
161	100	_	_	_	_	_	_	_	Seg=O
162	fg	_	_	_	_	_	_	_	Seg=O
163	fo	_	_	_	_	_	_	_	Seg=O
164	rM.	_	_	_	_	_	_	_	Seg=O
165	bovis	_	_	_	_	_	_	_	Seg=O
166	and	_	_	_	_	_	_	_	Seg=O
167	M.	_	_	_	_	_	_	_	Seg=O
168	bovirhinis	_	_	_	_	_	_	_	Seg=O
169	.	_	_	_	_	_	_	_	Seg=O
170	The	_	_	_	_	_	_	_	Seg=B-seg
171	analytical	_	_	_	_	_	_	_	Seg=O
172	specificity	_	_	_	_	_	_	_	Seg=O
173	of	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	RespoCheck	_	_	_	_	_	_	_	Seg=O
176	Mycoplasma	_	_	_	_	_	_	_	Seg=O
177	triplex	_	_	_	_	_	_	_	Seg=O
178	real	_	_	_	_	_	_	_	Seg=O
179	-	_	_	_	_	_	_	_	Seg=O
180	time	_	_	_	_	_	_	_	Seg=O
181	PCR	_	_	_	_	_	_	_	Seg=O
182	was	_	_	_	_	_	_	_	Seg=O
183	,	_	_	_	_	_	_	_	Seg=O
184	as	_	_	_	_	_	_	_	Seg=B-seg
185	determined	_	_	_	_	_	_	_	Seg=O
186	by	_	_	_	_	_	_	_	Seg=O
187	testing	_	_	_	_	_	_	_	Seg=O
188	Mycoplasmas	_	_	_	_	_	_	_	Seg=O
189	strains	_	_	_	_	_	_	_	Seg=O
190	(	_	_	_	_	_	_	_	Seg=B-seg
191	n	_	_	_	_	_	_	_	Seg=O
192	=	_	_	_	_	_	_	_	Seg=O
193	17	_	_	_	_	_	_	_	Seg=O
194	)	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=B-seg
196	other	_	_	_	_	_	_	_	Seg=O
197	bacterial	_	_	_	_	_	_	_	Seg=O
198	strains	_	_	_	_	_	_	_	Seg=O
199	(	_	_	_	_	_	_	_	Seg=B-seg
200	n	_	_	_	_	_	_	_	Seg=O
201	=	_	_	_	_	_	_	_	Seg=O
202	107	_	_	_	_	_	_	_	Seg=O
203	)	_	_	_	_	_	_	_	Seg=O
204	,	_	_	_	_	_	_	_	Seg=O
205	100	_	_	_	_	_	_	_	Seg=B-seg
206	,	_	_	_	_	_	_	_	Seg=O
207	98.2	_	_	_	_	_	_	_	Seg=O
208	and	_	_	_	_	_	_	_	Seg=O
209	99.1	_	_	_	_	_	_	_	Seg=O
210	%	_	_	_	_	_	_	_	Seg=O
211	for	_	_	_	_	_	_	_	Seg=O
212	M.	_	_	_	_	_	_	_	Seg=O
213	bovis	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	M.	_	_	_	_	_	_	_	Seg=O
216	dispar	_	_	_	_	_	_	_	Seg=O
217	and	_	_	_	_	_	_	_	Seg=O
218	M.	_	_	_	_	_	_	_	Seg=O
219	bovirhinis	_	_	_	_	_	_	_	Seg=O
220	respectively	_	_	_	_	_	_	_	Seg=O
221	.	_	_	_	_	_	_	_	Seg=O
222	The	_	_	_	_	_	_	_	Seg=B-seg
223	RespoCheck	_	_	_	_	_	_	_	Seg=O
224	Mycoplasma	_	_	_	_	_	_	_	Seg=O
225	triplex	_	_	_	_	_	_	_	Seg=O
226	real	_	_	_	_	_	_	_	Seg=O
227	-	_	_	_	_	_	_	_	Seg=O
228	time	_	_	_	_	_	_	_	Seg=O
229	PCR	_	_	_	_	_	_	_	Seg=O
230	was	_	_	_	_	_	_	_	Seg=O
231	compared	_	_	_	_	_	_	_	Seg=O
232	with	_	_	_	_	_	_	_	Seg=O
233	the	_	_	_	_	_	_	_	Seg=O
234	PCR	_	_	_	_	_	_	_	Seg=O
235	/	_	_	_	_	_	_	_	Seg=O
236	DGGE	_	_	_	_	_	_	_	Seg=O
237	analysis	_	_	_	_	_	_	_	Seg=O
238	for	_	_	_	_	_	_	_	Seg=O
239	M.	_	_	_	_	_	_	_	Seg=O
240	bovis	_	_	_	_	_	_	_	Seg=O
241	,	_	_	_	_	_	_	_	Seg=O
242	M.	_	_	_	_	_	_	_	Seg=O
243	dispar	_	_	_	_	_	_	_	Seg=O
244	and	_	_	_	_	_	_	_	Seg=O
245	M.	_	_	_	_	_	_	_	Seg=O
246	bovirhinis	_	_	_	_	_	_	_	Seg=O
247	respectively	_	_	_	_	_	_	_	Seg=O
248	by	_	_	_	_	_	_	_	Seg=B-seg
249	testing	_	_	_	_	_	_	_	Seg=O
250	44	_	_	_	_	_	_	_	Seg=O
251	BALF	_	_	_	_	_	_	_	Seg=O
252	samples	_	_	_	_	_	_	_	Seg=O
253	from	_	_	_	_	_	_	_	Seg=O
254	calves	_	_	_	_	_	_	_	Seg=O
255	.	_	_	_	_	_	_	_	Seg=O
256	Conclusion	_	_	_	_	_	_	_	Seg=B-seg
257	:	_	_	_	_	_	_	_	Seg=O
258	In	_	_	_	_	_	_	_	Seg=B-seg
259	conclusion	_	_	_	_	_	_	_	Seg=O
260	,	_	_	_	_	_	_	_	Seg=O
261	the	_	_	_	_	_	_	_	Seg=O
262	RespoCheck	_	_	_	_	_	_	_	Seg=O
263	PCR	_	_	_	_	_	_	_	Seg=O
264	assay	_	_	_	_	_	_	_	Seg=O
265	can	_	_	_	_	_	_	_	Seg=O
266	be	_	_	_	_	_	_	_	Seg=O
267	a	_	_	_	_	_	_	_	Seg=O
268	valuable	_	_	_	_	_	_	_	Seg=O
269	tool	_	_	_	_	_	_	_	Seg=O
270	for	_	_	_	_	_	_	_	Seg=O
271	timely	_	_	_	_	_	_	_	Seg=O
272	and	_	_	_	_	_	_	_	Seg=O
273	accurate	_	_	_	_	_	_	_	Seg=O
274	detection	_	_	_	_	_	_	_	Seg=O
275	of	_	_	_	_	_	_	_	Seg=O
276	three	_	_	_	_	_	_	_	Seg=O
277	Mycoplasma	_	_	_	_	_	_	_	Seg=O
278	species	_	_	_	_	_	_	_	Seg=O
279	associated	_	_	_	_	_	_	_	Seg=B-seg
280	with	_	_	_	_	_	_	_	Seg=O
281	in	_	_	_	_	_	_	_	Seg=O
282	bovine	_	_	_	_	_	_	_	Seg=O
283	respiratory	_	_	_	_	_	_	_	Seg=O
284	disease	_	_	_	_	_	_	_	Seg=O
285	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0c44f901baca3850ff6e79e5f26ee898faa9b68d
1	Emerging	_	_	_	_	_	_	_	Seg=B-seg
2	and	_	_	_	_	_	_	_	Seg=O
3	re	_	_	_	_	_	_	_	Seg=O
4	-	_	_	_	_	_	_	_	Seg=O
5	emerging	_	_	_	_	_	_	_	Seg=O
6	infectious	_	_	_	_	_	_	_	Seg=O
7	diseases	_	_	_	_	_	_	_	Seg=O
8	,	_	_	_	_	_	_	_	Seg=O
9	and	_	_	_	_	_	_	_	Seg=O
10	their	_	_	_	_	_	_	_	Seg=O
11	determinants	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	have	_	_	_	_	_	_	_	Seg=O
14	recently	_	_	_	_	_	_	_	Seg=O
15	attracted	_	_	_	_	_	_	_	Seg=O
16	substantial	_	_	_	_	_	_	_	Seg=O
17	scientific	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	popular	_	_	_	_	_	_	_	Seg=O
20	attention	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	HIV	_	_	_	_	_	_	_	Seg=B-seg
23	/	_	_	_	_	_	_	_	Seg=O
24	AIDS	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	severe	_	_	_	_	_	_	_	Seg=O
27	acute	_	_	_	_	_	_	_	Seg=O
28	respiratory	_	_	_	_	_	_	_	Seg=O
29	syndrome	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	H5N1	_	_	_	_	_	_	_	Seg=O
32	avian	_	_	_	_	_	_	_	Seg=O
33	influenza	_	_	_	_	_	_	_	Seg=O
34	,	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	many	_	_	_	_	_	_	_	Seg=O
37	other	_	_	_	_	_	_	_	Seg=O
38	emerging	_	_	_	_	_	_	_	Seg=O
39	diseases	_	_	_	_	_	_	_	Seg=O
40	have	_	_	_	_	_	_	_	Seg=O
41	either	_	_	_	_	_	_	_	Seg=O
42	proved	_	_	_	_	_	_	_	Seg=O
43	fatal	_	_	_	_	_	_	_	Seg=O
44	or	_	_	_	_	_	_	_	Seg=B-seg
45	caused	_	_	_	_	_	_	_	Seg=O
46	international	_	_	_	_	_	_	_	Seg=O
47	alarm	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	Common	_	_	_	_	_	_	_	Seg=B-seg
50	and	_	_	_	_	_	_	_	Seg=O
51	interactive	_	_	_	_	_	_	_	Seg=O
52	co	_	_	_	_	_	_	_	Seg=O
53	-	_	_	_	_	_	_	_	Seg=O
54	determinants	_	_	_	_	_	_	_	Seg=O
55	of	_	_	_	_	_	_	_	Seg=O
56	disease	_	_	_	_	_	_	_	Seg=O
57	emergence	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	including	_	_	_	_	_	_	_	Seg=B-seg
60	population	_	_	_	_	_	_	_	Seg=O
61	growth	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	travel	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	environmental	_	_	_	_	_	_	_	Seg=O
67	disruption	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	have	_	_	_	_	_	_	_	Seg=B-seg
70	been	_	_	_	_	_	_	_	Seg=O
71	increasingly	_	_	_	_	_	_	_	Seg=O
72	documented	_	_	_	_	_	_	_	Seg=O
73	and	_	_	_	_	_	_	_	Seg=B-seg
74	studied	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Are	_	_	_	_	_	_	_	Seg=B-seg
77	emerging	_	_	_	_	_	_	_	Seg=O
78	infections	_	_	_	_	_	_	_	Seg=O
79	a	_	_	_	_	_	_	_	Seg=O
80	new	_	_	_	_	_	_	_	Seg=O
81	phenomenon	_	_	_	_	_	_	_	Seg=O
82	related	_	_	_	_	_	_	_	Seg=B-seg
83	to	_	_	_	_	_	_	_	Seg=O
84	modern	_	_	_	_	_	_	_	Seg=O
85	life	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	or	_	_	_	_	_	_	_	Seg=B-seg
88	do	_	_	_	_	_	_	_	Seg=O
89	more	_	_	_	_	_	_	_	Seg=O
90	basic	_	_	_	_	_	_	_	Seg=O
91	determinants	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	transcending	_	_	_	_	_	_	_	Seg=B-seg
94	time	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	place	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	and	_	_	_	_	_	_	_	Seg=O
99	human	_	_	_	_	_	_	_	Seg=O
100	progress	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	govern	_	_	_	_	_	_	_	Seg=B-seg
103	disease	_	_	_	_	_	_	_	Seg=O
104	generation	_	_	_	_	_	_	_	Seg=O
105	?	_	_	_	_	_	_	_	Seg=O
106	By	_	_	_	_	_	_	_	Seg=B-seg
107	examining	_	_	_	_	_	_	_	Seg=O
108	a	_	_	_	_	_	_	_	Seg=O
109	number	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	historically	_	_	_	_	_	_	_	Seg=O
112	notable	_	_	_	_	_	_	_	Seg=O
113	epidemics	_	_	_	_	_	_	_	Seg=O
114	,	_	_	_	_	_	_	_	Seg=O
115	we	_	_	_	_	_	_	_	Seg=B-seg
116	suggest	_	_	_	_	_	_	_	Seg=O
117	that	_	_	_	_	_	_	_	Seg=B-seg
118	emerging	_	_	_	_	_	_	_	Seg=O
119	diseases	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	similar	_	_	_	_	_	_	_	Seg=B-seg
122	in	_	_	_	_	_	_	_	Seg=O
123	their	_	_	_	_	_	_	_	Seg=O
124	novelty	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	impact	_	_	_	_	_	_	_	Seg=O
127	,	_	_	_	_	_	_	_	Seg=O
128	and	_	_	_	_	_	_	_	Seg=O
129	elicitation	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	control	_	_	_	_	_	_	_	Seg=O
132	responses	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	have	_	_	_	_	_	_	_	Seg=B-seg
135	occurred	_	_	_	_	_	_	_	Seg=O
136	throughout	_	_	_	_	_	_	_	Seg=O
137	recorded	_	_	_	_	_	_	_	Seg=O
138	history	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	Fundamental	_	_	_	_	_	_	_	Seg=B-seg
141	determinants	_	_	_	_	_	_	_	Seg=O
142	,	_	_	_	_	_	_	_	Seg=O
143	typically	_	_	_	_	_	_	_	Seg=B-seg
144	acting	_	_	_	_	_	_	_	Seg=O
145	in	_	_	_	_	_	_	_	Seg=O
146	concert	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	seem	_	_	_	_	_	_	_	Seg=B-seg
149	to	_	_	_	_	_	_	_	Seg=O
150	underlie	_	_	_	_	_	_	_	Seg=O
151	their	_	_	_	_	_	_	_	Seg=O
152	emergence	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	and	_	_	_	_	_	_	_	Seg=B-seg
155	infections	_	_	_	_	_	_	_	Seg=O
156	such	_	_	_	_	_	_	_	Seg=O
157	as	_	_	_	_	_	_	_	Seg=O
158	these	_	_	_	_	_	_	_	Seg=O
159	are	_	_	_	_	_	_	_	Seg=O
160	likely	_	_	_	_	_	_	_	Seg=O
161	to	_	_	_	_	_	_	_	Seg=O
162	continue	_	_	_	_	_	_	_	Seg=O
163	to	_	_	_	_	_	_	_	Seg=O
164	remain	_	_	_	_	_	_	_	Seg=O
165	challenges	_	_	_	_	_	_	_	Seg=O
166	to	_	_	_	_	_	_	_	Seg=O
167	human	_	_	_	_	_	_	_	Seg=O
168	survival	_	_	_	_	_	_	_	Seg=O
169	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1399e34d62b515e482ccde6c4cae500b19546909
1	Influenza	_	_	_	_	_	_	_	Seg=B-seg
2	viruses	_	_	_	_	_	_	_	Seg=O
3	are	_	_	_	_	_	_	_	Seg=O
4	among	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	major	_	_	_	_	_	_	_	Seg=O
7	infectious	_	_	_	_	_	_	_	Seg=O
8	disease	_	_	_	_	_	_	_	Seg=O
9	threats	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	animal	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	human	_	_	_	_	_	_	_	Seg=O
14	health	_	_	_	_	_	_	_	Seg=O
15	.	_	_	_	_	_	_	_	Seg=O
16	This	_	_	_	_	_	_	_	Seg=B-seg
17	review	_	_	_	_	_	_	_	Seg=O
18	examines	_	_	_	_	_	_	_	Seg=O
19	the	_	_	_	_	_	_	_	Seg=O
20	recent	_	_	_	_	_	_	_	Seg=O
21	discovery	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	novel	_	_	_	_	_	_	_	Seg=O
24	influenza	_	_	_	_	_	_	_	Seg=O
25	viruses	_	_	_	_	_	_	_	Seg=O
26	in	_	_	_	_	_	_	_	Seg=O
27	bats	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	cattle	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	evolving	_	_	_	_	_	_	_	Seg=O
33	complexity	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	influenza	_	_	_	_	_	_	_	Seg=O
36	virus	_	_	_	_	_	_	_	Seg=O
37	host	_	_	_	_	_	_	_	Seg=O
38	range	_	_	_	_	_	_	_	Seg=O
39	including	_	_	_	_	_	_	_	Seg=B-seg
40	the	_	_	_	_	_	_	_	Seg=O
41	ability	_	_	_	_	_	_	_	Seg=O
42	to	_	_	_	_	_	_	_	Seg=B-seg
43	cross	_	_	_	_	_	_	_	Seg=O
44	species	_	_	_	_	_	_	_	Seg=O
45	barriers	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=O
47	geographic	_	_	_	_	_	_	_	Seg=O
48	boundaries	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	and	_	_	_	_	_	_	_	Seg=B-seg
51	implications	_	_	_	_	_	_	_	Seg=O
52	to	_	_	_	_	_	_	_	Seg=O
53	animal	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=O
55	human	_	_	_	_	_	_	_	Seg=O
56	health	_	_	_	_	_	_	_	Seg=O
57	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 13e4291652008b528006f89f67d55955c2aac729
1	Hepatitis	_	_	_	_	_	_	_	Seg=B-seg
2	B	_	_	_	_	_	_	_	Seg=O
3	virus	_	_	_	_	_	_	_	Seg=O
4	(	_	_	_	_	_	_	_	Seg=O
5	HBV	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	a	_	_	_	_	_	_	_	Seg=O
9	DNA	_	_	_	_	_	_	_	Seg=O
10	virus	_	_	_	_	_	_	_	Seg=O
11	that	_	_	_	_	_	_	_	Seg=B-seg
12	infects	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	liver	_	_	_	_	_	_	_	Seg=O
15	as	_	_	_	_	_	_	_	Seg=O
16	primary	_	_	_	_	_	_	_	Seg=O
17	target	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	Currently	_	_	_	_	_	_	_	Seg=B-seg
20	,	_	_	_	_	_	_	_	Seg=O
21	a	_	_	_	_	_	_	_	Seg=O
22	high	_	_	_	_	_	_	_	Seg=O
23	affinity	_	_	_	_	_	_	_	Seg=O
24	receptor	_	_	_	_	_	_	_	Seg=O
25	for	_	_	_	_	_	_	_	Seg=O
26	HBV	_	_	_	_	_	_	_	Seg=O
27	is	_	_	_	_	_	_	_	Seg=O
28	still	_	_	_	_	_	_	_	Seg=O
29	unknown	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	The	_	_	_	_	_	_	_	Seg=B-seg
32	dendritic	_	_	_	_	_	_	_	Seg=O
33	cell	_	_	_	_	_	_	_	Seg=O
34	specific	_	_	_	_	_	_	_	Seg=O
35	C	_	_	_	_	_	_	_	Seg=O
36	-	_	_	_	_	_	_	_	Seg=O
37	type	_	_	_	_	_	_	_	Seg=O
38	lectin	_	_	_	_	_	_	_	Seg=O
39	DC	_	_	_	_	_	_	_	Seg=O
40	-	_	_	_	_	_	_	_	Seg=O
41	SIGN	_	_	_	_	_	_	_	Seg=O
42	is	_	_	_	_	_	_	_	Seg=O
43	involved	_	_	_	_	_	_	_	Seg=O
44	in	_	_	_	_	_	_	_	Seg=O
45	pathogen	_	_	_	_	_	_	_	Seg=O
46	recognition	_	_	_	_	_	_	_	Seg=O
47	through	_	_	_	_	_	_	_	Seg=O
48	mannose	_	_	_	_	_	_	_	Seg=O
49	and	_	_	_	_	_	_	_	Seg=O
50	fucose	_	_	_	_	_	_	_	Seg=O
51	containing	_	_	_	_	_	_	_	Seg=B-seg
52	carbohydrates	_	_	_	_	_	_	_	Seg=O
53	leading	_	_	_	_	_	_	_	Seg=B-seg
54	to	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	induction	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	an	_	_	_	_	_	_	_	Seg=O
59	anti	_	_	_	_	_	_	_	Seg=O
60	-	_	_	_	_	_	_	_	Seg=O
61	viral	_	_	_	_	_	_	_	Seg=O
62	immune	_	_	_	_	_	_	_	Seg=O
63	response	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	Many	_	_	_	_	_	_	_	Seg=B-seg
66	glycosylated	_	_	_	_	_	_	_	Seg=O
67	viruses	_	_	_	_	_	_	_	Seg=O
68	subvert	_	_	_	_	_	_	_	Seg=O
69	this	_	_	_	_	_	_	_	Seg=O
70	immune	_	_	_	_	_	_	_	Seg=O
71	surveillance	_	_	_	_	_	_	_	Seg=O
72	function	_	_	_	_	_	_	_	Seg=O
73	and	_	_	_	_	_	_	_	Seg=B-seg
74	exploit	_	_	_	_	_	_	_	Seg=O
75	DC	_	_	_	_	_	_	_	Seg=O
76	-	_	_	_	_	_	_	_	Seg=O
77	SIGN	_	_	_	_	_	_	_	Seg=O
78	as	_	_	_	_	_	_	_	Seg=O
79	a	_	_	_	_	_	_	_	Seg=O
80	port	_	_	_	_	_	_	_	Seg=O
81	of	_	_	_	_	_	_	_	Seg=O
82	entry	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	for	_	_	_	_	_	_	_	Seg=O
85	trans	_	_	_	_	_	_	_	Seg=O
86	-	_	_	_	_	_	_	_	Seg=O
87	infection	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=O
89	target	_	_	_	_	_	_	_	Seg=O
90	cells	_	_	_	_	_	_	_	Seg=O
91	.	_	_	_	_	_	_	_	Seg=O
92	The	_	_	_	_	_	_	_	Seg=B-seg
93	glycosylation	_	_	_	_	_	_	_	Seg=O
94	pattern	_	_	_	_	_	_	_	Seg=O
95	on	_	_	_	_	_	_	_	Seg=O
96	HBV	_	_	_	_	_	_	_	Seg=O
97	surface	_	_	_	_	_	_	_	Seg=O
98	antigens	_	_	_	_	_	_	_	Seg=O
99	(	_	_	_	_	_	_	_	Seg=O
100	HBsAg	_	_	_	_	_	_	_	Seg=O
101	)	_	_	_	_	_	_	_	Seg=O
102	together	_	_	_	_	_	_	_	Seg=O
103	with	_	_	_	_	_	_	_	Seg=O
104	the	_	_	_	_	_	_	_	Seg=O
105	tissue	_	_	_	_	_	_	_	Seg=O
106	distribution	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	HBV	_	_	_	_	_	_	_	Seg=O
109	would	_	_	_	_	_	_	_	Seg=O
110	allow	_	_	_	_	_	_	_	Seg=O
111	interaction	_	_	_	_	_	_	_	Seg=O
112	between	_	_	_	_	_	_	_	Seg=O
113	HBV	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	DC	_	_	_	_	_	_	_	Seg=O
116	-	_	_	_	_	_	_	_	Seg=O
117	SIGN	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	its	_	_	_	_	_	_	_	Seg=O
120	liver	_	_	_	_	_	_	_	Seg=O
121	-	_	_	_	_	_	_	_	Seg=O
122	expressed	_	_	_	_	_	_	_	Seg=O
123	homologue	_	_	_	_	_	_	_	Seg=O
124	L	_	_	_	_	_	_	_	Seg=O
125	-	_	_	_	_	_	_	_	Seg=O
126	SIGN	_	_	_	_	_	_	_	Seg=O
127	.	_	_	_	_	_	_	_	Seg=O
128	Therefore	_	_	_	_	_	_	_	Seg=B-seg
129	,	_	_	_	_	_	_	_	Seg=O
130	a	_	_	_	_	_	_	_	Seg=O
131	detailed	_	_	_	_	_	_	_	Seg=O
132	study	_	_	_	_	_	_	_	Seg=O
133	to	_	_	_	_	_	_	_	Seg=B-seg
134	investigate	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	binding	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	HBV	_	_	_	_	_	_	_	Seg=O
139	to	_	_	_	_	_	_	_	Seg=O
140	DC	_	_	_	_	_	_	_	Seg=O
141	-	_	_	_	_	_	_	_	Seg=O
142	SIGN	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=O
144	L	_	_	_	_	_	_	_	Seg=O
145	-	_	_	_	_	_	_	_	Seg=O
146	SIGN	_	_	_	_	_	_	_	Seg=O
147	was	_	_	_	_	_	_	_	Seg=B-seg
148	performed	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	For	_	_	_	_	_	_	_	Seg=B-seg
151	HCV	_	_	_	_	_	_	_	Seg=O
152	,	_	_	_	_	_	_	_	Seg=O
153	both	_	_	_	_	_	_	_	Seg=O
154	DC	_	_	_	_	_	_	_	Seg=O
155	-	_	_	_	_	_	_	_	Seg=O
156	SIGN	_	_	_	_	_	_	_	Seg=O
157	and	_	_	_	_	_	_	_	Seg=O
158	L	_	_	_	_	_	_	_	Seg=O
159	-	_	_	_	_	_	_	_	Seg=O
160	SIGN	_	_	_	_	_	_	_	Seg=O
161	are	_	_	_	_	_	_	_	Seg=O
162	known	_	_	_	_	_	_	_	Seg=O
163	to	_	_	_	_	_	_	_	Seg=O
164	bind	_	_	_	_	_	_	_	Seg=O
165	envelope	_	_	_	_	_	_	_	Seg=O
166	glycoproteins	_	_	_	_	_	_	_	Seg=O
167	E1	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=O
169	E2	_	_	_	_	_	_	_	Seg=O
170	.	_	_	_	_	_	_	_	Seg=O
171	Soluble	_	_	_	_	_	_	_	Seg=B-seg
172	DC	_	_	_	_	_	_	_	Seg=O
173	-	_	_	_	_	_	_	_	Seg=O
174	SIGN	_	_	_	_	_	_	_	Seg=O
175	and	_	_	_	_	_	_	_	Seg=O
176	L	_	_	_	_	_	_	_	Seg=O
177	-	_	_	_	_	_	_	_	Seg=O
178	SIGN	_	_	_	_	_	_	_	Seg=O
179	specifically	_	_	_	_	_	_	_	Seg=O
180	bound	_	_	_	_	_	_	_	Seg=O
181	HCV	_	_	_	_	_	_	_	Seg=O
182	virus	_	_	_	_	_	_	_	Seg=O
183	-	_	_	_	_	_	_	_	Seg=O
184	like	_	_	_	_	_	_	_	Seg=O
185	particles	_	_	_	_	_	_	_	Seg=O
186	,	_	_	_	_	_	_	_	Seg=O
187	but	_	_	_	_	_	_	_	Seg=B-seg
188	no	_	_	_	_	_	_	_	Seg=O
189	interaction	_	_	_	_	_	_	_	Seg=O
190	with	_	_	_	_	_	_	_	Seg=O
191	either	_	_	_	_	_	_	_	Seg=O
192	HBsAg	_	_	_	_	_	_	_	Seg=O
193	or	_	_	_	_	_	_	_	Seg=O
194	HepG2.2.15-derived	_	_	_	_	_	_	_	Seg=O
195	HBV	_	_	_	_	_	_	_	Seg=O
196	was	_	_	_	_	_	_	_	Seg=O
197	detected	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	Also	_	_	_	_	_	_	_	Seg=B-seg
200	,	_	_	_	_	_	_	_	Seg=O
201	neither	_	_	_	_	_	_	_	Seg=O
202	DC	_	_	_	_	_	_	_	Seg=O
203	-	_	_	_	_	_	_	_	Seg=O
204	SIGN	_	_	_	_	_	_	_	Seg=O
205	nor	_	_	_	_	_	_	_	Seg=O
206	L	_	_	_	_	_	_	_	Seg=O
207	-	_	_	_	_	_	_	_	Seg=O
208	SIGN	_	_	_	_	_	_	_	Seg=O
209	transfected	_	_	_	_	_	_	_	Seg=O
210	Raji	_	_	_	_	_	_	_	Seg=O
211	cells	_	_	_	_	_	_	_	Seg=O
212	bound	_	_	_	_	_	_	_	Seg=O
213	HBsAg	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O
215	In	_	_	_	_	_	_	_	Seg=B-seg
216	contrast	_	_	_	_	_	_	_	Seg=O
217	,	_	_	_	_	_	_	_	Seg=O
218	highly	_	_	_	_	_	_	_	Seg=O
219	mannosylated	_	_	_	_	_	_	_	Seg=O
220	HBV	_	_	_	_	_	_	_	Seg=O
221	,	_	_	_	_	_	_	_	Seg=O
222	obtained	_	_	_	_	_	_	_	Seg=B-seg
223	by	_	_	_	_	_	_	_	Seg=B-seg
224	treating	_	_	_	_	_	_	_	Seg=O
225	HBV	_	_	_	_	_	_	_	Seg=O
226	producing	_	_	_	_	_	_	_	Seg=O
227	HepG2.2.15	_	_	_	_	_	_	_	Seg=O
228	cells	_	_	_	_	_	_	_	Seg=O
229	with	_	_	_	_	_	_	_	Seg=O
230	the	_	_	_	_	_	_	_	Seg=O
231	a	_	_	_	_	_	_	_	Seg=O
232	-	_	_	_	_	_	_	_	Seg=O
233	mannosidase	_	_	_	_	_	_	_	Seg=O
234	I	_	_	_	_	_	_	_	Seg=O
235	inhibitor	_	_	_	_	_	_	_	Seg=O
236	kifunensine	_	_	_	_	_	_	_	Seg=O
237	,	_	_	_	_	_	_	_	Seg=O
238	is	_	_	_	_	_	_	_	Seg=B-seg
239	recognized	_	_	_	_	_	_	_	Seg=O
240	by	_	_	_	_	_	_	_	Seg=O
241	DC	_	_	_	_	_	_	_	Seg=O
242	-	_	_	_	_	_	_	_	Seg=O
243	SIGN	_	_	_	_	_	_	_	Seg=O
244	.	_	_	_	_	_	_	_	Seg=O
245	The	_	_	_	_	_	_	_	Seg=B-seg
246	a	_	_	_	_	_	_	_	Seg=O
247	-	_	_	_	_	_	_	_	Seg=O
248	mannosidase	_	_	_	_	_	_	_	Seg=O
249	I	_	_	_	_	_	_	_	Seg=O
250	trimming	_	_	_	_	_	_	_	Seg=O
251	of	_	_	_	_	_	_	_	Seg=O
252	N	_	_	_	_	_	_	_	Seg=O
253	-	_	_	_	_	_	_	_	Seg=O
254	linked	_	_	_	_	_	_	_	Seg=O
255	oligosaccharide	_	_	_	_	_	_	_	Seg=O
256	structures	_	_	_	_	_	_	_	Seg=O
257	thus	_	_	_	_	_	_	_	Seg=O
258	prevents	_	_	_	_	_	_	_	Seg=O
259	recognition	_	_	_	_	_	_	_	Seg=O
260	by	_	_	_	_	_	_	_	Seg=O
261	DC	_	_	_	_	_	_	_	Seg=O
262	-	_	_	_	_	_	_	_	Seg=O
263	SIGN	_	_	_	_	_	_	_	Seg=O
264	.	_	_	_	_	_	_	_	Seg=O
265	On	_	_	_	_	_	_	_	Seg=B-seg
266	the	_	_	_	_	_	_	_	Seg=O
267	basis	_	_	_	_	_	_	_	Seg=O
268	of	_	_	_	_	_	_	_	Seg=O
269	these	_	_	_	_	_	_	_	Seg=O
270	findings	_	_	_	_	_	_	_	Seg=O
271	,	_	_	_	_	_	_	_	Seg=O
272	it	_	_	_	_	_	_	_	Seg=O
273	is	_	_	_	_	_	_	_	Seg=O
274	tempting	_	_	_	_	_	_	_	Seg=O
275	to	_	_	_	_	_	_	_	Seg=O
276	speculate	_	_	_	_	_	_	_	Seg=O
277	that	_	_	_	_	_	_	_	Seg=O
278	HBV	_	_	_	_	_	_	_	Seg=O
279	exploits	_	_	_	_	_	_	_	Seg=O
280	mannose	_	_	_	_	_	_	_	Seg=O
281	trimming	_	_	_	_	_	_	_	Seg=O
282	as	_	_	_	_	_	_	_	Seg=O
283	a	_	_	_	_	_	_	_	Seg=O
284	way	_	_	_	_	_	_	_	Seg=O
285	to	_	_	_	_	_	_	_	Seg=B-seg
286	escape	_	_	_	_	_	_	_	Seg=O
287	recognition	_	_	_	_	_	_	_	Seg=O
288	by	_	_	_	_	_	_	_	Seg=O
289	DC	_	_	_	_	_	_	_	Seg=O
290	-	_	_	_	_	_	_	_	Seg=O
291	SIGN	_	_	_	_	_	_	_	Seg=O
292	and	_	_	_	_	_	_	_	Seg=B-seg
293	thereby	_	_	_	_	_	_	_	Seg=O
294	subvert	_	_	_	_	_	_	_	Seg=O
295	a	_	_	_	_	_	_	_	Seg=O
296	possible	_	_	_	_	_	_	_	Seg=O
297	immune	_	_	_	_	_	_	_	Seg=O
298	activation	_	_	_	_	_	_	_	Seg=O
299	response	_	_	_	_	_	_	_	Seg=O
300	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1723e7c27aadbc83619fd69629fcc089e700418b
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	COVID-19	_	_	_	_	_	_	_	Seg=O
3	pandemic	_	_	_	_	_	_	_	Seg=O
4	has	_	_	_	_	_	_	_	Seg=O
5	forced	_	_	_	_	_	_	_	Seg=O
6	us	_	_	_	_	_	_	_	Seg=O
7	to	_	_	_	_	_	_	_	Seg=O
8	consider	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	physiologic	_	_	_	_	_	_	_	Seg=O
11	role	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	obesity	_	_	_	_	_	_	_	Seg=O
14	in	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	response	_	_	_	_	_	_	_	Seg=O
17	to	_	_	_	_	_	_	_	Seg=O
18	infectious	_	_	_	_	_	_	_	Seg=O
19	disease	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	There	_	_	_	_	_	_	_	Seg=B-seg
22	are	_	_	_	_	_	_	_	Seg=O
23	significant	_	_	_	_	_	_	_	Seg=O
24	disparities	_	_	_	_	_	_	_	Seg=O
25	in	_	_	_	_	_	_	_	Seg=O
26	morbidity	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=O
28	mortality	_	_	_	_	_	_	_	Seg=O
29	by	_	_	_	_	_	_	_	Seg=O
30	sex	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	weight	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	diabetes	_	_	_	_	_	_	_	Seg=O
35	status	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	Numerous	_	_	_	_	_	_	_	Seg=B-seg
38	endocrine	_	_	_	_	_	_	_	Seg=O
39	changes	_	_	_	_	_	_	_	Seg=O
40	might	_	_	_	_	_	_	_	Seg=O
41	drive	_	_	_	_	_	_	_	Seg=O
42	these	_	_	_	_	_	_	_	Seg=O
43	varied	_	_	_	_	_	_	_	Seg=O
44	responses	_	_	_	_	_	_	_	Seg=O
45	to	_	_	_	_	_	_	_	Seg=O
46	SARS	_	_	_	_	_	_	_	Seg=O
47	-	_	_	_	_	_	_	_	Seg=O
48	CoV-2	_	_	_	_	_	_	_	Seg=O
49	infection	_	_	_	_	_	_	_	Seg=O
50	including	_	_	_	_	_	_	_	Seg=B-seg
51	hormone	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	immune	_	_	_	_	_	_	_	Seg=O
54	mediators	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	hyperglycemia	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	leukocyte	_	_	_	_	_	_	_	Seg=O
59	responses	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	cytokine	_	_	_	_	_	_	_	Seg=O
62	secretion	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	tissue	_	_	_	_	_	_	_	Seg=O
66	dysfunction	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	Studies	_	_	_	_	_	_	_	Seg=B-seg
69	of	_	_	_	_	_	_	_	Seg=O
70	patients	_	_	_	_	_	_	_	Seg=O
71	with	_	_	_	_	_	_	_	Seg=O
72	severe	_	_	_	_	_	_	_	Seg=O
73	COVID-19	_	_	_	_	_	_	_	Seg=O
74	disease	_	_	_	_	_	_	_	Seg=O
75	have	_	_	_	_	_	_	_	Seg=O
76	revealed	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	importance	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	innate	_	_	_	_	_	_	_	Seg=O
81	immune	_	_	_	_	_	_	_	Seg=O
82	responses	_	_	_	_	_	_	_	Seg=O
83	in	_	_	_	_	_	_	_	Seg=B-seg
84	driving	_	_	_	_	_	_	_	Seg=O
85	immunopathology	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	tissue	_	_	_	_	_	_	_	Seg=O
88	injury	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O
90	In	_	_	_	_	_	_	_	Seg=B-seg
91	this	_	_	_	_	_	_	_	Seg=O
92	review	_	_	_	_	_	_	_	Seg=O
93	we	_	_	_	_	_	_	_	Seg=O
94	will	_	_	_	_	_	_	_	Seg=O
95	describe	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	impact	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	metabolically	_	_	_	_	_	_	_	Seg=O
101	induced	_	_	_	_	_	_	_	Seg=O
102	inflammation	_	_	_	_	_	_	_	Seg=O
103	(	_	_	_	_	_	_	_	Seg=O
104	meta	_	_	_	_	_	_	_	Seg=O
105	-	_	_	_	_	_	_	_	Seg=O
106	inflammation	_	_	_	_	_	_	_	Seg=O
107	)	_	_	_	_	_	_	_	Seg=O
108	that	_	_	_	_	_	_	_	Seg=B-seg
109	characterizes	_	_	_	_	_	_	_	Seg=O
110	obesity	_	_	_	_	_	_	_	Seg=O
111	on	_	_	_	_	_	_	_	Seg=O
112	innate	_	_	_	_	_	_	_	Seg=O
113	immunity	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	We	_	_	_	_	_	_	_	Seg=B-seg
116	consider	_	_	_	_	_	_	_	Seg=O
117	that	_	_	_	_	_	_	_	Seg=B-seg
118	obesity	_	_	_	_	_	_	_	Seg=O
119	-	_	_	_	_	_	_	_	Seg=O
120	driven	_	_	_	_	_	_	_	Seg=O
121	dysregulation	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	innate	_	_	_	_	_	_	_	Seg=O
124	immune	_	_	_	_	_	_	_	Seg=O
125	responses	_	_	_	_	_	_	_	Seg=O
126	may	_	_	_	_	_	_	_	Seg=O
127	drive	_	_	_	_	_	_	_	Seg=O
128	organ	_	_	_	_	_	_	_	Seg=O
129	injury	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=O
131	development	_	_	_	_	_	_	_	Seg=O
132	of	_	_	_	_	_	_	_	Seg=O
133	severe	_	_	_	_	_	_	_	Seg=O
134	COVID-19	_	_	_	_	_	_	_	Seg=O
135	and	_	_	_	_	_	_	_	Seg=O
136	impair	_	_	_	_	_	_	_	Seg=O
137	viral	_	_	_	_	_	_	_	Seg=O
138	clearance	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 17c5d5036721bc5935b23a9e23f69fde366ecc20
1	We	_	_	_	_	_	_	_	Seg=B-seg
2	investigate	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	difference	_	_	_	_	_	_	_	Seg=O
5	in	_	_	_	_	_	_	_	Seg=O
6	the	_	_	_	_	_	_	_	Seg=O
7	spread	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	COVID-19	_	_	_	_	_	_	_	Seg=O
10	between	_	_	_	_	_	_	_	Seg=O
11	the	_	_	_	_	_	_	_	Seg=O
12	states	_	_	_	_	_	_	_	Seg=O
13	won	_	_	_	_	_	_	_	Seg=B-seg
14	by	_	_	_	_	_	_	_	Seg=O
15	Donald	_	_	_	_	_	_	_	Seg=O
16	Trump	_	_	_	_	_	_	_	Seg=O
17	(	_	_	_	_	_	_	_	Seg=O
18	Red	_	_	_	_	_	_	_	Seg=O
19	)	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=B-seg
21	the	_	_	_	_	_	_	_	Seg=O
22	states	_	_	_	_	_	_	_	Seg=O
23	won	_	_	_	_	_	_	_	Seg=B-seg
24	by	_	_	_	_	_	_	_	Seg=O
25	Hillary	_	_	_	_	_	_	_	Seg=O
26	Clinton	_	_	_	_	_	_	_	Seg=O
27	(	_	_	_	_	_	_	_	Seg=O
28	Blue	_	_	_	_	_	_	_	Seg=O
29	)	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	2016	_	_	_	_	_	_	_	Seg=O
33	presidential	_	_	_	_	_	_	_	Seg=O
34	election	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	by	_	_	_	_	_	_	_	Seg=B-seg
37	mining	_	_	_	_	_	_	_	Seg=O
38	transportation	_	_	_	_	_	_	_	Seg=O
39	patterns	_	_	_	_	_	_	_	Seg=O
40	of	_	_	_	_	_	_	_	Seg=O
41	US	_	_	_	_	_	_	_	Seg=O
42	residents	_	_	_	_	_	_	_	Seg=O
43	from	_	_	_	_	_	_	_	Seg=O
44	March	_	_	_	_	_	_	_	Seg=O
45	2020	_	_	_	_	_	_	_	Seg=O
46	to	_	_	_	_	_	_	_	Seg=O
47	July	_	_	_	_	_	_	_	Seg=O
48	2020	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	To	_	_	_	_	_	_	_	Seg=B-seg
51	ensure	_	_	_	_	_	_	_	Seg=O
52	a	_	_	_	_	_	_	_	Seg=O
53	fair	_	_	_	_	_	_	_	Seg=O
54	comparison	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	we	_	_	_	_	_	_	_	Seg=B-seg
57	first	_	_	_	_	_	_	_	Seg=O
58	use	_	_	_	_	_	_	_	Seg=O
59	a	_	_	_	_	_	_	_	Seg=O
60	K	_	_	_	_	_	_	_	Seg=O
61	-	_	_	_	_	_	_	_	Seg=O
62	means	_	_	_	_	_	_	_	Seg=O
63	clustering	_	_	_	_	_	_	_	Seg=O
64	method	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=B-seg
66	group	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	50	_	_	_	_	_	_	_	Seg=O
69	states	_	_	_	_	_	_	_	Seg=O
70	into	_	_	_	_	_	_	_	Seg=O
71	five	_	_	_	_	_	_	_	Seg=O
72	clusters	_	_	_	_	_	_	_	Seg=O
73	according	_	_	_	_	_	_	_	Seg=O
74	to	_	_	_	_	_	_	_	Seg=O
75	their	_	_	_	_	_	_	_	Seg=O
76	population	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	area	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	population	_	_	_	_	_	_	_	Seg=O
81	density	_	_	_	_	_	_	_	Seg=O
82	.	_	_	_	_	_	_	_	Seg=O
83	We	_	_	_	_	_	_	_	Seg=B-seg
84	then	_	_	_	_	_	_	_	Seg=O
85	characterize	_	_	_	_	_	_	_	Seg=O
86	daily	_	_	_	_	_	_	_	Seg=O
87	transportation	_	_	_	_	_	_	_	Seg=O
88	patterns	_	_	_	_	_	_	_	Seg=O
89	of	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	residents	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	different	_	_	_	_	_	_	_	Seg=O
94	states	_	_	_	_	_	_	_	Seg=O
95	using	_	_	_	_	_	_	_	Seg=B-seg
96	the	_	_	_	_	_	_	_	Seg=O
97	mean	_	_	_	_	_	_	_	Seg=O
98	percentage	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	residents	_	_	_	_	_	_	_	Seg=O
101	traveling	_	_	_	_	_	_	_	Seg=B-seg
102	and	_	_	_	_	_	_	_	Seg=B-seg
103	the	_	_	_	_	_	_	_	Seg=O
104	number	_	_	_	_	_	_	_	Seg=O
105	of	_	_	_	_	_	_	_	Seg=O
106	trips	_	_	_	_	_	_	_	Seg=O
107	per	_	_	_	_	_	_	_	Seg=O
108	person	_	_	_	_	_	_	_	Seg=O
109	.	_	_	_	_	_	_	_	Seg=O
110	For	_	_	_	_	_	_	_	Seg=B-seg
111	each	_	_	_	_	_	_	_	Seg=O
112	state	_	_	_	_	_	_	_	Seg=O
113	,	_	_	_	_	_	_	_	Seg=O
114	we	_	_	_	_	_	_	_	Seg=O
115	study	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	correlations	_	_	_	_	_	_	_	Seg=O
118	between	_	_	_	_	_	_	_	Seg=O
119	travel	_	_	_	_	_	_	_	Seg=O
120	patterns	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	infection	_	_	_	_	_	_	_	Seg=O
123	rate	_	_	_	_	_	_	_	Seg=O
124	for	_	_	_	_	_	_	_	Seg=O
125	a	_	_	_	_	_	_	_	Seg=O
126	2-month	_	_	_	_	_	_	_	Seg=O
127	period	_	_	_	_	_	_	_	Seg=O
128	before	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	after	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	official	_	_	_	_	_	_	_	Seg=O
133	states	_	_	_	_	_	_	_	Seg=O
134	reopening	_	_	_	_	_	_	_	Seg=O
135	dates	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	We	_	_	_	_	_	_	_	Seg=B-seg
138	observe	_	_	_	_	_	_	_	Seg=O
139	that	_	_	_	_	_	_	_	Seg=B-seg
140	during	_	_	_	_	_	_	_	Seg=O
141	the	_	_	_	_	_	_	_	Seg=O
142	lock	_	_	_	_	_	_	_	Seg=O
143	-	_	_	_	_	_	_	_	Seg=O
144	down	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	Red	_	_	_	_	_	_	_	Seg=O
147	and	_	_	_	_	_	_	_	Seg=O
148	Blue	_	_	_	_	_	_	_	Seg=O
149	states	_	_	_	_	_	_	_	Seg=O
150	both	_	_	_	_	_	_	_	Seg=O
151	displayed	_	_	_	_	_	_	_	Seg=O
152	strong	_	_	_	_	_	_	_	Seg=O
153	positive	_	_	_	_	_	_	_	Seg=O
154	correlations	_	_	_	_	_	_	_	Seg=O
155	between	_	_	_	_	_	_	_	Seg=O
156	their	_	_	_	_	_	_	_	Seg=O
157	travel	_	_	_	_	_	_	_	Seg=O
158	patterns	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	infection	_	_	_	_	_	_	_	Seg=O
161	rates	_	_	_	_	_	_	_	Seg=O
162	.	_	_	_	_	_	_	_	Seg=O
163	However	_	_	_	_	_	_	_	Seg=B-seg
164	,	_	_	_	_	_	_	_	Seg=O
165	after	_	_	_	_	_	_	_	Seg=B-seg
166	states	_	_	_	_	_	_	_	Seg=O
167	reopened	_	_	_	_	_	_	_	Seg=O
168	we	_	_	_	_	_	_	_	Seg=B-seg
169	find	_	_	_	_	_	_	_	Seg=O
170	that	_	_	_	_	_	_	_	Seg=B-seg
171	Red	_	_	_	_	_	_	_	Seg=O
172	states	_	_	_	_	_	_	_	Seg=O
173	had	_	_	_	_	_	_	_	Seg=O
174	higher	_	_	_	_	_	_	_	Seg=O
175	travel	_	_	_	_	_	_	_	Seg=O
176	-	_	_	_	_	_	_	_	Seg=O
177	infection	_	_	_	_	_	_	_	Seg=O
178	correlations	_	_	_	_	_	_	_	Seg=O
179	than	_	_	_	_	_	_	_	Seg=O
180	Blue	_	_	_	_	_	_	_	Seg=O
181	states	_	_	_	_	_	_	_	Seg=O
182	in	_	_	_	_	_	_	_	Seg=O
183	all	_	_	_	_	_	_	_	Seg=O
184	five	_	_	_	_	_	_	_	Seg=O
185	state	_	_	_	_	_	_	_	Seg=O
186	clusters	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	We	_	_	_	_	_	_	_	Seg=B-seg
189	find	_	_	_	_	_	_	_	Seg=O
190	that	_	_	_	_	_	_	_	Seg=B-seg
191	the	_	_	_	_	_	_	_	Seg=O
192	residents	_	_	_	_	_	_	_	Seg=O
193	of	_	_	_	_	_	_	_	Seg=O
194	both	_	_	_	_	_	_	_	Seg=O
195	Red	_	_	_	_	_	_	_	Seg=O
196	and	_	_	_	_	_	_	_	Seg=O
197	Blue	_	_	_	_	_	_	_	Seg=O
198	states	_	_	_	_	_	_	_	Seg=O
199	displayed	_	_	_	_	_	_	_	Seg=O
200	similar	_	_	_	_	_	_	_	Seg=O
201	travel	_	_	_	_	_	_	_	Seg=O
202	patterns	_	_	_	_	_	_	_	Seg=O
203	during	_	_	_	_	_	_	_	Seg=O
204	the	_	_	_	_	_	_	_	Seg=O
205	period	_	_	_	_	_	_	_	Seg=O
206	post	_	_	_	_	_	_	_	Seg=O
207	the	_	_	_	_	_	_	_	Seg=O
208	reopening	_	_	_	_	_	_	_	Seg=O
209	of	_	_	_	_	_	_	_	Seg=O
210	states	_	_	_	_	_	_	_	Seg=O
211	,	_	_	_	_	_	_	_	Seg=O
212	leading	_	_	_	_	_	_	_	Seg=B-seg
213	us	_	_	_	_	_	_	_	Seg=O
214	to	_	_	_	_	_	_	_	Seg=O
215	conclude	_	_	_	_	_	_	_	Seg=O
216	that	_	_	_	_	_	_	_	Seg=B-seg
217	,	_	_	_	_	_	_	_	Seg=O
218	on	_	_	_	_	_	_	_	Seg=O
219	average	_	_	_	_	_	_	_	Seg=O
220	,	_	_	_	_	_	_	_	Seg=O
221	the	_	_	_	_	_	_	_	Seg=O
222	residents	_	_	_	_	_	_	_	Seg=O
223	in	_	_	_	_	_	_	_	Seg=O
224	Red	_	_	_	_	_	_	_	Seg=O
225	states	_	_	_	_	_	_	_	Seg=O
226	might	_	_	_	_	_	_	_	Seg=O
227	be	_	_	_	_	_	_	_	Seg=O
228	mobilizing	_	_	_	_	_	_	_	Seg=O
229	less	_	_	_	_	_	_	_	Seg=O
230	safely	_	_	_	_	_	_	_	Seg=O
231	than	_	_	_	_	_	_	_	Seg=O
232	the	_	_	_	_	_	_	_	Seg=O
233	residents	_	_	_	_	_	_	_	Seg=O
234	in	_	_	_	_	_	_	_	Seg=O
235	Blue	_	_	_	_	_	_	_	Seg=O
236	states	_	_	_	_	_	_	_	Seg=O
237	.	_	_	_	_	_	_	_	Seg=O
238	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
239	,	_	_	_	_	_	_	_	Seg=O
240	we	_	_	_	_	_	_	_	Seg=O
241	use	_	_	_	_	_	_	_	Seg=O
242	temperature	_	_	_	_	_	_	_	Seg=O
243	data	_	_	_	_	_	_	_	Seg=O
244	to	_	_	_	_	_	_	_	Seg=B-seg
245	attempt	_	_	_	_	_	_	_	Seg=O
246	to	_	_	_	_	_	_	_	Seg=O
247	explain	_	_	_	_	_	_	_	Seg=O
248	the	_	_	_	_	_	_	_	Seg=O
249	difference	_	_	_	_	_	_	_	Seg=O
250	in	_	_	_	_	_	_	_	Seg=O
251	the	_	_	_	_	_	_	_	Seg=O
252	way	_	_	_	_	_	_	_	Seg=O
253	residents	_	_	_	_	_	_	_	Seg=B-seg
254	travel	_	_	_	_	_	_	_	Seg=O
255	and	_	_	_	_	_	_	_	Seg=O
256	practice	_	_	_	_	_	_	_	Seg=O
257	safety	_	_	_	_	_	_	_	Seg=O
258	measures	_	_	_	_	_	_	_	Seg=O
259	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1b7c700ee3a33c0a675a5f7e71a20ce62467b900
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Human	_	_	_	_	_	_	_	Seg=B-seg
4	immunodeficiency	_	_	_	_	_	_	_	Seg=O
5	virus	_	_	_	_	_	_	_	Seg=O
6	type	_	_	_	_	_	_	_	Seg=O
7	1	_	_	_	_	_	_	_	Seg=O
8	(	_	_	_	_	_	_	_	Seg=O
9	HIV-1	_	_	_	_	_	_	_	Seg=O
10	)	_	_	_	_	_	_	_	Seg=O
11	has	_	_	_	_	_	_	_	Seg=O
12	infected	_	_	_	_	_	_	_	Seg=O
13	more	_	_	_	_	_	_	_	Seg=O
14	than	_	_	_	_	_	_	_	Seg=O
15	40	_	_	_	_	_	_	_	Seg=O
16	million	_	_	_	_	_	_	_	Seg=O
17	people	_	_	_	_	_	_	_	Seg=O
18	worldwide	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	mainly	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	sub	_	_	_	_	_	_	_	Seg=O
23	-	_	_	_	_	_	_	_	Seg=O
24	Saharan	_	_	_	_	_	_	_	Seg=O
25	Africa	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	The	_	_	_	_	_	_	_	Seg=B-seg
28	high	_	_	_	_	_	_	_	Seg=O
29	prevalence	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=O
31	HIV-1	_	_	_	_	_	_	_	Seg=O
32	subtype	_	_	_	_	_	_	_	Seg=O
33	C	_	_	_	_	_	_	_	Seg=O
34	in	_	_	_	_	_	_	_	Seg=O
35	southern	_	_	_	_	_	_	_	Seg=O
36	Africa	_	_	_	_	_	_	_	Seg=O
37	necessitates	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	development	_	_	_	_	_	_	_	Seg=O
40	of	_	_	_	_	_	_	_	Seg=O
41	cheap	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	effective	_	_	_	_	_	_	_	Seg=O
44	vaccines	_	_	_	_	_	_	_	Seg=O
45	.	_	_	_	_	_	_	_	Seg=O
46	One	_	_	_	_	_	_	_	Seg=B-seg
47	means	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	production	_	_	_	_	_	_	_	Seg=O
50	is	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	use	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	plants	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	for	_	_	_	_	_	_	_	Seg=B-seg
57	which	_	_	_	_	_	_	_	Seg=O
58	a	_	_	_	_	_	_	_	Seg=O
59	number	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	different	_	_	_	_	_	_	_	Seg=O
62	techniques	_	_	_	_	_	_	_	Seg=O
63	have	_	_	_	_	_	_	_	Seg=O
64	been	_	_	_	_	_	_	_	Seg=O
65	successfully	_	_	_	_	_	_	_	Seg=O
66	developed	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	HIV-1	_	_	_	_	_	_	_	Seg=B-seg
69	Pr55Gag	_	_	_	_	_	_	_	Seg=O
70	is	_	_	_	_	_	_	_	Seg=O
71	a	_	_	_	_	_	_	_	Seg=O
72	promising	_	_	_	_	_	_	_	Seg=O
73	HIV-1	_	_	_	_	_	_	_	Seg=O
74	vaccine	_	_	_	_	_	_	_	Seg=O
75	candidate	_	_	_	_	_	_	_	Seg=O
76	:	_	_	_	_	_	_	_	Seg=O
77	we	_	_	_	_	_	_	_	Seg=B-seg
78	compared	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	expression	_	_	_	_	_	_	_	Seg=O
81	of	_	_	_	_	_	_	_	Seg=O
82	this	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	a	_	_	_	_	_	_	_	Seg=O
85	truncated	_	_	_	_	_	_	_	Seg=O
86	Gag	_	_	_	_	_	_	_	Seg=O
87	(	_	_	_	_	_	_	_	Seg=O
88	p17	_	_	_	_	_	_	_	Seg=O
89	/	_	_	_	_	_	_	_	Seg=O
90	p24	_	_	_	_	_	_	_	Seg=O
91	)	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	p24	_	_	_	_	_	_	_	Seg=O
95	capsid	_	_	_	_	_	_	_	Seg=O
96	subunit	_	_	_	_	_	_	_	Seg=O
97	in	_	_	_	_	_	_	_	Seg=O
98	Nicotiana	_	_	_	_	_	_	_	Seg=O
99	spp	_	_	_	_	_	_	_	Seg=O
100	.	_	_	_	_	_	_	_	Seg=O
101	using	_	_	_	_	_	_	_	Seg=B-seg
102	transgenic	_	_	_	_	_	_	_	Seg=O
103	plants	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	transient	_	_	_	_	_	_	_	Seg=O
106	expression	_	_	_	_	_	_	_	Seg=O
107	via	_	_	_	_	_	_	_	Seg=O
108	Agrobacterium	_	_	_	_	_	_	_	Seg=O
109	tumefaciens	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=O
111	recombinant	_	_	_	_	_	_	_	Seg=O
112	tobamovirus	_	_	_	_	_	_	_	Seg=O
113	vectors	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	We	_	_	_	_	_	_	_	Seg=B-seg
116	also	_	_	_	_	_	_	_	Seg=O
117	investigated	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	influence	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	subcellular	_	_	_	_	_	_	_	Seg=O
122	localisation	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	recombinant	_	_	_	_	_	_	_	Seg=O
125	protein	_	_	_	_	_	_	_	Seg=O
126	to	_	_	_	_	_	_	_	Seg=O
127	the	_	_	_	_	_	_	_	Seg=O
128	chloroplast	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	endoplasmic	_	_	_	_	_	_	_	Seg=O
132	reticulum	_	_	_	_	_	_	_	Seg=O
133	(	_	_	_	_	_	_	_	Seg=O
134	ER	_	_	_	_	_	_	_	Seg=O
135	)	_	_	_	_	_	_	_	Seg=O
136	on	_	_	_	_	_	_	_	Seg=O
137	protein	_	_	_	_	_	_	_	Seg=O
138	yield	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	We	_	_	_	_	_	_	_	Seg=B-seg
141	partially	_	_	_	_	_	_	_	Seg=O
142	purified	_	_	_	_	_	_	_	Seg=O
143	a	_	_	_	_	_	_	_	Seg=O
144	selected	_	_	_	_	_	_	_	Seg=O
145	vaccine	_	_	_	_	_	_	_	Seg=O
146	candidate	_	_	_	_	_	_	_	Seg=O
147	and	_	_	_	_	_	_	_	Seg=B-seg
148	tested	_	_	_	_	_	_	_	Seg=O
149	its	_	_	_	_	_	_	_	Seg=O
150	stimulation	_	_	_	_	_	_	_	Seg=O
151	of	_	_	_	_	_	_	_	Seg=O
152	a	_	_	_	_	_	_	_	Seg=O
153	humoral	_	_	_	_	_	_	_	Seg=O
154	and	_	_	_	_	_	_	_	Seg=O
155	cellular	_	_	_	_	_	_	_	Seg=O
156	immune	_	_	_	_	_	_	_	Seg=O
157	response	_	_	_	_	_	_	_	Seg=O
158	in	_	_	_	_	_	_	_	Seg=O
159	mice	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O
161	Both	_	_	_	_	_	_	_	Seg=B-seg
162	transient	_	_	_	_	_	_	_	Seg=O
163	and	_	_	_	_	_	_	_	Seg=O
164	transgenic	_	_	_	_	_	_	_	Seg=O
165	expression	_	_	_	_	_	_	_	Seg=O
166	of	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	HIV	_	_	_	_	_	_	_	Seg=O
169	antigens	_	_	_	_	_	_	_	Seg=O
170	were	_	_	_	_	_	_	_	Seg=O
171	successful	_	_	_	_	_	_	_	Seg=O
172	,	_	_	_	_	_	_	_	Seg=O
173	although	_	_	_	_	_	_	_	Seg=B-seg
174	expression	_	_	_	_	_	_	_	Seg=O
175	of	_	_	_	_	_	_	_	Seg=O
176	Pr55Gag	_	_	_	_	_	_	_	Seg=O
177	was	_	_	_	_	_	_	_	Seg=O
178	low	_	_	_	_	_	_	_	Seg=O
179	in	_	_	_	_	_	_	_	Seg=O
180	all	_	_	_	_	_	_	_	Seg=O
181	systems	_	_	_	_	_	_	_	Seg=O
182	;	_	_	_	_	_	_	_	Seg=O
183	however	_	_	_	_	_	_	_	Seg=B-seg
184	,	_	_	_	_	_	_	_	Seg=O
185	the	_	_	_	_	_	_	_	Seg=O
186	Agrobacterium	_	_	_	_	_	_	_	Seg=O
187	-	_	_	_	_	_	_	_	Seg=O
188	mediated	_	_	_	_	_	_	_	Seg=O
189	transient	_	_	_	_	_	_	_	Seg=O
190	expression	_	_	_	_	_	_	_	Seg=O
191	of	_	_	_	_	_	_	_	Seg=O
192	p24	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=O
194	p17	_	_	_	_	_	_	_	Seg=O
195	/	_	_	_	_	_	_	_	Seg=O
196	p24	_	_	_	_	_	_	_	Seg=O
197	yielded	_	_	_	_	_	_	_	Seg=O
198	best	_	_	_	_	_	_	_	Seg=O
199	,	_	_	_	_	_	_	_	Seg=O
200	to	_	_	_	_	_	_	_	Seg=O
201	more	_	_	_	_	_	_	_	Seg=O
202	than	_	_	_	_	_	_	_	Seg=O
203	1	_	_	_	_	_	_	_	Seg=O
204	mg	_	_	_	_	_	_	_	Seg=O
205	p24	_	_	_	_	_	_	_	Seg=O
206	/	_	_	_	_	_	_	_	Seg=O
207	kg	_	_	_	_	_	_	_	Seg=O
208	fresh	_	_	_	_	_	_	_	Seg=O
209	weight	_	_	_	_	_	_	_	Seg=O
210	.	_	_	_	_	_	_	_	Seg=O
211	Chloroplast	_	_	_	_	_	_	_	Seg=B-seg
212	targeted	_	_	_	_	_	_	_	Seg=O
213	protein	_	_	_	_	_	_	_	Seg=O
214	levels	_	_	_	_	_	_	_	Seg=O
215	were	_	_	_	_	_	_	_	Seg=O
216	highest	_	_	_	_	_	_	_	Seg=O
217	in	_	_	_	_	_	_	_	Seg=O
218	transient	_	_	_	_	_	_	_	Seg=O
219	and	_	_	_	_	_	_	_	Seg=O
220	transgenic	_	_	_	_	_	_	_	Seg=O
221	expression	_	_	_	_	_	_	_	Seg=O
222	of	_	_	_	_	_	_	_	Seg=O
223	p24	_	_	_	_	_	_	_	Seg=O
224	and	_	_	_	_	_	_	_	Seg=O
225	p17	_	_	_	_	_	_	_	Seg=O
226	/	_	_	_	_	_	_	_	Seg=O
227	p24	_	_	_	_	_	_	_	Seg=O
228	.	_	_	_	_	_	_	_	Seg=O
229	The	_	_	_	_	_	_	_	Seg=B-seg
230	transiently	_	_	_	_	_	_	_	Seg=O
231	-	_	_	_	_	_	_	_	Seg=O
232	expressed	_	_	_	_	_	_	_	Seg=O
233	p17	_	_	_	_	_	_	_	Seg=O
234	/	_	_	_	_	_	_	_	Seg=O
235	p24	_	_	_	_	_	_	_	Seg=O
236	was	_	_	_	_	_	_	_	Seg=O
237	not	_	_	_	_	_	_	_	Seg=O
238	immunogenic	_	_	_	_	_	_	_	Seg=O
239	in	_	_	_	_	_	_	_	Seg=O
240	mice	_	_	_	_	_	_	_	Seg=O
241	as	_	_	_	_	_	_	_	Seg=O
242	a	_	_	_	_	_	_	_	Seg=O
243	homologous	_	_	_	_	_	_	_	Seg=O
244	vaccine	_	_	_	_	_	_	_	Seg=O
245	,	_	_	_	_	_	_	_	Seg=O
246	but	_	_	_	_	_	_	_	Seg=B-seg
247	it	_	_	_	_	_	_	_	Seg=O
248	significantly	_	_	_	_	_	_	_	Seg=O
249	boosted	_	_	_	_	_	_	_	Seg=O
250	a	_	_	_	_	_	_	_	Seg=O
251	humoral	_	_	_	_	_	_	_	Seg=O
252	and	_	_	_	_	_	_	_	Seg=O
253	T	_	_	_	_	_	_	_	Seg=O
254	cell	_	_	_	_	_	_	_	Seg=O
255	immune	_	_	_	_	_	_	_	Seg=O
256	response	_	_	_	_	_	_	_	Seg=O
257	primed	_	_	_	_	_	_	_	Seg=B-seg
258	by	_	_	_	_	_	_	_	Seg=O
259	a	_	_	_	_	_	_	_	Seg=O
260	gag	_	_	_	_	_	_	_	Seg=O
261	DNA	_	_	_	_	_	_	_	Seg=O
262	vaccine	_	_	_	_	_	_	_	Seg=O
263	,	_	_	_	_	_	_	_	Seg=O
264	pTHGagC.	_	_	_	_	_	_	_	Seg=O
265	Conclusion	_	_	_	_	_	_	_	Seg=B-seg
266	:	_	_	_	_	_	_	_	Seg=O
267	Transient	_	_	_	_	_	_	_	Seg=B-seg
268	agroinfiltration	_	_	_	_	_	_	_	Seg=O
269	was	_	_	_	_	_	_	_	Seg=O
270	best	_	_	_	_	_	_	_	Seg=O
271	for	_	_	_	_	_	_	_	Seg=O
272	expression	_	_	_	_	_	_	_	Seg=O
273	of	_	_	_	_	_	_	_	Seg=O
274	all	_	_	_	_	_	_	_	Seg=O
275	of	_	_	_	_	_	_	_	Seg=O
276	the	_	_	_	_	_	_	_	Seg=O
277	recombinant	_	_	_	_	_	_	_	Seg=O
278	proteins	_	_	_	_	_	_	_	Seg=O
279	tested	_	_	_	_	_	_	_	Seg=O
280	,	_	_	_	_	_	_	_	Seg=O
281	and	_	_	_	_	_	_	_	Seg=B-seg
282	p24	_	_	_	_	_	_	_	Seg=O
283	and	_	_	_	_	_	_	_	Seg=O
284	p17	_	_	_	_	_	_	_	Seg=O
285	/	_	_	_	_	_	_	_	Seg=O
286	p24	_	_	_	_	_	_	_	Seg=O
287	were	_	_	_	_	_	_	_	Seg=O
288	expressed	_	_	_	_	_	_	_	Seg=O
289	at	_	_	_	_	_	_	_	Seg=O
290	much	_	_	_	_	_	_	_	Seg=O
291	higher	_	_	_	_	_	_	_	Seg=O
292	levels	_	_	_	_	_	_	_	Seg=O
293	than	_	_	_	_	_	_	_	Seg=O
294	Pr55Gag	_	_	_	_	_	_	_	Seg=O
295	.	_	_	_	_	_	_	_	Seg=O
296	Our	_	_	_	_	_	_	_	Seg=B-seg
297	results	_	_	_	_	_	_	_	Seg=O
298	highlight	_	_	_	_	_	_	_	Seg=O
299	the	_	_	_	_	_	_	_	Seg=O
300	usefulness	_	_	_	_	_	_	_	Seg=O
301	of	_	_	_	_	_	_	_	Seg=O
302	plastid	_	_	_	_	_	_	_	Seg=O
303	signal	_	_	_	_	_	_	_	Seg=O
304	peptides	_	_	_	_	_	_	_	Seg=O
305	in	_	_	_	_	_	_	_	Seg=B-seg
306	enhancing	_	_	_	_	_	_	_	Seg=O
307	the	_	_	_	_	_	_	_	Seg=O
308	production	_	_	_	_	_	_	_	Seg=O
309	of	_	_	_	_	_	_	_	Seg=O
310	recombinant	_	_	_	_	_	_	_	Seg=O
311	proteins	_	_	_	_	_	_	_	Seg=O
312	meant	_	_	_	_	_	_	_	Seg=B-seg
313	for	_	_	_	_	_	_	_	Seg=O
314	use	_	_	_	_	_	_	_	Seg=O
315	as	_	_	_	_	_	_	_	Seg=O
316	vaccines	_	_	_	_	_	_	_	Seg=O
317	.	_	_	_	_	_	_	_	Seg=O
318	The	_	_	_	_	_	_	_	Seg=B-seg
319	p17	_	_	_	_	_	_	_	Seg=O
320	/	_	_	_	_	_	_	_	Seg=O
321	p24	_	_	_	_	_	_	_	Seg=O
322	protein	_	_	_	_	_	_	_	Seg=O
323	effectively	_	_	_	_	_	_	_	Seg=O
324	boosted	_	_	_	_	_	_	_	Seg=O
325	T	_	_	_	_	_	_	_	Seg=O
326	cell	_	_	_	_	_	_	_	Seg=O
327	and	_	_	_	_	_	_	_	Seg=O
328	humoral	_	_	_	_	_	_	_	Seg=O
329	responses	_	_	_	_	_	_	_	Seg=O
330	in	_	_	_	_	_	_	_	Seg=O
331	mice	_	_	_	_	_	_	_	Seg=O
332	primed	_	_	_	_	_	_	_	Seg=B-seg
333	by	_	_	_	_	_	_	_	Seg=O
334	the	_	_	_	_	_	_	_	Seg=O
335	DNA	_	_	_	_	_	_	_	Seg=O
336	vaccine	_	_	_	_	_	_	_	Seg=O
337	pTHGagC	_	_	_	_	_	_	_	Seg=O
338	,	_	_	_	_	_	_	_	Seg=O
339	showing	_	_	_	_	_	_	_	Seg=B-seg
340	that	_	_	_	_	_	_	_	Seg=B-seg
341	this	_	_	_	_	_	_	_	Seg=O
342	plant	_	_	_	_	_	_	_	Seg=O
343	-	_	_	_	_	_	_	_	Seg=O
344	produced	_	_	_	_	_	_	_	Seg=O
345	protein	_	_	_	_	_	_	_	Seg=O
346	has	_	_	_	_	_	_	_	Seg=O
347	potential	_	_	_	_	_	_	_	Seg=O
348	for	_	_	_	_	_	_	_	Seg=O
349	use	_	_	_	_	_	_	_	Seg=O
350	as	_	_	_	_	_	_	_	Seg=O
351	a	_	_	_	_	_	_	_	Seg=O
352	vaccine	_	_	_	_	_	_	_	Seg=O
353	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1ca87acde2d673e129b4360d84dce19f2555438b
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	development	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	a	_	_	_	_	_	_	_	Seg=O
5	"	_	_	_	_	_	_	_	Seg=O
6	cold	_	_	_	_	_	_	_	Seg=O
7	-	_	_	_	_	_	_	_	Seg=O
8	like	_	_	_	_	_	_	_	Seg=O
9	illness	_	_	_	_	_	_	_	Seg=O
10	"	_	_	_	_	_	_	_	Seg=O
11	(	_	_	_	_	_	_	_	Seg=O
12	CLI	_	_	_	_	_	_	_	Seg=O
13	)	_	_	_	_	_	_	_	Seg=O
14	usually	_	_	_	_	_	_	_	Seg=O
15	requires	_	_	_	_	_	_	_	Seg=O
16	infection	_	_	_	_	_	_	_	Seg=O
17	with	_	_	_	_	_	_	_	Seg=O
18	an	_	_	_	_	_	_	_	Seg=O
19	upper	_	_	_	_	_	_	_	Seg=O
20	respiratory	_	_	_	_	_	_	_	Seg=O
21	virus	_	_	_	_	_	_	_	Seg=O
22	such	_	_	_	_	_	_	_	Seg=O
23	as	_	_	_	_	_	_	_	Seg=O
24	rhinovirus	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	influenza	_	_	_	_	_	_	_	Seg=O
27	virus	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	respiratory	_	_	_	_	_	_	_	Seg=O
30	syncytial	_	_	_	_	_	_	_	Seg=O
31	virus	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	parainfluenza	_	_	_	_	_	_	_	Seg=O
34	virus	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	coronavirus	_	_	_	_	_	_	_	Seg=O
37	or	_	_	_	_	_	_	_	Seg=O
38	adenovirus	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	among	_	_	_	_	_	_	_	Seg=O
41	others	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	development	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	sufficient	_	_	_	_	_	_	_	Seg=O
48	signs	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	symptoms	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=O
52	pathophysiologies	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=B-seg
54	qualify	_	_	_	_	_	_	_	Seg=O
55	as	_	_	_	_	_	_	_	Seg=O
56	being	_	_	_	_	_	_	_	Seg=O
57	ill	_	_	_	_	_	_	_	Seg=O
58	based	_	_	_	_	_	_	_	Seg=B-seg
59	on	_	_	_	_	_	_	_	Seg=O
60	personal	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	cultural	_	_	_	_	_	_	_	Seg=O
63	definitions	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	A	_	_	_	_	_	_	_	Seg=B-seg
66	viral	_	_	_	_	_	_	_	Seg=O
67	upper	_	_	_	_	_	_	_	Seg=O
68	respiratory	_	_	_	_	_	_	_	Seg=O
69	tract	_	_	_	_	_	_	_	Seg=O
70	infection	_	_	_	_	_	_	_	Seg=O
71	(	_	_	_	_	_	_	_	Seg=O
72	vURTI	_	_	_	_	_	_	_	Seg=O
73	)	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	absence	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	overt	_	_	_	_	_	_	_	Seg=O
79	illness	_	_	_	_	_	_	_	Seg=O
80	(	_	_	_	_	_	_	_	Seg=O
81	subclinical	_	_	_	_	_	_	_	Seg=O
82	vURTI	_	_	_	_	_	_	_	Seg=O
83	)	_	_	_	_	_	_	_	Seg=O
84	will	_	_	_	_	_	_	_	Seg=O
85	not	_	_	_	_	_	_	_	Seg=O
86	be	_	_	_	_	_	_	_	Seg=O
87	made	_	_	_	_	_	_	_	Seg=O
88	manifest	_	_	_	_	_	_	_	Seg=O
89	to	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	individual	_	_	_	_	_	_	_	Seg=O
92	or	_	_	_	_	_	_	_	Seg=O
93	to	_	_	_	_	_	_	_	Seg=O
94	observers	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=B-seg
96	,	_	_	_	_	_	_	_	Seg=O
97	therefore	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	will	_	_	_	_	_	_	_	Seg=O
100	not	_	_	_	_	_	_	_	Seg=O
101	be	_	_	_	_	_	_	_	Seg=O
102	diagnosed	_	_	_	_	_	_	_	Seg=O
103	as	_	_	_	_	_	_	_	Seg=O
104	a	_	_	_	_	_	_	_	Seg=O
105	CLI	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	The	_	_	_	_	_	_	_	Seg=B-seg
108	degree	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=O
110	illness	_	_	_	_	_	_	_	Seg=O
111	occurring	_	_	_	_	_	_	_	Seg=B-seg
112	during	_	_	_	_	_	_	_	Seg=O
113	a	_	_	_	_	_	_	_	Seg=O
114	vURTI	_	_	_	_	_	_	_	Seg=O
115	is	_	_	_	_	_	_	_	Seg=B-seg
116	directly	_	_	_	_	_	_	_	Seg=O
117	related	_	_	_	_	_	_	_	Seg=O
118	to	_	_	_	_	_	_	_	Seg=O
119	the	_	_	_	_	_	_	_	Seg=O
120	extent	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	provoked	_	_	_	_	_	_	_	Seg=O
123	inflammation	_	_	_	_	_	_	_	Seg=O
124	,	_	_	_	_	_	_	_	Seg=O
125	which	_	_	_	_	_	_	_	Seg=B-seg
126	in	_	_	_	_	_	_	_	Seg=O
127	turn	_	_	_	_	_	_	_	Seg=O
128	depends	_	_	_	_	_	_	_	Seg=O
129	on	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	engagement	_	_	_	_	_	_	_	Seg=O
132	of	_	_	_	_	_	_	_	Seg=O
133	antiviral	_	_	_	_	_	_	_	Seg=O
134	defense	_	_	_	_	_	_	_	Seg=O
135	systems	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	Thus	_	_	_	_	_	_	_	Seg=B-seg
138	,	_	_	_	_	_	_	_	Seg=O
139	risk	_	_	_	_	_	_	_	Seg=O
140	factors	_	_	_	_	_	_	_	Seg=O
141	for	_	_	_	_	_	_	_	Seg=O
142	CLI	_	_	_	_	_	_	_	Seg=O
143	can	_	_	_	_	_	_	_	Seg=O
144	modulate	_	_	_	_	_	_	_	Seg=O
145	either	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	vURTI	_	_	_	_	_	_	_	Seg=O
148	risk	_	_	_	_	_	_	_	Seg=O
149	by	_	_	_	_	_	_	_	Seg=B-seg
150	affecting	_	_	_	_	_	_	_	Seg=O
151	virus	_	_	_	_	_	_	_	Seg=O
152	exposure	_	_	_	_	_	_	_	Seg=O
153	and/or	_	_	_	_	_	_	_	Seg=O
154	susceptibility	_	_	_	_	_	_	_	Seg=O
155	to	_	_	_	_	_	_	_	Seg=O
156	infection	_	_	_	_	_	_	_	Seg=O
157	,	_	_	_	_	_	_	_	Seg=O
158	or	_	_	_	_	_	_	_	Seg=B-seg
159	the	_	_	_	_	_	_	_	Seg=O
160	CLI	_	_	_	_	_	_	_	Seg=O
161	risk	_	_	_	_	_	_	_	Seg=O
162	given	_	_	_	_	_	_	_	Seg=O
163	a	_	_	_	_	_	_	_	Seg=O
164	vURTI	_	_	_	_	_	_	_	Seg=O
165	by	_	_	_	_	_	_	_	Seg=B-seg
166	affecting	_	_	_	_	_	_	_	Seg=O
167	immunocompetence	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	provoked	_	_	_	_	_	_	_	Seg=O
171	inflammation	_	_	_	_	_	_	_	Seg=O
172	and/or	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=O
174	interpretation	_	_	_	_	_	_	_	Seg=O
175	of	_	_	_	_	_	_	_	Seg=O
176	illness	_	_	_	_	_	_	_	Seg=O
177	as	_	_	_	_	_	_	_	Seg=O
178	a	_	_	_	_	_	_	_	Seg=O
179	CLI	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O
181	In	_	_	_	_	_	_	_	Seg=B-seg
182	this	_	_	_	_	_	_	_	Seg=O
183	chapter	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	we	_	_	_	_	_	_	_	Seg=O
186	review	_	_	_	_	_	_	_	Seg=O
187	published	_	_	_	_	_	_	_	Seg=O
188	studies	_	_	_	_	_	_	_	Seg=O
189	for	_	_	_	_	_	_	_	Seg=O
190	evidence	_	_	_	_	_	_	_	Seg=O
191	of	_	_	_	_	_	_	_	Seg=O
192	CLI	_	_	_	_	_	_	_	Seg=O
193	risk	_	_	_	_	_	_	_	Seg=O
194	-	_	_	_	_	_	_	_	Seg=O
195	modulating	_	_	_	_	_	_	_	Seg=O
196	factors	_	_	_	_	_	_	_	Seg=O
197	and	_	_	_	_	_	_	_	Seg=B-seg
198	report	_	_	_	_	_	_	_	Seg=O
199	that	_	_	_	_	_	_	_	Seg=B-seg
200	climate	_	_	_	_	_	_	_	Seg=O
201	,	_	_	_	_	_	_	_	Seg=O
202	crowding	_	_	_	_	_	_	_	Seg=O
203	and	_	_	_	_	_	_	_	Seg=O
204	perhaps	_	_	_	_	_	_	_	Seg=O
205	female	_	_	_	_	_	_	_	Seg=O
206	gender	_	_	_	_	_	_	_	Seg=O
207	can	_	_	_	_	_	_	_	Seg=O
208	affect	_	_	_	_	_	_	_	Seg=O
209	the	_	_	_	_	_	_	_	Seg=O
210	probability	_	_	_	_	_	_	_	Seg=O
211	of	_	_	_	_	_	_	_	Seg=O
212	exposure	_	_	_	_	_	_	_	Seg=O
213	to	_	_	_	_	_	_	_	Seg=O
214	vURTI	_	_	_	_	_	_	_	Seg=O
215	viruses	_	_	_	_	_	_	_	Seg=O
216	,	_	_	_	_	_	_	_	Seg=O
217	that	_	_	_	_	_	_	_	Seg=B-seg
218	extant	_	_	_	_	_	_	_	Seg=O
219	immunological	_	_	_	_	_	_	_	Seg=O
220	factors	_	_	_	_	_	_	_	Seg=O
221	and	_	_	_	_	_	_	_	Seg=O
222	age	_	_	_	_	_	_	_	Seg=O
223	can	_	_	_	_	_	_	_	Seg=O
224	affect	_	_	_	_	_	_	_	Seg=O
225	the	_	_	_	_	_	_	_	Seg=O
226	probability	_	_	_	_	_	_	_	Seg=O
227	of	_	_	_	_	_	_	_	Seg=O
228	virus	_	_	_	_	_	_	_	Seg=O
229	infection	_	_	_	_	_	_	_	Seg=O
230	given	_	_	_	_	_	_	_	Seg=B-seg
231	exposure	_	_	_	_	_	_	_	Seg=O
232	,	_	_	_	_	_	_	_	Seg=O
233	that	_	_	_	_	_	_	_	Seg=B-seg
234	stress	_	_	_	_	_	_	_	Seg=O
235	levels	_	_	_	_	_	_	_	Seg=O
236	(	_	_	_	_	_	_	_	Seg=B-seg
237	moderated	_	_	_	_	_	_	_	Seg=O
238	by	_	_	_	_	_	_	_	Seg=O
239	social	_	_	_	_	_	_	_	Seg=O
240	environment	_	_	_	_	_	_	_	Seg=O
241	)	_	_	_	_	_	_	_	Seg=O
242	,	_	_	_	_	_	_	_	Seg=O
243	health	_	_	_	_	_	_	_	Seg=B-seg
244	practices	_	_	_	_	_	_	_	Seg=O
245	(	_	_	_	_	_	_	_	Seg=B-seg
246	exercise	_	_	_	_	_	_	_	Seg=O
247	,	_	_	_	_	_	_	_	Seg=O
248	tobacco	_	_	_	_	_	_	_	Seg=O
249	and	_	_	_	_	_	_	_	Seg=O
250	alcohol	_	_	_	_	_	_	_	Seg=O
251	consumption	_	_	_	_	_	_	_	Seg=O
252	,	_	_	_	_	_	_	_	Seg=O
253	sleep	_	_	_	_	_	_	_	Seg=O
254	efficiency	_	_	_	_	_	_	_	Seg=O
255	)	_	_	_	_	_	_	_	Seg=O
256	and	_	_	_	_	_	_	_	Seg=B-seg
257	genetics	_	_	_	_	_	_	_	Seg=O
258	contribute	_	_	_	_	_	_	_	Seg=O
259	to	_	_	_	_	_	_	_	Seg=O
260	CLI	_	_	_	_	_	_	_	Seg=O
261	risk	_	_	_	_	_	_	_	Seg=O
262	most	_	_	_	_	_	_	_	Seg=B-seg
263	probably	_	_	_	_	_	_	_	Seg=O
264	by	_	_	_	_	_	_	_	Seg=O
265	modulating	_	_	_	_	_	_	_	Seg=O
266	the	_	_	_	_	_	_	_	Seg=O
267	immune	_	_	_	_	_	_	_	Seg=O
268	-	_	_	_	_	_	_	_	Seg=O
269	inflammatory	_	_	_	_	_	_	_	Seg=O
270	response	_	_	_	_	_	_	_	Seg=O
271	to	_	_	_	_	_	_	_	Seg=O
272	infection	_	_	_	_	_	_	_	Seg=O
273	,	_	_	_	_	_	_	_	Seg=O
274	and	_	_	_	_	_	_	_	Seg=B-seg
275	that	_	_	_	_	_	_	_	Seg=O
276	other	_	_	_	_	_	_	_	Seg=O
277	factors	_	_	_	_	_	_	_	Seg=O
278	such	_	_	_	_	_	_	_	Seg=B-seg
279	as	_	_	_	_	_	_	_	Seg=O
280	pollution	_	_	_	_	_	_	_	Seg=O
281	,	_	_	_	_	_	_	_	Seg=O
282	home	_	_	_	_	_	_	_	Seg=O
283	environment	_	_	_	_	_	_	_	Seg=O
284	and	_	_	_	_	_	_	_	Seg=O
285	certain	_	_	_	_	_	_	_	Seg=O
286	personality	_	_	_	_	_	_	_	Seg=O
287	traits	_	_	_	_	_	_	_	Seg=O
288	affect	_	_	_	_	_	_	_	Seg=B-seg
289	CLI	_	_	_	_	_	_	_	Seg=O
290	risk	_	_	_	_	_	_	_	Seg=O
291	by	_	_	_	_	_	_	_	Seg=B-seg
292	biasing	_	_	_	_	_	_	_	Seg=O
293	illness	_	_	_	_	_	_	_	Seg=O
294	interpretation	_	_	_	_	_	_	_	Seg=O
295	for	_	_	_	_	_	_	_	Seg=O
296	a	_	_	_	_	_	_	_	Seg=O
297	given	_	_	_	_	_	_	_	Seg=O
298	set	_	_	_	_	_	_	_	Seg=O
299	of	_	_	_	_	_	_	_	Seg=O
300	symptoms	_	_	_	_	_	_	_	Seg=O
301	and	_	_	_	_	_	_	_	Seg=O
302	signs	_	_	_	_	_	_	_	Seg=O
303	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1d5a95f805753e4ae9c605845a395adf47cabce8
1	Newcastle	_	_	_	_	_	_	_	Seg=B-seg
2	disease	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	Paramyxoviridae	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	highly	_	_	_	_	_	_	_	Seg=O
9	infectious	_	_	_	_	_	_	_	Seg=O
10	virus	_	_	_	_	_	_	_	Seg=O
11	shed	_	_	_	_	_	_	_	Seg=B-seg
12	in	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	faeces	_	_	_	_	_	_	_	Seg=O
15	of	_	_	_	_	_	_	_	Seg=O
16	infected	_	_	_	_	_	_	_	Seg=O
17	birds	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	Non	_	_	_	_	_	_	_	Seg=B-seg
20	-	_	_	_	_	_	_	_	Seg=O
21	biting	_	_	_	_	_	_	_	Seg=O
22	Muscid	_	_	_	_	_	_	_	Seg=O
23	flies	_	_	_	_	_	_	_	Seg=O
24	characteristically	_	_	_	_	_	_	_	Seg=O
25	visit	_	_	_	_	_	_	_	Seg=O
26	manure	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=O
28	decaying	_	_	_	_	_	_	_	Seg=O
29	organic	_	_	_	_	_	_	_	Seg=O
30	material	_	_	_	_	_	_	_	Seg=O
31	to	_	_	_	_	_	_	_	Seg=B-seg
32	feed	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=B-seg
34	oviposit	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	and	_	_	_	_	_	_	_	Seg=B-seg
37	may	_	_	_	_	_	_	_	Seg=O
38	contribute	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=O
40	disease	_	_	_	_	_	_	_	Seg=O
41	transmission	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	The	_	_	_	_	_	_	_	Seg=B-seg
44	housefly	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	Musca	_	_	_	_	_	_	_	Seg=O
47	domestica	_	_	_	_	_	_	_	Seg=O
48	(	_	_	_	_	_	_	_	Seg=O
49	Linnaeus	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	1758	_	_	_	_	_	_	_	Seg=O
52	)	_	_	_	_	_	_	_	Seg=O
53	(	_	_	_	_	_	_	_	Seg=O
54	Diptera	_	_	_	_	_	_	_	Seg=O
55	:	_	_	_	_	_	_	_	Seg=O
56	Muscidae	_	_	_	_	_	_	_	Seg=O
57	)	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	has	_	_	_	_	_	_	_	Seg=O
60	been	_	_	_	_	_	_	_	Seg=O
61	implicated	_	_	_	_	_	_	_	Seg=O
62	as	_	_	_	_	_	_	_	Seg=O
63	a	_	_	_	_	_	_	_	Seg=O
64	mechanical	_	_	_	_	_	_	_	Seg=O
65	vector	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	numerous	_	_	_	_	_	_	_	Seg=O
68	pathogens	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	In	_	_	_	_	_	_	_	Seg=B-seg
71	this	_	_	_	_	_	_	_	Seg=O
72	study	_	_	_	_	_	_	_	Seg=O
73	2000	_	_	_	_	_	_	_	Seg=O
74	aerial	_	_	_	_	_	_	_	Seg=O
75	net	_	_	_	_	_	_	_	Seg=O
76	-	_	_	_	_	_	_	_	Seg=O
77	captured	_	_	_	_	_	_	_	Seg=O
78	houseflies	_	_	_	_	_	_	_	Seg=O
79	were	_	_	_	_	_	_	_	Seg=O
80	examined	_	_	_	_	_	_	_	Seg=O
81	for	_	_	_	_	_	_	_	Seg=O
82	their	_	_	_	_	_	_	_	Seg=O
83	ability	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=B-seg
85	harbour	_	_	_	_	_	_	_	Seg=O
86	Newcastle	_	_	_	_	_	_	_	Seg=O
87	disease	_	_	_	_	_	_	_	Seg=O
88	virus	_	_	_	_	_	_	_	Seg=O
89	(	_	_	_	_	_	_	_	Seg=O
90	NDV	_	_	_	_	_	_	_	Seg=O
91	)	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	In	_	_	_	_	_	_	_	Seg=B-seg
94	an	_	_	_	_	_	_	_	Seg=O
95	adjacent	_	_	_	_	_	_	_	Seg=O
96	study	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	laboratory	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	reared	_	_	_	_	_	_	_	Seg=O
101	flies	_	_	_	_	_	_	_	Seg=O
102	were	_	_	_	_	_	_	_	Seg=O
103	experimentally	_	_	_	_	_	_	_	Seg=O
104	exposed	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=O
106	NDV	_	_	_	_	_	_	_	Seg=O
107	La	_	_	_	_	_	_	_	Seg=O
108	Sota	_	_	_	_	_	_	_	Seg=O
109	strain	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	The	_	_	_	_	_	_	_	Seg=B-seg
112	virus	_	_	_	_	_	_	_	Seg=O
113	was	_	_	_	_	_	_	_	Seg=O
114	detected	_	_	_	_	_	_	_	Seg=O
115	in	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	dissected	_	_	_	_	_	_	_	Seg=O
118	gastrointestinal	_	_	_	_	_	_	_	Seg=O
119	tract	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	laboratory	_	_	_	_	_	_	_	Seg=O
122	-	_	_	_	_	_	_	_	Seg=O
123	exposed	_	_	_	_	_	_	_	Seg=O
124	flies	_	_	_	_	_	_	_	Seg=O
125	for	_	_	_	_	_	_	_	Seg=O
126	up	_	_	_	_	_	_	_	Seg=O
127	to	_	_	_	_	_	_	_	Seg=O
128	72	_	_	_	_	_	_	_	Seg=O
129	h	_	_	_	_	_	_	_	Seg=O
130	post	_	_	_	_	_	_	_	Seg=O
131	-	_	_	_	_	_	_	_	Seg=O
132	exposure	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	whereas	_	_	_	_	_	_	_	Seg=B-seg
135	the	_	_	_	_	_	_	_	Seg=O
136	untreated	_	_	_	_	_	_	_	Seg=O
137	control	_	_	_	_	_	_	_	Seg=O
138	flies	_	_	_	_	_	_	_	Seg=O
139	were	_	_	_	_	_	_	_	Seg=O
140	negative	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1dc818a92b31dc871d7020ec659faaeb38e519c6
1	Respiratory	_	_	_	_	_	_	_	Seg=B-seg
2	viral	_	_	_	_	_	_	_	Seg=O
3	infections	_	_	_	_	_	_	_	Seg=O
4	in	_	_	_	_	_	_	_	Seg=O
5	infants	_	_	_	_	_	_	_	Seg=O
6	and	_	_	_	_	_	_	_	Seg=O
7	young	_	_	_	_	_	_	_	Seg=O
8	children	_	_	_	_	_	_	_	Seg=O
9	frequently	_	_	_	_	_	_	_	Seg=O
10	cause	_	_	_	_	_	_	_	Seg=O
11	illness	_	_	_	_	_	_	_	Seg=O
12	that	_	_	_	_	_	_	_	Seg=B-seg
13	can	_	_	_	_	_	_	_	Seg=O
14	easily	_	_	_	_	_	_	_	Seg=O
15	progress	_	_	_	_	_	_	_	Seg=O
16	to	_	_	_	_	_	_	_	Seg=O
17	hospitalization	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	death	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	There	_	_	_	_	_	_	_	Seg=B-seg
22	are	_	_	_	_	_	_	_	Seg=O
23	currently	_	_	_	_	_	_	_	Seg=O
24	no	_	_	_	_	_	_	_	Seg=O
25	licensed	_	_	_	_	_	_	_	Seg=O
26	vaccines	_	_	_	_	_	_	_	Seg=O
27	to	_	_	_	_	_	_	_	Seg=B-seg
28	prevent	_	_	_	_	_	_	_	Seg=O
29	respiratory	_	_	_	_	_	_	_	Seg=O
30	viral	_	_	_	_	_	_	_	Seg=O
31	disease	_	_	_	_	_	_	_	Seg=O
32	in	_	_	_	_	_	_	_	Seg=O
33	children	_	_	_	_	_	_	_	Seg=O
34	younger	_	_	_	_	_	_	_	Seg=O
35	than	_	_	_	_	_	_	_	Seg=O
36	6	_	_	_	_	_	_	_	Seg=O
37	months	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	reflecting	_	_	_	_	_	_	_	Seg=B-seg
40	safety	_	_	_	_	_	_	_	Seg=O
41	concerns	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	difficulty	_	_	_	_	_	_	_	Seg=O
45	in	_	_	_	_	_	_	_	Seg=B-seg
46	inducing	_	_	_	_	_	_	_	Seg=O
47	effective	_	_	_	_	_	_	_	Seg=O
48	immune	_	_	_	_	_	_	_	Seg=O
49	responses	_	_	_	_	_	_	_	Seg=O
50	in	_	_	_	_	_	_	_	Seg=O
51	infants	_	_	_	_	_	_	_	Seg=O
52	.	_	_	_	_	_	_	_	Seg=O
53	This	_	_	_	_	_	_	_	Seg=B-seg
54	review	_	_	_	_	_	_	_	Seg=O
55	discusses	_	_	_	_	_	_	_	Seg=O
56	vaccines	_	_	_	_	_	_	_	Seg=O
57	that	_	_	_	_	_	_	_	Seg=B-seg
58	have	_	_	_	_	_	_	_	Seg=O
59	been	_	_	_	_	_	_	_	Seg=O
60	developed	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	or	_	_	_	_	_	_	_	Seg=O
63	are	_	_	_	_	_	_	_	Seg=O
64	currently	_	_	_	_	_	_	_	Seg=O
65	being	_	_	_	_	_	_	_	Seg=O
66	developed	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	against	_	_	_	_	_	_	_	Seg=O
69	influenza	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	respiratory	_	_	_	_	_	_	_	Seg=O
72	syncytial	_	_	_	_	_	_	_	Seg=O
73	virus	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	with	_	_	_	_	_	_	_	Seg=O
76	a	_	_	_	_	_	_	_	Seg=O
77	focus	_	_	_	_	_	_	_	Seg=O
78	on	_	_	_	_	_	_	_	Seg=O
79	studies	_	_	_	_	_	_	_	Seg=O
80	performed	_	_	_	_	_	_	_	Seg=B-seg
81	to	_	_	_	_	_	_	_	Seg=B-seg
82	demonstrate	_	_	_	_	_	_	_	Seg=O
83	their	_	_	_	_	_	_	_	Seg=O
84	safety	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	efficacy	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	and	_	_	_	_	_	_	_	Seg=O
89	the	_	_	_	_	_	_	_	Seg=O
90	impact	_	_	_	_	_	_	_	Seg=O
91	of	_	_	_	_	_	_	_	Seg=O
92	immunologic	_	_	_	_	_	_	_	Seg=O
93	immaturity	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=O
95	maternal	_	_	_	_	_	_	_	Seg=O
96	antibodies	_	_	_	_	_	_	_	Seg=O
97	on	_	_	_	_	_	_	_	Seg=O
98	the	_	_	_	_	_	_	_	Seg=O
99	infant	_	_	_	_	_	_	_	Seg=O
100	response	_	_	_	_	_	_	_	Seg=O
101	to	_	_	_	_	_	_	_	Seg=O
102	vaccines	_	_	_	_	_	_	_	Seg=O
103	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1ea771012595cf18bfe22d4933e45b8a190881fc
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	novel	_	_	_	_	_	_	_	Seg=O
3	Coronavirus	_	_	_	_	_	_	_	Seg=O
4	has	_	_	_	_	_	_	_	Seg=O
5	caused	_	_	_	_	_	_	_	Seg=O
6	a	_	_	_	_	_	_	_	Seg=O
7	global	_	_	_	_	_	_	_	Seg=O
8	crisis	_	_	_	_	_	_	_	Seg=O
9	and	_	_	_	_	_	_	_	Seg=B-seg
10	many	_	_	_	_	_	_	_	Seg=O
11	governments	_	_	_	_	_	_	_	Seg=O
12	have	_	_	_	_	_	_	_	Seg=O
13	taken	_	_	_	_	_	_	_	Seg=O
14	social	_	_	_	_	_	_	_	Seg=O
15	measures	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	such	_	_	_	_	_	_	_	Seg=B-seg
18	as	_	_	_	_	_	_	_	Seg=O
19	home	_	_	_	_	_	_	_	Seg=O
20	quarantine	_	_	_	_	_	_	_	Seg=O
21	and	_	_	_	_	_	_	_	Seg=O
22	maintaining	_	_	_	_	_	_	_	Seg=O
23	social	_	_	_	_	_	_	_	Seg=O
24	distance	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	Many	_	_	_	_	_	_	_	Seg=B-seg
27	recent	_	_	_	_	_	_	_	Seg=O
28	studies	_	_	_	_	_	_	_	Seg=O
29	show	_	_	_	_	_	_	_	Seg=O
30	that	_	_	_	_	_	_	_	Seg=B-seg
31	network	_	_	_	_	_	_	_	Seg=O
32	structure	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	human	_	_	_	_	_	_	_	Seg=O
35	mobility	_	_	_	_	_	_	_	Seg=O
36	greatly	_	_	_	_	_	_	_	Seg=O
37	influence	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	dynamics	_	_	_	_	_	_	_	Seg=O
40	of	_	_	_	_	_	_	_	Seg=O
41	epidemic	_	_	_	_	_	_	_	Seg=O
42	spreading	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	In	_	_	_	_	_	_	_	Seg=B-seg
45	this	_	_	_	_	_	_	_	Seg=O
46	paper	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	we	_	_	_	_	_	_	_	Seg=O
49	utilize	_	_	_	_	_	_	_	Seg=O
50	a	_	_	_	_	_	_	_	Seg=O
51	discrete	_	_	_	_	_	_	_	Seg=O
52	-	_	_	_	_	_	_	_	Seg=O
53	time	_	_	_	_	_	_	_	Seg=O
54	Markov	_	_	_	_	_	_	_	Seg=O
55	chain	_	_	_	_	_	_	_	Seg=O
56	approach	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=B-seg
58	propose	_	_	_	_	_	_	_	Seg=O
59	an	_	_	_	_	_	_	_	Seg=O
60	epidemic	_	_	_	_	_	_	_	Seg=O
61	model	_	_	_	_	_	_	_	Seg=O
62	to	_	_	_	_	_	_	_	Seg=B-seg
63	describe	_	_	_	_	_	_	_	Seg=O
64	virus	_	_	_	_	_	_	_	Seg=O
65	propagation	_	_	_	_	_	_	_	Seg=O
66	in	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	heterogeneous	_	_	_	_	_	_	_	Seg=O
69	graph	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	which	_	_	_	_	_	_	_	Seg=B-seg
72	is	_	_	_	_	_	_	_	Seg=O
73	used	_	_	_	_	_	_	_	Seg=O
74	to	_	_	_	_	_	_	_	Seg=B-seg
75	represent	_	_	_	_	_	_	_	Seg=O
76	individuals	_	_	_	_	_	_	_	Seg=O
77	with	_	_	_	_	_	_	_	Seg=O
78	intra	_	_	_	_	_	_	_	Seg=O
79	social	_	_	_	_	_	_	_	Seg=O
80	connections	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	mobility	_	_	_	_	_	_	_	Seg=O
83	between	_	_	_	_	_	_	_	Seg=O
84	individuals	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	common	_	_	_	_	_	_	_	Seg=O
87	locations	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	There	_	_	_	_	_	_	_	Seg=B-seg
90	are	_	_	_	_	_	_	_	Seg=O
91	two	_	_	_	_	_	_	_	Seg=O
92	types	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=O
94	nodes	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	individuals	_	_	_	_	_	_	_	Seg=O
97	and	_	_	_	_	_	_	_	Seg=O
98	public	_	_	_	_	_	_	_	Seg=O
99	places	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	and	_	_	_	_	_	_	_	Seg=B-seg
102	disease	_	_	_	_	_	_	_	Seg=O
103	can	_	_	_	_	_	_	_	Seg=O
104	spread	_	_	_	_	_	_	_	Seg=O
105	by	_	_	_	_	_	_	_	Seg=O
106	social	_	_	_	_	_	_	_	Seg=O
107	contacts	_	_	_	_	_	_	_	Seg=O
108	among	_	_	_	_	_	_	_	Seg=O
109	individuals	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=O
111	people	_	_	_	_	_	_	_	Seg=O
112	gathering	_	_	_	_	_	_	_	Seg=B-seg
113	in	_	_	_	_	_	_	_	Seg=O
114	common	_	_	_	_	_	_	_	Seg=O
115	areas	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	We	_	_	_	_	_	_	_	Seg=B-seg
118	give	_	_	_	_	_	_	_	Seg=O
119	theoretical	_	_	_	_	_	_	_	Seg=O
120	results	_	_	_	_	_	_	_	Seg=O
121	about	_	_	_	_	_	_	_	Seg=O
122	epidemic	_	_	_	_	_	_	_	Seg=O
123	threshold	_	_	_	_	_	_	_	Seg=O
124	and	_	_	_	_	_	_	_	Seg=O
125	influence	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	isolation	_	_	_	_	_	_	_	Seg=O
128	factor	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	Several	_	_	_	_	_	_	_	Seg=B-seg
131	numerical	_	_	_	_	_	_	_	Seg=O
132	simulations	_	_	_	_	_	_	_	Seg=O
133	are	_	_	_	_	_	_	_	Seg=O
134	performed	_	_	_	_	_	_	_	Seg=O
135	and	_	_	_	_	_	_	_	Seg=B-seg
136	experimental	_	_	_	_	_	_	_	Seg=O
137	results	_	_	_	_	_	_	_	Seg=O
138	further	_	_	_	_	_	_	_	Seg=O
139	demonstrate	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	correctness	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	proposed	_	_	_	_	_	_	_	Seg=O
144	model	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	Non	_	_	_	_	_	_	_	Seg=B-seg
147	-	_	_	_	_	_	_	_	Seg=O
148	monotonic	_	_	_	_	_	_	_	Seg=O
149	relationship	_	_	_	_	_	_	_	Seg=O
150	between	_	_	_	_	_	_	_	Seg=O
151	mobility	_	_	_	_	_	_	_	Seg=O
152	possibility	_	_	_	_	_	_	_	Seg=O
153	and	_	_	_	_	_	_	_	Seg=O
154	epidemic	_	_	_	_	_	_	_	Seg=O
155	threshold	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	differences	_	_	_	_	_	_	_	Seg=O
158	between	_	_	_	_	_	_	_	Seg=O
159	Erdös	_	_	_	_	_	_	_	Seg=O
160	-	_	_	_	_	_	_	_	Seg=O
161	Rényi	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=O
163	power	_	_	_	_	_	_	_	Seg=O
164	-	_	_	_	_	_	_	_	Seg=O
165	law	_	_	_	_	_	_	_	Seg=O
166	social	_	_	_	_	_	_	_	Seg=O
167	connections	_	_	_	_	_	_	_	Seg=O
168	are	_	_	_	_	_	_	_	Seg=O
169	revealed	_	_	_	_	_	_	_	Seg=O
170	.	_	_	_	_	_	_	_	Seg=O
171	In	_	_	_	_	_	_	_	Seg=B-seg
172	summary	_	_	_	_	_	_	_	Seg=O
173	,	_	_	_	_	_	_	_	Seg=O
174	our	_	_	_	_	_	_	_	Seg=O
175	proposed	_	_	_	_	_	_	_	Seg=O
176	approach	_	_	_	_	_	_	_	Seg=O
177	and	_	_	_	_	_	_	_	Seg=O
178	findings	_	_	_	_	_	_	_	Seg=O
179	are	_	_	_	_	_	_	_	Seg=O
180	helpful	_	_	_	_	_	_	_	Seg=O
181	to	_	_	_	_	_	_	_	Seg=O
182	analyse	_	_	_	_	_	_	_	Seg=O
183	and	_	_	_	_	_	_	_	Seg=O
184	prevent	_	_	_	_	_	_	_	Seg=O
185	the	_	_	_	_	_	_	_	Seg=O
186	epidemic	_	_	_	_	_	_	_	Seg=O
187	spreading	_	_	_	_	_	_	_	Seg=O
188	in	_	_	_	_	_	_	_	Seg=O
189	networked	_	_	_	_	_	_	_	Seg=O
190	population	_	_	_	_	_	_	_	Seg=O
191	with	_	_	_	_	_	_	_	Seg=O
192	recurrent	_	_	_	_	_	_	_	Seg=O
193	mobility	_	_	_	_	_	_	_	Seg=O
194	pattern	_	_	_	_	_	_	_	Seg=O
195	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2074781d7ca96edc1ef37f4cc7196856653a14e0
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	paper	_	_	_	_	_	_	_	Seg=O
3	presents	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	dataset	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	survey	_	_	_	_	_	_	_	Seg=O
9	on	_	_	_	_	_	_	_	Seg=O
10	workplace	_	_	_	_	_	_	_	Seg=O
11	health	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	safety	_	_	_	_	_	_	_	Seg=O
14	training	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16-17	employees'	_	_	_	_	_	_	_	_
16	employees	_	_	_	_	_	_	_	Seg=O
17	'	_	_	_	_	_	_	_	Seg=O
18	risk	_	_	_	_	_	_	_	Seg=O
19	perceptions	_	_	_	_	_	_	_	Seg=O
20	,	_	_	_	_	_	_	_	Seg=O
21	behavioral	_	_	_	_	_	_	_	Seg=O
22	safety	_	_	_	_	_	_	_	Seg=O
23	compliance	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	perceived	_	_	_	_	_	_	_	Seg=O
27	job	_	_	_	_	_	_	_	Seg=O
28	insecurity	_	_	_	_	_	_	_	Seg=O
29	in	_	_	_	_	_	_	_	Seg=O
30	Vietnam	_	_	_	_	_	_	_	Seg=O
31	during	_	_	_	_	_	_	_	Seg=O
32	COVID-19	_	_	_	_	_	_	_	Seg=O
33	pandemic	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	The	_	_	_	_	_	_	_	Seg=B-seg
36	data	_	_	_	_	_	_	_	Seg=O
37	were	_	_	_	_	_	_	_	Seg=O
38	collected	_	_	_	_	_	_	_	Seg=O
39	through	_	_	_	_	_	_	_	Seg=O
40	an	_	_	_	_	_	_	_	Seg=O
41	online	_	_	_	_	_	_	_	Seg=O
42	questionnaire	_	_	_	_	_	_	_	Seg=O
43	completed	_	_	_	_	_	_	_	Seg=B-seg
44	by	_	_	_	_	_	_	_	Seg=O
45	Vietnamese	_	_	_	_	_	_	_	Seg=O
46	full	_	_	_	_	_	_	_	Seg=O
47	-	_	_	_	_	_	_	_	Seg=O
48	time	_	_	_	_	_	_	_	Seg=O
49	employees	_	_	_	_	_	_	_	Seg=O
50	between	_	_	_	_	_	_	_	Seg=O
51	April	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	June	_	_	_	_	_	_	_	Seg=O
54	2020	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	Using	_	_	_	_	_	_	_	Seg=B-seg
57	E	_	_	_	_	_	_	_	Seg=O
58	-	_	_	_	_	_	_	_	Seg=O
59	mail	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	LinkedIn	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	Facebook	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	the	_	_	_	_	_	_	_	Seg=B-seg
67	online	_	_	_	_	_	_	_	Seg=O
68	questionnaire	_	_	_	_	_	_	_	Seg=O
69	was	_	_	_	_	_	_	_	Seg=O
70	sent	_	_	_	_	_	_	_	Seg=O
71	to	_	_	_	_	_	_	_	Seg=O
72	respondents	_	_	_	_	_	_	_	Seg=O
73	who	_	_	_	_	_	_	_	Seg=B-seg
74	filled	_	_	_	_	_	_	_	Seg=O
75	it	_	_	_	_	_	_	_	Seg=O
76	out	_	_	_	_	_	_	_	Seg=O
77	voluntarily	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	A	_	_	_	_	_	_	_	Seg=B-seg
80	twowave	_	_	_	_	_	_	_	Seg=O
81	survey	_	_	_	_	_	_	_	Seg=O
82	was	_	_	_	_	_	_	_	Seg=O
83	conducted	_	_	_	_	_	_	_	Seg=O
84	in	_	_	_	_	_	_	_	Seg=B-seg
85	order	_	_	_	_	_	_	_	Seg=O
86	to	_	_	_	_	_	_	_	Seg=O
87	lessen	_	_	_	_	_	_	_	Seg=O
88	the	_	_	_	_	_	_	_	Seg=O
89	common	_	_	_	_	_	_	_	Seg=O
90	method	_	_	_	_	_	_	_	Seg=O
91	bias	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	Totally	_	_	_	_	_	_	_	Seg=B-seg
94	,	_	_	_	_	_	_	_	Seg=O
95	we	_	_	_	_	_	_	_	Seg=O
96	received	_	_	_	_	_	_	_	Seg=O
97	complete	_	_	_	_	_	_	_	Seg=O
98	matched	_	_	_	_	_	_	_	Seg=O
99	data	_	_	_	_	_	_	_	Seg=O
100	for	_	_	_	_	_	_	_	Seg=O
101	732	_	_	_	_	_	_	_	Seg=O
102	full	_	_	_	_	_	_	_	Seg=O
103	-	_	_	_	_	_	_	_	Seg=O
104	time	_	_	_	_	_	_	_	Seg=O
105	employees	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	All	_	_	_	_	_	_	_	Seg=B-seg
108	data	_	_	_	_	_	_	_	Seg=O
109	were	_	_	_	_	_	_	_	Seg=O
110	processed	_	_	_	_	_	_	_	Seg=O
111	through	_	_	_	_	_	_	_	Seg=O
112	SPSS	_	_	_	_	_	_	_	Seg=O
113	22.0	_	_	_	_	_	_	_	Seg=O
114	,	_	_	_	_	_	_	_	Seg=O
115	AMOS	_	_	_	_	_	_	_	Seg=O
116	23.0	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	Smart	_	_	_	_	_	_	_	Seg=O
119	PLS	_	_	_	_	_	_	_	Seg=O
120	3.0	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	Besides	_	_	_	_	_	_	_	Seg=B-seg
123	descriptive	_	_	_	_	_	_	_	Seg=O
124	statistics	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	results	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	explanatory	_	_	_	_	_	_	_	Seg=O
131	factor	_	_	_	_	_	_	_	Seg=O
132	analysis	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	confirmation	_	_	_	_	_	_	_	Seg=O
136	factor	_	_	_	_	_	_	_	Seg=O
137	analysis	_	_	_	_	_	_	_	Seg=O
138	were	_	_	_	_	_	_	_	Seg=O
139	included	_	_	_	_	_	_	_	Seg=O
140	in	_	_	_	_	_	_	_	Seg=O
141	this	_	_	_	_	_	_	_	Seg=O
142	paper	_	_	_	_	_	_	_	Seg=O
143	,	_	_	_	_	_	_	_	Seg=O
144	which	_	_	_	_	_	_	_	Seg=B-seg
145	may	_	_	_	_	_	_	_	Seg=O
146	serve	_	_	_	_	_	_	_	Seg=O
147	as	_	_	_	_	_	_	_	Seg=O
148	a	_	_	_	_	_	_	_	Seg=O
149	good	_	_	_	_	_	_	_	Seg=O
150	reference	_	_	_	_	_	_	_	Seg=O
151	for	_	_	_	_	_	_	_	Seg=O
152	future	_	_	_	_	_	_	_	Seg=O
153	studies	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 20ec367d459abe3e88b7db18a359f087c37bd90e
1	Enteroviruses	_	_	_	_	_	_	_	Seg=B-seg
2	are	_	_	_	_	_	_	_	Seg=O
3	common	_	_	_	_	_	_	_	Seg=O
4	human	_	_	_	_	_	_	_	Seg=O
5	pathogens	_	_	_	_	_	_	_	Seg=O
6	,	_	_	_	_	_	_	_	Seg=O
7	and	_	_	_	_	_	_	_	Seg=B-seg
8	infections	_	_	_	_	_	_	_	Seg=O
9	are	_	_	_	_	_	_	_	Seg=O
10	particularly	_	_	_	_	_	_	_	Seg=O
11	frequent	_	_	_	_	_	_	_	Seg=O
12	in	_	_	_	_	_	_	_	Seg=O
13	children	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	Severe	_	_	_	_	_	_	_	Seg=B-seg
16	infections	_	_	_	_	_	_	_	Seg=O
17	can	_	_	_	_	_	_	_	Seg=O
18	lead	_	_	_	_	_	_	_	Seg=O
19	to	_	_	_	_	_	_	_	Seg=O
20	a	_	_	_	_	_	_	_	Seg=O
21	variety	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	diseases	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	including	_	_	_	_	_	_	_	Seg=B-seg
26	poliomyelitis	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	aseptic	_	_	_	_	_	_	_	Seg=O
29	meningitis	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	myocarditis	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	neonatal	_	_	_	_	_	_	_	Seg=O
34	sepsis	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	Enterovirus	_	_	_	_	_	_	_	Seg=B-seg
37	infections	_	_	_	_	_	_	_	Seg=O
38	have	_	_	_	_	_	_	_	Seg=O
39	also	_	_	_	_	_	_	_	Seg=O
40	been	_	_	_	_	_	_	_	Seg=O
41	implicated	_	_	_	_	_	_	_	Seg=O
42	in	_	_	_	_	_	_	_	Seg=O
43	asthmatic	_	_	_	_	_	_	_	Seg=O
44	exacerbations	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=O
46	type	_	_	_	_	_	_	_	Seg=O
47	1	_	_	_	_	_	_	_	Seg=O
48	diabetes	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	The	_	_	_	_	_	_	_	Seg=B-seg
51	large	_	_	_	_	_	_	_	Seg=O
52	disease	_	_	_	_	_	_	_	Seg=O
53	spectrum	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	closely	_	_	_	_	_	_	_	Seg=O
57	related	_	_	_	_	_	_	_	Seg=O
58	enteroviruses	_	_	_	_	_	_	_	Seg=O
59	may	_	_	_	_	_	_	_	Seg=O
60	be	_	_	_	_	_	_	_	Seg=O
61	partially	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	but	_	_	_	_	_	_	_	Seg=O
64	not	_	_	_	_	_	_	_	Seg=O
65	fully	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	explained	_	_	_	_	_	_	_	Seg=O
68	by	_	_	_	_	_	_	_	Seg=O
69	differences	_	_	_	_	_	_	_	Seg=O
70	in	_	_	_	_	_	_	_	Seg=O
71	tissue	_	_	_	_	_	_	_	Seg=O
72	tropism	_	_	_	_	_	_	_	Seg=O
73	.	_	_	_	_	_	_	_	Seg=O
74	The	_	_	_	_	_	_	_	Seg=B-seg
75	molecular	_	_	_	_	_	_	_	Seg=O
76	mechanisms	_	_	_	_	_	_	_	Seg=O
77	by	_	_	_	_	_	_	_	Seg=B-seg
78	which	_	_	_	_	_	_	_	Seg=O
79	enteroviruses	_	_	_	_	_	_	_	Seg=O
80	cause	_	_	_	_	_	_	_	Seg=O
81	disease	_	_	_	_	_	_	_	Seg=O
82	are	_	_	_	_	_	_	_	Seg=B-seg
83	poorly	_	_	_	_	_	_	_	Seg=O
84	understood	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	but	_	_	_	_	_	_	_	Seg=B-seg
87	there	_	_	_	_	_	_	_	Seg=O
88	is	_	_	_	_	_	_	_	Seg=O
89	increasing	_	_	_	_	_	_	_	Seg=O
90	evidence	_	_	_	_	_	_	_	Seg=O
91	that	_	_	_	_	_	_	_	Seg=B-seg
92	the	_	_	_	_	_	_	_	Seg=O
93	two	_	_	_	_	_	_	_	Seg=O
94	enteroviral	_	_	_	_	_	_	_	Seg=O
95	proteases	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	2A	_	_	_	_	_	_	_	Seg=O
98	pro	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=O
100	3C	_	_	_	_	_	_	_	Seg=O
101	pro	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	are	_	_	_	_	_	_	_	Seg=O
104	important	_	_	_	_	_	_	_	Seg=O
105	mediators	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	pathology	_	_	_	_	_	_	_	Seg=O
108	.	_	_	_	_	_	_	_	Seg=O
109	These	_	_	_	_	_	_	_	Seg=B-seg
110	proteases	_	_	_	_	_	_	_	Seg=O
111	perform	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	posttranslational	_	_	_	_	_	_	_	Seg=O
114	proteolytic	_	_	_	_	_	_	_	Seg=O
115	processing	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	viral	_	_	_	_	_	_	_	Seg=O
119	polyprotein	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	but	_	_	_	_	_	_	_	Seg=B-seg
122	they	_	_	_	_	_	_	_	Seg=O
123	also	_	_	_	_	_	_	_	Seg=O
124	cleave	_	_	_	_	_	_	_	Seg=O
125	several	_	_	_	_	_	_	_	Seg=O
126	host	_	_	_	_	_	_	_	Seg=O
127	-	_	_	_	_	_	_	_	Seg=O
128	cell	_	_	_	_	_	_	_	Seg=O
129	proteins	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=B-seg
131	order	_	_	_	_	_	_	_	Seg=O
132	to	_	_	_	_	_	_	_	Seg=O
133	promote	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	production	_	_	_	_	_	_	_	Seg=O
136	of	_	_	_	_	_	_	_	Seg=O
137	new	_	_	_	_	_	_	_	Seg=O
138	virus	_	_	_	_	_	_	_	Seg=O
139	particles	_	_	_	_	_	_	_	Seg=O
140	,	_	_	_	_	_	_	_	Seg=O
141	as	_	_	_	_	_	_	_	Seg=B-seg
142	well	_	_	_	_	_	_	_	Seg=O
143	as	_	_	_	_	_	_	_	Seg=O
144	to	_	_	_	_	_	_	_	Seg=O
145	evade	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	cellular	_	_	_	_	_	_	_	Seg=O
148	antiviral	_	_	_	_	_	_	_	Seg=O
149	immune	_	_	_	_	_	_	_	Seg=O
150	responses	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	Enterovirus	_	_	_	_	_	_	_	Seg=B-seg
153	-	_	_	_	_	_	_	_	Seg=O
154	associated	_	_	_	_	_	_	_	Seg=O
155	processing	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	cellular	_	_	_	_	_	_	_	Seg=O
158	proteins	_	_	_	_	_	_	_	Seg=O
159	may	_	_	_	_	_	_	_	Seg=O
160	also	_	_	_	_	_	_	_	Seg=O
161	contribute	_	_	_	_	_	_	_	Seg=O
162	to	_	_	_	_	_	_	_	Seg=O
163	pathology	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	as	_	_	_	_	_	_	_	Seg=B-seg
166	elegantly	_	_	_	_	_	_	_	Seg=O
167	demonstrated	_	_	_	_	_	_	_	Seg=O
168	by	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	2A	_	_	_	_	_	_	_	Seg=O
171	pro	_	_	_	_	_	_	_	Seg=O
172	-mediated	_	_	_	_	_	_	_	Seg=O
173	cleavage	_	_	_	_	_	_	_	Seg=O
174	of	_	_	_	_	_	_	_	Seg=O
175	dystrophin	_	_	_	_	_	_	_	Seg=O
176	in	_	_	_	_	_	_	_	Seg=O
177	cardiomyocytes	_	_	_	_	_	_	_	Seg=O
178	contributing	_	_	_	_	_	_	_	Seg=B-seg
179	to	_	_	_	_	_	_	_	Seg=O
180	Coxsackievirus	_	_	_	_	_	_	_	Seg=O
181	-	_	_	_	_	_	_	_	Seg=O
182	induced	_	_	_	_	_	_	_	Seg=O
183	cardiomyopathy	_	_	_	_	_	_	_	Seg=O
184	.	_	_	_	_	_	_	_	Seg=O
185	It	_	_	_	_	_	_	_	Seg=B-seg
186	is	_	_	_	_	_	_	_	Seg=O
187	likely	_	_	_	_	_	_	_	Seg=O
188	that	_	_	_	_	_	_	_	Seg=O
189	improved	_	_	_	_	_	_	_	Seg=O
190	tools	_	_	_	_	_	_	_	Seg=O
191	to	_	_	_	_	_	_	_	Seg=B-seg
192	identify	_	_	_	_	_	_	_	Seg=O
193	targets	_	_	_	_	_	_	_	Seg=O
194	for	_	_	_	_	_	_	_	Seg=O
195	these	_	_	_	_	_	_	_	Seg=O
196	proteases	_	_	_	_	_	_	_	Seg=O
197	will	_	_	_	_	_	_	_	Seg=B-seg
198	reveal	_	_	_	_	_	_	_	Seg=O
199	additional	_	_	_	_	_	_	_	Seg=O
200	host	_	_	_	_	_	_	_	Seg=O
201	protein	_	_	_	_	_	_	_	Seg=O
202	substrates	_	_	_	_	_	_	_	Seg=O
203	that	_	_	_	_	_	_	_	Seg=B-seg
204	can	_	_	_	_	_	_	_	Seg=O
205	be	_	_	_	_	_	_	_	Seg=O
206	linked	_	_	_	_	_	_	_	Seg=O
207	to	_	_	_	_	_	_	_	Seg=O
208	specific	_	_	_	_	_	_	_	Seg=O
209	enterovirus	_	_	_	_	_	_	_	Seg=O
210	-	_	_	_	_	_	_	_	Seg=O
211	associated	_	_	_	_	_	_	_	Seg=O
212	diseases	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O
214	Here	_	_	_	_	_	_	_	Seg=B-seg
215	,	_	_	_	_	_	_	_	Seg=O
216	we	_	_	_	_	_	_	_	Seg=O
217	discuss	_	_	_	_	_	_	_	Seg=O
218	the	_	_	_	_	_	_	_	Seg=O
219	function	_	_	_	_	_	_	_	Seg=O
220	of	_	_	_	_	_	_	_	Seg=O
221	the	_	_	_	_	_	_	_	Seg=O
222	enteroviral	_	_	_	_	_	_	_	Seg=O
223	proteases	_	_	_	_	_	_	_	Seg=O
224	in	_	_	_	_	_	_	_	Seg=O
225	the	_	_	_	_	_	_	_	Seg=O
226	virus	_	_	_	_	_	_	_	Seg=O
227	replication	_	_	_	_	_	_	_	Seg=O
228	cycle	_	_	_	_	_	_	_	Seg=O
229	and	_	_	_	_	_	_	_	Seg=B-seg
230	review	_	_	_	_	_	_	_	Seg=O
231	the	_	_	_	_	_	_	_	Seg=O
232	current	_	_	_	_	_	_	_	Seg=O
233	knowledge	_	_	_	_	_	_	_	Seg=O
234	regarding	_	_	_	_	_	_	_	Seg=B-seg
235	how	_	_	_	_	_	_	_	Seg=O
236	these	_	_	_	_	_	_	_	Seg=O
237	proteases	_	_	_	_	_	_	_	Seg=O
238	modulate	_	_	_	_	_	_	_	Seg=O
239	the	_	_	_	_	_	_	_	Seg=O
240	infected	_	_	_	_	_	_	_	Seg=O
241	cell	_	_	_	_	_	_	_	Seg=O
242	in	_	_	_	_	_	_	_	Seg=B-seg
243	order	_	_	_	_	_	_	_	Seg=O
244	to	_	_	_	_	_	_	_	Seg=O
245	favour	_	_	_	_	_	_	_	Seg=O
246	virus	_	_	_	_	_	_	_	Seg=O
247	replication	_	_	_	_	_	_	_	Seg=O
248	,	_	_	_	_	_	_	_	Seg=O
249	including	_	_	_	_	_	_	_	Seg=B-seg
250	ways	_	_	_	_	_	_	_	Seg=O
251	to	_	_	_	_	_	_	_	Seg=B-seg
252	avoid	_	_	_	_	_	_	_	Seg=O
253	detection	_	_	_	_	_	_	_	Seg=O
254	by	_	_	_	_	_	_	_	Seg=O
255	the	_	_	_	_	_	_	_	Seg=O
256	immune	_	_	_	_	_	_	_	Seg=O
257	system	_	_	_	_	_	_	_	Seg=O
258	.	_	_	_	_	_	_	_	Seg=O
259	We	_	_	_	_	_	_	_	Seg=B-seg
260	also	_	_	_	_	_	_	_	Seg=O
261	highlight	_	_	_	_	_	_	_	Seg=O
262	new	_	_	_	_	_	_	_	Seg=O
263	possibilities	_	_	_	_	_	_	_	Seg=O
264	for	_	_	_	_	_	_	_	Seg=O
265	the	_	_	_	_	_	_	_	Seg=O
266	identification	_	_	_	_	_	_	_	Seg=O
267	of	_	_	_	_	_	_	_	Seg=O
268	protease	_	_	_	_	_	_	_	Seg=O
269	-	_	_	_	_	_	_	_	Seg=O
270	specific	_	_	_	_	_	_	_	Seg=O
271	cellular	_	_	_	_	_	_	_	Seg=O
272	targets	_	_	_	_	_	_	_	Seg=O
273	and	_	_	_	_	_	_	_	Seg=O
274	thereby	_	_	_	_	_	_	_	Seg=O
275	a	_	_	_	_	_	_	_	Seg=O
276	way	_	_	_	_	_	_	_	Seg=O
277	to	_	_	_	_	_	_	_	Seg=B-seg
278	discover	_	_	_	_	_	_	_	Seg=O
279	novel	_	_	_	_	_	_	_	Seg=O
280	mechanisms	_	_	_	_	_	_	_	Seg=O
281	contributing	_	_	_	_	_	_	_	Seg=B-seg
282	to	_	_	_	_	_	_	_	Seg=O
283	disease	_	_	_	_	_	_	_	Seg=O
284	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2134f97f11e3c3aee6903f4971a2d1195f9620b0
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	study	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	infectious	_	_	_	_	_	_	_	Seg=O
5	disease	_	_	_	_	_	_	_	Seg=O
6	outbreaks	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	required	_	_	_	_	_	_	_	Seg=O
9	to	_	_	_	_	_	_	_	Seg=B-seg
10	train	_	_	_	_	_	_	_	Seg=O
11-12	today's	_	_	_	_	_	_	_	_
11	today	_	_	_	_	_	_	_	Seg=O
12	's	_	_	_	_	_	_	_	Seg=O
13	epidemiologists	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	A	_	_	_	_	_	_	_	Seg=B-seg
16	typical	_	_	_	_	_	_	_	Seg=O
17	way	_	_	_	_	_	_	_	Seg=O
18	to	_	_	_	_	_	_	_	Seg=B-seg
19	introduce	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=O
21	explain	_	_	_	_	_	_	_	Seg=O
22	key	_	_	_	_	_	_	_	Seg=O
23	epidemiological	_	_	_	_	_	_	_	Seg=O
24	concepts	_	_	_	_	_	_	_	Seg=O
25	is	_	_	_	_	_	_	_	Seg=B-seg
26	through	_	_	_	_	_	_	_	Seg=O
27	the	_	_	_	_	_	_	_	Seg=O
28	analysis	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	a	_	_	_	_	_	_	_	Seg=O
31	historical	_	_	_	_	_	_	_	Seg=O
32	outbreak	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	There	_	_	_	_	_	_	_	Seg=B-seg
35	are	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	however	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	few	_	_	_	_	_	_	_	Seg=O
40	training	_	_	_	_	_	_	_	Seg=O
41	options	_	_	_	_	_	_	_	Seg=O
42	that	_	_	_	_	_	_	_	Seg=B-seg
43	explicitly	_	_	_	_	_	_	_	Seg=O
44	utilise	_	_	_	_	_	_	_	Seg=O
45	real	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	time	_	_	_	_	_	_	_	Seg=O
48	simulated	_	_	_	_	_	_	_	Seg=O
49	stochastic	_	_	_	_	_	_	_	Seg=O
50	outbreaks	_	_	_	_	_	_	_	Seg=O
51	where	_	_	_	_	_	_	_	Seg=B-seg
52	the	_	_	_	_	_	_	_	Seg=O
53	participants	_	_	_	_	_	_	_	Seg=O
54	themselves	_	_	_	_	_	_	_	Seg=O
55	comprise	_	_	_	_	_	_	_	Seg=O
56	the	_	_	_	_	_	_	_	Seg=O
57	dataset	_	_	_	_	_	_	_	Seg=O
58	they	_	_	_	_	_	_	_	Seg=B-seg
59	subsequently	_	_	_	_	_	_	_	Seg=O
60	analyse	_	_	_	_	_	_	_	Seg=O
61	.	_	_	_	_	_	_	_	Seg=O
62	In	_	_	_	_	_	_	_	Seg=B-seg
63	this	_	_	_	_	_	_	_	Seg=O
64	paper	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	we	_	_	_	_	_	_	_	Seg=O
67	present	_	_	_	_	_	_	_	Seg=O
68	a	_	_	_	_	_	_	_	Seg=O
69	teaching	_	_	_	_	_	_	_	Seg=O
70	exercise	_	_	_	_	_	_	_	Seg=O
71	in	_	_	_	_	_	_	_	Seg=B-seg
72	which	_	_	_	_	_	_	_	Seg=O
73	an	_	_	_	_	_	_	_	Seg=O
74	infectious	_	_	_	_	_	_	_	Seg=O
75	disease	_	_	_	_	_	_	_	Seg=O
76	outbreak	_	_	_	_	_	_	_	Seg=O
77	is	_	_	_	_	_	_	_	Seg=O
78	simulated	_	_	_	_	_	_	_	Seg=O
79	over	_	_	_	_	_	_	_	Seg=O
80	a	_	_	_	_	_	_	_	Seg=O
81	five	_	_	_	_	_	_	_	Seg=O
82	-	_	_	_	_	_	_	_	Seg=O
83	day	_	_	_	_	_	_	_	Seg=O
84	period	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=B-seg
86	subsequently	_	_	_	_	_	_	_	Seg=O
87	analysed	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	We	_	_	_	_	_	_	_	Seg=B-seg
90	iteratively	_	_	_	_	_	_	_	Seg=O
91	developed	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	teaching	_	_	_	_	_	_	_	Seg=O
94	exercise	_	_	_	_	_	_	_	Seg=O
95	to	_	_	_	_	_	_	_	Seg=B-seg
96	offer	_	_	_	_	_	_	_	Seg=O
97	additional	_	_	_	_	_	_	_	Seg=O
98	insight	_	_	_	_	_	_	_	Seg=O
99	into	_	_	_	_	_	_	_	Seg=O
100	analysing	_	_	_	_	_	_	_	Seg=O
101	an	_	_	_	_	_	_	_	Seg=O
102	outbreak	_	_	_	_	_	_	_	Seg=O
103	.	_	_	_	_	_	_	_	Seg=O
104	An	_	_	_	_	_	_	_	Seg=B-seg
105	R	_	_	_	_	_	_	_	Seg=O
106	package	_	_	_	_	_	_	_	Seg=O
107	for	_	_	_	_	_	_	_	Seg=O
108	visualisation	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	analysis	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=O
112	simulation	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	outbreak	_	_	_	_	_	_	_	Seg=O
116	data	_	_	_	_	_	_	_	Seg=O
117	was	_	_	_	_	_	_	_	Seg=O
118	developed	_	_	_	_	_	_	_	Seg=O
119	to	_	_	_	_	_	_	_	Seg=B-seg
120	accompany	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	practical	_	_	_	_	_	_	_	Seg=O
123	to	_	_	_	_	_	_	_	Seg=B-seg
124	reinforce	_	_	_	_	_	_	_	Seg=O
125	learning	_	_	_	_	_	_	_	Seg=O
126	outcomes	_	_	_	_	_	_	_	Seg=O
127	.	_	_	_	_	_	_	_	Seg=O
128	Computer	_	_	_	_	_	_	_	Seg=B-seg
129	simulations	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	outbreak	_	_	_	_	_	_	_	Seg=O
133	revealed	_	_	_	_	_	_	_	Seg=O
134	deviations	_	_	_	_	_	_	_	Seg=O
135	from	_	_	_	_	_	_	_	Seg=O
136	observed	_	_	_	_	_	_	_	Seg=O
137	dynamics	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	highlighting	_	_	_	_	_	_	_	Seg=B-seg
140	how	_	_	_	_	_	_	_	Seg=B-seg
141	simplifying	_	_	_	_	_	_	_	Seg=O
142	assumptions	_	_	_	_	_	_	_	Seg=O
143	conventionally	_	_	_	_	_	_	_	Seg=B-seg
144	made	_	_	_	_	_	_	_	Seg=O
145	in	_	_	_	_	_	_	_	Seg=O
146	mathematical	_	_	_	_	_	_	_	Seg=O
147	models	_	_	_	_	_	_	_	Seg=O
148	often	_	_	_	_	_	_	_	Seg=B-seg
149	differ	_	_	_	_	_	_	_	Seg=O
150	from	_	_	_	_	_	_	_	Seg=O
151	reality	_	_	_	_	_	_	_	Seg=O
152	.	_	_	_	_	_	_	_	Seg=O
153	Here	_	_	_	_	_	_	_	Seg=B-seg
154	we	_	_	_	_	_	_	_	Seg=O
155	provide	_	_	_	_	_	_	_	Seg=O
156	a	_	_	_	_	_	_	_	Seg=O
157	pedagogical	_	_	_	_	_	_	_	Seg=O
158	tool	_	_	_	_	_	_	_	Seg=O
159	for	_	_	_	_	_	_	_	Seg=O
160	others	_	_	_	_	_	_	_	Seg=O
161	to	_	_	_	_	_	_	_	Seg=B-seg
162	use	_	_	_	_	_	_	_	Seg=O
163	and	_	_	_	_	_	_	_	Seg=O
164	adapt	_	_	_	_	_	_	_	Seg=O
165	in	_	_	_	_	_	_	_	Seg=O
166	their	_	_	_	_	_	_	_	Seg=O
167	own	_	_	_	_	_	_	_	Seg=O
168	settings	_	_	_	_	_	_	_	Seg=O
169	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 21a551af356295ada6e657054646444bca9d202b
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	review	_	_	_	_	_	_	_	Seg=O
3	summarizes	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	current	_	_	_	_	_	_	_	Seg=O
6	knowledge	_	_	_	_	_	_	_	Seg=O
7	on	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	physiological	_	_	_	_	_	_	_	Seg=O
10	action	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	endogenous	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=O
14	exogenous	_	_	_	_	_	_	_	Seg=O
15	pulmonary	_	_	_	_	_	_	_	Seg=O
16	surfactant	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	role	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	different	_	_	_	_	_	_	_	Seg=O
22	types	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	animal	_	_	_	_	_	_	_	Seg=O
25	-	_	_	_	_	_	_	_	Seg=O
26	derived	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=O
28	synthetic	_	_	_	_	_	_	_	Seg=O
29	surfactants	_	_	_	_	_	_	_	Seg=O
30	for	_	_	_	_	_	_	_	Seg=O
31	RDS	_	_	_	_	_	_	_	Seg=O
32	therapy	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	different	_	_	_	_	_	_	_	Seg=O
35	modes	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	administration	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	potential	_	_	_	_	_	_	_	Seg=O
40	risks	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	strategies	_	_	_	_	_	_	_	Seg=O
43	of	_	_	_	_	_	_	_	Seg=O
44	ventilation	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=B-seg
47	highlights	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	most	_	_	_	_	_	_	_	Seg=O
50	promising	_	_	_	_	_	_	_	Seg=O
51	aims	_	_	_	_	_	_	_	Seg=O
52	for	_	_	_	_	_	_	_	Seg=O
53	future	_	_	_	_	_	_	_	Seg=O
54	development	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	Scientists	_	_	_	_	_	_	_	Seg=B-seg
57	have	_	_	_	_	_	_	_	Seg=O
58	clarified	_	_	_	_	_	_	_	Seg=O
59	the	_	_	_	_	_	_	_	Seg=O
60	physicochemical	_	_	_	_	_	_	_	Seg=O
61	properties	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	functions	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	different	_	_	_	_	_	_	_	Seg=O
67	components	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	surfactant	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=B-seg
72	part	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	this	_	_	_	_	_	_	_	Seg=O
75	successful	_	_	_	_	_	_	_	Seg=O
76	research	_	_	_	_	_	_	_	Seg=O
77	is	_	_	_	_	_	_	_	Seg=O
78	derived	_	_	_	_	_	_	_	Seg=O
79	from	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	characterization	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	genetic	_	_	_	_	_	_	_	Seg=O
84	diseases	_	_	_	_	_	_	_	Seg=O
85	affecting	_	_	_	_	_	_	_	Seg=B-seg
86	surfactant	_	_	_	_	_	_	_	Seg=O
87	composition	_	_	_	_	_	_	_	Seg=O
88	or	_	_	_	_	_	_	_	Seg=O
89	function	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O
91	Knowledge	_	_	_	_	_	_	_	Seg=B-seg
92	from	_	_	_	_	_	_	_	Seg=O
93	functional	_	_	_	_	_	_	_	Seg=O
94	tests	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	surfactant	_	_	_	_	_	_	_	Seg=O
97	action	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	its	_	_	_	_	_	_	_	Seg=O
100	immunochemistry	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	kinetics	_	_	_	_	_	_	_	Seg=O
103	and	_	_	_	_	_	_	_	Seg=O
104	homeostasis	_	_	_	_	_	_	_	Seg=O
105	are	_	_	_	_	_	_	_	Seg=O
106	important	_	_	_	_	_	_	_	Seg=O
107	also	_	_	_	_	_	_	_	Seg=B-seg
108	for	_	_	_	_	_	_	_	Seg=O
109	improving	_	_	_	_	_	_	_	Seg=O
110	therapy	_	_	_	_	_	_	_	Seg=O
111	with	_	_	_	_	_	_	_	Seg=O
112	animal	_	_	_	_	_	_	_	Seg=O
113	-	_	_	_	_	_	_	_	Seg=O
114	derived	_	_	_	_	_	_	_	Seg=O
115	surfactant	_	_	_	_	_	_	_	Seg=O
116	preparations	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	for	_	_	_	_	_	_	_	Seg=O
119	the	_	_	_	_	_	_	_	Seg=O
120	development	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	modified	_	_	_	_	_	_	_	Seg=O
123	surfactants	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	In	_	_	_	_	_	_	_	Seg=B-seg
126	the	_	_	_	_	_	_	_	Seg=O
127	past	_	_	_	_	_	_	_	Seg=O
128	decade	_	_	_	_	_	_	_	Seg=O
129	newly	_	_	_	_	_	_	_	Seg=O
130	designed	_	_	_	_	_	_	_	Seg=O
131	artificial	_	_	_	_	_	_	_	Seg=O
132	surfactants	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=O
134	additives	_	_	_	_	_	_	_	Seg=O
135	have	_	_	_	_	_	_	_	Seg=O
136	gained	_	_	_	_	_	_	_	Seg=O
137	much	_	_	_	_	_	_	_	Seg=O
138	attention	_	_	_	_	_	_	_	Seg=O
139	and	_	_	_	_	_	_	_	Seg=B-seg
140	have	_	_	_	_	_	_	_	Seg=O
141	proven	_	_	_	_	_	_	_	Seg=O
142	different	_	_	_	_	_	_	_	Seg=O
143	advantages	_	_	_	_	_	_	_	Seg=O
144	,	_	_	_	_	_	_	_	Seg=O
145	but	_	_	_	_	_	_	_	Seg=B-seg
146	their	_	_	_	_	_	_	_	Seg=O
147	particular	_	_	_	_	_	_	_	Seg=O
148	role	_	_	_	_	_	_	_	Seg=O
149	still	_	_	_	_	_	_	_	Seg=O
150	has	_	_	_	_	_	_	_	Seg=O
151	to	_	_	_	_	_	_	_	Seg=O
152	be	_	_	_	_	_	_	_	Seg=O
153	defined	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 21a572a6c0f75baa745480e28b596d73d4492cc8
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	COVID-19	_	_	_	_	_	_	_	Seg=O
3	pandemic	_	_	_	_	_	_	_	Seg=O
4	has	_	_	_	_	_	_	_	Seg=O
5	resulted	_	_	_	_	_	_	_	Seg=O
6	in	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	proliferation	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	clinical	_	_	_	_	_	_	_	Seg=O
11	trials	_	_	_	_	_	_	_	Seg=O
12	that	_	_	_	_	_	_	_	Seg=B-seg
13	are	_	_	_	_	_	_	_	Seg=O
14	designed	_	_	_	_	_	_	_	Seg=O
15	to	_	_	_	_	_	_	_	Seg=B-seg
16	slow	_	_	_	_	_	_	_	Seg=O
17	the	_	_	_	_	_	_	_	Seg=O
18	spread	_	_	_	_	_	_	_	Seg=O
19	of	_	_	_	_	_	_	_	Seg=O
20	SARS	_	_	_	_	_	_	_	Seg=O
21	-	_	_	_	_	_	_	_	Seg=O
22	CoV-2	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	virus	_	_	_	_	_	_	_	Seg=O
26	that	_	_	_	_	_	_	_	Seg=B-seg
27	causes	_	_	_	_	_	_	_	Seg=O
28	COVID-19	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	The	_	_	_	_	_	_	_	Seg=B-seg
31	overwhelming	_	_	_	_	_	_	_	Seg=O
32	majority	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	cardiovascular	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	cancer	_	_	_	_	_	_	_	Seg=O
37	patients	_	_	_	_	_	_	_	Seg=O
38	are	_	_	_	_	_	_	_	Seg=O
39	at	_	_	_	_	_	_	_	Seg=O
40	increased	_	_	_	_	_	_	_	Seg=O
41	risk	_	_	_	_	_	_	_	Seg=O
42	for	_	_	_	_	_	_	_	Seg=O
43	SARS	_	_	_	_	_	_	_	Seg=O
44	-	_	_	_	_	_	_	_	Seg=O
45	CoV-2	_	_	_	_	_	_	_	Seg=O
46	infection	_	_	_	_	_	_	_	Seg=O
47	;	_	_	_	_	_	_	_	Seg=O
48	accordingly	_	_	_	_	_	_	_	Seg=B-seg
49	,	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	cardiovascular	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	cardio	_	_	_	_	_	_	_	Seg=O
54	-	_	_	_	_	_	_	_	Seg=O
55	oncology	_	_	_	_	_	_	_	Seg=O
56	communities	_	_	_	_	_	_	_	Seg=O
57	are	_	_	_	_	_	_	_	Seg=O
58	playing	_	_	_	_	_	_	_	Seg=O
59	a	_	_	_	_	_	_	_	Seg=O
60	major	_	_	_	_	_	_	_	Seg=O
61	role	_	_	_	_	_	_	_	Seg=O
62	in	_	_	_	_	_	_	_	Seg=B-seg
63	caring	_	_	_	_	_	_	_	Seg=O
64	for	_	_	_	_	_	_	_	Seg=O
65	COVID-19	_	_	_	_	_	_	_	Seg=O
66	patients	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	Many	_	_	_	_	_	_	_	Seg=B-seg
69	of	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	therapeutic	_	_	_	_	_	_	_	Seg=O
72	agents	_	_	_	_	_	_	_	Seg=O
73	that	_	_	_	_	_	_	_	Seg=B-seg
74	are	_	_	_	_	_	_	_	Seg=O
75	being	_	_	_	_	_	_	_	Seg=O
76	used	_	_	_	_	_	_	_	Seg=O
77	to	_	_	_	_	_	_	_	Seg=B-seg
78	treat	_	_	_	_	_	_	_	Seg=O
79	patients	_	_	_	_	_	_	_	Seg=O
80	with	_	_	_	_	_	_	_	Seg=O
81	COVID-19	_	_	_	_	_	_	_	Seg=O
82	are	_	_	_	_	_	_	_	Seg=B-seg
83	repurposed	_	_	_	_	_	_	_	Seg=O
84	treatments	_	_	_	_	_	_	_	Seg=O
85	for	_	_	_	_	_	_	_	Seg=O
86	influenza	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	drugs	_	_	_	_	_	_	_	Seg=O
89	that	_	_	_	_	_	_	_	Seg=B-seg
90	were	_	_	_	_	_	_	_	Seg=O
91	not	_	_	_	_	_	_	_	Seg=O
92	effective	_	_	_	_	_	_	_	Seg=O
93	in	_	_	_	_	_	_	_	Seg=O
94	Ebola	_	_	_	_	_	_	_	Seg=O
95	patients	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	or	_	_	_	_	_	_	_	Seg=B-seg
98	treatments	_	_	_	_	_	_	_	Seg=O
99	for	_	_	_	_	_	_	_	Seg=O
100	malaria	_	_	_	_	_	_	_	Seg=O
101	that	_	_	_	_	_	_	_	Seg=B-seg
102	were	_	_	_	_	_	_	_	Seg=O
103	developed	_	_	_	_	_	_	_	Seg=O
104	decades	_	_	_	_	_	_	_	Seg=O
105	ago	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	and	_	_	_	_	_	_	_	Seg=B-seg
108	are	_	_	_	_	_	_	_	Seg=O
109	unlikely	_	_	_	_	_	_	_	Seg=O
110	to	_	_	_	_	_	_	_	Seg=O
111	be	_	_	_	_	_	_	_	Seg=O
112	familiar	_	_	_	_	_	_	_	Seg=O
113	to	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	cardiovascular	_	_	_	_	_	_	_	Seg=O
116	and	_	_	_	_	_	_	_	Seg=O
117	cardio	_	_	_	_	_	_	_	Seg=O
118	-	_	_	_	_	_	_	_	Seg=O
119	oncology	_	_	_	_	_	_	_	Seg=O
120	communities	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	Here	_	_	_	_	_	_	_	Seg=B-seg
123	we	_	_	_	_	_	_	_	Seg=O
124	have	_	_	_	_	_	_	_	Seg=O
125	provided	_	_	_	_	_	_	_	Seg=O
126	a	_	_	_	_	_	_	_	Seg=O
127	foundation	_	_	_	_	_	_	_	Seg=O
128	for	_	_	_	_	_	_	_	Seg=O
129	cardiovascular	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	cardio	_	_	_	_	_	_	_	Seg=O
132	-	_	_	_	_	_	_	_	Seg=O
133	oncology	_	_	_	_	_	_	_	Seg=O
134	physicians	_	_	_	_	_	_	_	Seg=O
135	who	_	_	_	_	_	_	_	Seg=B-seg
136	are	_	_	_	_	_	_	_	Seg=O
137	on	_	_	_	_	_	_	_	Seg=O
138	the	_	_	_	_	_	_	_	Seg=O
139	frontline	_	_	_	_	_	_	_	Seg=O
140	providing	_	_	_	_	_	_	_	Seg=B-seg
141	care	_	_	_	_	_	_	_	Seg=O
142	to	_	_	_	_	_	_	_	Seg=O
143	COVID-19	_	_	_	_	_	_	_	Seg=O
144	patients	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	so	_	_	_	_	_	_	_	Seg=B-seg
147	that	_	_	_	_	_	_	_	Seg=O
148	they	_	_	_	_	_	_	_	Seg=O
149	can	_	_	_	_	_	_	_	Seg=O
150	better	_	_	_	_	_	_	_	Seg=O
151	understand	_	_	_	_	_	_	_	Seg=O
152	the	_	_	_	_	_	_	_	Seg=O
153	emerging	_	_	_	_	_	_	_	Seg=O
154	cardiovascular	_	_	_	_	_	_	_	Seg=O
155	epidemiology	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	COVID-19	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	as	_	_	_	_	_	_	_	Seg=O
160	well	_	_	_	_	_	_	_	Seg=O
161	as	_	_	_	_	_	_	_	Seg=O
162	the	_	_	_	_	_	_	_	Seg=O
163	biological	_	_	_	_	_	_	_	Seg=O
164	rationale	_	_	_	_	_	_	_	Seg=O
165	for	_	_	_	_	_	_	_	Seg=O
166	the	_	_	_	_	_	_	_	Seg=O
167	clinical	_	_	_	_	_	_	_	Seg=O
168	trials	_	_	_	_	_	_	_	Seg=O
169	that	_	_	_	_	_	_	_	Seg=B-seg
170	are	_	_	_	_	_	_	_	Seg=O
171	ongoing	_	_	_	_	_	_	_	Seg=O
172	for	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=O
174	treatment	_	_	_	_	_	_	_	Seg=O
175	of	_	_	_	_	_	_	_	Seg=O
176	COVID-19	_	_	_	_	_	_	_	Seg=O
177	patients	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 23d06bd7a12e6e729f5b2b06bbe825eb9a91270e
1	Severe	_	_	_	_	_	_	_	Seg=B-seg
2	acute	_	_	_	_	_	_	_	Seg=O
3	respiratory	_	_	_	_	_	_	_	Seg=O
4	syndrome	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	SARS	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	is	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	recently	_	_	_	_	_	_	_	Seg=O
11	described	_	_	_	_	_	_	_	Seg=O
12	infectious	_	_	_	_	_	_	_	Seg=O
13	entity	_	_	_	_	_	_	_	Seg=O
14	with	_	_	_	_	_	_	_	Seg=O
15	salient	_	_	_	_	_	_	_	Seg=O
16	features	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	fever	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	headache	_	_	_	_	_	_	_	Seg=O
21	and	_	_	_	_	_	_	_	Seg=O
22	malaise	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	with	_	_	_	_	_	_	_	Seg=O
25	rapid	_	_	_	_	_	_	_	Seg=O
26	progression	_	_	_	_	_	_	_	Seg=O
27	to	_	_	_	_	_	_	_	Seg=O
28	pneumonitis	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	The	_	_	_	_	_	_	_	Seg=B-seg
31	etiology	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	SARS	_	_	_	_	_	_	_	Seg=O
34	is	_	_	_	_	_	_	_	Seg=O
35	likely	_	_	_	_	_	_	_	Seg=O
36	a	_	_	_	_	_	_	_	Seg=O
37	novel	_	_	_	_	_	_	_	Seg=O
38	coronavirus	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	During	_	_	_	_	_	_	_	Seg=B-seg
41	the	_	_	_	_	_	_	_	Seg=O
42	winter	_	_	_	_	_	_	_	Seg=O
43	of	_	_	_	_	_	_	_	Seg=O
44	2003	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	an	_	_	_	_	_	_	_	Seg=O
47	outbreak	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	SARS	_	_	_	_	_	_	_	Seg=O
50	involving	_	_	_	_	_	_	_	Seg=B-seg
51	several	_	_	_	_	_	_	_	Seg=O
52	hospitals	_	_	_	_	_	_	_	Seg=O
53	occurred	_	_	_	_	_	_	_	Seg=B-seg
54	in	_	_	_	_	_	_	_	Seg=O
55	Toronto	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	Canada	_	_	_	_	_	_	_	Seg=O
58	.	_	_	_	_	_	_	_	Seg=O
59	We	_	_	_	_	_	_	_	Seg=B-seg
60	describe	_	_	_	_	_	_	_	Seg=O
61	a	_	_	_	_	_	_	_	Seg=O
62	patient	_	_	_	_	_	_	_	Seg=O
63	post	_	_	_	_	_	_	_	Seg=O
64	liver	_	_	_	_	_	_	_	Seg=O
65	transplant	_	_	_	_	_	_	_	Seg=O
66	who	_	_	_	_	_	_	_	Seg=B-seg
67	contracted	_	_	_	_	_	_	_	Seg=O
68	SARS	_	_	_	_	_	_	_	Seg=O
69	and	_	_	_	_	_	_	_	Seg=B-seg
70	died	_	_	_	_	_	_	_	Seg=O
71	during	_	_	_	_	_	_	_	Seg=O
72	the	_	_	_	_	_	_	_	Seg=O
73	outbreak	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	with	_	_	_	_	_	_	_	Seg=O
76	subsequent	_	_	_	_	_	_	_	Seg=O
77	infection	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	family	_	_	_	_	_	_	_	Seg=O
80	and	_	_	_	_	_	_	_	Seg=O
81	several	_	_	_	_	_	_	_	Seg=O
82	health	_	_	_	_	_	_	_	Seg=O
83	-	_	_	_	_	_	_	_	Seg=O
84	care	_	_	_	_	_	_	_	Seg=O
85	workers	_	_	_	_	_	_	_	Seg=O
86	.	_	_	_	_	_	_	_	Seg=O
87	A	_	_	_	_	_	_	_	Seg=B-seg
88	novel	_	_	_	_	_	_	_	Seg=O
89	coronavirus	_	_	_	_	_	_	_	Seg=O
90	was	_	_	_	_	_	_	_	Seg=O
91	detected	_	_	_	_	_	_	_	Seg=O
92	in	_	_	_	_	_	_	_	Seg=O
93	respiratory	_	_	_	_	_	_	_	Seg=O
94	specimens	_	_	_	_	_	_	_	Seg=O
95	by	_	_	_	_	_	_	_	Seg=O
96	PCR	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	Due	_	_	_	_	_	_	_	Seg=B-seg
99	to	_	_	_	_	_	_	_	Seg=O
100	the	_	_	_	_	_	_	_	Seg=O
101	potential	_	_	_	_	_	_	_	Seg=O
102	severity	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	SARS	_	_	_	_	_	_	_	Seg=O
105	in	_	_	_	_	_	_	_	Seg=O
106	transplant	_	_	_	_	_	_	_	Seg=O
107	recipients	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	large	_	_	_	_	_	_	_	Seg=O
111	number	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	cases	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	SARS	_	_	_	_	_	_	_	Seg=O
116	in	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	community	_	_	_	_	_	_	_	Seg=O
119	,	_	_	_	_	_	_	_	Seg=O
120	in	_	_	_	_	_	_	_	Seg=B-seg
121	order	_	_	_	_	_	_	_	Seg=O
122	to	_	_	_	_	_	_	_	Seg=O
123	avoid	_	_	_	_	_	_	_	Seg=O
124	transmission	_	_	_	_	_	_	_	Seg=O
125	of	_	_	_	_	_	_	_	Seg=O
126	SARS	_	_	_	_	_	_	_	Seg=O
127	from	_	_	_	_	_	_	_	Seg=O
128	a	_	_	_	_	_	_	_	Seg=O
129	donor	_	_	_	_	_	_	_	Seg=O
130	,	_	_	_	_	_	_	_	Seg=O
131	we	_	_	_	_	_	_	_	Seg=B-seg
132	developed	_	_	_	_	_	_	_	Seg=O
133	guidelines	_	_	_	_	_	_	_	Seg=O
134	for	_	_	_	_	_	_	_	Seg=O
135	SARS	_	_	_	_	_	_	_	Seg=O
136	screening	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	organ	_	_	_	_	_	_	_	Seg=O
139	donors	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	A	_	_	_	_	_	_	_	Seg=B-seg
142	screening	_	_	_	_	_	_	_	Seg=O
143	tool	_	_	_	_	_	_	_	Seg=O
144	based	_	_	_	_	_	_	_	Seg=B-seg
145	on	_	_	_	_	_	_	_	Seg=O
146	potential	_	_	_	_	_	_	_	Seg=O
147	hospital	_	_	_	_	_	_	_	Seg=O
148	SARS	_	_	_	_	_	_	_	Seg=O
149	exposure	_	_	_	_	_	_	_	Seg=O
150	,	_	_	_	_	_	_	_	Seg=O
151	clinical	_	_	_	_	_	_	_	Seg=O
152	symptoms	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	and	_	_	_	_	_	_	_	Seg=O
155	epidemiological	_	_	_	_	_	_	_	Seg=O
156	exposure	_	_	_	_	_	_	_	Seg=O
157	was	_	_	_	_	_	_	_	Seg=B-seg
158	used	_	_	_	_	_	_	_	Seg=O
159	to	_	_	_	_	_	_	_	Seg=B-seg
160	stratify	_	_	_	_	_	_	_	Seg=O
161	donors	_	_	_	_	_	_	_	Seg=O
162	as	_	_	_	_	_	_	_	Seg=O
163	high	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	intermediate	_	_	_	_	_	_	_	Seg=O
166	or	_	_	_	_	_	_	_	Seg=O
167	low	_	_	_	_	_	_	_	Seg=O
168	risk	_	_	_	_	_	_	_	Seg=O
169	for	_	_	_	_	_	_	_	Seg=O
170	SARS	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	As	_	_	_	_	_	_	_	Seg=B-seg
173	SARS	_	_	_	_	_	_	_	Seg=O
174	spreads	_	_	_	_	_	_	_	Seg=O
175	throughout	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	world	_	_	_	_	_	_	_	Seg=O
178	,	_	_	_	_	_	_	_	Seg=O
179	it	_	_	_	_	_	_	_	Seg=B-seg
180	may	_	_	_	_	_	_	_	Seg=O
181	become	_	_	_	_	_	_	_	Seg=O
182	an	_	_	_	_	_	_	_	Seg=O
183	increasingly	_	_	_	_	_	_	_	Seg=O
184	significant	_	_	_	_	_	_	_	Seg=O
185	problem	_	_	_	_	_	_	_	Seg=O
186	for	_	_	_	_	_	_	_	Seg=O
187	transplant	_	_	_	_	_	_	_	Seg=O
188	patients	_	_	_	_	_	_	_	Seg=O
189	and	_	_	_	_	_	_	_	Seg=O
190	programs	_	_	_	_	_	_	_	Seg=O
191	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 247d3262ad1b15f331a89f70eec56b34dbe6b8b5
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	.	_	_	_	_	_	_	_	Seg=O
3	The	_	_	_	_	_	_	_	Seg=B-seg
4	negative	_	_	_	_	_	_	_	Seg=O
5	binomial	_	_	_	_	_	_	_	Seg=O
6	distribution	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	used	_	_	_	_	_	_	_	Seg=O
9	commonly	_	_	_	_	_	_	_	Seg=O
10	throughout	_	_	_	_	_	_	_	Seg=O
11	biology	_	_	_	_	_	_	_	Seg=O
12	as	_	_	_	_	_	_	_	Seg=O
13	a	_	_	_	_	_	_	_	Seg=O
14	model	_	_	_	_	_	_	_	Seg=O
15	for	_	_	_	_	_	_	_	Seg=O
16	overdispersed	_	_	_	_	_	_	_	Seg=O
17	count	_	_	_	_	_	_	_	Seg=O
18	data	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	with	_	_	_	_	_	_	_	Seg=O
21	attention	_	_	_	_	_	_	_	Seg=O
22	focused	_	_	_	_	_	_	_	Seg=B-seg
23	on	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	negative	_	_	_	_	_	_	_	Seg=O
26	binomial	_	_	_	_	_	_	_	Seg=O
27	dispersion	_	_	_	_	_	_	_	Seg=O
28	parameter	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	k.	_	_	_	_	_	_	_	Seg=O
31	A	_	_	_	_	_	_	_	Seg=B-seg
32	substantial	_	_	_	_	_	_	_	Seg=O
33	literature	_	_	_	_	_	_	_	Seg=O
34	exists	_	_	_	_	_	_	_	Seg=O
35	on	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	estimation	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	k	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	but	_	_	_	_	_	_	_	Seg=B-seg
42	most	_	_	_	_	_	_	_	Seg=O
43	attention	_	_	_	_	_	_	_	Seg=O
44	has	_	_	_	_	_	_	_	Seg=O
45	focused	_	_	_	_	_	_	_	Seg=O
46	on	_	_	_	_	_	_	_	Seg=O
47	datasets	_	_	_	_	_	_	_	Seg=O
48	that	_	_	_	_	_	_	_	Seg=B-seg
49	are	_	_	_	_	_	_	_	Seg=O
50	not	_	_	_	_	_	_	_	Seg=O
51	highly	_	_	_	_	_	_	_	Seg=O
52	overdispersed	_	_	_	_	_	_	_	Seg=O
53	(	_	_	_	_	_	_	_	Seg=B-seg
54	i.e.	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	those	_	_	_	_	_	_	_	Seg=O
57	with	_	_	_	_	_	_	_	Seg=O
58	k$1	_	_	_	_	_	_	_	Seg=O
59	)	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=B-seg
62	the	_	_	_	_	_	_	_	Seg=O
63	accuracy	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	confidence	_	_	_	_	_	_	_	Seg=O
66	intervals	_	_	_	_	_	_	_	Seg=O
67	estimated	_	_	_	_	_	_	_	Seg=B-seg
68	for	_	_	_	_	_	_	_	Seg=O
69	k	_	_	_	_	_	_	_	Seg=O
70	is	_	_	_	_	_	_	_	Seg=B-seg
71	typically	_	_	_	_	_	_	_	Seg=O
72	not	_	_	_	_	_	_	_	Seg=O
73	explored	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	Methodology	_	_	_	_	_	_	_	Seg=B-seg
76	.	_	_	_	_	_	_	_	Seg=O
77	This	_	_	_	_	_	_	_	Seg=B-seg
78	article	_	_	_	_	_	_	_	Seg=O
79	presents	_	_	_	_	_	_	_	Seg=O
80	a	_	_	_	_	_	_	_	Seg=O
81	simulation	_	_	_	_	_	_	_	Seg=O
82	study	_	_	_	_	_	_	_	Seg=O
83	exploring	_	_	_	_	_	_	_	Seg=B-seg
84	the	_	_	_	_	_	_	_	Seg=O
85	bias	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	precision	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	and	_	_	_	_	_	_	_	Seg=O
90	confidence	_	_	_	_	_	_	_	Seg=O
91	interval	_	_	_	_	_	_	_	Seg=O
92	coverage	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=O
94	maximum	_	_	_	_	_	_	_	Seg=O
95	-	_	_	_	_	_	_	_	Seg=O
96	likelihood	_	_	_	_	_	_	_	Seg=O
97	estimates	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	k	_	_	_	_	_	_	_	Seg=O
100	from	_	_	_	_	_	_	_	Seg=O
101	highly	_	_	_	_	_	_	_	Seg=O
102	overdispersed	_	_	_	_	_	_	_	Seg=O
103	distributions	_	_	_	_	_	_	_	Seg=O
104	.	_	_	_	_	_	_	_	Seg=O
105	In	_	_	_	_	_	_	_	Seg=B-seg
106	addition	_	_	_	_	_	_	_	Seg=O
107	to	_	_	_	_	_	_	_	Seg=O
108	exploring	_	_	_	_	_	_	_	Seg=O
109	small	_	_	_	_	_	_	_	Seg=O
110	-	_	_	_	_	_	_	_	Seg=O
111	sample	_	_	_	_	_	_	_	Seg=O
112	bias	_	_	_	_	_	_	_	Seg=O
113	on	_	_	_	_	_	_	_	Seg=O
114	negative	_	_	_	_	_	_	_	Seg=O
115	binomial	_	_	_	_	_	_	_	Seg=O
116	estimates	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	study	_	_	_	_	_	_	_	Seg=O
120	addresses	_	_	_	_	_	_	_	Seg=O
121	estimation	_	_	_	_	_	_	_	Seg=O
122	from	_	_	_	_	_	_	_	Seg=O
123	datasets	_	_	_	_	_	_	_	Seg=O
124	influenced	_	_	_	_	_	_	_	Seg=B-seg
125	by	_	_	_	_	_	_	_	Seg=O
126	two	_	_	_	_	_	_	_	Seg=O
127	types	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	event	_	_	_	_	_	_	_	Seg=O
130	under	_	_	_	_	_	_	_	Seg=O
131	-	_	_	_	_	_	_	_	Seg=O
132	counting	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	and	_	_	_	_	_	_	_	Seg=B-seg
135	from	_	_	_	_	_	_	_	Seg=O
136	disease	_	_	_	_	_	_	_	Seg=O
137	transmission	_	_	_	_	_	_	_	Seg=O
138	data	_	_	_	_	_	_	_	Seg=O
139	subject	_	_	_	_	_	_	_	Seg=O
140	to	_	_	_	_	_	_	_	Seg=O
141	selection	_	_	_	_	_	_	_	Seg=O
142	bias	_	_	_	_	_	_	_	Seg=O
143	for	_	_	_	_	_	_	_	Seg=O
144	successful	_	_	_	_	_	_	_	Seg=O
145	outbreaks	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
147	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
148	.	_	_	_	_	_	_	_	Seg=O
149	Results	_	_	_	_	_	_	_	Seg=B-seg
150	show	_	_	_	_	_	_	_	Seg=O
151	that	_	_	_	_	_	_	_	Seg=B-seg
152	maximum	_	_	_	_	_	_	_	Seg=O
153	likelihood	_	_	_	_	_	_	_	Seg=O
154	estimates	_	_	_	_	_	_	_	Seg=O
155	of	_	_	_	_	_	_	_	Seg=O
156	k	_	_	_	_	_	_	_	Seg=O
157	can	_	_	_	_	_	_	_	Seg=O
158	be	_	_	_	_	_	_	_	Seg=O
159	biased	_	_	_	_	_	_	_	Seg=O
160	upward	_	_	_	_	_	_	_	Seg=O
161	by	_	_	_	_	_	_	_	Seg=O
162	small	_	_	_	_	_	_	_	Seg=O
163	sample	_	_	_	_	_	_	_	Seg=O
164	size	_	_	_	_	_	_	_	Seg=O
165	or	_	_	_	_	_	_	_	Seg=O
166	under	_	_	_	_	_	_	_	Seg=O
167	-	_	_	_	_	_	_	_	Seg=O
168	reporting	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	zero	_	_	_	_	_	_	_	Seg=O
171	-	_	_	_	_	_	_	_	Seg=O
172	class	_	_	_	_	_	_	_	Seg=O
173	events	_	_	_	_	_	_	_	Seg=O
174	,	_	_	_	_	_	_	_	Seg=O
175	but	_	_	_	_	_	_	_	Seg=B-seg
176	are	_	_	_	_	_	_	_	Seg=O
177	not	_	_	_	_	_	_	_	Seg=O
178	biased	_	_	_	_	_	_	_	Seg=O
179	downward	_	_	_	_	_	_	_	Seg=O
180	by	_	_	_	_	_	_	_	Seg=O
181	any	_	_	_	_	_	_	_	Seg=O
182	of	_	_	_	_	_	_	_	Seg=O
183	the	_	_	_	_	_	_	_	Seg=O
184	factors	_	_	_	_	_	_	_	Seg=O
185	considered	_	_	_	_	_	_	_	Seg=O
186	.	_	_	_	_	_	_	_	Seg=O
187	Confidence	_	_	_	_	_	_	_	Seg=B-seg
188	intervals	_	_	_	_	_	_	_	Seg=O
189	estimated	_	_	_	_	_	_	_	Seg=B-seg
190	from	_	_	_	_	_	_	_	Seg=O
191	the	_	_	_	_	_	_	_	Seg=O
192	asymptotic	_	_	_	_	_	_	_	Seg=O
193	sampling	_	_	_	_	_	_	_	Seg=O
194	variance	_	_	_	_	_	_	_	Seg=O
195	tend	_	_	_	_	_	_	_	Seg=B-seg
196	to	_	_	_	_	_	_	_	Seg=O
197	exhibit	_	_	_	_	_	_	_	Seg=O
198	coverage	_	_	_	_	_	_	_	Seg=O
199	below	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	nominal	_	_	_	_	_	_	_	Seg=O
202	level	_	_	_	_	_	_	_	Seg=O
203	,	_	_	_	_	_	_	_	Seg=O
204	with	_	_	_	_	_	_	_	Seg=O
205	overestimates	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	k	_	_	_	_	_	_	_	Seg=O
208	comprising	_	_	_	_	_	_	_	Seg=B-seg
209	the	_	_	_	_	_	_	_	Seg=O
210	great	_	_	_	_	_	_	_	Seg=O
211	majority	_	_	_	_	_	_	_	Seg=O
212	of	_	_	_	_	_	_	_	Seg=O
213	coverage	_	_	_	_	_	_	_	Seg=O
214	errors	_	_	_	_	_	_	_	Seg=O
215	.	_	_	_	_	_	_	_	Seg=O
216	Estimation	_	_	_	_	_	_	_	Seg=B-seg
217	from	_	_	_	_	_	_	_	Seg=O
218	outbreak	_	_	_	_	_	_	_	Seg=O
219	datasets	_	_	_	_	_	_	_	Seg=O
220	does	_	_	_	_	_	_	_	Seg=O
221	not	_	_	_	_	_	_	_	Seg=O
222	increase	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	bias	_	_	_	_	_	_	_	Seg=O
225	of	_	_	_	_	_	_	_	Seg=O
226	k	_	_	_	_	_	_	_	Seg=O
227	estimates	_	_	_	_	_	_	_	Seg=O
228	,	_	_	_	_	_	_	_	Seg=O
229	but	_	_	_	_	_	_	_	Seg=B-seg
230	can	_	_	_	_	_	_	_	Seg=O
231	add	_	_	_	_	_	_	_	Seg=O
232	significant	_	_	_	_	_	_	_	Seg=O
233	upward	_	_	_	_	_	_	_	Seg=O
234	bias	_	_	_	_	_	_	_	Seg=O
235	to	_	_	_	_	_	_	_	Seg=O
236	estimates	_	_	_	_	_	_	_	Seg=O
237	of	_	_	_	_	_	_	_	Seg=O
238	the	_	_	_	_	_	_	_	Seg=O
239	mean	_	_	_	_	_	_	_	Seg=O
240	.	_	_	_	_	_	_	_	Seg=O
241	Because	_	_	_	_	_	_	_	Seg=B-seg
242	k	_	_	_	_	_	_	_	Seg=O
243	varies	_	_	_	_	_	_	_	Seg=O
244	inversely	_	_	_	_	_	_	_	Seg=O
245	with	_	_	_	_	_	_	_	Seg=O
246	the	_	_	_	_	_	_	_	Seg=O
247	degree	_	_	_	_	_	_	_	Seg=O
248	of	_	_	_	_	_	_	_	Seg=O
249	overdispersion	_	_	_	_	_	_	_	Seg=O
250	,	_	_	_	_	_	_	_	Seg=O
251	these	_	_	_	_	_	_	_	Seg=B-seg
252	findings	_	_	_	_	_	_	_	Seg=O
253	show	_	_	_	_	_	_	_	Seg=O
254	that	_	_	_	_	_	_	_	Seg=B-seg
255	overestimation	_	_	_	_	_	_	_	Seg=O
256	of	_	_	_	_	_	_	_	Seg=O
257	the	_	_	_	_	_	_	_	Seg=O
258	degree	_	_	_	_	_	_	_	Seg=O
259	of	_	_	_	_	_	_	_	Seg=O
260	overdispersion	_	_	_	_	_	_	_	Seg=O
261	is	_	_	_	_	_	_	_	Seg=O
262	very	_	_	_	_	_	_	_	Seg=O
263	rare	_	_	_	_	_	_	_	Seg=O
264	for	_	_	_	_	_	_	_	Seg=O
265	these	_	_	_	_	_	_	_	Seg=O
266	datasets	_	_	_	_	_	_	_	Seg=O
267	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 25aad84c22269cf7221d0c22737e2e01a36ec51b
1	RNA	_	_	_	_	_	_	_	Seg=B-seg
2	dependent	_	_	_	_	_	_	_	Seg=O
3	DNA	_	_	_	_	_	_	_	Seg=O
4	-	_	_	_	_	_	_	_	Seg=O
5	polymerases	_	_	_	_	_	_	_	Seg=O
6	,	_	_	_	_	_	_	_	Seg=O
7	reverse	_	_	_	_	_	_	_	Seg=O
8	transcriptases	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	are	_	_	_	_	_	_	_	Seg=O
11	key	_	_	_	_	_	_	_	Seg=O
12	enzymes	_	_	_	_	_	_	_	Seg=O
13	for	_	_	_	_	_	_	_	Seg=O
14	retroviruses	_	_	_	_	_	_	_	Seg=O
15	and	_	_	_	_	_	_	_	Seg=O
16	retroelements	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	Their	_	_	_	_	_	_	_	Seg=B-seg
19	fidelity	_	_	_	_	_	_	_	Seg=O
20	,	_	_	_	_	_	_	_	Seg=O
21	including	_	_	_	_	_	_	_	Seg=B-seg
22	indel	_	_	_	_	_	_	_	Seg=O
23	generation	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	is	_	_	_	_	_	_	_	Seg=B-seg
26	significant	_	_	_	_	_	_	_	Seg=O
27	for	_	_	_	_	_	_	_	Seg=O
28	their	_	_	_	_	_	_	_	Seg=O
29	use	_	_	_	_	_	_	_	Seg=O
30	as	_	_	_	_	_	_	_	Seg=O
31	reagents	_	_	_	_	_	_	_	Seg=O
32	including	_	_	_	_	_	_	_	Seg=B-seg
33	for	_	_	_	_	_	_	_	Seg=O
34	deep	_	_	_	_	_	_	_	Seg=O
35	sequencing	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	Here	_	_	_	_	_	_	_	Seg=B-seg
38	,	_	_	_	_	_	_	_	Seg=O
39	we	_	_	_	_	_	_	_	Seg=O
40	report	_	_	_	_	_	_	_	Seg=O
41	that	_	_	_	_	_	_	_	Seg=B-seg
42	certain	_	_	_	_	_	_	_	Seg=O
43	RNA	_	_	_	_	_	_	_	Seg=O
44	template	_	_	_	_	_	_	_	Seg=O
45	structures	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=O
47	G	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=O
49	rich	_	_	_	_	_	_	_	Seg=O
50	sequences	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	ahead	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	diverse	_	_	_	_	_	_	_	Seg=O
55	reverse	_	_	_	_	_	_	_	Seg=O
56	transcriptases	_	_	_	_	_	_	_	Seg=O
57	can	_	_	_	_	_	_	_	Seg=O
58	be	_	_	_	_	_	_	_	Seg=O
59	strong	_	_	_	_	_	_	_	Seg=O
60	stimulators	_	_	_	_	_	_	_	Seg=O
61	for	_	_	_	_	_	_	_	Seg=O
62	slippage	_	_	_	_	_	_	_	Seg=O
63	at	_	_	_	_	_	_	_	Seg=O
64	slippageprone	_	_	_	_	_	_	_	Seg=O
65	template	_	_	_	_	_	_	_	Seg=O
66	motif	_	_	_	_	_	_	_	Seg=O
67	sequence	_	_	_	_	_	_	_	Seg=O
68	3	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	such	_	_	_	_	_	_	_	Seg=O
71	'	_	_	_	_	_	_	_	Seg=O
72	slippagestimulatory	_	_	_	_	_	_	_	Seg=O
73	'	_	_	_	_	_	_	_	Seg=O
74	structures	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Where	_	_	_	_	_	_	_	Seg=B-seg
77	slippage	_	_	_	_	_	_	_	Seg=O
78	is	_	_	_	_	_	_	_	Seg=O
79	stimulated	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=B-seg
82	resulting	_	_	_	_	_	_	_	Seg=O
83	products	_	_	_	_	_	_	_	Seg=O
84	have	_	_	_	_	_	_	_	Seg=O
85	one	_	_	_	_	_	_	_	Seg=O
86	or	_	_	_	_	_	_	_	Seg=O
87	more	_	_	_	_	_	_	_	Seg=O
88	additional	_	_	_	_	_	_	_	Seg=O
89	base(s	_	_	_	_	_	_	_	Seg=O
90	)	_	_	_	_	_	_	_	Seg=O
91	compared	_	_	_	_	_	_	_	Seg=B-seg
92	to	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	corresponding	_	_	_	_	_	_	_	Seg=O
95	template	_	_	_	_	_	_	_	Seg=O
96	motif	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	Such	_	_	_	_	_	_	_	Seg=B-seg
99	structures	_	_	_	_	_	_	_	Seg=O
100	also	_	_	_	_	_	_	_	Seg=O
101	inhibit	_	_	_	_	_	_	_	Seg=O
102	slippagemediated	_	_	_	_	_	_	_	Seg=O
103	base	_	_	_	_	_	_	_	Seg=O
104	omission	_	_	_	_	_	_	_	Seg=O
105	which	_	_	_	_	_	_	_	Seg=B-seg
106	can	_	_	_	_	_	_	_	Seg=O
107	be	_	_	_	_	_	_	_	Seg=O
108	more	_	_	_	_	_	_	_	Seg=O
109	frequent	_	_	_	_	_	_	_	Seg=O
110	in	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	absence	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	a	_	_	_	_	_	_	_	Seg=O
115	relevant	_	_	_	_	_	_	_	Seg=O
116	stem	_	_	_	_	_	_	_	Seg=O
117	-	_	_	_	_	_	_	_	Seg=O
118	loop	_	_	_	_	_	_	_	Seg=O
119	.	_	_	_	_	_	_	_	Seg=O
120	Slippage	_	_	_	_	_	_	_	Seg=B-seg
121	directionality	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	base	_	_	_	_	_	_	_	Seg=O
124	insertion	_	_	_	_	_	_	_	Seg=O
125	and	_	_	_	_	_	_	_	Seg=O
126	omission	_	_	_	_	_	_	_	Seg=O
127	,	_	_	_	_	_	_	_	Seg=O
128	is	_	_	_	_	_	_	_	Seg=O
129	sensitive	_	_	_	_	_	_	_	Seg=O
130	to	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	relative	_	_	_	_	_	_	_	Seg=O
133	concentration	_	_	_	_	_	_	_	Seg=O
134	ratio	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	dNTPs	_	_	_	_	_	_	_	Seg=O
137	specified	_	_	_	_	_	_	_	Seg=B-seg
138	by	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	RNA	_	_	_	_	_	_	_	Seg=O
141	template	_	_	_	_	_	_	_	Seg=O
142	slippage	_	_	_	_	_	_	_	Seg=O
143	-	_	_	_	_	_	_	_	Seg=O
144	prone	_	_	_	_	_	_	_	Seg=O
145	sequence	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	its	_	_	_	_	_	_	_	Seg=O
148	5	_	_	_	_	_	_	_	Seg=O
149	adjacent	_	_	_	_	_	_	_	Seg=O
150	base	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	The	_	_	_	_	_	_	_	Seg=B-seg
153	retrotransposon	_	_	_	_	_	_	_	Seg=O
154	-	_	_	_	_	_	_	_	Seg=O
155	derived	_	_	_	_	_	_	_	Seg=O
156	enzyme	_	_	_	_	_	_	_	Seg=O
157	TGIRT	_	_	_	_	_	_	_	Seg=O
158	exhibits	_	_	_	_	_	_	_	Seg=O
159	more	_	_	_	_	_	_	_	Seg=O
160	slippage	_	_	_	_	_	_	_	Seg=O
161	in	_	_	_	_	_	_	_	Seg=O
162	vitro	_	_	_	_	_	_	_	Seg=O
163	than	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	retroviral	_	_	_	_	_	_	_	Seg=O
166	enzymes	_	_	_	_	_	_	_	Seg=O
167	tested	_	_	_	_	_	_	_	Seg=B-seg
168	including	_	_	_	_	_	_	_	Seg=B-seg
169	that	_	_	_	_	_	_	_	Seg=O
170	from	_	_	_	_	_	_	_	Seg=O
171	HIV	_	_	_	_	_	_	_	Seg=O
172	.	_	_	_	_	_	_	_	Seg=O
173	Structure	_	_	_	_	_	_	_	Seg=B-seg
174	-	_	_	_	_	_	_	_	Seg=O
175	mediated	_	_	_	_	_	_	_	Seg=O
176	slippage	_	_	_	_	_	_	_	Seg=O
177	may	_	_	_	_	_	_	_	Seg=O
178	be	_	_	_	_	_	_	_	Seg=O
179	exhibited	_	_	_	_	_	_	_	Seg=O
180	by	_	_	_	_	_	_	_	Seg=O
181	other	_	_	_	_	_	_	_	Seg=O
182	polymerases	_	_	_	_	_	_	_	Seg=O
183	and	_	_	_	_	_	_	_	Seg=O
184	enrich	_	_	_	_	_	_	_	Seg=O
185	gene	_	_	_	_	_	_	_	Seg=O
186	expression	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	A	_	_	_	_	_	_	_	Seg=B-seg
189	cassette	_	_	_	_	_	_	_	Seg=O
190	from	_	_	_	_	_	_	_	Seg=O
191	Drosophila	_	_	_	_	_	_	_	Seg=O
192	retrotransposon	_	_	_	_	_	_	_	Seg=O
193	Dme1	_	_	_	_	_	_	_	Seg=O
194	chrX	_	_	_	_	_	_	_	Seg=O
195	2630566	_	_	_	_	_	_	_	Seg=O
196	,	_	_	_	_	_	_	_	Seg=O
197	a	_	_	_	_	_	_	_	Seg=O
198	candidate	_	_	_	_	_	_	_	Seg=O
199	for	_	_	_	_	_	_	_	Seg=B-seg
200	utilizing	_	_	_	_	_	_	_	Seg=O
201	slippage	_	_	_	_	_	_	_	Seg=O
202	for	_	_	_	_	_	_	_	Seg=O
203	its	_	_	_	_	_	_	_	Seg=O
204	GagPol	_	_	_	_	_	_	_	Seg=O
205	synthesis	_	_	_	_	_	_	_	Seg=O
206	,	_	_	_	_	_	_	_	Seg=O
207	exhibits	_	_	_	_	_	_	_	Seg=B-seg
208	strong	_	_	_	_	_	_	_	Seg=O
209	slippage	_	_	_	_	_	_	_	Seg=O
210	in	_	_	_	_	_	_	_	Seg=O
211	vitro	_	_	_	_	_	_	_	Seg=O
212	.	_	_	_	_	_	_	_	Seg=O
213	Given	_	_	_	_	_	_	_	Seg=B-seg
214	the	_	_	_	_	_	_	_	Seg=O
215	widespread	_	_	_	_	_	_	_	Seg=O
216	occurrence	_	_	_	_	_	_	_	Seg=O
217	and	_	_	_	_	_	_	_	Seg=O
218	importance	_	_	_	_	_	_	_	Seg=O
219	of	_	_	_	_	_	_	_	Seg=O
220	retrotransposons	_	_	_	_	_	_	_	Seg=O
221	,	_	_	_	_	_	_	_	Seg=O
222	systematic	_	_	_	_	_	_	_	Seg=B-seg
223	studies	_	_	_	_	_	_	_	Seg=O
224	to	_	_	_	_	_	_	_	Seg=B-seg
225	reveal	_	_	_	_	_	_	_	Seg=O
226	the	_	_	_	_	_	_	_	Seg=O
227	extent	_	_	_	_	_	_	_	Seg=O
228	of	_	_	_	_	_	_	_	Seg=O
229	their	_	_	_	_	_	_	_	Seg=O
230	functional	_	_	_	_	_	_	_	Seg=O
231	utilization	_	_	_	_	_	_	_	Seg=O
232	of	_	_	_	_	_	_	_	Seg=O
233	RT	_	_	_	_	_	_	_	Seg=O
234	slippage	_	_	_	_	_	_	_	Seg=O
235	are	_	_	_	_	_	_	_	Seg=B-seg
236	merited	_	_	_	_	_	_	_	Seg=O
237	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2a32218f7d0b647b6bebeb1526245a0dc8856546
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	cell	_	_	_	_	_	_	_	Seg=O
3	intrinsic	_	_	_	_	_	_	_	Seg=O
4	innate	_	_	_	_	_	_	_	Seg=O
5	immune	_	_	_	_	_	_	_	Seg=O
6	responses	_	_	_	_	_	_	_	Seg=O
7	provide	_	_	_	_	_	_	_	Seg=O
8	a	_	_	_	_	_	_	_	Seg=O
9	first	_	_	_	_	_	_	_	Seg=O
10	line	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	defense	_	_	_	_	_	_	_	Seg=O
13	against	_	_	_	_	_	_	_	Seg=O
14	viral	_	_	_	_	_	_	_	Seg=O
15	infection	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=B-seg
18	often	_	_	_	_	_	_	_	Seg=O
19	function	_	_	_	_	_	_	_	Seg=O
20	by	_	_	_	_	_	_	_	Seg=B-seg
21	targeting	_	_	_	_	_	_	_	Seg=O
22	cellular	_	_	_	_	_	_	_	Seg=O
23	pathways	_	_	_	_	_	_	_	Seg=O
24	usurped	_	_	_	_	_	_	_	Seg=B-seg
25	by	_	_	_	_	_	_	_	Seg=O
26	the	_	_	_	_	_	_	_	Seg=O
27	virus	_	_	_	_	_	_	_	Seg=O
28	during	_	_	_	_	_	_	_	Seg=O
29	infection	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	In	_	_	_	_	_	_	_	Seg=B-seg
32	particular	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	many	_	_	_	_	_	_	_	Seg=O
35	viruses	_	_	_	_	_	_	_	Seg=O
36	manipulate	_	_	_	_	_	_	_	Seg=O
37	cellular	_	_	_	_	_	_	_	Seg=O
38	lipids	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=B-seg
40	form	_	_	_	_	_	_	_	Seg=O
41	complex	_	_	_	_	_	_	_	Seg=O
42	structures	_	_	_	_	_	_	_	Seg=O
43	required	_	_	_	_	_	_	_	Seg=B-seg
44	for	_	_	_	_	_	_	_	Seg=O
45	viral	_	_	_	_	_	_	_	Seg=O
46	replication	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	many	_	_	_	_	_	_	_	Seg=B-seg
49	of	_	_	_	_	_	_	_	Seg=O
50	which	_	_	_	_	_	_	_	Seg=O
51	are	_	_	_	_	_	_	_	Seg=O
52	dependent	_	_	_	_	_	_	_	Seg=O
53	on	_	_	_	_	_	_	_	Seg=O
54	de	_	_	_	_	_	_	_	Seg=O
55	novo	_	_	_	_	_	_	_	Seg=O
56	fatty	_	_	_	_	_	_	_	Seg=O
57	acid	_	_	_	_	_	_	_	Seg=O
58	synthesis	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	We	_	_	_	_	_	_	_	Seg=B-seg
61	found	_	_	_	_	_	_	_	Seg=O
62	that	_	_	_	_	_	_	_	Seg=B-seg
63	the	_	_	_	_	_	_	_	Seg=O
64	energy	_	_	_	_	_	_	_	Seg=O
65	regulator	_	_	_	_	_	_	_	Seg=O
66	AMPK	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	which	_	_	_	_	_	_	_	Seg=B-seg
69	potently	_	_	_	_	_	_	_	Seg=O
70	inhibits	_	_	_	_	_	_	_	Seg=O
71	fatty	_	_	_	_	_	_	_	Seg=O
72	acid	_	_	_	_	_	_	_	Seg=O
73	synthesis	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	restricts	_	_	_	_	_	_	_	Seg=B-seg
76	infection	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	Bunyavirus	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	Rift	_	_	_	_	_	_	_	Seg=O
82	Valley	_	_	_	_	_	_	_	Seg=O
83	Fever	_	_	_	_	_	_	_	Seg=O
84	Virus	_	_	_	_	_	_	_	Seg=O
85	(	_	_	_	_	_	_	_	Seg=O
86	RVFV	_	_	_	_	_	_	_	Seg=O
87	)	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	an	_	_	_	_	_	_	_	Seg=O
90	important	_	_	_	_	_	_	_	Seg=O
91	re	_	_	_	_	_	_	_	Seg=O
92	-	_	_	_	_	_	_	_	Seg=O
93	emerging	_	_	_	_	_	_	_	Seg=O
94	arthropod	_	_	_	_	_	_	_	Seg=O
95	-	_	_	_	_	_	_	_	Seg=O
96	borne	_	_	_	_	_	_	_	Seg=O
97	human	_	_	_	_	_	_	_	Seg=O
98	pathogen	_	_	_	_	_	_	_	Seg=O
99	for	_	_	_	_	_	_	_	Seg=B-seg
100	which	_	_	_	_	_	_	_	Seg=O
101	there	_	_	_	_	_	_	_	Seg=O
102	are	_	_	_	_	_	_	_	Seg=O
103	no	_	_	_	_	_	_	_	Seg=O
104	effective	_	_	_	_	_	_	_	Seg=O
105	vaccines	_	_	_	_	_	_	_	Seg=O
106	or	_	_	_	_	_	_	_	Seg=O
107	therapeutics	_	_	_	_	_	_	_	Seg=O
108	.	_	_	_	_	_	_	_	Seg=O
109	We	_	_	_	_	_	_	_	Seg=B-seg
110	show	_	_	_	_	_	_	_	Seg=O
111	restriction	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	RVFV	_	_	_	_	_	_	_	Seg=O
114	both	_	_	_	_	_	_	_	Seg=O
115	by	_	_	_	_	_	_	_	Seg=O
116	AMPK	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	its	_	_	_	_	_	_	_	Seg=O
119	upstream	_	_	_	_	_	_	_	Seg=O
120	activator	_	_	_	_	_	_	_	Seg=O
121	LKB1	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	indicating	_	_	_	_	_	_	_	Seg=B-seg
124	an	_	_	_	_	_	_	_	Seg=O
125	antiviral	_	_	_	_	_	_	_	Seg=O
126	role	_	_	_	_	_	_	_	Seg=O
127	for	_	_	_	_	_	_	_	Seg=O
128	this	_	_	_	_	_	_	_	Seg=O
129	signaling	_	_	_	_	_	_	_	Seg=O
130	pathway	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O
132	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
133	,	_	_	_	_	_	_	_	Seg=O
134	we	_	_	_	_	_	_	_	Seg=O
135	found	_	_	_	_	_	_	_	Seg=O
136	that	_	_	_	_	_	_	_	Seg=B-seg
137	AMPK	_	_	_	_	_	_	_	Seg=O
138	is	_	_	_	_	_	_	_	Seg=O
139	activated	_	_	_	_	_	_	_	Seg=O
140	during	_	_	_	_	_	_	_	Seg=O
141	RVFV	_	_	_	_	_	_	_	Seg=O
142	infection	_	_	_	_	_	_	_	Seg=O
143	,	_	_	_	_	_	_	_	Seg=O
144	leading	_	_	_	_	_	_	_	Seg=B-seg
145	to	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	phosphorylation	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=O
149	inhibition	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	acetyl	_	_	_	_	_	_	_	Seg=O
152	-	_	_	_	_	_	_	_	Seg=O
153	CoA	_	_	_	_	_	_	_	Seg=O
154	carboxylase	_	_	_	_	_	_	_	Seg=O
155	,	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	first	_	_	_	_	_	_	_	Seg=O
158	rate	_	_	_	_	_	_	_	Seg=O
159	-	_	_	_	_	_	_	_	Seg=O
160	limiting	_	_	_	_	_	_	_	Seg=O
161	enzyme	_	_	_	_	_	_	_	Seg=O
162	in	_	_	_	_	_	_	_	Seg=O
163	fatty	_	_	_	_	_	_	_	Seg=O
164	acid	_	_	_	_	_	_	_	Seg=O
165	synthesis	_	_	_	_	_	_	_	Seg=O
166	.	_	_	_	_	_	_	_	Seg=O
167	Activating	_	_	_	_	_	_	_	Seg=B-seg
168	AMPK	_	_	_	_	_	_	_	Seg=O
169	pharmacologically	_	_	_	_	_	_	_	Seg=O
170	both	_	_	_	_	_	_	_	Seg=O
171	restricted	_	_	_	_	_	_	_	Seg=O
172	infection	_	_	_	_	_	_	_	Seg=O
173	and	_	_	_	_	_	_	_	Seg=B-seg
174	reduced	_	_	_	_	_	_	_	Seg=O
175	lipid	_	_	_	_	_	_	_	Seg=O
176	levels	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O
178	This	_	_	_	_	_	_	_	Seg=B-seg
179	restriction	_	_	_	_	_	_	_	Seg=O
180	could	_	_	_	_	_	_	_	Seg=O
181	be	_	_	_	_	_	_	_	Seg=O
182	bypassed	_	_	_	_	_	_	_	Seg=O
183	by	_	_	_	_	_	_	_	Seg=O
184	treatment	_	_	_	_	_	_	_	Seg=O
185	with	_	_	_	_	_	_	_	Seg=O
186	the	_	_	_	_	_	_	_	Seg=O
187	fatty	_	_	_	_	_	_	_	Seg=O
188	acid	_	_	_	_	_	_	_	Seg=O
189	palmitate	_	_	_	_	_	_	_	Seg=O
190	,	_	_	_	_	_	_	_	Seg=O
191	demonstrating	_	_	_	_	_	_	_	Seg=B-seg
192	that	_	_	_	_	_	_	_	Seg=B-seg
193	AMPK	_	_	_	_	_	_	_	Seg=O
194	restricts	_	_	_	_	_	_	_	Seg=O
195	RVFV	_	_	_	_	_	_	_	Seg=O
196	infection	_	_	_	_	_	_	_	Seg=O
197	through	_	_	_	_	_	_	_	Seg=O
198	its	_	_	_	_	_	_	_	Seg=O
199	inhibition	_	_	_	_	_	_	_	Seg=O
200	of	_	_	_	_	_	_	_	Seg=O
201	fatty	_	_	_	_	_	_	_	Seg=O
202	acid	_	_	_	_	_	_	_	Seg=O
203	biosynthesis	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O
205	Lastly	_	_	_	_	_	_	_	Seg=B-seg
206	,	_	_	_	_	_	_	_	Seg=O
207	we	_	_	_	_	_	_	_	Seg=O
208	found	_	_	_	_	_	_	_	Seg=O
209	that	_	_	_	_	_	_	_	Seg=B-seg
210	this	_	_	_	_	_	_	_	Seg=O
211	pathway	_	_	_	_	_	_	_	Seg=O
212	plays	_	_	_	_	_	_	_	Seg=O
213	a	_	_	_	_	_	_	_	Seg=O
214	broad	_	_	_	_	_	_	_	Seg=O
215	role	_	_	_	_	_	_	_	Seg=O
216	in	_	_	_	_	_	_	_	Seg=O
217	antiviral	_	_	_	_	_	_	_	Seg=O
218	defense	_	_	_	_	_	_	_	Seg=O
219	since	_	_	_	_	_	_	_	Seg=B-seg
220	additional	_	_	_	_	_	_	_	Seg=O
221	viruses	_	_	_	_	_	_	_	Seg=O
222	from	_	_	_	_	_	_	_	Seg=O
223	disparate	_	_	_	_	_	_	_	Seg=O
224	families	_	_	_	_	_	_	_	Seg=O
225	were	_	_	_	_	_	_	_	Seg=O
226	also	_	_	_	_	_	_	_	Seg=O
227	restricted	_	_	_	_	_	_	_	Seg=O
228	by	_	_	_	_	_	_	_	Seg=O
229	AMPK	_	_	_	_	_	_	_	Seg=O
230	and	_	_	_	_	_	_	_	Seg=O
231	LKB1	_	_	_	_	_	_	_	Seg=O
232	.	_	_	_	_	_	_	_	Seg=O
233	Therefore	_	_	_	_	_	_	_	Seg=B-seg
234	,	_	_	_	_	_	_	_	Seg=O
235	AMPK	_	_	_	_	_	_	_	Seg=O
236	is	_	_	_	_	_	_	_	Seg=O
237	an	_	_	_	_	_	_	_	Seg=O
238	important	_	_	_	_	_	_	_	Seg=O
239	component	_	_	_	_	_	_	_	Seg=O
240	of	_	_	_	_	_	_	_	Seg=O
241	the	_	_	_	_	_	_	_	Seg=O
242	cell	_	_	_	_	_	_	_	Seg=O
243	intrinsic	_	_	_	_	_	_	_	Seg=O
244	immune	_	_	_	_	_	_	_	Seg=O
245	response	_	_	_	_	_	_	_	Seg=O
246	that	_	_	_	_	_	_	_	Seg=B-seg
247	restricts	_	_	_	_	_	_	_	Seg=O
248	infection	_	_	_	_	_	_	_	Seg=O
249	through	_	_	_	_	_	_	_	Seg=O
250	a	_	_	_	_	_	_	_	Seg=O
251	novel	_	_	_	_	_	_	_	Seg=O
252	mechanism	_	_	_	_	_	_	_	Seg=O
253	involving	_	_	_	_	_	_	_	Seg=B-seg
254	the	_	_	_	_	_	_	_	Seg=O
255	inhibition	_	_	_	_	_	_	_	Seg=O
256	of	_	_	_	_	_	_	_	Seg=O
257	fatty	_	_	_	_	_	_	_	Seg=O
258	acid	_	_	_	_	_	_	_	Seg=O
259	metabolism	_	_	_	_	_	_	_	Seg=O
260	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2a6d03c2466a88098a79eb95b0bccd23d91168ff
1	Antimicrobial	_	_	_	_	_	_	_	Seg=B-seg
2	stewardship	_	_	_	_	_	_	_	Seg=O
3	program	_	_	_	_	_	_	_	Seg=O
4	aims	_	_	_	_	_	_	_	Seg=O
5	to	_	_	_	_	_	_	_	Seg=O
6	reduce	_	_	_	_	_	_	_	Seg=O
7	antibiotic	_	_	_	_	_	_	_	Seg=O
8	use	_	_	_	_	_	_	_	Seg=O
9	.	_	_	_	_	_	_	_	Seg=O
10	Periodic	_	_	_	_	_	_	_	Seg=B-seg
11	measurement	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	monitoring	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	antibiotic	_	_	_	_	_	_	_	Seg=O
16	use	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=O
18	comparison	_	_	_	_	_	_	_	Seg=O
19	within	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	institution	_	_	_	_	_	_	_	Seg=O
22	as	_	_	_	_	_	_	_	Seg=O
23	well	_	_	_	_	_	_	_	Seg=O
24	as	_	_	_	_	_	_	_	Seg=O
25	with	_	_	_	_	_	_	_	Seg=O
26	other	_	_	_	_	_	_	_	Seg=O
27	organizations	_	_	_	_	_	_	_	Seg=O
28	are	_	_	_	_	_	_	_	Seg=O
29	important	_	_	_	_	_	_	_	Seg=O
30	indicators	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	We	_	_	_	_	_	_	_	Seg=B-seg
33	analyzed	_	_	_	_	_	_	_	Seg=O
34	antibiotic	_	_	_	_	_	_	_	Seg=O
35	usage	_	_	_	_	_	_	_	Seg=O
36	in	_	_	_	_	_	_	_	Seg=O
37	a	_	_	_	_	_	_	_	Seg=O
38	general	_	_	_	_	_	_	_	Seg=O
39	hospital	_	_	_	_	_	_	_	Seg=O
40	in	_	_	_	_	_	_	_	Seg=O
41	Saudi	_	_	_	_	_	_	_	Seg=O
42	Arabia	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	Antibiotic	_	_	_	_	_	_	_	Seg=B-seg
45	data	_	_	_	_	_	_	_	Seg=O
46	were	_	_	_	_	_	_	_	Seg=O
47	collected	_	_	_	_	_	_	_	Seg=O
48	retrospectively	_	_	_	_	_	_	_	Seg=O
49	for	_	_	_	_	_	_	_	Seg=O
50	2011	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=O
52	from	_	_	_	_	_	_	_	Seg=O
53	2013	_	_	_	_	_	_	_	Seg=O
54	to	_	_	_	_	_	_	_	Seg=O
55	2015	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=B-seg
58	only	_	_	_	_	_	_	_	Seg=O
59	adult	_	_	_	_	_	_	_	Seg=O
60	patients	_	_	_	_	_	_	_	Seg=O
61	(	_	_	_	_	_	_	_	Seg=B-seg
62	>	_	_	_	_	_	_	_	Seg=O
63	15	_	_	_	_	_	_	_	Seg=O
64	year	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=O
66	age	_	_	_	_	_	_	_	Seg=O
67	)	_	_	_	_	_	_	_	Seg=O
68	were	_	_	_	_	_	_	_	Seg=B-seg
69	included	_	_	_	_	_	_	_	Seg=O
70	in	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	study	_	_	_	_	_	_	_	Seg=O
73	.	_	_	_	_	_	_	_	Seg=O
74	Data	_	_	_	_	_	_	_	Seg=B-seg
75	were	_	_	_	_	_	_	_	Seg=O
76	presented	_	_	_	_	_	_	_	Seg=O
77	as	_	_	_	_	_	_	_	Seg=O
78	days	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	therapy	_	_	_	_	_	_	_	Seg=O
81	(	_	_	_	_	_	_	_	Seg=O
82	DOT	_	_	_	_	_	_	_	Seg=O
83	)	_	_	_	_	_	_	_	Seg=O
84	and	_	_	_	_	_	_	_	Seg=O
85	defined	_	_	_	_	_	_	_	Seg=O
86	daily	_	_	_	_	_	_	_	Seg=O
87	dose	_	_	_	_	_	_	_	Seg=O
88	(	_	_	_	_	_	_	_	Seg=O
89	DDD	_	_	_	_	_	_	_	Seg=O
90	)	_	_	_	_	_	_	_	Seg=O
91	.	_	_	_	_	_	_	_	Seg=O
92	DDD	_	_	_	_	_	_	_	Seg=B-seg
93	was	_	_	_	_	_	_	_	Seg=O
94	adjusted	_	_	_	_	_	_	_	Seg=O
95	per	_	_	_	_	_	_	_	Seg=O
96	100	_	_	_	_	_	_	_	Seg=O
97	bed	_	_	_	_	_	_	_	Seg=O
98	-	_	_	_	_	_	_	_	Seg=O
99	days	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=O
101	according	_	_	_	_	_	_	_	Seg=O
102	to	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	case	_	_	_	_	_	_	_	Seg=O
105	mix	_	_	_	_	_	_	_	Seg=O
106	index	_	_	_	_	_	_	_	Seg=O
107	(	_	_	_	_	_	_	_	Seg=O
108	CMI	_	_	_	_	_	_	_	Seg=O
109	)	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	The	_	_	_	_	_	_	_	Seg=B-seg
112	total	_	_	_	_	_	_	_	Seg=O
113	DDD	_	_	_	_	_	_	_	Seg=O
114	was	_	_	_	_	_	_	_	Seg=O
115	37,557	_	_	_	_	_	_	_	Seg=O
116	in	_	_	_	_	_	_	_	Seg=O
117	2013	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	36,550	_	_	_	_	_	_	_	Seg=O
120	in	_	_	_	_	_	_	_	Seg=O
121	2014	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	38,738	_	_	_	_	_	_	_	Seg=O
124	in	_	_	_	_	_	_	_	Seg=O
125	2015	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O
127	The	_	_	_	_	_	_	_	Seg=B-seg
128	DDD	_	_	_	_	_	_	_	Seg=O
129	per	_	_	_	_	_	_	_	Seg=O
130	100	_	_	_	_	_	_	_	Seg=O
131	patient	_	_	_	_	_	_	_	Seg=O
132	-	_	_	_	_	_	_	_	Seg=O
133	days	_	_	_	_	_	_	_	Seg=O
134	was	_	_	_	_	_	_	_	Seg=O
135	90.7	_	_	_	_	_	_	_	Seg=O
136	-	_	_	_	_	_	_	_	Seg=O
137	94.5	_	_	_	_	_	_	_	Seg=O
138	.	_	_	_	_	_	_	_	Seg=O
139	There	_	_	_	_	_	_	_	Seg=B-seg
140	was	_	_	_	_	_	_	_	Seg=O
141	a	_	_	_	_	_	_	_	Seg=O
142	discordant	_	_	_	_	_	_	_	Seg=O
143	findings	_	_	_	_	_	_	_	Seg=O
144	of	_	_	_	_	_	_	_	Seg=O
145	antibiotic	_	_	_	_	_	_	_	Seg=O
146	measurements	_	_	_	_	_	_	_	Seg=O
147	based	_	_	_	_	_	_	_	Seg=B-seg
148	on	_	_	_	_	_	_	_	Seg=O
149	the	_	_	_	_	_	_	_	Seg=O
150	DDD	_	_	_	_	_	_	_	Seg=O
151	compared	_	_	_	_	_	_	_	Seg=B-seg
152	to	_	_	_	_	_	_	_	Seg=O
153	DOT	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=B-seg
156	DDD/100	_	_	_	_	_	_	_	Seg=O
157	beddays	_	_	_	_	_	_	_	Seg=O
158	compared	_	_	_	_	_	_	_	Seg=B-seg
159	to	_	_	_	_	_	_	_	Seg=O
160	DOT/100	_	_	_	_	_	_	_	Seg=O
161	bed	_	_	_	_	_	_	_	Seg=O
162	-	_	_	_	_	_	_	_	Seg=O
163	days	_	_	_	_	_	_	_	Seg=O
164	.	_	_	_	_	_	_	_	Seg=O
165	There	_	_	_	_	_	_	_	Seg=B-seg
166	was	_	_	_	_	_	_	_	Seg=O
167	a	_	_	_	_	_	_	_	Seg=O
168	negative	_	_	_	_	_	_	_	Seg=O
169	correlation	_	_	_	_	_	_	_	Seg=O
170	between	_	_	_	_	_	_	_	Seg=O
171	CMI	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=O
173	DDD	_	_	_	_	_	_	_	Seg=O
174	per	_	_	_	_	_	_	_	Seg=O
175	100	_	_	_	_	_	_	_	Seg=O
176	bed	_	_	_	_	_	_	_	Seg=O
177	days	_	_	_	_	_	_	_	Seg=O
178	(	_	_	_	_	_	_	_	Seg=B-seg
179	r	_	_	_	_	_	_	_	Seg=O
180	−0.696	_	_	_	_	_	_	_	Seg=O
181	)	_	_	_	_	_	_	_	Seg=O
182	,	_	_	_	_	_	_	_	Seg=O
183	but	_	_	_	_	_	_	_	Seg=B-seg
184	a	_	_	_	_	_	_	_	Seg=O
185	positive	_	_	_	_	_	_	_	Seg=O
186	correlation	_	_	_	_	_	_	_	Seg=O
187	of	_	_	_	_	_	_	_	Seg=O
188	CMI	_	_	_	_	_	_	_	Seg=O
189	with	_	_	_	_	_	_	_	Seg=O
190	DOT	_	_	_	_	_	_	_	Seg=O
191	(	_	_	_	_	_	_	_	Seg=B-seg
192	r	_	_	_	_	_	_	_	Seg=O
193	+0.93	_	_	_	_	_	_	_	Seg=O
194	)	_	_	_	_	_	_	_	Seg=O
195	.	_	_	_	_	_	_	_	Seg=O
196	Adjusted	_	_	_	_	_	_	_	Seg=B-seg
197	DDD/100	_	_	_	_	_	_	_	Seg=O
198	bed	_	_	_	_	_	_	_	Seg=O
199	-	_	_	_	_	_	_	_	Seg=O
200	days	_	_	_	_	_	_	_	Seg=O
201	showed	_	_	_	_	_	_	_	Seg=O
202	decrease	_	_	_	_	_	_	_	Seg=O
203	in	_	_	_	_	_	_	_	Seg=O
204	the	_	_	_	_	_	_	_	Seg=O
205	usage	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	antibiotics	_	_	_	_	_	_	_	Seg=O
208	,	_	_	_	_	_	_	_	Seg=O
209	reflecting	_	_	_	_	_	_	_	Seg=B-seg
210	activities	_	_	_	_	_	_	_	Seg=O
211	of	_	_	_	_	_	_	_	Seg=O
212	the	_	_	_	_	_	_	_	Seg=O
213	antibiotic	_	_	_	_	_	_	_	Seg=O
214	stewardship	_	_	_	_	_	_	_	Seg=O
215	program	_	_	_	_	_	_	_	Seg=O
216	.	_	_	_	_	_	_	_	Seg=O
217	The	_	_	_	_	_	_	_	Seg=B-seg
218	increase	_	_	_	_	_	_	_	Seg=O
219	in	_	_	_	_	_	_	_	Seg=O
220	DOT/100	_	_	_	_	_	_	_	Seg=O
221	bed	_	_	_	_	_	_	_	Seg=O
222	-	_	_	_	_	_	_	_	Seg=O
223	days	_	_	_	_	_	_	_	Seg=O
224	may	_	_	_	_	_	_	_	Seg=O
225	indicate	_	_	_	_	_	_	_	Seg=O
226	the	_	_	_	_	_	_	_	Seg=O
227	favorable	_	_	_	_	_	_	_	Seg=O
228	utilization	_	_	_	_	_	_	_	Seg=O
229	of	_	_	_	_	_	_	_	Seg=O
230	combination	_	_	_	_	_	_	_	Seg=O
231	therapy	_	_	_	_	_	_	_	Seg=O
232	.	_	_	_	_	_	_	_	Seg=O
233	Antibiotic	_	_	_	_	_	_	_	Seg=B-seg
234	usage	_	_	_	_	_	_	_	Seg=O
235	needs	_	_	_	_	_	_	_	Seg=O
236	to	_	_	_	_	_	_	_	Seg=O
237	be	_	_	_	_	_	_	_	Seg=O
238	adjusted	_	_	_	_	_	_	_	Seg=O
239	per	_	_	_	_	_	_	_	Seg=O
240	100	_	_	_	_	_	_	_	Seg=O
241	bed	_	_	_	_	_	_	_	Seg=O
242	-	_	_	_	_	_	_	_	Seg=O
243	days	_	_	_	_	_	_	_	Seg=O
244	and	_	_	_	_	_	_	_	Seg=O
245	correlated	_	_	_	_	_	_	_	Seg=O
246	with	_	_	_	_	_	_	_	Seg=O
247	CMI	_	_	_	_	_	_	_	Seg=O
248	for	_	_	_	_	_	_	_	Seg=O
249	better	_	_	_	_	_	_	_	Seg=O
250	reflection	_	_	_	_	_	_	_	Seg=O
251	of	_	_	_	_	_	_	_	Seg=O
252	optimal	_	_	_	_	_	_	_	Seg=O
253	antibiotic	_	_	_	_	_	_	_	Seg=O
254	utilization	_	_	_	_	_	_	_	Seg=O
255	,	_	_	_	_	_	_	_	Seg=O
256	activities	_	_	_	_	_	_	_	Seg=O
257	of	_	_	_	_	_	_	_	Seg=O
258	the	_	_	_	_	_	_	_	Seg=O
259	antibiotic	_	_	_	_	_	_	_	Seg=O
260	stewardship	_	_	_	_	_	_	_	Seg=O
261	program	_	_	_	_	_	_	_	Seg=O
262	,	_	_	_	_	_	_	_	Seg=O
263	and	_	_	_	_	_	_	_	Seg=O
264	to	_	_	_	_	_	_	_	Seg=O
265	allow	_	_	_	_	_	_	_	Seg=O
266	benchmarking	_	_	_	_	_	_	_	Seg=O
267	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2bc85cf8715cbd57eb454b5a0d8966c787aca1e5
1	Pandemics	_	_	_	_	_	_	_	Seg=B-seg
2	and	_	_	_	_	_	_	_	Seg=O
3	other	_	_	_	_	_	_	_	Seg=O
4	crisis	_	_	_	_	_	_	_	Seg=O
5	situations	_	_	_	_	_	_	_	Seg=O
6	result	_	_	_	_	_	_	_	Seg=O
7	in	_	_	_	_	_	_	_	Seg=O
8	unsettled	_	_	_	_	_	_	_	Seg=O
9	times	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	or	_	_	_	_	_	_	_	Seg=O
12	ontologically	_	_	_	_	_	_	_	Seg=O
13	insecure	_	_	_	_	_	_	_	Seg=O
14	moments	_	_	_	_	_	_	_	Seg=O
15	when	_	_	_	_	_	_	_	Seg=B-seg
16	social	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=O
18	political	_	_	_	_	_	_	_	Seg=O
19	institutions	_	_	_	_	_	_	_	Seg=O
20	are	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	flux	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	During	_	_	_	_	_	_	_	Seg=B-seg
25	such	_	_	_	_	_	_	_	Seg=O
26	crises	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	ordinary	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	unnoticed	_	_	_	_	_	_	_	Seg=O
32	routines	_	_	_	_	_	_	_	Seg=O
33	that	_	_	_	_	_	_	_	Seg=B-seg
34	structure	_	_	_	_	_	_	_	Seg=O
35	everyday	_	_	_	_	_	_	_	Seg=O
36	life	_	_	_	_	_	_	_	Seg=O
37	are	_	_	_	_	_	_	_	Seg=B-seg
38	thrust	_	_	_	_	_	_	_	Seg=O
39	into	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	spotlight	_	_	_	_	_	_	_	Seg=O
42	as	_	_	_	_	_	_	_	Seg=B-seg
43	people	_	_	_	_	_	_	_	Seg=O
44	struggle	_	_	_	_	_	_	_	Seg=O
45	to	_	_	_	_	_	_	_	Seg=O
46	maintain	_	_	_	_	_	_	_	Seg=O
47	or	_	_	_	_	_	_	_	Seg=O
48	recreate	_	_	_	_	_	_	_	Seg=O
49	a	_	_	_	_	_	_	_	Seg=O
50	sense	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	normalcy	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	Drawing	_	_	_	_	_	_	_	Seg=B-seg
55	on	_	_	_	_	_	_	_	Seg=O
56	a	_	_	_	_	_	_	_	Seg=O
57	range	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	cases	_	_	_	_	_	_	_	Seg=O
60	including	_	_	_	_	_	_	_	Seg=B-seg
61	China	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	Russia	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	UK	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	and	_	_	_	_	_	_	_	Seg=O
69	USA	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	we	_	_	_	_	_	_	_	Seg=B-seg
72	examine	_	_	_	_	_	_	_	Seg=O
73	three	_	_	_	_	_	_	_	Seg=O
74	categories	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	everyday	_	_	_	_	_	_	_	Seg=O
77	practice	_	_	_	_	_	_	_	Seg=O
78	during	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	COVID-19	_	_	_	_	_	_	_	Seg=O
81	pandemic	_	_	_	_	_	_	_	Seg=O
82	that	_	_	_	_	_	_	_	Seg=B-seg
83	respond	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=O
85	disruptions	_	_	_	_	_	_	_	Seg=O
86	in	_	_	_	_	_	_	_	Seg=O
87	daily	_	_	_	_	_	_	_	Seg=O
88	routines	_	_	_	_	_	_	_	Seg=O
89	and	_	_	_	_	_	_	_	Seg=B-seg
90	seek	_	_	_	_	_	_	_	Seg=O
91	a	_	_	_	_	_	_	_	Seg=O
92	return	_	_	_	_	_	_	_	Seg=O
93	to	_	_	_	_	_	_	_	Seg=O
94	national	_	_	_	_	_	_	_	Seg=O
95	normality	_	_	_	_	_	_	_	Seg=O
96	:	_	_	_	_	_	_	_	Seg=O
97	performing	_	_	_	_	_	_	_	Seg=B-seg
98	national	_	_	_	_	_	_	_	Seg=O
99	solidarities	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=O
101	exclusions	_	_	_	_	_	_	_	Seg=O
102	by	_	_	_	_	_	_	_	Seg=B-seg
103	wearing	_	_	_	_	_	_	_	Seg=O
104	face	_	_	_	_	_	_	_	Seg=O
105	masks	_	_	_	_	_	_	_	Seg=O
106	;	_	_	_	_	_	_	_	Seg=O
107	consuming	_	_	_	_	_	_	_	Seg=B-seg
108	the	_	_	_	_	_	_	_	Seg=O
109	nation	_	_	_	_	_	_	_	Seg=O
110	in	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	form	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	panic	_	_	_	_	_	_	_	Seg=O
115	buying	_	_	_	_	_	_	_	Seg=O
116	and	_	_	_	_	_	_	_	Seg=O
117	conspiracy	_	_	_	_	_	_	_	Seg=O
118	theories	_	_	_	_	_	_	_	Seg=O
119	;	_	_	_	_	_	_	_	Seg=O
120	and	_	_	_	_	_	_	_	Seg=B-seg
121	enforcing	_	_	_	_	_	_	_	Seg=O
122	foreign	_	_	_	_	_	_	_	Seg=O
123	policies	_	_	_	_	_	_	_	Seg=O
124	through	_	_	_	_	_	_	_	Seg=O
125	social	_	_	_	_	_	_	_	Seg=O
126	media	_	_	_	_	_	_	_	Seg=O
127	and	_	_	_	_	_	_	_	Seg=O
128	embodiment	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	This	_	_	_	_	_	_	_	Seg=B-seg
131	analysis	_	_	_	_	_	_	_	Seg=O
132	thus	_	_	_	_	_	_	_	Seg=O
133	breaks	_	_	_	_	_	_	_	Seg=O
134	with	_	_	_	_	_	_	_	Seg=O
135	existing	_	_	_	_	_	_	_	Seg=O
136	works	_	_	_	_	_	_	_	Seg=O
137	on	_	_	_	_	_	_	_	Seg=O
138	everyday	_	_	_	_	_	_	_	Seg=O
139	nationalism	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=O
141	banal	_	_	_	_	_	_	_	Seg=O
142	nationalism	_	_	_	_	_	_	_	Seg=O
143	that	_	_	_	_	_	_	_	Seg=B-seg
144	typically	_	_	_	_	_	_	_	Seg=O
145	focus	_	_	_	_	_	_	_	Seg=O
146	on	_	_	_	_	_	_	_	Seg=O
147	pervasively	_	_	_	_	_	_	_	Seg=O
148	unnoticed	_	_	_	_	_	_	_	Seg=O
149	forms	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	nationalism	_	_	_	_	_	_	_	Seg=O
152	during	_	_	_	_	_	_	_	Seg=O
153	settled	_	_	_	_	_	_	_	Seg=O
154	times	_	_	_	_	_	_	_	Seg=O
155	,	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=B-seg
157	it	_	_	_	_	_	_	_	Seg=O
158	challenges	_	_	_	_	_	_	_	Seg=O
159	approaches	_	_	_	_	_	_	_	Seg=O
160	to	_	_	_	_	_	_	_	Seg=O
161	contentious	_	_	_	_	_	_	_	Seg=O
162	politics	_	_	_	_	_	_	_	Seg=O
163	that	_	_	_	_	_	_	_	Seg=B-seg
164	predict	_	_	_	_	_	_	_	Seg=O
165	protest	_	_	_	_	_	_	_	Seg=O
166	mobilization	_	_	_	_	_	_	_	Seg=O
167	for	_	_	_	_	_	_	_	Seg=O
168	change	_	_	_	_	_	_	_	Seg=O
169	rather	_	_	_	_	_	_	_	Seg=O
170	than	_	_	_	_	_	_	_	Seg=O
171	restoration	_	_	_	_	_	_	_	Seg=O
172	of	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=O
174	status	_	_	_	_	_	_	_	Seg=O
175	quo	_	_	_	_	_	_	_	Seg=O
176	ante	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O
178	In	_	_	_	_	_	_	_	Seg=B-seg
179	highlighting	_	_	_	_	_	_	_	Seg=O
180	the	_	_	_	_	_	_	_	Seg=O
181	ways	_	_	_	_	_	_	_	Seg=O
182	that	_	_	_	_	_	_	_	Seg=B-seg
183	unsettled	_	_	_	_	_	_	_	Seg=O
184	times	_	_	_	_	_	_	_	Seg=O
185	disrupt	_	_	_	_	_	_	_	Seg=O
186	domestic	_	_	_	_	_	_	_	Seg=O
187	and	_	_	_	_	_	_	_	Seg=O
188	international	_	_	_	_	_	_	_	Seg=O
189	structures	_	_	_	_	_	_	_	Seg=O
190	,	_	_	_	_	_	_	_	Seg=O
191	this	_	_	_	_	_	_	_	Seg=B-seg
192	work	_	_	_	_	_	_	_	Seg=O
193	also	_	_	_	_	_	_	_	Seg=O
194	presents	_	_	_	_	_	_	_	Seg=O
195	a	_	_	_	_	_	_	_	Seg=O
196	first	_	_	_	_	_	_	_	Seg=O
197	attempt	_	_	_	_	_	_	_	Seg=O
198	to	_	_	_	_	_	_	_	Seg=B-seg
199	link	_	_	_	_	_	_	_	Seg=O
200	everyday	_	_	_	_	_	_	_	Seg=O
201	nationalism	_	_	_	_	_	_	_	Seg=O
202	with	_	_	_	_	_	_	_	Seg=O
203	growing	_	_	_	_	_	_	_	Seg=O
204	work	_	_	_	_	_	_	_	Seg=O
205	on	_	_	_	_	_	_	_	Seg=O
206	international	_	_	_	_	_	_	_	Seg=O
207	practices	_	_	_	_	_	_	_	Seg=O
208	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2c798963aaa2245c095624af78d5638bebf60c2f
1	Air	_	_	_	_	_	_	_	Seg=B-seg
2	sampling	_	_	_	_	_	_	_	Seg=O
3	as	_	_	_	_	_	_	_	Seg=O
4	an	_	_	_	_	_	_	_	Seg=O
5	aid	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=O
7	infection	_	_	_	_	_	_	_	Seg=O
8	control	_	_	_	_	_	_	_	Seg=O
9	is	_	_	_	_	_	_	_	Seg=O
10	still	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	an	_	_	_	_	_	_	_	Seg=O
13	experimental	_	_	_	_	_	_	_	Seg=O
14	stage	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	as	_	_	_	_	_	_	_	Seg=B-seg
17	there	_	_	_	_	_	_	_	Seg=O
18	is	_	_	_	_	_	_	_	Seg=O
19	no	_	_	_	_	_	_	_	Seg=O
20	consensus	_	_	_	_	_	_	_	Seg=O
21	about	_	_	_	_	_	_	_	Seg=B-seg
22	which	_	_	_	_	_	_	_	Seg=O
23	air	_	_	_	_	_	_	_	Seg=O
24	samplers	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	pathogen	_	_	_	_	_	_	_	Seg=O
27	detection	_	_	_	_	_	_	_	Seg=O
28	methods	_	_	_	_	_	_	_	Seg=O
29	should	_	_	_	_	_	_	_	Seg=O
30	be	_	_	_	_	_	_	_	Seg=O
31	used	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	what	_	_	_	_	_	_	_	Seg=O
35	thresholds	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	specific	_	_	_	_	_	_	_	Seg=O
38	pathogens	_	_	_	_	_	_	_	Seg=O
39	in	_	_	_	_	_	_	_	Seg=O
40	specific	_	_	_	_	_	_	_	Seg=O
41	exposed	_	_	_	_	_	_	_	Seg=O
42	populations	_	_	_	_	_	_	_	Seg=O
43	(	_	_	_	_	_	_	_	Seg=B-seg
44	staff	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	patients	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	or	_	_	_	_	_	_	_	Seg=O
49	visitors	_	_	_	_	_	_	_	Seg=O
50	)	_	_	_	_	_	_	_	Seg=O
51	constitutes	_	_	_	_	_	_	_	Seg=B-seg
52	a	_	_	_	_	_	_	_	Seg=O
53	true	_	_	_	_	_	_	_	Seg=O
54	clinical	_	_	_	_	_	_	_	Seg=O
55	risk	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	This	_	_	_	_	_	_	_	Seg=B-seg
58	case	_	_	_	_	_	_	_	Seg=O
59	report	_	_	_	_	_	_	_	Seg=O
60	used	_	_	_	_	_	_	_	Seg=O
61	a	_	_	_	_	_	_	_	Seg=O
62	button	_	_	_	_	_	_	_	Seg=O
63	sampler	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	worn	_	_	_	_	_	_	_	Seg=B-seg
66	or	_	_	_	_	_	_	_	Seg=O
67	held	_	_	_	_	_	_	_	Seg=O
68	by	_	_	_	_	_	_	_	Seg=O
69	staff	_	_	_	_	_	_	_	Seg=O
70	or	_	_	_	_	_	_	_	Seg=B-seg
71	left	_	_	_	_	_	_	_	Seg=O
72	free	_	_	_	_	_	_	_	Seg=O
73	-	_	_	_	_	_	_	_	Seg=O
74	standing	_	_	_	_	_	_	_	Seg=O
75	in	_	_	_	_	_	_	_	Seg=O
76	a	_	_	_	_	_	_	_	Seg=O
77	fixed	_	_	_	_	_	_	_	Seg=O
78	location	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	for	_	_	_	_	_	_	_	Seg=B-seg
81	environmental	_	_	_	_	_	_	_	Seg=O
82	sampling	_	_	_	_	_	_	_	Seg=O
83	around	_	_	_	_	_	_	_	Seg=O
84	a	_	_	_	_	_	_	_	Seg=O
85	child	_	_	_	_	_	_	_	Seg=O
86	who	_	_	_	_	_	_	_	Seg=B-seg
87	was	_	_	_	_	_	_	_	Seg=O
88	chronically	_	_	_	_	_	_	_	Seg=O
89	infected	_	_	_	_	_	_	_	Seg=O
90	by	_	_	_	_	_	_	_	Seg=O
91	a	_	_	_	_	_	_	_	Seg=O
92	respiratory	_	_	_	_	_	_	_	Seg=O
93	adenovirus	_	_	_	_	_	_	_	Seg=O
94	,	_	_	_	_	_	_	_	Seg=O
95	to	_	_	_	_	_	_	_	Seg=B-seg
96	determine	_	_	_	_	_	_	_	Seg=O
97	whether	_	_	_	_	_	_	_	Seg=O
98	there	_	_	_	_	_	_	_	Seg=O
99	was	_	_	_	_	_	_	_	Seg=O
100	any	_	_	_	_	_	_	_	Seg=O
101	risk	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	secondary	_	_	_	_	_	_	_	Seg=O
104	adenovirus	_	_	_	_	_	_	_	Seg=O
105	infection	_	_	_	_	_	_	_	Seg=O
106	to	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	staff	_	_	_	_	_	_	_	Seg=O
109	managing	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	patient	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	Despite	_	_	_	_	_	_	_	Seg=B-seg
114	multiple	_	_	_	_	_	_	_	Seg=O
115	air	_	_	_	_	_	_	_	Seg=O
116	samples	_	_	_	_	_	_	_	Seg=O
117	taken	_	_	_	_	_	_	_	Seg=B-seg
118	on	_	_	_	_	_	_	_	Seg=O
119	difference	_	_	_	_	_	_	_	Seg=O
120	days	_	_	_	_	_	_	_	Seg=O
121	,	_	_	_	_	_	_	_	Seg=O
122	coinciding	_	_	_	_	_	_	_	Seg=B-seg
123	with	_	_	_	_	_	_	_	Seg=O
124	high	_	_	_	_	_	_	_	Seg=O
125	levels	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	adenovirus	_	_	_	_	_	_	_	Seg=O
128	detectable	_	_	_	_	_	_	_	Seg=O
129	in	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131-132	child's	_	_	_	_	_	_	_	_
131	child	_	_	_	_	_	_	_	Seg=O
132	's	_	_	_	_	_	_	_	Seg=O
133	nasopharyngeal	_	_	_	_	_	_	_	Seg=O
134	aspirates	_	_	_	_	_	_	_	Seg=O
135	(	_	_	_	_	_	_	_	Seg=O
136	NPAs	_	_	_	_	_	_	_	Seg=O
137	)	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	none	_	_	_	_	_	_	_	Seg=B-seg
140	of	_	_	_	_	_	_	_	Seg=O
141	the	_	_	_	_	_	_	_	Seg=O
142	air	_	_	_	_	_	_	_	Seg=O
143	samples	_	_	_	_	_	_	_	Seg=O
144	contained	_	_	_	_	_	_	_	Seg=O
145	any	_	_	_	_	_	_	_	Seg=O
146	detectable	_	_	_	_	_	_	_	Seg=O
147	adenovirus	_	_	_	_	_	_	_	Seg=O
148	DNA	_	_	_	_	_	_	_	Seg=O
149	using	_	_	_	_	_	_	_	Seg=B-seg
150	a	_	_	_	_	_	_	_	Seg=O
151	clinically	_	_	_	_	_	_	_	Seg=O
152	validated	_	_	_	_	_	_	_	Seg=O
153	diagnostic	_	_	_	_	_	_	_	Seg=O
154	polymerase	_	_	_	_	_	_	_	Seg=O
155	chain	_	_	_	_	_	_	_	Seg=O
156	reaction	_	_	_	_	_	_	_	Seg=O
157	(	_	_	_	_	_	_	_	Seg=O
158	PCR	_	_	_	_	_	_	_	Seg=O
159	)	_	_	_	_	_	_	_	Seg=O
160	assay	_	_	_	_	_	_	_	Seg=O
161	.	_	_	_	_	_	_	_	Seg=O
162	Although	_	_	_	_	_	_	_	Seg=B-seg
163	highly	_	_	_	_	_	_	_	Seg=O
164	sensitive	_	_	_	_	_	_	_	Seg=O
165	,	_	_	_	_	_	_	_	Seg=O
166	in	_	_	_	_	_	_	_	Seg=O
167	-	_	_	_	_	_	_	_	Seg=O
168	house	_	_	_	_	_	_	_	Seg=O
169	PCR	_	_	_	_	_	_	_	Seg=O
170	assays	_	_	_	_	_	_	_	Seg=O
171	have	_	_	_	_	_	_	_	Seg=O
172	been	_	_	_	_	_	_	_	Seg=O
173	developed	_	_	_	_	_	_	_	Seg=O
174	to	_	_	_	_	_	_	_	Seg=B-seg
175	detect	_	_	_	_	_	_	_	Seg=O
176	airborne	_	_	_	_	_	_	_	Seg=O
177	pathogen	_	_	_	_	_	_	_	Seg=O
178	RNA	_	_	_	_	_	_	_	Seg=O
179	/	_	_	_	_	_	_	_	Seg=O
180	DNA	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	it	_	_	_	_	_	_	_	Seg=B-seg
183	is	_	_	_	_	_	_	_	Seg=O
184	still	_	_	_	_	_	_	_	Seg=O
185	unclear	_	_	_	_	_	_	_	Seg=O
186	what	_	_	_	_	_	_	_	Seg=O
187	level	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	specific	_	_	_	_	_	_	_	Seg=O
190	pathogen	_	_	_	_	_	_	_	Seg=O
191	RNA	_	_	_	_	_	_	_	Seg=O
192	/	_	_	_	_	_	_	_	Seg=O
193	DNA	_	_	_	_	_	_	_	Seg=O
194	constitutes	_	_	_	_	_	_	_	Seg=O
195	a	_	_	_	_	_	_	_	Seg=O
196	true	_	_	_	_	_	_	_	Seg=O
197	clinical	_	_	_	_	_	_	_	Seg=O
198	risk	_	_	_	_	_	_	_	Seg=O
199	.	_	_	_	_	_	_	_	Seg=O
200	In	_	_	_	_	_	_	_	Seg=B-seg
201	this	_	_	_	_	_	_	_	Seg=O
202	case	_	_	_	_	_	_	_	Seg=O
203	,	_	_	_	_	_	_	_	Seg=O
204	the	_	_	_	_	_	_	_	Seg=O
205	absence	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	detectable	_	_	_	_	_	_	_	Seg=O
208	airborne	_	_	_	_	_	_	_	Seg=O
209	adenovirus	_	_	_	_	_	_	_	Seg=O
210	DNA	_	_	_	_	_	_	_	Seg=O
211	using	_	_	_	_	_	_	_	Seg=B-seg
212	a	_	_	_	_	_	_	_	Seg=O
213	conventional	_	_	_	_	_	_	_	Seg=O
214	diagnostic	_	_	_	_	_	_	_	Seg=O
215	assay	_	_	_	_	_	_	_	Seg=O
216	removed	_	_	_	_	_	_	_	Seg=B-seg
217	the	_	_	_	_	_	_	_	Seg=O
218	requirement	_	_	_	_	_	_	_	Seg=O
219	for	_	_	_	_	_	_	_	Seg=O
220	staff	_	_	_	_	_	_	_	Seg=O
221	to	_	_	_	_	_	_	_	Seg=O
222	wear	_	_	_	_	_	_	_	Seg=O
223	surgical	_	_	_	_	_	_	_	Seg=O
224	masks	_	_	_	_	_	_	_	Seg=O
225	and	_	_	_	_	_	_	_	Seg=O
226	face	_	_	_	_	_	_	_	Seg=O
227	visors	_	_	_	_	_	_	_	Seg=O
228	when	_	_	_	_	_	_	_	Seg=B-seg
229	they	_	_	_	_	_	_	_	Seg=O
230	entered	_	_	_	_	_	_	_	Seg=O
231	the	_	_	_	_	_	_	_	Seg=O
232-233	child's	_	_	_	_	_	_	_	_
232	child	_	_	_	_	_	_	_	Seg=O
233	's	_	_	_	_	_	_	_	Seg=O
234	room	_	_	_	_	_	_	_	Seg=O
235	.	_	_	_	_	_	_	_	Seg=O
236	No	_	_	_	_	_	_	_	Seg=B-seg
237	subsequent	_	_	_	_	_	_	_	Seg=O
238	staff	_	_	_	_	_	_	_	Seg=O
239	infections	_	_	_	_	_	_	_	Seg=O
240	or	_	_	_	_	_	_	_	Seg=O
241	outbreaks	_	_	_	_	_	_	_	Seg=O
242	of	_	_	_	_	_	_	_	Seg=O
243	adenovirus	_	_	_	_	_	_	_	Seg=O
244	have	_	_	_	_	_	_	_	Seg=O
245	so	_	_	_	_	_	_	_	Seg=O
246	far	_	_	_	_	_	_	_	Seg=O
247	been	_	_	_	_	_	_	_	Seg=O
248	identified	_	_	_	_	_	_	_	Seg=O
249	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2cd74646ef69d8ea8f04a046a88eb22dc7187dab
1	Transshipment	_	_	_	_	_	_	_	Seg=B-seg
2	hub	_	_	_	_	_	_	_	Seg=O
3	selection	_	_	_	_	_	_	_	Seg=O
4	becomes	_	_	_	_	_	_	_	Seg=O
5	increasingly	_	_	_	_	_	_	_	Seg=O
6	important	_	_	_	_	_	_	_	Seg=O
7	to	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	global	_	_	_	_	_	_	_	Seg=O
10	logistics	_	_	_	_	_	_	_	Seg=O
11	community	_	_	_	_	_	_	_	Seg=O
12	.	_	_	_	_	_	_	_	Seg=O
13	From	_	_	_	_	_	_	_	Seg=B-seg
14	the	_	_	_	_	_	_	_	Seg=O
15	perspectives	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	shippers	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	freight	_	_	_	_	_	_	_	Seg=O
20	forwarders	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	a	_	_	_	_	_	_	_	Seg=O
23	selection	_	_	_	_	_	_	_	Seg=O
24	must	_	_	_	_	_	_	_	Seg=O
25	align	_	_	_	_	_	_	_	Seg=O
26	with	_	_	_	_	_	_	_	Seg=O
27	cost	_	_	_	_	_	_	_	Seg=O
28	control	_	_	_	_	_	_	_	Seg=O
29	strategy	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=B-seg
31	sustain	_	_	_	_	_	_	_	Seg=O
32	service	_	_	_	_	_	_	_	Seg=O
33	reliability	_	_	_	_	_	_	_	Seg=O
34	across	_	_	_	_	_	_	_	Seg=O
35	cooperative	_	_	_	_	_	_	_	Seg=O
36	service	_	_	_	_	_	_	_	Seg=O
37	providers	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	This	_	_	_	_	_	_	_	Seg=B-seg
40	paper	_	_	_	_	_	_	_	Seg=O
41	assesses	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	selection	_	_	_	_	_	_	_	Seg=O
44	with	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	options	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	both	_	_	_	_	_	_	_	Seg=O
49	sea	_	_	_	_	_	_	_	Seg=O
50	and	_	_	_	_	_	_	_	Seg=O
51	air	_	_	_	_	_	_	_	Seg=O
52	transports	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=O
55	from	_	_	_	_	_	_	_	Seg=O
56	the	_	_	_	_	_	_	_	Seg=O
57	influence	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	country	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	origin	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	company	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Critical	_	_	_	_	_	_	_	Seg=B-seg
67	factors	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	transshipment	_	_	_	_	_	_	_	Seg=O
70	hub	_	_	_	_	_	_	_	Seg=O
71	selection	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	both	_	_	_	_	_	_	_	Seg=O
74	qualitative	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=O
76	quantitative	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	are	_	_	_	_	_	_	_	Seg=O
79	identified	_	_	_	_	_	_	_	Seg=O
80	through	_	_	_	_	_	_	_	Seg=O
81	focus	_	_	_	_	_	_	_	Seg=O
82	group	_	_	_	_	_	_	_	Seg=O
83	discussions	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	Relative	_	_	_	_	_	_	_	Seg=B-seg
86	importance	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	these	_	_	_	_	_	_	_	Seg=O
89	factors	_	_	_	_	_	_	_	Seg=O
90	is	_	_	_	_	_	_	_	Seg=O
91	determined	_	_	_	_	_	_	_	Seg=O
92	based	_	_	_	_	_	_	_	Seg=B-seg
93	on	_	_	_	_	_	_	_	Seg=O
94	collective	_	_	_	_	_	_	_	Seg=O
95	views	_	_	_	_	_	_	_	Seg=O
96	of	_	_	_	_	_	_	_	Seg=O
97	logistics	_	_	_	_	_	_	_	Seg=O
98	stakeholders	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	The	_	_	_	_	_	_	_	Seg=B-seg
101	competitiveness	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	transshipment	_	_	_	_	_	_	_	Seg=O
104	hubs	_	_	_	_	_	_	_	Seg=O
105	is	_	_	_	_	_	_	_	Seg=O
106	then	_	_	_	_	_	_	_	Seg=O
107	assessed	_	_	_	_	_	_	_	Seg=O
108	using	_	_	_	_	_	_	_	Seg=B-seg
109	an	_	_	_	_	_	_	_	Seg=O
110	AHP	_	_	_	_	_	_	_	Seg=O
111	approach	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	Our	_	_	_	_	_	_	_	Seg=B-seg
114	analysis	_	_	_	_	_	_	_	Seg=O
115	is	_	_	_	_	_	_	_	Seg=O
116	based	_	_	_	_	_	_	_	Seg=O
117	on	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	historical	_	_	_	_	_	_	_	Seg=O
120	implementation	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	direct	_	_	_	_	_	_	_	Seg=O
123	transportation	_	_	_	_	_	_	_	Seg=O
124	link	_	_	_	_	_	_	_	Seg=O
125	policy	_	_	_	_	_	_	_	Seg=O
126	between	_	_	_	_	_	_	_	Seg=O
127	Mainland	_	_	_	_	_	_	_	Seg=O
128	China	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	Taiwan	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O
132	With	_	_	_	_	_	_	_	Seg=B-seg
133	this	_	_	_	_	_	_	_	Seg=O
134	empirical	_	_	_	_	_	_	_	Seg=O
135	work	_	_	_	_	_	_	_	Seg=O
136	,	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	finding	_	_	_	_	_	_	_	Seg=O
139	suggests	_	_	_	_	_	_	_	Seg=O
140	that	_	_	_	_	_	_	_	Seg=B-seg
141	even	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	spawn	_	_	_	_	_	_	_	Seg=O
144	of	_	_	_	_	_	_	_	Seg=O
145	other	_	_	_	_	_	_	_	Seg=O
146	nearby	_	_	_	_	_	_	_	Seg=O
147	ports	_	_	_	_	_	_	_	Seg=O
148	with	_	_	_	_	_	_	_	Seg=O
149	shorter	_	_	_	_	_	_	_	Seg=O
150	transport	_	_	_	_	_	_	_	Seg=O
151	distance	_	_	_	_	_	_	_	Seg=O
152	and	_	_	_	_	_	_	_	Seg=O
153	closer	_	_	_	_	_	_	_	Seg=O
154	proximity	_	_	_	_	_	_	_	Seg=O
155	to	_	_	_	_	_	_	_	Seg=O
156	cargo	_	_	_	_	_	_	_	Seg=O
157	sources	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	there	_	_	_	_	_	_	_	Seg=O
160	remain	_	_	_	_	_	_	_	Seg=O
161	overriding	_	_	_	_	_	_	_	Seg=O
162	factors	_	_	_	_	_	_	_	Seg=O
163	such	_	_	_	_	_	_	_	Seg=B-seg
164	as	_	_	_	_	_	_	_	Seg=O
165	customs	_	_	_	_	_	_	_	Seg=O
166	regulations	_	_	_	_	_	_	_	Seg=O
167	&	_	_	_	_	_	_	_	Seg=O
168	government	_	_	_	_	_	_	_	Seg=O
169	policies	_	_	_	_	_	_	_	Seg=O
170	and	_	_	_	_	_	_	_	Seg=O
171	connectivity	_	_	_	_	_	_	_	Seg=O
172	that	_	_	_	_	_	_	_	Seg=B-seg
173	a	_	_	_	_	_	_	_	Seg=O
174	transshipment	_	_	_	_	_	_	_	Seg=O
175	hub	_	_	_	_	_	_	_	Seg=O
176	is	_	_	_	_	_	_	_	Seg=O
177	preferred	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2cfc9d870895fa21b90e90ab86d1343b0da35457
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	study	_	_	_	_	_	_	_	Seg=O
3	explores	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	divergence	_	_	_	_	_	_	_	Seg=O
6	pattern	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	SARS	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	CoV-2	_	_	_	_	_	_	_	Seg=O
11	using	_	_	_	_	_	_	_	Seg=B-seg
12	whole	_	_	_	_	_	_	_	Seg=O
13	genome	_	_	_	_	_	_	_	Seg=O
14	sequences	_	_	_	_	_	_	_	Seg=O
15	of	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	isolates	_	_	_	_	_	_	_	Seg=O
18	from	_	_	_	_	_	_	_	Seg=O
19	various	_	_	_	_	_	_	_	Seg=O
20	COVID-19	_	_	_	_	_	_	_	Seg=O
21	affected	_	_	_	_	_	_	_	Seg=O
22	countries	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	The	_	_	_	_	_	_	_	Seg=B-seg
25	phylogenomic	_	_	_	_	_	_	_	Seg=O
26	analysis	_	_	_	_	_	_	_	Seg=O
27	indicates	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	presence	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=O
31	at	_	_	_	_	_	_	_	Seg=O
32	least	_	_	_	_	_	_	_	Seg=O
33	four	_	_	_	_	_	_	_	Seg=O
34	distinct	_	_	_	_	_	_	_	Seg=O
35	groups	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	SARS	_	_	_	_	_	_	_	Seg=O
39	-	_	_	_	_	_	_	_	Seg=O
40	CoV-2	_	_	_	_	_	_	_	Seg=O
41	genomes	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	The	_	_	_	_	_	_	_	Seg=B-seg
44	emergent	_	_	_	_	_	_	_	Seg=O
45	groups	_	_	_	_	_	_	_	Seg=O
46	have	_	_	_	_	_	_	_	Seg=O
47	been	_	_	_	_	_	_	_	Seg=O
48	found	_	_	_	_	_	_	_	Seg=O
49	to	_	_	_	_	_	_	_	Seg=O
50	be	_	_	_	_	_	_	_	Seg=O
51	associated	_	_	_	_	_	_	_	Seg=O
52	with	_	_	_	_	_	_	_	Seg=O
53	signature	_	_	_	_	_	_	_	Seg=O
54	structural	_	_	_	_	_	_	_	Seg=O
55	changes	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=O
57	specific	_	_	_	_	_	_	_	Seg=O
58	proteins	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	Also	_	_	_	_	_	_	_	Seg=B-seg
61	,	_	_	_	_	_	_	_	Seg=O
62	this	_	_	_	_	_	_	_	Seg=O
63	study	_	_	_	_	_	_	_	Seg=O
64	reveals	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	differential	_	_	_	_	_	_	_	Seg=O
67	levels	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	divergence	_	_	_	_	_	_	_	Seg=O
70	patterns	_	_	_	_	_	_	_	Seg=O
71	for	_	_	_	_	_	_	_	Seg=O
72	the	_	_	_	_	_	_	_	Seg=O
73	protein	_	_	_	_	_	_	_	Seg=O
74	coding	_	_	_	_	_	_	_	Seg=O
75	regions	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	Moreover	_	_	_	_	_	_	_	Seg=B-seg
78	,	_	_	_	_	_	_	_	Seg=O
79	we	_	_	_	_	_	_	_	Seg=O
80	have	_	_	_	_	_	_	_	Seg=O
81	predicted	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	impact	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	structural	_	_	_	_	_	_	_	Seg=O
86	changes	_	_	_	_	_	_	_	Seg=O
87	on	_	_	_	_	_	_	_	Seg=O
88	a	_	_	_	_	_	_	_	Seg=O
89	couple	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	important	_	_	_	_	_	_	_	Seg=O
92	viral	_	_	_	_	_	_	_	Seg=O
93	proteins	_	_	_	_	_	_	_	Seg=O
94	via	_	_	_	_	_	_	_	Seg=O
95	structural	_	_	_	_	_	_	_	Seg=O
96	modelling	_	_	_	_	_	_	_	Seg=O
97	techniques	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	This	_	_	_	_	_	_	_	Seg=B-seg
100	study	_	_	_	_	_	_	_	Seg=O
101	further	_	_	_	_	_	_	_	Seg=O
102	advocates	_	_	_	_	_	_	_	Seg=O
103	for	_	_	_	_	_	_	_	Seg=O
104	more	_	_	_	_	_	_	_	Seg=O
105	viral	_	_	_	_	_	_	_	Seg=O
106	genetic	_	_	_	_	_	_	_	Seg=O
107	studies	_	_	_	_	_	_	_	Seg=O
108	with	_	_	_	_	_	_	_	Seg=O
109	associated	_	_	_	_	_	_	_	Seg=O
110	clinical	_	_	_	_	_	_	_	Seg=O
111	outcomes	_	_	_	_	_	_	_	Seg=O
112	and	_	_	_	_	_	_	_	Seg=O
113-114	hosts'	_	_	_	_	_	_	_	_
113	hosts	_	_	_	_	_	_	_	Seg=O
114	'	_	_	_	_	_	_	_	Seg=O
115	response	_	_	_	_	_	_	_	Seg=O
116	for	_	_	_	_	_	_	_	Seg=O
117	better	_	_	_	_	_	_	_	Seg=O
118	understanding	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	SARS	_	_	_	_	_	_	_	Seg=O
121	-	_	_	_	_	_	_	_	Seg=O
122	CoV-2	_	_	_	_	_	_	_	Seg=O
123	pathogenesis	_	_	_	_	_	_	_	Seg=O
124	enabling	_	_	_	_	_	_	_	Seg=B-seg
125	better	_	_	_	_	_	_	_	Seg=O
126	mitigation	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	this	_	_	_	_	_	_	_	Seg=O
129	pandemic	_	_	_	_	_	_	_	Seg=O
130	situation	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2e6263111a76ff0d43e7e3cde2692df04533e4f7
1	It	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	well	_	_	_	_	_	_	_	Seg=O
4	established	_	_	_	_	_	_	_	Seg=O
5	that	_	_	_	_	_	_	_	Seg=O
6	increasing	_	_	_	_	_	_	_	Seg=O
7	age	_	_	_	_	_	_	_	Seg=O
8	is	_	_	_	_	_	_	_	Seg=O
9	associated	_	_	_	_	_	_	_	Seg=O
10	with	_	_	_	_	_	_	_	Seg=O
11	a	_	_	_	_	_	_	_	Seg=O
12	decreased	_	_	_	_	_	_	_	Seg=O
13	capacity	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	immune	_	_	_	_	_	_	_	Seg=O
17	system	_	_	_	_	_	_	_	Seg=O
18	to	_	_	_	_	_	_	_	Seg=B-seg
19	mediate	_	_	_	_	_	_	_	Seg=O
20	effective	_	_	_	_	_	_	_	Seg=O
21	immune	_	_	_	_	_	_	_	Seg=O
22	responses	_	_	_	_	_	_	_	Seg=O
23	to	_	_	_	_	_	_	_	Seg=O
24	vaccination	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	invading	_	_	_	_	_	_	_	Seg=O
27	pathogens	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	Because	_	_	_	_	_	_	_	Seg=B-seg
30	of	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	inherent	_	_	_	_	_	_	_	Seg=O
33	limitations	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=B-seg
35	conducting	_	_	_	_	_	_	_	Seg=O
36	experiments	_	_	_	_	_	_	_	Seg=O
37	in	_	_	_	_	_	_	_	Seg=O
38	humans	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	much	_	_	_	_	_	_	_	Seg=B-seg
41	of	_	_	_	_	_	_	_	Seg=O
42	what	_	_	_	_	_	_	_	Seg=O
43	we	_	_	_	_	_	_	_	Seg=O
44	have	_	_	_	_	_	_	_	Seg=O
45	learned	_	_	_	_	_	_	_	Seg=O
46	is	_	_	_	_	_	_	_	Seg=O
47	owed	_	_	_	_	_	_	_	Seg=O
48	to	_	_	_	_	_	_	_	Seg=O
49	the	_	_	_	_	_	_	_	Seg=O
50	utility	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	experimental	_	_	_	_	_	_	_	Seg=O
53	mouse	_	_	_	_	_	_	_	Seg=O
54	models	_	_	_	_	_	_	_	Seg=O
55	of	_	_	_	_	_	_	_	Seg=O
56	aging	_	_	_	_	_	_	_	Seg=O
57	.	_	_	_	_	_	_	_	Seg=O
58	Recent	_	_	_	_	_	_	_	Seg=B-seg
59	studies	_	_	_	_	_	_	_	Seg=O
60	performed	_	_	_	_	_	_	_	Seg=B-seg
61	in	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	mouse	_	_	_	_	_	_	_	Seg=O
64	have	_	_	_	_	_	_	_	Seg=B-seg
65	demonstrated	_	_	_	_	_	_	_	Seg=O
66	mechanisms	_	_	_	_	_	_	_	Seg=O
67	responsible	_	_	_	_	_	_	_	Seg=O
68	for	_	_	_	_	_	_	_	Seg=O
69	age	_	_	_	_	_	_	_	Seg=O
70	-	_	_	_	_	_	_	_	Seg=O
71	related	_	_	_	_	_	_	_	Seg=O
72	declines	_	_	_	_	_	_	_	Seg=O
73	in	_	_	_	_	_	_	_	Seg=O
74	the	_	_	_	_	_	_	_	Seg=O
75	function	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	CD4	_	_	_	_	_	_	_	Seg=O
78	+	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	CD8	_	_	_	_	_	_	_	Seg=O
81	+	_	_	_	_	_	_	_	Seg=O
82	cells	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	This	_	_	_	_	_	_	_	Seg=B-seg
85	review	_	_	_	_	_	_	_	Seg=O
86	describes	_	_	_	_	_	_	_	Seg=O
87	key	_	_	_	_	_	_	_	Seg=O
88	findings	_	_	_	_	_	_	_	Seg=O
89	regarding	_	_	_	_	_	_	_	Seg=B-seg
90	age	_	_	_	_	_	_	_	Seg=O
91	-	_	_	_	_	_	_	_	Seg=O
92	related	_	_	_	_	_	_	_	Seg=O
93	defects	_	_	_	_	_	_	_	Seg=O
94	in	_	_	_	_	_	_	_	Seg=O
95	T	_	_	_	_	_	_	_	Seg=O
96	-	_	_	_	_	_	_	_	Seg=O
97	cell	_	_	_	_	_	_	_	Seg=O
98	function	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=B-seg
100	discusses	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	impact	_	_	_	_	_	_	_	Seg=O
103	these	_	_	_	_	_	_	_	Seg=B-seg
104	defects	_	_	_	_	_	_	_	Seg=O
105	have	_	_	_	_	_	_	_	Seg=O
106	on	_	_	_	_	_	_	_	Seg=O
107	vaccine	_	_	_	_	_	_	_	Seg=O
108	efficacy	_	_	_	_	_	_	_	Seg=O
109	and	_	_	_	_	_	_	_	Seg=O
110	immunity	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2ebd4ba5ce0c32a5c7ef6396e35262bd667f1dcc
1	Cytokine	_	_	_	_	_	_	_	Seg=B-seg
2	storm	_	_	_	_	_	_	_	Seg=O
3	during	_	_	_	_	_	_	_	Seg=O
4	viral	_	_	_	_	_	_	_	Seg=O
5	infection	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	prospective	_	_	_	_	_	_	_	Seg=O
9	predictor	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	morbidity	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	mortality	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	yet	_	_	_	_	_	_	_	Seg=B-seg
16	the	_	_	_	_	_	_	_	Seg=O
17	cellular	_	_	_	_	_	_	_	Seg=O
18	sources	_	_	_	_	_	_	_	Seg=O
19	remain	_	_	_	_	_	_	_	Seg=O
20	undefined	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	Here	_	_	_	_	_	_	_	Seg=B-seg
23	,	_	_	_	_	_	_	_	Seg=O
24	using	_	_	_	_	_	_	_	Seg=O
25	genetic	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	chemical	_	_	_	_	_	_	_	Seg=O
28	tools	_	_	_	_	_	_	_	Seg=O
29	to	_	_	_	_	_	_	_	Seg=B-seg
30	probe	_	_	_	_	_	_	_	Seg=O
31	functions	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	S1P	_	_	_	_	_	_	_	Seg=O
35	1	_	_	_	_	_	_	_	Seg=O
36	receptor	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	we	_	_	_	_	_	_	_	Seg=B-seg
39	elucidate	_	_	_	_	_	_	_	Seg=O
40	cellular	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	signaling	_	_	_	_	_	_	_	Seg=O
43	mechanisms	_	_	_	_	_	_	_	Seg=O
44	that	_	_	_	_	_	_	_	Seg=B-seg
45	are	_	_	_	_	_	_	_	Seg=O
46	important	_	_	_	_	_	_	_	Seg=O
47	in	_	_	_	_	_	_	_	Seg=O
48	initiating	_	_	_	_	_	_	_	Seg=O
49	cytokine	_	_	_	_	_	_	_	Seg=O
50	storm	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	Whereas	_	_	_	_	_	_	_	Seg=B-seg
53	S1P	_	_	_	_	_	_	_	Seg=O
54	1	_	_	_	_	_	_	_	Seg=O
55	receptor	_	_	_	_	_	_	_	Seg=O
56	is	_	_	_	_	_	_	_	Seg=O
57	expressed	_	_	_	_	_	_	_	Seg=O
58	on	_	_	_	_	_	_	_	Seg=O
59	endothelial	_	_	_	_	_	_	_	Seg=O
60	cells	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	lymphocytes	_	_	_	_	_	_	_	Seg=O
63	within	_	_	_	_	_	_	_	Seg=O
64	lung	_	_	_	_	_	_	_	Seg=O
65	tissue	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	S1P	_	_	_	_	_	_	_	Seg=B-seg
68	1	_	_	_	_	_	_	_	Seg=O
69	agonism	_	_	_	_	_	_	_	Seg=O
70	suppresses	_	_	_	_	_	_	_	Seg=O
71	cytokines	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=O
73	innate	_	_	_	_	_	_	_	Seg=O
74	immune	_	_	_	_	_	_	_	Seg=O
75	cell	_	_	_	_	_	_	_	Seg=O
76	recruitment	_	_	_	_	_	_	_	Seg=O
77	in	_	_	_	_	_	_	_	Seg=O
78	wild	_	_	_	_	_	_	_	Seg=O
79	-	_	_	_	_	_	_	_	Seg=O
80	type	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	lymphocyte	_	_	_	_	_	_	_	Seg=O
83	-	_	_	_	_	_	_	_	Seg=O
84	deficient	_	_	_	_	_	_	_	Seg=O
85	mice	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	identifying	_	_	_	_	_	_	_	Seg=B-seg
88	endothelial	_	_	_	_	_	_	_	Seg=O
89	cells	_	_	_	_	_	_	_	Seg=O
90	as	_	_	_	_	_	_	_	Seg=O
91	central	_	_	_	_	_	_	_	Seg=O
92	regulators	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=O
94	cytokine	_	_	_	_	_	_	_	Seg=O
95	storm	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
98	,	_	_	_	_	_	_	_	Seg=O
99	our	_	_	_	_	_	_	_	Seg=O
100	data	_	_	_	_	_	_	_	Seg=O
101	reveal	_	_	_	_	_	_	_	Seg=O
102	immune	_	_	_	_	_	_	_	Seg=O
103	cell	_	_	_	_	_	_	_	Seg=O
104	infiltration	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=O
106	cytokine	_	_	_	_	_	_	_	Seg=O
107	production	_	_	_	_	_	_	_	Seg=O
108	as	_	_	_	_	_	_	_	Seg=O
109	distinct	_	_	_	_	_	_	_	Seg=O
110	events	_	_	_	_	_	_	_	Seg=O
111	that	_	_	_	_	_	_	_	Seg=B-seg
112	are	_	_	_	_	_	_	_	Seg=O
113	both	_	_	_	_	_	_	_	Seg=O
114	orchestrated	_	_	_	_	_	_	_	Seg=O
115	by	_	_	_	_	_	_	_	Seg=O
116	endothelial	_	_	_	_	_	_	_	Seg=O
117	cells	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	Moreover	_	_	_	_	_	_	_	Seg=B-seg
120	,	_	_	_	_	_	_	_	Seg=O
121	we	_	_	_	_	_	_	_	Seg=O
122	demonstrate	_	_	_	_	_	_	_	Seg=O
123	that	_	_	_	_	_	_	_	Seg=B-seg
124	suppression	_	_	_	_	_	_	_	Seg=O
125	of	_	_	_	_	_	_	_	Seg=O
126	early	_	_	_	_	_	_	_	Seg=O
127	innate	_	_	_	_	_	_	_	Seg=O
128	immune	_	_	_	_	_	_	_	Seg=O
129	responses	_	_	_	_	_	_	_	Seg=O
130	through	_	_	_	_	_	_	_	Seg=O
131	S1P	_	_	_	_	_	_	_	Seg=O
132	1	_	_	_	_	_	_	_	Seg=O
133	signaling	_	_	_	_	_	_	_	Seg=O
134	results	_	_	_	_	_	_	_	Seg=O
135	in	_	_	_	_	_	_	_	Seg=O
136	reduced	_	_	_	_	_	_	_	Seg=O
137	mortality	_	_	_	_	_	_	_	Seg=O
138	during	_	_	_	_	_	_	_	Seg=O
139	infection	_	_	_	_	_	_	_	Seg=O
140	with	_	_	_	_	_	_	_	Seg=O
141	a	_	_	_	_	_	_	_	Seg=O
142	human	_	_	_	_	_	_	_	Seg=O
143	pathogenic	_	_	_	_	_	_	_	Seg=O
144	strain	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	influenza	_	_	_	_	_	_	_	Seg=O
147	virus	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	Modulation	_	_	_	_	_	_	_	Seg=B-seg
150	of	_	_	_	_	_	_	_	Seg=O
151	endothelium	_	_	_	_	_	_	_	Seg=O
152	with	_	_	_	_	_	_	_	Seg=O
153	a	_	_	_	_	_	_	_	Seg=O
154	specific	_	_	_	_	_	_	_	Seg=O
155	agonist	_	_	_	_	_	_	_	Seg=O
156	suggests	_	_	_	_	_	_	_	Seg=O
157	that	_	_	_	_	_	_	_	Seg=B-seg
158	diseases	_	_	_	_	_	_	_	Seg=O
159	in	_	_	_	_	_	_	_	Seg=B-seg
160	which	_	_	_	_	_	_	_	Seg=O
161	amplification	_	_	_	_	_	_	_	Seg=O
162	of	_	_	_	_	_	_	_	Seg=O
163	cytokine	_	_	_	_	_	_	_	Seg=O
164	storm	_	_	_	_	_	_	_	Seg=O
165	is	_	_	_	_	_	_	_	Seg=O
166	a	_	_	_	_	_	_	_	Seg=O
167	significant	_	_	_	_	_	_	_	Seg=O
168	pathological	_	_	_	_	_	_	_	Seg=O
169	component	_	_	_	_	_	_	_	Seg=O
170	could	_	_	_	_	_	_	_	Seg=B-seg
171	be	_	_	_	_	_	_	_	Seg=O
172	chemically	_	_	_	_	_	_	_	Seg=O
173	tractable	_	_	_	_	_	_	_	Seg=O
174	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2f071bf96a0a2a1c4fc270a41ca7f4535f474ec5
1	It	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	normal	_	_	_	_	_	_	_	Seg=O
4	for	_	_	_	_	_	_	_	Seg=O
5	hosts	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=O
7	be	_	_	_	_	_	_	_	Seg=O
8	co	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	infected	_	_	_	_	_	_	_	Seg=O
11	by	_	_	_	_	_	_	_	Seg=O
12	parasites	_	_	_	_	_	_	_	Seg=O
13	.	_	_	_	_	_	_	_	Seg=O
14	Interactions	_	_	_	_	_	_	_	Seg=B-seg
15	among	_	_	_	_	_	_	_	Seg=O
16	co	_	_	_	_	_	_	_	Seg=O
17	-	_	_	_	_	_	_	_	Seg=O
18	infecting	_	_	_	_	_	_	_	Seg=O
19	species	_	_	_	_	_	_	_	Seg=O
20	can	_	_	_	_	_	_	_	Seg=O
21	have	_	_	_	_	_	_	_	Seg=O
22	profound	_	_	_	_	_	_	_	Seg=O
23	consequences	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	including	_	_	_	_	_	_	_	Seg=B-seg
26	changing	_	_	_	_	_	_	_	Seg=O
27	parasite	_	_	_	_	_	_	_	Seg=O
28	transmission	_	_	_	_	_	_	_	Seg=O
29	dynamics	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	altering	_	_	_	_	_	_	_	Seg=O
32	disease	_	_	_	_	_	_	_	Seg=O
33	severity	_	_	_	_	_	_	_	Seg=O
34	and	_	_	_	_	_	_	_	Seg=O
35	confounding	_	_	_	_	_	_	_	Seg=O
36	attempts	_	_	_	_	_	_	_	Seg=O
37	at	_	_	_	_	_	_	_	Seg=O
38	parasite	_	_	_	_	_	_	_	Seg=O
39	control	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	Despite	_	_	_	_	_	_	_	Seg=B-seg
42	the	_	_	_	_	_	_	_	Seg=O
43	importance	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	co	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	infection	_	_	_	_	_	_	_	Seg=O
48	,	_	_	_	_	_	_	_	Seg=O
49	there	_	_	_	_	_	_	_	Seg=B-seg
50	is	_	_	_	_	_	_	_	Seg=O
51	currently	_	_	_	_	_	_	_	Seg=O
52	no	_	_	_	_	_	_	_	Seg=O
53	way	_	_	_	_	_	_	_	Seg=O
54	to	_	_	_	_	_	_	_	Seg=B-seg
55	predict	_	_	_	_	_	_	_	Seg=O
56	how	_	_	_	_	_	_	_	Seg=O
57	different	_	_	_	_	_	_	_	Seg=O
58	parasite	_	_	_	_	_	_	_	Seg=O
59	species	_	_	_	_	_	_	_	Seg=O
60	may	_	_	_	_	_	_	_	Seg=O
61	interact	_	_	_	_	_	_	_	Seg=O
62	with	_	_	_	_	_	_	_	Seg=O
63	one	_	_	_	_	_	_	_	Seg=O
64	another	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	nor	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	consequences	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	those	_	_	_	_	_	_	_	Seg=O
71	interactions	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	Here	_	_	_	_	_	_	_	Seg=B-seg
74	,	_	_	_	_	_	_	_	Seg=O
75	we	_	_	_	_	_	_	_	Seg=O
76	demonstrate	_	_	_	_	_	_	_	Seg=O
77	a	_	_	_	_	_	_	_	Seg=O
78	method	_	_	_	_	_	_	_	Seg=O
79	that	_	_	_	_	_	_	_	Seg=B-seg
80	enables	_	_	_	_	_	_	_	Seg=O
81	such	_	_	_	_	_	_	_	Seg=O
82	prediction	_	_	_	_	_	_	_	Seg=O
83	by	_	_	_	_	_	_	_	Seg=B-seg
84	identifying	_	_	_	_	_	_	_	Seg=O
85	two	_	_	_	_	_	_	_	Seg=O
86	nematode	_	_	_	_	_	_	_	Seg=O
87	parasite	_	_	_	_	_	_	_	Seg=O
88	groups	_	_	_	_	_	_	_	Seg=O
89	based	_	_	_	_	_	_	_	Seg=B-seg
90	on	_	_	_	_	_	_	_	Seg=O
91	taxonomy	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=O
93	characteristics	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	the	_	_	_	_	_	_	_	Seg=O
96	parasitological	_	_	_	_	_	_	_	Seg=O
97	niche	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	From	_	_	_	_	_	_	_	Seg=B-seg
100	an	_	_	_	_	_	_	_	Seg=O
101	understanding	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	interactions	_	_	_	_	_	_	_	Seg=O
105	between	_	_	_	_	_	_	_	Seg=O
106	the	_	_	_	_	_	_	_	Seg=O
107	two	_	_	_	_	_	_	_	Seg=O
108	defined	_	_	_	_	_	_	_	Seg=O
109	groups	_	_	_	_	_	_	_	Seg=O
110	in	_	_	_	_	_	_	_	Seg=O
111	one	_	_	_	_	_	_	_	Seg=O
112	host	_	_	_	_	_	_	_	Seg=O
113	system	_	_	_	_	_	_	_	Seg=O
114	(	_	_	_	_	_	_	_	Seg=B-seg
115	wild	_	_	_	_	_	_	_	Seg=O
116	rabbits	_	_	_	_	_	_	_	Seg=O
117	)	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	we	_	_	_	_	_	_	_	Seg=B-seg
120	predict	_	_	_	_	_	_	_	Seg=O
121	how	_	_	_	_	_	_	_	Seg=O
122	two	_	_	_	_	_	_	_	Seg=O
123	different	_	_	_	_	_	_	_	Seg=O
124	nematode	_	_	_	_	_	_	_	Seg=O
125	species	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	from	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	same	_	_	_	_	_	_	_	Seg=O
130	defined	_	_	_	_	_	_	_	Seg=O
131	groups	_	_	_	_	_	_	_	Seg=O
132	,	_	_	_	_	_	_	_	Seg=O
133	will	_	_	_	_	_	_	_	Seg=O
134	interact	_	_	_	_	_	_	_	Seg=O
135	in	_	_	_	_	_	_	_	Seg=O
136	co	_	_	_	_	_	_	_	Seg=O
137	-	_	_	_	_	_	_	_	Seg=O
138	infections	_	_	_	_	_	_	_	Seg=O
139	in	_	_	_	_	_	_	_	Seg=O
140	a	_	_	_	_	_	_	_	Seg=O
141	different	_	_	_	_	_	_	_	Seg=O
142	host	_	_	_	_	_	_	_	Seg=O
143	system	_	_	_	_	_	_	_	Seg=O
144	(	_	_	_	_	_	_	_	Seg=B-seg
145	sheep	_	_	_	_	_	_	_	Seg=O
146	)	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=B-seg
149	then	_	_	_	_	_	_	_	Seg=O
150	we	_	_	_	_	_	_	_	Seg=O
151	test	_	_	_	_	_	_	_	Seg=O
152	this	_	_	_	_	_	_	_	Seg=O
153	experimentally	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O
155	We	_	_	_	_	_	_	_	Seg=B-seg
156	show	_	_	_	_	_	_	_	Seg=O
157	that	_	_	_	_	_	_	_	Seg=B-seg
158	,	_	_	_	_	_	_	_	Seg=O
159	as	_	_	_	_	_	_	_	Seg=B-seg
160	predicted	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	in	_	_	_	_	_	_	_	Seg=B-seg
163	co	_	_	_	_	_	_	_	Seg=O
164	-	_	_	_	_	_	_	_	Seg=O
165	infections	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	blood	_	_	_	_	_	_	_	Seg=O
169	-	_	_	_	_	_	_	_	Seg=O
170	feeding	_	_	_	_	_	_	_	Seg=O
171	nematode	_	_	_	_	_	_	_	Seg=O
172	Haemonchus	_	_	_	_	_	_	_	Seg=O
173	contortus	_	_	_	_	_	_	_	Seg=O
174	suppresses	_	_	_	_	_	_	_	Seg=O
175	aspects	_	_	_	_	_	_	_	Seg=O
176	of	_	_	_	_	_	_	_	Seg=O
177	the	_	_	_	_	_	_	_	Seg=O
178	sheep	_	_	_	_	_	_	_	Seg=O
179	immune	_	_	_	_	_	_	_	Seg=O
180	response	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	thereby	_	_	_	_	_	_	_	Seg=B-seg
183	facilitating	_	_	_	_	_	_	_	Seg=O
184	the	_	_	_	_	_	_	_	Seg=O
185	establishment	_	_	_	_	_	_	_	Seg=O
186	and/or	_	_	_	_	_	_	_	Seg=O
187	survival	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	nematode	_	_	_	_	_	_	_	Seg=O
191	Trichostrongylus	_	_	_	_	_	_	_	Seg=O
192	colubriformis	_	_	_	_	_	_	_	Seg=O
193	;	_	_	_	_	_	_	_	Seg=O
194	and	_	_	_	_	_	_	_	Seg=B-seg
195	that	_	_	_	_	_	_	_	Seg=O
196	the	_	_	_	_	_	_	_	Seg=O
197	T.	_	_	_	_	_	_	_	Seg=O
198	colubriformis	_	_	_	_	_	_	_	Seg=O
199	-	_	_	_	_	_	_	_	Seg=O
200	induced	_	_	_	_	_	_	_	Seg=O
201	immune	_	_	_	_	_	_	_	Seg=O
202	response	_	_	_	_	_	_	_	Seg=O
203	negatively	_	_	_	_	_	_	_	Seg=O
204	affects	_	_	_	_	_	_	_	Seg=O
205	H.	_	_	_	_	_	_	_	Seg=O
206	contortus	_	_	_	_	_	_	_	Seg=O
207	.	_	_	_	_	_	_	_	Seg=O
208	This	_	_	_	_	_	_	_	Seg=B-seg
209	work	_	_	_	_	_	_	_	Seg=O
210	is	_	_	_	_	_	_	_	Seg=O
211	,	_	_	_	_	_	_	_	Seg=O
212	to	_	_	_	_	_	_	_	Seg=O
213	our	_	_	_	_	_	_	_	Seg=O
214	knowledge	_	_	_	_	_	_	_	Seg=O
215	,	_	_	_	_	_	_	_	Seg=O
216	the	_	_	_	_	_	_	_	Seg=O
217	first	_	_	_	_	_	_	_	Seg=O
218	to	_	_	_	_	_	_	_	Seg=B-seg
219	use	_	_	_	_	_	_	_	Seg=O
220	empirical	_	_	_	_	_	_	_	Seg=O
221	data	_	_	_	_	_	_	_	Seg=O
222	from	_	_	_	_	_	_	_	Seg=O
223	one	_	_	_	_	_	_	_	Seg=O
224	host	_	_	_	_	_	_	_	Seg=O
225	system	_	_	_	_	_	_	_	Seg=O
226	to	_	_	_	_	_	_	_	Seg=B-seg
227	successfully	_	_	_	_	_	_	_	Seg=O
228	predict	_	_	_	_	_	_	_	Seg=O
229	the	_	_	_	_	_	_	_	Seg=O
230	specific	_	_	_	_	_	_	_	Seg=O
231	outcome	_	_	_	_	_	_	_	Seg=O
232	of	_	_	_	_	_	_	_	Seg=O
233	a	_	_	_	_	_	_	_	Seg=O
234	different	_	_	_	_	_	_	_	Seg=O
235	co	_	_	_	_	_	_	_	Seg=O
236	-	_	_	_	_	_	_	_	Seg=O
237	infection	_	_	_	_	_	_	_	Seg=O
238	in	_	_	_	_	_	_	_	Seg=O
239	a	_	_	_	_	_	_	_	Seg=O
240	second	_	_	_	_	_	_	_	Seg=O
241	host	_	_	_	_	_	_	_	Seg=O
242	species	_	_	_	_	_	_	_	Seg=O
243	.	_	_	_	_	_	_	_	Seg=O
244	The	_	_	_	_	_	_	_	Seg=B-seg
245	study	_	_	_	_	_	_	_	Seg=O
246	therefore	_	_	_	_	_	_	_	Seg=O
247	takes	_	_	_	_	_	_	_	Seg=O
248	the	_	_	_	_	_	_	_	Seg=O
249	first	_	_	_	_	_	_	_	Seg=O
250	step	_	_	_	_	_	_	_	Seg=O
251	in	_	_	_	_	_	_	_	Seg=B-seg
252	defining	_	_	_	_	_	_	_	Seg=O
253	a	_	_	_	_	_	_	_	Seg=O
254	practical	_	_	_	_	_	_	_	Seg=O
255	framework	_	_	_	_	_	_	_	Seg=O
256	for	_	_	_	_	_	_	_	Seg=B-seg
257	predicting	_	_	_	_	_	_	_	Seg=O
258	interspecific	_	_	_	_	_	_	_	Seg=O
259	parasite	_	_	_	_	_	_	_	Seg=O
260	interactions	_	_	_	_	_	_	_	Seg=O
261	in	_	_	_	_	_	_	_	Seg=O
262	other	_	_	_	_	_	_	_	Seg=O
263	animal	_	_	_	_	_	_	_	Seg=O
264	systems	_	_	_	_	_	_	_	Seg=O
265	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2f6efc4edc0c9fffd3acc810efd8616e7772b28a
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	appearance	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	novel	_	_	_	_	_	_	_	Seg=O
6	betacoronavirus	_	_	_	_	_	_	_	Seg=O
7	SARS	_	_	_	_	_	_	_	Seg=O
8	-	_	_	_	_	_	_	_	Seg=O
9	CoV-2	_	_	_	_	_	_	_	Seg=O
10	represents	_	_	_	_	_	_	_	Seg=O
11	a	_	_	_	_	_	_	_	Seg=O
12	major	_	_	_	_	_	_	_	Seg=O
13	threat	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=O
15	human	_	_	_	_	_	_	_	Seg=O
16	health	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=B-seg
19	its	_	_	_	_	_	_	_	Seg=O
20	diffusion	_	_	_	_	_	_	_	Seg=O
21	around	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	world	_	_	_	_	_	_	_	Seg=O
24	is	_	_	_	_	_	_	_	Seg=O
25	causing	_	_	_	_	_	_	_	Seg=O
26	dramatic	_	_	_	_	_	_	_	Seg=O
27	consequences	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	The	_	_	_	_	_	_	_	Seg=B-seg
30	knowledge	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	3D	_	_	_	_	_	_	_	Seg=O
34	structures	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	SARS	_	_	_	_	_	_	_	Seg=O
37	-	_	_	_	_	_	_	_	Seg=O
38	CoV-2	_	_	_	_	_	_	_	Seg=O
39	proteins	_	_	_	_	_	_	_	Seg=O
40	can	_	_	_	_	_	_	_	Seg=O
41	facilitate	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	development	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	therapeutic	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=O
47	diagnostic	_	_	_	_	_	_	_	Seg=O
48	molecules	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	Specifically	_	_	_	_	_	_	_	Seg=B-seg
51	,	_	_	_	_	_	_	_	Seg=O
52	comparative	_	_	_	_	_	_	_	Seg=O
53	analyses	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	structures	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	SARS	_	_	_	_	_	_	_	Seg=O
59	-	_	_	_	_	_	_	_	Seg=O
60	CoV-2	_	_	_	_	_	_	_	Seg=O
61	proteins	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	homologous	_	_	_	_	_	_	_	Seg=O
64	proteins	_	_	_	_	_	_	_	Seg=O
65	from	_	_	_	_	_	_	_	Seg=O
66	previously	_	_	_	_	_	_	_	Seg=O
67	characterized	_	_	_	_	_	_	_	Seg=O
68	viruses	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	such	_	_	_	_	_	_	_	Seg=B-seg
71	as	_	_	_	_	_	_	_	Seg=O
72	SARS	_	_	_	_	_	_	_	Seg=O
73	-	_	_	_	_	_	_	_	Seg=O
74	CoV	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	can	_	_	_	_	_	_	_	Seg=B-seg
77	reveal	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	common	_	_	_	_	_	_	_	Seg=O
80	and/or	_	_	_	_	_	_	_	Seg=O
81	distinctive	_	_	_	_	_	_	_	Seg=O
82	traits	_	_	_	_	_	_	_	Seg=O
83	that	_	_	_	_	_	_	_	Seg=B-seg
84	underlie	_	_	_	_	_	_	_	Seg=O
85	the	_	_	_	_	_	_	_	Seg=O
86	mechanisms	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	recognition	_	_	_	_	_	_	_	Seg=O
89	of	_	_	_	_	_	_	_	Seg=O
90	cell	_	_	_	_	_	_	_	Seg=O
91	receptors	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=O
94	molecules	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	immune	_	_	_	_	_	_	_	Seg=O
98	system	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	Herein	_	_	_	_	_	_	_	Seg=B-seg
101	,	_	_	_	_	_	_	_	Seg=O
102	we	_	_	_	_	_	_	_	Seg=O
103	apply	_	_	_	_	_	_	_	Seg=O
104	our	_	_	_	_	_	_	_	Seg=O
105	recently	_	_	_	_	_	_	_	Seg=O
106	developed	_	_	_	_	_	_	_	Seg=O
107	energy	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	based	_	_	_	_	_	_	_	Seg=O
110	methods	_	_	_	_	_	_	_	Seg=O
111	for	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	prediction	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	antibodybinding	_	_	_	_	_	_	_	Seg=O
116	epitopes	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	protein	_	_	_	_	_	_	_	Seg=O
119	-	_	_	_	_	_	_	_	Seg=O
120	protein	_	_	_	_	_	_	_	Seg=O
121	interaction	_	_	_	_	_	_	_	Seg=O
122	regions	_	_	_	_	_	_	_	Seg=O
123	to	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	Receptor	_	_	_	_	_	_	_	Seg=O
126	Binding	_	_	_	_	_	_	_	Seg=O
127	Domain	_	_	_	_	_	_	_	Seg=O
128	(	_	_	_	_	_	_	_	Seg=O
129	RBD	_	_	_	_	_	_	_	Seg=O
130	)	_	_	_	_	_	_	_	Seg=O
131	of	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	Spike	_	_	_	_	_	_	_	Seg=O
134	proteins	_	_	_	_	_	_	_	Seg=O
135	from	_	_	_	_	_	_	_	Seg=O
136	SARS	_	_	_	_	_	_	_	Seg=O
137	-	_	_	_	_	_	_	_	Seg=O
138	CoV-2	_	_	_	_	_	_	_	Seg=O
139	and	_	_	_	_	_	_	_	Seg=O
140	SARS	_	_	_	_	_	_	_	Seg=O
141	-	_	_	_	_	_	_	_	Seg=O
142	CoV.	_	_	_	_	_	_	_	Seg=O
143	Our	_	_	_	_	_	_	_	Seg=B-seg
144	analysis	_	_	_	_	_	_	_	Seg=O
145	focusses	_	_	_	_	_	_	_	Seg=O
146	only	_	_	_	_	_	_	_	Seg=O
147	on	_	_	_	_	_	_	_	Seg=O
148	the	_	_	_	_	_	_	_	Seg=O
149	study	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	structure	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	RBDs	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	isolation	_	_	_	_	_	_	_	Seg=O
157	,	_	_	_	_	_	_	_	Seg=O
158	without	_	_	_	_	_	_	_	Seg=B-seg
159	making	_	_	_	_	_	_	_	Seg=O
160	use	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	any	_	_	_	_	_	_	_	Seg=O
163	previous	_	_	_	_	_	_	_	Seg=O
164	knowledge	_	_	_	_	_	_	_	Seg=O
165	of	_	_	_	_	_	_	_	Seg=O
166	binding	_	_	_	_	_	_	_	Seg=O
167	properties	_	_	_	_	_	_	_	Seg=O
168	.	_	_	_	_	_	_	_	Seg=O
169	Importantly	_	_	_	_	_	_	_	Seg=B-seg
170	,	_	_	_	_	_	_	_	Seg=O
171	our	_	_	_	_	_	_	_	Seg=O
172	results	_	_	_	_	_	_	_	Seg=O
173	highlight	_	_	_	_	_	_	_	Seg=O
174	structural	_	_	_	_	_	_	_	Seg=O
175	and	_	_	_	_	_	_	_	Seg=O
176	sequence	_	_	_	_	_	_	_	Seg=O
177	differences	_	_	_	_	_	_	_	Seg=O
178	among	_	_	_	_	_	_	_	Seg=O
179	the	_	_	_	_	_	_	_	Seg=O
180	regions	_	_	_	_	_	_	_	Seg=O
181	that	_	_	_	_	_	_	_	Seg=B-seg
182	are	_	_	_	_	_	_	_	Seg=O
183	predicted	_	_	_	_	_	_	_	Seg=O
184	to	_	_	_	_	_	_	_	Seg=O
185	be	_	_	_	_	_	_	_	Seg=O
186	immunoreactive	_	_	_	_	_	_	_	Seg=O
187	and	_	_	_	_	_	_	_	Seg=O
188	bind	_	_	_	_	_	_	_	Seg=O
189	/	_	_	_	_	_	_	_	Seg=O
190	elicit	_	_	_	_	_	_	_	Seg=O
191	antibodies	_	_	_	_	_	_	_	Seg=O
192	.	_	_	_	_	_	_	_	Seg=O
193	These	_	_	_	_	_	_	_	Seg=B-seg
194	results	_	_	_	_	_	_	_	Seg=O
195	provide	_	_	_	_	_	_	_	Seg=O
196	a	_	_	_	_	_	_	_	Seg=O
197	rational	_	_	_	_	_	_	_	Seg=O
198	basis	_	_	_	_	_	_	_	Seg=O
199	to	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	observation	_	_	_	_	_	_	_	Seg=O
202	that	_	_	_	_	_	_	_	Seg=B-seg
203	several	_	_	_	_	_	_	_	Seg=O
204	SARS	_	_	_	_	_	_	_	Seg=O
205	-	_	_	_	_	_	_	_	Seg=O
206	CoV	_	_	_	_	_	_	_	Seg=O
207	RDB	_	_	_	_	_	_	_	Seg=O
208	-	_	_	_	_	_	_	_	Seg=O
209	specific	_	_	_	_	_	_	_	Seg=O
210	monoclonal	_	_	_	_	_	_	_	Seg=O
211	antibodies	_	_	_	_	_	_	_	Seg=O
212	fail	_	_	_	_	_	_	_	Seg=O
213	to	_	_	_	_	_	_	_	Seg=O
214	appreciably	_	_	_	_	_	_	_	Seg=O
215	bind	_	_	_	_	_	_	_	Seg=O
216	the	_	_	_	_	_	_	_	Seg=O
217	SARS	_	_	_	_	_	_	_	Seg=O
218	-	_	_	_	_	_	_	_	Seg=O
219	CoV-2	_	_	_	_	_	_	_	Seg=O
220	counterpart	_	_	_	_	_	_	_	Seg=O
221	.	_	_	_	_	_	_	_	Seg=O
222	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
223	,	_	_	_	_	_	_	_	Seg=O
224	we	_	_	_	_	_	_	_	Seg=O
225	correctly	_	_	_	_	_	_	_	Seg=O
226	identify	_	_	_	_	_	_	_	Seg=O
227	the	_	_	_	_	_	_	_	Seg=O
228	region	_	_	_	_	_	_	_	Seg=O
229	of	_	_	_	_	_	_	_	Seg=O
230	SARS	_	_	_	_	_	_	_	Seg=O
231	-	_	_	_	_	_	_	_	Seg=O
232	CoV-2	_	_	_	_	_	_	_	Seg=O
233	RBD	_	_	_	_	_	_	_	Seg=O
234	that	_	_	_	_	_	_	_	Seg=B-seg
235	is	_	_	_	_	_	_	_	Seg=O
236	engaged	_	_	_	_	_	_	_	Seg=O
237	by	_	_	_	_	_	_	_	Seg=O
238	the	_	_	_	_	_	_	_	Seg=O
239	cell	_	_	_	_	_	_	_	Seg=O
240	receptor	_	_	_	_	_	_	_	Seg=O
241	ACE2	_	_	_	_	_	_	_	Seg=O
242	during	_	_	_	_	_	_	_	Seg=O
243	viral	_	_	_	_	_	_	_	Seg=O
244	entry	_	_	_	_	_	_	_	Seg=O
245	into	_	_	_	_	_	_	_	Seg=O
246	host	_	_	_	_	_	_	_	Seg=O
247	cells	_	_	_	_	_	_	_	Seg=O
248	.	_	_	_	_	_	_	_	Seg=O
249	The	_	_	_	_	_	_	_	Seg=B-seg
250	data	_	_	_	_	_	_	_	Seg=O
251	,	_	_	_	_	_	_	_	Seg=O
252	sequences	_	_	_	_	_	_	_	Seg=O
253	and	_	_	_	_	_	_	_	Seg=O
254	structures	_	_	_	_	_	_	_	Seg=O
255	we	_	_	_	_	_	_	_	Seg=B-seg
256	present	_	_	_	_	_	_	_	Seg=O
257	here	_	_	_	_	_	_	_	Seg=O
258	can	_	_	_	_	_	_	_	Seg=B-seg
259	be	_	_	_	_	_	_	_	Seg=O
260	useful	_	_	_	_	_	_	_	Seg=O
261	for	_	_	_	_	_	_	_	Seg=O
262	the	_	_	_	_	_	_	_	Seg=O
263	development	_	_	_	_	_	_	_	Seg=O
264	of	_	_	_	_	_	_	_	Seg=O
265	novel	_	_	_	_	_	_	_	Seg=O
266	therapeutic	_	_	_	_	_	_	_	Seg=O
267	and	_	_	_	_	_	_	_	Seg=O
268	diagnostic	_	_	_	_	_	_	_	Seg=O
269	interventions	_	_	_	_	_	_	_	Seg=O
270	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2f8012db8f2100bb1876e19722d6c131849e2315
1	Viruses	_	_	_	_	_	_	_	Seg=B-seg
2	have	_	_	_	_	_	_	_	Seg=O
3	evolved	_	_	_	_	_	_	_	Seg=O
4	elaborate	_	_	_	_	_	_	_	Seg=O
5	mechanisms	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=B-seg
7	evade	_	_	_	_	_	_	_	Seg=O
8	or	_	_	_	_	_	_	_	Seg=O
9	inactivate	_	_	_	_	_	_	_	Seg=O
10	the	_	_	_	_	_	_	_	Seg=O
11	complex	_	_	_	_	_	_	_	Seg=O
12	system	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	sensors	_	_	_	_	_	_	_	Seg=O
15	and	_	_	_	_	_	_	_	Seg=O
16	signaling	_	_	_	_	_	_	_	Seg=O
17	molecules	_	_	_	_	_	_	_	Seg=O
18	that	_	_	_	_	_	_	_	Seg=B-seg
19	make	_	_	_	_	_	_	_	Seg=O
20	up	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	host	_	_	_	_	_	_	_	Seg=O
23	innate	_	_	_	_	_	_	_	Seg=O
24	immune	_	_	_	_	_	_	_	Seg=O
25	response	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	Here	_	_	_	_	_	_	_	Seg=B-seg
28	we	_	_	_	_	_	_	_	Seg=O
29	show	_	_	_	_	_	_	_	Seg=O
30	that	_	_	_	_	_	_	_	Seg=B-seg
31	human	_	_	_	_	_	_	_	Seg=O
32	coronavirus	_	_	_	_	_	_	_	Seg=O
33	(	_	_	_	_	_	_	_	Seg=O
34	HCoV	_	_	_	_	_	_	_	Seg=O
35	)	_	_	_	_	_	_	_	Seg=O
36	NL63	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	severe	_	_	_	_	_	_	_	Seg=O
39	acute	_	_	_	_	_	_	_	Seg=O
40	respiratory	_	_	_	_	_	_	_	Seg=O
41	syndrome	_	_	_	_	_	_	_	Seg=O
42	(	_	_	_	_	_	_	_	Seg=O
43	SARS	_	_	_	_	_	_	_	Seg=O
44	)	_	_	_	_	_	_	_	Seg=O
45	CoV	_	_	_	_	_	_	_	Seg=O
46	papain	_	_	_	_	_	_	_	Seg=O
47	-	_	_	_	_	_	_	_	Seg=O
48	like	_	_	_	_	_	_	_	Seg=O
49	proteases	_	_	_	_	_	_	_	Seg=O
50	(	_	_	_	_	_	_	_	Seg=O
51	PLP	_	_	_	_	_	_	_	Seg=O
52	)	_	_	_	_	_	_	_	Seg=O
53	antagonize	_	_	_	_	_	_	_	Seg=O
54	innate	_	_	_	_	_	_	_	Seg=O
55	immune	_	_	_	_	_	_	_	Seg=O
56	signaling	_	_	_	_	_	_	_	Seg=O
57	mediated	_	_	_	_	_	_	_	Seg=B-seg
58	by	_	_	_	_	_	_	_	Seg=O
59	STING	_	_	_	_	_	_	_	Seg=O
60	(	_	_	_	_	_	_	_	Seg=B-seg
61	stimulator	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	interferon	_	_	_	_	_	_	_	Seg=O
64	genes	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	also	_	_	_	_	_	_	_	Seg=O
67	known	_	_	_	_	_	_	_	Seg=O
68	as	_	_	_	_	_	_	_	Seg=O
69	MITA	_	_	_	_	_	_	_	Seg=O
70	/	_	_	_	_	_	_	_	Seg=O
71	ERIS	_	_	_	_	_	_	_	Seg=O
72	/	_	_	_	_	_	_	_	Seg=O
73	MYPS	_	_	_	_	_	_	_	Seg=O
74	)	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	STING	_	_	_	_	_	_	_	Seg=B-seg
77	resides	_	_	_	_	_	_	_	Seg=O
78	in	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	endoplasmic	_	_	_	_	_	_	_	Seg=O
81	reticulum	_	_	_	_	_	_	_	Seg=O
82	and	_	_	_	_	_	_	_	Seg=B-seg
83	upon	_	_	_	_	_	_	_	Seg=O
84	activation	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	forms	_	_	_	_	_	_	_	Seg=O
87	dimers	_	_	_	_	_	_	_	Seg=O
88	which	_	_	_	_	_	_	_	Seg=B-seg
89	assemble	_	_	_	_	_	_	_	Seg=O
90	with	_	_	_	_	_	_	_	Seg=O
91	MAVS	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	TBK-1	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=O
95	IKKe	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	leading	_	_	_	_	_	_	_	Seg=B-seg
98	to	_	_	_	_	_	_	_	Seg=O
99	IRF-3	_	_	_	_	_	_	_	Seg=O
100	activation	_	_	_	_	_	_	_	Seg=O
101	and	_	_	_	_	_	_	_	Seg=O
102	subsequent	_	_	_	_	_	_	_	Seg=O
103	induction	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	interferon	_	_	_	_	_	_	_	Seg=O
106	(	_	_	_	_	_	_	_	Seg=O
107	IFN	_	_	_	_	_	_	_	Seg=O
108	)	_	_	_	_	_	_	_	Seg=O
109	.	_	_	_	_	_	_	_	Seg=O
110	We	_	_	_	_	_	_	_	Seg=B-seg
111	found	_	_	_	_	_	_	_	Seg=O
112	that	_	_	_	_	_	_	_	Seg=B-seg
113	expression	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	the	_	_	_	_	_	_	_	Seg=O
116	membrane	_	_	_	_	_	_	_	Seg=O
117	anchored	_	_	_	_	_	_	_	Seg=O
118	PLP	_	_	_	_	_	_	_	Seg=O
119	domain	_	_	_	_	_	_	_	Seg=O
120	from	_	_	_	_	_	_	_	Seg=O
121	human	_	_	_	_	_	_	_	Seg=O
122	HCoV	_	_	_	_	_	_	_	Seg=O
123	-	_	_	_	_	_	_	_	Seg=O
124	NL63	_	_	_	_	_	_	_	Seg=O
125	(	_	_	_	_	_	_	_	Seg=O
126	PLP2-TM	_	_	_	_	_	_	_	Seg=O
127	)	_	_	_	_	_	_	_	Seg=O
128	or	_	_	_	_	_	_	_	Seg=O
129	SARS	_	_	_	_	_	_	_	Seg=O
130	-	_	_	_	_	_	_	_	Seg=O
131	CoV	_	_	_	_	_	_	_	Seg=O
132	(	_	_	_	_	_	_	_	Seg=O
133	PLpro	_	_	_	_	_	_	_	Seg=O
134	-	_	_	_	_	_	_	_	Seg=O
135	TM	_	_	_	_	_	_	_	Seg=O
136	)	_	_	_	_	_	_	_	Seg=O
137	inhibits	_	_	_	_	_	_	_	Seg=O
138	STING	_	_	_	_	_	_	_	Seg=O
139	-	_	_	_	_	_	_	_	Seg=O
140	mediated	_	_	_	_	_	_	_	Seg=O
141	activation	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	IRF-3	_	_	_	_	_	_	_	Seg=O
144	nuclear	_	_	_	_	_	_	_	Seg=O
145	translocation	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	induction	_	_	_	_	_	_	_	Seg=O
148	of	_	_	_	_	_	_	_	Seg=O
149	IRF-3	_	_	_	_	_	_	_	Seg=O
150	dependent	_	_	_	_	_	_	_	Seg=O
151	promoters	_	_	_	_	_	_	_	Seg=O
152	.	_	_	_	_	_	_	_	Seg=O
153	Both	_	_	_	_	_	_	_	Seg=B-seg
154	catalytically	_	_	_	_	_	_	_	Seg=O
155	active	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	inactive	_	_	_	_	_	_	_	Seg=O
158	forms	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	CoV	_	_	_	_	_	_	_	Seg=O
161	PLPs	_	_	_	_	_	_	_	Seg=O
162	co	_	_	_	_	_	_	_	Seg=O
163	-	_	_	_	_	_	_	_	Seg=O
164	immunoprecipitated	_	_	_	_	_	_	_	Seg=O
165	with	_	_	_	_	_	_	_	Seg=O
166	STING	_	_	_	_	_	_	_	Seg=O
167	,	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=B-seg
169	viral	_	_	_	_	_	_	_	Seg=O
170	replicase	_	_	_	_	_	_	_	Seg=O
171	proteins	_	_	_	_	_	_	_	Seg=O
172	co	_	_	_	_	_	_	_	Seg=O
173	-	_	_	_	_	_	_	_	Seg=O
174	localize	_	_	_	_	_	_	_	Seg=O
175	with	_	_	_	_	_	_	_	Seg=O
176	STING	_	_	_	_	_	_	_	Seg=O
177	in	_	_	_	_	_	_	_	Seg=O
178	HCoV	_	_	_	_	_	_	_	Seg=O
179	-	_	_	_	_	_	_	_	Seg=O
180	NL63-infected	_	_	_	_	_	_	_	Seg=O
181	cells	_	_	_	_	_	_	_	Seg=O
182	.	_	_	_	_	_	_	_	Seg=O
183	Ectopic	_	_	_	_	_	_	_	Seg=B-seg
184	expression	_	_	_	_	_	_	_	Seg=O
185	of	_	_	_	_	_	_	_	Seg=O
186	catalytically	_	_	_	_	_	_	_	Seg=O
187	active	_	_	_	_	_	_	_	Seg=O
188	PLP2-TM	_	_	_	_	_	_	_	Seg=O
189	blocks	_	_	_	_	_	_	_	Seg=O
190	STING	_	_	_	_	_	_	_	Seg=O
191	dimer	_	_	_	_	_	_	_	Seg=O
192	formation	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=B-seg
194	negatively	_	_	_	_	_	_	_	Seg=O
195	regulates	_	_	_	_	_	_	_	Seg=O
196	assembly	_	_	_	_	_	_	_	Seg=O
197	of	_	_	_	_	_	_	_	Seg=O
198	STING	_	_	_	_	_	_	_	Seg=O
199	-	_	_	_	_	_	_	_	Seg=O
200	MAVS	_	_	_	_	_	_	_	Seg=O
201	-	_	_	_	_	_	_	_	Seg=O
202	TBK1	_	_	_	_	_	_	_	Seg=O
203	/	_	_	_	_	_	_	_	Seg=O
204	IKKe	_	_	_	_	_	_	_	Seg=O
205	complexes	_	_	_	_	_	_	_	Seg=O
206	required	_	_	_	_	_	_	_	Seg=B-seg
207	for	_	_	_	_	_	_	_	Seg=O
208	activation	_	_	_	_	_	_	_	Seg=O
209	of	_	_	_	_	_	_	_	Seg=O
210	IRF-3	_	_	_	_	_	_	_	Seg=O
211	.	_	_	_	_	_	_	_	Seg=O
212	STING	_	_	_	_	_	_	_	Seg=B-seg
213	dimerization	_	_	_	_	_	_	_	Seg=O
214	was	_	_	_	_	_	_	_	Seg=O
215	also	_	_	_	_	_	_	_	Seg=O
216	substantially	_	_	_	_	_	_	_	Seg=O
217	reduced	_	_	_	_	_	_	_	Seg=O
218	in	_	_	_	_	_	_	_	Seg=O
219	cells	_	_	_	_	_	_	_	Seg=O
220	infected	_	_	_	_	_	_	_	Seg=B-seg
221	with	_	_	_	_	_	_	_	Seg=O
222	SARS	_	_	_	_	_	_	_	Seg=O
223	-	_	_	_	_	_	_	_	Seg=O
224	CoV.	_	_	_	_	_	_	_	Seg=O
225	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
226	,	_	_	_	_	_	_	_	Seg=O
227	the	_	_	_	_	_	_	_	Seg=O
228	level	_	_	_	_	_	_	_	Seg=O
229	of	_	_	_	_	_	_	_	Seg=O
230	ubiquitinated	_	_	_	_	_	_	_	Seg=O
231	forms	_	_	_	_	_	_	_	Seg=O
232	of	_	_	_	_	_	_	_	Seg=O
233	STING	_	_	_	_	_	_	_	Seg=O
234	,	_	_	_	_	_	_	_	Seg=O
235	RIG	_	_	_	_	_	_	_	Seg=O
236	-	_	_	_	_	_	_	_	Seg=O
237	I	_	_	_	_	_	_	_	Seg=O
238	,	_	_	_	_	_	_	_	Seg=O
239	TBK1	_	_	_	_	_	_	_	Seg=O
240	and	_	_	_	_	_	_	_	Seg=O
241	IRF-3	_	_	_	_	_	_	_	Seg=O
242	are	_	_	_	_	_	_	_	Seg=O
243	reduced	_	_	_	_	_	_	_	Seg=O
244	in	_	_	_	_	_	_	_	Seg=O
245	cells	_	_	_	_	_	_	_	Seg=O
246	expressing	_	_	_	_	_	_	_	Seg=B-seg
247	wild	_	_	_	_	_	_	_	Seg=O
248	type	_	_	_	_	_	_	_	Seg=O
249	or	_	_	_	_	_	_	_	Seg=O
250	catalytic	_	_	_	_	_	_	_	Seg=O
251	mutants	_	_	_	_	_	_	_	Seg=O
252	of	_	_	_	_	_	_	_	Seg=O
253	PLP2-TM	_	_	_	_	_	_	_	Seg=O
254	,	_	_	_	_	_	_	_	Seg=O
255	likely	_	_	_	_	_	_	_	Seg=B-seg
256	contributing	_	_	_	_	_	_	_	Seg=O
257	to	_	_	_	_	_	_	_	Seg=O
258	disruption	_	_	_	_	_	_	_	Seg=O
259	of	_	_	_	_	_	_	_	Seg=O
260	signaling	_	_	_	_	_	_	_	Seg=O
261	required	_	_	_	_	_	_	_	Seg=B-seg
262	for	_	_	_	_	_	_	_	Seg=O
263	IFN	_	_	_	_	_	_	_	Seg=O
264	induction	_	_	_	_	_	_	_	Seg=O
265	.	_	_	_	_	_	_	_	Seg=O
266	These	_	_	_	_	_	_	_	Seg=B-seg
267	results	_	_	_	_	_	_	_	Seg=O
268	describe	_	_	_	_	_	_	_	Seg=O
269	a	_	_	_	_	_	_	_	Seg=O
270	new	_	_	_	_	_	_	_	Seg=O
271	mechanism	_	_	_	_	_	_	_	Seg=O
272	used	_	_	_	_	_	_	_	Seg=B-seg
273	by	_	_	_	_	_	_	_	Seg=O
274	CoVs	_	_	_	_	_	_	_	Seg=O
275	in	_	_	_	_	_	_	_	Seg=B-seg
276	which	_	_	_	_	_	_	_	Seg=O
277	CoV	_	_	_	_	_	_	_	Seg=O
278	PLPs	_	_	_	_	_	_	_	Seg=O
279	negatively	_	_	_	_	_	_	_	Seg=O
280	regulate	_	_	_	_	_	_	_	Seg=O
281	antiviral	_	_	_	_	_	_	_	Seg=O
282	defenses	_	_	_	_	_	_	_	Seg=O
283	by	_	_	_	_	_	_	_	Seg=B-seg
284	disrupting	_	_	_	_	_	_	_	Seg=O
285	the	_	_	_	_	_	_	_	Seg=O
286	STING	_	_	_	_	_	_	_	Seg=O
287	-	_	_	_	_	_	_	_	Seg=O
288	mediated	_	_	_	_	_	_	_	Seg=O
289	IFN	_	_	_	_	_	_	_	Seg=O
290	induction	_	_	_	_	_	_	_	Seg=O
291	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 31fae2807695521804442fedcd3f7b9f17d0f9ea
1	BACKGROUND	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Evaluation	_	_	_	_	_	_	_	Seg=B-seg
4	of	_	_	_	_	_	_	_	Seg=O
5	interindividual	_	_	_	_	_	_	_	Seg=O
6	variability	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	a	_	_	_	_	_	_	_	Seg=O
9	challenging	_	_	_	_	_	_	_	Seg=O
10	step	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	risk	_	_	_	_	_	_	_	Seg=O
13	assessment	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	For	_	_	_	_	_	_	_	Seg=B-seg
16	most	_	_	_	_	_	_	_	Seg=O
17	environmental	_	_	_	_	_	_	_	Seg=O
18	pollutants	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	including	_	_	_	_	_	_	_	Seg=B-seg
21	perchloroethylene	_	_	_	_	_	_	_	Seg=O
22	(	_	_	_	_	_	_	_	Seg=O
23	PERC	_	_	_	_	_	_	_	Seg=O
24	)	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	experimental	_	_	_	_	_	_	_	Seg=B-seg
27	data	_	_	_	_	_	_	_	Seg=O
28	are	_	_	_	_	_	_	_	Seg=O
29	lacking	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	resulting	_	_	_	_	_	_	_	Seg=B-seg
32	in	_	_	_	_	_	_	_	Seg=O
33	default	_	_	_	_	_	_	_	Seg=O
34	assumptions	_	_	_	_	_	_	_	Seg=O
35	being	_	_	_	_	_	_	_	Seg=B-seg
36	used	_	_	_	_	_	_	_	Seg=O
37	to	_	_	_	_	_	_	_	Seg=B-seg
38	account	_	_	_	_	_	_	_	Seg=O
39	for	_	_	_	_	_	_	_	Seg=O
40	variability	_	_	_	_	_	_	_	Seg=O
41	in	_	_	_	_	_	_	_	Seg=O
42	toxicokinetics	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	toxicodynamics	_	_	_	_	_	_	_	Seg=O
45	.	_	_	_	_	_	_	_	Seg=O
46	OBJECTIVE	_	_	_	_	_	_	_	Seg=B-seg
47	:	_	_	_	_	_	_	_	Seg=O
48	We	_	_	_	_	_	_	_	Seg=B-seg
49	quantitatively	_	_	_	_	_	_	_	Seg=O
50	examined	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	relationship	_	_	_	_	_	_	_	Seg=O
53	between	_	_	_	_	_	_	_	Seg=O
54	PERC	_	_	_	_	_	_	_	Seg=O
55	toxicokinetics	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=O
57	toxicodynamics	_	_	_	_	_	_	_	Seg=O
58	at	_	_	_	_	_	_	_	Seg=O
59	the	_	_	_	_	_	_	_	Seg=O
60	population	_	_	_	_	_	_	_	Seg=O
61	level	_	_	_	_	_	_	_	Seg=O
62	to	_	_	_	_	_	_	_	Seg=B-seg
63	test	_	_	_	_	_	_	_	Seg=O
64	whether	_	_	_	_	_	_	_	Seg=O
65	individuals	_	_	_	_	_	_	_	Seg=O
66	with	_	_	_	_	_	_	_	Seg=O
67	increased	_	_	_	_	_	_	_	Seg=O
68	oxidative	_	_	_	_	_	_	_	Seg=O
69	metabolism	_	_	_	_	_	_	_	Seg=O
70	are	_	_	_	_	_	_	_	Seg=O
71	be	_	_	_	_	_	_	_	Seg=O
72	more	_	_	_	_	_	_	_	Seg=O
73	sensitive	_	_	_	_	_	_	_	Seg=O
74	to	_	_	_	_	_	_	_	Seg=O
75	hepatotoxicity	_	_	_	_	_	_	_	Seg=O
76	following	_	_	_	_	_	_	_	Seg=B-seg
77	PERC	_	_	_	_	_	_	_	Seg=O
78	exposure	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	METHODS	_	_	_	_	_	_	_	Seg=B-seg
81	:	_	_	_	_	_	_	_	Seg=O
82	Male	_	_	_	_	_	_	_	Seg=B-seg
83	mice	_	_	_	_	_	_	_	Seg=O
84	from	_	_	_	_	_	_	_	Seg=O
85	45	_	_	_	_	_	_	_	Seg=O
86	strains	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	the	_	_	_	_	_	_	_	Seg=O
89	Collaborative	_	_	_	_	_	_	_	Seg=O
90	Cross	_	_	_	_	_	_	_	Seg=O
91	(	_	_	_	_	_	_	_	Seg=O
92	CC	_	_	_	_	_	_	_	Seg=O
93	)	_	_	_	_	_	_	_	Seg=O
94	were	_	_	_	_	_	_	_	Seg=O
95	orally	_	_	_	_	_	_	_	Seg=O
96	administered	_	_	_	_	_	_	_	Seg=O
97	a	_	_	_	_	_	_	_	Seg=O
98	single	_	_	_	_	_	_	_	Seg=O
99	dose	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	PERC	_	_	_	_	_	_	_	Seg=O
102	(	_	_	_	_	_	_	_	Seg=B-seg
103	1,000	_	_	_	_	_	_	_	Seg=O
104	mg	_	_	_	_	_	_	_	Seg=O
105	/	_	_	_	_	_	_	_	Seg=O
106	kg	_	_	_	_	_	_	_	Seg=O
107	)	_	_	_	_	_	_	_	Seg=O
108	or	_	_	_	_	_	_	_	Seg=B-seg
109	vehicle	_	_	_	_	_	_	_	Seg=O
110	(	_	_	_	_	_	_	_	Seg=B-seg
111	Alkamuls	_	_	_	_	_	_	_	Seg=O
112	-	_	_	_	_	_	_	_	Seg=O
113	EL620	_	_	_	_	_	_	_	Seg=O
114	)	_	_	_	_	_	_	_	Seg=O
115	and	_	_	_	_	_	_	_	Seg=B-seg
116	euthanized	_	_	_	_	_	_	_	Seg=O
117	at	_	_	_	_	_	_	_	Seg=O
118	various	_	_	_	_	_	_	_	Seg=O
119	time	_	_	_	_	_	_	_	Seg=O
120	points	_	_	_	_	_	_	_	Seg=O
121	(	_	_	_	_	_	_	_	Seg=B-seg
122	n	_	_	_	_	_	_	_	Seg=O
123	=	_	_	_	_	_	_	_	Seg=O
124	1	_	_	_	_	_	_	_	Seg=O
125	=	_	_	_	_	_	_	_	Seg=O
126	strain	_	_	_	_	_	_	_	Seg=O
127	=	_	_	_	_	_	_	_	Seg=O
128	time	_	_	_	_	_	_	_	Seg=O
129	)	_	_	_	_	_	_	_	Seg=O
130	.	_	_	_	_	_	_	_	Seg=O
131	Concentration	_	_	_	_	_	_	_	Seg=B-seg
132	-	_	_	_	_	_	_	_	Seg=O
133	time	_	_	_	_	_	_	_	Seg=O
134	profiles	_	_	_	_	_	_	_	Seg=O
135	were	_	_	_	_	_	_	_	Seg=O
136	generated	_	_	_	_	_	_	_	Seg=O
137	for	_	_	_	_	_	_	_	Seg=O
138	PERC	_	_	_	_	_	_	_	Seg=O
139	and	_	_	_	_	_	_	_	Seg=O
140	its	_	_	_	_	_	_	_	Seg=O
141	primary	_	_	_	_	_	_	_	Seg=O
142	oxidative	_	_	_	_	_	_	_	Seg=O
143	metabolite	_	_	_	_	_	_	_	Seg=O
144	trichloroacetate	_	_	_	_	_	_	_	Seg=O
145	(	_	_	_	_	_	_	_	Seg=O
146	TCA	_	_	_	_	_	_	_	Seg=O
147	)	_	_	_	_	_	_	_	Seg=O
148	in	_	_	_	_	_	_	_	Seg=O
149	multiple	_	_	_	_	_	_	_	Seg=O
150	tissues	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	Toxicodynamic	_	_	_	_	_	_	_	Seg=B-seg
153	phenotyping	_	_	_	_	_	_	_	Seg=O
154	was	_	_	_	_	_	_	_	Seg=O
155	also	_	_	_	_	_	_	_	Seg=O
156	performed	_	_	_	_	_	_	_	Seg=O
157	.	_	_	_	_	_	_	_	Seg=O
158	RESULTS	_	_	_	_	_	_	_	Seg=B-seg
159	:	_	_	_	_	_	_	_	Seg=O
160	Significant	_	_	_	_	_	_	_	Seg=B-seg
161	variability	_	_	_	_	_	_	_	Seg=O
162	among	_	_	_	_	_	_	_	Seg=O
163	strains	_	_	_	_	_	_	_	Seg=O
164	was	_	_	_	_	_	_	_	Seg=O
165	observed	_	_	_	_	_	_	_	Seg=O
166	in	_	_	_	_	_	_	_	Seg=O
167	toxicokinetics	_	_	_	_	_	_	_	Seg=O
168	of	_	_	_	_	_	_	_	Seg=O
169	PERC	_	_	_	_	_	_	_	Seg=O
170	and	_	_	_	_	_	_	_	Seg=O
171	TCA	_	_	_	_	_	_	_	Seg=O
172	in	_	_	_	_	_	_	_	Seg=O
173	every	_	_	_	_	_	_	_	Seg=O
174	tissue	_	_	_	_	_	_	_	Seg=O
175	examined	_	_	_	_	_	_	_	Seg=O
176	.	_	_	_	_	_	_	_	Seg=O
177	Based	_	_	_	_	_	_	_	Seg=B-seg
178	on	_	_	_	_	_	_	_	Seg=O
179	area	_	_	_	_	_	_	_	Seg=O
180	under	_	_	_	_	_	_	_	Seg=O
181	the	_	_	_	_	_	_	_	Seg=O
182	curve	_	_	_	_	_	_	_	Seg=O
183	(	_	_	_	_	_	_	_	Seg=O
184	AUC	_	_	_	_	_	_	_	Seg=O
185	)	_	_	_	_	_	_	_	Seg=O
186	,	_	_	_	_	_	_	_	Seg=O
187	the	_	_	_	_	_	_	_	Seg=B-seg
188	range	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	liver	_	_	_	_	_	_	_	Seg=O
191	TCA	_	_	_	_	_	_	_	Seg=O
192	levels	_	_	_	_	_	_	_	Seg=O
193	spanned	_	_	_	_	_	_	_	Seg=O
194	nearly	_	_	_	_	_	_	_	Seg=O
195	an	_	_	_	_	_	_	_	Seg=O
196	order	_	_	_	_	_	_	_	Seg=O
197	of	_	_	_	_	_	_	_	Seg=O
198	magnitude	_	_	_	_	_	_	_	Seg=O
199	(	_	_	_	_	_	_	_	Seg=B-seg
200	∼	_	_	_	_	_	_	_	Seg=O
201	8-fold	_	_	_	_	_	_	_	Seg=O
202	)	_	_	_	_	_	_	_	Seg=O
203	.	_	_	_	_	_	_	_	Seg=O
204	Expression	_	_	_	_	_	_	_	Seg=B-seg
205	of	_	_	_	_	_	_	_	Seg=O
206	liver	_	_	_	_	_	_	_	Seg=O
207	cytochrome	_	_	_	_	_	_	_	Seg=O
208	P4502E1	_	_	_	_	_	_	_	Seg=O
209	did	_	_	_	_	_	_	_	Seg=O
210	not	_	_	_	_	_	_	_	Seg=O
211	correlate	_	_	_	_	_	_	_	Seg=O
212	with	_	_	_	_	_	_	_	Seg=O
213	TCA	_	_	_	_	_	_	_	Seg=O
214	levels	_	_	_	_	_	_	_	Seg=O
215	.	_	_	_	_	_	_	_	Seg=O
216	Toxicodynamic	_	_	_	_	_	_	_	Seg=B-seg
217	phenotyping	_	_	_	_	_	_	_	Seg=O
218	revealed	_	_	_	_	_	_	_	Seg=O
219	an	_	_	_	_	_	_	_	Seg=O
220	effect	_	_	_	_	_	_	_	Seg=O
221	of	_	_	_	_	_	_	_	Seg=O
222	PERC	_	_	_	_	_	_	_	Seg=O
223	on	_	_	_	_	_	_	_	Seg=O
224	bodyweight	_	_	_	_	_	_	_	Seg=O
225	loss	_	_	_	_	_	_	_	Seg=O
226	,	_	_	_	_	_	_	_	Seg=O
227	induction	_	_	_	_	_	_	_	Seg=O
228	of	_	_	_	_	_	_	_	Seg=O
229	peroxisome	_	_	_	_	_	_	_	Seg=O
230	proliferator	_	_	_	_	_	_	_	Seg=O
231	activated	_	_	_	_	_	_	_	Seg=O
232	receptor	_	_	_	_	_	_	_	Seg=O
233	-	_	_	_	_	_	_	_	Seg=O
234	alpha	_	_	_	_	_	_	_	Seg=O
235	(	_	_	_	_	_	_	_	Seg=O
236	PPARa)-regulated	_	_	_	_	_	_	_	Seg=O
237	genes	_	_	_	_	_	_	_	Seg=O
238	,	_	_	_	_	_	_	_	Seg=O
239	and	_	_	_	_	_	_	_	Seg=O
240	dysregulation	_	_	_	_	_	_	_	Seg=O
241	of	_	_	_	_	_	_	_	Seg=O
242	hepatic	_	_	_	_	_	_	_	Seg=O
243	lipid	_	_	_	_	_	_	_	Seg=O
244	homeostasis	_	_	_	_	_	_	_	Seg=O
245	.	_	_	_	_	_	_	_	Seg=O
246	Clustering	_	_	_	_	_	_	_	Seg=B-seg
247	was	_	_	_	_	_	_	_	Seg=O
248	observed	_	_	_	_	_	_	_	Seg=O
249	among	_	_	_	_	_	_	_	Seg=O
250	a	_	_	_	_	_	_	_	Seg=O
251	)	_	_	_	_	_	_	_	Seg=O
252	liver	_	_	_	_	_	_	_	Seg=O
253	levels	_	_	_	_	_	_	_	Seg=O
254	of	_	_	_	_	_	_	_	Seg=O
255	PERC	_	_	_	_	_	_	_	Seg=O
256	,	_	_	_	_	_	_	_	Seg=O
257	TCA	_	_	_	_	_	_	_	Seg=O
258	,	_	_	_	_	_	_	_	Seg=O
259	and	_	_	_	_	_	_	_	Seg=O
260	triglycerides	_	_	_	_	_	_	_	Seg=O
261	;	_	_	_	_	_	_	_	Seg=O
262	b	_	_	_	_	_	_	_	Seg=O
263	)	_	_	_	_	_	_	_	Seg=O
264	TCA	_	_	_	_	_	_	_	Seg=O
265	levels	_	_	_	_	_	_	_	Seg=O
266	in	_	_	_	_	_	_	_	Seg=O
267	liver	_	_	_	_	_	_	_	Seg=O
268	and	_	_	_	_	_	_	_	Seg=O
269	kidney	_	_	_	_	_	_	_	Seg=O
270	;	_	_	_	_	_	_	_	Seg=O
271	and	_	_	_	_	_	_	_	Seg=O
272	c	_	_	_	_	_	_	_	Seg=O
273	)	_	_	_	_	_	_	_	Seg=O
274	TCA	_	_	_	_	_	_	_	Seg=O
275	levels	_	_	_	_	_	_	_	Seg=O
276	in	_	_	_	_	_	_	_	Seg=O
277	serum	_	_	_	_	_	_	_	Seg=O
278	,	_	_	_	_	_	_	_	Seg=O
279	brain	_	_	_	_	_	_	_	Seg=O
280	,	_	_	_	_	_	_	_	Seg=O
281	fat	_	_	_	_	_	_	_	Seg=O
282	,	_	_	_	_	_	_	_	Seg=O
283	and	_	_	_	_	_	_	_	Seg=O
284	lung	_	_	_	_	_	_	_	Seg=O
285	.	_	_	_	_	_	_	_	Seg=O
286	CONCLUSIONS	_	_	_	_	_	_	_	Seg=B-seg
287	:	_	_	_	_	_	_	_	Seg=O
288	Using	_	_	_	_	_	_	_	Seg=B-seg
289	the	_	_	_	_	_	_	_	Seg=O
290	CC	_	_	_	_	_	_	_	Seg=O
291	mouse	_	_	_	_	_	_	_	Seg=O
292	population	_	_	_	_	_	_	_	Seg=O
293	model	_	_	_	_	_	_	_	Seg=O
294	,	_	_	_	_	_	_	_	Seg=O
295	we	_	_	_	_	_	_	_	Seg=B-seg
296	have	_	_	_	_	_	_	_	Seg=O
297	demonstrated	_	_	_	_	_	_	_	Seg=O
298	a	_	_	_	_	_	_	_	Seg=O
299	complex	_	_	_	_	_	_	_	Seg=O
300	and	_	_	_	_	_	_	_	Seg=O
301	highly	_	_	_	_	_	_	_	Seg=O
302	variable	_	_	_	_	_	_	_	Seg=O
303	relationship	_	_	_	_	_	_	_	Seg=O
304	between	_	_	_	_	_	_	_	Seg=O
305	PERC	_	_	_	_	_	_	_	Seg=O
306	and	_	_	_	_	_	_	_	Seg=O
307	TCA	_	_	_	_	_	_	_	Seg=O
308	toxicokinetics	_	_	_	_	_	_	_	Seg=O
309	and	_	_	_	_	_	_	_	Seg=O
310	toxicodynamics	_	_	_	_	_	_	_	Seg=O
311	at	_	_	_	_	_	_	_	Seg=O
312	the	_	_	_	_	_	_	_	Seg=O
313	population	_	_	_	_	_	_	_	Seg=O
314	level	_	_	_	_	_	_	_	Seg=O
315	.	_	_	_	_	_	_	_	Seg=O
316	https://doi	_	_	_	_	_	_	_	Seg=B-seg
317	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 338d45deb88de8cc7f4cf5158c4752fb3533a0b7
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	Resequencing	_	_	_	_	_	_	_	Seg=O
3	Pathogen	_	_	_	_	_	_	_	Seg=O
4	Microarray	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	RPM	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	is	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	single	_	_	_	_	_	_	_	Seg=O
11	,	_	_	_	_	_	_	_	Seg=O
12	highly	_	_	_	_	_	_	_	Seg=O
13	multiplexed	_	_	_	_	_	_	_	Seg=O
14	assay	_	_	_	_	_	_	_	Seg=O
15	for	_	_	_	_	_	_	_	Seg=B-seg
16	detecting	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=O
18	differentiating	_	_	_	_	_	_	_	Seg=O
19	similarly	_	_	_	_	_	_	_	Seg=O
20	related	_	_	_	_	_	_	_	Seg=O
21	pathogens	_	_	_	_	_	_	_	Seg=O
22	by	_	_	_	_	_	_	_	Seg=B-seg
23	using	_	_	_	_	_	_	_	Seg=O
24	closely	_	_	_	_	_	_	_	Seg=O
25	overlapping	_	_	_	_	_	_	_	Seg=O
26	probe	_	_	_	_	_	_	_	Seg=O
27	sets	_	_	_	_	_	_	_	Seg=O
28	to	_	_	_	_	_	_	_	Seg=B-seg
29	determine	_	_	_	_	_	_	_	Seg=O
30	a	_	_	_	_	_	_	_	Seg=O
31	target	_	_	_	_	_	_	_	Seg=O
32-33	organism's	_	_	_	_	_	_	_	_
32	organism	_	_	_	_	_	_	_	Seg=O
33	's	_	_	_	_	_	_	_	Seg=O
34	nucleotide	_	_	_	_	_	_	_	Seg=O
35	sequence	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	In	_	_	_	_	_	_	_	Seg=B-seg
38	this	_	_	_	_	_	_	_	Seg=O
39	study	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	a	_	_	_	_	_	_	_	Seg=O
42	new	_	_	_	_	_	_	_	Seg=O
43	RPM	_	_	_	_	_	_	_	Seg=O
44	(	_	_	_	_	_	_	_	Seg=O
45	RPM	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	IVDC1	_	_	_	_	_	_	_	Seg=O
48	)	_	_	_	_	_	_	_	Seg=O
49	that	_	_	_	_	_	_	_	Seg=B-seg
50	consisted	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	224-bp	_	_	_	_	_	_	_	Seg=O
53	detector	_	_	_	_	_	_	_	Seg=O
54	tiles	_	_	_	_	_	_	_	Seg=O
55	corresponding	_	_	_	_	_	_	_	Seg=B-seg
56	to	_	_	_	_	_	_	_	Seg=O
57	9	_	_	_	_	_	_	_	Seg=O
58	influenza	_	_	_	_	_	_	_	Seg=O
59	A	_	_	_	_	_	_	_	Seg=O
60	subtypes	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	11	_	_	_	_	_	_	_	Seg=O
63	rhinoviruses	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	28	_	_	_	_	_	_	_	Seg=O
66	enteroviruses	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=O
68	38	_	_	_	_	_	_	_	Seg=O
69	other	_	_	_	_	_	_	_	Seg=O
70	respiratory	_	_	_	_	_	_	_	Seg=O
71	viruses	_	_	_	_	_	_	_	Seg=O
72	was	_	_	_	_	_	_	_	Seg=B-seg
73	developed	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=O
75	optimized	_	_	_	_	_	_	_	Seg=O
76	to	_	_	_	_	_	_	_	Seg=B-seg
77	provide	_	_	_	_	_	_	_	Seg=O
78	individual	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	simultaneous	_	_	_	_	_	_	_	Seg=O
81	detection	_	_	_	_	_	_	_	Seg=O
82	sensitivities	_	_	_	_	_	_	_	Seg=O
83	ranging	_	_	_	_	_	_	_	Seg=B-seg
84	from	_	_	_	_	_	_	_	Seg=O
85	15	_	_	_	_	_	_	_	Seg=O
86	to	_	_	_	_	_	_	_	Seg=O
87	750	_	_	_	_	_	_	_	Seg=O
88	genomic	_	_	_	_	_	_	_	Seg=O
89	copies	_	_	_	_	_	_	_	Seg=O
90	for	_	_	_	_	_	_	_	Seg=O
91	16	_	_	_	_	_	_	_	Seg=O
92	common	_	_	_	_	_	_	_	Seg=O
93	respiratory	_	_	_	_	_	_	_	Seg=O
94	pathogens	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	A	_	_	_	_	_	_	_	Seg=B-seg
97	total	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	110	_	_	_	_	_	_	_	Seg=O
100	consecutive	_	_	_	_	_	_	_	Seg=O
101	patients	_	_	_	_	_	_	_	Seg=O
102	with	_	_	_	_	_	_	_	Seg=O
103	community	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	acquired	_	_	_	_	_	_	_	Seg=O
106	pneumonia	_	_	_	_	_	_	_	Seg=O
107	(	_	_	_	_	_	_	_	Seg=O
108	CAP	_	_	_	_	_	_	_	Seg=O
109	)	_	_	_	_	_	_	_	Seg=O
110	admitted	_	_	_	_	_	_	_	Seg=B-seg
111	to	_	_	_	_	_	_	_	Seg=O
112	5	_	_	_	_	_	_	_	Seg=O
113	district	_	_	_	_	_	_	_	Seg=O
114	general	_	_	_	_	_	_	_	Seg=O
115	hospitals	_	_	_	_	_	_	_	Seg=O
116	in	_	_	_	_	_	_	_	Seg=O
117	Beijing	_	_	_	_	_	_	_	Seg=O
118	during	_	_	_	_	_	_	_	Seg=O
119	a	_	_	_	_	_	_	_	Seg=O
120	1-year	_	_	_	_	_	_	_	Seg=O
121	period	_	_	_	_	_	_	_	Seg=O
122	were	_	_	_	_	_	_	_	Seg=B-seg
123	assessed	_	_	_	_	_	_	_	Seg=O
124	using	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	new	_	_	_	_	_	_	_	Seg=O
127	assay	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	Among	_	_	_	_	_	_	_	Seg=B-seg
130	the	_	_	_	_	_	_	_	Seg=O
131	children	_	_	_	_	_	_	_	Seg=O
132	(	_	_	_	_	_	_	_	Seg=O
133	under	_	_	_	_	_	_	_	Seg=O
134	age	_	_	_	_	_	_	_	Seg=O
135	5	_	_	_	_	_	_	_	Seg=O
136	)	_	_	_	_	_	_	_	Seg=O
137	and	_	_	_	_	_	_	_	Seg=O
138	adult	_	_	_	_	_	_	_	Seg=O
139	patients	_	_	_	_	_	_	_	Seg=O
140	(	_	_	_	_	_	_	_	Seg=O
141	above	_	_	_	_	_	_	_	Seg=O
142	age	_	_	_	_	_	_	_	Seg=O
143	18	_	_	_	_	_	_	_	Seg=O
144	)	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	respiratory	_	_	_	_	_	_	_	Seg=O
147	syncytial	_	_	_	_	_	_	_	Seg=O
148	virus	_	_	_	_	_	_	_	Seg=O
149	(	_	_	_	_	_	_	_	Seg=O
150	RSV	_	_	_	_	_	_	_	Seg=O
151	)	_	_	_	_	_	_	_	Seg=O
152	and	_	_	_	_	_	_	_	Seg=O
153	rhinovirus	_	_	_	_	_	_	_	Seg=O
154	(	_	_	_	_	_	_	_	Seg=O
155	RV	_	_	_	_	_	_	_	Seg=O
156	)	_	_	_	_	_	_	_	Seg=O
157	were	_	_	_	_	_	_	_	Seg=O
158	the	_	_	_	_	_	_	_	Seg=O
159	most	_	_	_	_	_	_	_	Seg=O
160	common	_	_	_	_	_	_	_	Seg=O
161	etiological	_	_	_	_	_	_	_	Seg=O
162	agents	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	respectively	_	_	_	_	_	_	_	Seg=O
165	,	_	_	_	_	_	_	_	Seg=O
166	which	_	_	_	_	_	_	_	Seg=B-seg
167	is	_	_	_	_	_	_	_	Seg=O
168	consistent	_	_	_	_	_	_	_	Seg=O
169	with	_	_	_	_	_	_	_	Seg=O
170	reference	_	_	_	_	_	_	_	Seg=O
171	assays	_	_	_	_	_	_	_	Seg=O
172	.	_	_	_	_	_	_	_	Seg=O
173	Atypical	_	_	_	_	_	_	_	Seg=B-seg
174	pathogens	_	_	_	_	_	_	_	Seg=O
175	that	_	_	_	_	_	_	_	Seg=B-seg
176	may	_	_	_	_	_	_	_	Seg=O
177	cause	_	_	_	_	_	_	_	Seg=O
178	CAP	_	_	_	_	_	_	_	Seg=O
179	-	_	_	_	_	_	_	_	Seg=O
180	like	_	_	_	_	_	_	_	Seg=O
181	illness	_	_	_	_	_	_	_	Seg=O
182	,	_	_	_	_	_	_	_	Seg=O
183	including	_	_	_	_	_	_	_	Seg=B-seg
184	rubella	_	_	_	_	_	_	_	Seg=O
185	virus	_	_	_	_	_	_	_	Seg=O
186	,	_	_	_	_	_	_	_	Seg=O
187	measles	_	_	_	_	_	_	_	Seg=O
188	virus	_	_	_	_	_	_	_	Seg=O
189	,	_	_	_	_	_	_	_	Seg=O
190	influenza	_	_	_	_	_	_	_	Seg=O
191	type	_	_	_	_	_	_	_	Seg=O
192	C	_	_	_	_	_	_	_	Seg=O
193	virus	_	_	_	_	_	_	_	Seg=O
194	,	_	_	_	_	_	_	_	Seg=O
195	human	_	_	_	_	_	_	_	Seg=O
196	herpesvirus	_	_	_	_	_	_	_	Seg=O
197	(	_	_	_	_	_	_	_	Seg=O
198	HHV	_	_	_	_	_	_	_	Seg=O
199	)	_	_	_	_	_	_	_	Seg=O
200	were	_	_	_	_	_	_	_	Seg=B-seg
201	also	_	_	_	_	_	_	_	Seg=O
202	detected	_	_	_	_	_	_	_	Seg=O
203	.	_	_	_	_	_	_	_	Seg=O
204	The	_	_	_	_	_	_	_	Seg=B-seg
205	results	_	_	_	_	_	_	_	Seg=O
206	show	_	_	_	_	_	_	_	Seg=O
207	the	_	_	_	_	_	_	_	Seg=O
208	capability	_	_	_	_	_	_	_	Seg=O
209	of	_	_	_	_	_	_	_	Seg=O
210	RPM	_	_	_	_	_	_	_	Seg=O
211	-	_	_	_	_	_	_	_	Seg=O
212	IVDC1	_	_	_	_	_	_	_	Seg=O
213	for	_	_	_	_	_	_	_	Seg=O
214	the	_	_	_	_	_	_	_	Seg=O
215	accurate	_	_	_	_	_	_	_	Seg=O
216	detection	_	_	_	_	_	_	_	Seg=O
217	and	_	_	_	_	_	_	_	Seg=O
218	identification	_	_	_	_	_	_	_	Seg=O
219	of	_	_	_	_	_	_	_	Seg=O
220	multiple	_	_	_	_	_	_	_	Seg=O
221	virus	_	_	_	_	_	_	_	Seg=O
222	types	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	which	_	_	_	_	_	_	_	Seg=B-seg
225	may	_	_	_	_	_	_	_	Seg=O
226	be	_	_	_	_	_	_	_	Seg=O
227	of	_	_	_	_	_	_	_	Seg=O
228	significant	_	_	_	_	_	_	_	Seg=O
229	use	_	_	_	_	_	_	_	Seg=O
230	in	_	_	_	_	_	_	_	Seg=O
231	epidemic	_	_	_	_	_	_	_	Seg=O
232	surveillance	_	_	_	_	_	_	_	Seg=O
233	and	_	_	_	_	_	_	_	Seg=O
234	outbreak	_	_	_	_	_	_	_	Seg=O
235	investigations	_	_	_	_	_	_	_	Seg=O
236	of	_	_	_	_	_	_	_	Seg=O
237	atypical	_	_	_	_	_	_	_	Seg=O
238	pathogens	_	_	_	_	_	_	_	Seg=O
239	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 34694791cd158e785ad16404d5d34ad8559792c0
1	Recently	_	_	_	_	_	_	_	Seg=B-seg
2	a	_	_	_	_	_	_	_	Seg=O
3	number	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	publications	_	_	_	_	_	_	_	Seg=O
6	looked	_	_	_	_	_	_	_	Seg=O
7	at	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	association	_	_	_	_	_	_	_	Seg=O
10	between	_	_	_	_	_	_	_	Seg=O
11	COVID-19	_	_	_	_	_	_	_	Seg=O
12	morbidity	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=O
14	mortality	_	_	_	_	_	_	_	Seg=O
15	on	_	_	_	_	_	_	_	Seg=O
16	one	_	_	_	_	_	_	_	Seg=O
17	hand	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19-20	countries'	_	_	_	_	_	_	_	_
19	countries	_	_	_	_	_	_	_	Seg=O
20	'	_	_	_	_	_	_	_	Seg=O
21	policies	_	_	_	_	_	_	_	Seg=O
22	with	_	_	_	_	_	_	_	Seg=O
23	respect	_	_	_	_	_	_	_	Seg=O
24	to	_	_	_	_	_	_	_	Seg=O
25	BCG	_	_	_	_	_	_	_	Seg=O
26	vaccination	_	_	_	_	_	_	_	Seg=O
27	on	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	other	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	This	_	_	_	_	_	_	_	Seg=B-seg
32	connection	_	_	_	_	_	_	_	Seg=O
33	arises	_	_	_	_	_	_	_	Seg=O
34	from	_	_	_	_	_	_	_	Seg=O
35	differences	_	_	_	_	_	_	_	Seg=O
36	in	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	rates	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	infection	_	_	_	_	_	_	_	Seg=O
41	in	_	_	_	_	_	_	_	Seg=O
42	countries	_	_	_	_	_	_	_	Seg=O
43	where	_	_	_	_	_	_	_	Seg=B-seg
44	BCG	_	_	_	_	_	_	_	Seg=O
45	vaccination	_	_	_	_	_	_	_	Seg=O
46	is	_	_	_	_	_	_	_	Seg=O
47	mandatory	_	_	_	_	_	_	_	Seg=O
48	compared	_	_	_	_	_	_	_	Seg=B-seg
49	to	_	_	_	_	_	_	_	Seg=O
50	countries	_	_	_	_	_	_	_	Seg=O
51	where	_	_	_	_	_	_	_	Seg=B-seg
52	mandatory	_	_	_	_	_	_	_	Seg=O
53	vaccination	_	_	_	_	_	_	_	Seg=O
54	no	_	_	_	_	_	_	_	Seg=O
55	longer	_	_	_	_	_	_	_	Seg=O
56	exists	_	_	_	_	_	_	_	Seg=O
57	or	_	_	_	_	_	_	_	Seg=B-seg
58	was	_	_	_	_	_	_	_	Seg=O
59	never	_	_	_	_	_	_	_	Seg=O
60	implemented	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	first	_	_	_	_	_	_	_	Seg=O
64	place	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	In	_	_	_	_	_	_	_	Seg=B-seg
67	at	_	_	_	_	_	_	_	Seg=O
68	least	_	_	_	_	_	_	_	Seg=O
69	2	_	_	_	_	_	_	_	Seg=O
70	preprint	_	_	_	_	_	_	_	Seg=O
71	publications	_	_	_	_	_	_	_	Seg=O
72	the	_	_	_	_	_	_	_	Seg=O
73	authors	_	_	_	_	_	_	_	Seg=O
74	expressed	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	view	_	_	_	_	_	_	_	Seg=O
77	that	_	_	_	_	_	_	_	Seg=B-seg
78	the	_	_	_	_	_	_	_	Seg=O
79	"	_	_	_	_	_	_	_	Seg=O
80	known	_	_	_	_	_	_	_	Seg=O
81	immunological	_	_	_	_	_	_	_	Seg=O
82	benefits	_	_	_	_	_	_	_	Seg=O
83	"	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	BCG	_	_	_	_	_	_	_	Seg=O
86	vaccination	_	_	_	_	_	_	_	Seg=O
87	may	_	_	_	_	_	_	_	Seg=O
88	be	_	_	_	_	_	_	_	Seg=O
89	behind	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	biological	_	_	_	_	_	_	_	Seg=O
92	mechanism	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=O
94	such	_	_	_	_	_	_	_	Seg=O
95	observation	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	One	_	_	_	_	_	_	_	Seg=B-seg
98	study	_	_	_	_	_	_	_	Seg=O
99	accounted	_	_	_	_	_	_	_	Seg=O
100	for	_	_	_	_	_	_	_	Seg=O
101	different	_	_	_	_	_	_	_	Seg=O
102	income	_	_	_	_	_	_	_	Seg=O
103	levels	_	_	_	_	_	_	_	Seg=O
104	in	_	_	_	_	_	_	_	Seg=O
105	different	_	_	_	_	_	_	_	Seg=O
106	groups	_	_	_	_	_	_	_	Seg=O
107	.	_	_	_	_	_	_	_	Seg=O
108	Another	_	_	_	_	_	_	_	Seg=B-seg
109	study	_	_	_	_	_	_	_	Seg=O
110	did	_	_	_	_	_	_	_	Seg=O
111	not	_	_	_	_	_	_	_	Seg=O
112	attempted	_	_	_	_	_	_	_	Seg=O
113	to	_	_	_	_	_	_	_	Seg=O
114	do	_	_	_	_	_	_	_	Seg=O
115	so	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	instead	_	_	_	_	_	_	_	Seg=B-seg
118	exploring	_	_	_	_	_	_	_	Seg=O
119	the	_	_	_	_	_	_	_	Seg=O
120	differences	_	_	_	_	_	_	_	Seg=O
121	between	_	_	_	_	_	_	_	Seg=O
122	countries	_	_	_	_	_	_	_	Seg=O
123	where	_	_	_	_	_	_	_	Seg=B-seg
124	a	_	_	_	_	_	_	_	Seg=O
125	booster	_	_	_	_	_	_	_	Seg=O
126	shot	_	_	_	_	_	_	_	Seg=O
127	is	_	_	_	_	_	_	_	Seg=O
128	given	_	_	_	_	_	_	_	Seg=O
129	vs	_	_	_	_	_	_	_	Seg=B-seg
130	others	_	_	_	_	_	_	_	Seg=O
131	where	_	_	_	_	_	_	_	Seg=B-seg
132	no	_	_	_	_	_	_	_	Seg=O
133	such	_	_	_	_	_	_	_	Seg=O
134	practice	_	_	_	_	_	_	_	Seg=O
135	exists	_	_	_	_	_	_	_	Seg=O
136	(	_	_	_	_	_	_	_	Seg=O
137	finding	_	_	_	_	_	_	_	Seg=O
138	no	_	_	_	_	_	_	_	Seg=O
139	connection	_	_	_	_	_	_	_	Seg=O
140	)	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O
142	Both	_	_	_	_	_	_	_	Seg=B-seg
143	of	_	_	_	_	_	_	_	Seg=O
144	these	_	_	_	_	_	_	_	Seg=O
145	studies	_	_	_	_	_	_	_	Seg=O
146	did	_	_	_	_	_	_	_	Seg=O
147	not	_	_	_	_	_	_	_	Seg=O
148	explore	_	_	_	_	_	_	_	Seg=O
149	other	_	_	_	_	_	_	_	Seg=O
150	potential	_	_	_	_	_	_	_	Seg=O
151	confounding	_	_	_	_	_	_	_	Seg=O
152	factors	_	_	_	_	_	_	_	Seg=O
153	.	_	_	_	_	_	_	_	Seg=O
154	Meanwhile	_	_	_	_	_	_	_	Seg=B-seg
155	the	_	_	_	_	_	_	_	Seg=O
156	press	_	_	_	_	_	_	_	Seg=O
157	has	_	_	_	_	_	_	_	Seg=O
158	focused	_	_	_	_	_	_	_	Seg=O
159	on	_	_	_	_	_	_	_	Seg=O
160	these	_	_	_	_	_	_	_	Seg=O
161	headlines	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=B-seg
163	pushed	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	narrative	_	_	_	_	_	_	_	Seg=O
166	that	_	_	_	_	_	_	_	Seg=B-seg
167	BCG	_	_	_	_	_	_	_	Seg=O
168	vaccination	_	_	_	_	_	_	_	Seg=O
169	is	_	_	_	_	_	_	_	Seg=O
170	causally	_	_	_	_	_	_	_	Seg=O
171	linked	_	_	_	_	_	_	_	Seg=O
172	to	_	_	_	_	_	_	_	Seg=O
173	infection	_	_	_	_	_	_	_	Seg=O
174	and	_	_	_	_	_	_	_	Seg=O
175	mortality	_	_	_	_	_	_	_	Seg=O
176	rates	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O
178	This	_	_	_	_	_	_	_	Seg=B-seg
179	poses	_	_	_	_	_	_	_	Seg=O
180	a	_	_	_	_	_	_	_	Seg=O
181	serious	_	_	_	_	_	_	_	Seg=O
182	challenge	_	_	_	_	_	_	_	Seg=O
183	,	_	_	_	_	_	_	_	Seg=O
184	demonstrated	_	_	_	_	_	_	_	Seg=B-seg
185	by	_	_	_	_	_	_	_	Seg=O
186	the	_	_	_	_	_	_	_	Seg=O
187	recently	_	_	_	_	_	_	_	Seg=O
188	initiated	_	_	_	_	_	_	_	Seg=O
189	clinical	_	_	_	_	_	_	_	Seg=O
190	trials	_	_	_	_	_	_	_	Seg=O
191	on	_	_	_	_	_	_	_	Seg=O
192	BCG	_	_	_	_	_	_	_	Seg=O
193	vaccination	_	_	_	_	_	_	_	Seg=O
194	within	_	_	_	_	_	_	_	Seg=O
195	the	_	_	_	_	_	_	_	Seg=O
196	COVID19	_	_	_	_	_	_	_	Seg=O
197	context	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	This	_	_	_	_	_	_	_	Seg=B-seg
200	study	_	_	_	_	_	_	_	Seg=O
201	shows	_	_	_	_	_	_	_	Seg=O
202	that	_	_	_	_	_	_	_	Seg=B-seg
203	population	_	_	_	_	_	_	_	Seg=O
204	age	_	_	_	_	_	_	_	Seg=O
205	is	_	_	_	_	_	_	_	Seg=O
206	a	_	_	_	_	_	_	_	Seg=O
207	very	_	_	_	_	_	_	_	Seg=O
208	significant	_	_	_	_	_	_	_	Seg=O
209	confounding	_	_	_	_	_	_	_	Seg=O
210	factor	_	_	_	_	_	_	_	Seg=O
211	that	_	_	_	_	_	_	_	Seg=B-seg
212	explains	_	_	_	_	_	_	_	Seg=O
213	the	_	_	_	_	_	_	_	Seg=O
214	rates	_	_	_	_	_	_	_	Seg=O
215	of	_	_	_	_	_	_	_	Seg=O
216	infections	_	_	_	_	_	_	_	Seg=O
217	much	_	_	_	_	_	_	_	Seg=O
218	better	_	_	_	_	_	_	_	Seg=O
219	and	_	_	_	_	_	_	_	Seg=B-seg
220	has	_	_	_	_	_	_	_	Seg=O
221	a	_	_	_	_	_	_	_	Seg=O
222	solid	_	_	_	_	_	_	_	Seg=O
223	biology	_	_	_	_	_	_	_	Seg=O
224	mechanism	_	_	_	_	_	_	_	Seg=O
225	which	_	_	_	_	_	_	_	Seg=B-seg
226	explains	_	_	_	_	_	_	_	Seg=O
227	this	_	_	_	_	_	_	_	Seg=O
228	correlation	_	_	_	_	_	_	_	Seg=O
229	.	_	_	_	_	_	_	_	Seg=O
230	It	_	_	_	_	_	_	_	Seg=B-seg
231	suggests	_	_	_	_	_	_	_	Seg=O
232	that	_	_	_	_	_	_	_	Seg=B-seg
233	BCG	_	_	_	_	_	_	_	Seg=O
234	vaccination	_	_	_	_	_	_	_	Seg=O
235	may	_	_	_	_	_	_	_	Seg=O
236	have	_	_	_	_	_	_	_	Seg=O
237	little	_	_	_	_	_	_	_	Seg=O
238	or	_	_	_	_	_	_	_	Seg=O
239	no	_	_	_	_	_	_	_	Seg=O
240	causal	_	_	_	_	_	_	_	Seg=O
241	link	_	_	_	_	_	_	_	Seg=O
242	to	_	_	_	_	_	_	_	Seg=O
243	infection	_	_	_	_	_	_	_	Seg=O
244	rates	_	_	_	_	_	_	_	Seg=O
245	and	_	_	_	_	_	_	_	Seg=B-seg
246	advises	_	_	_	_	_	_	_	Seg=O
247	that	_	_	_	_	_	_	_	Seg=B-seg
248	any	_	_	_	_	_	_	_	Seg=O
249	follow	_	_	_	_	_	_	_	Seg=O
250	up	_	_	_	_	_	_	_	Seg=O
251	studies	_	_	_	_	_	_	_	Seg=O
252	should	_	_	_	_	_	_	_	Seg=O
253	control	_	_	_	_	_	_	_	Seg=O
254	for	_	_	_	_	_	_	_	Seg=O
255	several	_	_	_	_	_	_	_	Seg=O
256	confounding	_	_	_	_	_	_	_	Seg=O
257	factors	_	_	_	_	_	_	_	Seg=O
258	,	_	_	_	_	_	_	_	Seg=O
259	such	_	_	_	_	_	_	_	Seg=B-seg
260	as	_	_	_	_	_	_	_	Seg=O
261	population	_	_	_	_	_	_	_	Seg=O
262	age	_	_	_	_	_	_	_	Seg=O
263	,	_	_	_	_	_	_	_	Seg=O
264	ethnicity	_	_	_	_	_	_	_	Seg=O
265	,	_	_	_	_	_	_	_	Seg=O
266	rates	_	_	_	_	_	_	_	Seg=O
267	of	_	_	_	_	_	_	_	Seg=O
268	certain	_	_	_	_	_	_	_	Seg=O
269	chronic	_	_	_	_	_	_	_	Seg=O
270	diseases	_	_	_	_	_	_	_	Seg=O
271	,	_	_	_	_	_	_	_	Seg=O
272	time	_	_	_	_	_	_	_	Seg=O
273	from	_	_	_	_	_	_	_	Seg=O
274	community	_	_	_	_	_	_	_	Seg=O
275	spread	_	_	_	_	_	_	_	Seg=O
276	start	_	_	_	_	_	_	_	Seg=O
277	date	_	_	_	_	_	_	_	Seg=O
278	,	_	_	_	_	_	_	_	Seg=O
279	major	_	_	_	_	_	_	_	Seg=O
280	public	_	_	_	_	_	_	_	Seg=O
281	policy	_	_	_	_	_	_	_	Seg=O
282	decisions	_	_	_	_	_	_	_	Seg=O
283	and	_	_	_	_	_	_	_	Seg=O
284	income	_	_	_	_	_	_	_	Seg=O
285	levels	_	_	_	_	_	_	_	Seg=O
286	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 352657225f9b69e4693a466de17c2a4d55ccc1d3
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	integration	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	proteomic	_	_	_	_	_	_	_	Seg=O
5	methods	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=O
7	virology	_	_	_	_	_	_	_	Seg=O
8	has	_	_	_	_	_	_	_	Seg=O
9	facilitated	_	_	_	_	_	_	_	Seg=O
10	a	_	_	_	_	_	_	_	Seg=O
11	significant	_	_	_	_	_	_	_	Seg=O
12	breadth	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	biological	_	_	_	_	_	_	_	Seg=O
15	insight	_	_	_	_	_	_	_	Seg=O
16	into	_	_	_	_	_	_	_	Seg=O
17	mechanisms	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	virus	_	_	_	_	_	_	_	Seg=O
20	replication	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	antiviral	_	_	_	_	_	_	_	Seg=O
23	host	_	_	_	_	_	_	_	Seg=O
24	responses	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	viral	_	_	_	_	_	_	_	Seg=O
27	subversion	_	_	_	_	_	_	_	Seg=O
28	of	_	_	_	_	_	_	_	Seg=O
29	host	_	_	_	_	_	_	_	Seg=O
30	defenses	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	Throughout	_	_	_	_	_	_	_	Seg=B-seg
33	the	_	_	_	_	_	_	_	Seg=O
34	course	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	infection	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	these	_	_	_	_	_	_	_	Seg=O
39	cellular	_	_	_	_	_	_	_	Seg=O
40	mechanisms	_	_	_	_	_	_	_	Seg=O
41	rely	_	_	_	_	_	_	_	Seg=O
42	heavily	_	_	_	_	_	_	_	Seg=O
43	on	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	formation	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	temporally	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	spatially	_	_	_	_	_	_	_	Seg=O
50	regulated	_	_	_	_	_	_	_	Seg=O
51	virus	_	_	_	_	_	_	_	Seg=O
52	-	_	_	_	_	_	_	_	Seg=O
53	host	_	_	_	_	_	_	_	Seg=O
54	protein	_	_	_	_	_	_	_	Seg=O
55	-	_	_	_	_	_	_	_	Seg=O
56	protein	_	_	_	_	_	_	_	Seg=O
57	interactions	_	_	_	_	_	_	_	Seg=O
58	.	_	_	_	_	_	_	_	Seg=O
59	Reviewed	_	_	_	_	_	_	_	Seg=B-seg
60	here	_	_	_	_	_	_	_	Seg=O
61	are	_	_	_	_	_	_	_	Seg=O
62	proteomic	_	_	_	_	_	_	_	Seg=O
63	-	_	_	_	_	_	_	_	Seg=O
64	based	_	_	_	_	_	_	_	Seg=O
65	approaches	_	_	_	_	_	_	_	Seg=O
66	that	_	_	_	_	_	_	_	Seg=B-seg
67	have	_	_	_	_	_	_	_	Seg=O
68	been	_	_	_	_	_	_	_	Seg=O
69	used	_	_	_	_	_	_	_	Seg=O
70	to	_	_	_	_	_	_	_	Seg=B-seg
71	characterize	_	_	_	_	_	_	_	Seg=O
72	this	_	_	_	_	_	_	_	Seg=O
73	dynamic	_	_	_	_	_	_	_	Seg=O
74	virus	_	_	_	_	_	_	_	Seg=O
75	-	_	_	_	_	_	_	_	Seg=O
76	host	_	_	_	_	_	_	_	Seg=O
77	interplay	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	Specifically	_	_	_	_	_	_	_	Seg=B-seg
80	discussed	_	_	_	_	_	_	_	Seg=O
81	are	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	contribution	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	integrative	_	_	_	_	_	_	_	Seg=O
86	mass	_	_	_	_	_	_	_	Seg=O
87	spectrometry	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	antibodybased	_	_	_	_	_	_	_	Seg=O
90	affinity	_	_	_	_	_	_	_	Seg=O
91	purification	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	protein	_	_	_	_	_	_	_	Seg=O
94	complexes	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	cross	_	_	_	_	_	_	_	Seg=O
97	-	_	_	_	_	_	_	_	Seg=O
98	linking	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=O
100	protein	_	_	_	_	_	_	_	Seg=O
101	array	_	_	_	_	_	_	_	Seg=O
102	techniques	_	_	_	_	_	_	_	Seg=O
103	for	_	_	_	_	_	_	_	Seg=B-seg
104	elucidating	_	_	_	_	_	_	_	Seg=O
105	complex	_	_	_	_	_	_	_	Seg=O
106	networks	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	virus	_	_	_	_	_	_	_	Seg=O
109	-	_	_	_	_	_	_	_	Seg=O
110	host	_	_	_	_	_	_	_	Seg=O
111	protein	_	_	_	_	_	_	_	Seg=O
112	associations	_	_	_	_	_	_	_	Seg=O
113	during	_	_	_	_	_	_	_	Seg=O
114	infection	_	_	_	_	_	_	_	Seg=O
115	with	_	_	_	_	_	_	_	Seg=O
116	a	_	_	_	_	_	_	_	Seg=O
117	diverse	_	_	_	_	_	_	_	Seg=O
118	range	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	RNA	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	DNA	_	_	_	_	_	_	_	Seg=O
123	viruses	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	The	_	_	_	_	_	_	_	Seg=B-seg
126	benefits	_	_	_	_	_	_	_	Seg=O
127	and	_	_	_	_	_	_	_	Seg=O
128	limitations	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=B-seg
130	applying	_	_	_	_	_	_	_	Seg=O
131	proteomic	_	_	_	_	_	_	_	Seg=O
132	methods	_	_	_	_	_	_	_	Seg=O
133	to	_	_	_	_	_	_	_	Seg=O
134	virology	_	_	_	_	_	_	_	Seg=O
135	are	_	_	_	_	_	_	_	Seg=B-seg
136	explored	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=B-seg
139	the	_	_	_	_	_	_	_	Seg=O
140	contribution	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	these	_	_	_	_	_	_	_	Seg=O
143	approaches	_	_	_	_	_	_	_	Seg=O
144	to	_	_	_	_	_	_	_	Seg=O
145	important	_	_	_	_	_	_	_	Seg=O
146	biological	_	_	_	_	_	_	_	Seg=O
147	discoveries	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=O
149	to	_	_	_	_	_	_	_	Seg=O
150	inspiring	_	_	_	_	_	_	_	Seg=O
151	new	_	_	_	_	_	_	_	Seg=O
152	tractable	_	_	_	_	_	_	_	Seg=O
153	avenues	_	_	_	_	_	_	_	Seg=O
154	for	_	_	_	_	_	_	_	Seg=O
155	the	_	_	_	_	_	_	_	Seg=O
156	design	_	_	_	_	_	_	_	Seg=O
157	of	_	_	_	_	_	_	_	Seg=O
158	antiviral	_	_	_	_	_	_	_	Seg=O
159	therapeutics	_	_	_	_	_	_	_	Seg=O
160	is	_	_	_	_	_	_	_	Seg=O
161	highlighted	_	_	_	_	_	_	_	Seg=O
162	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 36f9ee4d21bf47a3f9f504f7fca3a1db625899d2
1	Coronaviruses	_	_	_	_	_	_	_	Seg=B-seg
2	are	_	_	_	_	_	_	_	Seg=O
3	positive	_	_	_	_	_	_	_	Seg=O
4	stranded	_	_	_	_	_	_	_	Seg=O
5	RNA	_	_	_	_	_	_	_	Seg=O
6	viruses	_	_	_	_	_	_	_	Seg=O
7	that	_	_	_	_	_	_	_	Seg=B-seg
8	cause	_	_	_	_	_	_	_	Seg=O
9	respiratory	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	enteric	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	central	_	_	_	_	_	_	_	Seg=O
14	nervous	_	_	_	_	_	_	_	Seg=O
15	system	_	_	_	_	_	_	_	Seg=O
16	diseases	_	_	_	_	_	_	_	Seg=O
17	in	_	_	_	_	_	_	_	Seg=O
18	many	_	_	_	_	_	_	_	Seg=O
19	species	_	_	_	_	_	_	_	Seg=O
20	,	_	_	_	_	_	_	_	Seg=O
21	including	_	_	_	_	_	_	_	Seg=B-seg
22	humans	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Until	_	_	_	_	_	_	_	Seg=B-seg
25	recently	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	the	_	_	_	_	_	_	_	Seg=O
28	relatively	_	_	_	_	_	_	_	Seg=O
29	low	_	_	_	_	_	_	_	Seg=O
30	burden	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	disease	_	_	_	_	_	_	_	Seg=O
33	in	_	_	_	_	_	_	_	Seg=O
34	humans	_	_	_	_	_	_	_	Seg=O
35	caused	_	_	_	_	_	_	_	Seg=B-seg
36	by	_	_	_	_	_	_	_	Seg=O
37	few	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	these	_	_	_	_	_	_	_	Seg=O
40	viruses	_	_	_	_	_	_	_	Seg=O
41	impeded	_	_	_	_	_	_	_	Seg=B-seg
42	the	_	_	_	_	_	_	_	Seg=O
43	development	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	coronavirus	_	_	_	_	_	_	_	Seg=O
46	specific	_	_	_	_	_	_	_	Seg=O
47	therapeutics	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	However	_	_	_	_	_	_	_	Seg=B-seg
50	,	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	emergence	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	severe	_	_	_	_	_	_	_	Seg=O
55	acute	_	_	_	_	_	_	_	Seg=O
56	respiratory	_	_	_	_	_	_	_	Seg=O
57	syndrome	_	_	_	_	_	_	_	Seg=O
58	coronavirus	_	_	_	_	_	_	_	Seg=O
59	(	_	_	_	_	_	_	_	Seg=O
60	SARS	_	_	_	_	_	_	_	Seg=O
61	-	_	_	_	_	_	_	_	Seg=O
62	CoV	_	_	_	_	_	_	_	Seg=O
63	)	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	more	_	_	_	_	_	_	_	Seg=O
67	recently	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	Middle	_	_	_	_	_	_	_	Seg=O
70	East	_	_	_	_	_	_	_	Seg=O
71	respiratory	_	_	_	_	_	_	_	Seg=O
72	syndrome	_	_	_	_	_	_	_	Seg=O
73	coronavirus	_	_	_	_	_	_	_	Seg=O
74	(	_	_	_	_	_	_	_	Seg=O
75	MERS	_	_	_	_	_	_	_	Seg=O
76	-	_	_	_	_	_	_	_	Seg=O
77	CoV	_	_	_	_	_	_	_	Seg=O
78	)	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	has	_	_	_	_	_	_	_	Seg=O
81	impelled	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	development	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	such	_	_	_	_	_	_	_	Seg=O
86	drugs	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	This	_	_	_	_	_	_	_	Seg=B-seg
89	review	_	_	_	_	_	_	_	Seg=O
90	focuses	_	_	_	_	_	_	_	Seg=O
91	on	_	_	_	_	_	_	_	Seg=O
92	some	_	_	_	_	_	_	_	Seg=O
93	newly	_	_	_	_	_	_	_	Seg=O
94	identified	_	_	_	_	_	_	_	Seg=O
95	SARS	_	_	_	_	_	_	_	Seg=O
96	-	_	_	_	_	_	_	_	Seg=O
97	CoV	_	_	_	_	_	_	_	Seg=O
98	inhibitors	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	with	_	_	_	_	_	_	_	Seg=O
101	known	_	_	_	_	_	_	_	Seg=O
102	mechanisms	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	action	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=O
106	their	_	_	_	_	_	_	_	Seg=O
107	potential	_	_	_	_	_	_	_	Seg=O
108	to	_	_	_	_	_	_	_	Seg=B-seg
109	inhibit	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	novel	_	_	_	_	_	_	_	Seg=O
112	MERS	_	_	_	_	_	_	_	Seg=O
113	-	_	_	_	_	_	_	_	Seg=O
114	CoV.	_	_	_	_	_	_	_	Seg=O
115	The	_	_	_	_	_	_	_	Seg=B-seg
116	clinical	_	_	_	_	_	_	_	Seg=O
117	development	_	_	_	_	_	_	_	Seg=O
118	of	_	_	_	_	_	_	_	Seg=O
119	optimized	_	_	_	_	_	_	_	Seg=O
120	versions	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	such	_	_	_	_	_	_	_	Seg=O
123	compounds	_	_	_	_	_	_	_	Seg=O
124	could	_	_	_	_	_	_	_	Seg=O
125	be	_	_	_	_	_	_	_	Seg=O
126	beneficial	_	_	_	_	_	_	_	Seg=O
127	for	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	treatment	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	control	_	_	_	_	_	_	_	Seg=O
132	of	_	_	_	_	_	_	_	Seg=O
133	SARS	_	_	_	_	_	_	_	Seg=O
134	-	_	_	_	_	_	_	_	Seg=O
135	CoV	_	_	_	_	_	_	_	Seg=O
136	,	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	current	_	_	_	_	_	_	_	Seg=O
139	MERS	_	_	_	_	_	_	_	Seg=O
140	-	_	_	_	_	_	_	_	Seg=O
141	CoV	_	_	_	_	_	_	_	Seg=O
142	and	_	_	_	_	_	_	_	Seg=O
143	other	_	_	_	_	_	_	_	Seg=O
144	future	_	_	_	_	_	_	_	Seg=O
145	SARS	_	_	_	_	_	_	_	Seg=O
146	-	_	_	_	_	_	_	_	Seg=O
147	like	_	_	_	_	_	_	_	Seg=O
148	epidemics	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 393df9f3bd2b9ab0e100ab48688cebc9e86c5a60
1	Pandemics	_	_	_	_	_	_	_	Seg=B-seg
2	have	_	_	_	_	_	_	_	Seg=O
3	a	_	_	_	_	_	_	_	Seg=O
4	profound	_	_	_	_	_	_	_	Seg=O
5	impact	_	_	_	_	_	_	_	Seg=O
6	on	_	_	_	_	_	_	_	Seg=O
7	our	_	_	_	_	_	_	_	Seg=O
8	world	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	causing	_	_	_	_	_	_	_	Seg=B-seg
11	loss	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	life	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	affecting	_	_	_	_	_	_	_	Seg=B-seg
16	our	_	_	_	_	_	_	_	Seg=O
17	culture	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=B-seg
19	historically	_	_	_	_	_	_	_	Seg=O
20	shaping	_	_	_	_	_	_	_	Seg=O
21	our	_	_	_	_	_	_	_	Seg=O
22	genetics	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	The	_	_	_	_	_	_	_	Seg=B-seg
25	response	_	_	_	_	_	_	_	Seg=O
26	to	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	pandemic	_	_	_	_	_	_	_	Seg=O
29	requires	_	_	_	_	_	_	_	Seg=O
30	both	_	_	_	_	_	_	_	Seg=O
31	resilience	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	imagination	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	It	_	_	_	_	_	_	_	Seg=B-seg
36	has	_	_	_	_	_	_	_	Seg=O
37	been	_	_	_	_	_	_	_	Seg=O
38	clearly	_	_	_	_	_	_	_	Seg=O
39	documented	_	_	_	_	_	_	_	Seg=O
40	that	_	_	_	_	_	_	_	Seg=O
41	obtaining	_	_	_	_	_	_	_	Seg=O
42	an	_	_	_	_	_	_	_	Seg=O
43	accurate	_	_	_	_	_	_	_	Seg=O
44	estimate	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=O
46	trends	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	actual	_	_	_	_	_	_	_	Seg=O
50	infection	_	_	_	_	_	_	_	Seg=O
51	rate	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	mortality	_	_	_	_	_	_	_	Seg=O
54	risk	_	_	_	_	_	_	_	Seg=O
55	are	_	_	_	_	_	_	_	Seg=O
56	very	_	_	_	_	_	_	_	Seg=O
57	important	_	_	_	_	_	_	_	Seg=O
58	for	_	_	_	_	_	_	_	Seg=O
59	policy	_	_	_	_	_	_	_	Seg=O
60	makers	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	medical	_	_	_	_	_	_	_	Seg=O
63	professionals	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	One	_	_	_	_	_	_	_	Seg=B-seg
66	can	_	_	_	_	_	_	_	Seg=O
67	not	_	_	_	_	_	_	_	Seg=O
68	estimate	_	_	_	_	_	_	_	Seg=O
69	mortality	_	_	_	_	_	_	_	Seg=O
70	rates	_	_	_	_	_	_	_	Seg=O
71	without	_	_	_	_	_	_	_	Seg=B-seg
72	an	_	_	_	_	_	_	_	Seg=O
73	accurate	_	_	_	_	_	_	_	Seg=O
74	assessment	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77	number	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	infected	_	_	_	_	_	_	_	Seg=O
80	individuals	_	_	_	_	_	_	_	Seg=O
81	in	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	population	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	This	_	_	_	_	_	_	_	Seg=B-seg
86	need	_	_	_	_	_	_	_	Seg=O
87	is	_	_	_	_	_	_	_	Seg=O
88	also	_	_	_	_	_	_	_	Seg=O
89	aligned	_	_	_	_	_	_	_	Seg=O
90	with	_	_	_	_	_	_	_	Seg=O
91	identifying	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	infected	_	_	_	_	_	_	_	Seg=O
94	individuals	_	_	_	_	_	_	_	Seg=O
95	so	_	_	_	_	_	_	_	Seg=B-seg
96	they	_	_	_	_	_	_	_	Seg=O
97	can	_	_	_	_	_	_	_	Seg=O
98	be	_	_	_	_	_	_	_	Seg=O
99	properly	_	_	_	_	_	_	_	Seg=O
100	treated	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	monitored	_	_	_	_	_	_	_	Seg=B-seg
103	and	_	_	_	_	_	_	_	Seg=B-seg
104	tracked	_	_	_	_	_	_	_	Seg=O
105	.	_	_	_	_	_	_	_	Seg=O
106	However	_	_	_	_	_	_	_	Seg=B-seg
107	,	_	_	_	_	_	_	_	Seg=O
108	accurate	_	_	_	_	_	_	_	Seg=O
109	estimation	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	infection	_	_	_	_	_	_	_	Seg=O
113	rate	_	_	_	_	_	_	_	Seg=O
114	,	_	_	_	_	_	_	_	Seg=O
115	locally	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	geographically	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	nationally	_	_	_	_	_	_	_	Seg=O
120	is	_	_	_	_	_	_	_	Seg=O
121	important	_	_	_	_	_	_	_	Seg=O
122	independently	_	_	_	_	_	_	_	Seg=O
123	.	_	_	_	_	_	_	_	Seg=O
124	These	_	_	_	_	_	_	_	Seg=B-seg
125	infection	_	_	_	_	_	_	_	Seg=O
126	rate	_	_	_	_	_	_	_	Seg=O
127	estimates	_	_	_	_	_	_	_	Seg=O
128	can	_	_	_	_	_	_	_	Seg=O
129	guide	_	_	_	_	_	_	_	Seg=O
130	policy	_	_	_	_	_	_	_	Seg=O
131	makers	_	_	_	_	_	_	_	Seg=O
132	at	_	_	_	_	_	_	_	Seg=O
133	both	_	_	_	_	_	_	_	Seg=O
134	state	_	_	_	_	_	_	_	Seg=O
135	,	_	_	_	_	_	_	_	Seg=O
136	national	_	_	_	_	_	_	_	Seg=O
137	or	_	_	_	_	_	_	_	Seg=O
138	world	_	_	_	_	_	_	_	Seg=O
139	level	_	_	_	_	_	_	_	Seg=O
140	to	_	_	_	_	_	_	_	Seg=O
141	achieve	_	_	_	_	_	_	_	Seg=O
142	a	_	_	_	_	_	_	_	Seg=O
143	better	_	_	_	_	_	_	_	Seg=O
144	management	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	risk	_	_	_	_	_	_	_	Seg=O
147	to	_	_	_	_	_	_	_	Seg=O
148	society	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	The	_	_	_	_	_	_	_	Seg=B-seg
151	decisions	_	_	_	_	_	_	_	Seg=O
152	facing	_	_	_	_	_	_	_	Seg=B-seg
153	policy	_	_	_	_	_	_	_	Seg=O
154	makers	_	_	_	_	_	_	_	Seg=O
155	are	_	_	_	_	_	_	_	Seg=B-seg
156	very	_	_	_	_	_	_	_	Seg=O
157	different	_	_	_	_	_	_	_	Seg=O
158	during	_	_	_	_	_	_	_	Seg=O
159	early	_	_	_	_	_	_	_	Seg=O
160	stages	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	an	_	_	_	_	_	_	_	Seg=O
163	emerging	_	_	_	_	_	_	_	Seg=O
164	epidemic	_	_	_	_	_	_	_	Seg=O
165	where	_	_	_	_	_	_	_	Seg=B-seg
166	the	_	_	_	_	_	_	_	Seg=O
167	infection	_	_	_	_	_	_	_	Seg=O
168	rate	_	_	_	_	_	_	_	Seg=O
169	is	_	_	_	_	_	_	_	Seg=O
170	low	_	_	_	_	_	_	_	Seg=O
171	,	_	_	_	_	_	_	_	Seg=O
172	middle	_	_	_	_	_	_	_	Seg=B-seg
173	stages	_	_	_	_	_	_	_	Seg=O
174	where	_	_	_	_	_	_	_	Seg=B-seg
175	the	_	_	_	_	_	_	_	Seg=O
176	rate	_	_	_	_	_	_	_	Seg=O
177	is	_	_	_	_	_	_	_	Seg=O
178	rapidly	_	_	_	_	_	_	_	Seg=O
179	climbing	_	_	_	_	_	_	_	Seg=O
180	,	_	_	_	_	_	_	_	Seg=O
181	and	_	_	_	_	_	_	_	Seg=B-seg
182	later	_	_	_	_	_	_	_	Seg=O
183	stages	_	_	_	_	_	_	_	Seg=O
184	where	_	_	_	_	_	_	_	Seg=B-seg
185	the	_	_	_	_	_	_	_	Seg=O
186	epidemic	_	_	_	_	_	_	_	Seg=O
187	curve	_	_	_	_	_	_	_	Seg=O
188	has	_	_	_	_	_	_	_	Seg=O
189	flattened	_	_	_	_	_	_	_	Seg=O
190	to	_	_	_	_	_	_	_	Seg=O
191	a	_	_	_	_	_	_	_	Seg=O
192	low	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=O
194	relatively	_	_	_	_	_	_	_	Seg=O
195	sustainable	_	_	_	_	_	_	_	Seg=O
196	rate	_	_	_	_	_	_	_	Seg=O
197	.	_	_	_	_	_	_	_	Seg=O
198	In	_	_	_	_	_	_	_	Seg=B-seg
199	this	_	_	_	_	_	_	_	Seg=O
200	paper	_	_	_	_	_	_	_	Seg=O
201	we	_	_	_	_	_	_	_	Seg=O
202	provide	_	_	_	_	_	_	_	Seg=O
203	relatively	_	_	_	_	_	_	_	Seg=O
204	efficient	_	_	_	_	_	_	_	Seg=O
205	pooling	_	_	_	_	_	_	_	Seg=O
206	methods	_	_	_	_	_	_	_	Seg=O
207	to	_	_	_	_	_	_	_	Seg=B-seg
208	both	_	_	_	_	_	_	_	Seg=O
209	estimate	_	_	_	_	_	_	_	Seg=O
210	infection	_	_	_	_	_	_	_	Seg=O
211	rates	_	_	_	_	_	_	_	Seg=O
212	and	_	_	_	_	_	_	_	Seg=B-seg
213	identify	_	_	_	_	_	_	_	Seg=O
214	infected	_	_	_	_	_	_	_	Seg=O
215	individuals	_	_	_	_	_	_	_	Seg=O
216	for	_	_	_	_	_	_	_	Seg=O
217	populations	_	_	_	_	_	_	_	Seg=O
218	with	_	_	_	_	_	_	_	Seg=O
219	low	_	_	_	_	_	_	_	Seg=O
220	infection	_	_	_	_	_	_	_	Seg=O
221	rates	_	_	_	_	_	_	_	Seg=O
222	.	_	_	_	_	_	_	_	Seg=O
223	These	_	_	_	_	_	_	_	Seg=B-seg
224	estimates	_	_	_	_	_	_	_	Seg=O
225	may	_	_	_	_	_	_	_	Seg=O
226	provide	_	_	_	_	_	_	_	Seg=O
227	significant	_	_	_	_	_	_	_	Seg=O
228	cost	_	_	_	_	_	_	_	Seg=O
229	reductions	_	_	_	_	_	_	_	Seg=O
230	for	_	_	_	_	_	_	_	Seg=B-seg
231	testing	_	_	_	_	_	_	_	Seg=O
232	in	_	_	_	_	_	_	_	Seg=O
233	rural	_	_	_	_	_	_	_	Seg=O
234	communities	_	_	_	_	_	_	_	Seg=O
235	,	_	_	_	_	_	_	_	Seg=O
236	third	_	_	_	_	_	_	_	Seg=O
237	world	_	_	_	_	_	_	_	Seg=O
238	countries	_	_	_	_	_	_	_	Seg=O
239	and	_	_	_	_	_	_	_	Seg=O
240	other	_	_	_	_	_	_	_	Seg=O
241	situations	_	_	_	_	_	_	_	Seg=O
242	where	_	_	_	_	_	_	_	Seg=B-seg
243	the	_	_	_	_	_	_	_	Seg=O
244	cost	_	_	_	_	_	_	_	Seg=O
245	of	_	_	_	_	_	_	_	Seg=O
246	testing	_	_	_	_	_	_	_	Seg=O
247	is	_	_	_	_	_	_	_	Seg=O
248	expensive	_	_	_	_	_	_	_	Seg=O
249	or	_	_	_	_	_	_	_	Seg=B-seg
250	testing	_	_	_	_	_	_	_	Seg=O
251	is	_	_	_	_	_	_	_	Seg=O
252	not	_	_	_	_	_	_	_	Seg=O
253	widely	_	_	_	_	_	_	_	Seg=O
254	available	_	_	_	_	_	_	_	Seg=O
255	.	_	_	_	_	_	_	_	Seg=O
256	As	_	_	_	_	_	_	_	Seg=B-seg
257	we	_	_	_	_	_	_	_	Seg=O
258	prepare	_	_	_	_	_	_	_	Seg=O
259	for	_	_	_	_	_	_	_	Seg=O
260	the	_	_	_	_	_	_	_	Seg=O
261	second	_	_	_	_	_	_	_	Seg=O
262	wave	_	_	_	_	_	_	_	Seg=O
263	of	_	_	_	_	_	_	_	Seg=O
264	the	_	_	_	_	_	_	_	Seg=O
265	pandemic	_	_	_	_	_	_	_	Seg=O
266	this	_	_	_	_	_	_	_	Seg=B-seg
267	line	_	_	_	_	_	_	_	Seg=O
268	of	_	_	_	_	_	_	_	Seg=O
269	work	_	_	_	_	_	_	_	Seg=O
270	may	_	_	_	_	_	_	_	Seg=O
271	provide	_	_	_	_	_	_	_	Seg=O
272	new	_	_	_	_	_	_	_	Seg=O
273	solutions	_	_	_	_	_	_	_	Seg=O
274	for	_	_	_	_	_	_	_	Seg=O
275	both	_	_	_	_	_	_	_	Seg=O
276	the	_	_	_	_	_	_	_	Seg=O
277	biomedical	_	_	_	_	_	_	_	Seg=O
278	community	_	_	_	_	_	_	_	Seg=O
279	and	_	_	_	_	_	_	_	Seg=O
280	policy	_	_	_	_	_	_	_	Seg=O
281	makers	_	_	_	_	_	_	_	Seg=O
282	at	_	_	_	_	_	_	_	Seg=O
283	all	_	_	_	_	_	_	_	Seg=O
284	levels	_	_	_	_	_	_	_	Seg=O
285	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3b2db322b3470bdbc2145b4b348b1dc2c8e054ec
1	Coronavirus	_	_	_	_	_	_	_	Seg=B-seg
2	disease	_	_	_	_	_	_	_	Seg=O
3	2019	_	_	_	_	_	_	_	Seg=O
4	caused	_	_	_	_	_	_	_	Seg=B-seg
5	by	_	_	_	_	_	_	_	Seg=O
6	severe	_	_	_	_	_	_	_	Seg=O
7	acute	_	_	_	_	_	_	_	Seg=O
8	respiratory	_	_	_	_	_	_	_	Seg=O
9	syndrome	_	_	_	_	_	_	_	Seg=O
10	coronavirus	_	_	_	_	_	_	_	Seg=O
11	2	_	_	_	_	_	_	_	Seg=O
12	has	_	_	_	_	_	_	_	Seg=B-seg
13	spread	_	_	_	_	_	_	_	Seg=O
14	rapidly	_	_	_	_	_	_	_	Seg=O
15	around	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	world	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=B-seg
19	is	_	_	_	_	_	_	_	Seg=O
20	a	_	_	_	_	_	_	_	Seg=O
21	significant	_	_	_	_	_	_	_	Seg=O
22	threat	_	_	_	_	_	_	_	Seg=O
23	to	_	_	_	_	_	_	_	Seg=O
24	global	_	_	_	_	_	_	_	Seg=O
25	health	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	Patients	_	_	_	_	_	_	_	Seg=B-seg
28	in	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=O
30	Neonatal	_	_	_	_	_	_	_	Seg=O
31	Surgery	_	_	_	_	_	_	_	Seg=O
32	Department	_	_	_	_	_	_	_	Seg=O
33	have	_	_	_	_	_	_	_	Seg=O
34	rapidly	_	_	_	_	_	_	_	Seg=O
35	progressing	_	_	_	_	_	_	_	Seg=O
36	diseases	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	immature	_	_	_	_	_	_	_	Seg=O
39	immunity	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	which	_	_	_	_	_	_	_	Seg=B-seg
42	makes	_	_	_	_	_	_	_	Seg=O
43	them	_	_	_	_	_	_	_	Seg=O
44	vulnerable	_	_	_	_	_	_	_	Seg=O
45	to	_	_	_	_	_	_	_	Seg=O
46	pulmonary	_	_	_	_	_	_	_	Seg=O
47	infection	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	a	_	_	_	_	_	_	_	Seg=O
50	relatively	_	_	_	_	_	_	_	Seg=O
51	higher	_	_	_	_	_	_	_	Seg=O
52	mortality	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	This	_	_	_	_	_	_	_	Seg=B-seg
55	means	_	_	_	_	_	_	_	Seg=O
56	that	_	_	_	_	_	_	_	Seg=B-seg
57	these	_	_	_	_	_	_	_	Seg=O
58	patients	_	_	_	_	_	_	_	Seg=O
59	require	_	_	_	_	_	_	_	Seg=O
60	multidisciplinary	_	_	_	_	_	_	_	Seg=O
61	treatment	_	_	_	_	_	_	_	Seg=O
62	including	_	_	_	_	_	_	_	Seg=B-seg
63	early	_	_	_	_	_	_	_	Seg=O
64	diagnosis	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	timely	_	_	_	_	_	_	_	Seg=O
67	transport	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	emergency	_	_	_	_	_	_	_	Seg=O
70	surgery	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	intensive	_	_	_	_	_	_	_	Seg=O
73	critical	_	_	_	_	_	_	_	Seg=O
74	care	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	The	_	_	_	_	_	_	_	Seg=B-seg
77	COVID-19	_	_	_	_	_	_	_	Seg=O
78	pandemic	_	_	_	_	_	_	_	Seg=O
79	poses	_	_	_	_	_	_	_	Seg=O
80	a	_	_	_	_	_	_	_	Seg=O
81	threat	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=O
83	carrying	_	_	_	_	_	_	_	Seg=O
84	out	_	_	_	_	_	_	_	Seg=O
85	these	_	_	_	_	_	_	_	Seg=O
86	treatments	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	To	_	_	_	_	_	_	_	Seg=B-seg
89	provide	_	_	_	_	_	_	_	Seg=O
90	support	_	_	_	_	_	_	_	Seg=O
91	for	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	health	_	_	_	_	_	_	_	Seg=O
94	protection	_	_	_	_	_	_	_	Seg=O
95	requirements	_	_	_	_	_	_	_	Seg=O
96	of	_	_	_	_	_	_	_	Seg=O
97	the	_	_	_	_	_	_	_	Seg=O
98	medical	_	_	_	_	_	_	_	Seg=O
99	services	_	_	_	_	_	_	_	Seg=O
100	in	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	Neonatal	_	_	_	_	_	_	_	Seg=O
103	Surgery	_	_	_	_	_	_	_	Seg=O
104	Department	_	_	_	_	_	_	_	Seg=O
105	,	_	_	_	_	_	_	_	Seg=O
106	we	_	_	_	_	_	_	_	Seg=B-seg
107	developed	_	_	_	_	_	_	_	Seg=O
108	recommendations	_	_	_	_	_	_	_	Seg=O
109	focusing	_	_	_	_	_	_	_	Seg=B-seg
110	on	_	_	_	_	_	_	_	Seg=O
111	patient	_	_	_	_	_	_	_	Seg=O
112	transport	_	_	_	_	_	_	_	Seg=O
113	,	_	_	_	_	_	_	_	Seg=O
114	surgery	_	_	_	_	_	_	_	Seg=O
115	selection	_	_	_	_	_	_	_	Seg=O
116	and	_	_	_	_	_	_	_	Seg=O
117	protection	_	_	_	_	_	_	_	Seg=O
118	requirements	_	_	_	_	_	_	_	Seg=O
119	with	_	_	_	_	_	_	_	Seg=B-seg
120	the	_	_	_	_	_	_	_	Seg=O
121	aim	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=B-seg
123	improving	_	_	_	_	_	_	_	Seg=O
124	treatment	_	_	_	_	_	_	_	Seg=O
125	strategies	_	_	_	_	_	_	_	Seg=O
126	for	_	_	_	_	_	_	_	Seg=O
127	patients	_	_	_	_	_	_	_	Seg=O
128	and	_	_	_	_	_	_	_	Seg=B-seg
129	preventing	_	_	_	_	_	_	_	Seg=O
130	infection	_	_	_	_	_	_	_	Seg=O
131	in	_	_	_	_	_	_	_	Seg=O
132	medical	_	_	_	_	_	_	_	Seg=O
133	staff	_	_	_	_	_	_	_	Seg=O
134	during	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	current	_	_	_	_	_	_	_	Seg=O
137	COVID-19	_	_	_	_	_	_	_	Seg=O
138	pandemic	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3d026627a1f1f6af6f6fbb07bbcb84d917c7c946
1	Identification	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	regulatory	_	_	_	_	_	_	_	Seg=O
4	elements	_	_	_	_	_	_	_	Seg=O
5	is	_	_	_	_	_	_	_	Seg=O
6	essential	_	_	_	_	_	_	_	Seg=O
7	for	_	_	_	_	_	_	_	Seg=B-seg
8	understanding	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	mechanism	_	_	_	_	_	_	_	Seg=O
11	behind	_	_	_	_	_	_	_	Seg=O
12	regulating	_	_	_	_	_	_	_	Seg=O
13	gene	_	_	_	_	_	_	_	Seg=O
14	expression	_	_	_	_	_	_	_	Seg=O
15	.	_	_	_	_	_	_	_	Seg=O
16	These	_	_	_	_	_	_	_	Seg=B-seg
17	regulatory	_	_	_	_	_	_	_	Seg=O
18	elements	_	_	_	_	_	_	_	Seg=O
19	-	_	_	_	_	_	_	_	Seg=B-seg
20	located	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	or	_	_	_	_	_	_	_	Seg=O
23	near	_	_	_	_	_	_	_	Seg=O
24	gene	_	_	_	_	_	_	_	Seg=O
25	-	_	_	_	_	_	_	_	Seg=O
26	bind	_	_	_	_	_	_	_	Seg=B-seg
27	to	_	_	_	_	_	_	_	Seg=O
28	proteins	_	_	_	_	_	_	_	Seg=O
29	called	_	_	_	_	_	_	_	Seg=B-seg
30	transcription	_	_	_	_	_	_	_	Seg=O
31	factors	_	_	_	_	_	_	_	Seg=O
32	to	_	_	_	_	_	_	_	Seg=B-seg
33	initiate	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	transcription	_	_	_	_	_	_	_	Seg=O
36	process	_	_	_	_	_	_	_	Seg=O
37	.	_	_	_	_	_	_	_	Seg=O
38	Their	_	_	_	_	_	_	_	Seg=B-seg
39	occurrences	_	_	_	_	_	_	_	Seg=O
40	are	_	_	_	_	_	_	_	Seg=O
41	influenced	_	_	_	_	_	_	_	Seg=O
42	by	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	GC	_	_	_	_	_	_	_	Seg=O
45	-	_	_	_	_	_	_	_	Seg=O
46	content	_	_	_	_	_	_	_	Seg=O
47	or	_	_	_	_	_	_	_	Seg=O
48	nucleotide	_	_	_	_	_	_	_	Seg=O
49	composition	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	For	_	_	_	_	_	_	_	Seg=B-seg
52	generating	_	_	_	_	_	_	_	Seg=O
53	synthetic	_	_	_	_	_	_	_	Seg=O
54	coding	_	_	_	_	_	_	_	Seg=O
55	sequences	_	_	_	_	_	_	_	Seg=O
56	with	_	_	_	_	_	_	_	Seg=O
57	pre	_	_	_	_	_	_	_	Seg=O
58	-	_	_	_	_	_	_	_	Seg=O
59	specified	_	_	_	_	_	_	_	Seg=O
60	amino	_	_	_	_	_	_	_	Seg=O
61	acid	_	_	_	_	_	_	_	Seg=O
62	sequence	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	desired	_	_	_	_	_	_	_	Seg=O
65	GC	_	_	_	_	_	_	_	Seg=O
66	-	_	_	_	_	_	_	_	Seg=O
67	content	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	there	_	_	_	_	_	_	_	Seg=B-seg
70	exist	_	_	_	_	_	_	_	Seg=O
71	two	_	_	_	_	_	_	_	Seg=O
72	stochastic	_	_	_	_	_	_	_	Seg=O
73	methods	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	multinomial	_	_	_	_	_	_	_	Seg=O
76	and	_	_	_	_	_	_	_	Seg=O
77	maximum	_	_	_	_	_	_	_	Seg=O
78	entropy	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	Both	_	_	_	_	_	_	_	Seg=B-seg
81	methods	_	_	_	_	_	_	_	Seg=O
82	rely	_	_	_	_	_	_	_	Seg=O
83	on	_	_	_	_	_	_	_	Seg=O
84	the	_	_	_	_	_	_	_	Seg=O
85	probability	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=B-seg
87	choosing	_	_	_	_	_	_	_	Seg=O
88	the	_	_	_	_	_	_	_	Seg=O
89	codon	_	_	_	_	_	_	_	Seg=O
90	synonymous	_	_	_	_	_	_	_	Seg=O
91	for	_	_	_	_	_	_	_	Seg=O
92	usage	_	_	_	_	_	_	_	Seg=O
93	in	_	_	_	_	_	_	_	Seg=O
94	regard	_	_	_	_	_	_	_	Seg=O
95	to	_	_	_	_	_	_	_	Seg=O
96	a	_	_	_	_	_	_	_	Seg=O
97	specific	_	_	_	_	_	_	_	Seg=O
98	amino	_	_	_	_	_	_	_	Seg=O
99	acid	_	_	_	_	_	_	_	Seg=O
100	.	_	_	_	_	_	_	_	Seg=O
101	In	_	_	_	_	_	_	_	Seg=B-seg
102	spite	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	latter	_	_	_	_	_	_	_	Seg=O
105	exhibited	_	_	_	_	_	_	_	Seg=O
106	unbiased	_	_	_	_	_	_	_	Seg=O
107	manner	_	_	_	_	_	_	_	Seg=O
108	,	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=B-seg
110	produced	_	_	_	_	_	_	_	Seg=O
111	sequences	_	_	_	_	_	_	_	Seg=O
112	are	_	_	_	_	_	_	_	Seg=O
113	not	_	_	_	_	_	_	_	Seg=O
114	exactly	_	_	_	_	_	_	_	Seg=O
115	obeying	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	GC	_	_	_	_	_	_	_	Seg=O
118	-	_	_	_	_	_	_	_	Seg=O
119	content	_	_	_	_	_	_	_	Seg=O
120	constraint	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	In	_	_	_	_	_	_	_	Seg=B-seg
123	this	_	_	_	_	_	_	_	Seg=O
124	paper	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	we	_	_	_	_	_	_	_	Seg=O
127	present	_	_	_	_	_	_	_	Seg=O
128	an	_	_	_	_	_	_	_	Seg=O
129	algorithmic	_	_	_	_	_	_	_	Seg=O
130	solution	_	_	_	_	_	_	_	Seg=O
131	to	_	_	_	_	_	_	_	Seg=B-seg
132	produce	_	_	_	_	_	_	_	Seg=O
133	coding	_	_	_	_	_	_	_	Seg=O
134	sequences	_	_	_	_	_	_	_	Seg=O
135	that	_	_	_	_	_	_	_	Seg=B-seg
136	follow	_	_	_	_	_	_	_	Seg=O
137	exactly	_	_	_	_	_	_	_	Seg=O
138	a	_	_	_	_	_	_	_	Seg=O
139	primary	_	_	_	_	_	_	_	Seg=O
140	amino	_	_	_	_	_	_	_	Seg=O
141	acid	_	_	_	_	_	_	_	Seg=O
142	sequence	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=O
144	a	_	_	_	_	_	_	_	Seg=O
145	desired	_	_	_	_	_	_	_	Seg=O
146	GC	_	_	_	_	_	_	_	Seg=O
147	-	_	_	_	_	_	_	_	Seg=O
148	content	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	The	_	_	_	_	_	_	_	Seg=B-seg
151	proposed	_	_	_	_	_	_	_	Seg=O
152	tool	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	namely	_	_	_	_	_	_	_	Seg=O
155	CodSeqGen	_	_	_	_	_	_	_	Seg=O
156	,	_	_	_	_	_	_	_	Seg=O
157	depends	_	_	_	_	_	_	_	Seg=O
158	on	_	_	_	_	_	_	_	Seg=O
159	random	_	_	_	_	_	_	_	Seg=O
160	selection	_	_	_	_	_	_	_	Seg=O
161	for	_	_	_	_	_	_	_	Seg=O
162	smaller	_	_	_	_	_	_	_	Seg=O
163	subsets	_	_	_	_	_	_	_	Seg=O
164	to	_	_	_	_	_	_	_	Seg=B-seg
165	be	_	_	_	_	_	_	_	Seg=O
166	traversed	_	_	_	_	_	_	_	Seg=O
167	using	_	_	_	_	_	_	_	Seg=B-seg
168	the	_	_	_	_	_	_	_	Seg=O
169	backtracking	_	_	_	_	_	_	_	Seg=O
170	approach	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3db88b442b2c693d0783756c733c55bcec669df0
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	this	_	_	_	_	_	_	_	Seg=O
3	paper	_	_	_	_	_	_	_	Seg=O
4	are	_	_	_	_	_	_	_	Seg=O
5	presented	_	_	_	_	_	_	_	Seg=O
6	mathematical	_	_	_	_	_	_	_	Seg=O
7	predictions	_	_	_	_	_	_	_	Seg=O
8	on	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	evolution	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	time	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	the	_	_	_	_	_	_	_	Seg=O
15	number	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	positive	_	_	_	_	_	_	_	Seg=O
18	cases	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	Italy	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	COVID-19	_	_	_	_	_	_	_	Seg=O
24	pandemic	_	_	_	_	_	_	_	Seg=O
25	based	_	_	_	_	_	_	_	Seg=B-seg
26	on	_	_	_	_	_	_	_	Seg=O
27	official	_	_	_	_	_	_	_	Seg=O
28	data	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	on	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	use	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	a	_	_	_	_	_	_	_	Seg=O
35	function	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	type	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	a	_	_	_	_	_	_	_	Seg=O
41	Gauss	_	_	_	_	_	_	_	Seg=O
42	error	_	_	_	_	_	_	_	Seg=O
43	function	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	with	_	_	_	_	_	_	_	Seg=O
46	four	_	_	_	_	_	_	_	Seg=O
47	parameters	_	_	_	_	_	_	_	Seg=O
48	,	_	_	_	_	_	_	_	Seg=O
49	as	_	_	_	_	_	_	_	Seg=O
50	a	_	_	_	_	_	_	_	Seg=O
51	cumulative	_	_	_	_	_	_	_	Seg=O
52	distribution	_	_	_	_	_	_	_	Seg=O
53	function	_	_	_	_	_	_	_	Seg=O
54	.	_	_	_	_	_	_	_	Seg=O
55	We	_	_	_	_	_	_	_	Seg=B-seg
56	have	_	_	_	_	_	_	_	Seg=O
57	analyzed	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	available	_	_	_	_	_	_	_	Seg=O
60	data	_	_	_	_	_	_	_	Seg=O
61	for	_	_	_	_	_	_	_	Seg=O
62	China	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	Italy	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	The	_	_	_	_	_	_	_	Seg=B-seg
67	evolution	_	_	_	_	_	_	_	Seg=O
68	in	_	_	_	_	_	_	_	Seg=O
69	time	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	number	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	cumulative	_	_	_	_	_	_	_	Seg=O
75	diagnosed	_	_	_	_	_	_	_	Seg=O
76	positive	_	_	_	_	_	_	_	Seg=O
77	cases	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	COVID-19	_	_	_	_	_	_	_	Seg=O
80	in	_	_	_	_	_	_	_	Seg=O
81	China	_	_	_	_	_	_	_	Seg=O
82	very	_	_	_	_	_	_	_	Seg=O
83	well	_	_	_	_	_	_	_	Seg=O
84	approximates	_	_	_	_	_	_	_	Seg=O
85	a	_	_	_	_	_	_	_	Seg=O
86	distribution	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	the	_	_	_	_	_	_	_	Seg=O
89	type	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	error	_	_	_	_	_	_	_	Seg=O
93	function	_	_	_	_	_	_	_	Seg=O
94	,	_	_	_	_	_	_	_	Seg=O
95	that	_	_	_	_	_	_	_	Seg=B-seg
96	is	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	the	_	_	_	_	_	_	_	Seg=O
99	integral	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	a	_	_	_	_	_	_	_	Seg=O
102	normal	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	Gaussian	_	_	_	_	_	_	_	Seg=O
105	distribution	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	We	_	_	_	_	_	_	_	Seg=B-seg
108	have	_	_	_	_	_	_	_	Seg=O
109	then	_	_	_	_	_	_	_	Seg=O
110	used	_	_	_	_	_	_	_	Seg=O
111	such	_	_	_	_	_	_	_	Seg=O
112	a	_	_	_	_	_	_	_	Seg=O
113	function	_	_	_	_	_	_	_	Seg=O
114	to	_	_	_	_	_	_	_	Seg=B-seg
115	study	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	potential	_	_	_	_	_	_	_	Seg=O
118	evolution	_	_	_	_	_	_	_	Seg=O
119	in	_	_	_	_	_	_	_	Seg=O
120	time	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	the	_	_	_	_	_	_	_	Seg=O
123	number	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	positive	_	_	_	_	_	_	_	Seg=O
126	cases	_	_	_	_	_	_	_	Seg=O
127	in	_	_	_	_	_	_	_	Seg=O
128	Italy	_	_	_	_	_	_	_	Seg=O
129	by	_	_	_	_	_	_	_	Seg=B-seg
130	performing	_	_	_	_	_	_	_	Seg=O
131	a	_	_	_	_	_	_	_	Seg=O
132	number	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	fits	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	official	_	_	_	_	_	_	_	Seg=O
138	data	_	_	_	_	_	_	_	Seg=O
139	so	_	_	_	_	_	_	_	Seg=O
140	far	_	_	_	_	_	_	_	Seg=O
141	available	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	We	_	_	_	_	_	_	_	Seg=B-seg
144	then	_	_	_	_	_	_	_	Seg=O
145	found	_	_	_	_	_	_	_	Seg=O
146	a	_	_	_	_	_	_	_	Seg=O
147	statistical	_	_	_	_	_	_	_	Seg=O
148	prediction	_	_	_	_	_	_	_	Seg=O
149	for	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=O
151	day	_	_	_	_	_	_	_	Seg=O
152	in	_	_	_	_	_	_	_	Seg=B-seg
153	which	_	_	_	_	_	_	_	Seg=O
154	the	_	_	_	_	_	_	_	Seg=O
155	peak	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	number	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	daily	_	_	_	_	_	_	_	Seg=O
161	positive	_	_	_	_	_	_	_	Seg=O
162	cases	_	_	_	_	_	_	_	Seg=O
163	in	_	_	_	_	_	_	_	Seg=O
164	Italy	_	_	_	_	_	_	_	Seg=O
165	occurs	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	corresponding	_	_	_	_	_	_	_	Seg=B-seg
168	to	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	flex	_	_	_	_	_	_	_	Seg=O
171	of	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	fit	_	_	_	_	_	_	_	Seg=O
174	,	_	_	_	_	_	_	_	Seg=O
175	that	_	_	_	_	_	_	_	Seg=B-seg
176	is	_	_	_	_	_	_	_	Seg=O
177	,	_	_	_	_	_	_	_	Seg=O
178	to	_	_	_	_	_	_	_	Seg=O
179	the	_	_	_	_	_	_	_	Seg=O
180	change	_	_	_	_	_	_	_	Seg=O
181	in	_	_	_	_	_	_	_	Seg=O
182	sign	_	_	_	_	_	_	_	Seg=O
183	of	_	_	_	_	_	_	_	Seg=O
184	its	_	_	_	_	_	_	_	Seg=O
185	second	_	_	_	_	_	_	_	Seg=O
186	derivative	_	_	_	_	_	_	_	Seg=O
187	(	_	_	_	_	_	_	_	Seg=B-seg
188	i.e.	_	_	_	_	_	_	_	Seg=O
189	,	_	_	_	_	_	_	_	Seg=O
190	the	_	_	_	_	_	_	_	Seg=O
191	change	_	_	_	_	_	_	_	Seg=O
192	from	_	_	_	_	_	_	_	Seg=O
193	acceleration	_	_	_	_	_	_	_	Seg=O
194	to	_	_	_	_	_	_	_	Seg=O
195	deceleration	_	_	_	_	_	_	_	Seg=O
196	)	_	_	_	_	_	_	_	Seg=O
197	,	_	_	_	_	_	_	_	Seg=O
198	as	_	_	_	_	_	_	_	Seg=B-seg
199	well	_	_	_	_	_	_	_	Seg=O
200	as	_	_	_	_	_	_	_	Seg=O
201	of	_	_	_	_	_	_	_	Seg=O
202	the	_	_	_	_	_	_	_	Seg=O
203	day	_	_	_	_	_	_	_	Seg=O
204	in	_	_	_	_	_	_	_	Seg=B-seg
205	which	_	_	_	_	_	_	_	Seg=O
206	a	_	_	_	_	_	_	_	Seg=O
207	substantial	_	_	_	_	_	_	_	Seg=O
208	attenuation	_	_	_	_	_	_	_	Seg=O
209	of	_	_	_	_	_	_	_	Seg=O
210	such	_	_	_	_	_	_	_	Seg=O
211	number	_	_	_	_	_	_	_	Seg=O
212	of	_	_	_	_	_	_	_	Seg=O
213	daily	_	_	_	_	_	_	_	Seg=O
214	cases	_	_	_	_	_	_	_	Seg=O
215	is	_	_	_	_	_	_	_	Seg=O
216	reached	_	_	_	_	_	_	_	Seg=O
217	.	_	_	_	_	_	_	_	Seg=O
218	We	_	_	_	_	_	_	_	Seg=B-seg
219	have	_	_	_	_	_	_	_	Seg=O
220	also	_	_	_	_	_	_	_	Seg=O
221	analyzed	_	_	_	_	_	_	_	Seg=O
222	the	_	_	_	_	_	_	_	Seg=O
223	predictions	_	_	_	_	_	_	_	Seg=O
224	of	_	_	_	_	_	_	_	Seg=O
225	the	_	_	_	_	_	_	_	Seg=O
226	cumulative	_	_	_	_	_	_	_	Seg=O
227	number	_	_	_	_	_	_	_	Seg=O
228	of	_	_	_	_	_	_	_	Seg=O
229	fatalities	_	_	_	_	_	_	_	Seg=O
230	in	_	_	_	_	_	_	_	Seg=O
231	both	_	_	_	_	_	_	_	Seg=O
232	China	_	_	_	_	_	_	_	Seg=O
233	and	_	_	_	_	_	_	_	Seg=O
234	Italy	_	_	_	_	_	_	_	Seg=O
235	,	_	_	_	_	_	_	_	Seg=O
236	obtaining	_	_	_	_	_	_	_	Seg=B-seg
237	consistent	_	_	_	_	_	_	_	Seg=O
238	results	_	_	_	_	_	_	_	Seg=O
239	.	_	_	_	_	_	_	_	Seg=O
240	We	_	_	_	_	_	_	_	Seg=B-seg
241	have	_	_	_	_	_	_	_	Seg=O
242	then	_	_	_	_	_	_	_	Seg=O
243	performed	_	_	_	_	_	_	_	Seg=O
244	150	_	_	_	_	_	_	_	Seg=O
245	Monte	_	_	_	_	_	_	_	Seg=O
246	Carlo	_	_	_	_	_	_	_	Seg=O
247	simulations	_	_	_	_	_	_	_	Seg=O
248	to	_	_	_	_	_	_	_	Seg=B-seg
249	have	_	_	_	_	_	_	_	Seg=O
250	a	_	_	_	_	_	_	_	Seg=O
251	more	_	_	_	_	_	_	_	Seg=O
252	robust	_	_	_	_	_	_	_	Seg=O
253	prediction	_	_	_	_	_	_	_	Seg=O
254	of	_	_	_	_	_	_	_	Seg=O
255	the	_	_	_	_	_	_	_	Seg=O
256	day	_	_	_	_	_	_	_	Seg=O
257	of	_	_	_	_	_	_	_	Seg=O
258	the	_	_	_	_	_	_	_	Seg=O
259	above	_	_	_	_	_	_	_	Seg=O
260	-	_	_	_	_	_	_	_	Seg=O
261	mentioned	_	_	_	_	_	_	_	Seg=O
262	peak	_	_	_	_	_	_	_	Seg=O
263	and	_	_	_	_	_	_	_	Seg=O
264	of	_	_	_	_	_	_	_	Seg=O
265	the	_	_	_	_	_	_	_	Seg=O
266	day	_	_	_	_	_	_	_	Seg=O
267	of	_	_	_	_	_	_	_	Seg=O
268	the	_	_	_	_	_	_	_	Seg=O
269	substantial	_	_	_	_	_	_	_	Seg=O
270	decrease	_	_	_	_	_	_	_	Seg=O
271	in	_	_	_	_	_	_	_	Seg=O
272	the	_	_	_	_	_	_	_	Seg=O
273	number	_	_	_	_	_	_	_	Seg=O
274	of	_	_	_	_	_	_	_	Seg=O
275	daily	_	_	_	_	_	_	_	Seg=O
276	positive	_	_	_	_	_	_	_	Seg=O
277	cases	_	_	_	_	_	_	_	Seg=O
278	and	_	_	_	_	_	_	_	Seg=O
279	fatalities	_	_	_	_	_	_	_	Seg=O
280	.	_	_	_	_	_	_	_	Seg=O
281	Although	_	_	_	_	_	_	_	Seg=B-seg
282	official	_	_	_	_	_	_	_	Seg=O
283	data	_	_	_	_	_	_	_	Seg=O
284	have	_	_	_	_	_	_	_	Seg=O
285	been	_	_	_	_	_	_	_	Seg=O
286	used	_	_	_	_	_	_	_	Seg=O
287	,	_	_	_	_	_	_	_	Seg=O
288	those	_	_	_	_	_	_	_	Seg=B-seg
289	predictions	_	_	_	_	_	_	_	Seg=O
290	are	_	_	_	_	_	_	_	Seg=O
291	obtained	_	_	_	_	_	_	_	Seg=O
292	with	_	_	_	_	_	_	_	Seg=O
293	a	_	_	_	_	_	_	_	Seg=O
294	heuristic	_	_	_	_	_	_	_	Seg=O
295	approach	_	_	_	_	_	_	_	Seg=O
296	since	_	_	_	_	_	_	_	Seg=B-seg
297	they	_	_	_	_	_	_	_	Seg=O
298	are	_	_	_	_	_	_	_	Seg=O
299	based	_	_	_	_	_	_	_	Seg=O
300	on	_	_	_	_	_	_	_	Seg=O
301	a	_	_	_	_	_	_	_	Seg=O
302	statistical	_	_	_	_	_	_	_	Seg=O
303	approach	_	_	_	_	_	_	_	Seg=O
304	and	_	_	_	_	_	_	_	Seg=B-seg
305	do	_	_	_	_	_	_	_	Seg=O
306	not	_	_	_	_	_	_	_	Seg=O
307	take	_	_	_	_	_	_	_	Seg=O
308	into	_	_	_	_	_	_	_	Seg=O
309	account	_	_	_	_	_	_	_	Seg=O
310	either	_	_	_	_	_	_	_	Seg=O
311	a	_	_	_	_	_	_	_	Seg=O
312	number	_	_	_	_	_	_	_	Seg=O
313	of	_	_	_	_	_	_	_	Seg=O
314	relevant	_	_	_	_	_	_	_	Seg=O
315	issues	_	_	_	_	_	_	_	Seg=O
316	(	_	_	_	_	_	_	_	Seg=B-seg
317	such	_	_	_	_	_	_	_	Seg=O
318	as	_	_	_	_	_	_	_	Seg=O
319	number	_	_	_	_	_	_	_	Seg=O
320	of	_	_	_	_	_	_	_	Seg=O
321	daily	_	_	_	_	_	_	_	Seg=O
322	nasopharyngeal	_	_	_	_	_	_	_	Seg=O
323	swabs	_	_	_	_	_	_	_	Seg=O
324	,	_	_	_	_	_	_	_	Seg=O
325	medical	_	_	_	_	_	_	_	Seg=O
326	,	_	_	_	_	_	_	_	Seg=O
327	social	_	_	_	_	_	_	_	Seg=O
328	distancing	_	_	_	_	_	_	_	Seg=O
329	,	_	_	_	_	_	_	_	Seg=O
330	virological	_	_	_	_	_	_	_	Seg=O
331	and	_	_	_	_	_	_	_	Seg=O
332	epidemiological	_	_	_	_	_	_	_	Seg=O
333	)	_	_	_	_	_	_	_	Seg=O
334	or	_	_	_	_	_	_	_	Seg=B-seg
335	models	_	_	_	_	_	_	_	Seg=O
336	of	_	_	_	_	_	_	_	Seg=O
337	contamination	_	_	_	_	_	_	_	Seg=O
338	diffusion	_	_	_	_	_	_	_	Seg=O
339	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3e8d0363f49f83917e0ddddf7b4322186da47dbc
1	Shotgun	_	_	_	_	_	_	_	Seg=B-seg
2	metagenomics	_	_	_	_	_	_	_	Seg=O
3	using	_	_	_	_	_	_	_	Seg=B-seg
4	next	_	_	_	_	_	_	_	Seg=O
5	generation	_	_	_	_	_	_	_	Seg=O
6	sequencing	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	NGS	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	is	_	_	_	_	_	_	_	Seg=B-seg
11	a	_	_	_	_	_	_	_	Seg=O
12	promising	_	_	_	_	_	_	_	Seg=O
13	technique	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=B-seg
15	analyze	_	_	_	_	_	_	_	Seg=O
16	both	_	_	_	_	_	_	_	Seg=O
17	DNA	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	RNA	_	_	_	_	_	_	_	Seg=O
20	microbial	_	_	_	_	_	_	_	Seg=O
21	material	_	_	_	_	_	_	_	Seg=O
22	from	_	_	_	_	_	_	_	Seg=O
23	patient	_	_	_	_	_	_	_	Seg=O
24	samples	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	Mostly	_	_	_	_	_	_	_	Seg=B-seg
27	used	_	_	_	_	_	_	_	Seg=O
28	in	_	_	_	_	_	_	_	Seg=O
29	a	_	_	_	_	_	_	_	Seg=O
30	research	_	_	_	_	_	_	_	Seg=O
31	setting	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	it	_	_	_	_	_	_	_	Seg=B-seg
34	is	_	_	_	_	_	_	_	Seg=O
35	now	_	_	_	_	_	_	_	Seg=O
36	increasingly	_	_	_	_	_	_	_	Seg=O
37	being	_	_	_	_	_	_	_	Seg=O
38	used	_	_	_	_	_	_	_	Seg=O
39	in	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	clinical	_	_	_	_	_	_	_	Seg=O
42	realm	_	_	_	_	_	_	_	Seg=O
43	as	_	_	_	_	_	_	_	Seg=O
44	well	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	notably	_	_	_	_	_	_	_	Seg=B-seg
47	to	_	_	_	_	_	_	_	Seg=O
48	support	_	_	_	_	_	_	_	Seg=O
49	diagnosis	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	viral	_	_	_	_	_	_	_	Seg=O
52	infections	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	thereby	_	_	_	_	_	_	_	Seg=B-seg
55	calling	_	_	_	_	_	_	_	Seg=O
56	for	_	_	_	_	_	_	_	Seg=O
57	quality	_	_	_	_	_	_	_	Seg=O
58	control	_	_	_	_	_	_	_	Seg=O
59	and	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	implementation	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	ring	_	_	_	_	_	_	_	Seg=O
64	trials	_	_	_	_	_	_	_	Seg=O
65	(	_	_	_	_	_	_	_	Seg=O
66	RT	_	_	_	_	_	_	_	Seg=O
67	)	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=B-seg
69	benchmark	_	_	_	_	_	_	_	Seg=O
70	pipelines	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=B-seg
72	ensure	_	_	_	_	_	_	_	Seg=O
73	comparable	_	_	_	_	_	_	_	Seg=O
74	results	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	The	_	_	_	_	_	_	_	Seg=B-seg
77	Swiss	_	_	_	_	_	_	_	Seg=O
78	NGS	_	_	_	_	_	_	_	Seg=O
79	clinical	_	_	_	_	_	_	_	Seg=O
80	virology	_	_	_	_	_	_	_	Seg=O
81	community	_	_	_	_	_	_	_	Seg=O
82	therefore	_	_	_	_	_	_	_	Seg=O
83	decided	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=O
85	conduct	_	_	_	_	_	_	_	Seg=O
86	a	_	_	_	_	_	_	_	Seg=O
87	RT	_	_	_	_	_	_	_	Seg=O
88	in	_	_	_	_	_	_	_	Seg=O
89	2018	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	in	_	_	_	_	_	_	_	Seg=B-seg
92	order	_	_	_	_	_	_	_	Seg=O
93	to	_	_	_	_	_	_	_	Seg=O
94	benchmark	_	_	_	_	_	_	_	Seg=O
95	current	_	_	_	_	_	_	_	Seg=O
96	metagenomic	_	_	_	_	_	_	_	Seg=O
97	workflows	_	_	_	_	_	_	_	Seg=O
98	used	_	_	_	_	_	_	_	Seg=B-seg
99	at	_	_	_	_	_	_	_	Seg=O
100	Swiss	_	_	_	_	_	_	_	Seg=O
101	clinical	_	_	_	_	_	_	_	Seg=O
102	virology	_	_	_	_	_	_	_	Seg=O
103	laboratories	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=B-seg
106	thereby	_	_	_	_	_	_	_	Seg=O
107	contribute	_	_	_	_	_	_	_	Seg=O
108	to	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	definition	_	_	_	_	_	_	_	Seg=O
111	of	_	_	_	_	_	_	_	Seg=O
112	common	_	_	_	_	_	_	_	Seg=O
113	best	_	_	_	_	_	_	_	Seg=O
114	practices	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	The	_	_	_	_	_	_	_	Seg=B-seg
117	RT	_	_	_	_	_	_	_	Seg=O
118	consisted	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	two	_	_	_	_	_	_	_	Seg=O
121	parts	_	_	_	_	_	_	_	Seg=O
122	(	_	_	_	_	_	_	_	Seg=B-seg
123	increments	_	_	_	_	_	_	_	Seg=O
124	)	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	in	_	_	_	_	_	_	_	Seg=B-seg
127	order	_	_	_	_	_	_	_	Seg=O
128	to	_	_	_	_	_	_	_	Seg=O
129	disentangle	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	variability	_	_	_	_	_	_	_	Seg=O
132	arising	_	_	_	_	_	_	_	Seg=B-seg
133	from	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	experimental	_	_	_	_	_	_	_	Seg=O
136	compared	_	_	_	_	_	_	_	Seg=B-seg
137	to	_	_	_	_	_	_	_	Seg=O
138	the	_	_	_	_	_	_	_	Seg=O
139	bioinformatics	_	_	_	_	_	_	_	Seg=O
140	parts	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	laboratory	_	_	_	_	_	_	_	Seg=O
144	pipeline	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	In	_	_	_	_	_	_	_	Seg=B-seg
147	addition	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	the	_	_	_	_	_	_	_	Seg=O
150	RT	_	_	_	_	_	_	_	Seg=O
151	was	_	_	_	_	_	_	_	Seg=O
152	also	_	_	_	_	_	_	_	Seg=O
153	designed	_	_	_	_	_	_	_	Seg=O
154	to	_	_	_	_	_	_	_	Seg=B-seg
155	assess	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	impact	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	databases	_	_	_	_	_	_	_	Seg=O
160	compared	_	_	_	_	_	_	_	Seg=B-seg
161	to	_	_	_	_	_	_	_	Seg=O
162	bioinformatics	_	_	_	_	_	_	_	Seg=O
163	algorithms	_	_	_	_	_	_	_	Seg=O
164	on	_	_	_	_	_	_	_	Seg=O
165	the	_	_	_	_	_	_	_	Seg=O
166	final	_	_	_	_	_	_	_	Seg=O
167	results	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	by	_	_	_	_	_	_	_	Seg=B-seg
170	asking	_	_	_	_	_	_	_	Seg=O
171	participants	_	_	_	_	_	_	_	Seg=O
172	to	_	_	_	_	_	_	_	Seg=O
173	perform	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	bioinformatics	_	_	_	_	_	_	_	Seg=O
176	analysis	_	_	_	_	_	_	_	Seg=O
177	with	_	_	_	_	_	_	_	Seg=O
178	a	_	_	_	_	_	_	_	Seg=O
179	common	_	_	_	_	_	_	_	Seg=O
180	database	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	in	_	_	_	_	_	_	_	Seg=B-seg
183	addition	_	_	_	_	_	_	_	Seg=O
184	to	_	_	_	_	_	_	_	Seg=O
185	using	_	_	_	_	_	_	_	Seg=O
186	their	_	_	_	_	_	_	_	Seg=O
187	own	_	_	_	_	_	_	_	Seg=O
188	in	_	_	_	_	_	_	_	Seg=O
189	-	_	_	_	_	_	_	_	Seg=O
190	house	_	_	_	_	_	_	_	Seg=O
191	database	_	_	_	_	_	_	_	Seg=O
192	.	_	_	_	_	_	_	_	Seg=O
193	Five	_	_	_	_	_	_	_	Seg=B-seg
194	laboratories	_	_	_	_	_	_	_	Seg=O
195	participated	_	_	_	_	_	_	_	Seg=O
196	in	_	_	_	_	_	_	_	Seg=O
197	the	_	_	_	_	_	_	_	Seg=O
198	RT	_	_	_	_	_	_	_	Seg=O
199	(	_	_	_	_	_	_	_	Seg=B-seg
200	seven	_	_	_	_	_	_	_	Seg=O
201	pipelines	_	_	_	_	_	_	_	Seg=O
202	were	_	_	_	_	_	_	_	Seg=O
203	tested	_	_	_	_	_	_	_	Seg=O
204	)	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O
206	We	_	_	_	_	_	_	_	Seg=B-seg
207	observed	_	_	_	_	_	_	_	Seg=O
208	that	_	_	_	_	_	_	_	Seg=B-seg
209	the	_	_	_	_	_	_	_	Seg=O
210	algorithms	_	_	_	_	_	_	_	Seg=O
211	had	_	_	_	_	_	_	_	Seg=O
212	a	_	_	_	_	_	_	_	Seg=O
213	stronger	_	_	_	_	_	_	_	Seg=O
214	impact	_	_	_	_	_	_	_	Seg=O
215	on	_	_	_	_	_	_	_	Seg=O
216	the	_	_	_	_	_	_	_	Seg=O
217	overall	_	_	_	_	_	_	_	Seg=O
218	performance	_	_	_	_	_	_	_	Seg=O
219	than	_	_	_	_	_	_	_	Seg=O
220	the	_	_	_	_	_	_	_	Seg=O
221	choice	_	_	_	_	_	_	_	Seg=O
222	of	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	reference	_	_	_	_	_	_	_	Seg=O
225	database	_	_	_	_	_	_	_	Seg=O
226	.	_	_	_	_	_	_	_	Seg=O
227	Our	_	_	_	_	_	_	_	Seg=B-seg
228	results	_	_	_	_	_	_	_	Seg=O
229	also	_	_	_	_	_	_	_	Seg=O
230	suggest	_	_	_	_	_	_	_	Seg=O
231	that	_	_	_	_	_	_	_	Seg=B-seg
232	differences	_	_	_	_	_	_	_	Seg=O
233	in	_	_	_	_	_	_	_	Seg=O
234	sample	_	_	_	_	_	_	_	Seg=O
235	preparation	_	_	_	_	_	_	_	Seg=O
236	can	_	_	_	_	_	_	_	Seg=O
237	lead	_	_	_	_	_	_	_	Seg=O
238	to	_	_	_	_	_	_	_	Seg=O
239	significant	_	_	_	_	_	_	_	Seg=O
240	differences	_	_	_	_	_	_	_	Seg=O
241	in	_	_	_	_	_	_	_	Seg=O
242	the	_	_	_	_	_	_	_	Seg=O
243	performance	_	_	_	_	_	_	_	Seg=O
244	,	_	_	_	_	_	_	_	Seg=O
245	and	_	_	_	_	_	_	_	Seg=B-seg
246	that	_	_	_	_	_	_	_	Seg=O
247	laboratories	_	_	_	_	_	_	_	Seg=O
248	should	_	_	_	_	_	_	_	Seg=O
249	aim	_	_	_	_	_	_	_	Seg=O
250	for	_	_	_	_	_	_	_	Seg=O
251	at	_	_	_	_	_	_	_	Seg=O
252	least	_	_	_	_	_	_	_	Seg=O
253	5	_	_	_	_	_	_	_	Seg=O
254	-	_	_	_	_	_	_	_	Seg=O
255	10	_	_	_	_	_	_	_	Seg=O
256	Mio	_	_	_	_	_	_	_	Seg=O
257	reads	_	_	_	_	_	_	_	Seg=O
258	per	_	_	_	_	_	_	_	Seg=O
259	sample	_	_	_	_	_	_	_	Seg=O
260	and	_	_	_	_	_	_	_	Seg=B-seg
261	use	_	_	_	_	_	_	_	Seg=O
262	depth	_	_	_	_	_	_	_	Seg=O
263	of	_	_	_	_	_	_	_	Seg=O
264	coverage	_	_	_	_	_	_	_	Seg=O
265	in	_	_	_	_	_	_	_	Seg=O
266	addition	_	_	_	_	_	_	_	Seg=O
267	to	_	_	_	_	_	_	_	Seg=O
268	other	_	_	_	_	_	_	_	Seg=O
269	interpretation	_	_	_	_	_	_	_	Seg=O
270	metrics	_	_	_	_	_	_	_	Seg=O
271	such	_	_	_	_	_	_	_	Seg=B-seg
272	as	_	_	_	_	_	_	_	Seg=O
273	the	_	_	_	_	_	_	_	Seg=O
274	percent	_	_	_	_	_	_	_	Seg=O
275	of	_	_	_	_	_	_	_	Seg=O
276	coverage	_	_	_	_	_	_	_	Seg=O
277	.	_	_	_	_	_	_	_	Seg=O
278	Performance	_	_	_	_	_	_	_	Seg=B-seg
279	was	_	_	_	_	_	_	_	Seg=O
280	generally	_	_	_	_	_	_	_	Seg=O
281	lower	_	_	_	_	_	_	_	Seg=O
282	when	_	_	_	_	_	_	_	Seg=B-seg
283	increasing	_	_	_	_	_	_	_	Seg=O
284	the	_	_	_	_	_	_	_	Seg=O
285	number	_	_	_	_	_	_	_	Seg=O
286	of	_	_	_	_	_	_	_	Seg=O
287	viruses	_	_	_	_	_	_	_	Seg=O
288	per	_	_	_	_	_	_	_	Seg=O
289	sample	_	_	_	_	_	_	_	Seg=O
290	.	_	_	_	_	_	_	_	Seg=O
291	The	_	_	_	_	_	_	_	Seg=B-seg
292	lessons	_	_	_	_	_	_	_	Seg=O
293	learned	_	_	_	_	_	_	_	Seg=B-seg
294	from	_	_	_	_	_	_	_	Seg=O
295	this	_	_	_	_	_	_	_	Seg=O
296	pilot	_	_	_	_	_	_	_	Seg=O
297	study	_	_	_	_	_	_	_	Seg=O
298	will	_	_	_	_	_	_	_	Seg=B-seg
299	be	_	_	_	_	_	_	_	Seg=O
300	useful	_	_	_	_	_	_	_	Seg=O
301	for	_	_	_	_	_	_	_	Seg=O
302	the	_	_	_	_	_	_	_	Seg=O
303	development	_	_	_	_	_	_	_	Seg=O
304	of	_	_	_	_	_	_	_	Seg=O
305	larger	_	_	_	_	_	_	_	Seg=O
306	-	_	_	_	_	_	_	_	Seg=O
307	scale	_	_	_	_	_	_	_	Seg=O
308	RTs	_	_	_	_	_	_	_	Seg=O
309	to	_	_	_	_	_	_	_	Seg=B-seg
310	serve	_	_	_	_	_	_	_	Seg=O
311	as	_	_	_	_	_	_	_	Seg=O
312	regular	_	_	_	_	_	_	_	Seg=O
313	quality	_	_	_	_	_	_	_	Seg=O
314	control	_	_	_	_	_	_	_	Seg=O
315	tests	_	_	_	_	_	_	_	Seg=O
316	for	_	_	_	_	_	_	_	Seg=O
317	laboratories	_	_	_	_	_	_	_	Seg=O
318	performing	_	_	_	_	_	_	_	Seg=B-seg
319	NGS	_	_	_	_	_	_	_	Seg=O
320	analyses	_	_	_	_	_	_	_	Seg=O
321	of	_	_	_	_	_	_	_	Seg=O
322	viruses	_	_	_	_	_	_	_	Seg=O
323	in	_	_	_	_	_	_	_	Seg=O
324	a	_	_	_	_	_	_	_	Seg=O
325	clinical	_	_	_	_	_	_	_	Seg=O
326	setting	_	_	_	_	_	_	_	Seg=O
327	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3f8d61cff42f5714412479237e85de075e817fae
1	Porcine	_	_	_	_	_	_	_	Seg=B-seg
2	β	_	_	_	_	_	_	_	Seg=O
3	-	_	_	_	_	_	_	_	Seg=O
4	defensin	_	_	_	_	_	_	_	Seg=O
5	2	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	PBD-2	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	expressed	_	_	_	_	_	_	_	Seg=B-seg
11	by	_	_	_	_	_	_	_	Seg=O
12	different	_	_	_	_	_	_	_	Seg=O
13	tissues	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	pigs	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	is	_	_	_	_	_	_	_	Seg=B-seg
18	a	_	_	_	_	_	_	_	Seg=O
19	multifunctional	_	_	_	_	_	_	_	Seg=O
20	cationic	_	_	_	_	_	_	_	Seg=O
21	peptide	_	_	_	_	_	_	_	Seg=O
22	with	_	_	_	_	_	_	_	Seg=O
23	antimicrobial	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	immunomodulatory	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	growth	_	_	_	_	_	_	_	Seg=O
28	-	_	_	_	_	_	_	_	Seg=O
29	promoting	_	_	_	_	_	_	_	Seg=O
30	abilities	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	As	_	_	_	_	_	_	_	Seg=B-seg
33	the	_	_	_	_	_	_	_	Seg=O
34	latest	_	_	_	_	_	_	_	Seg=O
35	generation	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	genome	_	_	_	_	_	_	_	Seg=O
38	-	_	_	_	_	_	_	_	Seg=O
39	editing	_	_	_	_	_	_	_	Seg=O
40	tool	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	CRISPR	_	_	_	_	_	_	_	Seg=O
43	/	_	_	_	_	_	_	_	Seg=O
44	Cas9	_	_	_	_	_	_	_	Seg=O
45	system	_	_	_	_	_	_	_	Seg=O
46	makes	_	_	_	_	_	_	_	Seg=O
47	it	_	_	_	_	_	_	_	Seg=O
48	possible	_	_	_	_	_	_	_	Seg=O
49	to	_	_	_	_	_	_	_	Seg=O
50	enhance	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	expression	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	PBD-2	_	_	_	_	_	_	_	Seg=O
55	in	_	_	_	_	_	_	_	Seg=O
56	pigs	_	_	_	_	_	_	_	Seg=O
57	by	_	_	_	_	_	_	_	Seg=O
58	site	_	_	_	_	_	_	_	Seg=O
59	-	_	_	_	_	_	_	_	Seg=O
60	specific	_	_	_	_	_	_	_	Seg=O
61	knock	_	_	_	_	_	_	_	Seg=O
62	-	_	_	_	_	_	_	_	Seg=O
63	in	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	pbd-2	_	_	_	_	_	_	_	Seg=O
66	gene	_	_	_	_	_	_	_	Seg=O
67	into	_	_	_	_	_	_	_	Seg=O
68	the	_	_	_	_	_	_	_	Seg=O
69	pig	_	_	_	_	_	_	_	Seg=O
70	genome	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	In	_	_	_	_	_	_	_	Seg=B-seg
73	this	_	_	_	_	_	_	_	Seg=O
74	study	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	we	_	_	_	_	_	_	_	Seg=O
77	aimed	_	_	_	_	_	_	_	Seg=O
78	to	_	_	_	_	_	_	_	Seg=O
79	generate	_	_	_	_	_	_	_	Seg=O
80	marker	_	_	_	_	_	_	_	Seg=O
81	-	_	_	_	_	_	_	_	Seg=O
82	free	_	_	_	_	_	_	_	Seg=O
83	pbd-2	_	_	_	_	_	_	_	Seg=O
84	knock	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	in	_	_	_	_	_	_	_	Seg=O
87	pigs	_	_	_	_	_	_	_	Seg=O
88	using	_	_	_	_	_	_	_	Seg=B-seg
89	the	_	_	_	_	_	_	_	Seg=O
90	CRISPR	_	_	_	_	_	_	_	Seg=O
91	/	_	_	_	_	_	_	_	Seg=O
92	Cas9	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=O
94	Cre	_	_	_	_	_	_	_	Seg=O
95	/	_	_	_	_	_	_	_	Seg=O
96	loxP	_	_	_	_	_	_	_	Seg=O
97	systems	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	Two	_	_	_	_	_	_	_	Seg=B-seg
100	copies	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	pbd-2	_	_	_	_	_	_	_	Seg=O
103	gene	_	_	_	_	_	_	_	Seg=O
104	linked	_	_	_	_	_	_	_	Seg=B-seg
105	by	_	_	_	_	_	_	_	Seg=O
106	a	_	_	_	_	_	_	_	Seg=O
107	T2A	_	_	_	_	_	_	_	Seg=O
108	sequence	_	_	_	_	_	_	_	Seg=O
109	were	_	_	_	_	_	_	_	Seg=B-seg
110	inserted	_	_	_	_	_	_	_	Seg=O
111	into	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	porcine	_	_	_	_	_	_	_	Seg=O
114	Rosa26	_	_	_	_	_	_	_	Seg=O
115	locus	_	_	_	_	_	_	_	Seg=O
116	through	_	_	_	_	_	_	_	Seg=O
117	CRISPR	_	_	_	_	_	_	_	Seg=O
118	/	_	_	_	_	_	_	_	Seg=O
119	Cas9-mediated	_	_	_	_	_	_	_	Seg=O
120	homology	_	_	_	_	_	_	_	Seg=O
121	-	_	_	_	_	_	_	_	Seg=O
122	directed	_	_	_	_	_	_	_	Seg=O
123	repair	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	The	_	_	_	_	_	_	_	Seg=B-seg
126	floxed	_	_	_	_	_	_	_	Seg=O
127	selectable	_	_	_	_	_	_	_	Seg=O
128	marker	_	_	_	_	_	_	_	Seg=O
129	gene	_	_	_	_	_	_	_	Seg=O
130	neoR	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	used	_	_	_	_	_	_	_	Seg=B-seg
133	for	_	_	_	_	_	_	_	Seg=O
134	G418	_	_	_	_	_	_	_	Seg=O
135	screening	_	_	_	_	_	_	_	Seg=O
136	of	_	_	_	_	_	_	_	Seg=O
137	positive	_	_	_	_	_	_	_	Seg=O
138	cell	_	_	_	_	_	_	_	Seg=O
139	clones	_	_	_	_	_	_	_	Seg=O
140	,	_	_	_	_	_	_	_	Seg=O
141	was	_	_	_	_	_	_	_	Seg=B-seg
142	removed	_	_	_	_	_	_	_	Seg=O
143	by	_	_	_	_	_	_	_	Seg=O
144	cell	_	_	_	_	_	_	_	Seg=O
145	-	_	_	_	_	_	_	_	Seg=O
146	penetrating	_	_	_	_	_	_	_	Seg=O
147	Cre	_	_	_	_	_	_	_	Seg=O
148	recombinase	_	_	_	_	_	_	_	Seg=O
149	with	_	_	_	_	_	_	_	Seg=O
150	a	_	_	_	_	_	_	_	Seg=O
151	recombination	_	_	_	_	_	_	_	Seg=O
152	efficiency	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	48.3	_	_	_	_	_	_	_	Seg=O
155	%	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	Cloned	_	_	_	_	_	_	_	Seg=B-seg
158	piglets	_	_	_	_	_	_	_	Seg=O
159	were	_	_	_	_	_	_	_	Seg=O
160	produced	_	_	_	_	_	_	_	Seg=O
161	via	_	_	_	_	_	_	_	Seg=O
162	somatic	_	_	_	_	_	_	_	Seg=O
163	cell	_	_	_	_	_	_	_	Seg=O
164	nuclear	_	_	_	_	_	_	_	Seg=O
165	transfer	_	_	_	_	_	_	_	Seg=O
166	and	_	_	_	_	_	_	_	Seg=B-seg
167	correct	_	_	_	_	_	_	_	Seg=O
168	insertion	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	pbd-2	_	_	_	_	_	_	_	Seg=O
171	genes	_	_	_	_	_	_	_	Seg=O
172	was	_	_	_	_	_	_	_	Seg=O
173	confirmed	_	_	_	_	_	_	_	Seg=O
174	by	_	_	_	_	_	_	_	Seg=O
175	PCR	_	_	_	_	_	_	_	Seg=O
176	and	_	_	_	_	_	_	_	Seg=O
177	Southern	_	_	_	_	_	_	_	Seg=O
178	blot	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O
180	Immunohistochemistry	_	_	_	_	_	_	_	Seg=B-seg
181	and	_	_	_	_	_	_	_	Seg=O
182	immunofluorescence	_	_	_	_	_	_	_	Seg=O
183	analyses	_	_	_	_	_	_	_	Seg=O
184	indicated	_	_	_	_	_	_	_	Seg=O
185	that	_	_	_	_	_	_	_	Seg=B-seg
186	expression	_	_	_	_	_	_	_	Seg=O
187	levels	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	PBD-2	_	_	_	_	_	_	_	Seg=O
190	in	_	_	_	_	_	_	_	Seg=O
191	different	_	_	_	_	_	_	_	Seg=O
192	tissues	_	_	_	_	_	_	_	Seg=O
193	of	_	_	_	_	_	_	_	Seg=O
194	transgenic	_	_	_	_	_	_	_	Seg=O
195	(	_	_	_	_	_	_	_	Seg=O
196	TG	_	_	_	_	_	_	_	Seg=O
197	)	_	_	_	_	_	_	_	Seg=O
198	piglets	_	_	_	_	_	_	_	Seg=O
199	were	_	_	_	_	_	_	_	Seg=O
200	significantly	_	_	_	_	_	_	_	Seg=O
201	higher	_	_	_	_	_	_	_	Seg=O
202	than	_	_	_	_	_	_	_	Seg=O
203	those	_	_	_	_	_	_	_	Seg=O
204	of	_	_	_	_	_	_	_	Seg=O
205	their	_	_	_	_	_	_	_	Seg=O
206	wild	_	_	_	_	_	_	_	Seg=O
207	-	_	_	_	_	_	_	_	Seg=O
208	type	_	_	_	_	_	_	_	Seg=O
209	(	_	_	_	_	_	_	_	Seg=O
210	WT	_	_	_	_	_	_	_	Seg=O
211	)	_	_	_	_	_	_	_	Seg=O
212	littermates	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O
214	Bactericidal	_	_	_	_	_	_	_	Seg=B-seg
215	assays	_	_	_	_	_	_	_	Seg=O
216	demonstrated	_	_	_	_	_	_	_	Seg=O
217	that	_	_	_	_	_	_	_	Seg=B-seg
218	there	_	_	_	_	_	_	_	Seg=O
219	was	_	_	_	_	_	_	_	Seg=O
220	a	_	_	_	_	_	_	_	Seg=O
221	significant	_	_	_	_	_	_	_	Seg=O
222	increase	_	_	_	_	_	_	_	Seg=O
223	in	_	_	_	_	_	_	_	Seg=O
224	the	_	_	_	_	_	_	_	Seg=O
225	antimicrobial	_	_	_	_	_	_	_	Seg=O
226	properties	_	_	_	_	_	_	_	Seg=O
227	of	_	_	_	_	_	_	_	Seg=O
228	the	_	_	_	_	_	_	_	Seg=O
229	cell	_	_	_	_	_	_	_	Seg=O
230	culture	_	_	_	_	_	_	_	Seg=O
231	supernatants	_	_	_	_	_	_	_	Seg=O
232	of	_	_	_	_	_	_	_	Seg=O
233	porcine	_	_	_	_	_	_	_	Seg=O
234	ear	_	_	_	_	_	_	_	Seg=O
235	fibroblasts	_	_	_	_	_	_	_	Seg=O
236	from	_	_	_	_	_	_	_	Seg=O
237	the	_	_	_	_	_	_	_	Seg=O
238	TG	_	_	_	_	_	_	_	Seg=O
239	pigs	_	_	_	_	_	_	_	Seg=O
240	in	_	_	_	_	_	_	_	Seg=B-seg
241	comparison	_	_	_	_	_	_	_	Seg=O
242	to	_	_	_	_	_	_	_	Seg=O
243	those	_	_	_	_	_	_	_	Seg=O
244	from	_	_	_	_	_	_	_	Seg=O
245	the	_	_	_	_	_	_	_	Seg=O
246	WT	_	_	_	_	_	_	_	Seg=O
247	pigs	_	_	_	_	_	_	_	Seg=O
248	.	_	_	_	_	_	_	_	Seg=O
249	Altogether	_	_	_	_	_	_	_	Seg=B-seg
250	,	_	_	_	_	_	_	_	Seg=O
251	our	_	_	_	_	_	_	_	Seg=O
252	study	_	_	_	_	_	_	_	Seg=O
253	improved	_	_	_	_	_	_	_	Seg=O
254	the	_	_	_	_	_	_	_	Seg=O
255	protein	_	_	_	_	_	_	_	Seg=O
256	expression	_	_	_	_	_	_	_	Seg=O
257	level	_	_	_	_	_	_	_	Seg=O
258	of	_	_	_	_	_	_	_	Seg=O
259	PBD-2	_	_	_	_	_	_	_	Seg=O
260	in	_	_	_	_	_	_	_	Seg=O
261	pigs	_	_	_	_	_	_	_	Seg=O
262	by	_	_	_	_	_	_	_	Seg=O
263	site	_	_	_	_	_	_	_	Seg=O
264	-	_	_	_	_	_	_	_	Seg=O
265	specific	_	_	_	_	_	_	_	Seg=O
266	integration	_	_	_	_	_	_	_	Seg=O
267	of	_	_	_	_	_	_	_	Seg=O
268	pbd-2	_	_	_	_	_	_	_	Seg=O
269	into	_	_	_	_	_	_	_	Seg=O
270	the	_	_	_	_	_	_	_	Seg=O
271	pig	_	_	_	_	_	_	_	Seg=O
272	genome	_	_	_	_	_	_	_	Seg=O
273	,	_	_	_	_	_	_	_	Seg=O
274	which	_	_	_	_	_	_	_	Seg=B-seg
275	not	_	_	_	_	_	_	_	Seg=O
276	only	_	_	_	_	_	_	_	Seg=O
277	provided	_	_	_	_	_	_	_	Seg=O
278	an	_	_	_	_	_	_	_	Seg=O
279	effective	_	_	_	_	_	_	_	Seg=O
280	pig	_	_	_	_	_	_	_	Seg=O
281	model	_	_	_	_	_	_	_	Seg=O
282	to	_	_	_	_	_	_	_	Seg=B-seg
283	study	_	_	_	_	_	_	_	Seg=O
284	the	_	_	_	_	_	_	_	Seg=O
285	anti	_	_	_	_	_	_	_	Seg=O
286	-	_	_	_	_	_	_	_	Seg=O
287	infection	_	_	_	_	_	_	_	Seg=O
288	mechanisms	_	_	_	_	_	_	_	Seg=O
289	of	_	_	_	_	_	_	_	Seg=O
290	PBD-2	_	_	_	_	_	_	_	Seg=O
291	but	_	_	_	_	_	_	_	Seg=B-seg
292	also	_	_	_	_	_	_	_	Seg=O
293	a	_	_	_	_	_	_	_	Seg=O
294	promising	_	_	_	_	_	_	_	Seg=O
295	genetic	_	_	_	_	_	_	_	Seg=O
296	material	_	_	_	_	_	_	_	Seg=O
297	for	_	_	_	_	_	_	_	Seg=O
298	the	_	_	_	_	_	_	_	Seg=O
299	breeding	_	_	_	_	_	_	_	Seg=O
300	of	_	_	_	_	_	_	_	Seg=O
301	disease	_	_	_	_	_	_	_	Seg=O
302	-	_	_	_	_	_	_	_	Seg=O
303	resistant	_	_	_	_	_	_	_	Seg=O
304	pigs	_	_	_	_	_	_	_	Seg=O
305	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 40276a234b15f83ca6f70b4956659025fd7b2ae5
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	HRV	_	_	_	_	_	_	_	Seg=B-seg
4	infections	_	_	_	_	_	_	_	Seg=O
5	are	_	_	_	_	_	_	_	Seg=O
6	generally	_	_	_	_	_	_	_	Seg=O
7	self	_	_	_	_	_	_	_	Seg=O
8	-	_	_	_	_	_	_	_	Seg=O
9	limiting	_	_	_	_	_	_	_	Seg=O
10	in	_	_	_	_	_	_	_	Seg=O
11	healthy	_	_	_	_	_	_	_	Seg=O
12	subjects	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	whereas	_	_	_	_	_	_	_	Seg=B-seg
15	in	_	_	_	_	_	_	_	Seg=O
16	immunocompromised	_	_	_	_	_	_	_	Seg=O
17	hosts	_	_	_	_	_	_	_	Seg=O
18	HRV	_	_	_	_	_	_	_	Seg=O
19	infections	_	_	_	_	_	_	_	Seg=O
20	can	_	_	_	_	_	_	_	Seg=O
21	lead	_	_	_	_	_	_	_	Seg=O
22	to	_	_	_	_	_	_	_	Seg=O
23	severe	_	_	_	_	_	_	_	Seg=O
24	complications	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	persistent	_	_	_	_	_	_	_	Seg=O
27	infections	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	The	_	_	_	_	_	_	_	Seg=B-seg
30	persistence	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	HRV	_	_	_	_	_	_	_	Seg=O
33	shedding	_	_	_	_	_	_	_	Seg=O
34	could	_	_	_	_	_	_	_	Seg=O
35	be	_	_	_	_	_	_	_	Seg=O
36	due	_	_	_	_	_	_	_	Seg=O
37	to	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	inefficient	_	_	_	_	_	_	_	Seg=O
40	immunological	_	_	_	_	_	_	_	Seg=O
41	control	_	_	_	_	_	_	_	Seg=O
42	of	_	_	_	_	_	_	_	Seg=O
43	a	_	_	_	_	_	_	_	Seg=O
44	single	_	_	_	_	_	_	_	Seg=O
45	infectious	_	_	_	_	_	_	_	Seg=O
46	episode	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	Objectives	_	_	_	_	_	_	_	Seg=B-seg
49	:	_	_	_	_	_	_	_	Seg=O
50	To	_	_	_	_	_	_	_	Seg=B-seg
51	investigate	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	clinical	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	virologic	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=O
57	immunologic	_	_	_	_	_	_	_	Seg=O
58	characteristics	_	_	_	_	_	_	_	Seg=O
59	of	_	_	_	_	_	_	_	Seg=O
60	pediatric	_	_	_	_	_	_	_	Seg=O
61	HSCT	_	_	_	_	_	_	_	Seg=O
62	recipients	_	_	_	_	_	_	_	Seg=O
63	with	_	_	_	_	_	_	_	Seg=O
64	HRV	_	_	_	_	_	_	_	Seg=O
65	-	_	_	_	_	_	_	_	Seg=O
66	PI	_	_	_	_	_	_	_	Seg=O
67	infection	_	_	_	_	_	_	_	Seg=O
68	.	_	_	_	_	_	_	_	Seg=O
69	Study	_	_	_	_	_	_	_	Seg=B-seg
70	design	_	_	_	_	_	_	_	Seg=O
71	:	_	_	_	_	_	_	_	Seg=O
72	During	_	_	_	_	_	_	_	Seg=B-seg
73	the	_	_	_	_	_	_	_	Seg=O
74	period	_	_	_	_	_	_	_	Seg=O
75	2006	_	_	_	_	_	_	_	Seg=O
76	-	_	_	_	_	_	_	_	Seg=O
77	2012	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	eight	_	_	_	_	_	_	_	Seg=O
80	hematopoietic	_	_	_	_	_	_	_	Seg=O
81	stem	_	_	_	_	_	_	_	Seg=O
82	cell	_	_	_	_	_	_	_	Seg=O
83	transplant	_	_	_	_	_	_	_	Seg=O
84	(	_	_	_	_	_	_	_	Seg=O
85	HSCT	_	_	_	_	_	_	_	Seg=O
86	)	_	_	_	_	_	_	_	Seg=O
87	recipients	_	_	_	_	_	_	_	Seg=O
88	presented	_	_	_	_	_	_	_	Seg=O
89	with	_	_	_	_	_	_	_	Seg=O
90	persistent	_	_	_	_	_	_	_	Seg=O
91	rhinovirus	_	_	_	_	_	_	_	Seg=O
92	infection	_	_	_	_	_	_	_	Seg=O
93	(	_	_	_	_	_	_	_	Seg=B-seg
94	HRV	_	_	_	_	_	_	_	Seg=O
95	-	_	_	_	_	_	_	_	Seg=O
96	PI	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	≥30	_	_	_	_	_	_	_	Seg=O
99	days	_	_	_	_	_	_	_	Seg=O
100	)	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	Viral	_	_	_	_	_	_	_	Seg=B-seg
103	load	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	T	_	_	_	_	_	_	_	Seg=O
106	-	_	_	_	_	_	_	_	Seg=O
107	CD4	_	_	_	_	_	_	_	Seg=O
108	+	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	T	_	_	_	_	_	_	_	Seg=O
111	-	_	_	_	_	_	_	_	Seg=O
112	CD8	_	_	_	_	_	_	_	Seg=O
113	+	_	_	_	_	_	_	_	Seg=O
114	,	_	_	_	_	_	_	_	Seg=O
115	B	_	_	_	_	_	_	_	Seg=O
116	and	_	_	_	_	_	_	_	Seg=O
117	NK	_	_	_	_	_	_	_	Seg=O
118	lymphocyte	_	_	_	_	_	_	_	Seg=O
119	counts	_	_	_	_	_	_	_	Seg=O
120	at	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	onset	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	infection	_	_	_	_	_	_	_	Seg=O
125	were	_	_	_	_	_	_	_	Seg=O
126	compared	_	_	_	_	_	_	_	Seg=O
127	with	_	_	_	_	_	_	_	Seg=O
128	those	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	fourteen	_	_	_	_	_	_	_	Seg=O
131	HSCT	_	_	_	_	_	_	_	Seg=O
132	recipients	_	_	_	_	_	_	_	Seg=O
133	with	_	_	_	_	_	_	_	Seg=O
134	acute	_	_	_	_	_	_	_	Seg=O
135	HRV	_	_	_	_	_	_	_	Seg=O
136	infection	_	_	_	_	_	_	_	Seg=O
137	(	_	_	_	_	_	_	_	Seg=B-seg
138	HRV	_	_	_	_	_	_	_	Seg=O
139	-	_	_	_	_	_	_	_	Seg=O
140	AI	_	_	_	_	_	_	_	Seg=O
141	,	_	_	_	_	_	_	_	Seg=O
142	≤15	_	_	_	_	_	_	_	Seg=O
143	days	_	_	_	_	_	_	_	Seg=O
144	)	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	Results	_	_	_	_	_	_	_	Seg=B-seg
147	:	_	_	_	_	_	_	_	Seg=O
148	The	_	_	_	_	_	_	_	Seg=B-seg
149	median	_	_	_	_	_	_	_	Seg=O
150	duration	_	_	_	_	_	_	_	Seg=O
151	of	_	_	_	_	_	_	_	Seg=O
152	HRV	_	_	_	_	_	_	_	Seg=O
153	positivity	_	_	_	_	_	_	_	Seg=O
154	in	_	_	_	_	_	_	_	Seg=O
155	patients	_	_	_	_	_	_	_	Seg=O
156	with	_	_	_	_	_	_	_	Seg=O
157	HRV	_	_	_	_	_	_	_	Seg=O
158	-	_	_	_	_	_	_	_	Seg=O
159	PI	_	_	_	_	_	_	_	Seg=O
160	was	_	_	_	_	_	_	_	Seg=O
161	61	_	_	_	_	_	_	_	Seg=O
162	days	_	_	_	_	_	_	_	Seg=O
163	(	_	_	_	_	_	_	_	Seg=B-seg
164	range	_	_	_	_	_	_	_	Seg=O
165	30	_	_	_	_	_	_	_	Seg=O
166	-	_	_	_	_	_	_	_	Seg=O
167	174	_	_	_	_	_	_	_	Seg=O
168	days	_	_	_	_	_	_	_	Seg=O
169	)	_	_	_	_	_	_	_	Seg=O
170	and	_	_	_	_	_	_	_	Seg=B-seg
171	phylogenetic	_	_	_	_	_	_	_	Seg=O
172	analysis	_	_	_	_	_	_	_	Seg=O
173	showed	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	persistence	_	_	_	_	_	_	_	Seg=O
176	of	_	_	_	_	_	_	_	Seg=O
177	a	_	_	_	_	_	_	_	Seg=O
178	single	_	_	_	_	_	_	_	Seg=O
179	HRV	_	_	_	_	_	_	_	Seg=O
180	type	_	_	_	_	_	_	_	Seg=O
181	in	_	_	_	_	_	_	_	Seg=O
182	all	_	_	_	_	_	_	_	Seg=O
183	patients	_	_	_	_	_	_	_	Seg=O
184	(	_	_	_	_	_	_	_	Seg=B-seg
185	100	_	_	_	_	_	_	_	Seg=O
186	%	_	_	_	_	_	_	_	Seg=O
187	)	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O
189	In	_	_	_	_	_	_	_	Seg=B-seg
190	HSCT	_	_	_	_	_	_	_	Seg=O
191	recipients	_	_	_	_	_	_	_	Seg=O
192	with	_	_	_	_	_	_	_	Seg=O
193	HRV	_	_	_	_	_	_	_	Seg=O
194	-	_	_	_	_	_	_	_	Seg=O
195	PI	_	_	_	_	_	_	_	Seg=O
196	,	_	_	_	_	_	_	_	Seg=O
197	T	_	_	_	_	_	_	_	Seg=O
198	-	_	_	_	_	_	_	_	Seg=O
199	CD4	_	_	_	_	_	_	_	Seg=O
200	+	_	_	_	_	_	_	_	Seg=O
201	,	_	_	_	_	_	_	_	Seg=O
202	T	_	_	_	_	_	_	_	Seg=O
203	-	_	_	_	_	_	_	_	Seg=O
204	CD8	_	_	_	_	_	_	_	Seg=O
205	+	_	_	_	_	_	_	_	Seg=O
206	and	_	_	_	_	_	_	_	Seg=O
207	NK	_	_	_	_	_	_	_	Seg=O
208	cell	_	_	_	_	_	_	_	Seg=O
209	counts	_	_	_	_	_	_	_	Seg=O
210	at	_	_	_	_	_	_	_	Seg=O
211	the	_	_	_	_	_	_	_	Seg=O
212	onset	_	_	_	_	_	_	_	Seg=O
213	of	_	_	_	_	_	_	_	Seg=O
214	infection	_	_	_	_	_	_	_	Seg=O
215	were	_	_	_	_	_	_	_	Seg=O
216	significantly	_	_	_	_	_	_	_	Seg=O
217	lower	_	_	_	_	_	_	_	Seg=O
218	than	_	_	_	_	_	_	_	Seg=O
219	those	_	_	_	_	_	_	_	Seg=O
220	observed	_	_	_	_	_	_	_	Seg=B-seg
221	in	_	_	_	_	_	_	_	Seg=O
222	recipients	_	_	_	_	_	_	_	Seg=O
223	with	_	_	_	_	_	_	_	Seg=O
224	HRV	_	_	_	_	_	_	_	Seg=O
225	-	_	_	_	_	_	_	_	Seg=O
226	AI	_	_	_	_	_	_	_	Seg=O
227	(	_	_	_	_	_	_	_	Seg=B-seg
228	p	_	_	_	_	_	_	_	Seg=O
229	<	_	_	_	_	_	_	_	Seg=O
230	0.01	_	_	_	_	_	_	_	Seg=O
231	)	_	_	_	_	_	_	_	Seg=O
232	,	_	_	_	_	_	_	_	Seg=O
233	while	_	_	_	_	_	_	_	Seg=B-seg
234	B	_	_	_	_	_	_	_	Seg=O
235	cell	_	_	_	_	_	_	_	Seg=O
236	counts	_	_	_	_	_	_	_	Seg=O
237	were	_	_	_	_	_	_	_	Seg=O
238	similar	_	_	_	_	_	_	_	Seg=O
239	in	_	_	_	_	_	_	_	Seg=O
240	the	_	_	_	_	_	_	_	Seg=O
241	two	_	_	_	_	_	_	_	Seg=O
242	groups	_	_	_	_	_	_	_	Seg=O
243	(	_	_	_	_	_	_	_	Seg=B-seg
244	p	_	_	_	_	_	_	_	Seg=O
245	=	_	_	_	_	_	_	_	Seg=O
246	0.25	_	_	_	_	_	_	_	Seg=O
247	)	_	_	_	_	_	_	_	Seg=O
248	.	_	_	_	_	_	_	_	Seg=O
249	A	_	_	_	_	_	_	_	Seg=B-seg
250	decrease	_	_	_	_	_	_	_	Seg=O
251	in	_	_	_	_	_	_	_	Seg=O
252	HRV	_	_	_	_	_	_	_	Seg=O
253	load	_	_	_	_	_	_	_	Seg=O
254	was	_	_	_	_	_	_	_	Seg=O
255	associated	_	_	_	_	_	_	_	Seg=O
256	with	_	_	_	_	_	_	_	Seg=O
257	a	_	_	_	_	_	_	_	Seg=O
258	significant	_	_	_	_	_	_	_	Seg=O
259	increase	_	_	_	_	_	_	_	Seg=O
260	in	_	_	_	_	_	_	_	Seg=O
261	T	_	_	_	_	_	_	_	Seg=O
262	-	_	_	_	_	_	_	_	Seg=O
263	CD4	_	_	_	_	_	_	_	Seg=O
264	+	_	_	_	_	_	_	_	Seg=O
265	,	_	_	_	_	_	_	_	Seg=O
266	T	_	_	_	_	_	_	_	Seg=O
267	-	_	_	_	_	_	_	_	Seg=O
268	CD8	_	_	_	_	_	_	_	Seg=O
269	+	_	_	_	_	_	_	_	Seg=O
270	and	_	_	_	_	_	_	_	Seg=O
271	NK	_	_	_	_	_	_	_	Seg=O
272	lymphocyte	_	_	_	_	_	_	_	Seg=O
273	counts	_	_	_	_	_	_	_	Seg=O
274	in	_	_	_	_	_	_	_	Seg=O
275	HRV	_	_	_	_	_	_	_	Seg=O
276	-	_	_	_	_	_	_	_	Seg=O
277	PI	_	_	_	_	_	_	_	Seg=O
278	patients	_	_	_	_	_	_	_	Seg=O
279	(	_	_	_	_	_	_	_	Seg=B-seg
280	p	_	_	_	_	_	_	_	Seg=O
281	<	_	_	_	_	_	_	_	Seg=O
282	0.01	_	_	_	_	_	_	_	Seg=O
283	)	_	_	_	_	_	_	_	Seg=O
284	.	_	_	_	_	_	_	_	Seg=O
285	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
286	:	_	_	_	_	_	_	_	Seg=O
287	This	_	_	_	_	_	_	_	Seg=B-seg
288	study	_	_	_	_	_	_	_	Seg=O
289	suggests	_	_	_	_	_	_	_	Seg=O
290	a	_	_	_	_	_	_	_	Seg=O
291	role	_	_	_	_	_	_	_	Seg=O
292	for	_	_	_	_	_	_	_	Seg=O
293	cellular	_	_	_	_	_	_	_	Seg=O
294	immunity	_	_	_	_	_	_	_	Seg=O
295	in	_	_	_	_	_	_	_	Seg=O
296	HRV	_	_	_	_	_	_	_	Seg=O
297	clearance	_	_	_	_	_	_	_	Seg=O
298	and	_	_	_	_	_	_	_	Seg=B-seg
299	highlights	_	_	_	_	_	_	_	Seg=O
300	the	_	_	_	_	_	_	_	Seg=O
301	importance	_	_	_	_	_	_	_	Seg=O
302	of	_	_	_	_	_	_	_	Seg=O
303	its	_	_	_	_	_	_	_	Seg=O
304	recovery	_	_	_	_	_	_	_	Seg=O
305	for	_	_	_	_	_	_	_	Seg=O
306	the	_	_	_	_	_	_	_	Seg=O
307	control	_	_	_	_	_	_	_	Seg=O
308	of	_	_	_	_	_	_	_	Seg=O
309	HRV	_	_	_	_	_	_	_	Seg=O
310	infection	_	_	_	_	_	_	_	Seg=O
311	in	_	_	_	_	_	_	_	Seg=O
312	HSCT	_	_	_	_	_	_	_	Seg=O
313	recipients	_	_	_	_	_	_	_	Seg=O
314	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 414d4a7cbe08a1904b9b3c2716562f40983f1087
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	COVID-19	_	_	_	_	_	_	_	Seg=O
3	epidemic	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	which	_	_	_	_	_	_	_	Seg=B-seg
6	is	_	_	_	_	_	_	_	Seg=O
7	caused	_	_	_	_	_	_	_	Seg=O
8	by	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	novel	_	_	_	_	_	_	_	Seg=O
11	coronavirus	_	_	_	_	_	_	_	Seg=O
12	SARS	_	_	_	_	_	_	_	Seg=O
13	-	_	_	_	_	_	_	_	Seg=O
14	CoV-2	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	has	_	_	_	_	_	_	_	Seg=B-seg
17	spread	_	_	_	_	_	_	_	Seg=O
18	rapidly	_	_	_	_	_	_	_	Seg=O
19	to	_	_	_	_	_	_	_	Seg=B-seg
20	become	_	_	_	_	_	_	_	Seg=O
21	a	_	_	_	_	_	_	_	Seg=O
22	world	_	_	_	_	_	_	_	Seg=O
23	-	_	_	_	_	_	_	_	Seg=O
24	wide	_	_	_	_	_	_	_	Seg=O
25	pandemic	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	Chest	_	_	_	_	_	_	_	Seg=B-seg
28	radiography	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	chest	_	_	_	_	_	_	_	Seg=O
31	CT	_	_	_	_	_	_	_	Seg=O
32	are	_	_	_	_	_	_	_	Seg=O
33	frequently	_	_	_	_	_	_	_	Seg=O
34	used	_	_	_	_	_	_	_	Seg=O
35	to	_	_	_	_	_	_	_	Seg=B-seg
36	support	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	diagnosis	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	COVID-19	_	_	_	_	_	_	_	Seg=O
41	infection	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	However	_	_	_	_	_	_	_	Seg=B-seg
44	,	_	_	_	_	_	_	_	Seg=O
45	multiple	_	_	_	_	_	_	_	Seg=O
46	cases	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	COVID-19	_	_	_	_	_	_	_	Seg=O
49	transmission	_	_	_	_	_	_	_	Seg=O
50	in	_	_	_	_	_	_	_	Seg=O
51	radiology	_	_	_	_	_	_	_	Seg=O
52	department	_	_	_	_	_	_	_	Seg=O
53	have	_	_	_	_	_	_	_	Seg=O
54	been	_	_	_	_	_	_	_	Seg=O
55	reported	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	Here	_	_	_	_	_	_	_	Seg=B-seg
58	we	_	_	_	_	_	_	_	Seg=O
59	summarize	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	lessons	_	_	_	_	_	_	_	Seg=O
62	we	_	_	_	_	_	_	_	Seg=B-seg
63	learned	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=B-seg
65	provide	_	_	_	_	_	_	_	Seg=O
66	suggestions	_	_	_	_	_	_	_	Seg=O
67	to	_	_	_	_	_	_	_	Seg=B-seg
68	improve	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	infection	_	_	_	_	_	_	_	Seg=O
71	control	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=O
73	prevention	_	_	_	_	_	_	_	Seg=O
74	practices	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	healthcare	_	_	_	_	_	_	_	Seg=O
77	workers	_	_	_	_	_	_	_	Seg=O
78	in	_	_	_	_	_	_	_	Seg=O
79	departments	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=O
81	radiology	_	_	_	_	_	_	_	Seg=O
82	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 422787d1a8391db8a23e809e861e477df0753c99
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	.	_	_	_	_	_	_	_	Seg=O
3	Brazil	_	_	_	_	_	_	_	Seg=B-seg
4	detected	_	_	_	_	_	_	_	Seg=O
5	community	_	_	_	_	_	_	_	Seg=O
6	transmission	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	COVID-19	_	_	_	_	_	_	_	Seg=O
9	on	_	_	_	_	_	_	_	Seg=O
10	March	_	_	_	_	_	_	_	Seg=O
11	13	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	2020	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	In	_	_	_	_	_	_	_	Seg=B-seg
16	this	_	_	_	_	_	_	_	Seg=O
17	study	_	_	_	_	_	_	_	Seg=O
18	we	_	_	_	_	_	_	_	Seg=O
19	identify	_	_	_	_	_	_	_	Seg=O
20	which	_	_	_	_	_	_	_	Seg=O
21	areas	_	_	_	_	_	_	_	Seg=O
22	in	_	_	_	_	_	_	_	Seg=O
23	the	_	_	_	_	_	_	_	Seg=O
24	country	_	_	_	_	_	_	_	Seg=O
25	are	_	_	_	_	_	_	_	Seg=O
26	most	_	_	_	_	_	_	_	Seg=O
27	vulnerable	_	_	_	_	_	_	_	Seg=O
28	for	_	_	_	_	_	_	_	Seg=O
29	COVID-19	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	both	_	_	_	_	_	_	_	Seg=O
32	in	_	_	_	_	_	_	_	Seg=O
33	terms	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	risk	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	arrival	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	COVID-19	_	_	_	_	_	_	_	Seg=O
41	cases	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	risk	_	_	_	_	_	_	_	Seg=O
45	of	_	_	_	_	_	_	_	Seg=O
46	sustained	_	_	_	_	_	_	_	Seg=O
47	transmission	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	The	_	_	_	_	_	_	_	Seg=B-seg
50	micro	_	_	_	_	_	_	_	Seg=O
51	-	_	_	_	_	_	_	_	Seg=O
52	regions	_	_	_	_	_	_	_	Seg=O
53	with	_	_	_	_	_	_	_	Seg=O
54	higher	_	_	_	_	_	_	_	Seg=O
55	social	_	_	_	_	_	_	_	Seg=O
56	vulnerability	_	_	_	_	_	_	_	Seg=O
57	are	_	_	_	_	_	_	_	Seg=O
58	also	_	_	_	_	_	_	_	Seg=O
59	identified	_	_	_	_	_	_	_	Seg=O
60	.	_	_	_	_	_	_	_	Seg=O
61	Methods	_	_	_	_	_	_	_	Seg=B-seg
62	.	_	_	_	_	_	_	_	Seg=O
63	Probabilistic	_	_	_	_	_	_	_	Seg=B-seg
64	models	_	_	_	_	_	_	_	Seg=O
65	were	_	_	_	_	_	_	_	Seg=O
66	used	_	_	_	_	_	_	_	Seg=O
67	to	_	_	_	_	_	_	_	Seg=B-seg
68	calculate	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	probability	_	_	_	_	_	_	_	Seg=O
71	of	_	_	_	_	_	_	_	Seg=O
72	COVID-19	_	_	_	_	_	_	_	Seg=O
73	spread	_	_	_	_	_	_	_	Seg=O
74	from	_	_	_	_	_	_	_	Seg=O
75	São	_	_	_	_	_	_	_	Seg=O
76	Paulo	_	_	_	_	_	_	_	Seg=O
77	and	_	_	_	_	_	_	_	Seg=O
78	Rio	_	_	_	_	_	_	_	Seg=O
79	de	_	_	_	_	_	_	_	Seg=O
80	Janeiro	_	_	_	_	_	_	_	Seg=O
81	,	_	_	_	_	_	_	_	Seg=O
82	according	_	_	_	_	_	_	_	Seg=O
83	to	_	_	_	_	_	_	_	Seg=O
84	previous	_	_	_	_	_	_	_	Seg=O
85	data	_	_	_	_	_	_	_	Seg=O
86	available	_	_	_	_	_	_	_	Seg=O
87	on	_	_	_	_	_	_	_	Seg=O
88	human	_	_	_	_	_	_	_	Seg=O
89	mobility	_	_	_	_	_	_	_	Seg=O
90	in	_	_	_	_	_	_	_	Seg=O
91	Brazil	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	We	_	_	_	_	_	_	_	Seg=B-seg
94	also	_	_	_	_	_	_	_	Seg=O
95	perform	_	_	_	_	_	_	_	Seg=O
96	a	_	_	_	_	_	_	_	Seg=O
97	multivariate	_	_	_	_	_	_	_	Seg=O
98	cluster	_	_	_	_	_	_	_	Seg=O
99	analysis	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	socio	_	_	_	_	_	_	_	Seg=O
102	-	_	_	_	_	_	_	_	Seg=O
103	economic	_	_	_	_	_	_	_	Seg=O
104	indices	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=B-seg
106	identify	_	_	_	_	_	_	_	Seg=O
107	areas	_	_	_	_	_	_	_	Seg=O
108	with	_	_	_	_	_	_	_	Seg=O
109	similar	_	_	_	_	_	_	_	Seg=O
110	social	_	_	_	_	_	_	_	Seg=O
111	vulnerability	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	Results	_	_	_	_	_	_	_	Seg=B-seg
114	.	_	_	_	_	_	_	_	Seg=O
115	The	_	_	_	_	_	_	_	Seg=B-seg
116	results	_	_	_	_	_	_	_	Seg=O
117	consist	_	_	_	_	_	_	_	Seg=O
118	of	_	_	_	_	_	_	_	Seg=O
119	a	_	_	_	_	_	_	_	Seg=O
120	series	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	maps	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	effective	_	_	_	_	_	_	_	Seg=O
125	distance	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	outbreak	_	_	_	_	_	_	_	Seg=O
128	probability	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	hospital	_	_	_	_	_	_	_	Seg=O
131	capacity	_	_	_	_	_	_	_	Seg=O
132	and	_	_	_	_	_	_	_	Seg=O
133	social	_	_	_	_	_	_	_	Seg=O
134	vulnerability	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	They	_	_	_	_	_	_	_	Seg=B-seg
137	show	_	_	_	_	_	_	_	Seg=O
138	areas	_	_	_	_	_	_	_	Seg=O
139	in	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	North	_	_	_	_	_	_	_	Seg=O
142	and	_	_	_	_	_	_	_	Seg=O
143	Northeast	_	_	_	_	_	_	_	Seg=O
144	with	_	_	_	_	_	_	_	Seg=O
145	high	_	_	_	_	_	_	_	Seg=O
146	risk	_	_	_	_	_	_	_	Seg=O
147	of	_	_	_	_	_	_	_	Seg=O
148	COVID-19	_	_	_	_	_	_	_	Seg=O
149	outbreak	_	_	_	_	_	_	_	Seg=O
150	that	_	_	_	_	_	_	_	Seg=B-seg
151	are	_	_	_	_	_	_	_	Seg=O
152	also	_	_	_	_	_	_	_	Seg=O
153	highly	_	_	_	_	_	_	_	Seg=O
154	vulnerable	_	_	_	_	_	_	_	Seg=O
155	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 43568a4ba8221af0f87a1c7d1ddbd2a48eb27e79
1	Objectives	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	this	_	_	_	_	_	_	_	Seg=O
4	study	_	_	_	_	_	_	_	Seg=O
5	were	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=O
7	determine	_	_	_	_	_	_	_	Seg=O
8	prevalence	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	infection	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	feral	_	_	_	_	_	_	_	Seg=O
13	cats	_	_	_	_	_	_	_	Seg=O
14	in	_	_	_	_	_	_	_	Seg=O
15	Northern	_	_	_	_	_	_	_	Seg=O
16	Florida	_	_	_	_	_	_	_	Seg=O
17	with	_	_	_	_	_	_	_	Seg=O
18	a	_	_	_	_	_	_	_	Seg=O
19	select	_	_	_	_	_	_	_	Seg=O
20	group	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	infectious	_	_	_	_	_	_	_	Seg=O
23	organisms	_	_	_	_	_	_	_	Seg=O
24	and	_	_	_	_	_	_	_	Seg=O
25	to	_	_	_	_	_	_	_	Seg=O
26	determine	_	_	_	_	_	_	_	Seg=O
27	risk	_	_	_	_	_	_	_	Seg=O
28	factors	_	_	_	_	_	_	_	Seg=O
29	for	_	_	_	_	_	_	_	Seg=O
30	infection	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	Blood	_	_	_	_	_	_	_	Seg=B-seg
33	samples	_	_	_	_	_	_	_	Seg=O
34	or	_	_	_	_	_	_	_	Seg=O
35	sera	_	_	_	_	_	_	_	Seg=O
36	from	_	_	_	_	_	_	_	Seg=O
37	553	_	_	_	_	_	_	_	Seg=O
38	cats	_	_	_	_	_	_	_	Seg=O
39	were	_	_	_	_	_	_	_	Seg=O
40	tested	_	_	_	_	_	_	_	Seg=O
41	with	_	_	_	_	_	_	_	Seg=O
42	a	_	_	_	_	_	_	_	Seg=O
43	panel	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	antibody	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	antigen	_	_	_	_	_	_	_	Seg=O
48	or	_	_	_	_	_	_	_	Seg=O
49	PCR	_	_	_	_	_	_	_	Seg=O
50	assays	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	Male	_	_	_	_	_	_	_	Seg=B-seg
53	cats	_	_	_	_	_	_	_	Seg=O
54	were	_	_	_	_	_	_	_	Seg=O
55	at	_	_	_	_	_	_	_	Seg=O
56	higher	_	_	_	_	_	_	_	Seg=O
57	risk	_	_	_	_	_	_	_	Seg=O
58	for	_	_	_	_	_	_	_	Seg=O
59	FIV	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	Mycoplasma	_	_	_	_	_	_	_	Seg=O
62	haemofelis	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	M.	_	_	_	_	_	_	_	Seg=O
66	haemominutum	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	Infection	_	_	_	_	_	_	_	Seg=B-seg
69	with	_	_	_	_	_	_	_	Seg=O
70	either	_	_	_	_	_	_	_	Seg=O
71	FeLV	_	_	_	_	_	_	_	Seg=O
72	or	_	_	_	_	_	_	_	Seg=O
73	FIV	_	_	_	_	_	_	_	Seg=O
74	was	_	_	_	_	_	_	_	Seg=O
75	associated	_	_	_	_	_	_	_	Seg=O
76	with	_	_	_	_	_	_	_	Seg=O
77	increased	_	_	_	_	_	_	_	Seg=O
78	risk	_	_	_	_	_	_	_	Seg=O
79	for	_	_	_	_	_	_	_	Seg=O
80	coinfection	_	_	_	_	_	_	_	Seg=O
81	with	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	other	_	_	_	_	_	_	_	Seg=O
84	retrovirus	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	M.	_	_	_	_	_	_	_	Seg=O
87	haemofelis	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	or	_	_	_	_	_	_	_	Seg=O
90	M.	_	_	_	_	_	_	_	Seg=O
91	haemominutum	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	Bartonella	_	_	_	_	_	_	_	Seg=B-seg
94	henselae	_	_	_	_	_	_	_	Seg=O
95	had	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	highest	_	_	_	_	_	_	_	Seg=O
98	prevalence	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=B-seg
100	was	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	only	_	_	_	_	_	_	_	Seg=O
103	organism	_	_	_	_	_	_	_	Seg=O
104	that	_	_	_	_	_	_	_	Seg=B-seg
105	did	_	_	_	_	_	_	_	Seg=O
106	not	_	_	_	_	_	_	_	Seg=O
107	have	_	_	_	_	_	_	_	Seg=O
108	any	_	_	_	_	_	_	_	Seg=O
109	associated	_	_	_	_	_	_	_	Seg=O
110	risk	_	_	_	_	_	_	_	Seg=O
111	for	_	_	_	_	_	_	_	Seg=O
112	coinfection	_	_	_	_	_	_	_	Seg=O
113	with	_	_	_	_	_	_	_	Seg=O
114	other	_	_	_	_	_	_	_	Seg=O
115	organisms	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	Feral	_	_	_	_	_	_	_	Seg=B-seg
118	cats	_	_	_	_	_	_	_	Seg=O
119	in	_	_	_	_	_	_	_	Seg=O
120	this	_	_	_	_	_	_	_	Seg=O
121	study	_	_	_	_	_	_	_	Seg=O
122	had	_	_	_	_	_	_	_	Seg=O
123	similar	_	_	_	_	_	_	_	Seg=O
124	or	_	_	_	_	_	_	_	Seg=O
125	lower	_	_	_	_	_	_	_	Seg=O
126	prevalence	_	_	_	_	_	_	_	Seg=O
127	rates	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	infections	_	_	_	_	_	_	_	Seg=O
130	than	_	_	_	_	_	_	_	Seg=O
131	those	_	_	_	_	_	_	_	Seg=O
132	published	_	_	_	_	_	_	_	Seg=B-seg
133	for	_	_	_	_	_	_	_	Seg=O
134	pet	_	_	_	_	_	_	_	Seg=O
135	cats	_	_	_	_	_	_	_	Seg=O
136	in	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	United	_	_	_	_	_	_	_	Seg=O
139	States	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	Thus	_	_	_	_	_	_	_	Seg=B-seg
142	,	_	_	_	_	_	_	_	Seg=O
143	feral	_	_	_	_	_	_	_	Seg=O
144	cats	_	_	_	_	_	_	_	Seg=O
145	assessed	_	_	_	_	_	_	_	Seg=B-seg
146	in	_	_	_	_	_	_	_	Seg=O
147	this	_	_	_	_	_	_	_	Seg=O
148	study	_	_	_	_	_	_	_	Seg=O
149	appear	_	_	_	_	_	_	_	Seg=B-seg
150	to	_	_	_	_	_	_	_	Seg=O
151	be	_	_	_	_	_	_	_	Seg=O
152	of	_	_	_	_	_	_	_	Seg=O
153	no	_	_	_	_	_	_	_	Seg=O
154	greater	_	_	_	_	_	_	_	Seg=O
155	risk	_	_	_	_	_	_	_	Seg=O
156	to	_	_	_	_	_	_	_	Seg=O
157	human	_	_	_	_	_	_	_	Seg=O
158	beings	_	_	_	_	_	_	_	Seg=O
159	or	_	_	_	_	_	_	_	Seg=O
160	other	_	_	_	_	_	_	_	Seg=O
161	cats	_	_	_	_	_	_	_	Seg=O
162	than	_	_	_	_	_	_	_	Seg=O
163	pet	_	_	_	_	_	_	_	Seg=O
164	cats	_	_	_	_	_	_	_	Seg=O
165	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4467298e39f2e2c43a48135ce26a887ea78b5706
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	ultimate	_	_	_	_	_	_	_	Seg=O
3	goal	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	proteomics	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	to	_	_	_	_	_	_	_	Seg=O
8	identify	_	_	_	_	_	_	_	Seg=O
9	biologically	_	_	_	_	_	_	_	Seg=O
10	active	_	_	_	_	_	_	_	Seg=O
11	proteins	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	to	_	_	_	_	_	_	_	Seg=O
14	produce	_	_	_	_	_	_	_	Seg=O
15	them	_	_	_	_	_	_	_	Seg=O
16	using	_	_	_	_	_	_	_	Seg=B-seg
17	biotechnology	_	_	_	_	_	_	_	Seg=O
18	tools	_	_	_	_	_	_	_	Seg=O
19	such	_	_	_	_	_	_	_	Seg=B-seg
20	as	_	_	_	_	_	_	_	Seg=O
21	bacterial	_	_	_	_	_	_	_	Seg=O
22	hosts	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	However	_	_	_	_	_	_	_	Seg=B-seg
25	,	_	_	_	_	_	_	_	Seg=O
26	proteins	_	_	_	_	_	_	_	Seg=O
27	produced	_	_	_	_	_	_	_	Seg=B-seg
28	by	_	_	_	_	_	_	_	Seg=O
29	Escherichia	_	_	_	_	_	_	_	Seg=O
30	coli	_	_	_	_	_	_	_	Seg=O
31	must	_	_	_	_	_	_	_	Seg=B-seg
32	be	_	_	_	_	_	_	_	Seg=O
33	refolded	_	_	_	_	_	_	_	Seg=O
34	to	_	_	_	_	_	_	_	Seg=O
35	their	_	_	_	_	_	_	_	Seg=O
36	native	_	_	_	_	_	_	_	Seg=O
37	state	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	Protein	_	_	_	_	_	_	_	Seg=B-seg
40	folding	_	_	_	_	_	_	_	Seg=O
41	liquid	_	_	_	_	_	_	_	Seg=O
42	chromatography	_	_	_	_	_	_	_	Seg=O
43	(	_	_	_	_	_	_	_	Seg=O
44	PFLC	_	_	_	_	_	_	_	Seg=O
45	)	_	_	_	_	_	_	_	Seg=O
46	is	_	_	_	_	_	_	_	Seg=O
47	a	_	_	_	_	_	_	_	Seg=O
48	new	_	_	_	_	_	_	_	Seg=O
49	method	_	_	_	_	_	_	_	Seg=O
50	developed	_	_	_	_	_	_	_	Seg=B-seg
51	in	_	_	_	_	_	_	_	Seg=O
52	recent	_	_	_	_	_	_	_	Seg=O
53	years	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=B-seg
56	it	_	_	_	_	_	_	_	Seg=O
57	is	_	_	_	_	_	_	_	Seg=O
58	widely	_	_	_	_	_	_	_	Seg=O
59	used	_	_	_	_	_	_	_	Seg=O
60	in	_	_	_	_	_	_	_	Seg=O
61	molecular	_	_	_	_	_	_	_	Seg=O
62	biology	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	biotechnology	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	In	_	_	_	_	_	_	_	Seg=B-seg
67	this	_	_	_	_	_	_	_	Seg=O
68	paper	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	new	_	_	_	_	_	_	_	Seg=O
72	method	_	_	_	_	_	_	_	Seg=O
73	,	_	_	_	_	_	_	_	Seg=O
74	PFLC	_	_	_	_	_	_	_	Seg=O
75	is	_	_	_	_	_	_	_	Seg=O
76	introduced	_	_	_	_	_	_	_	Seg=O
77	and	_	_	_	_	_	_	_	Seg=B-seg
78	its	_	_	_	_	_	_	_	Seg=O
79	recent	_	_	_	_	_	_	_	Seg=O
80	development	_	_	_	_	_	_	_	Seg=O
81	is	_	_	_	_	_	_	_	Seg=O
82	reviewed	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	In	_	_	_	_	_	_	_	Seg=B-seg
85	addition	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	paper	_	_	_	_	_	_	_	Seg=O
88	includes	_	_	_	_	_	_	_	Seg=O
89	definitions	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	advantages	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	principles	_	_	_	_	_	_	_	Seg=O
94	,	_	_	_	_	_	_	_	Seg=O
95	applications	_	_	_	_	_	_	_	Seg=O
96	for	_	_	_	_	_	_	_	Seg=O
97	both	_	_	_	_	_	_	_	Seg=O
98	laboratory	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=O
100	large	_	_	_	_	_	_	_	Seg=O
101	scales	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	apparatus	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=O
106	effecting	_	_	_	_	_	_	_	Seg=O
107	factors	_	_	_	_	_	_	_	Seg=O
108	of	_	_	_	_	_	_	_	Seg=O
109	PFLC	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	In	_	_	_	_	_	_	_	Seg=B-seg
112	addition	_	_	_	_	_	_	_	Seg=O
113	,	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	role	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	this	_	_	_	_	_	_	_	Seg=O
118	method	_	_	_	_	_	_	_	Seg=O
119	in	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	future	_	_	_	_	_	_	_	Seg=O
122	is	_	_	_	_	_	_	_	Seg=O
123	examined	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 48356622cf00b854864f09f21cacca3c5f444225
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	novel	_	_	_	_	_	_	_	Seg=O
3	coronavirus	_	_	_	_	_	_	_	Seg=O
4	disease-2019	_	_	_	_	_	_	_	Seg=O
5	,	_	_	_	_	_	_	_	Seg=O
6	caused	_	_	_	_	_	_	_	Seg=B-seg
7	by	_	_	_	_	_	_	_	Seg=O
8	severe	_	_	_	_	_	_	_	Seg=O
9	acute	_	_	_	_	_	_	_	Seg=O
10	respiratory	_	_	_	_	_	_	_	Seg=O
11	syndrome	_	_	_	_	_	_	_	Seg=O
12	coronavirus-2	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	has	_	_	_	_	_	_	_	Seg=B-seg
15	spread	_	_	_	_	_	_	_	Seg=O
16	worldwide	_	_	_	_	_	_	_	Seg=O
17	from	_	_	_	_	_	_	_	Seg=O
18	China	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	There	_	_	_	_	_	_	_	Seg=B-seg
21	are	_	_	_	_	_	_	_	Seg=O
22	no	_	_	_	_	_	_	_	Seg=O
23	case	_	_	_	_	_	_	_	Seg=O
24	reports	_	_	_	_	_	_	_	Seg=O
25	from	_	_	_	_	_	_	_	Seg=O
26	Asia	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	COVID-19	_	_	_	_	_	_	_	Seg=O
29	with	_	_	_	_	_	_	_	Seg=O
30	facial	_	_	_	_	_	_	_	Seg=O
31	paralysis	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	olfactory	_	_	_	_	_	_	_	Seg=O
34	disturbance	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	We	_	_	_	_	_	_	_	Seg=B-seg
37	herein	_	_	_	_	_	_	_	Seg=O
38	report	_	_	_	_	_	_	_	Seg=O
39	a	_	_	_	_	_	_	_	Seg=O
40	case	_	_	_	_	_	_	_	Seg=O
41	of	_	_	_	_	_	_	_	Seg=O
42	COVID-19	_	_	_	_	_	_	_	Seg=O
43	pneumonia	_	_	_	_	_	_	_	Seg=O
44	in	_	_	_	_	_	_	_	Seg=O
45	a	_	_	_	_	_	_	_	Seg=O
46	Japanese	_	_	_	_	_	_	_	Seg=O
47	woman	_	_	_	_	_	_	_	Seg=O
48	who	_	_	_	_	_	_	_	Seg=B-seg
49	showed	_	_	_	_	_	_	_	Seg=O
50	facial	_	_	_	_	_	_	_	Seg=O
51	nerve	_	_	_	_	_	_	_	Seg=O
52	palsy	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=O
54	olfactory	_	_	_	_	_	_	_	Seg=O
55	disturbance	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4894e8b3062d3304ef9cc17f72efcea7e66bbe4d
1	Chemical	_	_	_	_	_	_	_	Seg=B-seg
2	denaturant	_	_	_	_	_	_	_	Seg=O
3	sensitivity	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	dimeric	_	_	_	_	_	_	_	Seg=O
7	main	_	_	_	_	_	_	_	Seg=O
8	protease	_	_	_	_	_	_	_	Seg=O
9	from	_	_	_	_	_	_	_	Seg=O
10	severe	_	_	_	_	_	_	_	Seg=O
11	acute	_	_	_	_	_	_	_	Seg=O
12	respiratory	_	_	_	_	_	_	_	Seg=O
13	syndrome	_	_	_	_	_	_	_	Seg=O
14	(	_	_	_	_	_	_	_	Seg=O
15	SARS	_	_	_	_	_	_	_	Seg=O
16	)	_	_	_	_	_	_	_	Seg=O
17	coronavirus	_	_	_	_	_	_	_	Seg=O
18	to	_	_	_	_	_	_	_	Seg=O
19	guanidinium	_	_	_	_	_	_	_	Seg=O
20	chloride	_	_	_	_	_	_	_	Seg=O
21	was	_	_	_	_	_	_	_	Seg=O
22	examined	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	terms	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	fluorescence	_	_	_	_	_	_	_	Seg=O
27	spectroscopy	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	circular	_	_	_	_	_	_	_	Seg=O
30	dichroism	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	analytical	_	_	_	_	_	_	_	Seg=O
33	ultracentrifuge	_	_	_	_	_	_	_	Seg=O
34	,	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	enzyme	_	_	_	_	_	_	_	Seg=O
37	activity	_	_	_	_	_	_	_	Seg=O
38	change	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	The	_	_	_	_	_	_	_	Seg=B-seg
41	dimeric	_	_	_	_	_	_	_	Seg=O
42	enzyme	_	_	_	_	_	_	_	Seg=O
43	dissociated	_	_	_	_	_	_	_	Seg=O
44	at	_	_	_	_	_	_	_	Seg=O
45	guanidinium	_	_	_	_	_	_	_	Seg=O
46	chloride	_	_	_	_	_	_	_	Seg=O
47	concentration	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	0.4	_	_	_	_	_	_	_	Seg=O
51	M	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	at	_	_	_	_	_	_	_	Seg=B-seg
54	which	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	enzymatic	_	_	_	_	_	_	_	Seg=O
57	activity	_	_	_	_	_	_	_	Seg=O
58	loss	_	_	_	_	_	_	_	Seg=O
59	showed	_	_	_	_	_	_	_	Seg=O
60	close	_	_	_	_	_	_	_	Seg=O
61	correlation	_	_	_	_	_	_	_	Seg=O
62	with	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	subunit	_	_	_	_	_	_	_	Seg=O
65	dissociation	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	Further	_	_	_	_	_	_	_	Seg=B-seg
68	increase	_	_	_	_	_	_	_	Seg=O
69	in	_	_	_	_	_	_	_	Seg=O
70	guanidinium	_	_	_	_	_	_	_	Seg=O
71	chloride	_	_	_	_	_	_	_	Seg=O
72	induced	_	_	_	_	_	_	_	Seg=O
73	a	_	_	_	_	_	_	_	Seg=O
74	reversible	_	_	_	_	_	_	_	Seg=O
75	biphasic	_	_	_	_	_	_	_	Seg=O
76	unfolding	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	enzyme	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	The	_	_	_	_	_	_	_	Seg=B-seg
82	unfolding	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	the	_	_	_	_	_	_	_	Seg=O
85	C	_	_	_	_	_	_	_	Seg=O
86	-	_	_	_	_	_	_	_	Seg=O
87	terminal	_	_	_	_	_	_	_	Seg=O
88	domain	_	_	_	_	_	_	_	Seg=O
89	-	_	_	_	_	_	_	_	Seg=O
90	truncated	_	_	_	_	_	_	_	Seg=O
91	enzyme	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	on	_	_	_	_	_	_	_	Seg=O
94	the	_	_	_	_	_	_	_	Seg=O
95	other	_	_	_	_	_	_	_	Seg=O
96	hand	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	followed	_	_	_	_	_	_	_	Seg=O
99	a	_	_	_	_	_	_	_	Seg=O
100	monophasic	_	_	_	_	_	_	_	Seg=O
101	unfolding	_	_	_	_	_	_	_	Seg=O
102	curve	_	_	_	_	_	_	_	Seg=O
103	.	_	_	_	_	_	_	_	Seg=O
104	Different	_	_	_	_	_	_	_	Seg=B-seg
105	mutants	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	full	_	_	_	_	_	_	_	Seg=O
109	-	_	_	_	_	_	_	_	Seg=O
110	length	_	_	_	_	_	_	_	Seg=O
111	protease	_	_	_	_	_	_	_	Seg=O
112	(	_	_	_	_	_	_	_	Seg=B-seg
113	W31	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	W207	_	_	_	_	_	_	_	Seg=O
116	/	_	_	_	_	_	_	_	Seg=O
117	W218	_	_	_	_	_	_	_	Seg=O
118	)	_	_	_	_	_	_	_	Seg=O
119	,	_	_	_	_	_	_	_	Seg=O
120	with	_	_	_	_	_	_	_	Seg=B-seg
121	tryptophanyl	_	_	_	_	_	_	_	Seg=O
122	residue(s	_	_	_	_	_	_	_	Seg=O
123	)	_	_	_	_	_	_	_	Seg=O
124	mutated	_	_	_	_	_	_	_	Seg=B-seg
125	to	_	_	_	_	_	_	_	Seg=O
126	phenylalanine	_	_	_	_	_	_	_	Seg=O
127	at	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	C	_	_	_	_	_	_	_	Seg=O
130	-	_	_	_	_	_	_	_	Seg=O
131	terminal	_	_	_	_	_	_	_	Seg=O
132	or	_	_	_	_	_	_	_	Seg=O
133	N	_	_	_	_	_	_	_	Seg=O
134	-	_	_	_	_	_	_	_	Seg=O
135	terminal	_	_	_	_	_	_	_	Seg=O
136	domain	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	respectively	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	were	_	_	_	_	_	_	_	Seg=B-seg
141	constructed	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	Unfolding	_	_	_	_	_	_	_	Seg=B-seg
144	curves	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	these	_	_	_	_	_	_	_	Seg=O
147	mutants	_	_	_	_	_	_	_	Seg=O
148	were	_	_	_	_	_	_	_	Seg=O
149	monophasic	_	_	_	_	_	_	_	Seg=O
150	but	_	_	_	_	_	_	_	Seg=B-seg
151	corresponded	_	_	_	_	_	_	_	Seg=O
152	to	_	_	_	_	_	_	_	Seg=O
153	the	_	_	_	_	_	_	_	Seg=O
154	first	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=O
156	second	_	_	_	_	_	_	_	Seg=O
157	phases	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	the	_	_	_	_	_	_	_	Seg=O
160	protease	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	respectively	_	_	_	_	_	_	_	Seg=O
163	.	_	_	_	_	_	_	_	Seg=O
164	The	_	_	_	_	_	_	_	Seg=B-seg
165	unfolding	_	_	_	_	_	_	_	Seg=O
166	intermediate	_	_	_	_	_	_	_	Seg=O
167	of	_	_	_	_	_	_	_	Seg=O
168	the	_	_	_	_	_	_	_	Seg=O
169	protease	_	_	_	_	_	_	_	Seg=O
170	thus	_	_	_	_	_	_	_	Seg=O
171	represented	_	_	_	_	_	_	_	Seg=O
172	a	_	_	_	_	_	_	_	Seg=O
173	folded	_	_	_	_	_	_	_	Seg=O
174	C	_	_	_	_	_	_	_	Seg=O
175	-	_	_	_	_	_	_	_	Seg=O
176	terminal	_	_	_	_	_	_	_	Seg=O
177	domain	_	_	_	_	_	_	_	Seg=O
178	but	_	_	_	_	_	_	_	Seg=O
179	an	_	_	_	_	_	_	_	Seg=O
180	unfolded	_	_	_	_	_	_	_	Seg=O
181	N	_	_	_	_	_	_	_	Seg=O
182	-	_	_	_	_	_	_	_	Seg=O
183	terminal	_	_	_	_	_	_	_	Seg=O
184	domain	_	_	_	_	_	_	_	Seg=O
185	,	_	_	_	_	_	_	_	Seg=O
186	which	_	_	_	_	_	_	_	Seg=B-seg
187	is	_	_	_	_	_	_	_	Seg=O
188	enzymatically	_	_	_	_	_	_	_	Seg=O
189	inactive	_	_	_	_	_	_	_	Seg=O
190	due	_	_	_	_	_	_	_	Seg=B-seg
191	to	_	_	_	_	_	_	_	Seg=O
192	loss	_	_	_	_	_	_	_	Seg=O
193	of	_	_	_	_	_	_	_	Seg=O
194	regulatory	_	_	_	_	_	_	_	Seg=O
195	properties	_	_	_	_	_	_	_	Seg=O
196	.	_	_	_	_	_	_	_	Seg=O
197	The	_	_	_	_	_	_	_	Seg=B-seg
198	various	_	_	_	_	_	_	_	Seg=O
199	enzyme	_	_	_	_	_	_	_	Seg=O
200	forms	_	_	_	_	_	_	_	Seg=O
201	were	_	_	_	_	_	_	_	Seg=O
202	characterized	_	_	_	_	_	_	_	Seg=O
203	in	_	_	_	_	_	_	_	Seg=O
204	terms	_	_	_	_	_	_	_	Seg=O
205	of	_	_	_	_	_	_	_	Seg=O
206	hydrophobicity	_	_	_	_	_	_	_	Seg=O
207	and	_	_	_	_	_	_	_	Seg=O
208	size	_	_	_	_	_	_	_	Seg=O
209	-	_	_	_	_	_	_	_	Seg=O
210	and	_	_	_	_	_	_	_	Seg=O
211	-	_	_	_	_	_	_	_	Seg=O
212	shape	_	_	_	_	_	_	_	Seg=O
213	distributions	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O
215	We	_	_	_	_	_	_	_	Seg=B-seg
216	provide	_	_	_	_	_	_	_	Seg=O
217	direct	_	_	_	_	_	_	_	Seg=O
218	evidence	_	_	_	_	_	_	_	Seg=O
219	for	_	_	_	_	_	_	_	Seg=O
220	the	_	_	_	_	_	_	_	Seg=O
221	functional	_	_	_	_	_	_	_	Seg=O
222	role	_	_	_	_	_	_	_	Seg=O
223	of	_	_	_	_	_	_	_	Seg=O
224	C	_	_	_	_	_	_	_	Seg=O
225	-	_	_	_	_	_	_	_	Seg=O
226	terminal	_	_	_	_	_	_	_	Seg=O
227	domain	_	_	_	_	_	_	_	Seg=O
228	in	_	_	_	_	_	_	_	Seg=O
229	stabilization	_	_	_	_	_	_	_	Seg=O
230	of	_	_	_	_	_	_	_	Seg=O
231	the	_	_	_	_	_	_	_	Seg=O
232	catalytic	_	_	_	_	_	_	_	Seg=O
233	N	_	_	_	_	_	_	_	Seg=O
234	-	_	_	_	_	_	_	_	Seg=O
235	terminal	_	_	_	_	_	_	_	Seg=O
236	domain	_	_	_	_	_	_	_	Seg=O
237	of	_	_	_	_	_	_	_	Seg=O
238	SARS	_	_	_	_	_	_	_	Seg=O
239	coronavirus	_	_	_	_	_	_	_	Seg=O
240	main	_	_	_	_	_	_	_	Seg=O
241	protease	_	_	_	_	_	_	_	Seg=O
242	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 492a1c000e859332a6e5d333aef1d74c4147b4e1
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	coronavirus	_	_	_	_	_	_	_	Seg=O
3	disease	_	_	_	_	_	_	_	Seg=O
4	2019	_	_	_	_	_	_	_	Seg=O
5	,	_	_	_	_	_	_	_	Seg=O
6	which	_	_	_	_	_	_	_	Seg=B-seg
7	emerged	_	_	_	_	_	_	_	Seg=O
8	from	_	_	_	_	_	_	_	Seg=O
9	Wuhan	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	China	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	is	_	_	_	_	_	_	_	Seg=B-seg
14	now	_	_	_	_	_	_	_	Seg=O
15	a	_	_	_	_	_	_	_	Seg=O
16	pandemic	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	affecting	_	_	_	_	_	_	_	Seg=B-seg
19	across	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	globe	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	Government	_	_	_	_	_	_	_	Seg=B-seg
24	of	_	_	_	_	_	_	_	Seg=O
25	different	_	_	_	_	_	_	_	Seg=O
26	countries	_	_	_	_	_	_	_	Seg=O
27	have	_	_	_	_	_	_	_	Seg=O
28	developed	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	adopted	_	_	_	_	_	_	_	Seg=O
31	various	_	_	_	_	_	_	_	Seg=O
32	policies	_	_	_	_	_	_	_	Seg=O
33	to	_	_	_	_	_	_	_	Seg=B-seg
34	contain	_	_	_	_	_	_	_	Seg=O
35	this	_	_	_	_	_	_	_	Seg=O
36	epidemic	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=B-seg
38	the	_	_	_	_	_	_	_	Seg=O
39	most	_	_	_	_	_	_	_	Seg=O
40	common	_	_	_	_	_	_	_	Seg=O
41	were	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	social	_	_	_	_	_	_	_	Seg=O
44	distancing	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=O
46	lockdown	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	We	_	_	_	_	_	_	_	Seg=B-seg
49	proposed	_	_	_	_	_	_	_	Seg=O
50	a	_	_	_	_	_	_	_	Seg=O
51	SEIR	_	_	_	_	_	_	_	Seg=O
52	epidemic	_	_	_	_	_	_	_	Seg=O
53	model	_	_	_	_	_	_	_	Seg=O
54	that	_	_	_	_	_	_	_	Seg=B-seg
55	accommodates	_	_	_	_	_	_	_	Seg=O
56	the	_	_	_	_	_	_	_	Seg=O
57	effects	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	lockdown	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=O
61	individual	_	_	_	_	_	_	_	Seg=O
62	based	_	_	_	_	_	_	_	Seg=O
63	precautionary	_	_	_	_	_	_	_	Seg=O
64	measures	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=B-seg
66	used	_	_	_	_	_	_	_	Seg=O
67	it	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=B-seg
69	estimate	_	_	_	_	_	_	_	Seg=O
70	model	_	_	_	_	_	_	_	Seg=O
71	parameters	_	_	_	_	_	_	_	Seg=O
72	from	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	epidemic	_	_	_	_	_	_	_	Seg=O
75	data	_	_	_	_	_	_	_	Seg=O
76	up	_	_	_	_	_	_	_	Seg=O
77	to	_	_	_	_	_	_	_	Seg=O
78	2nd	_	_	_	_	_	_	_	Seg=O
79	April	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	2020	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	freely	_	_	_	_	_	_	_	Seg=B-seg
84	available	_	_	_	_	_	_	_	Seg=O
85	in	_	_	_	_	_	_	_	Seg=O
86	GitHub	_	_	_	_	_	_	_	Seg=O
87	repository	_	_	_	_	_	_	_	Seg=O
88	for	_	_	_	_	_	_	_	Seg=O
89	COVID-19	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	for	_	_	_	_	_	_	_	Seg=O
92	nine	_	_	_	_	_	_	_	Seg=O
93	developed	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=O
95	developing	_	_	_	_	_	_	_	Seg=O
96	countries	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	We	_	_	_	_	_	_	_	Seg=B-seg
99	used	_	_	_	_	_	_	_	Seg=O
100	the	_	_	_	_	_	_	_	Seg=O
101	estimated	_	_	_	_	_	_	_	Seg=O
102	parameters	_	_	_	_	_	_	_	Seg=O
103	to	_	_	_	_	_	_	_	Seg=B-seg
104	predict	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	disease	_	_	_	_	_	_	_	Seg=O
107	burden	_	_	_	_	_	_	_	Seg=O
108	in	_	_	_	_	_	_	_	Seg=O
109	these	_	_	_	_	_	_	_	Seg=O
110	countries	_	_	_	_	_	_	_	Seg=O
111	with	_	_	_	_	_	_	_	Seg=O
112	special	_	_	_	_	_	_	_	Seg=O
113	emphasis	_	_	_	_	_	_	_	Seg=O
114	on	_	_	_	_	_	_	_	Seg=O
115	India	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	Bangladesh	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	Pakistan	_	_	_	_	_	_	_	Seg=O
120	.	_	_	_	_	_	_	_	Seg=O
121	Our	_	_	_	_	_	_	_	Seg=B-seg
122	analysis	_	_	_	_	_	_	_	Seg=O
123	revealed	_	_	_	_	_	_	_	Seg=O
124	that	_	_	_	_	_	_	_	Seg=B-seg
125	the	_	_	_	_	_	_	_	Seg=O
126	lockdown	_	_	_	_	_	_	_	Seg=O
127	and	_	_	_	_	_	_	_	Seg=O
128	recommended	_	_	_	_	_	_	_	Seg=O
129	individual	_	_	_	_	_	_	_	Seg=O
130	hygiene	_	_	_	_	_	_	_	Seg=O
131	can	_	_	_	_	_	_	_	Seg=O
132	slow	_	_	_	_	_	_	_	Seg=O
133	down	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	outbreak	_	_	_	_	_	_	_	Seg=O
136	but	_	_	_	_	_	_	_	Seg=B-seg
137	unable	_	_	_	_	_	_	_	Seg=O
138	to	_	_	_	_	_	_	_	Seg=O
139	eradicate	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	disease	_	_	_	_	_	_	_	Seg=O
142	from	_	_	_	_	_	_	_	Seg=O
143	the	_	_	_	_	_	_	_	Seg=O
144	society	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	With	_	_	_	_	_	_	_	Seg=B-seg
147	the	_	_	_	_	_	_	_	Seg=O
148	current	_	_	_	_	_	_	_	Seg=O
149	human	_	_	_	_	_	_	_	Seg=O
150	-	_	_	_	_	_	_	_	Seg=O
151	to	_	_	_	_	_	_	_	Seg=O
152	-	_	_	_	_	_	_	_	Seg=O
153	human	_	_	_	_	_	_	_	Seg=O
154	transmission	_	_	_	_	_	_	_	Seg=O
155	rate	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	existing	_	_	_	_	_	_	_	Seg=O
158	level	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	personal	_	_	_	_	_	_	_	Seg=O
161	precautionary	_	_	_	_	_	_	_	Seg=O
162	,	_	_	_	_	_	_	_	Seg=O
163	the	_	_	_	_	_	_	_	Seg=B-seg
164	number	_	_	_	_	_	_	_	Seg=O
165	of	_	_	_	_	_	_	_	Seg=O
166	infected	_	_	_	_	_	_	_	Seg=O
167	individuals	_	_	_	_	_	_	_	Seg=O
168	in	_	_	_	_	_	_	_	Seg=O
169	India	_	_	_	_	_	_	_	Seg=O
170	will	_	_	_	_	_	_	_	Seg=O
171	be	_	_	_	_	_	_	_	Seg=O
172	increasing	_	_	_	_	_	_	_	Seg=O
173	at	_	_	_	_	_	_	_	Seg=O
174	least	_	_	_	_	_	_	_	Seg=O
175	for	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	next	_	_	_	_	_	_	_	Seg=O
178	3	_	_	_	_	_	_	_	Seg=O
179	months	_	_	_	_	_	_	_	Seg=O
180	and	_	_	_	_	_	_	_	Seg=B-seg
181	the	_	_	_	_	_	_	_	Seg=O
182	peak	_	_	_	_	_	_	_	Seg=O
183	will	_	_	_	_	_	_	_	Seg=O
184	come	_	_	_	_	_	_	_	Seg=O
185	in	_	_	_	_	_	_	_	Seg=O
186	5	_	_	_	_	_	_	_	Seg=O
187	months	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O
189	We	_	_	_	_	_	_	_	Seg=B-seg
190	can	_	_	_	_	_	_	_	Seg=O
191	,	_	_	_	_	_	_	_	Seg=O
192	however	_	_	_	_	_	_	_	Seg=O
193	,	_	_	_	_	_	_	_	Seg=O
194	reduce	_	_	_	_	_	_	_	Seg=O
195	the	_	_	_	_	_	_	_	Seg=O
196	epidemic	_	_	_	_	_	_	_	Seg=O
197	size	_	_	_	_	_	_	_	Seg=O
198	and	_	_	_	_	_	_	_	Seg=B-seg
199	prolong	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	time	_	_	_	_	_	_	_	Seg=O
202	to	_	_	_	_	_	_	_	Seg=B-seg
203	arrive	_	_	_	_	_	_	_	Seg=O
204	epidemic	_	_	_	_	_	_	_	Seg=O
205	peak	_	_	_	_	_	_	_	Seg=O
206	by	_	_	_	_	_	_	_	Seg=B-seg
207	seriously	_	_	_	_	_	_	_	Seg=O
208	following	_	_	_	_	_	_	_	Seg=O
209	the	_	_	_	_	_	_	_	Seg=O
210	measures	_	_	_	_	_	_	_	Seg=O
211	suggested	_	_	_	_	_	_	_	Seg=B-seg
212	by	_	_	_	_	_	_	_	Seg=O
213	the	_	_	_	_	_	_	_	Seg=O
214	authorities	_	_	_	_	_	_	_	Seg=O
215	.	_	_	_	_	_	_	_	Seg=O
216	We	_	_	_	_	_	_	_	Seg=B-seg
217	need	_	_	_	_	_	_	_	Seg=O
218	to	_	_	_	_	_	_	_	Seg=O
219	wait	_	_	_	_	_	_	_	Seg=O
220	for	_	_	_	_	_	_	_	Seg=O
221	another	_	_	_	_	_	_	_	Seg=O
222	one	_	_	_	_	_	_	_	Seg=O
223	month	_	_	_	_	_	_	_	Seg=O
224	to	_	_	_	_	_	_	_	Seg=B-seg
225	obtain	_	_	_	_	_	_	_	Seg=O
226	more	_	_	_	_	_	_	_	Seg=O
227	data	_	_	_	_	_	_	_	Seg=O
228	and	_	_	_	_	_	_	_	Seg=O
229	epidemiological	_	_	_	_	_	_	_	Seg=O
230	parameters	_	_	_	_	_	_	_	Seg=O
231	for	_	_	_	_	_	_	_	Seg=B-seg
232	giving	_	_	_	_	_	_	_	Seg=O
233	a	_	_	_	_	_	_	_	Seg=O
234	better	_	_	_	_	_	_	_	Seg=O
235	prediction	_	_	_	_	_	_	_	Seg=O
236	about	_	_	_	_	_	_	_	Seg=O
237	the	_	_	_	_	_	_	_	Seg=O
238	pandemic	_	_	_	_	_	_	_	Seg=O
239	.	_	_	_	_	_	_	_	Seg=O
240	It	_	_	_	_	_	_	_	Seg=B-seg
241	is	_	_	_	_	_	_	_	Seg=O
242	to	_	_	_	_	_	_	_	Seg=O
243	be	_	_	_	_	_	_	_	Seg=O
244	mentioned	_	_	_	_	_	_	_	Seg=O
245	that	_	_	_	_	_	_	_	Seg=O
246	research	_	_	_	_	_	_	_	Seg=O
247	community	_	_	_	_	_	_	_	Seg=O
248	is	_	_	_	_	_	_	_	Seg=O
249	working	_	_	_	_	_	_	_	Seg=O
250	for	_	_	_	_	_	_	_	Seg=O
251	drugs	_	_	_	_	_	_	_	Seg=O
252	and/	_	_	_	_	_	_	_	Seg=O
253	or	_	_	_	_	_	_	_	Seg=O
254	vaccines	_	_	_	_	_	_	_	Seg=O
255	against	_	_	_	_	_	_	_	Seg=O
256	COVID19	_	_	_	_	_	_	_	Seg=O
257	and	_	_	_	_	_	_	_	Seg=B-seg
258	the	_	_	_	_	_	_	_	Seg=O
259	presence	_	_	_	_	_	_	_	Seg=O
260	of	_	_	_	_	_	_	_	Seg=O
261	such	_	_	_	_	_	_	_	Seg=O
262	pharmaceutical	_	_	_	_	_	_	_	Seg=O
263	interventions	_	_	_	_	_	_	_	Seg=O
264	will	_	_	_	_	_	_	_	Seg=O
265	significantly	_	_	_	_	_	_	_	Seg=O
266	alter	_	_	_	_	_	_	_	Seg=O
267	the	_	_	_	_	_	_	_	Seg=O
268	results	_	_	_	_	_	_	_	Seg=O
269	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4c76e1e9a4f5afc01accd2dbbd43f0463744e8d2
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	current	_	_	_	_	_	_	_	Seg=O
3	Ebola	_	_	_	_	_	_	_	Seg=O
4	virus	_	_	_	_	_	_	_	Seg=O
5	outbreak	_	_	_	_	_	_	_	Seg=O
6	has	_	_	_	_	_	_	_	Seg=O
7	highlighted	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	uncertainties	_	_	_	_	_	_	_	Seg=O
10	surrounding	_	_	_	_	_	_	_	Seg=B-seg
11	many	_	_	_	_	_	_	_	Seg=O
12	aspects	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	Ebola	_	_	_	_	_	_	_	Seg=O
15	virus	_	_	_	_	_	_	_	Seg=O
16	virology	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	including	_	_	_	_	_	_	_	Seg=B-seg
19	routes	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	transmission	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	The	_	_	_	_	_	_	_	Seg=B-seg
24	scientific	_	_	_	_	_	_	_	Seg=O
25	community	_	_	_	_	_	_	_	Seg=O
26	played	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	leading	_	_	_	_	_	_	_	Seg=O
29	role	_	_	_	_	_	_	_	Seg=O
30	during	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	outbreak	_	_	_	_	_	_	_	Seg=O
33	-	_	_	_	_	_	_	_	Seg=B-seg
34	potentially	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	largest	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	its	_	_	_	_	_	_	_	Seg=O
40	kind	_	_	_	_	_	_	_	Seg=O
41	-	_	_	_	_	_	_	_	Seg=O
42	as	_	_	_	_	_	_	_	Seg=B-seg
43	many	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	questions	_	_	_	_	_	_	_	Seg=O
47	surrounding	_	_	_	_	_	_	_	Seg=B-seg
48	ebolaviruses	_	_	_	_	_	_	_	Seg=O
49	have	_	_	_	_	_	_	_	Seg=B-seg
50	only	_	_	_	_	_	_	_	Seg=O
51	been	_	_	_	_	_	_	_	Seg=O
52	interrogated	_	_	_	_	_	_	_	Seg=O
53	in	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	laboratory	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	Scientists	_	_	_	_	_	_	_	Seg=B-seg
58	provided	_	_	_	_	_	_	_	Seg=O
59	an	_	_	_	_	_	_	_	Seg=O
60	invaluable	_	_	_	_	_	_	_	Seg=O
61	resource	_	_	_	_	_	_	_	Seg=O
62	for	_	_	_	_	_	_	_	Seg=O
63	clinicians	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	public	_	_	_	_	_	_	_	Seg=O
66	health	_	_	_	_	_	_	_	Seg=O
67	officials	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	policy	_	_	_	_	_	_	_	Seg=O
70	makers	_	_	_	_	_	_	_	Seg=O
71	,	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	lay	_	_	_	_	_	_	_	Seg=O
75	public	_	_	_	_	_	_	_	Seg=O
76	in	_	_	_	_	_	_	_	Seg=B-seg
77	understanding	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	progress	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=O
81	Ebola	_	_	_	_	_	_	_	Seg=O
82	virus	_	_	_	_	_	_	_	Seg=O
83	disease	_	_	_	_	_	_	_	Seg=O
84	and	_	_	_	_	_	_	_	Seg=O
85	the	_	_	_	_	_	_	_	Seg=O
86	continuing	_	_	_	_	_	_	_	Seg=O
87	outbreak	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	Not	_	_	_	_	_	_	_	Seg=B-seg
90	all	_	_	_	_	_	_	_	Seg=O
91	of	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	scientific	_	_	_	_	_	_	_	Seg=O
94	communication	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	however	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	was	_	_	_	_	_	_	_	Seg=O
99	accurate	_	_	_	_	_	_	_	Seg=O
100	or	_	_	_	_	_	_	_	Seg=O
101	effective	_	_	_	_	_	_	_	Seg=O
102	.	_	_	_	_	_	_	_	Seg=O
103	There	_	_	_	_	_	_	_	Seg=B-seg
104	were	_	_	_	_	_	_	_	Seg=O
105	multiple	_	_	_	_	_	_	_	Seg=O
106	instances	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	published	_	_	_	_	_	_	_	Seg=O
109	articles	_	_	_	_	_	_	_	Seg=O
110	during	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	height	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	outbreak	_	_	_	_	_	_	_	Seg=O
116	containing	_	_	_	_	_	_	_	Seg=B-seg
117	potentially	_	_	_	_	_	_	_	Seg=O
118	misleading	_	_	_	_	_	_	_	Seg=O
119	scientific	_	_	_	_	_	_	_	Seg=O
120	language	_	_	_	_	_	_	_	Seg=O
121	that	_	_	_	_	_	_	_	Seg=B-seg
122	spurred	_	_	_	_	_	_	_	Seg=O
123	media	_	_	_	_	_	_	_	Seg=O
124	overreaction	_	_	_	_	_	_	_	Seg=O
125	and	_	_	_	_	_	_	_	Seg=B-seg
126	potentially	_	_	_	_	_	_	_	Seg=O
127	jeopardized	_	_	_	_	_	_	_	Seg=O
128	preparedness	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	policy	_	_	_	_	_	_	_	Seg=O
131	decisions	_	_	_	_	_	_	_	Seg=O
132	at	_	_	_	_	_	_	_	Seg=O
133	critical	_	_	_	_	_	_	_	Seg=O
134	points	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	Here	_	_	_	_	_	_	_	Seg=B-seg
137	,	_	_	_	_	_	_	_	Seg=O
138	we	_	_	_	_	_	_	_	Seg=O
139	use	_	_	_	_	_	_	_	Seg=O
140	articles	_	_	_	_	_	_	_	Seg=O
141	declaring	_	_	_	_	_	_	_	Seg=B-seg
142	the	_	_	_	_	_	_	_	Seg=O
143	potential	_	_	_	_	_	_	_	Seg=O
144	for	_	_	_	_	_	_	_	Seg=O
145	airborne	_	_	_	_	_	_	_	Seg=O
146	transmission	_	_	_	_	_	_	_	Seg=O
147	of	_	_	_	_	_	_	_	Seg=O
148	Ebola	_	_	_	_	_	_	_	Seg=O
149	virus	_	_	_	_	_	_	_	Seg=O
150	as	_	_	_	_	_	_	_	Seg=B-seg
151	a	_	_	_	_	_	_	_	Seg=O
152	case	_	_	_	_	_	_	_	Seg=O
153	study	_	_	_	_	_	_	_	Seg=O
154	in	_	_	_	_	_	_	_	Seg=O
155	the	_	_	_	_	_	_	_	Seg=O
156	inaccurate	_	_	_	_	_	_	_	Seg=O
157	reporting	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	basic	_	_	_	_	_	_	_	Seg=O
160	science	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=B-seg
163	we	_	_	_	_	_	_	_	Seg=O
164	provide	_	_	_	_	_	_	_	Seg=O
165	recommendations	_	_	_	_	_	_	_	Seg=O
166	for	_	_	_	_	_	_	_	Seg=B-seg
167	improving	_	_	_	_	_	_	_	Seg=O
168	the	_	_	_	_	_	_	_	Seg=O
169	communication	_	_	_	_	_	_	_	Seg=O
170	about	_	_	_	_	_	_	_	Seg=O
171	unknown	_	_	_	_	_	_	_	Seg=O
172	aspects	_	_	_	_	_	_	_	Seg=O
173	of	_	_	_	_	_	_	_	Seg=O
174	disease	_	_	_	_	_	_	_	Seg=O
175	during	_	_	_	_	_	_	_	Seg=O
176	public	_	_	_	_	_	_	_	Seg=O
177	health	_	_	_	_	_	_	_	Seg=O
178	crises	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O
180	Basic	_	_	_	_	_	_	_	Seg=B-seg
181	scientific	_	_	_	_	_	_	_	Seg=O
182	research	_	_	_	_	_	_	_	Seg=O
183	is	_	_	_	_	_	_	_	Seg=O
184	now	_	_	_	_	_	_	_	Seg=O
185	considered	_	_	_	_	_	_	_	Seg=O
186	an	_	_	_	_	_	_	_	Seg=O
187	integral	_	_	_	_	_	_	_	Seg=O
188	component	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	the	_	_	_	_	_	_	_	Seg=O
191	fight	_	_	_	_	_	_	_	Seg=O
192	against	_	_	_	_	_	_	_	Seg=O
193	emerging	_	_	_	_	_	_	_	Seg=O
194	infectious	_	_	_	_	_	_	_	Seg=O
195	diseases	_	_	_	_	_	_	_	Seg=O
196	like	_	_	_	_	_	_	_	Seg=O
197	Ebola	_	_	_	_	_	_	_	Seg=O
198	virus	_	_	_	_	_	_	_	Seg=O
199	.	_	_	_	_	_	_	_	Seg=O
200	The	_	_	_	_	_	_	_	Seg=B-seg
201	recent	_	_	_	_	_	_	_	Seg=O
202	Ebola	_	_	_	_	_	_	_	Seg=O
203	outbreak	_	_	_	_	_	_	_	Seg=O
204	,	_	_	_	_	_	_	_	Seg=O
205	however	_	_	_	_	_	_	_	Seg=O
206	,	_	_	_	_	_	_	_	Seg=O
207	demonstrates	_	_	_	_	_	_	_	Seg=O
208	how	_	_	_	_	_	_	_	Seg=B-seg
209	the	_	_	_	_	_	_	_	Seg=O
210	ineffective	_	_	_	_	_	_	_	Seg=O
211	communication	_	_	_	_	_	_	_	Seg=O
212	of	_	_	_	_	_	_	_	Seg=O
213	basic	_	_	_	_	_	_	_	Seg=O
214	science	_	_	_	_	_	_	_	Seg=O
215	can	_	_	_	_	_	_	_	Seg=O
216	stoke	_	_	_	_	_	_	_	Seg=O
217	public	_	_	_	_	_	_	_	Seg=O
218	panic	_	_	_	_	_	_	_	Seg=O
219	more	_	_	_	_	_	_	_	Seg=O
220	than	_	_	_	_	_	_	_	Seg=B-seg
221	it	_	_	_	_	_	_	_	Seg=O
222	provides	_	_	_	_	_	_	_	Seg=O
223	helpful	_	_	_	_	_	_	_	Seg=O
224	tools	_	_	_	_	_	_	_	Seg=O
225	to	_	_	_	_	_	_	_	Seg=O
226	responders	_	_	_	_	_	_	_	Seg=O
227	;	_	_	_	_	_	_	_	Seg=O
228	basic	_	_	_	_	_	_	_	Seg=B-seg
229	science	_	_	_	_	_	_	_	Seg=O
230	trades	_	_	_	_	_	_	_	Seg=O
231	in	_	_	_	_	_	_	_	Seg=O
232	probabilities	_	_	_	_	_	_	_	Seg=O
233	and	_	_	_	_	_	_	_	Seg=O
234	uncertainty	_	_	_	_	_	_	_	Seg=O
235	,	_	_	_	_	_	_	_	Seg=O
236	while	_	_	_	_	_	_	_	Seg=B-seg
237	public	_	_	_	_	_	_	_	Seg=O
238	communication	_	_	_	_	_	_	_	Seg=O
239	tends	_	_	_	_	_	_	_	Seg=O
240	to	_	_	_	_	_	_	_	Seg=O
241	favor	_	_	_	_	_	_	_	Seg=O
242	more	_	_	_	_	_	_	_	Seg=O
243	categorical	_	_	_	_	_	_	_	Seg=O
244	claims	_	_	_	_	_	_	_	Seg=O
245	.	_	_	_	_	_	_	_	Seg=O
246	Here	_	_	_	_	_	_	_	Seg=B-seg
247	,	_	_	_	_	_	_	_	Seg=O
248	we	_	_	_	_	_	_	_	Seg=O
249	discuss	_	_	_	_	_	_	_	Seg=O
250	the	_	_	_	_	_	_	_	Seg=O
251	ethics	_	_	_	_	_	_	_	Seg=O
252	of	_	_	_	_	_	_	_	Seg=B-seg
253	communicating	_	_	_	_	_	_	_	Seg=O
254	scientific	_	_	_	_	_	_	_	Seg=O
255	results	_	_	_	_	_	_	_	Seg=O
256	,	_	_	_	_	_	_	_	Seg=O
257	using	_	_	_	_	_	_	_	Seg=B-seg
258	,	_	_	_	_	_	_	_	Seg=O
259	as	_	_	_	_	_	_	_	Seg=O
260	a	_	_	_	_	_	_	_	Seg=O
261	case	_	_	_	_	_	_	_	Seg=O
262	study	_	_	_	_	_	_	_	Seg=O
263	,	_	_	_	_	_	_	_	Seg=O
264	the	_	_	_	_	_	_	_	Seg=O
265	recent	_	_	_	_	_	_	_	Seg=O
266	controversy	_	_	_	_	_	_	_	Seg=O
267	over	_	_	_	_	_	_	_	Seg=B-seg
268	whether	_	_	_	_	_	_	_	Seg=O
269	basic	_	_	_	_	_	_	_	Seg=O
270	life	_	_	_	_	_	_	_	Seg=O
271	sciences	_	_	_	_	_	_	_	Seg=O
272	research	_	_	_	_	_	_	_	Seg=O
273	demonstrates	_	_	_	_	_	_	_	Seg=O
274	that	_	_	_	_	_	_	_	Seg=B-seg
275	Ebola	_	_	_	_	_	_	_	Seg=O
276	could	_	_	_	_	_	_	_	Seg=O
277	become	_	_	_	_	_	_	_	Seg=O
278	transmissible	_	_	_	_	_	_	_	Seg=O
279	via	_	_	_	_	_	_	_	Seg=O
280	airborne	_	_	_	_	_	_	_	Seg=O
281	respiratory	_	_	_	_	_	_	_	Seg=O
282	droplet	_	_	_	_	_	_	_	Seg=O
283	nuclei	_	_	_	_	_	_	_	Seg=O
284	-	_	_	_	_	_	_	_	Seg=B-seg
285	popularly	_	_	_	_	_	_	_	Seg=O
286	known	_	_	_	_	_	_	_	Seg=O
287	as	_	_	_	_	_	_	_	Seg=O
288	a	_	_	_	_	_	_	_	Seg=O
289	virus	_	_	_	_	_	_	_	Seg=O
290	becoming	_	_	_	_	_	_	_	Seg=B-seg
291	"	_	_	_	_	_	_	_	Seg=O
292	airborne	_	_	_	_	_	_	_	Seg=O
293	.	_	_	_	_	_	_	_	Seg=O
294	"	_	_	_	_	_	_	_	Seg=O
295	We	_	_	_	_	_	_	_	Seg=B-seg
296	show	_	_	_	_	_	_	_	Seg=O
297	how	_	_	_	_	_	_	_	Seg=B-seg
298	the	_	_	_	_	_	_	_	Seg=O
299	science	_	_	_	_	_	_	_	Seg=O
300	does	_	_	_	_	_	_	_	Seg=O
301	not	_	_	_	_	_	_	_	Seg=O
302	demonstrate	_	_	_	_	_	_	_	Seg=O
303	this	_	_	_	_	_	_	_	Seg=O
304	possibility	_	_	_	_	_	_	_	Seg=O
305	,	_	_	_	_	_	_	_	Seg=O
306	despite	_	_	_	_	_	_	_	Seg=B-seg
307	claims	_	_	_	_	_	_	_	Seg=O
308	made	_	_	_	_	_	_	_	Seg=B-seg
309	in	_	_	_	_	_	_	_	Seg=O
310	the	_	_	_	_	_	_	_	Seg=O
311	popular	_	_	_	_	_	_	_	Seg=O
312	and	_	_	_	_	_	_	_	Seg=O
313	scientific	_	_	_	_	_	_	_	Seg=O
314	press	_	_	_	_	_	_	_	Seg=O
315	.	_	_	_	_	_	_	_	Seg=O
316	We	_	_	_	_	_	_	_	Seg=B-seg
317	then	_	_	_	_	_	_	_	Seg=O
318	recommend	_	_	_	_	_	_	_	Seg=O
319	that	_	_	_	_	_	_	_	Seg=B-seg
320	uncertain	_	_	_	_	_	_	_	Seg=O
321	scientific	_	_	_	_	_	_	_	Seg=O
322	results	_	_	_	_	_	_	_	Seg=O
323	in	_	_	_	_	_	_	_	Seg=O
324	the	_	_	_	_	_	_	_	Seg=O
325	context	_	_	_	_	_	_	_	Seg=O
326	of	_	_	_	_	_	_	_	Seg=O
327	public	_	_	_	_	_	_	_	Seg=O
328	health	_	_	_	_	_	_	_	Seg=O
329	crises	_	_	_	_	_	_	_	Seg=O
330	ought	_	_	_	_	_	_	_	Seg=O
331	to	_	_	_	_	_	_	_	Seg=O
332	be	_	_	_	_	_	_	_	Seg=O
333	communicated	_	_	_	_	_	_	_	Seg=O
334	with	_	_	_	_	_	_	_	Seg=O
335	humility	_	_	_	_	_	_	_	Seg=O
336	,	_	_	_	_	_	_	_	Seg=O
337	an	_	_	_	_	_	_	_	Seg=O
338	emphasis	_	_	_	_	_	_	_	Seg=O
339	on	_	_	_	_	_	_	_	Seg=O
340	what	_	_	_	_	_	_	_	Seg=O
341	is	_	_	_	_	_	_	_	Seg=O
342	unknown	_	_	_	_	_	_	_	Seg=O
343	,	_	_	_	_	_	_	_	Seg=O
344	and	_	_	_	_	_	_	_	Seg=O
345	a	_	_	_	_	_	_	_	Seg=O
346	clear	_	_	_	_	_	_	_	Seg=O
347	outline	_	_	_	_	_	_	_	Seg=O
348	of	_	_	_	_	_	_	_	Seg=O
349	the	_	_	_	_	_	_	_	Seg=O
350	kinds	_	_	_	_	_	_	_	Seg=O
351	of	_	_	_	_	_	_	_	Seg=O
352	evidence	_	_	_	_	_	_	_	Seg=O
353	that	_	_	_	_	_	_	_	Seg=B-seg
354	would	_	_	_	_	_	_	_	Seg=O
355	give	_	_	_	_	_	_	_	Seg=O
356	proof	_	_	_	_	_	_	_	Seg=O
357	to	_	_	_	_	_	_	_	Seg=O
358	controversial	_	_	_	_	_	_	_	Seg=O
359	claims	_	_	_	_	_	_	_	Seg=O
360	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4cace95b9b4e1f4af324d1fa278274c53c2b00af
1	We	_	_	_	_	_	_	_	Seg=B-seg
2	report	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	design	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	synthesis	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	a	_	_	_	_	_	_	_	Seg=O
9	series	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	dipeptide	_	_	_	_	_	_	_	Seg=O
12	-	_	_	_	_	_	_	_	Seg=O
13	type	_	_	_	_	_	_	_	Seg=O
14	inhibitors	_	_	_	_	_	_	_	Seg=O
15	with	_	_	_	_	_	_	_	Seg=O
16	novel	_	_	_	_	_	_	_	Seg=O
17	P3	_	_	_	_	_	_	_	Seg=O
18	scaffolds	_	_	_	_	_	_	_	Seg=O
19	that	_	_	_	_	_	_	_	Seg=B-seg
20	display	_	_	_	_	_	_	_	Seg=O
21	potent	_	_	_	_	_	_	_	Seg=O
22	inhibitory	_	_	_	_	_	_	_	Seg=O
23	activity	_	_	_	_	_	_	_	Seg=O
24	against	_	_	_	_	_	_	_	Seg=O
25	SARS	_	_	_	_	_	_	_	Seg=O
26	-	_	_	_	_	_	_	_	Seg=O
27	CoV	_	_	_	_	_	_	_	Seg=O
28	3CL	_	_	_	_	_	_	_	Seg=O
29	pro	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	A	_	_	_	_	_	_	_	Seg=B-seg
32	docking	_	_	_	_	_	_	_	Seg=O
33	study	_	_	_	_	_	_	_	Seg=O
34	involving	_	_	_	_	_	_	_	Seg=B-seg
35	binding	_	_	_	_	_	_	_	Seg=O
36	between	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	dipeptidic	_	_	_	_	_	_	_	Seg=O
39	lead	_	_	_	_	_	_	_	Seg=O
40	compound	_	_	_	_	_	_	_	Seg=O
41	4	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=O
43	3CL	_	_	_	_	_	_	_	Seg=O
44	pro	_	_	_	_	_	_	_	Seg=O
45	suggested	_	_	_	_	_	_	_	Seg=B-seg
46	the	_	_	_	_	_	_	_	Seg=O
47	modification	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	a	_	_	_	_	_	_	_	Seg=O
50	structurally	_	_	_	_	_	_	_	Seg=O
51	flexible	_	_	_	_	_	_	_	Seg=O
52	P3	_	_	_	_	_	_	_	Seg=O
53	N-(3methoxyphenyl)glycine	_	_	_	_	_	_	_	Seg=O
54	with	_	_	_	_	_	_	_	Seg=O
55	various	_	_	_	_	_	_	_	Seg=O
56	rigid	_	_	_	_	_	_	_	Seg=O
57	P3	_	_	_	_	_	_	_	Seg=O
58	moieties	_	_	_	_	_	_	_	Seg=O
59	in	_	_	_	_	_	_	_	Seg=O
60	4	_	_	_	_	_	_	_	Seg=O
61	.	_	_	_	_	_	_	_	Seg=O
62	The	_	_	_	_	_	_	_	Seg=B-seg
63	modifications	_	_	_	_	_	_	_	Seg=O
64	led	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=O
66	the	_	_	_	_	_	_	_	Seg=O
67	identification	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	several	_	_	_	_	_	_	_	Seg=O
70	potent	_	_	_	_	_	_	_	Seg=O
71	derivatives	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	including	_	_	_	_	_	_	_	Seg=B-seg
74	5cek	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=O
76	5n	_	_	_	_	_	_	_	Seg=O
77	with	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	inhibitory	_	_	_	_	_	_	_	Seg=O
80	activities	_	_	_	_	_	_	_	Seg=O
81	(	_	_	_	_	_	_	_	Seg=O
82	K	_	_	_	_	_	_	_	Seg=O
83	i	_	_	_	_	_	_	_	Seg=O
84	or	_	_	_	_	_	_	_	Seg=O
85	IC	_	_	_	_	_	_	_	Seg=O
86	50	_	_	_	_	_	_	_	Seg=O
87	)	_	_	_	_	_	_	_	Seg=O
88	in	_	_	_	_	_	_	_	Seg=O
89	the	_	_	_	_	_	_	_	Seg=O
90	submicromolar	_	_	_	_	_	_	_	Seg=O
91	to	_	_	_	_	_	_	_	Seg=O
92	nanomolar	_	_	_	_	_	_	_	Seg=O
93	range	_	_	_	_	_	_	_	Seg=O
94	.	_	_	_	_	_	_	_	Seg=O
95	Compound	_	_	_	_	_	_	_	Seg=B-seg
96	5h	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	in	_	_	_	_	_	_	_	Seg=O
99	particular	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	displayed	_	_	_	_	_	_	_	Seg=O
102	the	_	_	_	_	_	_	_	Seg=O
103	most	_	_	_	_	_	_	_	Seg=O
104	potent	_	_	_	_	_	_	_	Seg=O
105	inhibitory	_	_	_	_	_	_	_	Seg=O
106	activity	_	_	_	_	_	_	_	Seg=O
107	,	_	_	_	_	_	_	_	Seg=O
108	with	_	_	_	_	_	_	_	Seg=O
109	a	_	_	_	_	_	_	_	Seg=O
110	K	_	_	_	_	_	_	_	Seg=O
111	i	_	_	_	_	_	_	_	Seg=O
112	value	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	0.006	_	_	_	_	_	_	_	Seg=O
115	mM.	_	_	_	_	_	_	_	Seg=O
116	This	_	_	_	_	_	_	_	Seg=B-seg
117	potency	_	_	_	_	_	_	_	Seg=O
118	was	_	_	_	_	_	_	_	Seg=O
119	65-fold	_	_	_	_	_	_	_	Seg=O
120	higher	_	_	_	_	_	_	_	Seg=O
121	than	_	_	_	_	_	_	_	Seg=O
122	the	_	_	_	_	_	_	_	Seg=O
123	potency	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	lead	_	_	_	_	_	_	_	Seg=O
127	compound	_	_	_	_	_	_	_	Seg=O
128	4	_	_	_	_	_	_	_	Seg=O
129	(	_	_	_	_	_	_	_	Seg=O
130	K	_	_	_	_	_	_	_	Seg=O
131	i	_	_	_	_	_	_	_	Seg=O
132	¼	_	_	_	_	_	_	_	Seg=O
133	0.39	_	_	_	_	_	_	_	Seg=O
134	mM	_	_	_	_	_	_	_	Seg=O
135	)	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	In	_	_	_	_	_	_	_	Seg=B-seg
138	addition	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	K	_	_	_	_	_	_	_	Seg=O
142	i	_	_	_	_	_	_	_	Seg=O
143	value	_	_	_	_	_	_	_	Seg=O
144	of	_	_	_	_	_	_	_	Seg=O
145	5h	_	_	_	_	_	_	_	Seg=O
146	was	_	_	_	_	_	_	_	Seg=O
147	in	_	_	_	_	_	_	_	Seg=O
148	very	_	_	_	_	_	_	_	Seg=O
149	good	_	_	_	_	_	_	_	Seg=O
150	agreement	_	_	_	_	_	_	_	Seg=O
151	with	_	_	_	_	_	_	_	Seg=O
152	the	_	_	_	_	_	_	_	Seg=O
153	binding	_	_	_	_	_	_	_	Seg=O
154	affinity	_	_	_	_	_	_	_	Seg=O
155	(	_	_	_	_	_	_	_	Seg=O
156	16	_	_	_	_	_	_	_	Seg=O
157	nM	_	_	_	_	_	_	_	Seg=O
158	)	_	_	_	_	_	_	_	Seg=O
159	observed	_	_	_	_	_	_	_	Seg=B-seg
160	in	_	_	_	_	_	_	_	Seg=O
161	isothermal	_	_	_	_	_	_	_	Seg=O
162	titration	_	_	_	_	_	_	_	Seg=O
163	calorimetry	_	_	_	_	_	_	_	Seg=O
164	(	_	_	_	_	_	_	_	Seg=O
165	ITC	_	_	_	_	_	_	_	Seg=O
166	)	_	_	_	_	_	_	_	Seg=O
167	.	_	_	_	_	_	_	_	Seg=O
168	A	_	_	_	_	_	_	_	Seg=B-seg
169	SAR	_	_	_	_	_	_	_	Seg=O
170	study	_	_	_	_	_	_	_	Seg=O
171	around	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	P3	_	_	_	_	_	_	_	Seg=O
174	group	_	_	_	_	_	_	_	Seg=O
175	in	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	lead	_	_	_	_	_	_	_	Seg=O
178	4	_	_	_	_	_	_	_	Seg=O
179	led	_	_	_	_	_	_	_	Seg=O
180	to	_	_	_	_	_	_	_	Seg=O
181	the	_	_	_	_	_	_	_	Seg=O
182	identification	_	_	_	_	_	_	_	Seg=O
183	of	_	_	_	_	_	_	_	Seg=O
184	a	_	_	_	_	_	_	_	Seg=O
185	rigid	_	_	_	_	_	_	_	Seg=O
186	indole-2-carbonyl	_	_	_	_	_	_	_	Seg=O
187	unit	_	_	_	_	_	_	_	Seg=O
188	as	_	_	_	_	_	_	_	Seg=O
189	one	_	_	_	_	_	_	_	Seg=O
190	of	_	_	_	_	_	_	_	Seg=O
191	the	_	_	_	_	_	_	_	Seg=O
192	best	_	_	_	_	_	_	_	Seg=O
193	P3	_	_	_	_	_	_	_	Seg=O
194	moieties	_	_	_	_	_	_	_	Seg=O
195	(	_	_	_	_	_	_	_	Seg=O
196	5c	_	_	_	_	_	_	_	Seg=O
197	)	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	Further	_	_	_	_	_	_	_	Seg=B-seg
200	optimization	_	_	_	_	_	_	_	Seg=O
201	showed	_	_	_	_	_	_	_	Seg=O
202	that	_	_	_	_	_	_	_	Seg=B-seg
203	a	_	_	_	_	_	_	_	Seg=O
204	methoxy	_	_	_	_	_	_	_	Seg=O
205	substitution	_	_	_	_	_	_	_	Seg=O
206	at	_	_	_	_	_	_	_	Seg=O
207	the	_	_	_	_	_	_	_	Seg=O
208	4-position	_	_	_	_	_	_	_	Seg=O
209	on	_	_	_	_	_	_	_	Seg=O
210	the	_	_	_	_	_	_	_	Seg=O
211	indole	_	_	_	_	_	_	_	Seg=O
212	unit	_	_	_	_	_	_	_	Seg=O
213	was	_	_	_	_	_	_	_	Seg=O
214	highly	_	_	_	_	_	_	_	Seg=O
215	favorable	_	_	_	_	_	_	_	Seg=O
216	for	_	_	_	_	_	_	_	Seg=O
217	enhancing	_	_	_	_	_	_	_	Seg=O
218	the	_	_	_	_	_	_	_	Seg=O
219	inhibitory	_	_	_	_	_	_	_	Seg=O
220	potency	_	_	_	_	_	_	_	Seg=O
221	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4d2366b0ee4d6b5ec8c8b7376e7b343fa15e0ff8
1	Until	_	_	_	_	_	_	_	Seg=B-seg
2	recently	_	_	_	_	_	_	_	Seg=O
3	,	_	_	_	_	_	_	_	Seg=O
4	conventional	_	_	_	_	_	_	_	Seg=O
5	culture	_	_	_	_	_	_	_	Seg=O
6	techniques	_	_	_	_	_	_	_	Seg=O
7	and	_	_	_	_	_	_	_	Seg=O
8	immunofluorecence	_	_	_	_	_	_	_	Seg=O
9	assays	_	_	_	_	_	_	_	Seg=O
10	were	_	_	_	_	_	_	_	Seg=O
11	considered	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	gold	_	_	_	_	_	_	_	Seg=O
14	standard	_	_	_	_	_	_	_	Seg=O
15	for	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	detection	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	respiratory	_	_	_	_	_	_	_	Seg=O
20	viruses	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	even	_	_	_	_	_	_	_	Seg=B-seg
23	though	_	_	_	_	_	_	_	Seg=O
24	results	_	_	_	_	_	_	_	Seg=O
25	are	_	_	_	_	_	_	_	Seg=O
26	mostly	_	_	_	_	_	_	_	Seg=O
27	available	_	_	_	_	_	_	_	Seg=O
28	too	_	_	_	_	_	_	_	Seg=O
29	late	_	_	_	_	_	_	_	Seg=O
30	or	_	_	_	_	_	_	_	Seg=B-seg
31	lacked	_	_	_	_	_	_	_	Seg=O
32	specificity	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	sensitivity	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	These	_	_	_	_	_	_	_	Seg=B-seg
37	methods	_	_	_	_	_	_	_	Seg=O
38	are	_	_	_	_	_	_	_	Seg=O
39	now	_	_	_	_	_	_	_	Seg=O
40	widely	_	_	_	_	_	_	_	Seg=O
41	replaced	_	_	_	_	_	_	_	Seg=O
42	with	_	_	_	_	_	_	_	Seg=O
43	appropriate	_	_	_	_	_	_	_	Seg=O
44	DNA	_	_	_	_	_	_	_	Seg=O
45	-	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=O
47	RNA	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=O
49	based	_	_	_	_	_	_	_	Seg=O
50	amplification	_	_	_	_	_	_	_	Seg=O
51	techniques	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	in	_	_	_	_	_	_	_	Seg=O
54	particular	_	_	_	_	_	_	_	Seg=O
55	real	_	_	_	_	_	_	_	Seg=O
56	time	_	_	_	_	_	_	_	Seg=O
57	PCR	_	_	_	_	_	_	_	Seg=O
58	amplification	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	for	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	detection	_	_	_	_	_	_	_	Seg=O
63	of	_	_	_	_	_	_	_	Seg=O
64	an	_	_	_	_	_	_	_	Seg=O
65	extended	_	_	_	_	_	_	_	Seg=O
66	number	_	_	_	_	_	_	_	Seg=O
67	of	_	_	_	_	_	_	_	Seg=O
68	agents	_	_	_	_	_	_	_	Seg=O
69	responsible	_	_	_	_	_	_	_	Seg=O
70	for	_	_	_	_	_	_	_	Seg=O
71	acute	_	_	_	_	_	_	_	Seg=O
72	respiratory	_	_	_	_	_	_	_	Seg=O
73	infections	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	Real	_	_	_	_	_	_	_	Seg=B-seg
76	-	_	_	_	_	_	_	_	Seg=O
77	time	_	_	_	_	_	_	_	Seg=O
78	PCR	_	_	_	_	_	_	_	Seg=O
79	offers	_	_	_	_	_	_	_	Seg=O
80	rapid	_	_	_	_	_	_	_	Seg=O
81	results	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	efficiencies	_	_	_	_	_	_	_	Seg=O
84	in	_	_	_	_	_	_	_	Seg=O
85	work	_	_	_	_	_	_	_	Seg=O
86	flow	_	_	_	_	_	_	_	Seg=O
87	and	_	_	_	_	_	_	_	Seg=O
88	a	_	_	_	_	_	_	_	Seg=O
89	reduced	_	_	_	_	_	_	_	Seg=O
90	risk	_	_	_	_	_	_	_	Seg=O
91	of	_	_	_	_	_	_	_	Seg=O
92	false	_	_	_	_	_	_	_	Seg=O
93	positive	_	_	_	_	_	_	_	Seg=O
94	results	_	_	_	_	_	_	_	Seg=O
95	due	_	_	_	_	_	_	_	Seg=B-seg
96	to	_	_	_	_	_	_	_	Seg=O
97	contamination	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	As	_	_	_	_	_	_	_	Seg=B-seg
100	a	_	_	_	_	_	_	_	Seg=O
101	result	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	better	_	_	_	_	_	_	_	Seg=O
104	patient	_	_	_	_	_	_	_	Seg=O
105	management	_	_	_	_	_	_	_	Seg=O
106	or	_	_	_	_	_	_	_	Seg=O
107	reduction	_	_	_	_	_	_	_	Seg=O
108	of	_	_	_	_	_	_	_	Seg=O
109	unnecessary	_	_	_	_	_	_	_	Seg=O
110	antibiotic	_	_	_	_	_	_	_	Seg=O
111	administration	_	_	_	_	_	_	_	Seg=O
112	will	_	_	_	_	_	_	_	Seg=O
113	be	_	_	_	_	_	_	_	Seg=O
114	possible	_	_	_	_	_	_	_	Seg=O
115	leading	_	_	_	_	_	_	_	Seg=B-seg
116	to	_	_	_	_	_	_	_	Seg=O
117	enhanced	_	_	_	_	_	_	_	Seg=O
118	efficiencies	_	_	_	_	_	_	_	Seg=O
119	in	_	_	_	_	_	_	_	Seg=O
120	health	_	_	_	_	_	_	_	Seg=O
121	care	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	In	_	_	_	_	_	_	_	Seg=B-seg
124	applying	_	_	_	_	_	_	_	Seg=O
125	molecular	_	_	_	_	_	_	_	Seg=O
126	methods	_	_	_	_	_	_	_	Seg=O
127	to	_	_	_	_	_	_	_	Seg=O
128	diagnostic	_	_	_	_	_	_	_	Seg=O
129	use	_	_	_	_	_	_	_	Seg=O
130	,	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=B-seg
132	laboratory	_	_	_	_	_	_	_	Seg=O
133	can	_	_	_	_	_	_	_	Seg=O
134	optimise	_	_	_	_	_	_	_	Seg=O
135	its	_	_	_	_	_	_	_	Seg=O
136	diagnostic	_	_	_	_	_	_	_	Seg=O
137	strategy	_	_	_	_	_	_	_	Seg=O
138	by	_	_	_	_	_	_	_	Seg=B-seg
139	applying	_	_	_	_	_	_	_	Seg=O
140	a	_	_	_	_	_	_	_	Seg=O
141	combination	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	real	_	_	_	_	_	_	_	Seg=O
144	-	_	_	_	_	_	_	_	Seg=O
145	time	_	_	_	_	_	_	_	Seg=O
146	amplification	_	_	_	_	_	_	_	Seg=O
147	tests	_	_	_	_	_	_	_	Seg=O
148	for	_	_	_	_	_	_	_	Seg=O
149	respiratory	_	_	_	_	_	_	_	Seg=O
150	viruses	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=O
152	the	_	_	_	_	_	_	_	Seg=O
153	non	_	_	_	_	_	_	_	Seg=O
154	-	_	_	_	_	_	_	_	Seg=O
155	viral	_	_	_	_	_	_	_	Seg=O
156	respiratory	_	_	_	_	_	_	_	Seg=O
157	bacterial	_	_	_	_	_	_	_	Seg=O
158	pathogens	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O
160	However	_	_	_	_	_	_	_	Seg=B-seg
161	this	_	_	_	_	_	_	_	Seg=O
162	must	_	_	_	_	_	_	_	Seg=O
163	be	_	_	_	_	_	_	_	Seg=O
164	done	_	_	_	_	_	_	_	Seg=O
165	within	_	_	_	_	_	_	_	Seg=O
166	a	_	_	_	_	_	_	_	Seg=O
167	context	_	_	_	_	_	_	_	Seg=O
168	of	_	_	_	_	_	_	_	Seg=O
169	resource	_	_	_	_	_	_	_	Seg=O
170	availability	_	_	_	_	_	_	_	Seg=O
171	,	_	_	_	_	_	_	_	Seg=O
172	technical	_	_	_	_	_	_	_	Seg=O
173	expertise	_	_	_	_	_	_	_	Seg=O
174	available	_	_	_	_	_	_	_	Seg=O
175	and	_	_	_	_	_	_	_	Seg=O
176	clinical	_	_	_	_	_	_	_	Seg=O
177	utility	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O
179	It	_	_	_	_	_	_	_	Seg=B-seg
180	seems	_	_	_	_	_	_	_	Seg=O
181	certain	_	_	_	_	_	_	_	Seg=O
182	that	_	_	_	_	_	_	_	Seg=O
183	molecular	_	_	_	_	_	_	_	Seg=O
184	microbiology	_	_	_	_	_	_	_	Seg=O
185	will	_	_	_	_	_	_	_	Seg=O
186	continue	_	_	_	_	_	_	_	Seg=O
187	to	_	_	_	_	_	_	_	Seg=O
188	develop	_	_	_	_	_	_	_	Seg=O
189	,	_	_	_	_	_	_	_	Seg=O
190	leading	_	_	_	_	_	_	_	Seg=B-seg
191	to	_	_	_	_	_	_	_	Seg=O
192	further	_	_	_	_	_	_	_	Seg=O
193	applications	_	_	_	_	_	_	_	Seg=O
194	in	_	_	_	_	_	_	_	Seg=O
195	diagnostic	_	_	_	_	_	_	_	Seg=O
196	technology	_	_	_	_	_	_	_	Seg=O
197	,	_	_	_	_	_	_	_	Seg=O
198	thereby	_	_	_	_	_	_	_	Seg=B-seg
199	improving	_	_	_	_	_	_	_	Seg=O
200	our	_	_	_	_	_	_	_	Seg=O
201	understanding	_	_	_	_	_	_	_	Seg=O
202	of	_	_	_	_	_	_	_	Seg=O
203	disease	_	_	_	_	_	_	_	Seg=O
204	processes	_	_	_	_	_	_	_	Seg=O
205	and	_	_	_	_	_	_	_	Seg=B-seg
206	enhancing	_	_	_	_	_	_	_	Seg=O
207	our	_	_	_	_	_	_	_	Seg=O
208	knowledge	_	_	_	_	_	_	_	Seg=O
209	of	_	_	_	_	_	_	_	Seg=O
210	the	_	_	_	_	_	_	_	Seg=O
211	pathogens	_	_	_	_	_	_	_	Seg=O
212	responsible	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 50cde1e9f6887bf2ef3e41f30b17011e4e58aba8
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	order	_	_	_	_	_	_	_	Seg=O
3	to	_	_	_	_	_	_	_	Seg=O
4	survey	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	infectious	_	_	_	_	_	_	_	Seg=O
7	situation	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	canine	_	_	_	_	_	_	_	Seg=O
10	coronavirus	_	_	_	_	_	_	_	Seg=O
11	(	_	_	_	_	_	_	_	Seg=O
12	CCV	_	_	_	_	_	_	_	Seg=O
13	)	_	_	_	_	_	_	_	Seg=O
14	in	_	_	_	_	_	_	_	Seg=O
15	giant	_	_	_	_	_	_	_	Seg=O
16	panda	_	_	_	_	_	_	_	Seg=O
17	population	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	a	_	_	_	_	_	_	_	Seg=B-seg
20	virus	_	_	_	_	_	_	_	Seg=O
21	neutralization	_	_	_	_	_	_	_	Seg=O
22	test	_	_	_	_	_	_	_	Seg=O
23	detecting	_	_	_	_	_	_	_	Seg=B-seg
24	specific	_	_	_	_	_	_	_	Seg=O
25	antibodies	_	_	_	_	_	_	_	Seg=O
26	against	_	_	_	_	_	_	_	Seg=O
27	CCV	_	_	_	_	_	_	_	Seg=O
28	in	_	_	_	_	_	_	_	Seg=O
29	giant	_	_	_	_	_	_	_	Seg=O
30-31	panda's	_	_	_	_	_	_	_	_
30	panda	_	_	_	_	_	_	_	Seg=O
31	's	_	_	_	_	_	_	_	Seg=O
32	sera	_	_	_	_	_	_	_	Seg=O
33	was	_	_	_	_	_	_	_	Seg=B-seg
34	established	_	_	_	_	_	_	_	Seg=O
35	by	_	_	_	_	_	_	_	Seg=B-seg
36	using	_	_	_	_	_	_	_	Seg=O
37	two	_	_	_	_	_	_	_	Seg=O
38	-	_	_	_	_	_	_	_	Seg=O
39	fold	_	_	_	_	_	_	_	Seg=O
40	dilutions	_	_	_	_	_	_	_	Seg=O
41	of	_	_	_	_	_	_	_	Seg=O
42	serum	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	100	_	_	_	_	_	_	_	Seg=O
45	TCIDso	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	virus	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	The	_	_	_	_	_	_	_	Seg=B-seg
51	62	_	_	_	_	_	_	_	Seg=O
52	sera	_	_	_	_	_	_	_	Seg=O
53	samples	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	giant	_	_	_	_	_	_	_	Seg=O
56	pandas	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	which	_	_	_	_	_	_	_	Seg=B-seg
59	were	_	_	_	_	_	_	_	Seg=O
60	gathered	_	_	_	_	_	_	_	Seg=O
61	from	_	_	_	_	_	_	_	Seg=O
62	zoos	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	reserve	_	_	_	_	_	_	_	Seg=O
65	region	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	Sichuan	_	_	_	_	_	_	_	Seg=O
68	Province	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	China	_	_	_	_	_	_	_	Seg=O
71	were	_	_	_	_	_	_	_	Seg=B-seg
72	detected	_	_	_	_	_	_	_	Seg=O
73	.	_	_	_	_	_	_	_	Seg=O
74	The	_	_	_	_	_	_	_	Seg=B-seg
75	neutralization	_	_	_	_	_	_	_	Seg=O
76	antibody	_	_	_	_	_	_	_	Seg=O
77	titer	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	1:4	_	_	_	_	_	_	_	Seg=O
80	was	_	_	_	_	_	_	_	Seg=O
81	recognized	_	_	_	_	_	_	_	Seg=O
82	as	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	positive	_	_	_	_	_	_	_	Seg=O
85	criterion	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	8	_	_	_	_	_	_	_	Seg=B-seg
88	sera	_	_	_	_	_	_	_	Seg=O
89	samples	_	_	_	_	_	_	_	Seg=O
90	were	_	_	_	_	_	_	_	Seg=O
91	detected	_	_	_	_	_	_	_	Seg=O
92	to	_	_	_	_	_	_	_	Seg=O
93	be	_	_	_	_	_	_	_	Seg=O
94	positive	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	and	_	_	_	_	_	_	_	Seg=B-seg
97	the	_	_	_	_	_	_	_	Seg=O
98	positive	_	_	_	_	_	_	_	Seg=O
99	rate	_	_	_	_	_	_	_	Seg=O
100	was	_	_	_	_	_	_	_	Seg=O
101	12.9	_	_	_	_	_	_	_	Seg=O
102	%	_	_	_	_	_	_	_	Seg=O
103	.	_	_	_	_	_	_	_	Seg=O
104	The	_	_	_	_	_	_	_	Seg=B-seg
105	titers	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	neutralizing	_	_	_	_	_	_	_	Seg=O
108	antibody	_	_	_	_	_	_	_	Seg=O
109	ranged	_	_	_	_	_	_	_	Seg=O
110	from	_	_	_	_	_	_	_	Seg=O
111	1:8	_	_	_	_	_	_	_	Seg=O
112	to	_	_	_	_	_	_	_	Seg=O
113	1:32	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	It	_	_	_	_	_	_	_	Seg=B-seg
116	was	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	first	_	_	_	_	_	_	_	Seg=O
119	comprehensive	_	_	_	_	_	_	_	Seg=O
120	investigation	_	_	_	_	_	_	_	Seg=O
121	on	_	_	_	_	_	_	_	Seg=O
122	neutralization	_	_	_	_	_	_	_	Seg=O
123	antibodies	_	_	_	_	_	_	_	Seg=O
124	against	_	_	_	_	_	_	_	Seg=O
125	CCV	_	_	_	_	_	_	_	Seg=O
126	in	_	_	_	_	_	_	_	Seg=O
127	giant	_	_	_	_	_	_	_	Seg=O
128	panda	_	_	_	_	_	_	_	Seg=O
129	population	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=O
131	China	_	_	_	_	_	_	_	Seg=O
132	.	_	_	_	_	_	_	_	Seg=O
133	The	_	_	_	_	_	_	_	Seg=B-seg
134	results	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	study	_	_	_	_	_	_	_	Seg=O
137	showed	_	_	_	_	_	_	_	Seg=O
138	that	_	_	_	_	_	_	_	Seg=B-seg
139	the	_	_	_	_	_	_	_	Seg=O
140	infection	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	CCV	_	_	_	_	_	_	_	Seg=O
143	in	_	_	_	_	_	_	_	Seg=O
144	giant	_	_	_	_	_	_	_	Seg=O
145	panda	_	_	_	_	_	_	_	Seg=O
146	population	_	_	_	_	_	_	_	Seg=O
147	was	_	_	_	_	_	_	_	Seg=O
148	universal	_	_	_	_	_	_	_	Seg=O
149	,	_	_	_	_	_	_	_	Seg=O
150	which	_	_	_	_	_	_	_	Seg=B-seg
151	has	_	_	_	_	_	_	_	Seg=O
152	posed	_	_	_	_	_	_	_	Seg=O
153	a	_	_	_	_	_	_	_	Seg=O
154	threat	_	_	_	_	_	_	_	Seg=O
155	to	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	health	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	giant	_	_	_	_	_	_	_	Seg=O
160	panda	_	_	_	_	_	_	_	Seg=O
161	.	_	_	_	_	_	_	_	Seg=O
162	Therefore	_	_	_	_	_	_	_	Seg=B-seg
163	,	_	_	_	_	_	_	_	Seg=O
164	it	_	_	_	_	_	_	_	Seg=O
165	is	_	_	_	_	_	_	_	Seg=O
166	incumbent	_	_	_	_	_	_	_	Seg=O
167	on	_	_	_	_	_	_	_	Seg=O
168	us	_	_	_	_	_	_	_	Seg=O
169	to	_	_	_	_	_	_	_	Seg=O
170	study	_	_	_	_	_	_	_	Seg=O
171	safe	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=O
173	effective	_	_	_	_	_	_	_	Seg=O
174	vaccines	_	_	_	_	_	_	_	Seg=O
175	to	_	_	_	_	_	_	_	Seg=B-seg
176	protect	_	_	_	_	_	_	_	Seg=O
177	giant	_	_	_	_	_	_	_	Seg=O
178	panda	_	_	_	_	_	_	_	Seg=O
179	against	_	_	_	_	_	_	_	Seg=O
180	CCV	_	_	_	_	_	_	_	Seg=O
181	infection	_	_	_	_	_	_	_	Seg=O
182	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5405330f85660bb35ec960a144e904c54c4c67a7
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	this	_	_	_	_	_	_	_	Seg=O
3	demo	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	we	_	_	_	_	_	_	_	Seg=O
6	introduce	_	_	_	_	_	_	_	Seg=O
7	an	_	_	_	_	_	_	_	Seg=O
8	interactive	_	_	_	_	_	_	_	Seg=O
9	system	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	which	_	_	_	_	_	_	_	Seg=B-seg
12	effectively	_	_	_	_	_	_	_	Seg=O
13	applies	_	_	_	_	_	_	_	Seg=O
14	multiple	_	_	_	_	_	_	_	Seg=O
15	criteria	_	_	_	_	_	_	_	Seg=O
16	analysis	_	_	_	_	_	_	_	Seg=O
17	to	_	_	_	_	_	_	_	Seg=B-seg
18	rank	_	_	_	_	_	_	_	Seg=O
19	association	_	_	_	_	_	_	_	Seg=O
20	rules	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	We	_	_	_	_	_	_	_	Seg=B-seg
23	first	_	_	_	_	_	_	_	Seg=O
24	use	_	_	_	_	_	_	_	Seg=O
25	association	_	_	_	_	_	_	_	Seg=O
26	rules	_	_	_	_	_	_	_	Seg=O
27	techniques	_	_	_	_	_	_	_	Seg=O
28	to	_	_	_	_	_	_	_	Seg=B-seg
29	explore	_	_	_	_	_	_	_	Seg=O
30	the	_	_	_	_	_	_	_	Seg=O
31	correlations	_	_	_	_	_	_	_	Seg=O
32	between	_	_	_	_	_	_	_	Seg=O
33	variables	_	_	_	_	_	_	_	Seg=O
34	in	_	_	_	_	_	_	_	Seg=O
35	given	_	_	_	_	_	_	_	Seg=O
36	data	_	_	_	_	_	_	_	Seg=O
37	(	_	_	_	_	_	_	_	Seg=B-seg
38	i.e.	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	database	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	linked	_	_	_	_	_	_	_	Seg=O
43	data	_	_	_	_	_	_	_	Seg=O
44	(	_	_	_	_	_	_	_	Seg=O
45	LD	_	_	_	_	_	_	_	Seg=O
46	)	_	_	_	_	_	_	_	Seg=O
47	)	_	_	_	_	_	_	_	Seg=O
48	,	_	_	_	_	_	_	_	Seg=O
49	and	_	_	_	_	_	_	_	Seg=B-seg
50	secondly	_	_	_	_	_	_	_	Seg=O
51	apply	_	_	_	_	_	_	_	Seg=O
52	multiple	_	_	_	_	_	_	_	Seg=O
53	criteria	_	_	_	_	_	_	_	Seg=O
54	analysis	_	_	_	_	_	_	_	Seg=O
55	(	_	_	_	_	_	_	_	Seg=O
56	MCA	_	_	_	_	_	_	_	Seg=O
57	)	_	_	_	_	_	_	_	Seg=O
58	to	_	_	_	_	_	_	_	Seg=B-seg
59	select	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	most	_	_	_	_	_	_	_	Seg=O
62	relevant	_	_	_	_	_	_	_	Seg=O
63	rules	_	_	_	_	_	_	_	Seg=O
64	according	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=O
66	user	_	_	_	_	_	_	_	Seg=O
67	preferences	_	_	_	_	_	_	_	Seg=O
68	.	_	_	_	_	_	_	_	Seg=O
69	The	_	_	_	_	_	_	_	Seg=B-seg
70	developed	_	_	_	_	_	_	_	Seg=O
71	system	_	_	_	_	_	_	_	Seg=O
72	is	_	_	_	_	_	_	_	Seg=O
73	flexible	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=B-seg
75	allows	_	_	_	_	_	_	_	Seg=O
76	intuitive	_	_	_	_	_	_	_	Seg=O
77	creation	_	_	_	_	_	_	_	Seg=O
78	and	_	_	_	_	_	_	_	Seg=O
79	execution	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=O
81	different	_	_	_	_	_	_	_	Seg=O
82	algorithms	_	_	_	_	_	_	_	Seg=O
83	for	_	_	_	_	_	_	_	Seg=O
84	an	_	_	_	_	_	_	_	Seg=O
85	extensive	_	_	_	_	_	_	_	Seg=O
86	range	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	advanced	_	_	_	_	_	_	_	Seg=O
89	data	_	_	_	_	_	_	_	Seg=O
90	analysis	_	_	_	_	_	_	_	Seg=O
91	topics	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
94	,	_	_	_	_	_	_	_	Seg=O
95	we	_	_	_	_	_	_	_	Seg=O
96	demonstrate	_	_	_	_	_	_	_	Seg=O
97	a	_	_	_	_	_	_	_	Seg=O
98	case	_	_	_	_	_	_	_	Seg=O
99	study	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	association	_	_	_	_	_	_	_	Seg=O
102	rule	_	_	_	_	_	_	_	Seg=O
103	mining	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	ranking	_	_	_	_	_	_	_	Seg=O
106	on	_	_	_	_	_	_	_	Seg=O
107	road	_	_	_	_	_	_	_	Seg=O
108	accident	_	_	_	_	_	_	_	Seg=O
109	data	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 55cb2d0edd96f893cd0f5e11ef9b7052841eec3a
1	Tuberculosis	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	deadliest	_	_	_	_	_	_	_	Seg=O
5	infection	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	our	_	_	_	_	_	_	_	Seg=O
8	time	_	_	_	_	_	_	_	Seg=O
9	.	_	_	_	_	_	_	_	Seg=O
10	In	_	_	_	_	_	_	_	Seg=B-seg
11	contrast	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	about	_	_	_	_	_	_	_	Seg=O
14	11,000	_	_	_	_	_	_	_	Seg=O
15	people	_	_	_	_	_	_	_	Seg=O
16	died	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	Ebola	_	_	_	_	_	_	_	Seg=O
19	between	_	_	_	_	_	_	_	Seg=O
20	2014	_	_	_	_	_	_	_	Seg=O
21	and	_	_	_	_	_	_	_	Seg=O
22	2016	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Despite	_	_	_	_	_	_	_	Seg=B-seg
25	this	_	_	_	_	_	_	_	Seg=O
26	manifest	_	_	_	_	_	_	_	Seg=O
27	difference	_	_	_	_	_	_	_	Seg=O
28	in	_	_	_	_	_	_	_	Seg=O
29	mortality	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	there	_	_	_	_	_	_	_	Seg=B-seg
32	is	_	_	_	_	_	_	_	Seg=O
33	now	_	_	_	_	_	_	_	Seg=O
34	a	_	_	_	_	_	_	_	Seg=O
35	vaccine	_	_	_	_	_	_	_	Seg=O
36	licensed	_	_	_	_	_	_	_	Seg=B-seg
37	in	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	United	_	_	_	_	_	_	_	Seg=O
40	States	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	by	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	European	_	_	_	_	_	_	_	Seg=O
45	Medicines	_	_	_	_	_	_	_	Seg=O
46	Agency	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	with	_	_	_	_	_	_	_	Seg=B-seg
49	up	_	_	_	_	_	_	_	Seg=O
50	to	_	_	_	_	_	_	_	Seg=O
51	100	_	_	_	_	_	_	_	Seg=O
52	%	_	_	_	_	_	_	_	Seg=O
53	efficacy	_	_	_	_	_	_	_	Seg=O
54	against	_	_	_	_	_	_	_	Seg=O
55	Ebola	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	The	_	_	_	_	_	_	_	Seg=B-seg
58	developments	_	_	_	_	_	_	_	Seg=O
59	that	_	_	_	_	_	_	_	Seg=B-seg
60	led	_	_	_	_	_	_	_	Seg=O
61	to	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	trialing	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	Ebola	_	_	_	_	_	_	_	Seg=O
67	vaccine	_	_	_	_	_	_	_	Seg=O
68	were	_	_	_	_	_	_	_	Seg=B-seg
69	historic	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	unprecedented	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	The	_	_	_	_	_	_	_	Seg=B-seg
74	single	_	_	_	_	_	_	_	Seg=O
75	licensed	_	_	_	_	_	_	_	Seg=O
76	TB	_	_	_	_	_	_	_	Seg=O
77	vaccine	_	_	_	_	_	_	_	Seg=O
78	(	_	_	_	_	_	_	_	Seg=O
79	BCG	_	_	_	_	_	_	_	Seg=O
80	)	_	_	_	_	_	_	_	Seg=O
81	has	_	_	_	_	_	_	_	Seg=O
82	limited	_	_	_	_	_	_	_	Seg=O
83	efficacy	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	There	_	_	_	_	_	_	_	Seg=B-seg
86	is	_	_	_	_	_	_	_	Seg=O
87	a	_	_	_	_	_	_	_	Seg=O
88	dire	_	_	_	_	_	_	_	Seg=O
89	need	_	_	_	_	_	_	_	Seg=O
90	for	_	_	_	_	_	_	_	Seg=O
91	a	_	_	_	_	_	_	_	Seg=O
92	more	_	_	_	_	_	_	_	Seg=O
93	efficacious	_	_	_	_	_	_	_	Seg=O
94	TB	_	_	_	_	_	_	_	Seg=O
95	vaccine	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	To	_	_	_	_	_	_	_	Seg=B-seg
98	deploy	_	_	_	_	_	_	_	Seg=O
99	such	_	_	_	_	_	_	_	Seg=O
100	vaccines	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	trials	_	_	_	_	_	_	_	Seg=B-seg
103	are	_	_	_	_	_	_	_	Seg=O
104	needed	_	_	_	_	_	_	_	Seg=O
105	in	_	_	_	_	_	_	_	Seg=O
106	sites	_	_	_	_	_	_	_	Seg=O
107	that	_	_	_	_	_	_	_	Seg=B-seg
108	combine	_	_	_	_	_	_	_	Seg=O
109	high	_	_	_	_	_	_	_	Seg=O
110	disease	_	_	_	_	_	_	_	Seg=O
111	incidence	_	_	_	_	_	_	_	Seg=O
112	and	_	_	_	_	_	_	_	Seg=O
113	research	_	_	_	_	_	_	_	Seg=O
114	infrastructure	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	We	_	_	_	_	_	_	_	Seg=B-seg
117	describe	_	_	_	_	_	_	_	Seg=O
118	our	_	_	_	_	_	_	_	Seg=O
119	twelve	_	_	_	_	_	_	_	Seg=O
120	-	_	_	_	_	_	_	_	Seg=O
121	year	_	_	_	_	_	_	_	Seg=O
122	experience	_	_	_	_	_	_	_	Seg=O
123	building	_	_	_	_	_	_	_	Seg=B-seg
124	a	_	_	_	_	_	_	_	Seg=O
125	TB	_	_	_	_	_	_	_	Seg=O
126	vaccine	_	_	_	_	_	_	_	Seg=O
127	trial	_	_	_	_	_	_	_	Seg=O
128	site	_	_	_	_	_	_	_	Seg=O
129	in	_	_	_	_	_	_	_	Seg=B-seg
130	contrast	_	_	_	_	_	_	_	Seg=O
131	to	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	process	_	_	_	_	_	_	_	Seg=O
134	in	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	recent	_	_	_	_	_	_	_	Seg=O
137	Ebola	_	_	_	_	_	_	_	Seg=O
138	outbreak	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	There	_	_	_	_	_	_	_	Seg=B-seg
141	are	_	_	_	_	_	_	_	Seg=O
142	additional	_	_	_	_	_	_	_	Seg=O
143	differences	_	_	_	_	_	_	_	Seg=O
144	.	_	_	_	_	_	_	_	Seg=O
145	Relative	_	_	_	_	_	_	_	Seg=B-seg
146	to	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	Ebola	_	_	_	_	_	_	_	Seg=O
149	pipeline	_	_	_	_	_	_	_	Seg=O
150	,	_	_	_	_	_	_	_	Seg=O
151	TB	_	_	_	_	_	_	_	Seg=B-seg
152	vaccines	_	_	_	_	_	_	_	Seg=O
153	have	_	_	_	_	_	_	_	Seg=O
154	fewer	_	_	_	_	_	_	_	Seg=O
155	trials	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	a	_	_	_	_	_	_	_	Seg=O
158	paucity	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	government	_	_	_	_	_	_	_	Seg=O
161	and	_	_	_	_	_	_	_	Seg=O
162	industry	_	_	_	_	_	_	_	Seg=O
163	led	_	_	_	_	_	_	_	Seg=O
164	trials	_	_	_	_	_	_	_	Seg=O
165	.	_	_	_	_	_	_	_	Seg=O
166	While	_	_	_	_	_	_	_	Seg=B-seg
167	pathogens	_	_	_	_	_	_	_	Seg=O
168	have	_	_	_	_	_	_	_	Seg=O
169	varying	_	_	_	_	_	_	_	Seg=O
170	levels	_	_	_	_	_	_	_	Seg=O
171	of	_	_	_	_	_	_	_	Seg=O
172	difficulty	_	_	_	_	_	_	_	Seg=O
173	in	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	development	_	_	_	_	_	_	_	Seg=O
176	of	_	_	_	_	_	_	_	Seg=O
177	new	_	_	_	_	_	_	_	Seg=O
178	vaccine	_	_	_	_	_	_	_	Seg=O
179	candidates	_	_	_	_	_	_	_	Seg=O
180	,	_	_	_	_	_	_	_	Seg=O
181	there	_	_	_	_	_	_	_	Seg=B-seg
182	yet	_	_	_	_	_	_	_	Seg=O
183	appears	_	_	_	_	_	_	_	Seg=O
184	to	_	_	_	_	_	_	_	Seg=O
185	be	_	_	_	_	_	_	_	Seg=O
186	greater	_	_	_	_	_	_	_	Seg=O
187	interest	_	_	_	_	_	_	_	Seg=O
188	in	_	_	_	_	_	_	_	Seg=O
189	funding	_	_	_	_	_	_	_	Seg=O
190	and	_	_	_	_	_	_	_	Seg=O
191	coordinating	_	_	_	_	_	_	_	Seg=O
192	Ebola	_	_	_	_	_	_	_	Seg=O
193	interventions	_	_	_	_	_	_	_	Seg=O
194	.	_	_	_	_	_	_	_	Seg=O
195	TB	_	_	_	_	_	_	_	Seg=B-seg
196	is	_	_	_	_	_	_	_	Seg=O
197	a	_	_	_	_	_	_	_	Seg=O
198	global	_	_	_	_	_	_	_	Seg=O
199	threat	_	_	_	_	_	_	_	Seg=O
200	that	_	_	_	_	_	_	_	Seg=B-seg
201	requires	_	_	_	_	_	_	_	Seg=O
202	similar	_	_	_	_	_	_	_	Seg=O
203	concerted	_	_	_	_	_	_	_	Seg=O
204	effort	_	_	_	_	_	_	_	Seg=O
205	for	_	_	_	_	_	_	_	Seg=O
206	elimination	_	_	_	_	_	_	_	Seg=O
207	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 59f5a1087f771959fc4d01b18ea5bf91bf95bb94
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	current	_	_	_	_	_	_	_	Seg=O
3	coronavirus	_	_	_	_	_	_	_	Seg=O
4	disease	_	_	_	_	_	_	_	Seg=O
5	pandemic	_	_	_	_	_	_	_	Seg=O
6	caused	_	_	_	_	_	_	_	Seg=B-seg
7	by	_	_	_	_	_	_	_	Seg=O
8	severe	_	_	_	_	_	_	_	Seg=O
9	acute	_	_	_	_	_	_	_	Seg=O
10	respiratory	_	_	_	_	_	_	_	Seg=O
11	syndrome	_	_	_	_	_	_	_	Seg=O
12	coronavirus	_	_	_	_	_	_	_	Seg=O
13	2	_	_	_	_	_	_	_	Seg=O
14	has	_	_	_	_	_	_	_	Seg=B-seg
15	led	_	_	_	_	_	_	_	Seg=O
16	to	_	_	_	_	_	_	_	Seg=O
17	immense	_	_	_	_	_	_	_	Seg=O
18	strain	_	_	_	_	_	_	_	Seg=O
19	on	_	_	_	_	_	_	_	Seg=O
20	healthcare	_	_	_	_	_	_	_	Seg=O
21	systems	_	_	_	_	_	_	_	Seg=O
22	and	_	_	_	_	_	_	_	Seg=O
23	workers	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	Patients	_	_	_	_	_	_	_	Seg=B-seg
26	with	_	_	_	_	_	_	_	Seg=O
27	severe	_	_	_	_	_	_	_	Seg=O
28	symptoms	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	COVID-19	_	_	_	_	_	_	_	Seg=O
31	may	_	_	_	_	_	_	_	Seg=O
32	also	_	_	_	_	_	_	_	Seg=O
33	present	_	_	_	_	_	_	_	Seg=O
34	with	_	_	_	_	_	_	_	Seg=O
35	acute	_	_	_	_	_	_	_	Seg=O
36	neurological	_	_	_	_	_	_	_	Seg=O
37	emergencies	_	_	_	_	_	_	_	Seg=O
38	such	_	_	_	_	_	_	_	Seg=B-seg
39	as	_	_	_	_	_	_	_	Seg=O
40	ischemic	_	_	_	_	_	_	_	Seg=O
41	stroke	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	Ischemic	_	_	_	_	_	_	_	Seg=B-seg
44	stroke	_	_	_	_	_	_	_	Seg=O
45	in	_	_	_	_	_	_	_	Seg=O
46	these	_	_	_	_	_	_	_	Seg=O
47	patients	_	_	_	_	_	_	_	Seg=O
48	may	_	_	_	_	_	_	_	Seg=O
49	result	_	_	_	_	_	_	_	Seg=O
50	from	_	_	_	_	_	_	_	Seg=O
51	COVID-19	_	_	_	_	_	_	_	Seg=O
52	related	_	_	_	_	_	_	_	Seg=O
53	complications	_	_	_	_	_	_	_	Seg=O
54	or	_	_	_	_	_	_	_	Seg=O
55	decompensation	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	previously	_	_	_	_	_	_	_	Seg=O
58	asymptomatic	_	_	_	_	_	_	_	Seg=O
59	cerebrovascular	_	_	_	_	_	_	_	Seg=O
60	disorders	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	or	_	_	_	_	_	_	_	Seg=O
63	concurrent	_	_	_	_	_	_	_	Seg=O
64	ischemic	_	_	_	_	_	_	_	Seg=O
65	stroke	_	_	_	_	_	_	_	Seg=O
66	from	_	_	_	_	_	_	_	Seg=O
67	common	_	_	_	_	_	_	_	Seg=O
68	stroke	_	_	_	_	_	_	_	Seg=O
69	risk	_	_	_	_	_	_	_	Seg=O
70	factors	_	_	_	_	_	_	_	Seg=O
71	in	_	_	_	_	_	_	_	Seg=O
72	a	_	_	_	_	_	_	_	Seg=O
73	patient	_	_	_	_	_	_	_	Seg=O
74	with	_	_	_	_	_	_	_	Seg=O
75	COVID-19	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	Acute	_	_	_	_	_	_	_	Seg=B-seg
78	ischemic	_	_	_	_	_	_	_	Seg=O
79	stroke	_	_	_	_	_	_	_	Seg=O
80	patients	_	_	_	_	_	_	_	Seg=O
81	with	_	_	_	_	_	_	_	Seg=O
82	large	_	_	_	_	_	_	_	Seg=O
83	vessel	_	_	_	_	_	_	_	Seg=O
84	occlusions	_	_	_	_	_	_	_	Seg=O
85	require	_	_	_	_	_	_	_	Seg=O
86	emergent	_	_	_	_	_	_	_	Seg=O
87	triage	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	intensive	_	_	_	_	_	_	_	Seg=O
90	care	_	_	_	_	_	_	_	Seg=O
91	,	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=O
93	mechanical	_	_	_	_	_	_	_	Seg=O
94	thrombectomy	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	Management	_	_	_	_	_	_	_	Seg=B-seg
97	of	_	_	_	_	_	_	_	Seg=O
98	patients	_	_	_	_	_	_	_	Seg=O
99	with	_	_	_	_	_	_	_	Seg=O
100	large	_	_	_	_	_	_	_	Seg=O
101	vessel	_	_	_	_	_	_	_	Seg=O
102	occlusions	_	_	_	_	_	_	_	Seg=O
103	(	_	_	_	_	_	_	_	Seg=O
104	LVO	_	_	_	_	_	_	_	Seg=O
105	)	_	_	_	_	_	_	_	Seg=O
106	requires	_	_	_	_	_	_	_	Seg=O
107	special	_	_	_	_	_	_	_	Seg=O
108	considerations	_	_	_	_	_	_	_	Seg=O
109	in	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	current	_	_	_	_	_	_	_	Seg=O
112	pandemic	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Physicians	_	_	_	_	_	_	_	Seg=B-seg
115	must	_	_	_	_	_	_	_	Seg=O
116	now	_	_	_	_	_	_	_	Seg=O
117	account	_	_	_	_	_	_	_	Seg=O
118	for	_	_	_	_	_	_	_	Seg=O
119	prognosis	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	severe	_	_	_	_	_	_	_	Seg=O
122	COVID-19	_	_	_	_	_	_	_	Seg=O
123	,	_	_	_	_	_	_	_	Seg=O
124	resource	_	_	_	_	_	_	_	Seg=O
125	utilization	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	and	_	_	_	_	_	_	_	Seg=O
128	risk	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	infection	_	_	_	_	_	_	_	Seg=O
131	to	_	_	_	_	_	_	_	Seg=O
132	healthcare	_	_	_	_	_	_	_	Seg=O
133	workers	_	_	_	_	_	_	_	Seg=O
134	when	_	_	_	_	_	_	_	Seg=B-seg
135	determining	_	_	_	_	_	_	_	Seg=O
136	eligibility	_	_	_	_	_	_	_	Seg=O
137	for	_	_	_	_	_	_	_	Seg=O
138	mechanical	_	_	_	_	_	_	_	Seg=O
139	thrombectomy	_	_	_	_	_	_	_	Seg=O
140	(	_	_	_	_	_	_	_	Seg=O
141	MT	_	_	_	_	_	_	_	Seg=O
142	)	_	_	_	_	_	_	_	Seg=O
143	.	_	_	_	_	_	_	_	Seg=O
144	Here	_	_	_	_	_	_	_	Seg=B-seg
145	,	_	_	_	_	_	_	_	Seg=O
146	we	_	_	_	_	_	_	_	Seg=O
147	describe	_	_	_	_	_	_	_	Seg=O
148	important	_	_	_	_	_	_	_	Seg=O
149	prognostic	_	_	_	_	_	_	_	Seg=O
150	factors	_	_	_	_	_	_	_	Seg=O
151	including	_	_	_	_	_	_	_	Seg=B-seg
152	age	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	laboratory	_	_	_	_	_	_	_	Seg=O
155	,	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	imaging	_	_	_	_	_	_	_	Seg=O
158	findings	_	_	_	_	_	_	_	Seg=O
159	to	_	_	_	_	_	_	_	Seg=B-seg
160	consider	_	_	_	_	_	_	_	Seg=O
161	for	_	_	_	_	_	_	_	Seg=O
162	MT	_	_	_	_	_	_	_	Seg=O
163	selection	_	_	_	_	_	_	_	Seg=O
164	and	_	_	_	_	_	_	_	Seg=B-seg
165	provide	_	_	_	_	_	_	_	Seg=O
166	suggestions	_	_	_	_	_	_	_	Seg=O
167	for	_	_	_	_	_	_	_	Seg=B-seg
168	taking	_	_	_	_	_	_	_	Seg=O
169	care	_	_	_	_	_	_	_	Seg=O
170	of	_	_	_	_	_	_	_	Seg=O
171	patients	_	_	_	_	_	_	_	Seg=O
172	with	_	_	_	_	_	_	_	Seg=O
173	LVO	_	_	_	_	_	_	_	Seg=O
174	and	_	_	_	_	_	_	_	Seg=O
175	possible	_	_	_	_	_	_	_	Seg=O
176	or	_	_	_	_	_	_	_	Seg=O
177	confirmed	_	_	_	_	_	_	_	Seg=O
178	COVID-19	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O
180	It	_	_	_	_	_	_	_	Seg=B-seg
181	is	_	_	_	_	_	_	_	Seg=O
182	recommended	_	_	_	_	_	_	_	Seg=O
183	to	_	_	_	_	_	_	_	Seg=O
184	perform	_	_	_	_	_	_	_	Seg=O
185	MT	_	_	_	_	_	_	_	Seg=O
186	in	_	_	_	_	_	_	_	Seg=O
187	patients	_	_	_	_	_	_	_	Seg=O
188	within	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	established	_	_	_	_	_	_	_	Seg=O
191	guidelines	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=O
194	consider	_	_	_	_	_	_	_	Seg=O
195	a	_	_	_	_	_	_	_	Seg=O
196	conservative	_	_	_	_	_	_	_	Seg=O
197	approach	_	_	_	_	_	_	_	Seg=O
198	in	_	_	_	_	_	_	_	Seg=O
199	cases	_	_	_	_	_	_	_	Seg=O
200	where	_	_	_	_	_	_	_	Seg=B-seg
201	there	_	_	_	_	_	_	_	Seg=O
202	is	_	_	_	_	_	_	_	Seg=O
203	clinical	_	_	_	_	_	_	_	Seg=O
204	equipoise	_	_	_	_	_	_	_	Seg=O
205	to	_	_	_	_	_	_	_	Seg=B-seg
206	minimize	_	_	_	_	_	_	_	Seg=O
207	futile	_	_	_	_	_	_	_	Seg=O
208	reperfusion	_	_	_	_	_	_	_	Seg=O
209	.	_	_	_	_	_	_	_	Seg=O
210	Lastly	_	_	_	_	_	_	_	Seg=B-seg
211	,	_	_	_	_	_	_	_	Seg=O
212	we	_	_	_	_	_	_	_	Seg=O
213	describe	_	_	_	_	_	_	_	Seg=O
214	an	_	_	_	_	_	_	_	Seg=O
215	illustrative	_	_	_	_	_	_	_	Seg=O
216	case	_	_	_	_	_	_	_	Seg=O
217	of	_	_	_	_	_	_	_	Seg=O
218	a	_	_	_	_	_	_	_	Seg=O
219	patient	_	_	_	_	_	_	_	Seg=O
220	with	_	_	_	_	_	_	_	Seg=O
221	ischemic	_	_	_	_	_	_	_	Seg=O
222	stroke	_	_	_	_	_	_	_	Seg=O
223	and	_	_	_	_	_	_	_	Seg=O
224	COVID-19	_	_	_	_	_	_	_	Seg=O
225	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5c2bd95f80ed7229802a7fd01731a2586702f8b3
1	Activation	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	thrombotic	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	complement	_	_	_	_	_	_	_	Seg=O
7	systems	_	_	_	_	_	_	_	Seg=O
8	is	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	main	_	_	_	_	_	_	_	Seg=O
11	recognition	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	effector	_	_	_	_	_	_	_	Seg=O
14	mechanisms	_	_	_	_	_	_	_	Seg=O
15	in	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	multiple	_	_	_	_	_	_	_	Seg=O
18	adverse	_	_	_	_	_	_	_	Seg=O
19	biological	_	_	_	_	_	_	_	Seg=O
20	responses	_	_	_	_	_	_	_	Seg=O
21	triggered	_	_	_	_	_	_	_	Seg=B-seg
22	when	_	_	_	_	_	_	_	Seg=B-seg
23	biomaterials	_	_	_	_	_	_	_	Seg=O
24	or	_	_	_	_	_	_	_	Seg=O
25	therapeutic	_	_	_	_	_	_	_	Seg=O
26	cells	_	_	_	_	_	_	_	Seg=O
27	come	_	_	_	_	_	_	_	Seg=O
28	into	_	_	_	_	_	_	_	Seg=O
29	blood	_	_	_	_	_	_	_	Seg=O
30	contact	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	We	_	_	_	_	_	_	_	Seg=B-seg
33	have	_	_	_	_	_	_	_	Seg=O
34	created	_	_	_	_	_	_	_	Seg=O
35	a	_	_	_	_	_	_	_	Seg=O
36	surface	_	_	_	_	_	_	_	Seg=O
37	which	_	_	_	_	_	_	_	Seg=B-seg
38	is	_	_	_	_	_	_	_	Seg=O
39	auto	_	_	_	_	_	_	_	Seg=O
40	-	_	_	_	_	_	_	_	Seg=O
41	protective	_	_	_	_	_	_	_	Seg=O
42	to	_	_	_	_	_	_	_	Seg=O
43	human	_	_	_	_	_	_	_	Seg=O
44	innate	_	_	_	_	_	_	_	Seg=O
45	immunity	_	_	_	_	_	_	_	Seg=O
46	by	_	_	_	_	_	_	_	Seg=B-seg
47	combining	_	_	_	_	_	_	_	Seg=O
48	three	_	_	_	_	_	_	_	Seg=O
49	fundamentally	_	_	_	_	_	_	_	Seg=O
50	different	_	_	_	_	_	_	_	Seg=O
51	strategies	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	all	_	_	_	_	_	_	_	Seg=B-seg
54	developed	_	_	_	_	_	_	_	Seg=O
55	by	_	_	_	_	_	_	_	Seg=O
56	us	_	_	_	_	_	_	_	Seg=O
57	previously	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	which	_	_	_	_	_	_	_	Seg=B-seg
60	have	_	_	_	_	_	_	_	Seg=O
61	been	_	_	_	_	_	_	_	Seg=O
62	shown	_	_	_	_	_	_	_	Seg=O
63	to	_	_	_	_	_	_	_	Seg=O
64	induce	_	_	_	_	_	_	_	Seg=O
65	substantial	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	but	_	_	_	_	_	_	_	Seg=O
68	incomplete	_	_	_	_	_	_	_	Seg=O
69	hemocompatibility	_	_	_	_	_	_	_	Seg=O
70	when	_	_	_	_	_	_	_	Seg=B-seg
71	used	_	_	_	_	_	_	_	Seg=O
72	separately	_	_	_	_	_	_	_	Seg=O
73	.	_	_	_	_	_	_	_	Seg=O
74	In	_	_	_	_	_	_	_	Seg=B-seg
75	summary	_	_	_	_	_	_	_	Seg=O
76	,	_	_	_	_	_	_	_	Seg=O
77	we	_	_	_	_	_	_	_	Seg=O
78	have	_	_	_	_	_	_	_	Seg=O
79	conjugated	_	_	_	_	_	_	_	Seg=O
80	a	_	_	_	_	_	_	_	Seg=O
81	factor	_	_	_	_	_	_	_	Seg=O
82	Hebinding	_	_	_	_	_	_	_	Seg=O
83	peptide	_	_	_	_	_	_	_	Seg=O
84	;	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	an	_	_	_	_	_	_	_	Seg=O
87	ADP	_	_	_	_	_	_	_	Seg=O
88	-	_	_	_	_	_	_	_	Seg=O
89	degrading	_	_	_	_	_	_	_	Seg=O
90	enzyme	_	_	_	_	_	_	_	Seg=O
91	;	_	_	_	_	_	_	_	Seg=O
92	using	_	_	_	_	_	_	_	Seg=B-seg
93	a	_	_	_	_	_	_	_	Seg=O
94	PEG	_	_	_	_	_	_	_	Seg=O
95	linker	_	_	_	_	_	_	_	Seg=O
96	on	_	_	_	_	_	_	_	Seg=O
97	both	_	_	_	_	_	_	_	Seg=O
98	material	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=O
100	cellular	_	_	_	_	_	_	_	Seg=O
101	surfaces	_	_	_	_	_	_	_	Seg=O
102	.	_	_	_	_	_	_	_	Seg=O
103	When	_	_	_	_	_	_	_	Seg=B-seg
104	exposed	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=O
106	human	_	_	_	_	_	_	_	Seg=O
107	whole	_	_	_	_	_	_	_	Seg=O
108	blood	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	factor	_	_	_	_	_	_	_	Seg=B-seg
111	H	_	_	_	_	_	_	_	Seg=O
112	was	_	_	_	_	_	_	_	Seg=O
113	specifically	_	_	_	_	_	_	_	Seg=O
114	recruited	_	_	_	_	_	_	_	Seg=O
115	to	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	modified	_	_	_	_	_	_	_	Seg=O
118	surfaces	_	_	_	_	_	_	_	Seg=O
119	and	_	_	_	_	_	_	_	Seg=B-seg
120	inhibited	_	_	_	_	_	_	_	Seg=O
121	complement	_	_	_	_	_	_	_	Seg=O
122	attack	_	_	_	_	_	_	_	Seg=O
123	.	_	_	_	_	_	_	_	Seg=O
124	In	_	_	_	_	_	_	_	Seg=B-seg
125	addition	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	activation	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	platelets	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	coagulation	_	_	_	_	_	_	_	Seg=O
132	was	_	_	_	_	_	_	_	Seg=O
133	efficiently	_	_	_	_	_	_	_	Seg=O
134	attenuated	_	_	_	_	_	_	_	Seg=O
135	,	_	_	_	_	_	_	_	Seg=O
136	by	_	_	_	_	_	_	_	Seg=B-seg
137	degrading	_	_	_	_	_	_	_	Seg=O
138	ADP	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	Thus	_	_	_	_	_	_	_	Seg=B-seg
141	,	_	_	_	_	_	_	_	Seg=O
142	by	_	_	_	_	_	_	_	Seg=B-seg
143	inhibiting	_	_	_	_	_	_	_	Seg=O
144	thromboinflammation	_	_	_	_	_	_	_	Seg=O
145	using	_	_	_	_	_	_	_	Seg=B-seg
146	a	_	_	_	_	_	_	_	Seg=O
147	multicomponent	_	_	_	_	_	_	_	Seg=O
148	approach	_	_	_	_	_	_	_	Seg=O
149	,	_	_	_	_	_	_	_	Seg=O
150	we	_	_	_	_	_	_	_	Seg=B-seg
151	have	_	_	_	_	_	_	_	Seg=O
152	created	_	_	_	_	_	_	_	Seg=O
153	a	_	_	_	_	_	_	_	Seg=O
154	hybrid	_	_	_	_	_	_	_	Seg=O
155	surface	_	_	_	_	_	_	_	Seg=O
156	with	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	potential	_	_	_	_	_	_	_	Seg=O
159	to	_	_	_	_	_	_	_	Seg=B-seg
160	greatly	_	_	_	_	_	_	_	Seg=O
161	reduce	_	_	_	_	_	_	_	Seg=O
162	incompatibility	_	_	_	_	_	_	_	Seg=O
163	reactions	_	_	_	_	_	_	_	Seg=O
164	involving	_	_	_	_	_	_	_	Seg=B-seg
165	biomaterials	_	_	_	_	_	_	_	Seg=O
166	and	_	_	_	_	_	_	_	Seg=O
167	transplantation	_	_	_	_	_	_	_	Seg=O
168	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5cfb44ecdfb61b2898b6cf7315b1e810874a9560
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	2019-nCoV	_	_	_	_	_	_	_	Seg=O
3	outbreak	_	_	_	_	_	_	_	Seg=O
4	has	_	_	_	_	_	_	_	Seg=O
5	raised	_	_	_	_	_	_	_	Seg=O
6	concern	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	global	_	_	_	_	_	_	_	Seg=O
9	spread	_	_	_	_	_	_	_	Seg=O
10	.	_	_	_	_	_	_	_	Seg=O
11	While	_	_	_	_	_	_	_	Seg=B-seg
12	person	_	_	_	_	_	_	_	Seg=O
13	-	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=O
15	-	_	_	_	_	_	_	_	Seg=O
16	person	_	_	_	_	_	_	_	Seg=O
17	transmission	_	_	_	_	_	_	_	Seg=O
18	within	_	_	_	_	_	_	_	Seg=O
19	the	_	_	_	_	_	_	_	Seg=O
20	Wuhan	_	_	_	_	_	_	_	Seg=O
21	district	_	_	_	_	_	_	_	Seg=O
22	has	_	_	_	_	_	_	_	Seg=O
23	led	_	_	_	_	_	_	_	Seg=O
24	to	_	_	_	_	_	_	_	Seg=O
25	a	_	_	_	_	_	_	_	Seg=O
26	large	_	_	_	_	_	_	_	Seg=O
27	outbreak	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=B-seg
30	transmission	_	_	_	_	_	_	_	Seg=O
31	potential	_	_	_	_	_	_	_	Seg=O
32	outside	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	region	_	_	_	_	_	_	_	Seg=O
36	remains	_	_	_	_	_	_	_	Seg=O
37	unclear	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	Here	_	_	_	_	_	_	_	Seg=B-seg
40	we	_	_	_	_	_	_	_	Seg=O
41	present	_	_	_	_	_	_	_	Seg=O
42	a	_	_	_	_	_	_	_	Seg=O
43	simple	_	_	_	_	_	_	_	Seg=O
44	approach	_	_	_	_	_	_	_	Seg=O
45	for	_	_	_	_	_	_	_	Seg=B-seg
46	determining	_	_	_	_	_	_	_	Seg=O
47	whether	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	upper	_	_	_	_	_	_	_	Seg=O
50	limit	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	confidence	_	_	_	_	_	_	_	Seg=O
54	interval	_	_	_	_	_	_	_	Seg=O
55	for	_	_	_	_	_	_	_	Seg=O
56	the	_	_	_	_	_	_	_	Seg=O
57	reproduction	_	_	_	_	_	_	_	Seg=O
58	number	_	_	_	_	_	_	_	Seg=O
59	exceeds	_	_	_	_	_	_	_	Seg=O
60	one	_	_	_	_	_	_	_	Seg=O
61	for	_	_	_	_	_	_	_	Seg=O
62	transmission	_	_	_	_	_	_	_	Seg=O
63	in	_	_	_	_	_	_	_	Seg=O
64	the	_	_	_	_	_	_	_	Seg=O
65	United	_	_	_	_	_	_	_	Seg=O
66	States	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	which	_	_	_	_	_	_	_	Seg=B-seg
69	would	_	_	_	_	_	_	_	Seg=O
70	allow	_	_	_	_	_	_	_	Seg=O
71	endemic	_	_	_	_	_	_	_	Seg=O
72	transmission	_	_	_	_	_	_	_	Seg=O
73	.	_	_	_	_	_	_	_	Seg=O
74	As	_	_	_	_	_	_	_	Seg=B-seg
75	of	_	_	_	_	_	_	_	Seg=O
76	February	_	_	_	_	_	_	_	Seg=O
77	7	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	2020	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	number	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	cases	_	_	_	_	_	_	_	Seg=O
85	in	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	United	_	_	_	_	_	_	_	Seg=O
88	states	_	_	_	_	_	_	_	Seg=O
89	support	_	_	_	_	_	_	_	Seg=O
90	subcritical	_	_	_	_	_	_	_	Seg=O
91	transmission	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	rather	_	_	_	_	_	_	_	Seg=O
94	than	_	_	_	_	_	_	_	Seg=O
95	ongoing	_	_	_	_	_	_	_	Seg=O
96	transmission	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	However	_	_	_	_	_	_	_	Seg=B-seg
99	,	_	_	_	_	_	_	_	Seg=O
100	this	_	_	_	_	_	_	_	Seg=O
101	conclusion	_	_	_	_	_	_	_	Seg=O
102	can	_	_	_	_	_	_	_	Seg=O
103	change	_	_	_	_	_	_	_	Seg=O
104	if	_	_	_	_	_	_	_	Seg=B-seg
105	pre	_	_	_	_	_	_	_	Seg=O
106	-	_	_	_	_	_	_	_	Seg=O
107	symptomatic	_	_	_	_	_	_	_	Seg=O
108	cases	_	_	_	_	_	_	_	Seg=O
109	resulting	_	_	_	_	_	_	_	Seg=B-seg
110	from	_	_	_	_	_	_	_	Seg=O
111	human	_	_	_	_	_	_	_	Seg=O
112	-	_	_	_	_	_	_	_	Seg=O
113	to	_	_	_	_	_	_	_	Seg=O
114	-	_	_	_	_	_	_	_	Seg=O
115	human	_	_	_	_	_	_	_	Seg=O
116	transmission	_	_	_	_	_	_	_	Seg=O
117	have	_	_	_	_	_	_	_	Seg=B-seg
118	not	_	_	_	_	_	_	_	Seg=O
119	yet	_	_	_	_	_	_	_	Seg=O
120	been	_	_	_	_	_	_	_	Seg=O
121	identified	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	The	_	_	_	_	_	_	_	Seg=B-seg
124	2019-nCoV	_	_	_	_	_	_	_	Seg=O
125	outbreak	_	_	_	_	_	_	_	Seg=O
126	is	_	_	_	_	_	_	_	Seg=O
127	a	_	_	_	_	_	_	_	Seg=O
128	global	_	_	_	_	_	_	_	Seg=O
129	health	_	_	_	_	_	_	_	Seg=O
130	risk	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	especially	_	_	_	_	_	_	_	Seg=B-seg
133	considering	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	number	_	_	_	_	_	_	_	Seg=O
136	of	_	_	_	_	_	_	_	Seg=O
137	patients	_	_	_	_	_	_	_	Seg=O
138	who	_	_	_	_	_	_	_	Seg=B-seg
139	have	_	_	_	_	_	_	_	Seg=O
140	already	_	_	_	_	_	_	_	Seg=O
141	died	_	_	_	_	_	_	_	Seg=O
142	after	_	_	_	_	_	_	_	Seg=B-seg
143	becoming	_	_	_	_	_	_	_	Seg=O
144	infected	_	_	_	_	_	_	_	Seg=O
145	in	_	_	_	_	_	_	_	Seg=O
146	Wuhan	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	China	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	Many	_	_	_	_	_	_	_	Seg=B-seg
151	initial	_	_	_	_	_	_	_	Seg=O
152	characterizations	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	the	_	_	_	_	_	_	_	Seg=O
155	virus	_	_	_	_	_	_	_	Seg=O
156	have	_	_	_	_	_	_	_	Seg=O
157	focused	_	_	_	_	_	_	_	Seg=O
158	on	_	_	_	_	_	_	_	Seg=O
159	the	_	_	_	_	_	_	_	Seg=O
160	basic	_	_	_	_	_	_	_	Seg=O
161	reproduction	_	_	_	_	_	_	_	Seg=O
162	number	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	R	_	_	_	_	_	_	_	Seg=O
165	,	_	_	_	_	_	_	_	Seg=O
166	which	_	_	_	_	_	_	_	Seg=B-seg
167	reflects	_	_	_	_	_	_	_	Seg=O
168	the	_	_	_	_	_	_	_	Seg=O
169	average	_	_	_	_	_	_	_	Seg=O
170	number	_	_	_	_	_	_	_	Seg=O
171	of	_	_	_	_	_	_	_	Seg=O
172	infections	_	_	_	_	_	_	_	Seg=O
173	that	_	_	_	_	_	_	_	Seg=B-seg
174	each	_	_	_	_	_	_	_	Seg=O
175	new	_	_	_	_	_	_	_	Seg=O
176	infection	_	_	_	_	_	_	_	Seg=O
177	causes	_	_	_	_	_	_	_	Seg=O
178	in	_	_	_	_	_	_	_	Seg=O
179	a	_	_	_	_	_	_	_	Seg=O
180	susceptible	_	_	_	_	_	_	_	Seg=O
181	population	_	_	_	_	_	_	_	Seg=O
182	.	_	_	_	_	_	_	_	Seg=O
183	Whenever	_	_	_	_	_	_	_	Seg=B-seg
184	R	_	_	_	_	_	_	_	Seg=O
185	is	_	_	_	_	_	_	_	Seg=O
186	greater	_	_	_	_	_	_	_	Seg=O
187	than	_	_	_	_	_	_	_	Seg=O
188	one	_	_	_	_	_	_	_	Seg=O
189	,	_	_	_	_	_	_	_	Seg=O
190	epidemic	_	_	_	_	_	_	_	Seg=B-seg
191	transition	_	_	_	_	_	_	_	Seg=O
192	becomes	_	_	_	_	_	_	_	Seg=O
193	possible	_	_	_	_	_	_	_	Seg=O
194	and	_	_	_	_	_	_	_	Seg=B-seg
195	within	_	_	_	_	_	_	_	Seg=O
196	the	_	_	_	_	_	_	_	Seg=O
197	Wuhan	_	_	_	_	_	_	_	Seg=O
198	province	_	_	_	_	_	_	_	Seg=O
199	,	_	_	_	_	_	_	_	Seg=O
200	R	_	_	_	_	_	_	_	Seg=O
201	has	_	_	_	_	_	_	_	Seg=O
202	been	_	_	_	_	_	_	_	Seg=O
203	estimated	_	_	_	_	_	_	_	Seg=O
204	as	_	_	_	_	_	_	_	Seg=O
205	high	_	_	_	_	_	_	_	Seg=O
206	as	_	_	_	_	_	_	_	Seg=O
207	4.1	_	_	_	_	_	_	_	Seg=O
208	1	_	_	_	_	_	_	_	Seg=O
209	-	_	_	_	_	_	_	_	Seg=O
210	3	_	_	_	_	_	_	_	Seg=O
211	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5e2c1be088e0e4406e9446e7efc610a6a53d2315
1	Feline	_	_	_	_	_	_	_	Seg=B-seg
2	calicivirus	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	FCV	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	small	_	_	_	_	_	_	_	Seg=O
9	non	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	enveloped	_	_	_	_	_	_	_	Seg=O
12	virus	_	_	_	_	_	_	_	Seg=O
13	containing	_	_	_	_	_	_	_	Seg=B-seg
14	a	_	_	_	_	_	_	_	Seg=O
15	single	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	stranded	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	positive	_	_	_	_	_	_	_	Seg=O
20	-	_	_	_	_	_	_	_	Seg=O
21	sense	_	_	_	_	_	_	_	Seg=O
22	RNA	_	_	_	_	_	_	_	Seg=O
23	genome	_	_	_	_	_	_	_	Seg=O
24	of	_	_	_	_	_	_	_	Seg=O
25	approximately	_	_	_	_	_	_	_	Seg=O
26	7.7	_	_	_	_	_	_	_	Seg=O
27	kb	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	FCV	_	_	_	_	_	_	_	Seg=B-seg
30	is	_	_	_	_	_	_	_	Seg=O
31	a	_	_	_	_	_	_	_	Seg=O
32	highly	_	_	_	_	_	_	_	Seg=O
33	infectious	_	_	_	_	_	_	_	Seg=O
34	pathogen	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	cats	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=B-seg
38	typically	_	_	_	_	_	_	_	Seg=O
39	causes	_	_	_	_	_	_	_	Seg=O
40	moderate	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	self	_	_	_	_	_	_	_	Seg=O
43	-	_	_	_	_	_	_	_	Seg=O
44	limiting	_	_	_	_	_	_	_	Seg=O
45	acute	_	_	_	_	_	_	_	Seg=O
46	oral	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=O
48	upper	_	_	_	_	_	_	_	Seg=O
49	respiratory	_	_	_	_	_	_	_	Seg=O
50	tract	_	_	_	_	_	_	_	Seg=O
51	diseases	_	_	_	_	_	_	_	Seg=O
52	or	_	_	_	_	_	_	_	Seg=O
53	chronic	_	_	_	_	_	_	_	Seg=O
54	oral	_	_	_	_	_	_	_	Seg=O
55	diseases	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	In	_	_	_	_	_	_	_	Seg=B-seg
58	addition	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	in	_	_	_	_	_	_	_	Seg=O
61	recent	_	_	_	_	_	_	_	Seg=O
62	years	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	virulent	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	systemic	_	_	_	_	_	_	_	Seg=O
67	FCV	_	_	_	_	_	_	_	Seg=O
68	(	_	_	_	_	_	_	_	Seg=O
69	vs	_	_	_	_	_	_	_	Seg=O
70	-	_	_	_	_	_	_	_	Seg=O
71	FCV	_	_	_	_	_	_	_	Seg=O
72	)	_	_	_	_	_	_	_	Seg=O
73	strains	_	_	_	_	_	_	_	Seg=O
74	causing	_	_	_	_	_	_	_	Seg=B-seg
75	severe	_	_	_	_	_	_	_	Seg=O
76	systemic	_	_	_	_	_	_	_	Seg=O
77	diseases	_	_	_	_	_	_	_	Seg=O
78	with	_	_	_	_	_	_	_	Seg=O
79	a	_	_	_	_	_	_	_	Seg=O
80	high	_	_	_	_	_	_	_	Seg=O
81	mortality	_	_	_	_	_	_	_	Seg=O
82	rate	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	up	_	_	_	_	_	_	_	Seg=O
85	to	_	_	_	_	_	_	_	Seg=O
86	67	_	_	_	_	_	_	_	Seg=O
87	%	_	_	_	_	_	_	_	Seg=O
88	have	_	_	_	_	_	_	_	Seg=B-seg
89	been	_	_	_	_	_	_	_	Seg=O
90	reported	_	_	_	_	_	_	_	Seg=O
91	in	_	_	_	_	_	_	_	Seg=O
92	cats	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	Although	_	_	_	_	_	_	_	Seg=B-seg
95	FCV	_	_	_	_	_	_	_	Seg=O
96	vaccines	_	_	_	_	_	_	_	Seg=O
97	are	_	_	_	_	_	_	_	Seg=O
98	commercially	_	_	_	_	_	_	_	Seg=O
99	available	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	their	_	_	_	_	_	_	_	Seg=B-seg
102	efficacy	_	_	_	_	_	_	_	Seg=O
103	is	_	_	_	_	_	_	_	Seg=O
104	limited	_	_	_	_	_	_	_	Seg=O
105	due	_	_	_	_	_	_	_	Seg=B-seg
106	to	_	_	_	_	_	_	_	Seg=O
107	antigenic	_	_	_	_	_	_	_	Seg=O
108	diversity	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=O
110	FCV	_	_	_	_	_	_	_	Seg=O
111	strains	_	_	_	_	_	_	_	Seg=O
112	and	_	_	_	_	_	_	_	Seg=O
113	short	_	_	_	_	_	_	_	Seg=O
114	duration	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	immunity	_	_	_	_	_	_	_	Seg=O
117	.	_	_	_	_	_	_	_	Seg=O
118	In	_	_	_	_	_	_	_	Seg=B-seg
119	this	_	_	_	_	_	_	_	Seg=O
120	study	_	_	_	_	_	_	_	Seg=O
121	,	_	_	_	_	_	_	_	Seg=O
122	we	_	_	_	_	_	_	_	Seg=O
123	identified	_	_	_	_	_	_	_	Seg=O
124	fexaramine	_	_	_	_	_	_	_	Seg=O
125	as	_	_	_	_	_	_	_	Seg=O
126	a	_	_	_	_	_	_	_	Seg=O
127	potent	_	_	_	_	_	_	_	Seg=O
128	inhibitor	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	FCV	_	_	_	_	_	_	_	Seg=O
131	including	_	_	_	_	_	_	_	Seg=B-seg
132	vs	_	_	_	_	_	_	_	Seg=O
133	-	_	_	_	_	_	_	_	Seg=O
134	FCV	_	_	_	_	_	_	_	Seg=O
135	strains	_	_	_	_	_	_	_	Seg=O
136	in	_	_	_	_	_	_	_	Seg=O
137	cell	_	_	_	_	_	_	_	Seg=O
138	culture	_	_	_	_	_	_	_	Seg=O
139	and	_	_	_	_	_	_	_	Seg=B-seg
140	demonstrated	_	_	_	_	_	_	_	Seg=O
141	that	_	_	_	_	_	_	_	Seg=B-seg
142	fexaramine	_	_	_	_	_	_	_	Seg=O
143	is	_	_	_	_	_	_	_	Seg=O
144	a	_	_	_	_	_	_	_	Seg=O
145	entry	_	_	_	_	_	_	_	Seg=O
146	blocker	_	_	_	_	_	_	_	Seg=O
147	for	_	_	_	_	_	_	_	Seg=O
148	FCV	_	_	_	_	_	_	_	Seg=O
149	by	_	_	_	_	_	_	_	Seg=B-seg
150	using	_	_	_	_	_	_	_	Seg=O
151	various	_	_	_	_	_	_	_	Seg=O
152	experiments	_	_	_	_	_	_	_	Seg=O
153	including	_	_	_	_	_	_	_	Seg=B-seg
154	time	_	_	_	_	_	_	_	Seg=O
155	-	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	-	_	_	_	_	_	_	_	Seg=O
158	addition	_	_	_	_	_	_	_	Seg=O
159	studies	_	_	_	_	_	_	_	Seg=O
160	,	_	_	_	_	_	_	_	Seg=O
161	generation	_	_	_	_	_	_	_	Seg=O
162	of	_	_	_	_	_	_	_	Seg=O
163	resistant	_	_	_	_	_	_	_	Seg=O
164	viruses	_	_	_	_	_	_	_	Seg=O
165	in	_	_	_	_	_	_	_	Seg=O
166	cell	_	_	_	_	_	_	_	Seg=O
167	culture	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	reverse	_	_	_	_	_	_	_	Seg=O
171	genetics	_	_	_	_	_	_	_	Seg=O
172	system	_	_	_	_	_	_	_	Seg=O
173	.	_	_	_	_	_	_	_	Seg=O
174	A	_	_	_	_	_	_	_	Seg=B-seg
175	fexaramine	_	_	_	_	_	_	_	Seg=O
176	resistant	_	_	_	_	_	_	_	Seg=O
177	FCV	_	_	_	_	_	_	_	Seg=O
178	mutant	_	_	_	_	_	_	_	Seg=O
179	has	_	_	_	_	_	_	_	Seg=O
180	a	_	_	_	_	_	_	_	Seg=O
181	single	_	_	_	_	_	_	_	Seg=O
182	amino	_	_	_	_	_	_	_	Seg=O
183	acid	_	_	_	_	_	_	_	Seg=O
184	change	_	_	_	_	_	_	_	Seg=O
185	in	_	_	_	_	_	_	_	Seg=O
186	the	_	_	_	_	_	_	_	Seg=O
187	P2	_	_	_	_	_	_	_	Seg=O
188	domain	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	VP1	_	_	_	_	_	_	_	Seg=O
191	(	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	major	_	_	_	_	_	_	_	Seg=O
194	capsid	_	_	_	_	_	_	_	Seg=O
195	)	_	_	_	_	_	_	_	Seg=O
196	,	_	_	_	_	_	_	_	Seg=O
197	and	_	_	_	_	_	_	_	Seg=B-seg
198	the	_	_	_	_	_	_	_	Seg=O
199	importance	_	_	_	_	_	_	_	Seg=O
200	of	_	_	_	_	_	_	_	Seg=O
201	this	_	_	_	_	_	_	_	Seg=O
202	mutation	_	_	_	_	_	_	_	Seg=O
203	for	_	_	_	_	_	_	_	Seg=O
204	conferring	_	_	_	_	_	_	_	Seg=O
205	resistance	_	_	_	_	_	_	_	Seg=O
206	was	_	_	_	_	_	_	_	Seg=O
207	confirmed	_	_	_	_	_	_	_	Seg=O
208	using	_	_	_	_	_	_	_	Seg=B-seg
209	the	_	_	_	_	_	_	_	Seg=O
210	reverse	_	_	_	_	_	_	_	Seg=O
211	genetics	_	_	_	_	_	_	_	Seg=O
212	system	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O
214	A	_	_	_	_	_	_	_	Seg=B-seg
215	comparative	_	_	_	_	_	_	_	Seg=O
216	analysis	_	_	_	_	_	_	_	Seg=O
217	of	_	_	_	_	_	_	_	Seg=O
218	viral	_	_	_	_	_	_	_	Seg=O
219	resistance	_	_	_	_	_	_	_	Seg=O
220	was	_	_	_	_	_	_	_	Seg=O
221	also	_	_	_	_	_	_	_	Seg=O
222	performed	_	_	_	_	_	_	_	Seg=O
223	using	_	_	_	_	_	_	_	Seg=B-seg
224	a	_	_	_	_	_	_	_	Seg=O
225	peptidyl	_	_	_	_	_	_	_	Seg=O
226	inhibitor	_	_	_	_	_	_	_	Seg=O
227	(	_	_	_	_	_	_	_	Seg=O
228	NPI52	_	_	_	_	_	_	_	Seg=O
229	)	_	_	_	_	_	_	_	Seg=O
230	targeting	_	_	_	_	_	_	_	Seg=B-seg
231	FCV	_	_	_	_	_	_	_	Seg=O
232	3C	_	_	_	_	_	_	_	Seg=O
233	-	_	_	_	_	_	_	_	Seg=O
234	like	_	_	_	_	_	_	_	Seg=O
235	protease	_	_	_	_	_	_	_	Seg=O
236	.	_	_	_	_	_	_	_	Seg=O
237	Finally	_	_	_	_	_	_	_	Seg=B-seg
238	,	_	_	_	_	_	_	_	Seg=O
239	the	_	_	_	_	_	_	_	Seg=O
240	effects	_	_	_	_	_	_	_	Seg=O
241	of	_	_	_	_	_	_	_	Seg=O
242	combination	_	_	_	_	_	_	_	Seg=O
243	treatment	_	_	_	_	_	_	_	Seg=O
244	of	_	_	_	_	_	_	_	Seg=O
245	fexaramine	_	_	_	_	_	_	_	Seg=O
246	and	_	_	_	_	_	_	_	Seg=O
247	NPI52	_	_	_	_	_	_	_	Seg=O
248	against	_	_	_	_	_	_	_	Seg=O
249	FCV	_	_	_	_	_	_	_	Seg=O
250	replication	_	_	_	_	_	_	_	Seg=O
251	and	_	_	_	_	_	_	_	Seg=O
252	emergence	_	_	_	_	_	_	_	Seg=O
253	of	_	_	_	_	_	_	_	Seg=O
254	resistant	_	_	_	_	_	_	_	Seg=O
255	viruses	_	_	_	_	_	_	_	Seg=O
256	were	_	_	_	_	_	_	_	Seg=O
257	investigated	_	_	_	_	_	_	_	Seg=O
258	in	_	_	_	_	_	_	_	Seg=O
259	cell	_	_	_	_	_	_	_	Seg=O
260	culture	_	_	_	_	_	_	_	Seg=O
261	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6197b0f53a6a883f99c2602a89309b8b2f27da92
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	early	_	_	_	_	_	_	_	Seg=O
3	detection	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	SARS	_	_	_	_	_	_	_	Seg=O
6	-	_	_	_	_	_	_	_	Seg=O
7	CoV-2	_	_	_	_	_	_	_	Seg=O
8	,	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	causative	_	_	_	_	_	_	_	Seg=O
11	agent	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	(	_	_	_	_	_	_	_	Seg=O
14	COVID-19	_	_	_	_	_	_	_	Seg=O
15	)	_	_	_	_	_	_	_	Seg=O
16	is	_	_	_	_	_	_	_	Seg=O
17	now	_	_	_	_	_	_	_	Seg=O
18	a	_	_	_	_	_	_	_	Seg=O
19	critical	_	_	_	_	_	_	_	Seg=O
20	task	_	_	_	_	_	_	_	Seg=O
21	for	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	clinical	_	_	_	_	_	_	_	Seg=O
24	practitioners	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	The	_	_	_	_	_	_	_	Seg=B-seg
27	COVID-19	_	_	_	_	_	_	_	Seg=O
28	spread	_	_	_	_	_	_	_	Seg=O
29	is	_	_	_	_	_	_	_	Seg=O
30	announced	_	_	_	_	_	_	_	Seg=O
31	as	_	_	_	_	_	_	_	Seg=O
32	pandemic	_	_	_	_	_	_	_	Seg=O
33	outbreak	_	_	_	_	_	_	_	Seg=O
34	between	_	_	_	_	_	_	_	Seg=O
35	people	_	_	_	_	_	_	_	Seg=O
36	worldwide	_	_	_	_	_	_	_	Seg=O
37	by	_	_	_	_	_	_	_	Seg=O
38	WHO	_	_	_	_	_	_	_	Seg=O
39	since	_	_	_	_	_	_	_	Seg=O
40	11/	_	_	_	_	_	_	_	Seg=O
41	March/	_	_	_	_	_	_	_	Seg=O
42	2020	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	In	_	_	_	_	_	_	_	Seg=B-seg
45	this	_	_	_	_	_	_	_	Seg=O
46	consequence	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	it	_	_	_	_	_	_	_	Seg=O
49	is	_	_	_	_	_	_	_	Seg=O
50	top	_	_	_	_	_	_	_	Seg=O
51	critical	_	_	_	_	_	_	_	Seg=O
52	priority	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=O
54	become	_	_	_	_	_	_	_	Seg=O
55	aware	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	infected	_	_	_	_	_	_	_	Seg=O
59	people	_	_	_	_	_	_	_	Seg=O
60	so	_	_	_	_	_	_	_	Seg=B-seg
61	that	_	_	_	_	_	_	_	Seg=O
62	prevention	_	_	_	_	_	_	_	Seg=O
63	procedures	_	_	_	_	_	_	_	Seg=O
64	can	_	_	_	_	_	_	_	Seg=O
65	be	_	_	_	_	_	_	_	Seg=O
66	processed	_	_	_	_	_	_	_	Seg=O
67	to	_	_	_	_	_	_	_	Seg=B-seg
68	minimize	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	COVID-19	_	_	_	_	_	_	_	Seg=O
71	spread	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=B-seg
73	to	_	_	_	_	_	_	_	Seg=O
74	begin	_	_	_	_	_	_	_	Seg=O
75	early	_	_	_	_	_	_	_	Seg=O
76	medical	_	_	_	_	_	_	_	Seg=O
77	health	_	_	_	_	_	_	_	Seg=O
78	care	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	those	_	_	_	_	_	_	_	Seg=O
81	infected	_	_	_	_	_	_	_	Seg=O
82	persons	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	In	_	_	_	_	_	_	_	Seg=B-seg
85	this	_	_	_	_	_	_	_	Seg=O
86	paper	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	the	_	_	_	_	_	_	_	Seg=O
89	deep	_	_	_	_	_	_	_	Seg=O
90	studying	_	_	_	_	_	_	_	Seg=O
91	based	_	_	_	_	_	_	_	Seg=O
92	totally	_	_	_	_	_	_	_	Seg=O
93	methodology	_	_	_	_	_	_	_	Seg=O
94	is	_	_	_	_	_	_	_	Seg=O
95	usually	_	_	_	_	_	_	_	Seg=O
96	recommended	_	_	_	_	_	_	_	Seg=O
97	for	_	_	_	_	_	_	_	Seg=O
98	the	_	_	_	_	_	_	_	Seg=O
99	detection	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	COVID-19	_	_	_	_	_	_	_	Seg=O
102	infected	_	_	_	_	_	_	_	Seg=O
103	patients	_	_	_	_	_	_	_	Seg=O
104	using	_	_	_	_	_	_	_	Seg=B-seg
105	X	_	_	_	_	_	_	_	Seg=O
106	-	_	_	_	_	_	_	_	Seg=O
107	ray	_	_	_	_	_	_	_	Seg=O
108	images	_	_	_	_	_	_	_	Seg=O
109	.	_	_	_	_	_	_	_	Seg=O
110	The	_	_	_	_	_	_	_	Seg=B-seg
111	help	_	_	_	_	_	_	_	Seg=O
112	vector	_	_	_	_	_	_	_	Seg=O
113	gadget	_	_	_	_	_	_	_	Seg=O
114	classifies	_	_	_	_	_	_	_	Seg=O
115	the	_	_	_	_	_	_	_	Seg=O
116	corona	_	_	_	_	_	_	_	Seg=O
117	affected	_	_	_	_	_	_	_	Seg=O
118	X	_	_	_	_	_	_	_	Seg=O
119	-	_	_	_	_	_	_	_	Seg=O
120	ray	_	_	_	_	_	_	_	Seg=O
121	images	_	_	_	_	_	_	_	Seg=O
122	from	_	_	_	_	_	_	_	Seg=O
123	others	_	_	_	_	_	_	_	Seg=O
124	through	_	_	_	_	_	_	_	Seg=O
125	usage	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	the	_	_	_	_	_	_	_	Seg=O
128	deep	_	_	_	_	_	_	_	Seg=O
129	features	_	_	_	_	_	_	_	Seg=O
130	.	_	_	_	_	_	_	_	Seg=O
131	The	_	_	_	_	_	_	_	Seg=B-seg
132	technique	_	_	_	_	_	_	_	Seg=O
133	is	_	_	_	_	_	_	_	Seg=O
134	useful	_	_	_	_	_	_	_	Seg=O
135	for	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	clinical	_	_	_	_	_	_	_	Seg=O
138	practitioners	_	_	_	_	_	_	_	Seg=O
139	for	_	_	_	_	_	_	_	Seg=O
140	early	_	_	_	_	_	_	_	Seg=O
141	detection	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	COVID-19	_	_	_	_	_	_	_	Seg=O
144	infected	_	_	_	_	_	_	_	Seg=O
145	patients	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
147	The	_	_	_	_	_	_	_	Seg=B-seg
148	suggested	_	_	_	_	_	_	_	Seg=O
149	system	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	multi	_	_	_	_	_	_	_	Seg=O
152	-	_	_	_	_	_	_	_	Seg=O
153	level	_	_	_	_	_	_	_	Seg=O
154	thresholding	_	_	_	_	_	_	_	Seg=O
155	plus	_	_	_	_	_	_	_	Seg=O
156	SVM	_	_	_	_	_	_	_	Seg=O
157	presented	_	_	_	_	_	_	_	Seg=O
158	high	_	_	_	_	_	_	_	Seg=O
159	accuracy	_	_	_	_	_	_	_	Seg=O
160	in	_	_	_	_	_	_	_	Seg=O
161	classification	_	_	_	_	_	_	_	Seg=O
162	of	_	_	_	_	_	_	_	Seg=O
163	the	_	_	_	_	_	_	_	Seg=O
164	infected	_	_	_	_	_	_	_	Seg=O
165	lung	_	_	_	_	_	_	_	Seg=O
166	with	_	_	_	_	_	_	_	Seg=O
167	Covid-19	_	_	_	_	_	_	_	Seg=O
168	.	_	_	_	_	_	_	_	Seg=O
169	All	_	_	_	_	_	_	_	Seg=B-seg
170	images	_	_	_	_	_	_	_	Seg=O
171	were	_	_	_	_	_	_	_	Seg=O
172	of	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=O
174	same	_	_	_	_	_	_	_	Seg=O
175	size	_	_	_	_	_	_	_	Seg=O
176	and	_	_	_	_	_	_	_	Seg=B-seg
177	stored	_	_	_	_	_	_	_	Seg=O
178	in	_	_	_	_	_	_	_	Seg=O
179	JPEG	_	_	_	_	_	_	_	Seg=O
180	format	_	_	_	_	_	_	_	Seg=O
181	with	_	_	_	_	_	_	_	Seg=O
182	512	_	_	_	_	_	_	_	Seg=O
183	*	_	_	_	_	_	_	_	Seg=O
184	512	_	_	_	_	_	_	_	Seg=O
185	pixels	_	_	_	_	_	_	_	Seg=O
186	.	_	_	_	_	_	_	_	Seg=O
187	The	_	_	_	_	_	_	_	Seg=B-seg
188	average	_	_	_	_	_	_	_	Seg=O
189	sensitivity	_	_	_	_	_	_	_	Seg=O
190	,	_	_	_	_	_	_	_	Seg=O
191	specificity	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=O
194	accuracy	_	_	_	_	_	_	_	Seg=O
195	of	_	_	_	_	_	_	_	Seg=O
196	the	_	_	_	_	_	_	_	Seg=O
197	lung	_	_	_	_	_	_	_	Seg=O
198	classification	_	_	_	_	_	_	_	Seg=O
199	using	_	_	_	_	_	_	_	Seg=B-seg
200	the	_	_	_	_	_	_	_	Seg=O
201	proposed	_	_	_	_	_	_	_	Seg=O
202	model	_	_	_	_	_	_	_	Seg=O
203	results	_	_	_	_	_	_	_	Seg=O
204	were	_	_	_	_	_	_	_	Seg=B-seg
205	95.76	_	_	_	_	_	_	_	Seg=O
206	%	_	_	_	_	_	_	_	Seg=O
207	,	_	_	_	_	_	_	_	Seg=O
208	99.7	_	_	_	_	_	_	_	Seg=O
209	%	_	_	_	_	_	_	_	Seg=O
210	,	_	_	_	_	_	_	_	Seg=O
211	and	_	_	_	_	_	_	_	Seg=O
212	97.48	_	_	_	_	_	_	_	Seg=O
213	%	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	respectively	_	_	_	_	_	_	_	Seg=O
216	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 628c524b306aaaa50ae9b6a7017423445fd97c44
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Anecdotal	_	_	_	_	_	_	_	Seg=B-seg
4	reports	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	mood	_	_	_	_	_	_	_	Seg=O
7	disorder	_	_	_	_	_	_	_	Seg=O
8	following	_	_	_	_	_	_	_	Seg=B-seg
9	infection	_	_	_	_	_	_	_	Seg=O
10	with	_	_	_	_	_	_	_	Seg=O
11	common	_	_	_	_	_	_	_	Seg=O
12	respiratory	_	_	_	_	_	_	_	Seg=O
13	viruses	_	_	_	_	_	_	_	Seg=O
14	with	_	_	_	_	_	_	_	Seg=O
15	neurotropic	_	_	_	_	_	_	_	Seg=O
16	potential	_	_	_	_	_	_	_	Seg=O
17	have	_	_	_	_	_	_	_	Seg=B-seg
18	been	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	existence	_	_	_	_	_	_	_	Seg=O
21	since	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	last	_	_	_	_	_	_	_	Seg=O
24	century	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	Nevertheless	_	_	_	_	_	_	_	Seg=B-seg
27	,	_	_	_	_	_	_	_	Seg=O
28	systematic	_	_	_	_	_	_	_	Seg=O
29	studies	_	_	_	_	_	_	_	Seg=O
30	on	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	association	_	_	_	_	_	_	_	Seg=O
33	between	_	_	_	_	_	_	_	Seg=O
34	these	_	_	_	_	_	_	_	Seg=O
35	viruses	_	_	_	_	_	_	_	Seg=O
36	and	_	_	_	_	_	_	_	Seg=O
37	mood	_	_	_	_	_	_	_	Seg=O
38	disorders	_	_	_	_	_	_	_	Seg=O
39	are	_	_	_	_	_	_	_	Seg=O
40	lacking	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	Methods	_	_	_	_	_	_	_	Seg=B-seg
43	:	_	_	_	_	_	_	_	Seg=O
44	Influenza	_	_	_	_	_	_	_	Seg=B-seg
45	A	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	B	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	coronavirus	_	_	_	_	_	_	_	Seg=O
50	antibody	_	_	_	_	_	_	_	Seg=O
51	titers	_	_	_	_	_	_	_	Seg=O
52	were	_	_	_	_	_	_	_	Seg=O
53	measured	_	_	_	_	_	_	_	Seg=O
54	in	_	_	_	_	_	_	_	Seg=O
55	257	_	_	_	_	_	_	_	Seg=O
56	subjects	_	_	_	_	_	_	_	Seg=O
57	with	_	_	_	_	_	_	_	Seg=O
58	recurrent	_	_	_	_	_	_	_	Seg=O
59	unipolar	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=O
61	bipolar	_	_	_	_	_	_	_	Seg=O
62	disorder	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	healthy	_	_	_	_	_	_	_	Seg=O
65	controls	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	by	_	_	_	_	_	_	_	Seg=O
68	SCID	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70-71	Pearson's	_	_	_	_	_	_	_	_
70	Pearson	_	_	_	_	_	_	_	Seg=B-seg
71	's	_	_	_	_	_	_	_	Seg=O
72	χ²	_	_	_	_	_	_	_	Seg=O
73	tests	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=O
75	logistic	_	_	_	_	_	_	_	Seg=O
76	regression	_	_	_	_	_	_	_	Seg=O
77	models	_	_	_	_	_	_	_	Seg=O
78	were	_	_	_	_	_	_	_	Seg=O
79	used	_	_	_	_	_	_	_	Seg=O
80	to	_	_	_	_	_	_	_	Seg=B-seg
81	analyze	_	_	_	_	_	_	_	Seg=O
82	associations	_	_	_	_	_	_	_	Seg=O
83	between	_	_	_	_	_	_	_	Seg=O
84	seropositivity	_	_	_	_	_	_	_	Seg=O
85	for	_	_	_	_	_	_	_	Seg=O
86	coronaviruses	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	influenza	_	_	_	_	_	_	_	Seg=O
89	A	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=O
91	B	_	_	_	_	_	_	_	Seg=O
92	viruses	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=O
94	the	_	_	_	_	_	_	_	Seg=O
95	following	_	_	_	_	_	_	_	Seg=O
96	:	_	_	_	_	_	_	_	Seg=O
97	a	_	_	_	_	_	_	_	Seg=B-seg
98	)	_	_	_	_	_	_	_	Seg=O
99	history	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	recurrent	_	_	_	_	_	_	_	Seg=O
102	mood	_	_	_	_	_	_	_	Seg=O
103	disorders	_	_	_	_	_	_	_	Seg=O
104	b	_	_	_	_	_	_	_	Seg=O
105	)	_	_	_	_	_	_	_	Seg=O
106	having	_	_	_	_	_	_	_	Seg=O
107	attempted	_	_	_	_	_	_	_	Seg=O
108	suicide	_	_	_	_	_	_	_	Seg=O
109	in	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	past	_	_	_	_	_	_	_	Seg=O
112	c	_	_	_	_	_	_	_	Seg=O
113	)	_	_	_	_	_	_	_	Seg=O
114	uni	_	_	_	_	_	_	_	Seg=O
115	-	_	_	_	_	_	_	_	Seg=O
116	vs	_	_	_	_	_	_	_	Seg=O
117	.	_	_	_	_	_	_	_	Seg=O
118	bi	_	_	_	_	_	_	_	Seg=O
119	-	_	_	_	_	_	_	_	Seg=O
120	polarity	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	d	_	_	_	_	_	_	_	Seg=O
123	)	_	_	_	_	_	_	_	Seg=O
124	presence	_	_	_	_	_	_	_	Seg=O
125	of	_	_	_	_	_	_	_	Seg=O
126	psychotic	_	_	_	_	_	_	_	Seg=O
127	symptoms	_	_	_	_	_	_	_	Seg=O
128	during	_	_	_	_	_	_	_	Seg=O
129	mood	_	_	_	_	_	_	_	Seg=O
130	episodes	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O
132	Results	_	_	_	_	_	_	_	Seg=B-seg
133	:	_	_	_	_	_	_	_	Seg=O
134	Seropositivity	_	_	_	_	_	_	_	Seg=B-seg
135	for	_	_	_	_	_	_	_	Seg=O
136	influenza	_	_	_	_	_	_	_	Seg=O
137	A	_	_	_	_	_	_	_	Seg=O
138	(	_	_	_	_	_	_	_	Seg=B-seg
139	p	_	_	_	_	_	_	_	Seg=O
140	=	_	_	_	_	_	_	_	Seg=O
141	0.004	_	_	_	_	_	_	_	Seg=O
142	)	_	_	_	_	_	_	_	Seg=O
143	,	_	_	_	_	_	_	_	Seg=O
144	B	_	_	_	_	_	_	_	Seg=B-seg
145	(	_	_	_	_	_	_	_	Seg=B-seg
146	p	_	_	_	_	_	_	_	Seg=O
147	b	_	_	_	_	_	_	_	Seg=O
148	0.0001	_	_	_	_	_	_	_	Seg=O
149	)	_	_	_	_	_	_	_	Seg=O
150	and	_	_	_	_	_	_	_	Seg=B-seg
151	coronaviruses	_	_	_	_	_	_	_	Seg=O
152	(	_	_	_	_	_	_	_	Seg=B-seg
153	p	_	_	_	_	_	_	_	Seg=O
154	b	_	_	_	_	_	_	_	Seg=O
155	0.0001	_	_	_	_	_	_	_	Seg=O
156	)	_	_	_	_	_	_	_	Seg=O
157	were	_	_	_	_	_	_	_	Seg=B-seg
158	associated	_	_	_	_	_	_	_	Seg=O
159	with	_	_	_	_	_	_	_	Seg=O
160	history	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	mood	_	_	_	_	_	_	_	Seg=O
163	disorders	_	_	_	_	_	_	_	Seg=O
164	but	_	_	_	_	_	_	_	Seg=O
165	not	_	_	_	_	_	_	_	Seg=O
166	with	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	specific	_	_	_	_	_	_	_	Seg=O
169	diagnosis	_	_	_	_	_	_	_	Seg=O
170	of	_	_	_	_	_	_	_	Seg=O
171	unipolar	_	_	_	_	_	_	_	Seg=O
172	or	_	_	_	_	_	_	_	Seg=O
173	bipolar	_	_	_	_	_	_	_	Seg=O
174	depression	_	_	_	_	_	_	_	Seg=O
175	.	_	_	_	_	_	_	_	Seg=O
176	Seropositivity	_	_	_	_	_	_	_	Seg=B-seg
177	for	_	_	_	_	_	_	_	Seg=O
178	influenza	_	_	_	_	_	_	_	Seg=O
179	B	_	_	_	_	_	_	_	Seg=O
180	was	_	_	_	_	_	_	_	Seg=O
181	significantly	_	_	_	_	_	_	_	Seg=O
182	associated	_	_	_	_	_	_	_	Seg=O
183	with	_	_	_	_	_	_	_	Seg=O
184	a	_	_	_	_	_	_	_	Seg=O
185	history	_	_	_	_	_	_	_	Seg=O
186	of	_	_	_	_	_	_	_	Seg=O
187	suicide	_	_	_	_	_	_	_	Seg=O
188	attempt	_	_	_	_	_	_	_	Seg=O
189	(	_	_	_	_	_	_	_	Seg=B-seg
190	p	_	_	_	_	_	_	_	Seg=O
191	=	_	_	_	_	_	_	_	Seg=O
192	0.001	_	_	_	_	_	_	_	Seg=O
193	)	_	_	_	_	_	_	_	Seg=O
194	and	_	_	_	_	_	_	_	Seg=B-seg
195	history	_	_	_	_	_	_	_	Seg=O
196	of	_	_	_	_	_	_	_	Seg=O
197	psychotic	_	_	_	_	_	_	_	Seg=O
198	symptoms	_	_	_	_	_	_	_	Seg=O
199	(	_	_	_	_	_	_	_	Seg=B-seg
200	p	_	_	_	_	_	_	_	Seg=O
201	=	_	_	_	_	_	_	_	Seg=O
202	0.005	_	_	_	_	_	_	_	Seg=O
203	)	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O
205	Limitations	_	_	_	_	_	_	_	Seg=B-seg
206	:	_	_	_	_	_	_	_	Seg=O
207	The	_	_	_	_	_	_	_	Seg=B-seg
208	design	_	_	_	_	_	_	_	Seg=O
209	was	_	_	_	_	_	_	_	Seg=O
210	cross	_	_	_	_	_	_	_	Seg=O
211	-	_	_	_	_	_	_	_	Seg=O
212	sectional	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O
214	Socioeconomic	_	_	_	_	_	_	_	Seg=B-seg
215	factors	_	_	_	_	_	_	_	Seg=O
216	,	_	_	_	_	_	_	_	Seg=O
217	inflammatory	_	_	_	_	_	_	_	Seg=O
218	markers	_	_	_	_	_	_	_	Seg=O
219	,	_	_	_	_	_	_	_	Seg=O
220	and	_	_	_	_	_	_	_	Seg=O
221	axis	_	_	_	_	_	_	_	Seg=O
222	II	_	_	_	_	_	_	_	Seg=O
223	psychopathology	_	_	_	_	_	_	_	Seg=O
224	were	_	_	_	_	_	_	_	Seg=O
225	not	_	_	_	_	_	_	_	Seg=O
226	assessed	_	_	_	_	_	_	_	Seg=O
227	.	_	_	_	_	_	_	_	Seg=O
228	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
229	:	_	_	_	_	_	_	_	Seg=O
230	The	_	_	_	_	_	_	_	Seg=B-seg
231	association	_	_	_	_	_	_	_	Seg=O
232	of	_	_	_	_	_	_	_	Seg=O
233	seropositivity	_	_	_	_	_	_	_	Seg=O
234	for	_	_	_	_	_	_	_	Seg=O
235	influenza	_	_	_	_	_	_	_	Seg=O
236	and	_	_	_	_	_	_	_	Seg=O
237	coronaviruses	_	_	_	_	_	_	_	Seg=O
238	with	_	_	_	_	_	_	_	Seg=O
239	a	_	_	_	_	_	_	_	Seg=O
240	history	_	_	_	_	_	_	_	Seg=O
241	of	_	_	_	_	_	_	_	Seg=O
242	mood	_	_	_	_	_	_	_	Seg=O
243	disorders	_	_	_	_	_	_	_	Seg=O
244	,	_	_	_	_	_	_	_	Seg=O
245	and	_	_	_	_	_	_	_	Seg=O
246	influenza	_	_	_	_	_	_	_	Seg=O
247	B	_	_	_	_	_	_	_	Seg=O
248	with	_	_	_	_	_	_	_	Seg=O
249	suicidal	_	_	_	_	_	_	_	Seg=O
250	behavior	_	_	_	_	_	_	_	Seg=O
251	require	_	_	_	_	_	_	_	Seg=O
252	replication	_	_	_	_	_	_	_	Seg=O
253	in	_	_	_	_	_	_	_	Seg=O
254	larger	_	_	_	_	_	_	_	Seg=O
255	longitudinal	_	_	_	_	_	_	_	Seg=O
256	samples	_	_	_	_	_	_	_	Seg=O
257	.	_	_	_	_	_	_	_	Seg=O
258	The	_	_	_	_	_	_	_	Seg=B-seg
259	need	_	_	_	_	_	_	_	Seg=O
260	for	_	_	_	_	_	_	_	Seg=O
261	these	_	_	_	_	_	_	_	Seg=O
262	studies	_	_	_	_	_	_	_	Seg=O
263	is	_	_	_	_	_	_	_	Seg=O
264	additionally	_	_	_	_	_	_	_	Seg=O
265	supported	_	_	_	_	_	_	_	Seg=O
266	by	_	_	_	_	_	_	_	Seg=O
267	the	_	_	_	_	_	_	_	Seg=O
268	high	_	_	_	_	_	_	_	Seg=O
269	incidence	_	_	_	_	_	_	_	Seg=O
270	of	_	_	_	_	_	_	_	Seg=O
271	these	_	_	_	_	_	_	_	Seg=O
272	viral	_	_	_	_	_	_	_	Seg=O
273	infections	_	_	_	_	_	_	_	Seg=O
274	,	_	_	_	_	_	_	_	Seg=O
275	the	_	_	_	_	_	_	_	Seg=O
276	high	_	_	_	_	_	_	_	Seg=O
277	prevalence	_	_	_	_	_	_	_	Seg=O
278	of	_	_	_	_	_	_	_	Seg=O
279	mood	_	_	_	_	_	_	_	Seg=O
280	disorders	_	_	_	_	_	_	_	Seg=O
281	,	_	_	_	_	_	_	_	Seg=O
282	and	_	_	_	_	_	_	_	Seg=O
283	resilience	_	_	_	_	_	_	_	Seg=O
284	of	_	_	_	_	_	_	_	Seg=O
285	suicide	_	_	_	_	_	_	_	Seg=O
286	epidemics	_	_	_	_	_	_	_	Seg=O
287	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 64a850b409d63712791c985be7166bfc378315a3
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	novel	_	_	_	_	_	_	_	Seg=O
3-4	coronavirus'	_	_	_	_	_	_	_	_
3	coronavirus	_	_	_	_	_	_	_	Seg=O
4	'	_	_	_	_	_	_	_	Seg=O
5	high	_	_	_	_	_	_	_	Seg=O
6	rate	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	asymptomatic	_	_	_	_	_	_	_	Seg=O
9	transmission	_	_	_	_	_	_	_	Seg=O
10	combined	_	_	_	_	_	_	_	Seg=B-seg
11	with	_	_	_	_	_	_	_	Seg=O
12	a	_	_	_	_	_	_	_	Seg=O
13	lack	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	testing	_	_	_	_	_	_	_	Seg=O
16	kits	_	_	_	_	_	_	_	Seg=O
17	call	_	_	_	_	_	_	_	Seg=B-seg
18	for	_	_	_	_	_	_	_	Seg=O
19	a	_	_	_	_	_	_	_	Seg=O
20	different	_	_	_	_	_	_	_	Seg=O
21	approach	_	_	_	_	_	_	_	Seg=O
22	to	_	_	_	_	_	_	_	Seg=B-seg
23	monitor	_	_	_	_	_	_	_	Seg=O
24	its	_	_	_	_	_	_	_	Seg=O
25	spread	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	severity	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	We	_	_	_	_	_	_	_	Seg=B-seg
30	proposed	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	use	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	hospitalizations	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	hospital	_	_	_	_	_	_	_	Seg=O
37	utilization	_	_	_	_	_	_	_	Seg=O
38	data	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=B-seg
40	monitor	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	spread	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	severity	_	_	_	_	_	_	_	Seg=O
45	.	_	_	_	_	_	_	_	Seg=O
46	A	_	_	_	_	_	_	_	Seg=B-seg
47	proposed	_	_	_	_	_	_	_	Seg=O
48	threshold	_	_	_	_	_	_	_	Seg=O
49	of	_	_	_	_	_	_	_	Seg=O
50	a	_	_	_	_	_	_	_	Seg=O
51	declining	_	_	_	_	_	_	_	Seg=O
52	7-day	_	_	_	_	_	_	_	Seg=O
53	moving	_	_	_	_	_	_	_	Seg=O
54	average	_	_	_	_	_	_	_	Seg=O
55	over	_	_	_	_	_	_	_	Seg=O
56	a	_	_	_	_	_	_	_	Seg=O
57	14-day	_	_	_	_	_	_	_	Seg=O
58	period	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	"	_	_	_	_	_	_	_	Seg=O
61	7&14	_	_	_	_	_	_	_	Seg=O
62	"	_	_	_	_	_	_	_	Seg=O
63	was	_	_	_	_	_	_	_	Seg=O
64	set	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=B-seg
66	communicate	_	_	_	_	_	_	_	Seg=O
67	when	_	_	_	_	_	_	_	Seg=O
68	a	_	_	_	_	_	_	_	Seg=O
69	wave	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	novel	_	_	_	_	_	_	_	Seg=O
73	coronavirus	_	_	_	_	_	_	_	Seg=O
74	may	_	_	_	_	_	_	_	Seg=O
75	have	_	_	_	_	_	_	_	Seg=O
76	passed	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O
78	The	_	_	_	_	_	_	_	Seg=B-seg
79	state	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=O
81	Ohio	_	_	_	_	_	_	_	Seg=O
82	was	_	_	_	_	_	_	_	Seg=O
83	chosen	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=B-seg
85	illustrate	_	_	_	_	_	_	_	Seg=O
86	this	_	_	_	_	_	_	_	Seg=O
87	threshold	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	While	_	_	_	_	_	_	_	Seg=B-seg
90	not	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	ideal	_	_	_	_	_	_	_	Seg=O
93	solution	_	_	_	_	_	_	_	Seg=O
94	for	_	_	_	_	_	_	_	Seg=B-seg
95	monitoring	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	spread	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	epidemic	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	the	_	_	_	_	_	_	_	Seg=B-seg
103	proposed	_	_	_	_	_	_	_	Seg=O
104	approach	_	_	_	_	_	_	_	Seg=O
105	is	_	_	_	_	_	_	_	Seg=O
106	an	_	_	_	_	_	_	_	Seg=O
107	easy	_	_	_	_	_	_	_	Seg=O
108	to	_	_	_	_	_	_	_	Seg=O
109	implement	_	_	_	_	_	_	_	Seg=O
110	framework	_	_	_	_	_	_	_	Seg=O
111	accounting	_	_	_	_	_	_	_	Seg=B-seg
112	for	_	_	_	_	_	_	_	Seg=O
113	limitations	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	the	_	_	_	_	_	_	_	Seg=O
116	data	_	_	_	_	_	_	_	Seg=O
117	inherent	_	_	_	_	_	_	_	Seg=B-seg
118	in	_	_	_	_	_	_	_	Seg=O
119	the	_	_	_	_	_	_	_	Seg=O
120	current	_	_	_	_	_	_	_	Seg=O
121	epidemic	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	Hospital	_	_	_	_	_	_	_	Seg=B-seg
124	administrators	_	_	_	_	_	_	_	Seg=O
125	and	_	_	_	_	_	_	_	Seg=O
126	policy	_	_	_	_	_	_	_	Seg=O
127	makers	_	_	_	_	_	_	_	Seg=O
128	may	_	_	_	_	_	_	_	Seg=O
129	benefit	_	_	_	_	_	_	_	Seg=O
130	from	_	_	_	_	_	_	_	Seg=O
131	incorporating	_	_	_	_	_	_	_	Seg=O
132	this	_	_	_	_	_	_	_	Seg=O
133	approach	_	_	_	_	_	_	_	Seg=O
134	into	_	_	_	_	_	_	_	Seg=O
135	their	_	_	_	_	_	_	_	Seg=O
136	decision	_	_	_	_	_	_	_	Seg=O
137	making	_	_	_	_	_	_	_	Seg=O
138	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6b72cc2cfb96b6ed68bbf031175f2ff18ac80d2c
1	Severe	_	_	_	_	_	_	_	Seg=B-seg
2	acute	_	_	_	_	_	_	_	Seg=O
3	respiratory	_	_	_	_	_	_	_	Seg=O
4	syndrome	_	_	_	_	_	_	_	Seg=O
5	coronavirus	_	_	_	_	_	_	_	Seg=O
6	2	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	SARS	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	CoV-2	_	_	_	_	_	_	_	Seg=O
11	)	_	_	_	_	_	_	_	Seg=O
12	caused	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	COVID-19	_	_	_	_	_	_	_	Seg=O
15	pandemic	_	_	_	_	_	_	_	Seg=O
16	that	_	_	_	_	_	_	_	Seg=B-seg
17	has	_	_	_	_	_	_	_	Seg=O
18	been	_	_	_	_	_	_	_	Seg=O
19	spreading	_	_	_	_	_	_	_	Seg=O
20	around	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	world	_	_	_	_	_	_	_	Seg=O
23	since	_	_	_	_	_	_	_	Seg=O
24	December	_	_	_	_	_	_	_	Seg=O
25	2019	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	More	_	_	_	_	_	_	_	Seg=B-seg
28	than	_	_	_	_	_	_	_	Seg=O
29	10	_	_	_	_	_	_	_	Seg=O
30	million	_	_	_	_	_	_	_	Seg=O
31	affected	_	_	_	_	_	_	_	Seg=O
32	cases	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	more	_	_	_	_	_	_	_	Seg=O
35	than	_	_	_	_	_	_	_	Seg=O
36	half	_	_	_	_	_	_	_	Seg=O
37	a	_	_	_	_	_	_	_	Seg=O
38	million	_	_	_	_	_	_	_	Seg=O
39	deaths	_	_	_	_	_	_	_	Seg=O
40	have	_	_	_	_	_	_	_	Seg=O
41	been	_	_	_	_	_	_	_	Seg=O
42	reported	_	_	_	_	_	_	_	Seg=O
43	so	_	_	_	_	_	_	_	Seg=O
44	far	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	while	_	_	_	_	_	_	_	Seg=B-seg
47	no	_	_	_	_	_	_	_	Seg=O
48	vaccine	_	_	_	_	_	_	_	Seg=O
49	is	_	_	_	_	_	_	_	Seg=O
50	yet	_	_	_	_	_	_	_	Seg=O
51	available	_	_	_	_	_	_	_	Seg=O
52	as	_	_	_	_	_	_	_	Seg=O
53	a	_	_	_	_	_	_	_	Seg=O
54	treatment	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	Considering	_	_	_	_	_	_	_	Seg=B-seg
57	the	_	_	_	_	_	_	_	Seg=O
58	global	_	_	_	_	_	_	_	Seg=O
59	healthcare	_	_	_	_	_	_	_	Seg=O
60	urgency	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	several	_	_	_	_	_	_	_	Seg=B-seg
63	techniques	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	including	_	_	_	_	_	_	_	Seg=B-seg
66	whole	_	_	_	_	_	_	_	Seg=O
67	genome	_	_	_	_	_	_	_	Seg=O
68	sequencing	_	_	_	_	_	_	_	Seg=O
69	and	_	_	_	_	_	_	_	Seg=O
70	computed	_	_	_	_	_	_	_	Seg=O
71	tomography	_	_	_	_	_	_	_	Seg=O
72	imaging	_	_	_	_	_	_	_	Seg=O
73	have	_	_	_	_	_	_	_	Seg=B-seg
74	been	_	_	_	_	_	_	_	Seg=O
75	employed	_	_	_	_	_	_	_	Seg=O
76	for	_	_	_	_	_	_	_	Seg=B-seg
77	diagnosing	_	_	_	_	_	_	_	Seg=O
78	infected	_	_	_	_	_	_	_	Seg=O
79	people	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	Considerable	_	_	_	_	_	_	_	Seg=B-seg
82	efforts	_	_	_	_	_	_	_	Seg=O
83	are	_	_	_	_	_	_	_	Seg=O
84	also	_	_	_	_	_	_	_	Seg=O
85	directed	_	_	_	_	_	_	_	Seg=O
86	at	_	_	_	_	_	_	_	Seg=O
87	detecting	_	_	_	_	_	_	_	Seg=O
88	and	_	_	_	_	_	_	_	Seg=O
89	preventing	_	_	_	_	_	_	_	Seg=O
90	different	_	_	_	_	_	_	_	Seg=O
91	modes	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	community	_	_	_	_	_	_	_	Seg=O
94	transmission	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	Among	_	_	_	_	_	_	_	Seg=B-seg
97	them	_	_	_	_	_	_	_	Seg=O
98	is	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	rapid	_	_	_	_	_	_	_	Seg=O
101	detection	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	virus	_	_	_	_	_	_	_	Seg=O
104	presence	_	_	_	_	_	_	_	Seg=O
105	on	_	_	_	_	_	_	_	Seg=O
106	different	_	_	_	_	_	_	_	Seg=O
107	surfaces	_	_	_	_	_	_	_	Seg=O
108	with	_	_	_	_	_	_	_	Seg=B-seg
109	which	_	_	_	_	_	_	_	Seg=O
110	people	_	_	_	_	_	_	_	Seg=O
111	may	_	_	_	_	_	_	_	Seg=O
112	come	_	_	_	_	_	_	_	Seg=O
113	in	_	_	_	_	_	_	_	Seg=O
114	contact	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	Detection	_	_	_	_	_	_	_	Seg=B-seg
117	based	_	_	_	_	_	_	_	Seg=B-seg
118	on	_	_	_	_	_	_	_	Seg=O
119	non	_	_	_	_	_	_	_	Seg=O
120	-	_	_	_	_	_	_	_	Seg=O
121	contact	_	_	_	_	_	_	_	Seg=O
122	optical	_	_	_	_	_	_	_	Seg=O
123	techniques	_	_	_	_	_	_	_	Seg=O
124	is	_	_	_	_	_	_	_	Seg=B-seg
125	very	_	_	_	_	_	_	_	Seg=O
126	helpful	_	_	_	_	_	_	_	Seg=O
127	in	_	_	_	_	_	_	_	Seg=O
128	managing	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	spread	_	_	_	_	_	_	_	Seg=O
131	of	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	virus	_	_	_	_	_	_	_	Seg=O
134	,	_	_	_	_	_	_	_	Seg=O
135	and	_	_	_	_	_	_	_	Seg=O
136	to	_	_	_	_	_	_	_	Seg=O
137	aid	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	disinfection	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	surfaces	_	_	_	_	_	_	_	Seg=O
143	.	_	_	_	_	_	_	_	Seg=O
144	Nanomaterial	_	_	_	_	_	_	_	Seg=B-seg
145	-	_	_	_	_	_	_	_	Seg=O
146	based	_	_	_	_	_	_	_	Seg=O
147	methods	_	_	_	_	_	_	_	Seg=O
148	are	_	_	_	_	_	_	_	Seg=O
149	proven	_	_	_	_	_	_	_	Seg=O
150	suitable	_	_	_	_	_	_	_	Seg=O
151	for	_	_	_	_	_	_	_	Seg=O
152	rapid	_	_	_	_	_	_	_	Seg=O
153	detection	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O
155	Given	_	_	_	_	_	_	_	Seg=B-seg
156	the	_	_	_	_	_	_	_	Seg=O
157	immense	_	_	_	_	_	_	_	Seg=O
158	need	_	_	_	_	_	_	_	Seg=O
159	for	_	_	_	_	_	_	_	Seg=O
160	science	_	_	_	_	_	_	_	Seg=O
161	led	_	_	_	_	_	_	_	Seg=O
162	innovative	_	_	_	_	_	_	_	Seg=O
163	solutions	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	this	_	_	_	_	_	_	_	Seg=B-seg
166	manuscript	_	_	_	_	_	_	_	Seg=O
167	critically	_	_	_	_	_	_	_	Seg=O
168	reviews	_	_	_	_	_	_	_	Seg=O
169	recent	_	_	_	_	_	_	_	Seg=O
170	literature	_	_	_	_	_	_	_	Seg=O
171	to	_	_	_	_	_	_	_	Seg=B-seg
172	specifically	_	_	_	_	_	_	_	Seg=O
173	illustrate	_	_	_	_	_	_	_	Seg=O
174	nano	_	_	_	_	_	_	_	Seg=O
175	-	_	_	_	_	_	_	_	Seg=O
176	engineered	_	_	_	_	_	_	_	Seg=O
177	effective	_	_	_	_	_	_	_	Seg=O
178	and	_	_	_	_	_	_	_	Seg=O
179	rapid	_	_	_	_	_	_	_	Seg=O
180	solutions	_	_	_	_	_	_	_	Seg=O
181	.	_	_	_	_	_	_	_	Seg=O
182	In	_	_	_	_	_	_	_	Seg=B-seg
183	addition	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	all	_	_	_	_	_	_	_	Seg=O
186	the	_	_	_	_	_	_	_	Seg=O
187	different	_	_	_	_	_	_	_	Seg=O
188	techniques	_	_	_	_	_	_	_	Seg=O
189	are	_	_	_	_	_	_	_	Seg=O
190	critically	_	_	_	_	_	_	_	Seg=O
191	analyzed	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	compared	_	_	_	_	_	_	_	Seg=B-seg
194	,	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=B-seg
196	contrasted	_	_	_	_	_	_	_	Seg=O
197	to	_	_	_	_	_	_	_	Seg=B-seg
198	identify	_	_	_	_	_	_	_	Seg=O
199	the	_	_	_	_	_	_	_	Seg=O
200	most	_	_	_	_	_	_	_	Seg=O
201	promising	_	_	_	_	_	_	_	Seg=O
202	methods	_	_	_	_	_	_	_	Seg=O
203	.	_	_	_	_	_	_	_	Seg=O
204	Moreover	_	_	_	_	_	_	_	Seg=B-seg
205	,	_	_	_	_	_	_	_	Seg=O
206	promising	_	_	_	_	_	_	_	Seg=O
207	research	_	_	_	_	_	_	_	Seg=O
208	ideas	_	_	_	_	_	_	_	Seg=O
209	for	_	_	_	_	_	_	_	Seg=O
210	high	_	_	_	_	_	_	_	Seg=O
211	accuracy	_	_	_	_	_	_	_	Seg=O
212	of	_	_	_	_	_	_	_	Seg=O
213	detection	_	_	_	_	_	_	_	Seg=O
214	in	_	_	_	_	_	_	_	Seg=O
215	trace	_	_	_	_	_	_	_	Seg=O
216	concentrations	_	_	_	_	_	_	_	Seg=O
217	,	_	_	_	_	_	_	_	Seg=O
218	via	_	_	_	_	_	_	_	Seg=O
219	color	_	_	_	_	_	_	_	Seg=O
220	change	_	_	_	_	_	_	_	Seg=O
221	and	_	_	_	_	_	_	_	Seg=O
222	light	_	_	_	_	_	_	_	Seg=O
223	-	_	_	_	_	_	_	_	Seg=O
224	sensitive	_	_	_	_	_	_	_	Seg=O
225	nanostructures	_	_	_	_	_	_	_	Seg=O
226	,	_	_	_	_	_	_	_	Seg=O
227	to	_	_	_	_	_	_	_	Seg=B-seg
228	assist	_	_	_	_	_	_	_	Seg=O
229	fingerprint	_	_	_	_	_	_	_	Seg=O
230	techniques	_	_	_	_	_	_	_	Seg=O
231	(	_	_	_	_	_	_	_	Seg=B-seg
232	to	_	_	_	_	_	_	_	Seg=O
233	identify	_	_	_	_	_	_	_	Seg=O
234	the	_	_	_	_	_	_	_	Seg=O
235	virus	_	_	_	_	_	_	_	Seg=O
236	at	_	_	_	_	_	_	_	Seg=O
237	the	_	_	_	_	_	_	_	Seg=O
238	contact	_	_	_	_	_	_	_	Seg=O
239	surface	_	_	_	_	_	_	_	Seg=O
240	of	_	_	_	_	_	_	_	Seg=O
241	the	_	_	_	_	_	_	_	Seg=O
242	gas	_	_	_	_	_	_	_	Seg=O
243	and	_	_	_	_	_	_	_	Seg=O
244	solid	_	_	_	_	_	_	_	Seg=O
245	phase	_	_	_	_	_	_	_	Seg=O
246	)	_	_	_	_	_	_	_	Seg=O
247	are	_	_	_	_	_	_	_	Seg=B-seg
248	also	_	_	_	_	_	_	_	Seg=O
249	presented	_	_	_	_	_	_	_	Seg=O
250	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6e704c9d3e78ca76678b668e56990e6a02c0e966
1	We	_	_	_	_	_	_	_	Seg=B-seg
2	argue	_	_	_	_	_	_	_	Seg=O
3	that	_	_	_	_	_	_	_	Seg=B-seg
4	the	_	_	_	_	_	_	_	Seg=O
5	incentive	_	_	_	_	_	_	_	Seg=O
6	structure	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	all	_	_	_	_	_	_	_	Seg=O
9	individual	_	_	_	_	_	_	_	Seg=O
10	and	_	_	_	_	_	_	_	Seg=O
11	coordinated	_	_	_	_	_	_	_	Seg=O
12	measures	_	_	_	_	_	_	_	Seg=O
13	across	_	_	_	_	_	_	_	Seg=O
14	countries	_	_	_	_	_	_	_	Seg=O
15	to	_	_	_	_	_	_	_	Seg=B-seg
16	contain	_	_	_	_	_	_	_	Seg=O
17	the	_	_	_	_	_	_	_	Seg=O
18	corona	_	_	_	_	_	_	_	Seg=O
19	-	_	_	_	_	_	_	_	Seg=O
20	pandemic	_	_	_	_	_	_	_	Seg=O
21	is	_	_	_	_	_	_	_	Seg=B-seg
22	that	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	a	_	_	_	_	_	_	_	Seg=O
25	weakest	_	_	_	_	_	_	_	Seg=O
26	-	_	_	_	_	_	_	_	Seg=O
27	link	_	_	_	_	_	_	_	Seg=O
28	public	_	_	_	_	_	_	_	Seg=O
29	good	_	_	_	_	_	_	_	Seg=O
30	game	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	We	_	_	_	_	_	_	_	Seg=B-seg
33	discuss	_	_	_	_	_	_	_	Seg=O
34	a	_	_	_	_	_	_	_	Seg=O
35	selection	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	theoretical	_	_	_	_	_	_	_	Seg=O
38	and	_	_	_	_	_	_	_	Seg=O
39	experimental	_	_	_	_	_	_	_	Seg=O
40	key	_	_	_	_	_	_	_	Seg=O
41	results	_	_	_	_	_	_	_	Seg=O
42	of	_	_	_	_	_	_	_	Seg=O
43	weakest	_	_	_	_	_	_	_	Seg=O
44	-	_	_	_	_	_	_	_	Seg=O
45	link	_	_	_	_	_	_	_	Seg=O
46	games	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=B-seg
48	interpret	_	_	_	_	_	_	_	Seg=O
49	them	_	_	_	_	_	_	_	Seg=O
50	in	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	light	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	corona	_	_	_	_	_	_	_	Seg=O
56	-	_	_	_	_	_	_	_	Seg=O
57	pandemic	_	_	_	_	_	_	_	Seg=O
58	.	_	_	_	_	_	_	_	Seg=O
59	First	_	_	_	_	_	_	_	Seg=B-seg
60	,	_	_	_	_	_	_	_	Seg=O
61	we	_	_	_	_	_	_	_	Seg=O
62	highlight	_	_	_	_	_	_	_	Seg=O
63	that	_	_	_	_	_	_	_	Seg=B-seg
64	experimental	_	_	_	_	_	_	_	Seg=O
65	evidence	_	_	_	_	_	_	_	Seg=O
66	does	_	_	_	_	_	_	_	Seg=O
67	not	_	_	_	_	_	_	_	Seg=O
68	support	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	assumption	_	_	_	_	_	_	_	Seg=O
71	that	_	_	_	_	_	_	_	Seg=B-seg
72	coordination	_	_	_	_	_	_	_	Seg=O
73	can	_	_	_	_	_	_	_	Seg=O
74	be	_	_	_	_	_	_	_	Seg=O
75	trivially	_	_	_	_	_	_	_	Seg=O
76	solved	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	even	_	_	_	_	_	_	_	Seg=O
79	among	_	_	_	_	_	_	_	Seg=O
80	symmetric	_	_	_	_	_	_	_	Seg=O
81	players	_	_	_	_	_	_	_	Seg=O
82	.	_	_	_	_	_	_	_	Seg=O
83	Second	_	_	_	_	_	_	_	Seg=B-seg
84	,	_	_	_	_	_	_	_	Seg=O
85	we	_	_	_	_	_	_	_	Seg=O
86	argue	_	_	_	_	_	_	_	Seg=O
87	that	_	_	_	_	_	_	_	Seg=B-seg
88	for	_	_	_	_	_	_	_	Seg=O
89	asymmetric	_	_	_	_	_	_	_	Seg=O
90	countries	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	weakest	_	_	_	_	_	_	_	Seg=O
93	-	_	_	_	_	_	_	_	Seg=O
94	link	_	_	_	_	_	_	_	Seg=O
95	game	_	_	_	_	_	_	_	Seg=O
96	does	_	_	_	_	_	_	_	Seg=O
97	not	_	_	_	_	_	_	_	Seg=O
98	only	_	_	_	_	_	_	_	Seg=O
99	pose	_	_	_	_	_	_	_	Seg=O
100	a	_	_	_	_	_	_	_	Seg=O
101	problem	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	coordination	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	but	_	_	_	_	_	_	_	Seg=B-seg
106	also	_	_	_	_	_	_	_	Seg=O
107	a	_	_	_	_	_	_	_	Seg=O
108	problem	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=O
110	cooperation	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	Third	_	_	_	_	_	_	_	Seg=B-seg
113	,	_	_	_	_	_	_	_	Seg=O
114	we	_	_	_	_	_	_	_	Seg=O
115	show	_	_	_	_	_	_	_	Seg=O
116	how	_	_	_	_	_	_	_	Seg=B-seg
117	and	_	_	_	_	_	_	_	Seg=O
118	under	_	_	_	_	_	_	_	Seg=O
119	which	_	_	_	_	_	_	_	Seg=O
120	conditions	_	_	_	_	_	_	_	Seg=O
121	self	_	_	_	_	_	_	_	Seg=O
122	-	_	_	_	_	_	_	_	Seg=O
123	enforcing	_	_	_	_	_	_	_	Seg=O
124	treaties	_	_	_	_	_	_	_	Seg=O
125	can	_	_	_	_	_	_	_	Seg=O
126	foster	_	_	_	_	_	_	_	Seg=O
127	coordination	_	_	_	_	_	_	_	Seg=O
128	and	_	_	_	_	_	_	_	Seg=O
129	cooperation	_	_	_	_	_	_	_	Seg=O
130	.	_	_	_	_	_	_	_	Seg=O
131	We	_	_	_	_	_	_	_	Seg=B-seg
132	account	_	_	_	_	_	_	_	Seg=O
133	for	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	possibility	_	_	_	_	_	_	_	Seg=O
136	that	_	_	_	_	_	_	_	Seg=B-seg
137	countries	_	_	_	_	_	_	_	Seg=O
138	make	_	_	_	_	_	_	_	Seg=O
139	mistakes	_	_	_	_	_	_	_	Seg=O
140	when	_	_	_	_	_	_	_	Seg=B-seg
141	choosing	_	_	_	_	_	_	_	Seg=O
142	their	_	_	_	_	_	_	_	Seg=O
143	actions	_	_	_	_	_	_	_	Seg=O
144	.	_	_	_	_	_	_	_	Seg=O
145	Our	_	_	_	_	_	_	_	Seg=B-seg
146	discussion	_	_	_	_	_	_	_	Seg=O
147	shows	_	_	_	_	_	_	_	Seg=O
148	that	_	_	_	_	_	_	_	Seg=B-seg
149	North	_	_	_	_	_	_	_	Seg=O
150	-	_	_	_	_	_	_	_	Seg=O
151	South	_	_	_	_	_	_	_	Seg=O
152	cooperation	_	_	_	_	_	_	_	Seg=O
153	is	_	_	_	_	_	_	_	Seg=O
154	relevant	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=B-seg
156	likely	_	_	_	_	_	_	_	Seg=O
157	to	_	_	_	_	_	_	_	Seg=O
158	be	_	_	_	_	_	_	_	Seg=O
159	self	_	_	_	_	_	_	_	Seg=O
160	-	_	_	_	_	_	_	_	Seg=O
161	enforcing	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=B-seg
163	that	_	_	_	_	_	_	_	Seg=O
164	regional	_	_	_	_	_	_	_	Seg=O
165	cooperation	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	e.g.	_	_	_	_	_	_	_	Seg=B-seg
168	,	_	_	_	_	_	_	_	Seg=O
169	within	_	_	_	_	_	_	_	Seg=O
170	the	_	_	_	_	_	_	_	Seg=O
171	EU	_	_	_	_	_	_	_	Seg=O
172	,	_	_	_	_	_	_	_	Seg=O
173	will	_	_	_	_	_	_	_	Seg=B-seg
174	also	_	_	_	_	_	_	_	Seg=O
175	be	_	_	_	_	_	_	_	Seg=O
176	important	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 714d9af12264fb74a536d77b974cbd6ad65f44e2
1	Severe	_	_	_	_	_	_	_	Seg=B-seg
2	Acute	_	_	_	_	_	_	_	Seg=O
3	Respiratory	_	_	_	_	_	_	_	Seg=O
4	Syndrome	_	_	_	_	_	_	_	Seg=O
5	Coronavirus-2	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	SARS	_	_	_	_	_	_	_	Seg=O
8	-	_	_	_	_	_	_	_	Seg=O
9	CoV-2	_	_	_	_	_	_	_	Seg=O
10	)	_	_	_	_	_	_	_	Seg=O
11	has	_	_	_	_	_	_	_	Seg=O
12	recently	_	_	_	_	_	_	_	Seg=O
13	caused	_	_	_	_	_	_	_	Seg=O
14	a	_	_	_	_	_	_	_	Seg=O
15	pandemic	_	_	_	_	_	_	_	Seg=O
16	that	_	_	_	_	_	_	_	Seg=B-seg
17	has	_	_	_	_	_	_	_	Seg=O
18	involved	_	_	_	_	_	_	_	Seg=O
19	Italy	_	_	_	_	_	_	_	Seg=O
20	as	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	second	_	_	_	_	_	_	_	Seg=O
23	worldwide	_	_	_	_	_	_	_	Seg=O
24	nation	_	_	_	_	_	_	_	Seg=O
25	in	_	_	_	_	_	_	_	Seg=O
26	terms	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	infected	_	_	_	_	_	_	_	Seg=O
29	patients	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	deaths	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	The	_	_	_	_	_	_	_	Seg=B-seg
34	clinical	_	_	_	_	_	_	_	Seg=O
35	manifestation	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	Covid-19	_	_	_	_	_	_	_	Seg=O
38	ranges	_	_	_	_	_	_	_	Seg=O
39	from	_	_	_	_	_	_	_	Seg=O
40	asymptomatic	_	_	_	_	_	_	_	Seg=O
41	carrier	_	_	_	_	_	_	_	Seg=O
42	status	_	_	_	_	_	_	_	Seg=O
43	to	_	_	_	_	_	_	_	Seg=O
44	severe	_	_	_	_	_	_	_	Seg=O
45	pneumonia	_	_	_	_	_	_	_	Seg=O
46	.	_	_	_	_	_	_	_	Seg=O
47	Asymptomatic	_	_	_	_	_	_	_	Seg=B-seg
48	individuals	_	_	_	_	_	_	_	Seg=O
49	in	_	_	_	_	_	_	_	Seg=O
50	Covid-19	_	_	_	_	_	_	_	Seg=O
51	are	_	_	_	_	_	_	_	Seg=O
52	those	_	_	_	_	_	_	_	Seg=O
53	who	_	_	_	_	_	_	_	Seg=B-seg
54	are	_	_	_	_	_	_	_	Seg=O
55	carriers	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	virus	_	_	_	_	_	_	_	Seg=O
59	but	_	_	_	_	_	_	_	Seg=B-seg
60	do	_	_	_	_	_	_	_	Seg=O
61	not	_	_	_	_	_	_	_	Seg=O
62	show	_	_	_	_	_	_	_	Seg=O
63	clinical	_	_	_	_	_	_	_	Seg=O
64	symptoms	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=B-seg
66	are	_	_	_	_	_	_	_	Seg=O
67	able	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=O
69	transmit	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	disease	_	_	_	_	_	_	_	Seg=O
72	in	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	same	_	_	_	_	_	_	_	Seg=O
75	degree	_	_	_	_	_	_	_	Seg=O
76	as	_	_	_	_	_	_	_	Seg=O
77	symptomatic	_	_	_	_	_	_	_	Seg=O
78	carriers	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	In	_	_	_	_	_	_	_	Seg=B-seg
81	order	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=O
83	contain	_	_	_	_	_	_	_	Seg=O
84	contagions	_	_	_	_	_	_	_	Seg=O
85	is	_	_	_	_	_	_	_	Seg=B-seg
86	of	_	_	_	_	_	_	_	Seg=O
87	supreme	_	_	_	_	_	_	_	Seg=O
88	importance	_	_	_	_	_	_	_	Seg=O
89	to	_	_	_	_	_	_	_	Seg=O
90	identify	_	_	_	_	_	_	_	Seg=O
91	asymptomatic	_	_	_	_	_	_	_	Seg=O
92	patients	_	_	_	_	_	_	_	Seg=O
93	because	_	_	_	_	_	_	_	Seg=B-seg
94	this	_	_	_	_	_	_	_	Seg=O
95	subpopulation	_	_	_	_	_	_	_	Seg=O
96	is	_	_	_	_	_	_	_	Seg=O
97	one	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	main	_	_	_	_	_	_	_	Seg=O
101	factors	_	_	_	_	_	_	_	Seg=O
102	contributing	_	_	_	_	_	_	_	Seg=B-seg
103	to	_	_	_	_	_	_	_	Seg=O
104	the	_	_	_	_	_	_	_	Seg=O
105	spread	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	this	_	_	_	_	_	_	_	Seg=O
108	disease	_	_	_	_	_	_	_	Seg=O
109	.	_	_	_	_	_	_	_	Seg=O
110	We	_	_	_	_	_	_	_	Seg=B-seg
111	report	_	_	_	_	_	_	_	Seg=O
112	on	_	_	_	_	_	_	_	Seg=O
113	six	_	_	_	_	_	_	_	Seg=O
114	Italian	_	_	_	_	_	_	_	Seg=O
115	patients	_	_	_	_	_	_	_	Seg=O
116	with	_	_	_	_	_	_	_	Seg=O
117	COVID-19	_	_	_	_	_	_	_	Seg=O
118	who	_	_	_	_	_	_	_	Seg=B-seg
119	presented	_	_	_	_	_	_	_	Seg=O
120	sudden	_	_	_	_	_	_	_	Seg=O
121	hyposmia	_	_	_	_	_	_	_	Seg=O
122	as	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	only	_	_	_	_	_	_	_	Seg=O
125	or	_	_	_	_	_	_	_	Seg=O
126	most	_	_	_	_	_	_	_	Seg=O
127	prominent	_	_	_	_	_	_	_	Seg=O
128	disease	_	_	_	_	_	_	_	Seg=O
129	manifestation	_	_	_	_	_	_	_	Seg=O
130	,	_	_	_	_	_	_	_	Seg=O
131	without	_	_	_	_	_	_	_	Seg=O
132	upper	_	_	_	_	_	_	_	Seg=O
133	or	_	_	_	_	_	_	_	Seg=O
134	lower	_	_	_	_	_	_	_	Seg=O
135	respiratory	_	_	_	_	_	_	_	Seg=O
136	tract	_	_	_	_	_	_	_	Seg=O
137	involvement	_	_	_	_	_	_	_	Seg=O
138	or	_	_	_	_	_	_	_	Seg=O
139	other	_	_	_	_	_	_	_	Seg=O
140	major	_	_	_	_	_	_	_	Seg=O
141	features	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	the	_	_	_	_	_	_	_	Seg=O
144	disease	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	A	_	_	_	_	_	_	_	Seg=B-seg
147	supra	_	_	_	_	_	_	_	Seg=O
148	-	_	_	_	_	_	_	_	Seg=O
149	threshold	_	_	_	_	_	_	_	Seg=O
150	olfaction	_	_	_	_	_	_	_	Seg=O
151	test	_	_	_	_	_	_	_	Seg=O
152	confirmed	_	_	_	_	_	_	_	Seg=O
153	the	_	_	_	_	_	_	_	Seg=O
154	hyposmia	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	all	_	_	_	_	_	_	_	Seg=O
157	patients	_	_	_	_	_	_	_	Seg=O
158	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 74c27dd895ee9f14d0b9584b8a3551a0600f05e2
1	Plant	_	_	_	_	_	_	_	Seg=B-seg
2	artificial	_	_	_	_	_	_	_	Seg=O
3	micro	_	_	_	_	_	_	_	Seg=O
4	-	_	_	_	_	_	_	_	Seg=O
5	RNAs	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	amiRs	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	have	_	_	_	_	_	_	_	Seg=O
10	been	_	_	_	_	_	_	_	Seg=O
11	engineered	_	_	_	_	_	_	_	Seg=O
12	to	_	_	_	_	_	_	_	Seg=B-seg
13	target	_	_	_	_	_	_	_	Seg=O
14	viral	_	_	_	_	_	_	_	Seg=O
15	genomes	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=B-seg
17	induce	_	_	_	_	_	_	_	Seg=O
18	their	_	_	_	_	_	_	_	Seg=O
19	degradation	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	However	_	_	_	_	_	_	_	Seg=B-seg
22	,	_	_	_	_	_	_	_	Seg=O
23	the	_	_	_	_	_	_	_	Seg=O
24	exceptional	_	_	_	_	_	_	_	Seg=O
25	evolutionary	_	_	_	_	_	_	_	Seg=O
26	plasticity	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	RNA	_	_	_	_	_	_	_	Seg=O
29	viruses	_	_	_	_	_	_	_	Seg=O
30	threatens	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	durability	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	resistance	_	_	_	_	_	_	_	Seg=O
36	conferred	_	_	_	_	_	_	_	Seg=B-seg
37	by	_	_	_	_	_	_	_	Seg=O
38	these	_	_	_	_	_	_	_	Seg=O
39	amiRs	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	It	_	_	_	_	_	_	_	Seg=B-seg
42	has	_	_	_	_	_	_	_	Seg=O
43	recently	_	_	_	_	_	_	_	Seg=O
44	been	_	_	_	_	_	_	_	Seg=O
45	shown	_	_	_	_	_	_	_	Seg=O
46	that	_	_	_	_	_	_	_	Seg=O
47	viral	_	_	_	_	_	_	_	Seg=O
48	populations	_	_	_	_	_	_	_	Seg=O
49	not	_	_	_	_	_	_	_	Seg=B-seg
50	experiencing	_	_	_	_	_	_	_	Seg=O
51	strong	_	_	_	_	_	_	_	Seg=O
52	selective	_	_	_	_	_	_	_	Seg=O
53	pressure	_	_	_	_	_	_	_	Seg=O
54	from	_	_	_	_	_	_	_	Seg=O
55	an	_	_	_	_	_	_	_	Seg=O
56	antiviral	_	_	_	_	_	_	_	Seg=O
57	amiR	_	_	_	_	_	_	_	Seg=O
58	may	_	_	_	_	_	_	_	Seg=B-seg
59	already	_	_	_	_	_	_	_	Seg=O
60	contain	_	_	_	_	_	_	_	Seg=O
61	enough	_	_	_	_	_	_	_	Seg=O
62	genetic	_	_	_	_	_	_	_	Seg=O
63	variability	_	_	_	_	_	_	_	Seg=O
64	in	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	target	_	_	_	_	_	_	_	Seg=O
67	sequence	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=B-seg
69	escape	_	_	_	_	_	_	_	Seg=O
70	plant	_	_	_	_	_	_	_	Seg=O
71	resistance	_	_	_	_	_	_	_	Seg=O
72	in	_	_	_	_	_	_	_	Seg=O
73	an	_	_	_	_	_	_	_	Seg=O
74	almost	_	_	_	_	_	_	_	Seg=O
75	deterministic	_	_	_	_	_	_	_	Seg=O
76	manner	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O
78	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
79	,	_	_	_	_	_	_	_	Seg=O
80	it	_	_	_	_	_	_	_	Seg=O
81	has	_	_	_	_	_	_	_	Seg=O
82	also	_	_	_	_	_	_	_	Seg=O
83	been	_	_	_	_	_	_	_	Seg=O
84	shown	_	_	_	_	_	_	_	Seg=O
85	that	_	_	_	_	_	_	_	Seg=O
86	viral	_	_	_	_	_	_	_	Seg=O
87	populations	_	_	_	_	_	_	_	Seg=O
88	exposed	_	_	_	_	_	_	_	Seg=B-seg
89	to	_	_	_	_	_	_	_	Seg=O
90	subinhibitory	_	_	_	_	_	_	_	Seg=O
91	concentrations	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	antiviral	_	_	_	_	_	_	_	Seg=O
95	amiR	_	_	_	_	_	_	_	Seg=O
96	speed	_	_	_	_	_	_	_	Seg=B-seg
97	up	_	_	_	_	_	_	_	Seg=O
98	this	_	_	_	_	_	_	_	Seg=O
99	process	_	_	_	_	_	_	_	Seg=O
100	.	_	_	_	_	_	_	_	Seg=O
101	In	_	_	_	_	_	_	_	Seg=B-seg
102	this	_	_	_	_	_	_	_	Seg=O
103	article	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	we	_	_	_	_	_	_	_	Seg=O
106	have	_	_	_	_	_	_	_	Seg=O
107	characterized	_	_	_	_	_	_	_	Seg=O
108	the	_	_	_	_	_	_	_	Seg=O
109	molecular	_	_	_	_	_	_	_	Seg=O
110	evolutionary	_	_	_	_	_	_	_	Seg=O
111	dynamics	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	an	_	_	_	_	_	_	_	Seg=O
114	amiR	_	_	_	_	_	_	_	Seg=O
115	target	_	_	_	_	_	_	_	Seg=O
116	sequence	_	_	_	_	_	_	_	Seg=O
117	in	_	_	_	_	_	_	_	Seg=O
118	a	_	_	_	_	_	_	_	Seg=O
119	viral	_	_	_	_	_	_	_	Seg=O
120	genome	_	_	_	_	_	_	_	Seg=O
121	under	_	_	_	_	_	_	_	Seg=O
122	both	_	_	_	_	_	_	_	Seg=O
123	conditions	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	The	_	_	_	_	_	_	_	Seg=B-seg
126	use	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	Illumina	_	_	_	_	_	_	_	Seg=O
129	ultradeep	_	_	_	_	_	_	_	Seg=O
130	sequencing	_	_	_	_	_	_	_	Seg=O
131	has	_	_	_	_	_	_	_	Seg=O
132	allowed	_	_	_	_	_	_	_	Seg=O
133	us	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=O
135	identify	_	_	_	_	_	_	_	Seg=O
136	virus	_	_	_	_	_	_	_	Seg=O
137	sequence	_	_	_	_	_	_	_	Seg=O
138	variants	_	_	_	_	_	_	_	Seg=O
139	at	_	_	_	_	_	_	_	Seg=O
140	frequencies	_	_	_	_	_	_	_	Seg=O
141	as	_	_	_	_	_	_	_	Seg=O
142	low	_	_	_	_	_	_	_	Seg=O
143	as	_	_	_	_	_	_	_	Seg=O
144	2	_	_	_	_	_	_	_	Seg=O
145	Â	_	_	_	_	_	_	_	Seg=O
146	10	_	_	_	_	_	_	_	Seg=O
147	À6	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=O
149	to	_	_	_	_	_	_	_	Seg=O
150	track	_	_	_	_	_	_	_	Seg=O
151	their	_	_	_	_	_	_	_	Seg=O
152	variation	_	_	_	_	_	_	_	Seg=O
153	in	_	_	_	_	_	_	_	Seg=O
154	time	_	_	_	_	_	_	_	Seg=O
155	before	_	_	_	_	_	_	_	Seg=B-seg
156	and	_	_	_	_	_	_	_	Seg=O
157	after	_	_	_	_	_	_	_	Seg=O
158	the	_	_	_	_	_	_	_	Seg=O
159	viral	_	_	_	_	_	_	_	Seg=O
160	population	_	_	_	_	_	_	_	Seg=O
161	was	_	_	_	_	_	_	_	Seg=O
162	able	_	_	_	_	_	_	_	Seg=O
163	of	_	_	_	_	_	_	_	Seg=O
164	successfully	_	_	_	_	_	_	_	Seg=O
165	infecting	_	_	_	_	_	_	_	Seg=O
166	plants	_	_	_	_	_	_	_	Seg=O
167	fully	_	_	_	_	_	_	_	Seg=O
168	resistant	_	_	_	_	_	_	_	Seg=O
169	to	_	_	_	_	_	_	_	Seg=O
170	the	_	_	_	_	_	_	_	Seg=O
171	ancestral	_	_	_	_	_	_	_	Seg=O
172	virus	_	_	_	_	_	_	_	Seg=O
173	.	_	_	_	_	_	_	_	Seg=O
174	We	_	_	_	_	_	_	_	Seg=B-seg
175	found	_	_	_	_	_	_	_	Seg=O
176	that	_	_	_	_	_	_	_	Seg=B-seg
177	every	_	_	_	_	_	_	_	Seg=O
178	site	_	_	_	_	_	_	_	Seg=O
179	in	_	_	_	_	_	_	_	Seg=O
180	the	_	_	_	_	_	_	_	Seg=O
181	amiR	_	_	_	_	_	_	_	Seg=O
182	-	_	_	_	_	_	_	_	Seg=O
183	target	_	_	_	_	_	_	_	Seg=O
184	sequence	_	_	_	_	_	_	_	Seg=O
185	of	_	_	_	_	_	_	_	Seg=O
186	the	_	_	_	_	_	_	_	Seg=O
187	viral	_	_	_	_	_	_	_	Seg=O
188	genome	_	_	_	_	_	_	_	Seg=O
189	presented	_	_	_	_	_	_	_	Seg=O
190	variation	_	_	_	_	_	_	_	Seg=O
191	and	_	_	_	_	_	_	_	Seg=B-seg
192	that	_	_	_	_	_	_	_	Seg=O
193	the	_	_	_	_	_	_	_	Seg=O
194	variant	_	_	_	_	_	_	_	Seg=O
195	that	_	_	_	_	_	_	_	Seg=B-seg
196	eventually	_	_	_	_	_	_	_	Seg=O
197	broke	_	_	_	_	_	_	_	Seg=O
198	resistance	_	_	_	_	_	_	_	Seg=O
199	was	_	_	_	_	_	_	_	Seg=B-seg
200	sampled	_	_	_	_	_	_	_	Seg=O
201	among	_	_	_	_	_	_	_	Seg=O
202	the	_	_	_	_	_	_	_	Seg=O
203	many	_	_	_	_	_	_	_	Seg=O
204	coexisting	_	_	_	_	_	_	_	Seg=O
205	ones	_	_	_	_	_	_	_	Seg=O
206	.	_	_	_	_	_	_	_	Seg=O
207	In	_	_	_	_	_	_	_	Seg=B-seg
208	this	_	_	_	_	_	_	_	Seg=O
209	system	_	_	_	_	_	_	_	Seg=O
210	,	_	_	_	_	_	_	_	Seg=O
211	viral	_	_	_	_	_	_	_	Seg=O
212	evolution	_	_	_	_	_	_	_	Seg=O
213	in	_	_	_	_	_	_	_	Seg=O
214	fully	_	_	_	_	_	_	_	Seg=O
215	susceptible	_	_	_	_	_	_	_	Seg=O
216	plants	_	_	_	_	_	_	_	Seg=O
217	results	_	_	_	_	_	_	_	Seg=O
218	from	_	_	_	_	_	_	_	Seg=O
219	an	_	_	_	_	_	_	_	Seg=O
220	equilibrium	_	_	_	_	_	_	_	Seg=O
221	between	_	_	_	_	_	_	_	Seg=O
222	mutation	_	_	_	_	_	_	_	Seg=O
223	and	_	_	_	_	_	_	_	Seg=O
224	genetic	_	_	_	_	_	_	_	Seg=O
225	drift	_	_	_	_	_	_	_	Seg=O
226	,	_	_	_	_	_	_	_	Seg=O
227	whereas	_	_	_	_	_	_	_	Seg=B-seg
228	evolution	_	_	_	_	_	_	_	Seg=O
229	in	_	_	_	_	_	_	_	Seg=O
230	partially	_	_	_	_	_	_	_	Seg=O
231	resistant	_	_	_	_	_	_	_	Seg=O
232	plants	_	_	_	_	_	_	_	Seg=O
233	originates	_	_	_	_	_	_	_	Seg=O
234	from	_	_	_	_	_	_	_	Seg=O
235	more	_	_	_	_	_	_	_	Seg=O
236	complex	_	_	_	_	_	_	_	Seg=O
237	dynamics	_	_	_	_	_	_	_	Seg=O
238	involving	_	_	_	_	_	_	_	Seg=B-seg
239	mutation	_	_	_	_	_	_	_	Seg=O
240	,	_	_	_	_	_	_	_	Seg=O
241	selection	_	_	_	_	_	_	_	Seg=O
242	,	_	_	_	_	_	_	_	Seg=O
243	and	_	_	_	_	_	_	_	Seg=O
244	drift	_	_	_	_	_	_	_	Seg=O
245	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 762f9b6467251b8e21ad0a838c12a2c6c5ab9a10
1	Avian	_	_	_	_	_	_	_	Seg=B-seg
2	infectious	_	_	_	_	_	_	_	Seg=O
3	bronchitis	_	_	_	_	_	_	_	Seg=O
4	virus	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	IBV	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	is	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	member	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	group	_	_	_	_	_	_	_	Seg=O
14	III	_	_	_	_	_	_	_	Seg=O
15	coronaviruses	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	which	_	_	_	_	_	_	_	Seg=B-seg
18	differ	_	_	_	_	_	_	_	Seg=O
19	from	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	other	_	_	_	_	_	_	_	Seg=O
22	groups	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	coronaviruses	_	_	_	_	_	_	_	Seg=O
25	in	_	_	_	_	_	_	_	Seg=B-seg
26	that	_	_	_	_	_	_	_	Seg=O
27	they	_	_	_	_	_	_	_	Seg=O
28	do	_	_	_	_	_	_	_	Seg=O
29	not	_	_	_	_	_	_	_	Seg=O
30	encode	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	essential	_	_	_	_	_	_	_	Seg=O
33	pathogenic	_	_	_	_	_	_	_	Seg=O
34	factor	_	_	_	_	_	_	_	Seg=O
35	nonstructural	_	_	_	_	_	_	_	Seg=O
36	protein	_	_	_	_	_	_	_	Seg=O
37	1	_	_	_	_	_	_	_	Seg=O
38	(	_	_	_	_	_	_	_	Seg=O
39	nsp1	_	_	_	_	_	_	_	Seg=O
40	)	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=B-seg
42	instead	_	_	_	_	_	_	_	Seg=O
43	start	_	_	_	_	_	_	_	Seg=O
44	with	_	_	_	_	_	_	_	Seg=O
45	nsp2	_	_	_	_	_	_	_	Seg=O
46	.	_	_	_	_	_	_	_	Seg=O
47	IBV	_	_	_	_	_	_	_	Seg=B-seg
48	nsp2	_	_	_	_	_	_	_	Seg=O
49	is	_	_	_	_	_	_	_	Seg=O
50	one	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	first	_	_	_	_	_	_	_	Seg=O
54	replicase	_	_	_	_	_	_	_	Seg=O
55	proteins	_	_	_	_	_	_	_	Seg=O
56	to	_	_	_	_	_	_	_	Seg=B-seg
57	be	_	_	_	_	_	_	_	Seg=O
58	translated	_	_	_	_	_	_	_	Seg=O
59	and	_	_	_	_	_	_	_	Seg=O
60	processed	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	viral	_	_	_	_	_	_	_	Seg=O
64	life	_	_	_	_	_	_	_	Seg=O
65	cycle	_	_	_	_	_	_	_	Seg=O
66	;	_	_	_	_	_	_	_	Seg=O
67	however	_	_	_	_	_	_	_	Seg=B-seg
68	,	_	_	_	_	_	_	_	Seg=O
69	it	_	_	_	_	_	_	_	Seg=O
70	has	_	_	_	_	_	_	_	Seg=O
71	an	_	_	_	_	_	_	_	Seg=O
72	entirely	_	_	_	_	_	_	_	Seg=O
73	unknown	_	_	_	_	_	_	_	Seg=O
74	function	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	In	_	_	_	_	_	_	_	Seg=B-seg
77	order	_	_	_	_	_	_	_	Seg=O
78	to	_	_	_	_	_	_	_	Seg=O
79	better	_	_	_	_	_	_	_	Seg=O
80	understand	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	structural	_	_	_	_	_	_	_	Seg=O
83	details	_	_	_	_	_	_	_	Seg=O
84	and	_	_	_	_	_	_	_	Seg=O
85	functional	_	_	_	_	_	_	_	Seg=O
86	mechanism	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	IBV	_	_	_	_	_	_	_	Seg=O
89	nsp2	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=B-seg
92	recombinant	_	_	_	_	_	_	_	Seg=O
93	protein	_	_	_	_	_	_	_	Seg=O
94	was	_	_	_	_	_	_	_	Seg=O
95	cloned	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	overexpressed	_	_	_	_	_	_	_	Seg=B-seg
98	in	_	_	_	_	_	_	_	Seg=O
99	Escherichia	_	_	_	_	_	_	_	Seg=O
100	coli	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	purified	_	_	_	_	_	_	_	Seg=B-seg
103	and	_	_	_	_	_	_	_	Seg=B-seg
104	crystallized	_	_	_	_	_	_	_	Seg=O
105	.	_	_	_	_	_	_	_	Seg=O
106	The	_	_	_	_	_	_	_	Seg=B-seg
107	crystals	_	_	_	_	_	_	_	Seg=O
108	diffracted	_	_	_	_	_	_	_	Seg=O
109	to	_	_	_	_	_	_	_	Seg=O
110	2.8	_	_	_	_	_	_	_	Seg=O
111	Å	_	_	_	_	_	_	_	Seg=O
112	resolution	_	_	_	_	_	_	_	Seg=O
113	and	_	_	_	_	_	_	_	Seg=B-seg
114	belonged	_	_	_	_	_	_	_	Seg=O
115	to	_	_	_	_	_	_	_	Seg=O
116	space	_	_	_	_	_	_	_	Seg=O
117	group	_	_	_	_	_	_	_	Seg=O
118	P2	_	_	_	_	_	_	_	Seg=O
119	1	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	with	_	_	_	_	_	_	_	Seg=O
122	unit	_	_	_	_	_	_	_	Seg=O
123	-	_	_	_	_	_	_	_	Seg=O
124	cell	_	_	_	_	_	_	_	Seg=O
125	parameters	_	_	_	_	_	_	_	Seg=O
126	a	_	_	_	_	_	_	_	Seg=O
127	=	_	_	_	_	_	_	_	Seg=O
128	57.0	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	b	_	_	_	_	_	_	_	Seg=O
131	=	_	_	_	_	_	_	_	Seg=O
132	192.3	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	c	_	_	_	_	_	_	_	Seg=O
135	=	_	_	_	_	_	_	_	Seg=O
136	105.7	_	_	_	_	_	_	_	Seg=O
137	Å	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	=	_	_	_	_	_	_	_	Seg=O
140	90.8	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O
142	Two	_	_	_	_	_	_	_	Seg=B-seg
143	molecules	_	_	_	_	_	_	_	Seg=O
144	were	_	_	_	_	_	_	_	Seg=O
145	found	_	_	_	_	_	_	_	Seg=O
146	in	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	asymmetric	_	_	_	_	_	_	_	Seg=O
149	unit	_	_	_	_	_	_	_	Seg=O
150	;	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=B-seg
152	Matthews	_	_	_	_	_	_	_	Seg=O
153	coefficient	_	_	_	_	_	_	_	Seg=O
154	was	_	_	_	_	_	_	_	Seg=O
155	3.9	_	_	_	_	_	_	_	Seg=O
156	Å	_	_	_	_	_	_	_	Seg=O
157	3	_	_	_	_	_	_	_	Seg=O
158	Da	_	_	_	_	_	_	_	Seg=O
159	À1	_	_	_	_	_	_	_	Seg=O
160	,	_	_	_	_	_	_	_	Seg=O
161	corresponding	_	_	_	_	_	_	_	Seg=B-seg
162	to	_	_	_	_	_	_	_	Seg=O
163	a	_	_	_	_	_	_	_	Seg=O
164	solvent	_	_	_	_	_	_	_	Seg=O
165	content	_	_	_	_	_	_	_	Seg=O
166	of	_	_	_	_	_	_	_	Seg=O
167	68.2	_	_	_	_	_	_	_	Seg=O
168	%	_	_	_	_	_	_	_	Seg=O
169	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 79fa8fdc827ebf13a568461671621f811d9af7f5
1	Canine	_	_	_	_	_	_	_	Seg=B-seg
2	parvovirus	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	CPV	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	number	_	_	_	_	_	_	_	Seg=O
9	one	_	_	_	_	_	_	_	Seg=O
10	viral	_	_	_	_	_	_	_	Seg=O
11	cause	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	enteritis	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	morbidity	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=O
18	mortality	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	8-week	_	_	_	_	_	_	_	Seg=O
21	-	_	_	_	_	_	_	_	Seg=O
22	old	_	_	_	_	_	_	_	Seg=O
23	young	_	_	_	_	_	_	_	Seg=O
24	puppies	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	We	_	_	_	_	_	_	_	Seg=B-seg
27	have	_	_	_	_	_	_	_	Seg=O
28	developed	_	_	_	_	_	_	_	Seg=O
29	twin	_	_	_	_	_	_	_	Seg=O
30	assays	_	_	_	_	_	_	_	Seg=O
31	(	_	_	_	_	_	_	_	Seg=B-seg
32	slide	_	_	_	_	_	_	_	Seg=O
33	agglutination	_	_	_	_	_	_	_	Seg=O
34	test	_	_	_	_	_	_	_	Seg=O
35	[	_	_	_	_	_	_	_	Seg=O
36	SAT	_	_	_	_	_	_	_	Seg=O
37	]	_	_	_	_	_	_	_	Seg=O
38	for	_	_	_	_	_	_	_	Seg=O
39	CPV	_	_	_	_	_	_	_	Seg=O
40	antigen	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	slide	_	_	_	_	_	_	_	Seg=O
43	inhibition	_	_	_	_	_	_	_	Seg=O
44	test	_	_	_	_	_	_	_	Seg=O
45	[	_	_	_	_	_	_	_	Seg=O
46	SIT	_	_	_	_	_	_	_	Seg=O
47	]	_	_	_	_	_	_	_	Seg=O
48	for	_	_	_	_	_	_	_	Seg=O
49	CPV	_	_	_	_	_	_	_	Seg=O
50	antibody	_	_	_	_	_	_	_	Seg=O
51	)	_	_	_	_	_	_	_	Seg=O
52	that	_	_	_	_	_	_	_	Seg=B-seg
53	are	_	_	_	_	_	_	_	Seg=O
54	sensitive	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	specific	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	cost	_	_	_	_	_	_	_	Seg=O
59	-	_	_	_	_	_	_	_	Seg=O
60	effective	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	generic	_	_	_	_	_	_	_	Seg=O
63	for	_	_	_	_	_	_	_	Seg=O
64	all	_	_	_	_	_	_	_	Seg=O
65	genotypes	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	CPV	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	and	_	_	_	_	_	_	_	Seg=B-seg
70	provide	_	_	_	_	_	_	_	Seg=O
71	instant	_	_	_	_	_	_	_	Seg=O
72	results	_	_	_	_	_	_	_	Seg=O
73	for	_	_	_	_	_	_	_	Seg=O
74	CPV	_	_	_	_	_	_	_	Seg=O
75	antigen	_	_	_	_	_	_	_	Seg=O
76	detection	_	_	_	_	_	_	_	Seg=O
77	in	_	_	_	_	_	_	_	Seg=O
78	feces	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	antibody	_	_	_	_	_	_	_	Seg=O
81	quantification	_	_	_	_	_	_	_	Seg=O
82	in	_	_	_	_	_	_	_	Seg=O
83	serum	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	We	_	_	_	_	_	_	_	Seg=B-seg
86	found	_	_	_	_	_	_	_	Seg=O
87	these	_	_	_	_	_	_	_	Seg=O
88	assays	_	_	_	_	_	_	_	Seg=O
89	to	_	_	_	_	_	_	_	Seg=O
90	be	_	_	_	_	_	_	_	Seg=O
91	useful	_	_	_	_	_	_	_	Seg=O
92	for	_	_	_	_	_	_	_	Seg=O
93	routine	_	_	_	_	_	_	_	Seg=O
94	applications	_	_	_	_	_	_	_	Seg=O
95	in	_	_	_	_	_	_	_	Seg=O
96	kennels	_	_	_	_	_	_	_	Seg=O
97	with	_	_	_	_	_	_	_	Seg=O
98	large	_	_	_	_	_	_	_	Seg=O
99	numbers	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	puppies	_	_	_	_	_	_	_	Seg=O
102	at	_	_	_	_	_	_	_	Seg=O
103	risk	_	_	_	_	_	_	_	Seg=O
104	.	_	_	_	_	_	_	_	Seg=O
105	The	_	_	_	_	_	_	_	Seg=B-seg
106	results	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	these	_	_	_	_	_	_	_	Seg=O
109	assays	_	_	_	_	_	_	_	Seg=O
110	are	_	_	_	_	_	_	_	Seg=O
111	available	_	_	_	_	_	_	_	Seg=O
112	in	_	_	_	_	_	_	_	Seg=O
113	1	_	_	_	_	_	_	_	Seg=O
114	min	_	_	_	_	_	_	_	Seg=O
115	and	_	_	_	_	_	_	_	Seg=B-seg
116	do	_	_	_	_	_	_	_	Seg=O
117	not	_	_	_	_	_	_	_	Seg=O
118	require	_	_	_	_	_	_	_	Seg=O
119	any	_	_	_	_	_	_	_	Seg=O
120	special	_	_	_	_	_	_	_	Seg=O
121	instrumentation	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	SAT	_	_	_	_	_	_	_	Seg=B-seg
124	-	_	_	_	_	_	_	_	Seg=O
125	SIT	_	_	_	_	_	_	_	Seg=O
126	technology	_	_	_	_	_	_	_	Seg=O
127	will	_	_	_	_	_	_	_	Seg=O
128	find	_	_	_	_	_	_	_	Seg=O
129	applications	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=O
131	rapid	_	_	_	_	_	_	_	Seg=O
132	screening	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	samples	_	_	_	_	_	_	_	Seg=O
135	for	_	_	_	_	_	_	_	Seg=O
136	other	_	_	_	_	_	_	_	Seg=O
137	hemagglutinating	_	_	_	_	_	_	_	Seg=O
138	emerging	_	_	_	_	_	_	_	Seg=O
139	viruses	_	_	_	_	_	_	_	Seg=O
140	of	_	_	_	_	_	_	_	Seg=O
141	animals	_	_	_	_	_	_	_	Seg=O
142	and	_	_	_	_	_	_	_	Seg=O
143	humans	_	_	_	_	_	_	_	Seg=O
144	(	_	_	_	_	_	_	_	Seg=B-seg
145	influenza	_	_	_	_	_	_	_	Seg=O
146	virus	_	_	_	_	_	_	_	Seg=O
147	and	_	_	_	_	_	_	_	Seg=O
148	severe	_	_	_	_	_	_	_	Seg=O
149	acute	_	_	_	_	_	_	_	Seg=O
150	respiratory	_	_	_	_	_	_	_	Seg=O
151	syndrome	_	_	_	_	_	_	_	Seg=O
152	coronavirus	_	_	_	_	_	_	_	Seg=O
153	)	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 7a2057b8b17dac8f41d6e811296470fbca62165e
1	Introduction	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Myocarditis	_	_	_	_	_	_	_	Seg=B-seg
4	is	_	_	_	_	_	_	_	Seg=O
5	rarely	_	_	_	_	_	_	_	Seg=O
6	reported	_	_	_	_	_	_	_	Seg=O
7	as	_	_	_	_	_	_	_	Seg=O
8	an	_	_	_	_	_	_	_	Seg=O
9	extra	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	pulmonary	_	_	_	_	_	_	_	Seg=O
12	manifestation	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	influenza	_	_	_	_	_	_	_	Seg=O
15	while	_	_	_	_	_	_	_	Seg=B-seg
16	pregnancy	_	_	_	_	_	_	_	Seg=O
17	is	_	_	_	_	_	_	_	Seg=O
18	a	_	_	_	_	_	_	_	Seg=O
19	rare	_	_	_	_	_	_	_	Seg=O
20	cause	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	cardiomyopathy	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Pregnancy	_	_	_	_	_	_	_	Seg=B-seg
25	was	_	_	_	_	_	_	_	Seg=O
26	identified	_	_	_	_	_	_	_	Seg=O
27	as	_	_	_	_	_	_	_	Seg=O
28	a	_	_	_	_	_	_	_	Seg=O
29	major	_	_	_	_	_	_	_	Seg=O
30	risk	_	_	_	_	_	_	_	Seg=O
31	factor	_	_	_	_	_	_	_	Seg=O
32	for	_	_	_	_	_	_	_	Seg=O
33	increased	_	_	_	_	_	_	_	Seg=O
34	mortality	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	morbidity	_	_	_	_	_	_	_	Seg=O
37	due	_	_	_	_	_	_	_	Seg=B-seg
38	to	_	_	_	_	_	_	_	Seg=O
39	H	_	_	_	_	_	_	_	Seg=O
40	1	_	_	_	_	_	_	_	Seg=O
41	N	_	_	_	_	_	_	_	Seg=O
42	1	_	_	_	_	_	_	_	Seg=O
43	influenza	_	_	_	_	_	_	_	Seg=O
44	in	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	pandemic	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	2009	_	_	_	_	_	_	_	Seg=O
49	to	_	_	_	_	_	_	_	Seg=O
50	2010	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	However	_	_	_	_	_	_	_	Seg=B-seg
53	,	_	_	_	_	_	_	_	Seg=O
54	to	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	best	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	our	_	_	_	_	_	_	_	Seg=O
59	knowledge	_	_	_	_	_	_	_	Seg=O
60	there	_	_	_	_	_	_	_	Seg=O
61	are	_	_	_	_	_	_	_	Seg=O
62	no	_	_	_	_	_	_	_	Seg=O
63	previous	_	_	_	_	_	_	_	Seg=O
64	reports	_	_	_	_	_	_	_	Seg=O
65	in	_	_	_	_	_	_	_	Seg=O
66	the	_	_	_	_	_	_	_	Seg=O
67	literature	_	_	_	_	_	_	_	Seg=O
68	linking	_	_	_	_	_	_	_	Seg=B-seg
69	H	_	_	_	_	_	_	_	Seg=O
70	1	_	_	_	_	_	_	_	Seg=O
71	N	_	_	_	_	_	_	_	Seg=O
72	1	_	_	_	_	_	_	_	Seg=O
73	with	_	_	_	_	_	_	_	Seg=O
74	myocarditis	_	_	_	_	_	_	_	Seg=O
75	in	_	_	_	_	_	_	_	Seg=O
76	pregnancy	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O
78	Case	_	_	_	_	_	_	_	Seg=B-seg
79	presentation	_	_	_	_	_	_	_	Seg=O
80	:	_	_	_	_	_	_	_	Seg=O
81	We	_	_	_	_	_	_	_	Seg=B-seg
82	report	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	cases	_	_	_	_	_	_	_	Seg=O
85	of	_	_	_	_	_	_	_	Seg=O
86	two	_	_	_	_	_	_	_	Seg=O
87	pregnant	_	_	_	_	_	_	_	Seg=O
88	Caucasian	_	_	_	_	_	_	_	Seg=O
89	women	_	_	_	_	_	_	_	Seg=O
90	(	_	_	_	_	_	_	_	Seg=B-seg
91	aged	_	_	_	_	_	_	_	Seg=O
92	29	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=O
94	30	_	_	_	_	_	_	_	Seg=O
95	)	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	with	_	_	_	_	_	_	_	Seg=B-seg
98	no	_	_	_	_	_	_	_	Seg=O
99	preexisting	_	_	_	_	_	_	_	Seg=O
100	illness	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	presenting	_	_	_	_	_	_	_	Seg=B-seg
103	with	_	_	_	_	_	_	_	Seg=O
104	respiratory	_	_	_	_	_	_	_	Seg=O
105	manifestations	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	H	_	_	_	_	_	_	_	Seg=O
108	1	_	_	_	_	_	_	_	Seg=O
109	N	_	_	_	_	_	_	_	Seg=O
110	1	_	_	_	_	_	_	_	Seg=O
111	influenza	_	_	_	_	_	_	_	Seg=O
112	virus	_	_	_	_	_	_	_	Seg=O
113	infection	_	_	_	_	_	_	_	Seg=O
114	in	_	_	_	_	_	_	_	Seg=O
115	their	_	_	_	_	_	_	_	Seg=O
116	third	_	_	_	_	_	_	_	Seg=O
117	trimester	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	Both	_	_	_	_	_	_	_	Seg=B-seg
120	women	_	_	_	_	_	_	_	Seg=O
121	developed	_	_	_	_	_	_	_	Seg=O
122	evidence	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	myocarditis	_	_	_	_	_	_	_	Seg=O
125	.	_	_	_	_	_	_	_	Seg=O
126	One	_	_	_	_	_	_	_	Seg=B-seg
127	woman	_	_	_	_	_	_	_	Seg=O
128	developed	_	_	_	_	_	_	_	Seg=O
129	acute	_	_	_	_	_	_	_	Seg=O
130	respiratory	_	_	_	_	_	_	_	Seg=O
131	distress	_	_	_	_	_	_	_	Seg=O
132	syndrome	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	almost	_	_	_	_	_	_	_	Seg=B-seg
135	reaching	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	point	_	_	_	_	_	_	_	Seg=O
138	of	_	_	_	_	_	_	_	Seg=O
139	requiring	_	_	_	_	_	_	_	Seg=O
140	extra	_	_	_	_	_	_	_	Seg=O
141	-	_	_	_	_	_	_	_	Seg=O
142	corporeal	_	_	_	_	_	_	_	Seg=O
143	membrane	_	_	_	_	_	_	_	Seg=O
144	oxygenation	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=B-seg
147	subsequently	_	_	_	_	_	_	_	Seg=O
148	developed	_	_	_	_	_	_	_	Seg=O
149	persistent	_	_	_	_	_	_	_	Seg=O
150	cardiomyopathy	_	_	_	_	_	_	_	Seg=O
151	;	_	_	_	_	_	_	_	Seg=O
152	the	_	_	_	_	_	_	_	Seg=B-seg
153	other	_	_	_	_	_	_	_	Seg=O
154	recovered	_	_	_	_	_	_	_	Seg=O
155	without	_	_	_	_	_	_	_	Seg=O
156	any	_	_	_	_	_	_	_	Seg=O
157	long	_	_	_	_	_	_	_	Seg=O
158	-	_	_	_	_	_	_	_	Seg=O
159	term	_	_	_	_	_	_	_	Seg=O
160	consequence	_	_	_	_	_	_	_	Seg=O
161	.	_	_	_	_	_	_	_	Seg=O
162	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
163	:	_	_	_	_	_	_	_	Seg=O
164	While	_	_	_	_	_	_	_	Seg=B-seg
165	it	_	_	_	_	_	_	_	Seg=O
166	is	_	_	_	_	_	_	_	Seg=O
167	not	_	_	_	_	_	_	_	Seg=O
168	possible	_	_	_	_	_	_	_	Seg=O
169	to	_	_	_	_	_	_	_	Seg=O
170	ascertain	_	_	_	_	_	_	_	Seg=O
171	retrospectively	_	_	_	_	_	_	_	Seg=O
172	if	_	_	_	_	_	_	_	Seg=O
173	myocarditis	_	_	_	_	_	_	_	Seg=O
174	was	_	_	_	_	_	_	_	Seg=O
175	caused	_	_	_	_	_	_	_	Seg=O
176	by	_	_	_	_	_	_	_	Seg=O
177	either	_	_	_	_	_	_	_	Seg=O
178	infection	_	_	_	_	_	_	_	Seg=O
179	with	_	_	_	_	_	_	_	Seg=O
180	H	_	_	_	_	_	_	_	Seg=O
181	1	_	_	_	_	_	_	_	Seg=O
182	N	_	_	_	_	_	_	_	Seg=O
183	1	_	_	_	_	_	_	_	Seg=O
184	virus	_	_	_	_	_	_	_	Seg=O
185	or	_	_	_	_	_	_	_	Seg=O
186	as	_	_	_	_	_	_	_	Seg=O
187	a	_	_	_	_	_	_	_	Seg=O
188	result	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	pregnancy	_	_	_	_	_	_	_	Seg=O
191	(	_	_	_	_	_	_	_	Seg=O
192	in	_	_	_	_	_	_	_	Seg=O
193	the	_	_	_	_	_	_	_	Seg=O
194	absence	_	_	_	_	_	_	_	Seg=O
195	of	_	_	_	_	_	_	_	Seg=O
196	endomyocardial	_	_	_	_	_	_	_	Seg=O
197	biopsies	_	_	_	_	_	_	_	Seg=O
198	)	_	_	_	_	_	_	_	Seg=O
199	,	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=B-seg
201	significant	_	_	_	_	_	_	_	Seg=O
202	association	_	_	_	_	_	_	_	Seg=O
203	with	_	_	_	_	_	_	_	Seg=O
204	myocardial	_	_	_	_	_	_	_	Seg=O
205	involvement	_	_	_	_	_	_	_	Seg=O
206	in	_	_	_	_	_	_	_	Seg=O
207	both	_	_	_	_	_	_	_	Seg=O
208	women	_	_	_	_	_	_	_	Seg=O
209	demonstrates	_	_	_	_	_	_	_	Seg=O
210	the	_	_	_	_	_	_	_	Seg=O
211	increased	_	_	_	_	_	_	_	Seg=O
212	risk	_	_	_	_	_	_	_	Seg=O
213	of	_	_	_	_	_	_	_	Seg=O
214	exposure	_	_	_	_	_	_	_	Seg=O
215	to	_	_	_	_	_	_	_	Seg=O
216	H	_	_	_	_	_	_	_	Seg=O
217	1	_	_	_	_	_	_	_	Seg=O
218	N	_	_	_	_	_	_	_	Seg=O
219	1	_	_	_	_	_	_	_	Seg=O
220	influenza	_	_	_	_	_	_	_	Seg=O
221	virus	_	_	_	_	_	_	_	Seg=O
222	in	_	_	_	_	_	_	_	Seg=O
223	pregnant	_	_	_	_	_	_	_	Seg=O
224	women	_	_	_	_	_	_	_	Seg=O
225	.	_	_	_	_	_	_	_	Seg=O
226	This	_	_	_	_	_	_	_	Seg=B-seg
227	highlights	_	_	_	_	_	_	_	Seg=O
228	the	_	_	_	_	_	_	_	Seg=O
229	need	_	_	_	_	_	_	_	Seg=O
230	for	_	_	_	_	_	_	_	Seg=O
231	health	_	_	_	_	_	_	_	Seg=O
232	care	_	_	_	_	_	_	_	Seg=O
233	providers	_	_	_	_	_	_	_	Seg=O
234	to	_	_	_	_	_	_	_	Seg=O
235	increase	_	_	_	_	_	_	_	Seg=O
236	awareness	_	_	_	_	_	_	_	Seg=O
237	amongst	_	_	_	_	_	_	_	Seg=O
238	caregivers	_	_	_	_	_	_	_	Seg=O
239	to	_	_	_	_	_	_	_	Seg=B-seg
240	target	_	_	_	_	_	_	_	Seg=O
241	this	_	_	_	_	_	_	_	Seg=O
242	'	_	_	_	_	_	_	_	Seg=O
243	at	_	_	_	_	_	_	_	Seg=O
244	risk	_	_	_	_	_	_	_	Seg=O
245	'	_	_	_	_	_	_	_	Seg=O
246	group	_	_	_	_	_	_	_	Seg=O
247	aggressively	_	_	_	_	_	_	_	Seg=O
248	with	_	_	_	_	_	_	_	Seg=O
249	vaccination	_	_	_	_	_	_	_	Seg=O
250	and	_	_	_	_	_	_	_	Seg=O
251	prompt	_	_	_	_	_	_	_	Seg=O
252	treatment	_	_	_	_	_	_	_	Seg=O
253	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 7f4558c4cb1d6fb9bbe9a522ca25924740e76b0a
1	SARS	_	_	_	_	_	_	_	Seg=B-seg
2	-	_	_	_	_	_	_	_	Seg=O
3	CoV-2	_	_	_	_	_	_	_	Seg=O
4	is	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	new	_	_	_	_	_	_	_	Seg=O
7	RNA	_	_	_	_	_	_	_	Seg=O
8	virus	_	_	_	_	_	_	_	Seg=O
9	affecting	_	_	_	_	_	_	_	Seg=B-seg
10	humans	_	_	_	_	_	_	_	Seg=O
11	and	_	_	_	_	_	_	_	Seg=B-seg
12	spreads	_	_	_	_	_	_	_	Seg=O
13	extensively	_	_	_	_	_	_	_	Seg=O
14	through	_	_	_	_	_	_	_	Seg=O
15	world	_	_	_	_	_	_	_	Seg=O
16	populations	_	_	_	_	_	_	_	Seg=O
17	since	_	_	_	_	_	_	_	Seg=O
18	its	_	_	_	_	_	_	_	Seg=O
19	first	_	_	_	_	_	_	_	Seg=O
20	outbreak	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	late	_	_	_	_	_	_	_	Seg=O
23	December	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	2019	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	Whether	_	_	_	_	_	_	_	Seg=B-seg
28	the	_	_	_	_	_	_	_	Seg=O
29	transmissibility	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	pathogenicity	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	SARS	_	_	_	_	_	_	_	Seg=O
34	-	_	_	_	_	_	_	_	Seg=O
35	CoV-2	_	_	_	_	_	_	_	Seg=O
36	is	_	_	_	_	_	_	_	Seg=O
37	actively	_	_	_	_	_	_	_	Seg=O
38	evolving	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	and	_	_	_	_	_	_	_	Seg=O
41	driven	_	_	_	_	_	_	_	Seg=O
42	by	_	_	_	_	_	_	_	Seg=O
43	adaptation	_	_	_	_	_	_	_	Seg=O
44	to	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	new	_	_	_	_	_	_	_	Seg=O
47	host	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	environments	_	_	_	_	_	_	_	Seg=O
50	is	_	_	_	_	_	_	_	Seg=O
51	still	_	_	_	_	_	_	_	Seg=O
52	unknown	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	Understanding	_	_	_	_	_	_	_	Seg=B-seg
55	the	_	_	_	_	_	_	_	Seg=O
56	evolutionary	_	_	_	_	_	_	_	Seg=O
57	mechanism	_	_	_	_	_	_	_	Seg=O
58	underlying	_	_	_	_	_	_	_	Seg=B-seg
59	epidemiological	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=O
61	pathological	_	_	_	_	_	_	_	Seg=O
62	characteristics	_	_	_	_	_	_	_	Seg=O
63	of	_	_	_	_	_	_	_	Seg=O
64	COVID-19	_	_	_	_	_	_	_	Seg=O
65	is	_	_	_	_	_	_	_	Seg=B-seg
66	essential	_	_	_	_	_	_	_	Seg=O
67	for	_	_	_	_	_	_	_	Seg=O
68	predicting	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	epidemic	_	_	_	_	_	_	_	Seg=O
71	trend	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	and	_	_	_	_	_	_	_	Seg=B-seg
74	providing	_	_	_	_	_	_	_	Seg=O
75	guidance	_	_	_	_	_	_	_	Seg=O
76	for	_	_	_	_	_	_	_	Seg=O
77	disease	_	_	_	_	_	_	_	Seg=O
78	control	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	treatments	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	Interrogating	_	_	_	_	_	_	_	Seg=B-seg
83	22,078	_	_	_	_	_	_	_	Seg=O
84	SARS	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	CoV-2	_	_	_	_	_	_	_	Seg=O
87	genome	_	_	_	_	_	_	_	Seg=O
88	sequences	_	_	_	_	_	_	_	Seg=O
89	of	_	_	_	_	_	_	_	Seg=O
90	84	_	_	_	_	_	_	_	Seg=O
91	countries	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	we	_	_	_	_	_	_	_	Seg=B-seg
94	demonstrate	_	_	_	_	_	_	_	Seg=O
95	with	_	_	_	_	_	_	_	Seg=O
96	convincing	_	_	_	_	_	_	_	Seg=O
97	evidence	_	_	_	_	_	_	_	Seg=O
98	that	_	_	_	_	_	_	_	Seg=B-seg
99	(	_	_	_	_	_	_	_	Seg=O
100	i	_	_	_	_	_	_	_	Seg=O
101	)	_	_	_	_	_	_	_	Seg=O
102	SARS	_	_	_	_	_	_	_	Seg=O
103	-	_	_	_	_	_	_	_	Seg=O
104	CoV-2	_	_	_	_	_	_	_	Seg=O
105	genomes	_	_	_	_	_	_	_	Seg=O
106	are	_	_	_	_	_	_	_	Seg=O
107	overall	_	_	_	_	_	_	_	Seg=O
108	conserved	_	_	_	_	_	_	_	Seg=O
109	under	_	_	_	_	_	_	_	Seg=O
110	purifying	_	_	_	_	_	_	_	Seg=O
111	selection	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	(	_	_	_	_	_	_	_	Seg=B-seg
114	ii	_	_	_	_	_	_	_	Seg=O
115	)	_	_	_	_	_	_	_	Seg=O
116	Ongoing	_	_	_	_	_	_	_	Seg=O
117	positive	_	_	_	_	_	_	_	Seg=O
118	selection	_	_	_	_	_	_	_	Seg=O
119	is	_	_	_	_	_	_	_	Seg=O
120	actively	_	_	_	_	_	_	_	Seg=O
121	driving	_	_	_	_	_	_	_	Seg=O
122	the	_	_	_	_	_	_	_	Seg=O
123	evolution	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	specific	_	_	_	_	_	_	_	Seg=O
126	genes	_	_	_	_	_	_	_	Seg=O
127	.	_	_	_	_	_	_	_	Seg=O
128	Notably	_	_	_	_	_	_	_	Seg=B-seg
129	,	_	_	_	_	_	_	_	Seg=O
130	genes	_	_	_	_	_	_	_	Seg=O
131	related	_	_	_	_	_	_	_	Seg=B-seg
132	to	_	_	_	_	_	_	_	Seg=O
133	coronavirus	_	_	_	_	_	_	_	Seg=O
134	infection	_	_	_	_	_	_	_	Seg=O
135	and	_	_	_	_	_	_	_	Seg=O
136	host	_	_	_	_	_	_	_	Seg=O
137	immune	_	_	_	_	_	_	_	Seg=O
138	system	_	_	_	_	_	_	_	Seg=O
139	defense	_	_	_	_	_	_	_	Seg=O
140	are	_	_	_	_	_	_	_	Seg=B-seg
141	under	_	_	_	_	_	_	_	Seg=O
142	adaptive	_	_	_	_	_	_	_	Seg=O
143	evolution	_	_	_	_	_	_	_	Seg=O
144	while	_	_	_	_	_	_	_	Seg=B-seg
145	genes	_	_	_	_	_	_	_	Seg=O
146	related	_	_	_	_	_	_	_	Seg=B-seg
147	to	_	_	_	_	_	_	_	Seg=O
148	viral	_	_	_	_	_	_	_	Seg=O
149	RNA	_	_	_	_	_	_	_	Seg=O
150	replication	_	_	_	_	_	_	_	Seg=O
151	,	_	_	_	_	_	_	_	Seg=O
152	transcription	_	_	_	_	_	_	_	Seg=O
153	and	_	_	_	_	_	_	_	Seg=O
154	translation	_	_	_	_	_	_	_	Seg=O
155	are	_	_	_	_	_	_	_	Seg=B-seg
156	under	_	_	_	_	_	_	_	Seg=O
157	purifying	_	_	_	_	_	_	_	Seg=O
158	selection	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O
160	A	_	_	_	_	_	_	_	Seg=B-seg
161	spatial	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=O
163	temporal	_	_	_	_	_	_	_	Seg=O
164	landscape	_	_	_	_	_	_	_	Seg=O
165	of	_	_	_	_	_	_	_	Seg=O
166	54	_	_	_	_	_	_	_	Seg=O
167	critical	_	_	_	_	_	_	_	Seg=O
168	mutants	_	_	_	_	_	_	_	Seg=O
169	is	_	_	_	_	_	_	_	Seg=O
170	constructed	_	_	_	_	_	_	_	Seg=O
171	based	_	_	_	_	_	_	_	Seg=B-seg
172	on	_	_	_	_	_	_	_	Seg=O
173	their	_	_	_	_	_	_	_	Seg=O
174	divergence	_	_	_	_	_	_	_	Seg=O
175	among	_	_	_	_	_	_	_	Seg=O
176	viral	_	_	_	_	_	_	_	Seg=O
177	haplotype	_	_	_	_	_	_	_	Seg=O
178	clusters	_	_	_	_	_	_	_	Seg=O
179	,	_	_	_	_	_	_	_	Seg=O
180	of	_	_	_	_	_	_	_	Seg=B-seg
181	which	_	_	_	_	_	_	_	Seg=O
182	multiple	_	_	_	_	_	_	_	Seg=O
183	mutants	_	_	_	_	_	_	_	Seg=O
184	potentially	_	_	_	_	_	_	_	Seg=O
185	conferring	_	_	_	_	_	_	_	Seg=O
186	viral	_	_	_	_	_	_	_	Seg=O
187	transmissibility	_	_	_	_	_	_	_	Seg=O
188	,	_	_	_	_	_	_	_	Seg=O
189	infectivity	_	_	_	_	_	_	_	Seg=O
190	and	_	_	_	_	_	_	_	Seg=O
191	virulence	_	_	_	_	_	_	_	Seg=O
192	of	_	_	_	_	_	_	_	Seg=O
193	SARS	_	_	_	_	_	_	_	Seg=O
194	-	_	_	_	_	_	_	_	Seg=O
195	CoV-2	_	_	_	_	_	_	_	Seg=O
196	are	_	_	_	_	_	_	_	Seg=O
197	highlighted	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 804c9ade797c3eae734ac34ddbaa256b02672668
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	current	_	_	_	_	_	_	_	Seg=O
3	health	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	political	_	_	_	_	_	_	_	Seg=O
6	,	_	_	_	_	_	_	_	Seg=O
7	and	_	_	_	_	_	_	_	Seg=O
8	environmental	_	_	_	_	_	_	_	Seg=O
9	crisis	_	_	_	_	_	_	_	Seg=O
10	ongoing	_	_	_	_	_	_	_	Seg=B-seg
11	in	_	_	_	_	_	_	_	Seg=O
12	Brazil	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=B-seg
14	the	_	_	_	_	_	_	_	Seg=O
15	advances	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	the	_	_	_	_	_	_	_	Seg=O
18	impacts	_	_	_	_	_	_	_	Seg=O
19	of	_	_	_	_	_	_	_	Seg=O
20	COVID-19	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	traditional	_	_	_	_	_	_	_	Seg=O
23	populations	_	_	_	_	_	_	_	Seg=O
24	(	_	_	_	_	_	_	_	Seg=O
25	as	_	_	_	_	_	_	_	Seg=O
26	indigenous	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=O
28	quilombolas	_	_	_	_	_	_	_	Seg=O
29	)	_	_	_	_	_	_	_	Seg=O
30	are	_	_	_	_	_	_	_	Seg=O
31	not	_	_	_	_	_	_	_	Seg=O
32	yet	_	_	_	_	_	_	_	Seg=O
33	prioritized	_	_	_	_	_	_	_	Seg=O
34	in	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	scientific	_	_	_	_	_	_	_	Seg=O
37	production	_	_	_	_	_	_	_	Seg=O
38	about	_	_	_	_	_	_	_	Seg=O
39	the	_	_	_	_	_	_	_	Seg=O
40	novel	_	_	_	_	_	_	_	Seg=O
41	coronavirus	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	We	_	_	_	_	_	_	_	Seg=B-seg
44	performed	_	_	_	_	_	_	_	Seg=O
45	spatial	_	_	_	_	_	_	_	Seg=O
46	correlation	_	_	_	_	_	_	_	Seg=O
47	analysis	_	_	_	_	_	_	_	Seg=O
48	to	_	_	_	_	_	_	_	Seg=B-seg
49	map	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	clusters	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	outliers	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	COVID-19	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=O
57	South	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	Brazil	_	_	_	_	_	_	_	Seg=O
60	to	_	_	_	_	_	_	_	Seg=B-seg
61	identify	_	_	_	_	_	_	_	Seg=O
62	indigenous	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	quilombolas	_	_	_	_	_	_	_	Seg=O
65	communities	_	_	_	_	_	_	_	Seg=O
66	impacted	_	_	_	_	_	_	_	Seg=B-seg
67	right	_	_	_	_	_	_	_	Seg=O
68	now	_	_	_	_	_	_	_	Seg=O
69	in	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	pandemic	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	We	_	_	_	_	_	_	_	Seg=B-seg
74	show	_	_	_	_	_	_	_	Seg=O
75	that	_	_	_	_	_	_	_	Seg=B-seg
76	communities	_	_	_	_	_	_	_	Seg=O
77	located	_	_	_	_	_	_	_	Seg=B-seg
78	nearby	_	_	_	_	_	_	_	Seg=O
79	metropolitan	_	_	_	_	_	_	_	Seg=O
80	areas	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	mid	_	_	_	_	_	_	_	Seg=O
83	-	_	_	_	_	_	_	_	Seg=O
84	sized	_	_	_	_	_	_	_	Seg=O
85	cities	_	_	_	_	_	_	_	Seg=O
86	are	_	_	_	_	_	_	_	Seg=B-seg
87	the	_	_	_	_	_	_	_	Seg=O
88	most	_	_	_	_	_	_	_	Seg=O
89	impacted	_	_	_	_	_	_	_	Seg=O
90	by	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	COVID-19	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=B-seg
94	the	_	_	_	_	_	_	_	Seg=O
95	advance	_	_	_	_	_	_	_	Seg=O
96	of	_	_	_	_	_	_	_	Seg=O
97	the	_	_	_	_	_	_	_	Seg=O
98	transmission	_	_	_	_	_	_	_	Seg=O
99	to	_	_	_	_	_	_	_	Seg=O
100	inner	_	_	_	_	_	_	_	Seg=O
101	states	_	_	_	_	_	_	_	Seg=O
102	may	_	_	_	_	_	_	_	Seg=O
103	intensify	_	_	_	_	_	_	_	Seg=O
104	the	_	_	_	_	_	_	_	Seg=O
105	ongoing	_	_	_	_	_	_	_	Seg=O
106	historical	_	_	_	_	_	_	_	Seg=O
107	process	_	_	_	_	_	_	_	Seg=O
108	of	_	_	_	_	_	_	_	Seg=O
109	elimination	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	indigenous	_	_	_	_	_	_	_	Seg=O
112	and	_	_	_	_	_	_	_	Seg=O
113	quilombolas	_	_	_	_	_	_	_	Seg=O
114	people	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	We	_	_	_	_	_	_	_	Seg=B-seg
117	call	_	_	_	_	_	_	_	Seg=O
118	for	_	_	_	_	_	_	_	Seg=O
119	a	_	_	_	_	_	_	_	Seg=O
120	global	_	_	_	_	_	_	_	Seg=O
121	response	_	_	_	_	_	_	_	Seg=O
122	to	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	indigenous	_	_	_	_	_	_	_	Seg=O
125	and	_	_	_	_	_	_	_	Seg=O
126	quilombolas	_	_	_	_	_	_	_	Seg=O
127	situation	_	_	_	_	_	_	_	Seg=O
128	in	_	_	_	_	_	_	_	Seg=O
129	Brazil	_	_	_	_	_	_	_	Seg=O
130	,	_	_	_	_	_	_	_	Seg=O
131	pointing	_	_	_	_	_	_	_	Seg=B-seg
132	to	_	_	_	_	_	_	_	Seg=O
133	the	_	_	_	_	_	_	_	Seg=O
134	need	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	more	_	_	_	_	_	_	_	Seg=O
137	analysis	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	country	_	_	_	_	_	_	_	Seg=O
141	;	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 80bd28c8ba829f2173211a2fad8f98657676e0a6
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	COVID-19	_	_	_	_	_	_	_	Seg=O
3	pandemic	_	_	_	_	_	_	_	Seg=O
4	is	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	most	_	_	_	_	_	_	_	Seg=O
7	devastating	_	_	_	_	_	_	_	Seg=O
8	health	_	_	_	_	_	_	_	Seg=O
9	emergency	_	_	_	_	_	_	_	Seg=O
10	that	_	_	_	_	_	_	_	Seg=B-seg
11	humans	_	_	_	_	_	_	_	Seg=O
12	have	_	_	_	_	_	_	_	Seg=O
13	seen	_	_	_	_	_	_	_	Seg=O
14	over	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	past	_	_	_	_	_	_	_	Seg=O
17	century	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	The	_	_	_	_	_	_	_	Seg=B-seg
20	war	_	_	_	_	_	_	_	Seg=O
21	against	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	disease	_	_	_	_	_	_	_	Seg=O
24	has	_	_	_	_	_	_	_	Seg=O
25	been	_	_	_	_	_	_	_	Seg=O
26	handicapped	_	_	_	_	_	_	_	Seg=O
27	by	_	_	_	_	_	_	_	Seg=O
28	unavailability	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	effective	_	_	_	_	_	_	_	Seg=O
31	therapeutic	_	_	_	_	_	_	_	Seg=O
32	options	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	Till	_	_	_	_	_	_	_	Seg=B-seg
35	date	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	there	_	_	_	_	_	_	_	Seg=O
38	is	_	_	_	_	_	_	_	Seg=O
39	no	_	_	_	_	_	_	_	Seg=O
40	clinically	_	_	_	_	_	_	_	Seg=O
41	approved	_	_	_	_	_	_	_	Seg=O
42	vaccine	_	_	_	_	_	_	_	Seg=O
43	or	_	_	_	_	_	_	_	Seg=O
44	drug	_	_	_	_	_	_	_	Seg=O
45	for	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	treatment	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	COVID-19	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=B-seg
52	the	_	_	_	_	_	_	_	Seg=O
53	ongoing	_	_	_	_	_	_	_	Seg=O
54	search	_	_	_	_	_	_	_	Seg=O
55	to	_	_	_	_	_	_	_	Seg=B-seg
56	find	_	_	_	_	_	_	_	Seg=O
57	a	_	_	_	_	_	_	_	Seg=O
58	novel	_	_	_	_	_	_	_	Seg=O
59	therapy	_	_	_	_	_	_	_	Seg=O
60	is	_	_	_	_	_	_	_	Seg=B-seg
61	progressing	_	_	_	_	_	_	_	Seg=O
62	at	_	_	_	_	_	_	_	Seg=O
63	pandemic	_	_	_	_	_	_	_	Seg=O
64	pace	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Herein	_	_	_	_	_	_	_	Seg=B-seg
67	,	_	_	_	_	_	_	_	Seg=O
68	we	_	_	_	_	_	_	_	Seg=O
69	propose	_	_	_	_	_	_	_	Seg=O
70	a	_	_	_	_	_	_	_	Seg=O
71	novel	_	_	_	_	_	_	_	Seg=O
72	hypothesis	_	_	_	_	_	_	_	Seg=O
73	based	_	_	_	_	_	_	_	Seg=B-seg
74	on	_	_	_	_	_	_	_	Seg=O
75	sound	_	_	_	_	_	_	_	Seg=O
76	research	_	_	_	_	_	_	_	Seg=O
77	evidence	_	_	_	_	_	_	_	Seg=O
78	that	_	_	_	_	_	_	_	Seg=B-seg
79	electric	_	_	_	_	_	_	_	Seg=O
80	stimulation	_	_	_	_	_	_	_	Seg=O
81	can	_	_	_	_	_	_	_	Seg=O
82	be	_	_	_	_	_	_	_	Seg=O
83	a	_	_	_	_	_	_	_	Seg=O
84	potential	_	_	_	_	_	_	_	Seg=O
85	adjuvant	_	_	_	_	_	_	_	Seg=O
86	to	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	currently	_	_	_	_	_	_	_	Seg=O
89	used	_	_	_	_	_	_	_	Seg=O
90	symptomatic	_	_	_	_	_	_	_	Seg=O
91	therapies	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=O
93	antiviral	_	_	_	_	_	_	_	Seg=O
94	drugs	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	Based	_	_	_	_	_	_	_	Seg=B-seg
97	on	_	_	_	_	_	_	_	Seg=O
98	preclinical	_	_	_	_	_	_	_	Seg=O
99	evidence	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	we	_	_	_	_	_	_	_	Seg=B-seg
102	propose	_	_	_	_	_	_	_	Seg=O
103	that	_	_	_	_	_	_	_	Seg=B-seg
104	electric	_	_	_	_	_	_	_	Seg=O
105	stimulation	_	_	_	_	_	_	_	Seg=O
106	can	_	_	_	_	_	_	_	Seg=O
107	improve	_	_	_	_	_	_	_	Seg=O
108	respiratory	_	_	_	_	_	_	_	Seg=O
109	functions	_	_	_	_	_	_	_	Seg=O
110	,	_	_	_	_	_	_	_	Seg=O
111	inhibit	_	_	_	_	_	_	_	Seg=B-seg
112	SARS	_	_	_	_	_	_	_	Seg=O
113	-	_	_	_	_	_	_	_	Seg=O
114	CoV-2	_	_	_	_	_	_	_	Seg=O
115	growth	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	reduce	_	_	_	_	_	_	_	Seg=B-seg
118	pain	_	_	_	_	_	_	_	Seg=O
119	,	_	_	_	_	_	_	_	Seg=O
120	boost	_	_	_	_	_	_	_	Seg=B-seg
121	immunity	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=B-seg
123	improve	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	penetration	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	antiviral	_	_	_	_	_	_	_	Seg=O
128	drugs	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	We	_	_	_	_	_	_	_	Seg=B-seg
131	envisage	_	_	_	_	_	_	_	Seg=O
132	that	_	_	_	_	_	_	_	Seg=B-seg
133	our	_	_	_	_	_	_	_	Seg=O
134	hypothesis	_	_	_	_	_	_	_	Seg=O
135	,	_	_	_	_	_	_	_	Seg=O
136	if	_	_	_	_	_	_	_	Seg=B-seg
137	used	_	_	_	_	_	_	_	Seg=O
138	clinically	_	_	_	_	_	_	_	Seg=O
139	as	_	_	_	_	_	_	_	Seg=O
140	an	_	_	_	_	_	_	_	Seg=O
141	adjuvant	_	_	_	_	_	_	_	Seg=O
142	,	_	_	_	_	_	_	_	Seg=O
143	may	_	_	_	_	_	_	_	Seg=B-seg
144	significantly	_	_	_	_	_	_	_	Seg=O
145	improve	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	therapeutic	_	_	_	_	_	_	_	Seg=O
148	outcomes	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=O
151	current	_	_	_	_	_	_	_	Seg=O
152	treatment	_	_	_	_	_	_	_	Seg=O
153	regimen	_	_	_	_	_	_	_	Seg=O
154	being	_	_	_	_	_	_	_	Seg=B-seg
155	used	_	_	_	_	_	_	_	Seg=O
156	around	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	globe	_	_	_	_	_	_	_	Seg=O
159	for	_	_	_	_	_	_	_	Seg=O
160	the	_	_	_	_	_	_	_	Seg=O
161	management	_	_	_	_	_	_	_	Seg=O
162	of	_	_	_	_	_	_	_	Seg=O
163	COVID-19	_	_	_	_	_	_	_	Seg=O
164	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 8872c8e69ad8ba0f3df7454eb8121c712e60011b
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	central	_	_	_	_	_	_	_	Seg=O
3	nervous	_	_	_	_	_	_	_	Seg=O
4	system	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	CNS	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	disorder	_	_	_	_	_	_	_	Seg=O
9	characterized	_	_	_	_	_	_	_	Seg=B-seg
10	by	_	_	_	_	_	_	_	Seg=O
11	non	_	_	_	_	_	_	_	Seg=O
12	-	_	_	_	_	_	_	_	Seg=O
13	suppurative	_	_	_	_	_	_	_	Seg=O
14	encephalomyelitis	_	_	_	_	_	_	_	Seg=O
15	with	_	_	_	_	_	_	_	Seg=O
16	neurological	_	_	_	_	_	_	_	Seg=O
17	signs	_	_	_	_	_	_	_	Seg=O
18	was	_	_	_	_	_	_	_	Seg=B-seg
19	induced	_	_	_	_	_	_	_	Seg=O
20	experimentally	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	gnotobiotic	_	_	_	_	_	_	_	Seg=O
23	pigs	_	_	_	_	_	_	_	Seg=O
24	by	_	_	_	_	_	_	_	Seg=O
25	intravenous	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	oral	_	_	_	_	_	_	_	Seg=O
28	or	_	_	_	_	_	_	_	Seg=O
29	intranasal	_	_	_	_	_	_	_	Seg=O
30	inoculation	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	porcine	_	_	_	_	_	_	_	Seg=O
34	teschovirus	_	_	_	_	_	_	_	Seg=O
35	(	_	_	_	_	_	_	_	Seg=O
36	PTV	_	_	_	_	_	_	_	Seg=O
37	)	_	_	_	_	_	_	_	Seg=O
38	Toyama	_	_	_	_	_	_	_	Seg=O
39	2002	_	_	_	_	_	_	_	Seg=O
40	strain	_	_	_	_	_	_	_	Seg=O
41	isolated	_	_	_	_	_	_	_	Seg=B-seg
42	from	_	_	_	_	_	_	_	Seg=O
43	breeding	_	_	_	_	_	_	_	Seg=O
44	pigs	_	_	_	_	_	_	_	Seg=O
45	in	_	_	_	_	_	_	_	Seg=O
46	Japan	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	Lesions	_	_	_	_	_	_	_	Seg=B-seg
49	consisting	_	_	_	_	_	_	_	Seg=B-seg
50	of	_	_	_	_	_	_	_	Seg=O
51	perivascular	_	_	_	_	_	_	_	Seg=O
52	cuffing	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	mononuclear	_	_	_	_	_	_	_	Seg=O
55	cells	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	focal	_	_	_	_	_	_	_	Seg=O
58	gliosis	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	neuronal	_	_	_	_	_	_	_	Seg=O
61	necrosis	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	neuronophagia	_	_	_	_	_	_	_	Seg=O
64	were	_	_	_	_	_	_	_	Seg=B-seg
65	observed	_	_	_	_	_	_	_	Seg=O
66	in	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	brainstem	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	cerebellum	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	spinal	_	_	_	_	_	_	_	Seg=O
73	cord	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	Non	_	_	_	_	_	_	_	Seg=B-seg
76	-	_	_	_	_	_	_	_	Seg=O
77	suppurative	_	_	_	_	_	_	_	Seg=O
78	ganglionitis	_	_	_	_	_	_	_	Seg=O
79	in	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	spinal	_	_	_	_	_	_	_	Seg=O
82	ganglion	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	neuritis	_	_	_	_	_	_	_	Seg=O
85	in	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	spinal	_	_	_	_	_	_	_	Seg=O
88	root	_	_	_	_	_	_	_	Seg=O
89	were	_	_	_	_	_	_	_	Seg=O
90	also	_	_	_	_	_	_	_	Seg=O
91	observed	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	Regardless	_	_	_	_	_	_	_	Seg=B-seg
94	of	_	_	_	_	_	_	_	Seg=O
95	the	_	_	_	_	_	_	_	Seg=O
96	route	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	inoculation	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	all	_	_	_	_	_	_	_	Seg=B-seg
101	pigs	_	_	_	_	_	_	_	Seg=O
102	infected	_	_	_	_	_	_	_	Seg=B-seg
103	experimentally	_	_	_	_	_	_	_	Seg=O
104	with	_	_	_	_	_	_	_	Seg=O
105	PTV	_	_	_	_	_	_	_	Seg=O
106	showed	_	_	_	_	_	_	_	Seg=B-seg
107	a	_	_	_	_	_	_	_	Seg=O
108	similar	_	_	_	_	_	_	_	Seg=O
109	distribution	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	CNS	_	_	_	_	_	_	_	Seg=O
112	lesions	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Histological	_	_	_	_	_	_	_	Seg=B-seg
115	lesions	_	_	_	_	_	_	_	Seg=O
116	in	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	CNS	_	_	_	_	_	_	_	Seg=O
119	caused	_	_	_	_	_	_	_	Seg=B-seg
120	by	_	_	_	_	_	_	_	Seg=O
121	oral	_	_	_	_	_	_	_	Seg=O
122	or	_	_	_	_	_	_	_	Seg=O
123	intranasal	_	_	_	_	_	_	_	Seg=O
124	inoculation	_	_	_	_	_	_	_	Seg=O
125	of	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	virus	_	_	_	_	_	_	_	Seg=O
128	were	_	_	_	_	_	_	_	Seg=B-seg
129	mild	_	_	_	_	_	_	_	Seg=O
130	compared	_	_	_	_	_	_	_	Seg=B-seg
131	with	_	_	_	_	_	_	_	Seg=O
132	those	_	_	_	_	_	_	_	Seg=O
133	induced	_	_	_	_	_	_	_	Seg=B-seg
134	by	_	_	_	_	_	_	_	Seg=O
135	intravenous	_	_	_	_	_	_	_	Seg=O
136	infection	_	_	_	_	_	_	_	Seg=O
137	.	_	_	_	_	_	_	_	Seg=O
138	Immunohistochemically	_	_	_	_	_	_	_	Seg=B-seg
139	,	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	distribution	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	PTV	_	_	_	_	_	_	_	Seg=O
144	antigens	_	_	_	_	_	_	_	Seg=O
145	corresponded	_	_	_	_	_	_	_	Seg=O
146	closely	_	_	_	_	_	_	_	Seg=O
147	with	_	_	_	_	_	_	_	Seg=O
148	the	_	_	_	_	_	_	_	Seg=O
149	distribution	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	brain	_	_	_	_	_	_	_	Seg=O
152	lesions	_	_	_	_	_	_	_	Seg=O
153	.	_	_	_	_	_	_	_	Seg=O
154	PTV	_	_	_	_	_	_	_	Seg=B-seg
155	particles	_	_	_	_	_	_	_	Seg=O
156	were	_	_	_	_	_	_	_	Seg=O
157	detected	_	_	_	_	_	_	_	Seg=O
158	via	_	_	_	_	_	_	_	Seg=O
159	electron	_	_	_	_	_	_	_	Seg=O
160	microscopy	_	_	_	_	_	_	_	Seg=O
161	in	_	_	_	_	_	_	_	Seg=O
162	the	_	_	_	_	_	_	_	Seg=O
163	cytoplasm	_	_	_	_	_	_	_	Seg=O
164	of	_	_	_	_	_	_	_	Seg=O
165	nerve	_	_	_	_	_	_	_	Seg=O
166	cells	_	_	_	_	_	_	_	Seg=O
167	and	_	_	_	_	_	_	_	Seg=O
168	the	_	_	_	_	_	_	_	Seg=O
169	endothelial	_	_	_	_	_	_	_	Seg=O
170	cells	_	_	_	_	_	_	_	Seg=O
171	of	_	_	_	_	_	_	_	Seg=O
172	blood	_	_	_	_	_	_	_	Seg=O
173	vessels	_	_	_	_	_	_	_	Seg=O
174	in	_	_	_	_	_	_	_	Seg=O
175	the	_	_	_	_	_	_	_	Seg=O
176	spinal	_	_	_	_	_	_	_	Seg=O
177	cord	_	_	_	_	_	_	_	Seg=O
178	of	_	_	_	_	_	_	_	Seg=O
179	inoculated	_	_	_	_	_	_	_	Seg=O
180	pigs	_	_	_	_	_	_	_	Seg=O
181	.	_	_	_	_	_	_	_	Seg=O
182	Polymerase	_	_	_	_	_	_	_	Seg=B-seg
183	chain	_	_	_	_	_	_	_	Seg=O
184	reaction	_	_	_	_	_	_	_	Seg=O
185	analysis	_	_	_	_	_	_	_	Seg=O
186	demonstrated	_	_	_	_	_	_	_	Seg=O
187	the	_	_	_	_	_	_	_	Seg=O
188	presence	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	PTV	_	_	_	_	_	_	_	Seg=O
191	RNA	_	_	_	_	_	_	_	Seg=O
192	in	_	_	_	_	_	_	_	Seg=O
193	the	_	_	_	_	_	_	_	Seg=O
194	CNS	_	_	_	_	_	_	_	Seg=O
195	,	_	_	_	_	_	_	_	Seg=O
196	tonsils	_	_	_	_	_	_	_	Seg=O
197	and	_	_	_	_	_	_	_	Seg=O
198	large	_	_	_	_	_	_	_	Seg=O
199	intestines	_	_	_	_	_	_	_	Seg=O
200	of	_	_	_	_	_	_	_	Seg=O
201	21	_	_	_	_	_	_	_	Seg=O
202	of	_	_	_	_	_	_	_	Seg=O
203	the	_	_	_	_	_	_	_	Seg=O
204	22	_	_	_	_	_	_	_	Seg=O
205	pigs	_	_	_	_	_	_	_	Seg=O
206	inoculated	_	_	_	_	_	_	_	Seg=O
207	.	_	_	_	_	_	_	_	Seg=O
208	Direct	_	_	_	_	_	_	_	Seg=B-seg
209	CNS	_	_	_	_	_	_	_	Seg=O
210	invasion	_	_	_	_	_	_	_	Seg=O
211	via	_	_	_	_	_	_	_	Seg=O
212	the	_	_	_	_	_	_	_	Seg=O
213	blood	_	_	_	_	_	_	_	Seg=O
214	vessels	_	_	_	_	_	_	_	Seg=O
215	appears	_	_	_	_	_	_	_	Seg=O
216	to	_	_	_	_	_	_	_	Seg=O
217	be	_	_	_	_	_	_	_	Seg=O
218	a	_	_	_	_	_	_	_	Seg=O
219	major	_	_	_	_	_	_	_	Seg=O
220	route	_	_	_	_	_	_	_	Seg=O
221	of	_	_	_	_	_	_	_	Seg=O
222	infection	_	_	_	_	_	_	_	Seg=O
223	for	_	_	_	_	_	_	_	Seg=O
224	PTV	_	_	_	_	_	_	_	Seg=O
225	.	_	_	_	_	_	_	_	Seg=O
226	The	_	_	_	_	_	_	_	Seg=B-seg
227	gnotobiotic	_	_	_	_	_	_	_	Seg=O
228	pig	_	_	_	_	_	_	_	Seg=O
229	provides	_	_	_	_	_	_	_	Seg=O
230	a	_	_	_	_	_	_	_	Seg=O
231	useful	_	_	_	_	_	_	_	Seg=O
232	model	_	_	_	_	_	_	_	Seg=O
233	for	_	_	_	_	_	_	_	Seg=O
234	further	_	_	_	_	_	_	_	Seg=O
235	study	_	_	_	_	_	_	_	Seg=O
236	of	_	_	_	_	_	_	_	Seg=O
237	PTV	_	_	_	_	_	_	_	Seg=O
238	pathogenesis	_	_	_	_	_	_	_	Seg=O
239	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 8d0569b9fe93d0997ca38060117ffc6381122957
1	RNA	_	_	_	_	_	_	_	Seg=B-seg
2	interference	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	RNAi	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	process	_	_	_	_	_	_	_	Seg=O
9	in	_	_	_	_	_	_	_	Seg=B-seg
10	which	_	_	_	_	_	_	_	Seg=O
11	double	_	_	_	_	_	_	_	Seg=O
12	-	_	_	_	_	_	_	_	Seg=O
13	stranded	_	_	_	_	_	_	_	Seg=O
14	RNA	_	_	_	_	_	_	_	Seg=O
15	induces	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	post	_	_	_	_	_	_	_	Seg=O
18	-	_	_	_	_	_	_	_	Seg=O
19	transcriptional	_	_	_	_	_	_	_	Seg=O
20	sequence	_	_	_	_	_	_	_	Seg=O
21	-	_	_	_	_	_	_	_	Seg=O
22	specific	_	_	_	_	_	_	_	Seg=O
23	degradation	_	_	_	_	_	_	_	Seg=O
24	of	_	_	_	_	_	_	_	Seg=O
25	homologous	_	_	_	_	_	_	_	Seg=O
26	messenger	_	_	_	_	_	_	_	Seg=O
27	RNA	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	The	_	_	_	_	_	_	_	Seg=B-seg
30	present	_	_	_	_	_	_	_	Seg=O
31	study	_	_	_	_	_	_	_	Seg=O
32	was	_	_	_	_	_	_	_	Seg=O
33	carried	_	_	_	_	_	_	_	Seg=O
34	out	_	_	_	_	_	_	_	Seg=O
35	to	_	_	_	_	_	_	_	Seg=B-seg
36	apply	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	RNAi	_	_	_	_	_	_	_	Seg=O
39	technology	_	_	_	_	_	_	_	Seg=O
40	to	_	_	_	_	_	_	_	Seg=B-seg
41	inhibit	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	replication	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	feline	_	_	_	_	_	_	_	Seg=O
46	immunodeficiency	_	_	_	_	_	_	_	Seg=O
47	virus	_	_	_	_	_	_	_	Seg=O
48	(	_	_	_	_	_	_	_	Seg=O
49	FIV	_	_	_	_	_	_	_	Seg=O
50	)	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	Four	_	_	_	_	_	_	_	Seg=B-seg
53	small	_	_	_	_	_	_	_	Seg=O
54	interfering	_	_	_	_	_	_	_	Seg=O
55	RNAs	_	_	_	_	_	_	_	Seg=O
56	(	_	_	_	_	_	_	_	Seg=O
57	siRNAs	_	_	_	_	_	_	_	Seg=O
58	)	_	_	_	_	_	_	_	Seg=O
59	homologous	_	_	_	_	_	_	_	Seg=O
60	to	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	FIV	_	_	_	_	_	_	_	Seg=O
63	gag	_	_	_	_	_	_	_	Seg=O
64	gene	_	_	_	_	_	_	_	Seg=O
65	were	_	_	_	_	_	_	_	Seg=O
66	synthesized	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=B-seg
68	transfected	_	_	_	_	_	_	_	Seg=O
69	into	_	_	_	_	_	_	_	Seg=O
70	a	_	_	_	_	_	_	_	Seg=O
71	feline	_	_	_	_	_	_	_	Seg=O
72	fibroblastic	_	_	_	_	_	_	_	Seg=O
73	cell	_	_	_	_	_	_	_	Seg=O
74	line	_	_	_	_	_	_	_	Seg=O
75	chronically	_	_	_	_	_	_	_	Seg=B-seg
76	infected	_	_	_	_	_	_	_	Seg=O
77	with	_	_	_	_	_	_	_	Seg=O
78	FIV	_	_	_	_	_	_	_	Seg=O
79	(	_	_	_	_	_	_	_	Seg=O
80	CRFK	_	_	_	_	_	_	_	Seg=O
81	/	_	_	_	_	_	_	_	Seg=O
82	FIV	_	_	_	_	_	_	_	Seg=O
83	)	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	These	_	_	_	_	_	_	_	Seg=B-seg
86	synthetic	_	_	_	_	_	_	_	Seg=O
87	siRNAs	_	_	_	_	_	_	_	Seg=O
88	efficiently	_	_	_	_	_	_	_	Seg=O
89	inhibited	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	replication	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	FIV	_	_	_	_	_	_	_	Seg=O
94	.	_	_	_	_	_	_	_	Seg=O
95	Next	_	_	_	_	_	_	_	Seg=B-seg
96	,	_	_	_	_	_	_	_	Seg=O
97	we	_	_	_	_	_	_	_	Seg=O
98	examined	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	effect	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	retroviral	_	_	_	_	_	_	_	Seg=O
103	vector	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	mediated	_	_	_	_	_	_	_	Seg=O
106	transfer	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	FIVspecific	_	_	_	_	_	_	_	Seg=O
109	short	_	_	_	_	_	_	_	Seg=O
110	hairpin	_	_	_	_	_	_	_	Seg=O
111	RNA	_	_	_	_	_	_	_	Seg=O
112	(	_	_	_	_	_	_	_	Seg=O
113	shRNA	_	_	_	_	_	_	_	Seg=O
114	)	_	_	_	_	_	_	_	Seg=O
115	on	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	replication	_	_	_	_	_	_	_	Seg=O
118	of	_	_	_	_	_	_	_	Seg=O
119	FIV	_	_	_	_	_	_	_	Seg=O
120	in	_	_	_	_	_	_	_	Seg=O
121	a	_	_	_	_	_	_	_	Seg=O
122	feline	_	_	_	_	_	_	_	Seg=O
123	T	_	_	_	_	_	_	_	Seg=O
124	-	_	_	_	_	_	_	_	Seg=O
125	cell	_	_	_	_	_	_	_	Seg=O
126	line	_	_	_	_	_	_	_	Seg=O
127	chronically	_	_	_	_	_	_	_	Seg=B-seg
128	infected	_	_	_	_	_	_	_	Seg=O
129	with	_	_	_	_	_	_	_	Seg=O
130	FIV	_	_	_	_	_	_	_	Seg=O
131	(	_	_	_	_	_	_	_	Seg=O
132	FL4	_	_	_	_	_	_	_	Seg=O
133	)	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O
135	The	_	_	_	_	_	_	_	Seg=B-seg
136	retroviral	_	_	_	_	_	_	_	Seg=O
137	vector	_	_	_	_	_	_	_	Seg=O
138	-	_	_	_	_	_	_	_	Seg=O
139	mediated	_	_	_	_	_	_	_	Seg=O
140	transfer	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	FIV	_	_	_	_	_	_	_	Seg=O
143	-	_	_	_	_	_	_	_	Seg=O
144	specific	_	_	_	_	_	_	_	Seg=O
145	shRNA	_	_	_	_	_	_	_	Seg=O
146	was	_	_	_	_	_	_	_	Seg=O
147	shown	_	_	_	_	_	_	_	Seg=O
148	to	_	_	_	_	_	_	_	Seg=O
149	markedly	_	_	_	_	_	_	_	Seg=O
150	inhibit	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	replication	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	FIV	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	FL4	_	_	_	_	_	_	_	Seg=O
158	cells	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O
160	These	_	_	_	_	_	_	_	Seg=B-seg
161	results	_	_	_	_	_	_	_	Seg=O
162	provide	_	_	_	_	_	_	_	Seg=O
163	useful	_	_	_	_	_	_	_	Seg=O
164	information	_	_	_	_	_	_	_	Seg=O
165	for	_	_	_	_	_	_	_	Seg=O
166	the	_	_	_	_	_	_	_	Seg=O
167	development	_	_	_	_	_	_	_	Seg=O
168	of	_	_	_	_	_	_	_	Seg=O
169	RNAi	_	_	_	_	_	_	_	Seg=O
170	-	_	_	_	_	_	_	_	Seg=O
171	based	_	_	_	_	_	_	_	Seg=O
172	gene	_	_	_	_	_	_	_	Seg=O
173	therapy	_	_	_	_	_	_	_	Seg=O
174	strategy	_	_	_	_	_	_	_	Seg=O
175	to	_	_	_	_	_	_	_	Seg=B-seg
176	control	_	_	_	_	_	_	_	Seg=O
177	FIV	_	_	_	_	_	_	_	Seg=O
178	infection	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 8e0331893b4854ecd4c22be2f4661f1c6e444405
1	Multilayer	_	_	_	_	_	_	_	Seg=B-seg
2	networks	_	_	_	_	_	_	_	Seg=O
3	proved	_	_	_	_	_	_	_	Seg=O
4	to	_	_	_	_	_	_	_	Seg=O
5	be	_	_	_	_	_	_	_	Seg=O
6	suitable	_	_	_	_	_	_	_	Seg=O
7	in	_	_	_	_	_	_	_	Seg=O
8	extracting	_	_	_	_	_	_	_	Seg=O
9	and	_	_	_	_	_	_	_	Seg=O
10	providing	_	_	_	_	_	_	_	Seg=O
11	dependency	_	_	_	_	_	_	_	Seg=O
12	information	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	different	_	_	_	_	_	_	_	Seg=O
15	complex	_	_	_	_	_	_	_	Seg=O
16	systems	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	The	_	_	_	_	_	_	_	Seg=B-seg
19	construction	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	these	_	_	_	_	_	_	_	Seg=O
22	networks	_	_	_	_	_	_	_	Seg=O
23	is	_	_	_	_	_	_	_	Seg=O
24	difficult	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=B-seg
26	is	_	_	_	_	_	_	_	Seg=O
27	mostly	_	_	_	_	_	_	_	Seg=O
28	done	_	_	_	_	_	_	_	Seg=O
29	with	_	_	_	_	_	_	_	Seg=O
30	a	_	_	_	_	_	_	_	Seg=O
31	static	_	_	_	_	_	_	_	Seg=O
32	approach	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	neglecting	_	_	_	_	_	_	_	Seg=B-seg
35	time	_	_	_	_	_	_	_	Seg=O
36	delayed	_	_	_	_	_	_	_	Seg=O
37	interdependences	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	Tensors	_	_	_	_	_	_	_	Seg=B-seg
40	are	_	_	_	_	_	_	_	Seg=O
41	objects	_	_	_	_	_	_	_	Seg=O
42	that	_	_	_	_	_	_	_	Seg=B-seg
43	naturally	_	_	_	_	_	_	_	Seg=O
44	represent	_	_	_	_	_	_	_	Seg=O
45	multilayer	_	_	_	_	_	_	_	Seg=O
46	networks	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=B-seg
48	in	_	_	_	_	_	_	_	Seg=O
49	this	_	_	_	_	_	_	_	Seg=O
50	paper	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	we	_	_	_	_	_	_	_	Seg=O
53	propose	_	_	_	_	_	_	_	Seg=O
54	a	_	_	_	_	_	_	_	Seg=O
55	new	_	_	_	_	_	_	_	Seg=O
56	methodology	_	_	_	_	_	_	_	Seg=O
57	based	_	_	_	_	_	_	_	Seg=B-seg
58	on	_	_	_	_	_	_	_	Seg=O
59	Tucker	_	_	_	_	_	_	_	Seg=O
60	tensor	_	_	_	_	_	_	_	Seg=O
61	autoregression	_	_	_	_	_	_	_	Seg=O
62	in	_	_	_	_	_	_	_	Seg=B-seg
63	order	_	_	_	_	_	_	_	Seg=O
64	to	_	_	_	_	_	_	_	Seg=O
65	build	_	_	_	_	_	_	_	Seg=O
66	a	_	_	_	_	_	_	_	Seg=O
67	multilayer	_	_	_	_	_	_	_	Seg=O
68	network	_	_	_	_	_	_	_	Seg=O
69	directly	_	_	_	_	_	_	_	Seg=O
70	from	_	_	_	_	_	_	_	Seg=O
71	data	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	This	_	_	_	_	_	_	_	Seg=B-seg
74	methodology	_	_	_	_	_	_	_	Seg=O
75	captures	_	_	_	_	_	_	_	Seg=O
76	within	_	_	_	_	_	_	_	Seg=O
77	and	_	_	_	_	_	_	_	Seg=O
78	between	_	_	_	_	_	_	_	Seg=O
79	connections	_	_	_	_	_	_	_	Seg=O
80	across	_	_	_	_	_	_	_	Seg=O
81	layers	_	_	_	_	_	_	_	Seg=O
82	and	_	_	_	_	_	_	_	Seg=B-seg
83	makes	_	_	_	_	_	_	_	Seg=O
84	use	_	_	_	_	_	_	_	Seg=O
85	of	_	_	_	_	_	_	_	Seg=O
86	a	_	_	_	_	_	_	_	Seg=O
87	filtering	_	_	_	_	_	_	_	Seg=O
88	procedure	_	_	_	_	_	_	_	Seg=O
89	to	_	_	_	_	_	_	_	Seg=B-seg
90	extract	_	_	_	_	_	_	_	Seg=O
91	relevant	_	_	_	_	_	_	_	Seg=O
92	information	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=B-seg
94	improve	_	_	_	_	_	_	_	Seg=O
95	visualization	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	We	_	_	_	_	_	_	_	Seg=B-seg
98	show	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	application	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	this	_	_	_	_	_	_	_	Seg=O
103	methodology	_	_	_	_	_	_	_	Seg=O
104	to	_	_	_	_	_	_	_	Seg=O
105	different	_	_	_	_	_	_	_	Seg=O
106	stationary	_	_	_	_	_	_	_	Seg=O
107	fractionally	_	_	_	_	_	_	_	Seg=O
108	differenced	_	_	_	_	_	_	_	Seg=O
109	financial	_	_	_	_	_	_	_	Seg=O
110	data	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	We	_	_	_	_	_	_	_	Seg=B-seg
113	argue	_	_	_	_	_	_	_	Seg=O
114	that	_	_	_	_	_	_	_	Seg=B-seg
115	our	_	_	_	_	_	_	_	Seg=O
116	result	_	_	_	_	_	_	_	Seg=O
117	is	_	_	_	_	_	_	_	Seg=O
118	useful	_	_	_	_	_	_	_	Seg=O
119	to	_	_	_	_	_	_	_	Seg=O
120	understand	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	dependencies	_	_	_	_	_	_	_	Seg=O
123	across	_	_	_	_	_	_	_	Seg=O
124	three	_	_	_	_	_	_	_	Seg=O
125	different	_	_	_	_	_	_	_	Seg=O
126	aspects	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	financial	_	_	_	_	_	_	_	Seg=O
129	risk	_	_	_	_	_	_	_	Seg=O
130	,	_	_	_	_	_	_	_	Seg=O
131	namely	_	_	_	_	_	_	_	Seg=B-seg
132	market	_	_	_	_	_	_	_	Seg=O
133	risk	_	_	_	_	_	_	_	Seg=O
134	,	_	_	_	_	_	_	_	Seg=O
135	liquidity	_	_	_	_	_	_	_	Seg=O
136	risk	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=O
139	volatility	_	_	_	_	_	_	_	Seg=O
140	risk	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O
142	Indeed	_	_	_	_	_	_	_	Seg=B-seg
143	,	_	_	_	_	_	_	_	Seg=O
144	we	_	_	_	_	_	_	_	Seg=O
145	show	_	_	_	_	_	_	_	Seg=O
146	how	_	_	_	_	_	_	_	Seg=B-seg
147	the	_	_	_	_	_	_	_	Seg=O
148	resulting	_	_	_	_	_	_	_	Seg=O
149	visualization	_	_	_	_	_	_	_	Seg=O
150	is	_	_	_	_	_	_	_	Seg=O
151	a	_	_	_	_	_	_	_	Seg=O
152	useful	_	_	_	_	_	_	_	Seg=O
153	tool	_	_	_	_	_	_	_	Seg=O
154	for	_	_	_	_	_	_	_	Seg=O
155	risk	_	_	_	_	_	_	_	Seg=O
156	managers	_	_	_	_	_	_	_	Seg=O
157	depicting	_	_	_	_	_	_	_	Seg=B-seg
158	dependency	_	_	_	_	_	_	_	Seg=O
159	asymmetries	_	_	_	_	_	_	_	Seg=O
160	between	_	_	_	_	_	_	_	Seg=O
161	different	_	_	_	_	_	_	_	Seg=O
162	risk	_	_	_	_	_	_	_	Seg=O
163	factors	_	_	_	_	_	_	_	Seg=O
164	and	_	_	_	_	_	_	_	Seg=B-seg
165	accounting	_	_	_	_	_	_	_	Seg=O
166	for	_	_	_	_	_	_	_	Seg=O
167	delayed	_	_	_	_	_	_	_	Seg=O
168	cross	_	_	_	_	_	_	_	Seg=O
169	dependencies	_	_	_	_	_	_	_	Seg=O
170	.	_	_	_	_	_	_	_	Seg=O
171	The	_	_	_	_	_	_	_	Seg=B-seg
172	constructed	_	_	_	_	_	_	_	Seg=O
173	multilayer	_	_	_	_	_	_	_	Seg=O
174	network	_	_	_	_	_	_	_	Seg=O
175	shows	_	_	_	_	_	_	_	Seg=O
176	a	_	_	_	_	_	_	_	Seg=O
177	strong	_	_	_	_	_	_	_	Seg=O
178	interconnection	_	_	_	_	_	_	_	Seg=O
179	between	_	_	_	_	_	_	_	Seg=O
180	the	_	_	_	_	_	_	_	Seg=O
181	volumes	_	_	_	_	_	_	_	Seg=O
182	and	_	_	_	_	_	_	_	Seg=O
183	prices	_	_	_	_	_	_	_	Seg=O
184	layers	_	_	_	_	_	_	_	Seg=O
185	across	_	_	_	_	_	_	_	Seg=O
186	all	_	_	_	_	_	_	_	Seg=O
187	the	_	_	_	_	_	_	_	Seg=O
188	stocks	_	_	_	_	_	_	_	Seg=O
189	considered	_	_	_	_	_	_	_	Seg=O
190	while	_	_	_	_	_	_	_	Seg=B-seg
191	a	_	_	_	_	_	_	_	Seg=O
192	lower	_	_	_	_	_	_	_	Seg=O
193	number	_	_	_	_	_	_	_	Seg=O
194	of	_	_	_	_	_	_	_	Seg=O
195	interconnections	_	_	_	_	_	_	_	Seg=O
196	between	_	_	_	_	_	_	_	Seg=O
197	the	_	_	_	_	_	_	_	Seg=O
198	uncertainty	_	_	_	_	_	_	_	Seg=O
199	measures	_	_	_	_	_	_	_	Seg=O
200	is	_	_	_	_	_	_	_	Seg=O
201	identified	_	_	_	_	_	_	_	Seg=O
202	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 8ed17fe60158dbfa61e3d0f39f2838d687bd6dd8
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	novel	_	_	_	_	_	_	_	Seg=O
3	coronavirus	_	_	_	_	_	_	_	Seg=O
4	(	_	_	_	_	_	_	_	Seg=O
5	CoV	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	that	_	_	_	_	_	_	_	Seg=B-seg
8	causes	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	severe	_	_	_	_	_	_	_	Seg=O
11	lower	_	_	_	_	_	_	_	Seg=O
12	respiratory	_	_	_	_	_	_	_	Seg=O
13	tract	_	_	_	_	_	_	_	Seg=O
14	infection	_	_	_	_	_	_	_	Seg=O
15	in	_	_	_	_	_	_	_	Seg=O
16	humans	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	emerged	_	_	_	_	_	_	_	Seg=B-seg
19	in	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	Middle	_	_	_	_	_	_	_	Seg=O
22	East	_	_	_	_	_	_	_	Seg=O
23	region	_	_	_	_	_	_	_	Seg=O
24	in	_	_	_	_	_	_	_	Seg=O
25	2012	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	This	_	_	_	_	_	_	_	Seg=B-seg
28	virus	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	named	_	_	_	_	_	_	_	Seg=B-seg
31	Middle	_	_	_	_	_	_	_	Seg=O
32	East	_	_	_	_	_	_	_	Seg=O
33	respiratory	_	_	_	_	_	_	_	Seg=O
34	syndrome	_	_	_	_	_	_	_	Seg=O
35	(	_	_	_	_	_	_	_	Seg=O
36	MERS)-CoV	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	is	_	_	_	_	_	_	_	Seg=B-seg
39	phylogenetically	_	_	_	_	_	_	_	Seg=O
40	related	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=O
42	bat	_	_	_	_	_	_	_	Seg=O
43	CoVs	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	but	_	_	_	_	_	_	_	Seg=B-seg
46	other	_	_	_	_	_	_	_	Seg=O
47	animal	_	_	_	_	_	_	_	Seg=O
48	species	_	_	_	_	_	_	_	Seg=O
49	like	_	_	_	_	_	_	_	Seg=O
50	dromedary	_	_	_	_	_	_	_	Seg=O
51	camels	_	_	_	_	_	_	_	Seg=O
52	may	_	_	_	_	_	_	_	Seg=O
53	potentially	_	_	_	_	_	_	_	Seg=O
54	act	_	_	_	_	_	_	_	Seg=O
55	as	_	_	_	_	_	_	_	Seg=O
56	intermediate	_	_	_	_	_	_	_	Seg=O
57	hosts	_	_	_	_	_	_	_	Seg=O
58	by	_	_	_	_	_	_	_	Seg=B-seg
59	spreading	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	virus	_	_	_	_	_	_	_	Seg=O
62	to	_	_	_	_	_	_	_	Seg=O
63	humans	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	Although	_	_	_	_	_	_	_	Seg=B-seg
66	human	_	_	_	_	_	_	_	Seg=O
67	to	_	_	_	_	_	_	_	Seg=O
68	human	_	_	_	_	_	_	_	Seg=O
69	transmission	_	_	_	_	_	_	_	Seg=O
70	has	_	_	_	_	_	_	_	Seg=O
71	been	_	_	_	_	_	_	_	Seg=O
72	demonstrated	_	_	_	_	_	_	_	Seg=O
73	,	_	_	_	_	_	_	_	Seg=O
74	analysis	_	_	_	_	_	_	_	Seg=B-seg
75	of	_	_	_	_	_	_	_	Seg=O
76	human	_	_	_	_	_	_	_	Seg=O
77	MERS	_	_	_	_	_	_	_	Seg=O
78	clusters	_	_	_	_	_	_	_	Seg=O
79	indicated	_	_	_	_	_	_	_	Seg=O
80	that	_	_	_	_	_	_	_	Seg=B-seg
81	chains	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	transmission	_	_	_	_	_	_	_	Seg=O
84	were	_	_	_	_	_	_	_	Seg=O
85	not	_	_	_	_	_	_	_	Seg=O
86	self	_	_	_	_	_	_	_	Seg=O
87	-	_	_	_	_	_	_	_	Seg=O
88	sustaining	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	especially	_	_	_	_	_	_	_	Seg=B-seg
91	when	_	_	_	_	_	_	_	Seg=O
92	infection	_	_	_	_	_	_	_	Seg=O
93	control	_	_	_	_	_	_	_	Seg=O
94	was	_	_	_	_	_	_	_	Seg=O
95	implemented	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	Thus	_	_	_	_	_	_	_	Seg=B-seg
98	,	_	_	_	_	_	_	_	Seg=O
99	timely	_	_	_	_	_	_	_	Seg=O
100	identification	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	new	_	_	_	_	_	_	_	Seg=O
103	MERS	_	_	_	_	_	_	_	Seg=O
104	cases	_	_	_	_	_	_	_	Seg=O
105	followed	_	_	_	_	_	_	_	Seg=B-seg
106	by	_	_	_	_	_	_	_	Seg=O
107	their	_	_	_	_	_	_	_	Seg=O
108	quarantine	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	combined	_	_	_	_	_	_	_	Seg=B-seg
111	with	_	_	_	_	_	_	_	Seg=O
112	measures	_	_	_	_	_	_	_	Seg=O
113	to	_	_	_	_	_	_	_	Seg=B-seg
114	limit	_	_	_	_	_	_	_	Seg=O
115	spread	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	virus	_	_	_	_	_	_	_	Seg=O
119	from	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	(	_	_	_	_	_	_	_	Seg=O
122	intermediate	_	_	_	_	_	_	_	Seg=O
123	)	_	_	_	_	_	_	_	Seg=O
124	host	_	_	_	_	_	_	_	Seg=O
125	to	_	_	_	_	_	_	_	Seg=O
126	humans	_	_	_	_	_	_	_	Seg=O
127	,	_	_	_	_	_	_	_	Seg=O
128	may	_	_	_	_	_	_	_	Seg=B-seg
129	be	_	_	_	_	_	_	_	Seg=O
130	crucial	_	_	_	_	_	_	_	Seg=O
131	in	_	_	_	_	_	_	_	Seg=O
132	controlling	_	_	_	_	_	_	_	Seg=O
133	the	_	_	_	_	_	_	_	Seg=O
134	outbreak	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	this	_	_	_	_	_	_	_	Seg=O
137	emerging	_	_	_	_	_	_	_	Seg=O
138	CoV.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 90662d7dc7b09e018829ae2bc13e167b218931d8
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Human	_	_	_	_	_	_	_	Seg=B-seg
4	monoclonal	_	_	_	_	_	_	_	Seg=O
5	antibodies	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	mAbs	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	generated	_	_	_	_	_	_	_	Seg=B-seg
10	as	_	_	_	_	_	_	_	Seg=O
11	a	_	_	_	_	_	_	_	Seg=O
12	result	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	the	_	_	_	_	_	_	_	Seg=O
15	immune	_	_	_	_	_	_	_	Seg=O
16	response	_	_	_	_	_	_	_	Seg=O
17	are	_	_	_	_	_	_	_	Seg=B-seg
18	likely	_	_	_	_	_	_	_	Seg=O
19	to	_	_	_	_	_	_	_	Seg=O
20	be	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	most	_	_	_	_	_	_	_	Seg=O
23	effective	_	_	_	_	_	_	_	Seg=O
24	therapeutic	_	_	_	_	_	_	_	Seg=O
25	antibodies	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	particularly	_	_	_	_	_	_	_	Seg=O
28	in	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=O
30	case	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	infectious	_	_	_	_	_	_	_	Seg=O
33	diseases	_	_	_	_	_	_	_	Seg=O
34	against	_	_	_	_	_	_	_	Seg=B-seg
35	which	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	immune	_	_	_	_	_	_	_	Seg=O
38	response	_	_	_	_	_	_	_	Seg=O
39	is	_	_	_	_	_	_	_	Seg=O
40	protective	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	Human	_	_	_	_	_	_	_	Seg=B-seg
43	cytomegalovirus	_	_	_	_	_	_	_	Seg=O
44	(	_	_	_	_	_	_	_	Seg=O
45	HCMV	_	_	_	_	_	_	_	Seg=O
46	)	_	_	_	_	_	_	_	Seg=O
47	is	_	_	_	_	_	_	_	Seg=O
48	an	_	_	_	_	_	_	_	Seg=O
49	ubiquitous	_	_	_	_	_	_	_	Seg=O
50	opportunistic	_	_	_	_	_	_	_	Seg=O
51	virus	_	_	_	_	_	_	_	Seg=O
52	that	_	_	_	_	_	_	_	Seg=B-seg
53	is	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	most	_	_	_	_	_	_	_	Seg=O
56	serious	_	_	_	_	_	_	_	Seg=O
57	pathogenic	_	_	_	_	_	_	_	Seg=O
58	agent	_	_	_	_	_	_	_	Seg=O
59	in	_	_	_	_	_	_	_	Seg=O
60	transplant	_	_	_	_	_	_	_	Seg=O
61	patients	_	_	_	_	_	_	_	Seg=O
62	.	_	_	_	_	_	_	_	Seg=O
63	The	_	_	_	_	_	_	_	Seg=B-seg
64	available	_	_	_	_	_	_	_	Seg=O
65	therapeutic	_	_	_	_	_	_	_	Seg=O
66	armamentarium	_	_	_	_	_	_	_	Seg=O
67	(	_	_	_	_	_	_	_	Seg=B-seg
68	e.g.	_	_	_	_	_	_	_	Seg=O
69	HCMV	_	_	_	_	_	_	_	Seg=O
70	hyperimmune	_	_	_	_	_	_	_	Seg=O
71	globulins	_	_	_	_	_	_	_	Seg=O
72	or	_	_	_	_	_	_	_	Seg=O
73	antivirals	_	_	_	_	_	_	_	Seg=O
74	)	_	_	_	_	_	_	_	Seg=O
75	is	_	_	_	_	_	_	_	Seg=B-seg
76	associated	_	_	_	_	_	_	_	Seg=O
77	with	_	_	_	_	_	_	_	Seg=O
78	severe	_	_	_	_	_	_	_	Seg=O
79	side	_	_	_	_	_	_	_	Seg=O
80	effects	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	emergence	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	drug	_	_	_	_	_	_	_	Seg=O
86	-	_	_	_	_	_	_	_	Seg=O
87	resistant	_	_	_	_	_	_	_	Seg=O
88	strains	_	_	_	_	_	_	_	Seg=O
89	;	_	_	_	_	_	_	_	Seg=O
90	therefore	_	_	_	_	_	_	_	Seg=B-seg
91	,	_	_	_	_	_	_	_	Seg=O
92	neutralizing	_	_	_	_	_	_	_	Seg=O
93	human	_	_	_	_	_	_	_	Seg=O
94	mAb	_	_	_	_	_	_	_	Seg=O
95	may	_	_	_	_	_	_	_	Seg=O
96	be	_	_	_	_	_	_	_	Seg=O
97	a	_	_	_	_	_	_	_	Seg=O
98	decisive	_	_	_	_	_	_	_	Seg=O
99	alternative	_	_	_	_	_	_	_	Seg=O
100	in	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	prevention	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	primary	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=O
106	re	_	_	_	_	_	_	_	Seg=O
107	-	_	_	_	_	_	_	_	Seg=O
108	activated	_	_	_	_	_	_	_	Seg=O
109	HCMV	_	_	_	_	_	_	_	Seg=O
110	infections	_	_	_	_	_	_	_	Seg=O
111	in	_	_	_	_	_	_	_	Seg=O
112	these	_	_	_	_	_	_	_	Seg=O
113	patients	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	The	_	_	_	_	_	_	_	Seg=B-seg
116	purpose	_	_	_	_	_	_	_	Seg=O
117	of	_	_	_	_	_	_	_	Seg=O
118	this	_	_	_	_	_	_	_	Seg=O
119	study	_	_	_	_	_	_	_	Seg=O
120	was	_	_	_	_	_	_	_	Seg=O
121	to	_	_	_	_	_	_	_	Seg=O
122	generate	_	_	_	_	_	_	_	Seg=O
123	neutralizing	_	_	_	_	_	_	_	Seg=O
124	mAb	_	_	_	_	_	_	_	Seg=O
125	against	_	_	_	_	_	_	_	Seg=O
126	HCMV	_	_	_	_	_	_	_	Seg=O
127	from	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	immunological	_	_	_	_	_	_	_	Seg=O
130	repertoire	_	_	_	_	_	_	_	Seg=O
131	of	_	_	_	_	_	_	_	Seg=O
132	immune	_	_	_	_	_	_	_	Seg=O
133	donors	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O
135	To	_	_	_	_	_	_	_	Seg=B-seg
136	this	_	_	_	_	_	_	_	Seg=O
137	aim	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	we	_	_	_	_	_	_	_	Seg=O
140	designed	_	_	_	_	_	_	_	Seg=O
141	an	_	_	_	_	_	_	_	Seg=O
142	efficient	_	_	_	_	_	_	_	Seg=O
143	technology	_	_	_	_	_	_	_	Seg=O
144	relying	_	_	_	_	_	_	_	Seg=B-seg
145	on	_	_	_	_	_	_	_	Seg=O
146	two	_	_	_	_	_	_	_	Seg=O
147	discrete	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=O
149	sequential	_	_	_	_	_	_	_	Seg=O
150	steps	_	_	_	_	_	_	_	Seg=O
151	:	_	_	_	_	_	_	_	Seg=O
152	first	_	_	_	_	_	_	_	Seg=B-seg
153	,	_	_	_	_	_	_	_	Seg=O
154	human	_	_	_	_	_	_	_	Seg=O
155	B	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	lymphocytes	_	_	_	_	_	_	_	Seg=O
158	are	_	_	_	_	_	_	_	Seg=O
159	stimulated	_	_	_	_	_	_	_	Seg=O
160	with	_	_	_	_	_	_	_	Seg=O
161	TLR9-agonists	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=O
163	IL-2	_	_	_	_	_	_	_	Seg=O
164	;	_	_	_	_	_	_	_	Seg=O
165	second	_	_	_	_	_	_	_	Seg=B-seg
166	,	_	_	_	_	_	_	_	Seg=O
167	after	_	_	_	_	_	_	_	Seg=B-seg
168	both	_	_	_	_	_	_	_	Seg=O
169	additives	_	_	_	_	_	_	_	Seg=O
170	are	_	_	_	_	_	_	_	Seg=O
171	removed	_	_	_	_	_	_	_	Seg=O
172	,	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=B-seg
174	cells	_	_	_	_	_	_	_	Seg=O
175	are	_	_	_	_	_	_	_	Seg=O
176	infected	_	_	_	_	_	_	_	Seg=O
177	with	_	_	_	_	_	_	_	Seg=O
178	EBV	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O
180	Using	_	_	_	_	_	_	_	Seg=B-seg
181	this	_	_	_	_	_	_	_	Seg=O
182	strategy	_	_	_	_	_	_	_	Seg=O
183	we	_	_	_	_	_	_	_	Seg=B-seg
184	obtained	_	_	_	_	_	_	_	Seg=O
185	29	_	_	_	_	_	_	_	Seg=O
186	clones	_	_	_	_	_	_	_	Seg=O
187	secreting	_	_	_	_	_	_	_	Seg=B-seg
188	IgG	_	_	_	_	_	_	_	Seg=O
189	neutralizing	_	_	_	_	_	_	_	Seg=B-seg
190	the	_	_	_	_	_	_	_	Seg=O
191	HCMV	_	_	_	_	_	_	_	Seg=O
192	infectivity	_	_	_	_	_	_	_	Seg=O
193	;	_	_	_	_	_	_	_	Seg=O
194	four	_	_	_	_	_	_	_	Seg=B-seg
195	among	_	_	_	_	_	_	_	Seg=O
196	these	_	_	_	_	_	_	_	Seg=O
197	were	_	_	_	_	_	_	_	Seg=O
198	further	_	_	_	_	_	_	_	Seg=O
199	characterized	_	_	_	_	_	_	_	Seg=O
200	.	_	_	_	_	_	_	_	Seg=O
201	All	_	_	_	_	_	_	_	Seg=B-seg
202	of	_	_	_	_	_	_	_	Seg=O
203	the	_	_	_	_	_	_	_	Seg=O
204	mAbs	_	_	_	_	_	_	_	Seg=O
205	neutralize	_	_	_	_	_	_	_	Seg=O
206	the	_	_	_	_	_	_	_	Seg=O
207	infection	_	_	_	_	_	_	_	Seg=O
208	in	_	_	_	_	_	_	_	Seg=O
209	different	_	_	_	_	_	_	_	Seg=O
210	combinations	_	_	_	_	_	_	_	Seg=O
211	of	_	_	_	_	_	_	_	Seg=O
212	HCMV	_	_	_	_	_	_	_	Seg=O
213	strains	_	_	_	_	_	_	_	Seg=O
214	and	_	_	_	_	_	_	_	Seg=O
215	target	_	_	_	_	_	_	_	Seg=O
216	cells	_	_	_	_	_	_	_	Seg=O
217	,	_	_	_	_	_	_	_	Seg=O
218	with	_	_	_	_	_	_	_	Seg=O
219	a	_	_	_	_	_	_	_	Seg=O
220	potency	_	_	_	_	_	_	_	Seg=O
221	~20	_	_	_	_	_	_	_	Seg=O
222	fold	_	_	_	_	_	_	_	Seg=O
223	higher	_	_	_	_	_	_	_	Seg=O
224	than	_	_	_	_	_	_	_	Seg=O
225	that	_	_	_	_	_	_	_	Seg=O
226	of	_	_	_	_	_	_	_	Seg=O
227	the	_	_	_	_	_	_	_	Seg=O
228	HCMV	_	_	_	_	_	_	_	Seg=O
229	hyperimmune	_	_	_	_	_	_	_	Seg=O
230	globulins	_	_	_	_	_	_	_	Seg=O
231	,	_	_	_	_	_	_	_	Seg=O
232	currently	_	_	_	_	_	_	_	Seg=B-seg
233	used	_	_	_	_	_	_	_	Seg=O
234	in	_	_	_	_	_	_	_	Seg=O
235	transplant	_	_	_	_	_	_	_	Seg=O
236	recipients	_	_	_	_	_	_	_	Seg=O
237	.	_	_	_	_	_	_	_	Seg=O
238	Recombinant	_	_	_	_	_	_	_	Seg=B-seg
239	human	_	_	_	_	_	_	_	Seg=O
240	monoclonal	_	_	_	_	_	_	_	Seg=O
241	IgG1	_	_	_	_	_	_	_	Seg=O
242	suitable	_	_	_	_	_	_	_	Seg=O
243	as	_	_	_	_	_	_	_	Seg=O
244	a	_	_	_	_	_	_	_	Seg=O
245	prophylactic	_	_	_	_	_	_	_	Seg=O
246	or	_	_	_	_	_	_	_	Seg=O
247	therapeutic	_	_	_	_	_	_	_	Seg=O
248	tool	_	_	_	_	_	_	_	Seg=O
249	in	_	_	_	_	_	_	_	Seg=O
250	clinical	_	_	_	_	_	_	_	Seg=O
251	applications	_	_	_	_	_	_	_	Seg=O
252	has	_	_	_	_	_	_	_	Seg=O
253	been	_	_	_	_	_	_	_	Seg=O
254	generated	_	_	_	_	_	_	_	Seg=O
255	.	_	_	_	_	_	_	_	Seg=O
256	The	_	_	_	_	_	_	_	Seg=B-seg
257	technology	_	_	_	_	_	_	_	Seg=O
258	described	_	_	_	_	_	_	_	Seg=O
259	has	_	_	_	_	_	_	_	Seg=O
260	proven	_	_	_	_	_	_	_	Seg=O
261	to	_	_	_	_	_	_	_	Seg=O
262	be	_	_	_	_	_	_	_	Seg=O
263	more	_	_	_	_	_	_	_	Seg=O
264	reproducible	_	_	_	_	_	_	_	Seg=O
265	,	_	_	_	_	_	_	_	Seg=O
266	efficient	_	_	_	_	_	_	_	Seg=O
267	and	_	_	_	_	_	_	_	Seg=O
268	rapid	_	_	_	_	_	_	_	Seg=O
269	than	_	_	_	_	_	_	_	Seg=O
270	previously	_	_	_	_	_	_	_	Seg=O
271	reported	_	_	_	_	_	_	_	Seg=O
272	techniques	_	_	_	_	_	_	_	Seg=O
273	,	_	_	_	_	_	_	_	Seg=O
274	and	_	_	_	_	_	_	_	Seg=B-seg
275	can	_	_	_	_	_	_	_	Seg=O
276	be	_	_	_	_	_	_	_	Seg=O
277	adopted	_	_	_	_	_	_	_	Seg=O
278	at	_	_	_	_	_	_	_	Seg=O
279	low	_	_	_	_	_	_	_	Seg=O
280	overall	_	_	_	_	_	_	_	Seg=O
281	costs	_	_	_	_	_	_	_	Seg=O
282	by	_	_	_	_	_	_	_	Seg=O
283	any	_	_	_	_	_	_	_	Seg=O
284	cell	_	_	_	_	_	_	_	Seg=O
285	biology	_	_	_	_	_	_	_	Seg=O
286	laboratory	_	_	_	_	_	_	_	Seg=O
287	for	_	_	_	_	_	_	_	Seg=O
288	the	_	_	_	_	_	_	_	Seg=O
289	development	_	_	_	_	_	_	_	Seg=O
290	of	_	_	_	_	_	_	_	Seg=O
291	fully	_	_	_	_	_	_	_	Seg=O
292	human	_	_	_	_	_	_	_	Seg=O
293	mAbs	_	_	_	_	_	_	_	Seg=O
294	for	_	_	_	_	_	_	_	Seg=O
295	immunotherapeutic	_	_	_	_	_	_	_	Seg=O
296	uses	_	_	_	_	_	_	_	Seg=O
297	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 909b7a89053c834c12a9d4348e977e66c6116d42
1	Among	_	_	_	_	_	_	_	Seg=B-seg
2	coronaviruses	_	_	_	_	_	_	_	Seg=O
3	,	_	_	_	_	_	_	_	Seg=O
4	several	_	_	_	_	_	_	_	Seg=O
5	members	_	_	_	_	_	_	_	Seg=O
6	are	_	_	_	_	_	_	_	Seg=O
7	able	_	_	_	_	_	_	_	Seg=O
8	to	_	_	_	_	_	_	_	Seg=O
9	interact	_	_	_	_	_	_	_	Seg=O
10	with	_	_	_	_	_	_	_	Seg=O
11	sialic	_	_	_	_	_	_	_	Seg=O
12	acids	_	_	_	_	_	_	_	Seg=O
13	.	_	_	_	_	_	_	_	Seg=O
14	For	_	_	_	_	_	_	_	Seg=B-seg
15	bovine	_	_	_	_	_	_	_	Seg=O
16	coronavirus	_	_	_	_	_	_	_	Seg=O
17	(	_	_	_	_	_	_	_	Seg=O
18	BCoV	_	_	_	_	_	_	_	Seg=O
19	)	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=O
21	related	_	_	_	_	_	_	_	Seg=O
22	viruses	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	binding	_	_	_	_	_	_	_	Seg=O
25	to	_	_	_	_	_	_	_	Seg=O
26	cell	_	_	_	_	_	_	_	Seg=O
27	surface	_	_	_	_	_	_	_	Seg=O
28	components	_	_	_	_	_	_	_	Seg=O
29	containing	_	_	_	_	_	_	_	Seg=B-seg
30	N	_	_	_	_	_	_	_	Seg=O
31	-acetyl-9-O	_	_	_	_	_	_	_	Seg=O
32	-	_	_	_	_	_	_	_	Seg=O
33	acetylneuraminic	_	_	_	_	_	_	_	Seg=O
34	acid	_	_	_	_	_	_	_	Seg=O
35	is	_	_	_	_	_	_	_	Seg=B-seg
36	essential	_	_	_	_	_	_	_	Seg=O
37	for	_	_	_	_	_	_	_	Seg=O
38	initiation	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	an	_	_	_	_	_	_	_	Seg=O
41	infection	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	These	_	_	_	_	_	_	_	Seg=B-seg
44	viruses	_	_	_	_	_	_	_	Seg=O
45	resemble	_	_	_	_	_	_	_	Seg=O
46	influenza	_	_	_	_	_	_	_	Seg=O
47	C	_	_	_	_	_	_	_	Seg=O
48	viruses	_	_	_	_	_	_	_	Seg=O
49	because	_	_	_	_	_	_	_	Seg=B-seg
50	they	_	_	_	_	_	_	_	Seg=O
51	share	_	_	_	_	_	_	_	Seg=O
52	not	_	_	_	_	_	_	_	Seg=O
53	only	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	receptor	_	_	_	_	_	_	_	Seg=O
56	determinant	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	but	_	_	_	_	_	_	_	Seg=B-seg
59	also	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	presence	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	an	_	_	_	_	_	_	_	Seg=O
64	acetylesterase	_	_	_	_	_	_	_	Seg=O
65	that	_	_	_	_	_	_	_	Seg=B-seg
66	releases	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	9-O	_	_	_	_	_	_	_	Seg=O
69	-	_	_	_	_	_	_	_	Seg=O
70	acetyl	_	_	_	_	_	_	_	Seg=O
71	group	_	_	_	_	_	_	_	Seg=O
72	from	_	_	_	_	_	_	_	Seg=O
73	sialic	_	_	_	_	_	_	_	Seg=O
74	acid	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=B-seg
76	thus	_	_	_	_	_	_	_	Seg=O
77	abolishes	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	ability	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	respective	_	_	_	_	_	_	_	Seg=O
83	sialoglycoconjugate	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=O
85	function	_	_	_	_	_	_	_	Seg=O
86	as	_	_	_	_	_	_	_	Seg=O
87	a	_	_	_	_	_	_	_	Seg=O
88	receptor	_	_	_	_	_	_	_	Seg=O
89	for	_	_	_	_	_	_	_	Seg=O
90	BCoV.	_	_	_	_	_	_	_	Seg=O
91	As	_	_	_	_	_	_	_	Seg=B-seg
92	in	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	case	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	influenza	_	_	_	_	_	_	_	Seg=O
97	viruses	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	receptor	_	_	_	_	_	_	_	Seg=O
101	-	_	_	_	_	_	_	_	Seg=O
102	destroying	_	_	_	_	_	_	_	Seg=O
103	enzyme	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	BCoV	_	_	_	_	_	_	_	Seg=O
106	is	_	_	_	_	_	_	_	Seg=O
107	believed	_	_	_	_	_	_	_	Seg=O
108	to	_	_	_	_	_	_	_	Seg=O
109	facilitate	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	spread	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	virus	_	_	_	_	_	_	_	Seg=O
114	infection	_	_	_	_	_	_	_	Seg=O
115	by	_	_	_	_	_	_	_	Seg=B-seg
116	removing	_	_	_	_	_	_	_	Seg=O
117	receptor	_	_	_	_	_	_	_	Seg=O
118	determinants	_	_	_	_	_	_	_	Seg=O
119	from	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	surface	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	infected	_	_	_	_	_	_	_	Seg=O
124	cells	_	_	_	_	_	_	_	Seg=O
125	and	_	_	_	_	_	_	_	Seg=B-seg
126	by	_	_	_	_	_	_	_	Seg=O
127	preventing	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	formation	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	virus	_	_	_	_	_	_	_	Seg=O
132	aggregates	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O
134	Another	_	_	_	_	_	_	_	Seg=B-seg
135	coronavirus	_	_	_	_	_	_	_	Seg=O
136	,	_	_	_	_	_	_	_	Seg=O
137	porcine	_	_	_	_	_	_	_	Seg=O
138	transmissible	_	_	_	_	_	_	_	Seg=O
139	gastroenteritis	_	_	_	_	_	_	_	Seg=O
140	virus	_	_	_	_	_	_	_	Seg=O
141	(	_	_	_	_	_	_	_	Seg=O
142	TGEV	_	_	_	_	_	_	_	Seg=O
143	)	_	_	_	_	_	_	_	Seg=O
144	preferentially	_	_	_	_	_	_	_	Seg=O
145	recognizes	_	_	_	_	_	_	_	Seg=O
146	N	_	_	_	_	_	_	_	Seg=O
147	-glycolylneuraminic	_	_	_	_	_	_	_	Seg=O
148	acid	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	TGEV	_	_	_	_	_	_	_	Seg=B-seg
151	does	_	_	_	_	_	_	_	Seg=O
152	not	_	_	_	_	_	_	_	Seg=O
153	contain	_	_	_	_	_	_	_	Seg=O
154	a	_	_	_	_	_	_	_	Seg=O
155	receptor	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	destroying	_	_	_	_	_	_	_	Seg=O
158	enzyme	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=B-seg
160	does	_	_	_	_	_	_	_	Seg=O
161	not	_	_	_	_	_	_	_	Seg=O
162	depend	_	_	_	_	_	_	_	Seg=O
163	on	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	sialic	_	_	_	_	_	_	_	Seg=O
166	acid	_	_	_	_	_	_	_	Seg=O
167	binding	_	_	_	_	_	_	_	Seg=O
168	activity	_	_	_	_	_	_	_	Seg=O
169	for	_	_	_	_	_	_	_	Seg=O
170	infection	_	_	_	_	_	_	_	Seg=O
171	of	_	_	_	_	_	_	_	Seg=O
172	cultured	_	_	_	_	_	_	_	Seg=O
173	cells	_	_	_	_	_	_	_	Seg=O
174	.	_	_	_	_	_	_	_	Seg=O
175	However	_	_	_	_	_	_	_	Seg=B-seg
176	,	_	_	_	_	_	_	_	Seg=O
177	binding	_	_	_	_	_	_	_	Seg=O
178	to	_	_	_	_	_	_	_	Seg=O
179	sialic	_	_	_	_	_	_	_	Seg=O
180	acids	_	_	_	_	_	_	_	Seg=O
181	is	_	_	_	_	_	_	_	Seg=O
182	required	_	_	_	_	_	_	_	Seg=O
183	for	_	_	_	_	_	_	_	Seg=O
184	the	_	_	_	_	_	_	_	Seg=O
185	enteropathogenicity	_	_	_	_	_	_	_	Seg=O
186	of	_	_	_	_	_	_	_	Seg=O
187	TGEV	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O
189	Interaction	_	_	_	_	_	_	_	Seg=B-seg
190	with	_	_	_	_	_	_	_	Seg=O
191	sialoglycoconjugates	_	_	_	_	_	_	_	Seg=O
192	may	_	_	_	_	_	_	_	Seg=O
193	help	_	_	_	_	_	_	_	Seg=O
194	the	_	_	_	_	_	_	_	Seg=O
195	virus	_	_	_	_	_	_	_	Seg=O
196	to	_	_	_	_	_	_	_	Seg=O
197	pass	_	_	_	_	_	_	_	Seg=O
198	through	_	_	_	_	_	_	_	Seg=O
199	the	_	_	_	_	_	_	_	Seg=O
200	sialic	_	_	_	_	_	_	_	Seg=O
201	acid	_	_	_	_	_	_	_	Seg=O
202	-	_	_	_	_	_	_	_	Seg=O
203	rich	_	_	_	_	_	_	_	Seg=O
204	mucus	_	_	_	_	_	_	_	Seg=O
205	layer	_	_	_	_	_	_	_	Seg=O
206	that	_	_	_	_	_	_	_	Seg=B-seg
207	covers	_	_	_	_	_	_	_	Seg=O
208	the	_	_	_	_	_	_	_	Seg=O
209	viral	_	_	_	_	_	_	_	Seg=O
210	target	_	_	_	_	_	_	_	Seg=O
211	cells	_	_	_	_	_	_	_	Seg=O
212	in	_	_	_	_	_	_	_	Seg=O
213	the	_	_	_	_	_	_	_	Seg=O
214	epithelium	_	_	_	_	_	_	_	Seg=O
215	of	_	_	_	_	_	_	_	Seg=O
216	the	_	_	_	_	_	_	_	Seg=O
217	small	_	_	_	_	_	_	_	Seg=O
218	intestine	_	_	_	_	_	_	_	Seg=O
219	.	_	_	_	_	_	_	_	Seg=O
220	We	_	_	_	_	_	_	_	Seg=B-seg
221	discuss	_	_	_	_	_	_	_	Seg=O
222	that	_	_	_	_	_	_	_	Seg=B-seg
223	the	_	_	_	_	_	_	_	Seg=O
224	BCoV	_	_	_	_	_	_	_	Seg=O
225	group	_	_	_	_	_	_	_	Seg=O
226	of	_	_	_	_	_	_	_	Seg=O
227	viruses	_	_	_	_	_	_	_	Seg=O
228	may	_	_	_	_	_	_	_	Seg=O
229	have	_	_	_	_	_	_	_	Seg=O
230	evolved	_	_	_	_	_	_	_	Seg=O
231	from	_	_	_	_	_	_	_	Seg=O
232	a	_	_	_	_	_	_	_	Seg=O
233	TGEV	_	_	_	_	_	_	_	Seg=O
234	-	_	_	_	_	_	_	_	Seg=O
235	like	_	_	_	_	_	_	_	Seg=O
236	ancestor	_	_	_	_	_	_	_	Seg=O
237	by	_	_	_	_	_	_	_	Seg=B-seg
238	acquiring	_	_	_	_	_	_	_	Seg=O
239	an	_	_	_	_	_	_	_	Seg=O
240	acetylesterase	_	_	_	_	_	_	_	Seg=O
241	gene	_	_	_	_	_	_	_	Seg=O
242	through	_	_	_	_	_	_	_	Seg=O
243	heterologous	_	_	_	_	_	_	_	Seg=O
244	recombination	_	_	_	_	_	_	_	Seg=O
245	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 91595c90cb3ae1139a1090369bab9b25abbf6f1d
1	Two	_	_	_	_	_	_	_	Seg=B-seg
2	recently	_	_	_	_	_	_	_	Seg=O
3	detected	_	_	_	_	_	_	_	Seg=O
4	viruses	_	_	_	_	_	_	_	Seg=O
5	,	_	_	_	_	_	_	_	Seg=O
6	human	_	_	_	_	_	_	_	Seg=O
7	metapneumovirus	_	_	_	_	_	_	_	Seg=O
8	(	_	_	_	_	_	_	_	Seg=O
9	hMPV	_	_	_	_	_	_	_	Seg=O
10	)	_	_	_	_	_	_	_	Seg=O
11	and	_	_	_	_	_	_	_	Seg=O
12	coronavirus	_	_	_	_	_	_	_	Seg=O
13	NL63	_	_	_	_	_	_	_	Seg=O
14	(	_	_	_	_	_	_	_	Seg=O
15	HCoV	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	NL63	_	_	_	_	_	_	_	Seg=O
18	)	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	have	_	_	_	_	_	_	_	Seg=O
21	been	_	_	_	_	_	_	_	Seg=O
22	associated	_	_	_	_	_	_	_	Seg=O
23	with	_	_	_	_	_	_	_	Seg=O
24	acute	_	_	_	_	_	_	_	Seg=O
25	respiratory	_	_	_	_	_	_	_	Seg=O
26	tract	_	_	_	_	_	_	_	Seg=O
27	infections	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	particularly	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	young	_	_	_	_	_	_	_	Seg=O
32	children	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	This	_	_	_	_	_	_	_	Seg=B-seg
35	study	_	_	_	_	_	_	_	Seg=O
36	investigated	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	frequency	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	hMPV	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	HCoV	_	_	_	_	_	_	_	Seg=O
43	-	_	_	_	_	_	_	_	Seg=O
44	NL63	_	_	_	_	_	_	_	Seg=O
45	infections	_	_	_	_	_	_	_	Seg=O
46	in	_	_	_	_	_	_	_	Seg=O
47	Swedish	_	_	_	_	_	_	_	Seg=O
48	children	_	_	_	_	_	_	_	Seg=O
49	by	_	_	_	_	_	_	_	Seg=B-seg
50	screening	_	_	_	_	_	_	_	Seg=O
51	221	_	_	_	_	_	_	_	Seg=O
52	nasopharyngeal	_	_	_	_	_	_	_	Seg=O
53	aspirates	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	collected	_	_	_	_	_	_	_	Seg=B-seg
56	between	_	_	_	_	_	_	_	Seg=O
57	November	_	_	_	_	_	_	_	Seg=O
58	2003	_	_	_	_	_	_	_	Seg=O
59	and	_	_	_	_	_	_	_	Seg=O
60	May	_	_	_	_	_	_	_	Seg=O
61	2005	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	from	_	_	_	_	_	_	_	Seg=B-seg
64	212	_	_	_	_	_	_	_	Seg=O
65	children	_	_	_	_	_	_	_	Seg=O
66	attending	_	_	_	_	_	_	_	Seg=B-seg
67	the	_	_	_	_	_	_	_	Seg=O
68	paediatric	_	_	_	_	_	_	_	Seg=O
69	department	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	a	_	_	_	_	_	_	_	Seg=O
72	county	_	_	_	_	_	_	_	Seg=O
73	hospital	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	Sweden	_	_	_	_	_	_	_	Seg=O
76	or	_	_	_	_	_	_	_	Seg=B-seg
77	submitted	_	_	_	_	_	_	_	Seg=O
78	from	_	_	_	_	_	_	_	Seg=O
79	local	_	_	_	_	_	_	_	Seg=O
80	general	_	_	_	_	_	_	_	Seg=O
81	practitioners	_	_	_	_	_	_	_	Seg=O
82	.	_	_	_	_	_	_	_	Seg=O
83	The	_	_	_	_	_	_	_	Seg=B-seg
84	samples	_	_	_	_	_	_	_	Seg=O
85	were	_	_	_	_	_	_	_	Seg=O
86	originally	_	_	_	_	_	_	_	Seg=O
87	submitted	_	_	_	_	_	_	_	Seg=O
88	to	_	_	_	_	_	_	_	Seg=B-seg
89	be	_	_	_	_	_	_	_	Seg=O
90	tested	_	_	_	_	_	_	_	Seg=O
91	for	_	_	_	_	_	_	_	Seg=O
92	respiratory	_	_	_	_	_	_	_	Seg=O
93	syncytial	_	_	_	_	_	_	_	Seg=O
94	virus	_	_	_	_	_	_	_	Seg=O
95	(	_	_	_	_	_	_	_	Seg=O
96	RSV	_	_	_	_	_	_	_	Seg=O
97	)	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=B-seg
100	were	_	_	_	_	_	_	_	Seg=O
101	examined	_	_	_	_	_	_	_	Seg=O
102	retrospectively	_	_	_	_	_	_	_	Seg=O
103	for	_	_	_	_	_	_	_	Seg=O
104	hMPV	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=O
106	HCoV	_	_	_	_	_	_	_	Seg=O
107	-	_	_	_	_	_	_	_	Seg=O
108	NL63	_	_	_	_	_	_	_	Seg=O
109	by	_	_	_	_	_	_	_	Seg=O
110	RT	_	_	_	_	_	_	_	Seg=O
111	-	_	_	_	_	_	_	_	Seg=O
112	PCR	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Of	_	_	_	_	_	_	_	Seg=B-seg
115	the	_	_	_	_	_	_	_	Seg=O
116	212	_	_	_	_	_	_	_	Seg=O
117	patients	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	101	_	_	_	_	_	_	_	Seg=O
120	were	_	_	_	_	_	_	_	Seg=O
121	positive	_	_	_	_	_	_	_	Seg=O
122	for	_	_	_	_	_	_	_	Seg=O
123	RSV	_	_	_	_	_	_	_	Seg=O
124	(	_	_	_	_	_	_	_	Seg=B-seg
125	48	_	_	_	_	_	_	_	Seg=O
126	%	_	_	_	_	_	_	_	Seg=O
127	)	_	_	_	_	_	_	_	Seg=O
128	,	_	_	_	_	_	_	_	Seg=O
129	22	_	_	_	_	_	_	_	Seg=B-seg
130	(	_	_	_	_	_	_	_	Seg=B-seg
131	10	_	_	_	_	_	_	_	Seg=O
132	%	_	_	_	_	_	_	_	Seg=O
133	)	_	_	_	_	_	_	_	Seg=O
134	were	_	_	_	_	_	_	_	Seg=B-seg
135	positive	_	_	_	_	_	_	_	Seg=O
136	for	_	_	_	_	_	_	_	Seg=O
137	hMPV	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	and	_	_	_	_	_	_	_	Seg=B-seg
140	12	_	_	_	_	_	_	_	Seg=O
141	(	_	_	_	_	_	_	_	Seg=B-seg
142	6	_	_	_	_	_	_	_	Seg=O
143	%	_	_	_	_	_	_	_	Seg=O
144	)	_	_	_	_	_	_	_	Seg=O
145	were	_	_	_	_	_	_	_	Seg=B-seg
146	positive	_	_	_	_	_	_	_	Seg=O
147	for	_	_	_	_	_	_	_	Seg=O
148	HCoV	_	_	_	_	_	_	_	Seg=O
149	-	_	_	_	_	_	_	_	Seg=O
150	NL63	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	The	_	_	_	_	_	_	_	Seg=B-seg
153	frequency	_	_	_	_	_	_	_	Seg=O
154	of	_	_	_	_	_	_	_	Seg=O
155	HCoV	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	NL63	_	_	_	_	_	_	_	Seg=O
158	infection	_	_	_	_	_	_	_	Seg=O
159	increased	_	_	_	_	_	_	_	Seg=O
160	from	_	_	_	_	_	_	_	Seg=O
161	1	_	_	_	_	_	_	_	Seg=O
162	%	_	_	_	_	_	_	_	Seg=O
163	in	_	_	_	_	_	_	_	Seg=O
164	2003	_	_	_	_	_	_	_	Seg=O
165	-	_	_	_	_	_	_	_	Seg=O
166	2004	_	_	_	_	_	_	_	Seg=O
167	to	_	_	_	_	_	_	_	Seg=O
168	10	_	_	_	_	_	_	_	Seg=O
169	%	_	_	_	_	_	_	_	Seg=O
170	in	_	_	_	_	_	_	_	Seg=O
171	2004	_	_	_	_	_	_	_	Seg=O
172	-	_	_	_	_	_	_	_	Seg=O
173	2005	_	_	_	_	_	_	_	Seg=O
174	.	_	_	_	_	_	_	_	Seg=O
175	Sequence	_	_	_	_	_	_	_	Seg=B-seg
176	analysis	_	_	_	_	_	_	_	Seg=O
177	of	_	_	_	_	_	_	_	Seg=O
178	parts	_	_	_	_	_	_	_	Seg=O
179	of	_	_	_	_	_	_	_	Seg=O
180	the	_	_	_	_	_	_	_	Seg=O
181	coronavirus	_	_	_	_	_	_	_	Seg=O
182	genomes	_	_	_	_	_	_	_	Seg=O
183	showed	_	_	_	_	_	_	_	Seg=O
184	considerable	_	_	_	_	_	_	_	Seg=O
185	similarity	_	_	_	_	_	_	_	Seg=O
186	to	_	_	_	_	_	_	_	Seg=O
187	the	_	_	_	_	_	_	_	Seg=O
188	HCoV	_	_	_	_	_	_	_	Seg=O
189	-	_	_	_	_	_	_	_	Seg=O
190	NL63	_	_	_	_	_	_	_	Seg=O
191	prototype	_	_	_	_	_	_	_	Seg=O
192	sequence	_	_	_	_	_	_	_	Seg=O
193	.	_	_	_	_	_	_	_	Seg=O
194	The	_	_	_	_	_	_	_	Seg=B-seg
195	study	_	_	_	_	_	_	_	Seg=O
196	demonstrated	_	_	_	_	_	_	_	Seg=O
197	that	_	_	_	_	_	_	_	Seg=B-seg
198	HCoV	_	_	_	_	_	_	_	Seg=O
199	-	_	_	_	_	_	_	_	Seg=O
200	NL63	_	_	_	_	_	_	_	Seg=O
201	and	_	_	_	_	_	_	_	Seg=O
202	hMPV	_	_	_	_	_	_	_	Seg=O
203	occur	_	_	_	_	_	_	_	Seg=O
204	in	_	_	_	_	_	_	_	Seg=O
205	south	_	_	_	_	_	_	_	Seg=O
206	-	_	_	_	_	_	_	_	Seg=O
207	west	_	_	_	_	_	_	_	Seg=O
208	Sweden	_	_	_	_	_	_	_	Seg=O
209	with	_	_	_	_	_	_	_	Seg=O
210	essentially	_	_	_	_	_	_	_	Seg=O
211	the	_	_	_	_	_	_	_	Seg=O
212	same	_	_	_	_	_	_	_	Seg=O
213	frequency	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	seasonal	_	_	_	_	_	_	_	Seg=O
216	distribution	_	_	_	_	_	_	_	Seg=O
217	and	_	_	_	_	_	_	_	Seg=O
218	clinical	_	_	_	_	_	_	_	Seg=O
219	characteristics	_	_	_	_	_	_	_	Seg=O
220	as	_	_	_	_	_	_	_	Seg=B-seg
221	have	_	_	_	_	_	_	_	Seg=O
222	been	_	_	_	_	_	_	_	Seg=O
223	reported	_	_	_	_	_	_	_	Seg=O
224	in	_	_	_	_	_	_	_	Seg=O
225	other	_	_	_	_	_	_	_	Seg=O
226	countries	_	_	_	_	_	_	_	Seg=O
227	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 94156e6941fe78191b5997cdeb10cb3fd06e1221
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Acute	_	_	_	_	_	_	_	Seg=B-seg
4	viral	_	_	_	_	_	_	_	Seg=O
5	necrosis	_	_	_	_	_	_	_	Seg=O
6	virus	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	AVNV	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	is	_	_	_	_	_	_	_	Seg=O
11	the	_	_	_	_	_	_	_	Seg=O
12	causative	_	_	_	_	_	_	_	Seg=O
13	agent	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	a	_	_	_	_	_	_	_	Seg=O
16	serious	_	_	_	_	_	_	_	Seg=O
17	disease	_	_	_	_	_	_	_	Seg=O
18	resulting	_	_	_	_	_	_	_	Seg=B-seg
19	in	_	_	_	_	_	_	_	Seg=O
20	high	_	_	_	_	_	_	_	Seg=O
21	mortality	_	_	_	_	_	_	_	Seg=O
22	in	_	_	_	_	_	_	_	Seg=O
23	cultured	_	_	_	_	_	_	_	Seg=O
24	Chinese	_	_	_	_	_	_	_	Seg=O
25	scallops	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	Chlamys	_	_	_	_	_	_	_	Seg=O
28	farreri	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	We	_	_	_	_	_	_	_	Seg=B-seg
31	have	_	_	_	_	_	_	_	Seg=O
32	sequenced	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	analyzed	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	complete	_	_	_	_	_	_	_	Seg=O
37	genome	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	AVNV	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	Results	_	_	_	_	_	_	_	Seg=B-seg
42	:	_	_	_	_	_	_	_	Seg=O
43	The	_	_	_	_	_	_	_	Seg=B-seg
44	AVNV	_	_	_	_	_	_	_	Seg=O
45	genome	_	_	_	_	_	_	_	Seg=O
46	is	_	_	_	_	_	_	_	Seg=O
47	a	_	_	_	_	_	_	_	Seg=O
48	linear	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	double	_	_	_	_	_	_	_	Seg=O
51	-	_	_	_	_	_	_	_	Seg=O
52	stranded	_	_	_	_	_	_	_	Seg=O
53	DNA	_	_	_	_	_	_	_	Seg=O
54	molecule	_	_	_	_	_	_	_	Seg=O
55	of	_	_	_	_	_	_	_	Seg=O
56	210,993	_	_	_	_	_	_	_	Seg=O
57	bp	_	_	_	_	_	_	_	Seg=O
58	with	_	_	_	_	_	_	_	Seg=O
59	a	_	_	_	_	_	_	_	Seg=O
60	nucleotide	_	_	_	_	_	_	_	Seg=O
61	composition	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	38.5	_	_	_	_	_	_	_	Seg=O
64	%	_	_	_	_	_	_	_	Seg=O
65	G	_	_	_	_	_	_	_	Seg=O
66	+	_	_	_	_	_	_	_	Seg=O
67	C.	_	_	_	_	_	_	_	Seg=O
68	A	_	_	_	_	_	_	_	Seg=B-seg
69	total	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	123	_	_	_	_	_	_	_	Seg=O
72	open	_	_	_	_	_	_	_	Seg=O
73	reading	_	_	_	_	_	_	_	Seg=O
74	frames	_	_	_	_	_	_	_	Seg=O
75	were	_	_	_	_	_	_	_	Seg=O
76	predicted	_	_	_	_	_	_	_	Seg=O
77	to	_	_	_	_	_	_	_	Seg=B-seg
78	encode	_	_	_	_	_	_	_	Seg=O
79	functional	_	_	_	_	_	_	_	Seg=O
80	proteins	_	_	_	_	_	_	_	Seg=O
81	,	_	_	_	_	_	_	_	Seg=O
82	ranging	_	_	_	_	_	_	_	Seg=B-seg
83	from	_	_	_	_	_	_	_	Seg=O
84	41	_	_	_	_	_	_	_	Seg=O
85	to	_	_	_	_	_	_	_	Seg=O
86	1,878	_	_	_	_	_	_	_	Seg=O
87	amino	_	_	_	_	_	_	_	Seg=O
88	acid	_	_	_	_	_	_	_	Seg=O
89	residues	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O
91	The	_	_	_	_	_	_	_	Seg=B-seg
92	DNA	_	_	_	_	_	_	_	Seg=O
93	sequence	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	AVNV	_	_	_	_	_	_	_	Seg=O
96	is	_	_	_	_	_	_	_	Seg=O
97	97	_	_	_	_	_	_	_	Seg=O
98	%	_	_	_	_	_	_	_	Seg=O
99	identical	_	_	_	_	_	_	_	Seg=O
100	to	_	_	_	_	_	_	_	Seg=O
101	that	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	ostreid	_	_	_	_	_	_	_	Seg=O
104	herpesvirus	_	_	_	_	_	_	_	Seg=O
105	1	_	_	_	_	_	_	_	Seg=O
106	(	_	_	_	_	_	_	_	Seg=O
107	OsHV-1	_	_	_	_	_	_	_	Seg=O
108	)	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=B-seg
111	the	_	_	_	_	_	_	_	Seg=O
112	amino	_	_	_	_	_	_	_	Seg=O
113	acid	_	_	_	_	_	_	_	Seg=O
114	sequences	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	encoded	_	_	_	_	_	_	_	Seg=O
118	proteins	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	these	_	_	_	_	_	_	_	Seg=O
121	two	_	_	_	_	_	_	_	Seg=O
122	viruses	_	_	_	_	_	_	_	Seg=O
123	are	_	_	_	_	_	_	_	Seg=O
124	94	_	_	_	_	_	_	_	Seg=O
125	-	_	_	_	_	_	_	_	Seg=O
126	100	_	_	_	_	_	_	_	Seg=O
127	%	_	_	_	_	_	_	_	Seg=O
128	identical	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	The	_	_	_	_	_	_	_	Seg=B-seg
131	genomic	_	_	_	_	_	_	_	Seg=O
132	organization	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	AVNV	_	_	_	_	_	_	_	Seg=O
135	is	_	_	_	_	_	_	_	Seg=O
136	similar	_	_	_	_	_	_	_	Seg=O
137	to	_	_	_	_	_	_	_	Seg=O
138	that	_	_	_	_	_	_	_	Seg=O
139	of	_	_	_	_	_	_	_	Seg=O
140	OsHV-1	_	_	_	_	_	_	_	Seg=O
141	,	_	_	_	_	_	_	_	Seg=O
142	and	_	_	_	_	_	_	_	Seg=B-seg
143	consists	_	_	_	_	_	_	_	Seg=O
144	of	_	_	_	_	_	_	_	Seg=O
145	two	_	_	_	_	_	_	_	Seg=O
146	unique	_	_	_	_	_	_	_	Seg=O
147	regions	_	_	_	_	_	_	_	Seg=O
148	(	_	_	_	_	_	_	_	Seg=B-seg
149	170.4	_	_	_	_	_	_	_	Seg=O
150	kb	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=O
152	3.4	_	_	_	_	_	_	_	Seg=O
153	kb	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	respectively	_	_	_	_	_	_	_	Seg=O
156	)	_	_	_	_	_	_	_	Seg=O
157	,	_	_	_	_	_	_	_	Seg=O
158	each	_	_	_	_	_	_	_	Seg=B-seg
159	flanked	_	_	_	_	_	_	_	Seg=O
160	by	_	_	_	_	_	_	_	Seg=O
161	two	_	_	_	_	_	_	_	Seg=O
162	inverted	_	_	_	_	_	_	_	Seg=O
163	repeats	_	_	_	_	_	_	_	Seg=O
164	(	_	_	_	_	_	_	_	Seg=B-seg
165	7.6	_	_	_	_	_	_	_	Seg=O
166	kb	_	_	_	_	_	_	_	Seg=O
167	and	_	_	_	_	_	_	_	Seg=O
168	10.2	_	_	_	_	_	_	_	Seg=O
169	kb	_	_	_	_	_	_	_	Seg=O
170	,	_	_	_	_	_	_	_	Seg=O
171	respectively	_	_	_	_	_	_	_	Seg=O
172	)	_	_	_	_	_	_	_	Seg=O
173	,	_	_	_	_	_	_	_	Seg=O
174	with	_	_	_	_	_	_	_	Seg=B-seg
175	a	_	_	_	_	_	_	_	Seg=O
176	third	_	_	_	_	_	_	_	Seg=O
177	unique	_	_	_	_	_	_	_	Seg=O
178	region	_	_	_	_	_	_	_	Seg=O
179	(	_	_	_	_	_	_	_	Seg=B-seg
180	1.5	_	_	_	_	_	_	_	Seg=O
181	kb	_	_	_	_	_	_	_	Seg=O
182	)	_	_	_	_	_	_	_	Seg=O
183	situated	_	_	_	_	_	_	_	Seg=B-seg
184	between	_	_	_	_	_	_	_	Seg=O
185	the	_	_	_	_	_	_	_	Seg=O
186	two	_	_	_	_	_	_	_	Seg=O
187	internal	_	_	_	_	_	_	_	Seg=O
188	repeats	_	_	_	_	_	_	_	Seg=O
189	.	_	_	_	_	_	_	_	Seg=O
190	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
191	:	_	_	_	_	_	_	_	Seg=O
192	Our	_	_	_	_	_	_	_	Seg=B-seg
193	results	_	_	_	_	_	_	_	Seg=O
194	indicate	_	_	_	_	_	_	_	Seg=O
195	that	_	_	_	_	_	_	_	Seg=B-seg
196	AVNV	_	_	_	_	_	_	_	Seg=O
197	is	_	_	_	_	_	_	_	Seg=O
198	a	_	_	_	_	_	_	_	Seg=O
199	variant	_	_	_	_	_	_	_	Seg=O
200	of	_	_	_	_	_	_	_	Seg=O
201	OsHV-1	_	_	_	_	_	_	_	Seg=O
202	.	_	_	_	_	_	_	_	Seg=O
203	The	_	_	_	_	_	_	_	Seg=B-seg
204	AVNV	_	_	_	_	_	_	_	Seg=O
205	genome	_	_	_	_	_	_	_	Seg=O
206	sequence	_	_	_	_	_	_	_	Seg=O
207	provides	_	_	_	_	_	_	_	Seg=O
208	information	_	_	_	_	_	_	_	Seg=O
209	useful	_	_	_	_	_	_	_	Seg=B-seg
210	for	_	_	_	_	_	_	_	Seg=O
211	understanding	_	_	_	_	_	_	_	Seg=O
212	the	_	_	_	_	_	_	_	Seg=O
213	evolution	_	_	_	_	_	_	_	Seg=O
214	and	_	_	_	_	_	_	_	Seg=O
215	divergence	_	_	_	_	_	_	_	Seg=O
216	of	_	_	_	_	_	_	_	Seg=O
217	OsHV-1	_	_	_	_	_	_	_	Seg=O
218	in	_	_	_	_	_	_	_	Seg=O
219	marine	_	_	_	_	_	_	_	Seg=O
220	molluscs	_	_	_	_	_	_	_	Seg=O
221	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 97adff711db916914190dd5fde9ec4923a13f46d
1	Rheum	_	_	_	_	_	_	_	Seg=B-seg
2	palmatum	_	_	_	_	_	_	_	Seg=O
3	,	_	_	_	_	_	_	_	Seg=O
4	Chinese	_	_	_	_	_	_	_	Seg=O
5	traditional	_	_	_	_	_	_	_	Seg=O
6	herb	_	_	_	_	_	_	_	Seg=O
7	,	_	_	_	_	_	_	_	Seg=O
8	exhibits	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	great	_	_	_	_	_	_	_	Seg=O
11	variety	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	anti	_	_	_	_	_	_	_	Seg=O
14	-	_	_	_	_	_	_	_	Seg=O
15	cancer	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=O
17	anti	_	_	_	_	_	_	_	Seg=O
18	-	_	_	_	_	_	_	_	Seg=O
19	viruses	_	_	_	_	_	_	_	Seg=O
20	properties	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	This	_	_	_	_	_	_	_	Seg=B-seg
23	study	_	_	_	_	_	_	_	Seg=O
24	rates	_	_	_	_	_	_	_	Seg=O
25	antiviral	_	_	_	_	_	_	_	Seg=O
26	activity	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	R.	_	_	_	_	_	_	_	Seg=O
29	palmatum	_	_	_	_	_	_	_	Seg=O
30	extracts	_	_	_	_	_	_	_	Seg=O
31	and	_	_	_	_	_	_	_	Seg=O
32	its	_	_	_	_	_	_	_	Seg=O
33	components	_	_	_	_	_	_	_	Seg=O
34	against	_	_	_	_	_	_	_	Seg=O
35	Japanese	_	_	_	_	_	_	_	Seg=O
36	encephalitis	_	_	_	_	_	_	_	Seg=O
37	virus	_	_	_	_	_	_	_	Seg=O
38	(	_	_	_	_	_	_	_	Seg=O
39	JEV	_	_	_	_	_	_	_	Seg=O
40	)	_	_	_	_	_	_	_	Seg=O
41	in	_	_	_	_	_	_	_	Seg=O
42	vitro	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	Methanol	_	_	_	_	_	_	_	Seg=B-seg
45	extract	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	R.	_	_	_	_	_	_	_	Seg=O
48	palmatum	_	_	_	_	_	_	_	Seg=O
49	contained	_	_	_	_	_	_	_	Seg=O
50	higher	_	_	_	_	_	_	_	Seg=O
51	levels	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	aloe	_	_	_	_	_	_	_	Seg=O
54	emodin	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	chrysophanol	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	rhein	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	emodin	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	physcion	_	_	_	_	_	_	_	Seg=O
63	than	_	_	_	_	_	_	_	Seg=O
64	water	_	_	_	_	_	_	_	Seg=O
65	extract	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	Methanol	_	_	_	_	_	_	_	Seg=B-seg
68	extract	_	_	_	_	_	_	_	Seg=O
69	(	_	_	_	_	_	_	_	Seg=B-seg
70	IC	_	_	_	_	_	_	_	Seg=O
71	50	_	_	_	_	_	_	_	Seg=O
72	=	_	_	_	_	_	_	_	Seg=O
73	15.04	_	_	_	_	_	_	_	Seg=O
74	lg	_	_	_	_	_	_	_	Seg=O
75	/	_	_	_	_	_	_	_	Seg=O
76	ml	_	_	_	_	_	_	_	Seg=O
77	)	_	_	_	_	_	_	_	Seg=O
78	exhibited	_	_	_	_	_	_	_	Seg=B-seg
79	more	_	_	_	_	_	_	_	Seg=O
80	potent	_	_	_	_	_	_	_	Seg=O
81	inhibitory	_	_	_	_	_	_	_	Seg=O
82	effects	_	_	_	_	_	_	_	Seg=O
83	on	_	_	_	_	_	_	_	Seg=O
84	JEV	_	_	_	_	_	_	_	Seg=O
85	plaque	_	_	_	_	_	_	_	Seg=O
86	reduction	_	_	_	_	_	_	_	Seg=O
87	than	_	_	_	_	_	_	_	Seg=O
88	water	_	_	_	_	_	_	_	Seg=O
89	extract	_	_	_	_	_	_	_	Seg=O
90	(	_	_	_	_	_	_	_	Seg=B-seg
91	IC	_	_	_	_	_	_	_	Seg=O
92	50	_	_	_	_	_	_	_	Seg=O
93	=	_	_	_	_	_	_	_	Seg=O
94	51.41	_	_	_	_	_	_	_	Seg=O
95	lg	_	_	_	_	_	_	_	Seg=O
96	/	_	_	_	_	_	_	_	Seg=O
97	ml	_	_	_	_	_	_	_	Seg=O
98	)	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	Meanwhile	_	_	_	_	_	_	_	Seg=B-seg
101	,	_	_	_	_	_	_	_	Seg=O
102	IC	_	_	_	_	_	_	_	Seg=O
103	50	_	_	_	_	_	_	_	Seg=O
104	values	_	_	_	_	_	_	_	Seg=O
105	determined	_	_	_	_	_	_	_	Seg=B-seg
106	by	_	_	_	_	_	_	_	Seg=O
107	plaque	_	_	_	_	_	_	_	Seg=O
108	reduction	_	_	_	_	_	_	_	Seg=O
109	assay	_	_	_	_	_	_	_	Seg=O
110	were	_	_	_	_	_	_	_	Seg=B-seg
111	15.82	_	_	_	_	_	_	_	Seg=O
112	lg	_	_	_	_	_	_	_	Seg=O
113	/	_	_	_	_	_	_	_	Seg=O
114	ml	_	_	_	_	_	_	_	Seg=O
115	for	_	_	_	_	_	_	_	Seg=O
116	chrysophanol	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	17.39	_	_	_	_	_	_	_	Seg=O
119	lg	_	_	_	_	_	_	_	Seg=O
120	/	_	_	_	_	_	_	_	Seg=O
121	ml	_	_	_	_	_	_	_	Seg=O
122	for	_	_	_	_	_	_	_	Seg=O
123	aloe	_	_	_	_	_	_	_	Seg=O
124	-	_	_	_	_	_	_	_	Seg=O
125	emodin	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	respectively	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	Virucidal	_	_	_	_	_	_	_	Seg=B-seg
130	activity	_	_	_	_	_	_	_	Seg=O
131	of	_	_	_	_	_	_	_	Seg=O
132	agents	_	_	_	_	_	_	_	Seg=O
133	correlated	_	_	_	_	_	_	_	Seg=O
134	with	_	_	_	_	_	_	_	Seg=O
135	anti	_	_	_	_	_	_	_	Seg=O
136	-	_	_	_	_	_	_	_	Seg=O
137	JEV	_	_	_	_	_	_	_	Seg=O
138	activity	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	while	_	_	_	_	_	_	_	Seg=B-seg
141	virucidal	_	_	_	_	_	_	_	Seg=O
142	IC	_	_	_	_	_	_	_	Seg=O
143	50	_	_	_	_	_	_	_	Seg=O
144	values	_	_	_	_	_	_	_	Seg=O
145	were	_	_	_	_	_	_	_	Seg=O
146	7.58	_	_	_	_	_	_	_	Seg=O
147	lg	_	_	_	_	_	_	_	Seg=O
148	/	_	_	_	_	_	_	_	Seg=O
149	ml	_	_	_	_	_	_	_	Seg=O
150	for	_	_	_	_	_	_	_	Seg=O
151	methanol	_	_	_	_	_	_	_	Seg=O
152	extract	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	17.36	_	_	_	_	_	_	_	Seg=O
155	lg	_	_	_	_	_	_	_	Seg=O
156	/	_	_	_	_	_	_	_	Seg=O
157	ml	_	_	_	_	_	_	_	Seg=O
158	for	_	_	_	_	_	_	_	Seg=O
159	water	_	_	_	_	_	_	_	Seg=O
160	extract	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	0.75	_	_	_	_	_	_	_	Seg=O
163	lg	_	_	_	_	_	_	_	Seg=O
164	/	_	_	_	_	_	_	_	Seg=O
165	ml	_	_	_	_	_	_	_	Seg=O
166	for	_	_	_	_	_	_	_	Seg=O
167	chrysophanol	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=O
169	0.46	_	_	_	_	_	_	_	Seg=O
170	lg	_	_	_	_	_	_	_	Seg=O
171	/	_	_	_	_	_	_	_	Seg=O
172	ml	_	_	_	_	_	_	_	Seg=O
173	for	_	_	_	_	_	_	_	Seg=O
174	aloe	_	_	_	_	_	_	_	Seg=O
175	-	_	_	_	_	_	_	_	Seg=O
176	emodin	_	_	_	_	_	_	_	Seg=O
177	,	_	_	_	_	_	_	_	Seg=O
178	respectively	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O
180	In	_	_	_	_	_	_	_	Seg=B-seg
181	addition	_	_	_	_	_	_	_	Seg=O
182	,	_	_	_	_	_	_	_	Seg=O
183	10	_	_	_	_	_	_	_	Seg=O
184	lg	_	_	_	_	_	_	_	Seg=O
185	/	_	_	_	_	_	_	_	Seg=O
186	ml	_	_	_	_	_	_	_	Seg=O
187	of	_	_	_	_	_	_	_	Seg=O
188	extract	_	_	_	_	_	_	_	Seg=O
189	,	_	_	_	_	_	_	_	Seg=O
190	chrysophanol	_	_	_	_	_	_	_	Seg=O
191	or	_	_	_	_	_	_	_	Seg=O
192	aloe	_	_	_	_	_	_	_	Seg=O
193	emodin	_	_	_	_	_	_	_	Seg=O
194	caused	_	_	_	_	_	_	_	Seg=O
195	90	_	_	_	_	_	_	_	Seg=O
196	%	_	_	_	_	_	_	_	Seg=O
197	inhibition	_	_	_	_	_	_	_	Seg=O
198	of	_	_	_	_	_	_	_	Seg=O
199	JEV	_	_	_	_	_	_	_	Seg=O
200	yields	_	_	_	_	_	_	_	Seg=O
201	in	_	_	_	_	_	_	_	Seg=O
202	cells	_	_	_	_	_	_	_	Seg=O
203	and	_	_	_	_	_	_	_	Seg=B-seg
204	significantly	_	_	_	_	_	_	_	Seg=O
205	activated	_	_	_	_	_	_	_	Seg=O
206	gamma	_	_	_	_	_	_	_	Seg=O
207	activated	_	_	_	_	_	_	_	Seg=O
208	sequence	_	_	_	_	_	_	_	Seg=O
209	-	_	_	_	_	_	_	_	Seg=O
210	driven	_	_	_	_	_	_	_	Seg=O
211	promoters	_	_	_	_	_	_	_	Seg=O
212	.	_	_	_	_	_	_	_	Seg=O
213	Hence	_	_	_	_	_	_	_	Seg=B-seg
214	,	_	_	_	_	_	_	_	Seg=O
215	methanol	_	_	_	_	_	_	_	Seg=O
216	extract	_	_	_	_	_	_	_	Seg=O
217	of	_	_	_	_	_	_	_	Seg=O
218	R.	_	_	_	_	_	_	_	Seg=O
219	palmatum	_	_	_	_	_	_	_	Seg=O
220	and	_	_	_	_	_	_	_	Seg=O
221	chrysophanol	_	_	_	_	_	_	_	Seg=O
222	with	_	_	_	_	_	_	_	Seg=O
223	high	_	_	_	_	_	_	_	Seg=O
224	therapeutic	_	_	_	_	_	_	_	Seg=O
225	index	_	_	_	_	_	_	_	Seg=O
226	might	_	_	_	_	_	_	_	Seg=O
227	be	_	_	_	_	_	_	_	Seg=O
228	useful	_	_	_	_	_	_	_	Seg=O
229	for	_	_	_	_	_	_	_	Seg=O
230	development	_	_	_	_	_	_	_	Seg=O
231	of	_	_	_	_	_	_	_	Seg=O
232	antiviral	_	_	_	_	_	_	_	Seg=O
233	agents	_	_	_	_	_	_	_	Seg=O
234	against	_	_	_	_	_	_	_	Seg=O
235	JEV	_	_	_	_	_	_	_	Seg=O
236	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 980c48327d3bfbfcb0373fdbef063cd1a3d1d339
1	Pathology	_	_	_	_	_	_	_	Seg=B-seg
2	practice	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	increasingly	_	_	_	_	_	_	_	Seg=O
5	augmented	_	_	_	_	_	_	_	Seg=O
6	with	_	_	_	_	_	_	_	Seg=O
7	molecular	_	_	_	_	_	_	_	Seg=O
8	tests	_	_	_	_	_	_	_	Seg=O
9	for	_	_	_	_	_	_	_	Seg=O
10	improved	_	_	_	_	_	_	_	Seg=O
11	diagnostics	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	patient	_	_	_	_	_	_	_	Seg=O
14	management	_	_	_	_	_	_	_	Seg=O
15	.	_	_	_	_	_	_	_	Seg=O
16	The	_	_	_	_	_	_	_	Seg=B-seg
17	polymerase	_	_	_	_	_	_	_	Seg=O
18	chain	_	_	_	_	_	_	_	Seg=O
19	reaction	_	_	_	_	_	_	_	Seg=O
20	(	_	_	_	_	_	_	_	Seg=O
21	PCR	_	_	_	_	_	_	_	Seg=O
22	)	_	_	_	_	_	_	_	Seg=O
23	is	_	_	_	_	_	_	_	Seg=O
24	foremost	_	_	_	_	_	_	_	Seg=O
25	amongst	_	_	_	_	_	_	_	Seg=O
26	these	_	_	_	_	_	_	_	Seg=O
27	techniques	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	This	_	_	_	_	_	_	_	Seg=B-seg
30	review	_	_	_	_	_	_	_	Seg=O
31	explains	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	principles	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	PCR	_	_	_	_	_	_	_	Seg=O
36	and	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	methodological	_	_	_	_	_	_	_	Seg=O
39	factors	_	_	_	_	_	_	_	Seg=O
40	that	_	_	_	_	_	_	_	Seg=B-seg
41	contribute	_	_	_	_	_	_	_	Seg=O
42	to	_	_	_	_	_	_	_	Seg=O
43	a	_	_	_	_	_	_	_	Seg=O
44	successful	_	_	_	_	_	_	_	Seg=O
45	assay	_	_	_	_	_	_	_	Seg=O
46	.	_	_	_	_	_	_	_	Seg=O
47	Key	_	_	_	_	_	_	_	Seg=B-seg
48	PCR	_	_	_	_	_	_	_	Seg=O
49	technique	_	_	_	_	_	_	_	Seg=O
50	variations	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	such	_	_	_	_	_	_	_	Seg=B-seg
53	as	_	_	_	_	_	_	_	Seg=O
54	reverse	_	_	_	_	_	_	_	Seg=O
55	transcription	_	_	_	_	_	_	_	Seg=O
56	(	_	_	_	_	_	_	_	Seg=O
57	RT)-PCR	_	_	_	_	_	_	_	Seg=O
58	and	_	_	_	_	_	_	_	Seg=O
59	quantitative	_	_	_	_	_	_	_	Seg=O
60	real	_	_	_	_	_	_	_	Seg=O
61	-	_	_	_	_	_	_	_	Seg=O
62	time	_	_	_	_	_	_	_	Seg=O
63	(	_	_	_	_	_	_	_	Seg=O
64	q	_	_	_	_	_	_	_	Seg=O
65	)	_	_	_	_	_	_	_	Seg=O
66	PCR	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	are	_	_	_	_	_	_	_	Seg=B-seg
69	described	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=B-seg
71	an	_	_	_	_	_	_	_	Seg=O
72	overview	_	_	_	_	_	_	_	Seg=O
73	is	_	_	_	_	_	_	_	Seg=O
74	provided	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=B-seg
76	how	_	_	_	_	_	_	_	Seg=O
77	PCR	_	_	_	_	_	_	_	Seg=O
78	products	_	_	_	_	_	_	_	Seg=O
79	are	_	_	_	_	_	_	_	Seg=O
80	analysed	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	The	_	_	_	_	_	_	_	Seg=B-seg
83	review	_	_	_	_	_	_	_	Seg=O
84	includes	_	_	_	_	_	_	_	Seg=O
85	examples	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=O
87	PCR	_	_	_	_	_	_	_	Seg=O
88	usage	_	_	_	_	_	_	_	Seg=O
89	in	_	_	_	_	_	_	_	Seg=O
90	clinical	_	_	_	_	_	_	_	Seg=O
91	practice	_	_	_	_	_	_	_	Seg=O
92	for	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	detection	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	infectious	_	_	_	_	_	_	_	Seg=O
97	and	_	_	_	_	_	_	_	Seg=O
98	genetic	_	_	_	_	_	_	_	Seg=O
99	diseases	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	for	_	_	_	_	_	_	_	Seg=O
102	tumour	_	_	_	_	_	_	_	Seg=O
103	diagnostics	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	in	_	_	_	_	_	_	_	Seg=O
106	molecular	_	_	_	_	_	_	_	Seg=O
107	forensic	_	_	_	_	_	_	_	Seg=O
108	applications	_	_	_	_	_	_	_	Seg=O
109	such	_	_	_	_	_	_	_	Seg=B-seg
110	as	_	_	_	_	_	_	_	Seg=O
111	specimen	_	_	_	_	_	_	_	Seg=O
112	identity	_	_	_	_	_	_	_	Seg=O
113	confirmation	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	The	_	_	_	_	_	_	_	Seg=B-seg
116	polymerase	_	_	_	_	_	_	_	Seg=O
117	chain	_	_	_	_	_	_	_	Seg=O
118	reaction	_	_	_	_	_	_	_	Seg=O
119	(	_	_	_	_	_	_	_	Seg=O
120	PCR	_	_	_	_	_	_	_	Seg=O
121	)	_	_	_	_	_	_	_	Seg=O
122	is	_	_	_	_	_	_	_	Seg=O
123	a	_	_	_	_	_	_	_	Seg=O
124	method	_	_	_	_	_	_	_	Seg=O
125	for	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	in	_	_	_	_	_	_	_	Seg=O
128	vitro	_	_	_	_	_	_	_	Seg=O
129	amplification	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	DNA	_	_	_	_	_	_	_	Seg=O
132	sequences	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=B-seg
134	involves	_	_	_	_	_	_	_	Seg=O
135	automated	_	_	_	_	_	_	_	Seg=O
136	cycles	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	denaturation	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	annealing	_	_	_	_	_	_	_	Seg=O
141	and	_	_	_	_	_	_	_	Seg=O
142	extension	_	_	_	_	_	_	_	Seg=O
143	or	_	_	_	_	_	_	_	Seg=O
144	synthesis	_	_	_	_	_	_	_	Seg=O
145	using	_	_	_	_	_	_	_	Seg=B-seg
146	a	_	_	_	_	_	_	_	Seg=O
147	thermocycler	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	PCR	_	_	_	_	_	_	_	Seg=B-seg
150	was	_	_	_	_	_	_	_	Seg=O
151	conceived	_	_	_	_	_	_	_	Seg=O
152	and	_	_	_	_	_	_	_	Seg=O
153	developed	_	_	_	_	_	_	_	Seg=O
154	in	_	_	_	_	_	_	_	Seg=O
155	the	_	_	_	_	_	_	_	Seg=O
156	early	_	_	_	_	_	_	_	Seg=O
157	1980s	_	_	_	_	_	_	_	Seg=O
158	by	_	_	_	_	_	_	_	Seg=O
159	Kary	_	_	_	_	_	_	_	Seg=O
160	Mullis	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	who	_	_	_	_	_	_	_	Seg=B-seg
163	was	_	_	_	_	_	_	_	Seg=O
164	awarded	_	_	_	_	_	_	_	Seg=O
165	the	_	_	_	_	_	_	_	Seg=O
166	Nobel	_	_	_	_	_	_	_	Seg=O
167	Prize	_	_	_	_	_	_	_	Seg=O
168	for	_	_	_	_	_	_	_	Seg=O
169	Chemistry	_	_	_	_	_	_	_	Seg=O
170	for	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	invention	_	_	_	_	_	_	_	Seg=O
173	in	_	_	_	_	_	_	_	Seg=O
174	1993	_	_	_	_	_	_	_	Seg=O
175	.	_	_	_	_	_	_	_	Seg=O
176	1	_	_	_	_	_	_	_	Seg=O
177	The	_	_	_	_	_	_	_	Seg=B-seg
178	technique	_	_	_	_	_	_	_	Seg=O
179	allows	_	_	_	_	_	_	_	Seg=O
180	the	_	_	_	_	_	_	_	Seg=O
181	sensitive	_	_	_	_	_	_	_	Seg=O
182	detection	_	_	_	_	_	_	_	Seg=O
183	and	_	_	_	_	_	_	_	Seg=O
184	analysis	_	_	_	_	_	_	_	Seg=O
185	of	_	_	_	_	_	_	_	Seg=O
186	miniscule	_	_	_	_	_	_	_	Seg=O
187	quantities	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	nucleic	_	_	_	_	_	_	_	Seg=O
190	acids	_	_	_	_	_	_	_	Seg=O
191	.	_	_	_	_	_	_	_	Seg=O
192	PCR	_	_	_	_	_	_	_	Seg=B-seg
193	has	_	_	_	_	_	_	_	Seg=O
194	become	_	_	_	_	_	_	_	Seg=O
195	established	_	_	_	_	_	_	_	Seg=O
196	as	_	_	_	_	_	_	_	Seg=O
197	a	_	_	_	_	_	_	_	Seg=O
198	routine	_	_	_	_	_	_	_	Seg=O
199	method	_	_	_	_	_	_	_	Seg=O
200	in	_	_	_	_	_	_	_	Seg=O
201	pathology	_	_	_	_	_	_	_	Seg=O
202	diagnostics	_	_	_	_	_	_	_	Seg=O
203	and	_	_	_	_	_	_	_	Seg=B-seg
204	has	_	_	_	_	_	_	_	Seg=O
205	been	_	_	_	_	_	_	_	Seg=O
206	adapted	_	_	_	_	_	_	_	Seg=O
207	for	_	_	_	_	_	_	_	Seg=O
208	the	_	_	_	_	_	_	_	Seg=O
209	detection	_	_	_	_	_	_	_	Seg=O
210	of	_	_	_	_	_	_	_	Seg=O
211	infectious	_	_	_	_	_	_	_	Seg=O
212	agents	_	_	_	_	_	_	_	Seg=O
213	,	_	_	_	_	_	_	_	Seg=O
214	mutations	_	_	_	_	_	_	_	Seg=O
215	,	_	_	_	_	_	_	_	Seg=O
216	translocations	_	_	_	_	_	_	_	Seg=O
217	and	_	_	_	_	_	_	_	Seg=O
218	gene	_	_	_	_	_	_	_	Seg=O
219	amplifications	_	_	_	_	_	_	_	Seg=O
220	,	_	_	_	_	_	_	_	Seg=O
221	and	_	_	_	_	_	_	_	Seg=O
222	for	_	_	_	_	_	_	_	Seg=O
223	molecular	_	_	_	_	_	_	_	Seg=O
224	forensic	_	_	_	_	_	_	_	Seg=O
225	applications	_	_	_	_	_	_	_	Seg=O
226	including	_	_	_	_	_	_	_	Seg=B-seg
227	identity	_	_	_	_	_	_	_	Seg=O
228	testing	_	_	_	_	_	_	_	Seg=O
229	.	_	_	_	_	_	_	_	Seg=O
230	This	_	_	_	_	_	_	_	Seg=B-seg
231	review	_	_	_	_	_	_	_	Seg=O
232	covers	_	_	_	_	_	_	_	Seg=O
233	the	_	_	_	_	_	_	_	Seg=O
234	basics	_	_	_	_	_	_	_	Seg=O
235	of	_	_	_	_	_	_	_	Seg=O
236	the	_	_	_	_	_	_	_	Seg=O
237	PCR	_	_	_	_	_	_	_	Seg=O
238	assay	_	_	_	_	_	_	_	Seg=O
239	,	_	_	_	_	_	_	_	Seg=O
240	describes	_	_	_	_	_	_	_	Seg=B-seg
241	PCR	_	_	_	_	_	_	_	Seg=O
242	method	_	_	_	_	_	_	_	Seg=O
243	variations	_	_	_	_	_	_	_	Seg=O
244	and	_	_	_	_	_	_	_	Seg=B-seg
245	details	_	_	_	_	_	_	_	Seg=O
246	current	_	_	_	_	_	_	_	Seg=O
247	pathology	_	_	_	_	_	_	_	Seg=O
248	applications	_	_	_	_	_	_	_	Seg=O
249	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 998006100007fee546077ce3c05ded0d35d08ff8
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	goal	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	this	_	_	_	_	_	_	_	Seg=O
5	article	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	to	_	_	_	_	_	_	_	Seg=O
8	analyze	_	_	_	_	_	_	_	Seg=O
9	some	_	_	_	_	_	_	_	Seg=O
10	compartmental	_	_	_	_	_	_	_	Seg=O
11	models	_	_	_	_	_	_	_	Seg=O
12	specially	_	_	_	_	_	_	_	Seg=B-seg
13	designed	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=B-seg
15	model	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	spread	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	a	_	_	_	_	_	_	_	Seg=O
20	disease	_	_	_	_	_	_	_	Seg=O
21	whose	_	_	_	_	_	_	_	Seg=B-seg
22	transmission	_	_	_	_	_	_	_	Seg=O
23	has	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	same	_	_	_	_	_	_	_	Seg=O
26	features	_	_	_	_	_	_	_	Seg=O
27	as	_	_	_	_	_	_	_	Seg=O
28	COVID-19	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	The	_	_	_	_	_	_	_	Seg=B-seg
31	major	_	_	_	_	_	_	_	Seg=O
32	contributions	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	this	_	_	_	_	_	_	_	Seg=O
35	article	_	_	_	_	_	_	_	Seg=O
36	are	_	_	_	_	_	_	_	Seg=O
37	:	_	_	_	_	_	_	_	Seg=O
38	(	_	_	_	_	_	_	_	Seg=B-seg
39	1	_	_	_	_	_	_	_	Seg=O
40	)	_	_	_	_	_	_	_	Seg=O
41	Rigorously	_	_	_	_	_	_	_	Seg=O
42	find	_	_	_	_	_	_	_	Seg=O
43	sufficient	_	_	_	_	_	_	_	Seg=O
44	conditions	_	_	_	_	_	_	_	Seg=O
45	for	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	outbreak	_	_	_	_	_	_	_	Seg=O
48	to	_	_	_	_	_	_	_	Seg=O
49	only	_	_	_	_	_	_	_	Seg=O
50	have	_	_	_	_	_	_	_	Seg=O
51	one	_	_	_	_	_	_	_	Seg=O
52	peak	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	i.e.	_	_	_	_	_	_	_	Seg=B-seg
55	for	_	_	_	_	_	_	_	Seg=O
56	no	_	_	_	_	_	_	_	Seg=O
57	second	_	_	_	_	_	_	_	Seg=O
58	wave	_	_	_	_	_	_	_	Seg=O
59	of	_	_	_	_	_	_	_	Seg=O
60	infection	_	_	_	_	_	_	_	Seg=O
61	to	_	_	_	_	_	_	_	Seg=O
62	form	_	_	_	_	_	_	_	Seg=O
63	;	_	_	_	_	_	_	_	Seg=O
64	(	_	_	_	_	_	_	_	Seg=B-seg
65	2	_	_	_	_	_	_	_	Seg=O
66	)	_	_	_	_	_	_	_	Seg=O
67	Investigate	_	_	_	_	_	_	_	Seg=O
68	the	_	_	_	_	_	_	_	Seg=O
69	formation	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	other	_	_	_	_	_	_	_	Seg=O
72	waves	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	infection	_	_	_	_	_	_	_	Seg=O
75	when	_	_	_	_	_	_	_	Seg=B-seg
76	such	_	_	_	_	_	_	_	Seg=O
77	conditions	_	_	_	_	_	_	_	Seg=O
78	are	_	_	_	_	_	_	_	Seg=O
79	not	_	_	_	_	_	_	_	Seg=O
80	met	_	_	_	_	_	_	_	Seg=O
81	;	_	_	_	_	_	_	_	Seg=O
82	(	_	_	_	_	_	_	_	Seg=B-seg
83	3	_	_	_	_	_	_	_	Seg=O
84	)	_	_	_	_	_	_	_	Seg=O
85	Use	_	_	_	_	_	_	_	Seg=O
86	numerical	_	_	_	_	_	_	_	Seg=O
87	simulations	_	_	_	_	_	_	_	Seg=O
88	to	_	_	_	_	_	_	_	Seg=B-seg
89	analyze	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	different	_	_	_	_	_	_	_	Seg=O
92	roles	_	_	_	_	_	_	_	Seg=O
93	asymptomatic	_	_	_	_	_	_	_	Seg=B-seg
94	carriers	_	_	_	_	_	_	_	Seg=O
95	can	_	_	_	_	_	_	_	Seg=O
96	have	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	We	_	_	_	_	_	_	_	Seg=B-seg
99	also	_	_	_	_	_	_	_	Seg=O
100	argue	_	_	_	_	_	_	_	Seg=O
101	that	_	_	_	_	_	_	_	Seg=B-seg
102	dividing	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	population	_	_	_	_	_	_	_	Seg=O
105	into	_	_	_	_	_	_	_	Seg=O
106	non	_	_	_	_	_	_	_	Seg=O
107	-	_	_	_	_	_	_	_	Seg=O
108	interacting	_	_	_	_	_	_	_	Seg=O
109	groups	_	_	_	_	_	_	_	Seg=O
110	leads	_	_	_	_	_	_	_	Seg=O
111	to	_	_	_	_	_	_	_	Seg=O
112	an	_	_	_	_	_	_	_	Seg=O
113	effective	_	_	_	_	_	_	_	Seg=O
114	reduction	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	transmission	_	_	_	_	_	_	_	Seg=O
118	rates	_	_	_	_	_	_	_	Seg=O
119	.	_	_	_	_	_	_	_	Seg=O
120	As	_	_	_	_	_	_	_	Seg=B-seg
121	in	_	_	_	_	_	_	_	Seg=O
122	any	_	_	_	_	_	_	_	Seg=O
123	compartmental	_	_	_	_	_	_	_	Seg=O
124	model	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	goal	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	this	_	_	_	_	_	_	_	Seg=O
130	article	_	_	_	_	_	_	_	Seg=O
131	is	_	_	_	_	_	_	_	Seg=O
132	to	_	_	_	_	_	_	_	Seg=O
133	provide	_	_	_	_	_	_	_	Seg=O
134	qualitative	_	_	_	_	_	_	_	Seg=O
135	understanding	_	_	_	_	_	_	_	Seg=O
136	rather	_	_	_	_	_	_	_	Seg=O
137	than	_	_	_	_	_	_	_	Seg=O
138	exact	_	_	_	_	_	_	_	Seg=O
139	quantitative	_	_	_	_	_	_	_	Seg=O
140	predictions	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 9ddc68cec5cd84cb4e0ffebe2950149cca597811
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	first	_	_	_	_	_	_	_	Seg=O
3	person	_	_	_	_	_	_	_	Seg=O
4	-	_	_	_	_	_	_	_	Seg=O
5	to	_	_	_	_	_	_	_	Seg=O
6	-	_	_	_	_	_	_	_	Seg=O
7	person	_	_	_	_	_	_	_	Seg=O
8	transmission	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	the	_	_	_	_	_	_	_	Seg=O
11	2019-novel	_	_	_	_	_	_	_	Seg=O
12	coronavirus	_	_	_	_	_	_	_	Seg=O
13	in	_	_	_	_	_	_	_	Seg=O
14	Italy	_	_	_	_	_	_	_	Seg=O
15	on	_	_	_	_	_	_	_	Seg=O
16	21	_	_	_	_	_	_	_	Seg=O
17	February	_	_	_	_	_	_	_	Seg=O
18	2020	_	_	_	_	_	_	_	Seg=O
19	led	_	_	_	_	_	_	_	Seg=O
20	to	_	_	_	_	_	_	_	Seg=O
21	an	_	_	_	_	_	_	_	Seg=O
22	infection	_	_	_	_	_	_	_	Seg=O
23	chain	_	_	_	_	_	_	_	Seg=O
24	that	_	_	_	_	_	_	_	Seg=B-seg
25	represents	_	_	_	_	_	_	_	Seg=O
26	one	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	largest	_	_	_	_	_	_	_	Seg=O
30	known	_	_	_	_	_	_	_	Seg=O
31	COVID-19	_	_	_	_	_	_	_	Seg=O
32	outbreaks	_	_	_	_	_	_	_	Seg=O
33	outside	_	_	_	_	_	_	_	Seg=O
34	Asia	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	Hospitals	_	_	_	_	_	_	_	Seg=B-seg
37	have	_	_	_	_	_	_	_	Seg=O
38	been	_	_	_	_	_	_	_	Seg=O
39	forced	_	_	_	_	_	_	_	Seg=O
40	to	_	_	_	_	_	_	_	Seg=O
41	reorganized	_	_	_	_	_	_	_	Seg=O
42	their	_	_	_	_	_	_	_	Seg=O
43	units	_	_	_	_	_	_	_	Seg=O
44	in	_	_	_	_	_	_	_	Seg=O
45	response	_	_	_	_	_	_	_	Seg=O
46	to	_	_	_	_	_	_	_	Seg=B-seg
47	prepare	_	_	_	_	_	_	_	Seg=O
48	for	_	_	_	_	_	_	_	Seg=O
49	an	_	_	_	_	_	_	_	Seg=O
50	unforeseen	_	_	_	_	_	_	_	Seg=O
51	healthcare	_	_	_	_	_	_	_	Seg=O
52	emergency	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	In	_	_	_	_	_	_	_	Seg=B-seg
55	this	_	_	_	_	_	_	_	Seg=O
56	context	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	our	_	_	_	_	_	_	_	Seg=O
59	laboratory	_	_	_	_	_	_	_	Seg=O
60	(	_	_	_	_	_	_	_	Seg=B-seg
61	Molecular	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	Genomic	_	_	_	_	_	_	_	Seg=O
64	Diagnostics	_	_	_	_	_	_	_	Seg=O
65	Unit	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	Fondazione	_	_	_	_	_	_	_	Seg=O
68	Policlinico	_	_	_	_	_	_	_	Seg=O
69	Universitario	_	_	_	_	_	_	_	Seg=O
70	Agostino	_	_	_	_	_	_	_	Seg=O
71	Gemelli	_	_	_	_	_	_	_	Seg=O
72	IRCCS	_	_	_	_	_	_	_	Seg=O
73	)	_	_	_	_	_	_	_	Seg=O
74	re	_	_	_	_	_	_	_	Seg=B-seg
75	-	_	_	_	_	_	_	_	Seg=O
76	modulated	_	_	_	_	_	_	_	Seg=O
77	its	_	_	_	_	_	_	_	Seg=O
78	priorities	_	_	_	_	_	_	_	Seg=O
79	by	_	_	_	_	_	_	_	Seg=B-seg
80	temporarily	_	_	_	_	_	_	_	Seg=O
81	interrupting	_	_	_	_	_	_	_	Seg=O
82	most	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	the	_	_	_	_	_	_	_	Seg=O
85	molecular	_	_	_	_	_	_	_	Seg=O
86	tests	_	_	_	_	_	_	_	Seg=O
87	guaranteeing	_	_	_	_	_	_	_	Seg=B-seg
88	only	_	_	_	_	_	_	_	Seg=O
89	those	_	_	_	_	_	_	_	Seg=O
90	considered	_	_	_	_	_	_	_	Seg=B-seg
91	"	_	_	_	_	_	_	_	Seg=O
92	urgent	_	_	_	_	_	_	_	Seg=O
93	"	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=O
95	not	_	_	_	_	_	_	_	Seg=O
96	postponable	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	In	_	_	_	_	_	_	_	Seg=B-seg
99	particular	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	this	_	_	_	_	_	_	_	Seg=O
102	paper	_	_	_	_	_	_	_	Seg=O
103	details	_	_	_	_	_	_	_	Seg=O
104	changes	_	_	_	_	_	_	_	Seg=O
105	regarding	_	_	_	_	_	_	_	Seg=B-seg
106	the	_	_	_	_	_	_	_	Seg=O
107	execution	_	_	_	_	_	_	_	Seg=O
108	of	_	_	_	_	_	_	_	Seg=O
109	germline	_	_	_	_	_	_	_	Seg=O
110	BRCA	_	_	_	_	_	_	_	Seg=O
111	(	_	_	_	_	_	_	_	Seg=O
112	gBRCA	_	_	_	_	_	_	_	Seg=O
113	)	_	_	_	_	_	_	_	Seg=O
114	testing	_	_	_	_	_	_	_	Seg=O
115	in	_	_	_	_	_	_	_	Seg=O
116	our	_	_	_	_	_	_	_	Seg=O
117	laboratory	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	A	_	_	_	_	_	_	_	Seg=B-seg
120	substantial	_	_	_	_	_	_	_	Seg=O
121	reduction	_	_	_	_	_	_	_	Seg=O
122	in	_	_	_	_	_	_	_	Seg=O
123	gBRCA	_	_	_	_	_	_	_	Seg=O
124	testing	_	_	_	_	_	_	_	Seg=O
125	(	_	_	_	_	_	_	_	Seg=B-seg
126	about	_	_	_	_	_	_	_	Seg=O
127	60	_	_	_	_	_	_	_	Seg=O
128	%	_	_	_	_	_	_	_	Seg=O
129	)	_	_	_	_	_	_	_	Seg=O
130	compared	_	_	_	_	_	_	_	Seg=B-seg
131	to	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	first	_	_	_	_	_	_	_	Seg=O
134	2	_	_	_	_	_	_	_	Seg=O
135	months	_	_	_	_	_	_	_	Seg=O
136	of	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	current	_	_	_	_	_	_	_	Seg=O
139	year	_	_	_	_	_	_	_	Seg=O
140	was	_	_	_	_	_	_	_	Seg=B-seg
141	registered	_	_	_	_	_	_	_	Seg=O
142	,	_	_	_	_	_	_	_	Seg=O
143	but	_	_	_	_	_	_	_	Seg=B-seg
144	the	_	_	_	_	_	_	_	Seg=O
145	requests	_	_	_	_	_	_	_	Seg=O
146	have	_	_	_	_	_	_	_	Seg=O
147	not	_	_	_	_	_	_	_	Seg=O
148	been	_	_	_	_	_	_	_	Seg=O
149	reset	_	_	_	_	_	_	_	Seg=O
150	.	_	_	_	_	_	_	_	Seg=O
151	The	_	_	_	_	_	_	_	Seg=B-seg
152	requesting	_	_	_	_	_	_	_	Seg=O
153	physicians	_	_	_	_	_	_	_	Seg=O
154	were	_	_	_	_	_	_	_	Seg=O
155	mainly	_	_	_	_	_	_	_	Seg=O
156	gynaecologists	_	_	_	_	_	_	_	Seg=O
157	and	_	_	_	_	_	_	_	Seg=O
158	oncologists	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O
160	These	_	_	_	_	_	_	_	Seg=B-seg
161	evidences	_	_	_	_	_	_	_	Seg=O
162	further	_	_	_	_	_	_	_	Seg=O
163	emphasize	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	new	_	_	_	_	_	_	_	Seg=O
166	era	_	_	_	_	_	_	_	Seg=O
167	of	_	_	_	_	_	_	_	Seg=O
168	gBRCA	_	_	_	_	_	_	_	Seg=O
169	testing	_	_	_	_	_	_	_	Seg=O
170	in	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	management	_	_	_	_	_	_	_	Seg=O
173	of	_	_	_	_	_	_	_	Seg=O
174	cancer	_	_	_	_	_	_	_	Seg=O
175	patients	_	_	_	_	_	_	_	Seg=O
176	and	_	_	_	_	_	_	_	Seg=B-seg
177	confirms	_	_	_	_	_	_	_	Seg=O
178	definitively	_	_	_	_	_	_	_	Seg=O
179	the	_	_	_	_	_	_	_	Seg=O
180	integration	_	_	_	_	_	_	_	Seg=O
181	of	_	_	_	_	_	_	_	Seg=O
182	gBRCA	_	_	_	_	_	_	_	Seg=O
183	testing	_	_	_	_	_	_	_	Seg=O
184	/	_	_	_	_	_	_	_	Seg=O
185	Next	_	_	_	_	_	_	_	Seg=O
186	Generation	_	_	_	_	_	_	_	Seg=O
187	Sequencing	_	_	_	_	_	_	_	Seg=O
188	(	_	_	_	_	_	_	_	Seg=O
189	NGS	_	_	_	_	_	_	_	Seg=O
190	)	_	_	_	_	_	_	_	Seg=O
191	into	_	_	_	_	_	_	_	Seg=O
192	clinical	_	_	_	_	_	_	_	Seg=O
193	oncology	_	_	_	_	_	_	_	Seg=O
194	.	_	_	_	_	_	_	_	Seg=O
195	Finally	_	_	_	_	_	_	_	Seg=B-seg
196	,	_	_	_	_	_	_	_	Seg=O
197	a	_	_	_	_	_	_	_	Seg=O
198	re	_	_	_	_	_	_	_	Seg=O
199	-	_	_	_	_	_	_	_	Seg=O
200	organization	_	_	_	_	_	_	_	Seg=O
201	of	_	_	_	_	_	_	_	Seg=O
202	gBRCA	_	_	_	_	_	_	_	Seg=O
203	testing	_	_	_	_	_	_	_	Seg=O
204	in	_	_	_	_	_	_	_	Seg=O
205	our	_	_	_	_	_	_	_	Seg=O
206	Unit	_	_	_	_	_	_	_	Seg=O
207	,	_	_	_	_	_	_	_	Seg=O
208	mainly	_	_	_	_	_	_	_	Seg=B-seg
209	related	_	_	_	_	_	_	_	Seg=O
210	to	_	_	_	_	_	_	_	Seg=O
211	delayed	_	_	_	_	_	_	_	Seg=O
212	and	_	_	_	_	_	_	_	Seg=O
213	reduced	_	_	_	_	_	_	_	Seg=O
214	arrival	_	_	_	_	_	_	_	Seg=O
215	of	_	_	_	_	_	_	_	Seg=O
216	tests	_	_	_	_	_	_	_	Seg=O
217	was	_	_	_	_	_	_	_	Seg=B-seg
218	necessary	_	_	_	_	_	_	_	Seg=O
219	,	_	_	_	_	_	_	_	Seg=O
220	ensuring	_	_	_	_	_	_	_	Seg=B-seg
221	,	_	_	_	_	_	_	_	Seg=O
222	however	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	a	_	_	_	_	_	_	_	Seg=O
225	high	_	_	_	_	_	_	_	Seg=O
226	-	_	_	_	_	_	_	_	Seg=O
227	quality	_	_	_	_	_	_	_	Seg=O
228	standard	_	_	_	_	_	_	_	Seg=O
229	and	_	_	_	_	_	_	_	Seg=O
230	reliability	_	_	_	_	_	_	_	Seg=O
231	,	_	_	_	_	_	_	_	Seg=O
232	mandatory	_	_	_	_	_	_	_	Seg=O
233	for	_	_	_	_	_	_	_	Seg=O
234	gBRCA	_	_	_	_	_	_	_	Seg=O
235	testing	_	_	_	_	_	_	_	Seg=O
236	in	_	_	_	_	_	_	_	Seg=O
237	a	_	_	_	_	_	_	_	Seg=O
238	clinical	_	_	_	_	_	_	_	Seg=O
239	setting	_	_	_	_	_	_	_	Seg=O
240	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 9f75a36d8f57e382a717ee506b636cbdb355802a
1	Cases	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	COVID-19	_	_	_	_	_	_	_	Seg=O
4	are	_	_	_	_	_	_	_	Seg=O
5	escalating	_	_	_	_	_	_	_	Seg=O
6	rapidly	_	_	_	_	_	_	_	Seg=O
7	across	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	globe	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	with	_	_	_	_	_	_	_	Seg=B-seg
12	the	_	_	_	_	_	_	_	Seg=O
13	mortality	_	_	_	_	_	_	_	Seg=O
14	risk	_	_	_	_	_	_	_	Seg=O
15	being	_	_	_	_	_	_	_	Seg=O
16	especially	_	_	_	_	_	_	_	Seg=O
17	high	_	_	_	_	_	_	_	Seg=O
18	among	_	_	_	_	_	_	_	Seg=O
19	those	_	_	_	_	_	_	_	Seg=O
20	with	_	_	_	_	_	_	_	Seg=O
21	existing	_	_	_	_	_	_	_	Seg=O
22	illness	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=O
24	multimorbidity	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	This	_	_	_	_	_	_	_	Seg=B-seg
27	study	_	_	_	_	_	_	_	Seg=O
28	aimed	_	_	_	_	_	_	_	Seg=O
29	to	_	_	_	_	_	_	_	Seg=O
30	synthesise	_	_	_	_	_	_	_	Seg=O
31	evidence	_	_	_	_	_	_	_	Seg=O
32	for	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	role	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	response	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	palliative	_	_	_	_	_	_	_	Seg=O
39	care	_	_	_	_	_	_	_	Seg=O
40	and	_	_	_	_	_	_	_	Seg=O
41	hospice	_	_	_	_	_	_	_	Seg=O
42	teams	_	_	_	_	_	_	_	Seg=O
43	to	_	_	_	_	_	_	_	Seg=O
44	viral	_	_	_	_	_	_	_	Seg=O
45	epi	_	_	_	_	_	_	_	Seg=O
46	/	_	_	_	_	_	_	_	Seg=O
47	pandemics	_	_	_	_	_	_	_	Seg=O
48	,	_	_	_	_	_	_	_	Seg=O
49	to	_	_	_	_	_	_	_	Seg=B-seg
50	inform	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	COVID-19	_	_	_	_	_	_	_	Seg=O
53	pandemic	_	_	_	_	_	_	_	Seg=O
54	response	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	We	_	_	_	_	_	_	_	Seg=B-seg
57	conducted	_	_	_	_	_	_	_	Seg=O
58	a	_	_	_	_	_	_	_	Seg=O
59	rapid	_	_	_	_	_	_	_	Seg=O
60	systematic	_	_	_	_	_	_	_	Seg=O
61	review	_	_	_	_	_	_	_	Seg=O
62	according	_	_	_	_	_	_	_	Seg=O
63	to	_	_	_	_	_	_	_	Seg=O
64	PRISMA	_	_	_	_	_	_	_	Seg=O
65	guidelines	_	_	_	_	_	_	_	Seg=O
66	in	_	_	_	_	_	_	_	Seg=O
67	five	_	_	_	_	_	_	_	Seg=O
68	databases	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	Of	_	_	_	_	_	_	_	Seg=B-seg
71	3094	_	_	_	_	_	_	_	Seg=O
72	papers	_	_	_	_	_	_	_	Seg=O
73	identified	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	ten	_	_	_	_	_	_	_	Seg=O
76	were	_	_	_	_	_	_	_	Seg=O
77	included	_	_	_	_	_	_	_	Seg=O
78	in	_	_	_	_	_	_	_	Seg=O
79	this	_	_	_	_	_	_	_	Seg=O
80	narrative	_	_	_	_	_	_	_	Seg=O
81	synthesis	_	_	_	_	_	_	_	Seg=O
82	.	_	_	_	_	_	_	_	Seg=O
83	Included	_	_	_	_	_	_	_	Seg=B-seg
84	studies	_	_	_	_	_	_	_	Seg=O
85	were	_	_	_	_	_	_	_	Seg=O
86	from	_	_	_	_	_	_	_	Seg=O
87	West	_	_	_	_	_	_	_	Seg=O
88	Africa	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	Taiwan	_	_	_	_	_	_	_	Seg=O
91	,	_	_	_	_	_	_	_	Seg=O
92	Hong	_	_	_	_	_	_	_	Seg=O
93	Kong	_	_	_	_	_	_	_	Seg=O
94	,	_	_	_	_	_	_	_	Seg=O
95	Singapore	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	the	_	_	_	_	_	_	_	Seg=O
98	United	_	_	_	_	_	_	_	Seg=O
99	States	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=O
101	Italy	_	_	_	_	_	_	_	Seg=O
102	.	_	_	_	_	_	_	_	Seg=O
103	All	_	_	_	_	_	_	_	Seg=B-seg
104	had	_	_	_	_	_	_	_	Seg=O
105	an	_	_	_	_	_	_	_	Seg=O
106	observational	_	_	_	_	_	_	_	Seg=O
107	design	_	_	_	_	_	_	_	Seg=O
108	.	_	_	_	_	_	_	_	Seg=O
109	Findings	_	_	_	_	_	_	_	Seg=B-seg
110	were	_	_	_	_	_	_	_	Seg=O
111	synthesised	_	_	_	_	_	_	_	Seg=O
112	using	_	_	_	_	_	_	_	Seg=B-seg
113	a	_	_	_	_	_	_	_	Seg=O
114	previously	_	_	_	_	_	_	_	Seg=O
115	proposed	_	_	_	_	_	_	_	Seg=O
116	framework	_	_	_	_	_	_	_	Seg=O
117	according	_	_	_	_	_	_	_	Seg=B-seg
118	to	_	_	_	_	_	_	_	Seg=O
119	'	_	_	_	_	_	_	_	Seg=O
120	systems	_	_	_	_	_	_	_	Seg=O
121	'	_	_	_	_	_	_	_	Seg=O
122	(	_	_	_	_	_	_	_	Seg=B-seg
123	policies	_	_	_	_	_	_	_	Seg=O
124	,	_	_	_	_	_	_	_	Seg=O
125	training	_	_	_	_	_	_	_	Seg=O
126	and	_	_	_	_	_	_	_	Seg=O
127	protocols	_	_	_	_	_	_	_	Seg=O
128	,	_	_	_	_	_	_	_	Seg=O
129	communication	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	coordination	_	_	_	_	_	_	_	Seg=O
132	,	_	_	_	_	_	_	_	Seg=O
133	data	_	_	_	_	_	_	_	Seg=O
134	)	_	_	_	_	_	_	_	Seg=O
135	,	_	_	_	_	_	_	_	Seg=O
136	'	_	_	_	_	_	_	_	Seg=B-seg
137	staff	_	_	_	_	_	_	_	Seg=O
138	'	_	_	_	_	_	_	_	Seg=O
139	(	_	_	_	_	_	_	_	Seg=B-seg
140	deployment	_	_	_	_	_	_	_	Seg=O
141	,	_	_	_	_	_	_	_	Seg=O
142	skill	_	_	_	_	_	_	_	Seg=O
143	mix	_	_	_	_	_	_	_	Seg=O
144	,	_	_	_	_	_	_	_	Seg=O
145	resilience	_	_	_	_	_	_	_	Seg=O
146	)	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	'	_	_	_	_	_	_	_	Seg=B-seg
149	space	_	_	_	_	_	_	_	Seg=O
150	'	_	_	_	_	_	_	_	Seg=O
151	(	_	_	_	_	_	_	_	Seg=B-seg
152	community	_	_	_	_	_	_	_	Seg=O
153	provision	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	use	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	technology	_	_	_	_	_	_	_	Seg=O
158	)	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=B-seg
160	'	_	_	_	_	_	_	_	Seg=O
161	stuff	_	_	_	_	_	_	_	Seg=O
162	'	_	_	_	_	_	_	_	Seg=O
163	(	_	_	_	_	_	_	_	Seg=B-seg
164	medicines	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=O
166	equipment	_	_	_	_	_	_	_	Seg=O
167	,	_	_	_	_	_	_	_	Seg=O
168	personal	_	_	_	_	_	_	_	Seg=O
169	protective	_	_	_	_	_	_	_	Seg=O
170	equipment	_	_	_	_	_	_	_	Seg=O
171	)	_	_	_	_	_	_	_	Seg=O
172	.	_	_	_	_	_	_	_	Seg=O
173	We	_	_	_	_	_	_	_	Seg=B-seg
174	conclude	_	_	_	_	_	_	_	Seg=O
175	that	_	_	_	_	_	_	_	Seg=B-seg
176	hospice	_	_	_	_	_	_	_	Seg=O
177	and	_	_	_	_	_	_	_	Seg=O
178	palliative	_	_	_	_	_	_	_	Seg=O
179	services	_	_	_	_	_	_	_	Seg=O
180	have	_	_	_	_	_	_	_	Seg=O
181	an	_	_	_	_	_	_	_	Seg=O
182	essential	_	_	_	_	_	_	_	Seg=O
183	role	_	_	_	_	_	_	_	Seg=O
184	in	_	_	_	_	_	_	_	Seg=O
185	the	_	_	_	_	_	_	_	Seg=O
186	response	_	_	_	_	_	_	_	Seg=O
187	to	_	_	_	_	_	_	_	Seg=O
188	COVID-19	_	_	_	_	_	_	_	Seg=O
189	by	_	_	_	_	_	_	_	Seg=O
190	:	_	_	_	_	_	_	_	Seg=O
191	1	_	_	_	_	_	_	_	Seg=B-seg
192	)	_	_	_	_	_	_	_	Seg=O
193	responding	_	_	_	_	_	_	_	Seg=O
194	rapidly	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=O
196	flexibly	_	_	_	_	_	_	_	Seg=O
197	;	_	_	_	_	_	_	_	Seg=O
198	2	_	_	_	_	_	_	_	Seg=B-seg
199	)	_	_	_	_	_	_	_	Seg=O
200	ensuring	_	_	_	_	_	_	_	Seg=O
201	protocols	_	_	_	_	_	_	_	Seg=O
202	for	_	_	_	_	_	_	_	Seg=O
203	symptom	_	_	_	_	_	_	_	Seg=O
204	management	_	_	_	_	_	_	_	Seg=O
205	are	_	_	_	_	_	_	_	Seg=O
206	available	_	_	_	_	_	_	_	Seg=O
207	,	_	_	_	_	_	_	_	Seg=O
208	and	_	_	_	_	_	_	_	Seg=B-seg
209	training	_	_	_	_	_	_	_	Seg=O
210	non	_	_	_	_	_	_	_	Seg=O
211	-	_	_	_	_	_	_	_	Seg=O
212	specialists	_	_	_	_	_	_	_	Seg=O
213	in	_	_	_	_	_	_	_	Seg=O
214	their	_	_	_	_	_	_	_	Seg=O
215	use	_	_	_	_	_	_	_	Seg=O
216	;	_	_	_	_	_	_	_	Seg=O
217	3	_	_	_	_	_	_	_	Seg=B-seg
218	)	_	_	_	_	_	_	_	Seg=O
219	being	_	_	_	_	_	_	_	Seg=O
220	involved	_	_	_	_	_	_	_	Seg=O
221	in	_	_	_	_	_	_	_	Seg=O
222	triage	_	_	_	_	_	_	_	Seg=O
223	;	_	_	_	_	_	_	_	Seg=O
224	4	_	_	_	_	_	_	_	Seg=B-seg
225	)	_	_	_	_	_	_	_	Seg=O
226	considering	_	_	_	_	_	_	_	Seg=O
227	shifting	_	_	_	_	_	_	_	Seg=O
228	resources	_	_	_	_	_	_	_	Seg=O
229	into	_	_	_	_	_	_	_	Seg=O
230	the	_	_	_	_	_	_	_	Seg=O
231	community	_	_	_	_	_	_	_	Seg=O
232	;	_	_	_	_	_	_	_	Seg=O
233	5	_	_	_	_	_	_	_	Seg=B-seg
234	)	_	_	_	_	_	_	_	Seg=O
235	considering	_	_	_	_	_	_	_	Seg=O
236	redeploying	_	_	_	_	_	_	_	Seg=O
237	volunteers	_	_	_	_	_	_	_	Seg=O
238	to	_	_	_	_	_	_	_	Seg=B-seg
239	provide	_	_	_	_	_	_	_	Seg=O
240	psychosocial	_	_	_	_	_	_	_	Seg=O
241	and	_	_	_	_	_	_	_	Seg=O
242	bereavement	_	_	_	_	_	_	_	Seg=O
243	care	_	_	_	_	_	_	_	Seg=O
244	;	_	_	_	_	_	_	_	Seg=O
245	6	_	_	_	_	_	_	_	Seg=B-seg
246	)	_	_	_	_	_	_	_	Seg=O
247	facilitating	_	_	_	_	_	_	_	Seg=O
248	camaraderie	_	_	_	_	_	_	_	Seg=O
249	among	_	_	_	_	_	_	_	Seg=O
250	staff	_	_	_	_	_	_	_	Seg=O
251	and	_	_	_	_	_	_	_	Seg=B-seg
252	adopt	_	_	_	_	_	_	_	Seg=O
253	measures	_	_	_	_	_	_	_	Seg=O
254	to	_	_	_	_	_	_	_	Seg=B-seg
255	deal	_	_	_	_	_	_	_	Seg=O
256	with	_	_	_	_	_	_	_	Seg=O
257	stress	_	_	_	_	_	_	_	Seg=O
258	;	_	_	_	_	_	_	_	Seg=O
259	7	_	_	_	_	_	_	_	Seg=B-seg
260	)	_	_	_	_	_	_	_	Seg=O
261	using	_	_	_	_	_	_	_	Seg=O
262	technology	_	_	_	_	_	_	_	Seg=O
263	to	_	_	_	_	_	_	_	Seg=B-seg
264	communicate	_	_	_	_	_	_	_	Seg=O
265	with	_	_	_	_	_	_	_	Seg=O
266	patients	_	_	_	_	_	_	_	Seg=O
267	and	_	_	_	_	_	_	_	Seg=O
268	carers	_	_	_	_	_	_	_	Seg=O
269	;	_	_	_	_	_	_	_	Seg=O
270	8)	_	_	_	_	_	_	_	Seg=B-seg
271	adopting	_	_	_	_	_	_	_	Seg=O
272	standardised	_	_	_	_	_	_	_	Seg=O
273	data	_	_	_	_	_	_	_	Seg=O
274	collection	_	_	_	_	_	_	_	Seg=O
275	systems	_	_	_	_	_	_	_	Seg=O
276	to	_	_	_	_	_	_	_	Seg=B-seg
277	inform	_	_	_	_	_	_	_	Seg=O
278	operational	_	_	_	_	_	_	_	Seg=O
279	changes	_	_	_	_	_	_	_	Seg=O
280	and	_	_	_	_	_	_	_	Seg=B-seg
281	improve	_	_	_	_	_	_	_	Seg=O
282	care	_	_	_	_	_	_	_	Seg=O
283	.	_	_	_	_	_	_	_	Seg=O
284	An	_	_	_	_	_	_	_	Seg=B-seg
285	evidence	_	_	_	_	_	_	_	Seg=O
286	synthesis	_	_	_	_	_	_	_	Seg=O
287	on	_	_	_	_	_	_	_	Seg=O
288	the	_	_	_	_	_	_	_	Seg=O
289	role	_	_	_	_	_	_	_	Seg=O
290	and	_	_	_	_	_	_	_	Seg=O
291	response	_	_	_	_	_	_	_	Seg=O
292	of	_	_	_	_	_	_	_	Seg=O
293	hospice	_	_	_	_	_	_	_	Seg=O
294	and	_	_	_	_	_	_	_	Seg=O
295	palliative	_	_	_	_	_	_	_	Seg=O
296	care	_	_	_	_	_	_	_	Seg=O
297	in	_	_	_	_	_	_	_	Seg=O
298	epi	_	_	_	_	_	_	_	Seg=O
299	/	_	_	_	_	_	_	_	Seg=O
300	pandemics	_	_	_	_	_	_	_	Seg=O
301	,	_	_	_	_	_	_	_	Seg=O
302	to	_	_	_	_	_	_	_	Seg=B-seg
303	inform	_	_	_	_	_	_	_	Seg=O
304	response	_	_	_	_	_	_	_	Seg=O
305	to	_	_	_	_	_	_	_	Seg=O
306	COVID-19	_	_	_	_	_	_	_	Seg=O
307	.	_	_	_	_	_	_	_	Seg=O
308	Hospice	_	_	_	_	_	_	_	Seg=B-seg
309	and	_	_	_	_	_	_	_	Seg=O
310	palliative	_	_	_	_	_	_	_	Seg=O
311	care	_	_	_	_	_	_	_	Seg=O
312	services	_	_	_	_	_	_	_	Seg=O
313	should	_	_	_	_	_	_	_	Seg=O
314	:	_	_	_	_	_	_	_	Seg=O
315	respond	_	_	_	_	_	_	_	Seg=B-seg
316	rapidly	_	_	_	_	_	_	_	Seg=O
317	and	_	_	_	_	_	_	_	Seg=O
318	flexibly	_	_	_	_	_	_	_	Seg=O
319	;	_	_	_	_	_	_	_	Seg=O
320	produce	_	_	_	_	_	_	_	Seg=B-seg
321	protocols	_	_	_	_	_	_	_	Seg=O
322	;	_	_	_	_	_	_	_	Seg=O
323	shift	_	_	_	_	_	_	_	Seg=B-seg
324	resources	_	_	_	_	_	_	_	Seg=O
325	to	_	_	_	_	_	_	_	Seg=O
326	the	_	_	_	_	_	_	_	Seg=O
327	community	_	_	_	_	_	_	_	Seg=O
328	;	_	_	_	_	_	_	_	Seg=O
329	redeploy	_	_	_	_	_	_	_	Seg=B-seg
330	volunteers	_	_	_	_	_	_	_	Seg=O
331	;	_	_	_	_	_	_	_	Seg=O
332	facilitate	_	_	_	_	_	_	_	Seg=B-seg
333	staff	_	_	_	_	_	_	_	Seg=O
334	camaraderie	_	_	_	_	_	_	_	Seg=O
335	;	_	_	_	_	_	_	_	Seg=O
336	communicate	_	_	_	_	_	_	_	Seg=B-seg
337	with	_	_	_	_	_	_	_	Seg=O
338	patients	_	_	_	_	_	_	_	Seg=O
339	/	_	_	_	_	_	_	_	Seg=O
340	carers	_	_	_	_	_	_	_	Seg=O
341	via	_	_	_	_	_	_	_	Seg=O
342	technology	_	_	_	_	_	_	_	Seg=O
343	;	_	_	_	_	_	_	_	Seg=O
344	standardise	_	_	_	_	_	_	_	Seg=B-seg
345	data	_	_	_	_	_	_	_	Seg=O
346	collection	_	_	_	_	_	_	_	Seg=O
347	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = a5ff05575328a71f49ebc06441902568fc955c72
1	RNA	_	_	_	_	_	_	_	Seg=B-seg
2	viruses	_	_	_	_	_	_	_	Seg=O
3	show	_	_	_	_	_	_	_	Seg=O
4	enormous	_	_	_	_	_	_	_	Seg=O
5	capacity	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=B-seg
7	evolve	_	_	_	_	_	_	_	Seg=O
8	and	_	_	_	_	_	_	_	Seg=B-seg
9	adapt	_	_	_	_	_	_	_	Seg=O
10	to	_	_	_	_	_	_	_	Seg=O
11	new	_	_	_	_	_	_	_	Seg=O
12	cellular	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=O
14	molecular	_	_	_	_	_	_	_	Seg=O
15	contexts	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	a	_	_	_	_	_	_	_	Seg=B-seg
18	consequence	_	_	_	_	_	_	_	Seg=O
19	of	_	_	_	_	_	_	_	Seg=O
20	mutations	_	_	_	_	_	_	_	Seg=O
21	arising	_	_	_	_	_	_	_	Seg=B-seg
22	from	_	_	_	_	_	_	_	Seg=O
23	errors	_	_	_	_	_	_	_	Seg=O
24	made	_	_	_	_	_	_	_	Seg=B-seg
25	by	_	_	_	_	_	_	_	Seg=O
26	viral	_	_	_	_	_	_	_	Seg=O
27	RNA	_	_	_	_	_	_	_	Seg=O
28	-	_	_	_	_	_	_	_	Seg=O
29	dependent	_	_	_	_	_	_	_	Seg=O
30	RNA	_	_	_	_	_	_	_	Seg=O
31	polymerase	_	_	_	_	_	_	_	Seg=O
32	during	_	_	_	_	_	_	_	Seg=O
33	replication	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	Sequence	_	_	_	_	_	_	_	Seg=B-seg
36	variation	_	_	_	_	_	_	_	Seg=O
37	must	_	_	_	_	_	_	_	Seg=O
38	occur	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	however	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	without	_	_	_	_	_	_	_	Seg=B-seg
43	compromising	_	_	_	_	_	_	_	Seg=O
44	functions	_	_	_	_	_	_	_	Seg=O
45	essential	_	_	_	_	_	_	_	Seg=B-seg
46	for	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	completion	_	_	_	_	_	_	_	Seg=O
49	of	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	viral	_	_	_	_	_	_	_	Seg=O
52	cycle	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	RNA	_	_	_	_	_	_	_	Seg=B-seg
55	viruses	_	_	_	_	_	_	_	Seg=O
56	are	_	_	_	_	_	_	_	Seg=O
57	safeguarded	_	_	_	_	_	_	_	Seg=O
58	in	_	_	_	_	_	_	_	Seg=O
59	this	_	_	_	_	_	_	_	Seg=O
60	respect	_	_	_	_	_	_	_	Seg=O
61	by	_	_	_	_	_	_	_	Seg=O
62	their	_	_	_	_	_	_	_	Seg=O
63	genome	_	_	_	_	_	_	_	Seg=O
64	carrying	_	_	_	_	_	_	_	Seg=B-seg
65	conserved	_	_	_	_	_	_	_	Seg=O
66	information	_	_	_	_	_	_	_	Seg=O
67	that	_	_	_	_	_	_	_	Seg=B-seg
68	does	_	_	_	_	_	_	_	Seg=O
69	not	_	_	_	_	_	_	_	Seg=O
70	code	_	_	_	_	_	_	_	Seg=O
71	only	_	_	_	_	_	_	_	Seg=O
72	for	_	_	_	_	_	_	_	Seg=O
73	proteins	_	_	_	_	_	_	_	Seg=O
74	but	_	_	_	_	_	_	_	Seg=B-seg
75	also	_	_	_	_	_	_	_	Seg=O
76	for	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	formation	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	structurally	_	_	_	_	_	_	_	Seg=O
81	conserved	_	_	_	_	_	_	_	Seg=O
82	RNA	_	_	_	_	_	_	_	Seg=O
83	domains	_	_	_	_	_	_	_	Seg=O
84	that	_	_	_	_	_	_	_	Seg=B-seg
85	directly	_	_	_	_	_	_	_	Seg=O
86	perform	_	_	_	_	_	_	_	Seg=O
87	these	_	_	_	_	_	_	_	Seg=O
88	critical	_	_	_	_	_	_	_	Seg=O
89	functions	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O
91	Functional	_	_	_	_	_	_	_	Seg=B-seg
92	RNA	_	_	_	_	_	_	_	Seg=O
93	domains	_	_	_	_	_	_	_	Seg=O
94	can	_	_	_	_	_	_	_	Seg=O
95	interact	_	_	_	_	_	_	_	Seg=O
96	with	_	_	_	_	_	_	_	Seg=O
97	other	_	_	_	_	_	_	_	Seg=O
98	regions	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	the	_	_	_	_	_	_	_	Seg=O
101	viral	_	_	_	_	_	_	_	Seg=O
102	genome	_	_	_	_	_	_	_	Seg=O
103	and/or	_	_	_	_	_	_	_	Seg=O
104	proteins	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=B-seg
106	direct	_	_	_	_	_	_	_	Seg=O
107	viral	_	_	_	_	_	_	_	Seg=O
108	translation	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	replication	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=O
112	encapsidation	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	They	_	_	_	_	_	_	_	Seg=B-seg
115	are	_	_	_	_	_	_	_	Seg=O
116	therefore	_	_	_	_	_	_	_	Seg=O
117	potential	_	_	_	_	_	_	_	Seg=O
118	targets	_	_	_	_	_	_	_	Seg=O
119	for	_	_	_	_	_	_	_	Seg=O
120	novel	_	_	_	_	_	_	_	Seg=O
121	therapeutic	_	_	_	_	_	_	_	Seg=O
122	strategies	_	_	_	_	_	_	_	Seg=O
123	.	_	_	_	_	_	_	_	Seg=O
124	This	_	_	_	_	_	_	_	Seg=B-seg
125	review	_	_	_	_	_	_	_	Seg=O
126	summarises	_	_	_	_	_	_	_	Seg=O
127	our	_	_	_	_	_	_	_	Seg=O
128	knowledge	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	functional	_	_	_	_	_	_	_	Seg=O
132	RNA	_	_	_	_	_	_	_	Seg=O
133	domains	_	_	_	_	_	_	_	Seg=O
134	of	_	_	_	_	_	_	_	Seg=O
135	human	_	_	_	_	_	_	_	Seg=O
136	RNA	_	_	_	_	_	_	_	Seg=O
137	viruses	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=B-seg
139	examines	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	achievements	_	_	_	_	_	_	_	Seg=O
142	made	_	_	_	_	_	_	_	Seg=B-seg
143	in	_	_	_	_	_	_	_	Seg=O
144	the	_	_	_	_	_	_	_	Seg=O
145	design	_	_	_	_	_	_	_	Seg=O
146	of	_	_	_	_	_	_	_	Seg=O
147	antiviral	_	_	_	_	_	_	_	Seg=O
148	compounds	_	_	_	_	_	_	_	Seg=O
149	that	_	_	_	_	_	_	_	Seg=B-seg
150	interfere	_	_	_	_	_	_	_	Seg=O
151	with	_	_	_	_	_	_	_	Seg=O
152	their	_	_	_	_	_	_	_	Seg=O
153	folding	_	_	_	_	_	_	_	Seg=O
154	and	_	_	_	_	_	_	_	Seg=O
155	therefore	_	_	_	_	_	_	_	Seg=O
156	their	_	_	_	_	_	_	_	Seg=O
157	function	_	_	_	_	_	_	_	Seg=O
158	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = a64f73ac0e74f9eca66d9c4876006757c8399e49
1	There	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	limited	_	_	_	_	_	_	_	Seg=O
4	evidence	_	_	_	_	_	_	_	Seg=O
5	as	_	_	_	_	_	_	_	Seg=B-seg
6	to	_	_	_	_	_	_	_	Seg=O
7	how	_	_	_	_	_	_	_	Seg=O
8	COVID-19	_	_	_	_	_	_	_	Seg=O
9	infection	_	_	_	_	_	_	_	Seg=O
10	fatality	_	_	_	_	_	_	_	Seg=O
11	rates	_	_	_	_	_	_	_	Seg=O
12	(	_	_	_	_	_	_	_	Seg=O
13	IFR	_	_	_	_	_	_	_	Seg=O
14	)	_	_	_	_	_	_	_	Seg=O
15	may	_	_	_	_	_	_	_	Seg=O
16	vary	_	_	_	_	_	_	_	Seg=O
17	by	_	_	_	_	_	_	_	Seg=O
18	ethnicity	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	We	_	_	_	_	_	_	_	Seg=B-seg
21	combine	_	_	_	_	_	_	_	Seg=O
22	demographic	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=O
24	health	_	_	_	_	_	_	_	Seg=O
25	data	_	_	_	_	_	_	_	Seg=O
26	for	_	_	_	_	_	_	_	Seg=O
27	ethnic	_	_	_	_	_	_	_	Seg=O
28	groupings	_	_	_	_	_	_	_	Seg=O
29	in	_	_	_	_	_	_	_	Seg=O
30	Aotearoa	_	_	_	_	_	_	_	Seg=O
31	New	_	_	_	_	_	_	_	Seg=O
32	Zealand	_	_	_	_	_	_	_	Seg=O
33	with	_	_	_	_	_	_	_	Seg=O
34	international	_	_	_	_	_	_	_	Seg=O
35	data	_	_	_	_	_	_	_	Seg=O
36	on	_	_	_	_	_	_	_	Seg=O
37	IFR	_	_	_	_	_	_	_	Seg=O
38	for	_	_	_	_	_	_	_	Seg=O
39	different	_	_	_	_	_	_	_	Seg=O
40	age	_	_	_	_	_	_	_	Seg=O
41	groups	_	_	_	_	_	_	_	Seg=O
42	to	_	_	_	_	_	_	_	Seg=B-seg
43	estimate	_	_	_	_	_	_	_	Seg=O
44	inequities	_	_	_	_	_	_	_	Seg=O
45	in	_	_	_	_	_	_	_	Seg=O
46	IFR	_	_	_	_	_	_	_	Seg=O
47	by	_	_	_	_	_	_	_	Seg=O
48	ethnicity	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	We	_	_	_	_	_	_	_	Seg=B-seg
51	find	_	_	_	_	_	_	_	Seg=O
52	that	_	_	_	_	_	_	_	Seg=B-seg
53	,	_	_	_	_	_	_	_	Seg=O
54	if	_	_	_	_	_	_	_	Seg=B-seg
55	age	_	_	_	_	_	_	_	Seg=O
56	is	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	dominant	_	_	_	_	_	_	_	Seg=O
59	factor	_	_	_	_	_	_	_	Seg=O
60	determining	_	_	_	_	_	_	_	Seg=O
61	IFR	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	estimated	_	_	_	_	_	_	_	Seg=B-seg
64	IFR	_	_	_	_	_	_	_	Seg=O
65	for	_	_	_	_	_	_	_	Seg=O
66	Māori	_	_	_	_	_	_	_	Seg=O
67	is	_	_	_	_	_	_	_	Seg=O
68	around	_	_	_	_	_	_	_	Seg=O
69	50	_	_	_	_	_	_	_	Seg=O
70	%	_	_	_	_	_	_	_	Seg=O
71	higher	_	_	_	_	_	_	_	Seg=O
72	than	_	_	_	_	_	_	_	Seg=O
73	non	_	_	_	_	_	_	_	Seg=O
74	-	_	_	_	_	_	_	_	Seg=O
75	Māori	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	If	_	_	_	_	_	_	_	Seg=B-seg
78	underlying	_	_	_	_	_	_	_	Seg=O
79	health	_	_	_	_	_	_	_	Seg=O
80	conditions	_	_	_	_	_	_	_	Seg=O
81	are	_	_	_	_	_	_	_	Seg=O
82	more	_	_	_	_	_	_	_	Seg=O
83	important	_	_	_	_	_	_	_	Seg=O
84	than	_	_	_	_	_	_	_	Seg=O
85	age	_	_	_	_	_	_	_	Seg=O
86	per	_	_	_	_	_	_	_	Seg=O
87	se	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	then	_	_	_	_	_	_	_	Seg=B-seg
90	estimated	_	_	_	_	_	_	_	Seg=O
91	IFR	_	_	_	_	_	_	_	Seg=O
92	for	_	_	_	_	_	_	_	Seg=O
93	Māori	_	_	_	_	_	_	_	Seg=O
94	is	_	_	_	_	_	_	_	Seg=O
95	more	_	_	_	_	_	_	_	Seg=O
96	than	_	_	_	_	_	_	_	Seg=O
97	2.5	_	_	_	_	_	_	_	Seg=O
98	times	_	_	_	_	_	_	_	Seg=O
99	that	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	New	_	_	_	_	_	_	_	Seg=O
102	Zealand	_	_	_	_	_	_	_	Seg=O
103	European	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=B-seg
106	estimated	_	_	_	_	_	_	_	Seg=O
107	IFR	_	_	_	_	_	_	_	Seg=O
108	for	_	_	_	_	_	_	_	Seg=O
109	Pasifika	_	_	_	_	_	_	_	Seg=O
110	is	_	_	_	_	_	_	_	Seg=O
111	almost	_	_	_	_	_	_	_	Seg=O
112	double	_	_	_	_	_	_	_	Seg=O
113	that	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	New	_	_	_	_	_	_	_	Seg=O
116	Zealand	_	_	_	_	_	_	_	Seg=O
117	European	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	IFRs	_	_	_	_	_	_	_	Seg=B-seg
120	for	_	_	_	_	_	_	_	Seg=O
121	Māori	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	Pasifika	_	_	_	_	_	_	_	Seg=O
124	are	_	_	_	_	_	_	_	Seg=O
125	likely	_	_	_	_	_	_	_	Seg=O
126	to	_	_	_	_	_	_	_	Seg=O
127	be	_	_	_	_	_	_	_	Seg=O
128	increased	_	_	_	_	_	_	_	Seg=O
129	above	_	_	_	_	_	_	_	Seg=O
130	these	_	_	_	_	_	_	_	Seg=O
131	estimates	_	_	_	_	_	_	_	Seg=O
132	by	_	_	_	_	_	_	_	Seg=O
133	racism	_	_	_	_	_	_	_	Seg=O
134	within	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	healthcare	_	_	_	_	_	_	_	Seg=O
137	system	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=O
139	other	_	_	_	_	_	_	_	Seg=O
140	inequities	_	_	_	_	_	_	_	Seg=O
141	not	_	_	_	_	_	_	_	Seg=B-seg
142	reflected	_	_	_	_	_	_	_	Seg=O
143	in	_	_	_	_	_	_	_	Seg=O
144	official	_	_	_	_	_	_	_	Seg=O
145	data	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
147	IFR	_	_	_	_	_	_	_	Seg=B-seg
148	does	_	_	_	_	_	_	_	Seg=O
149	not	_	_	_	_	_	_	_	Seg=O
150	account	_	_	_	_	_	_	_	Seg=O
151	for	_	_	_	_	_	_	_	Seg=O
152	differences	_	_	_	_	_	_	_	Seg=O
153	among	_	_	_	_	_	_	_	Seg=O
154	ethnicities	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	COVID-19	_	_	_	_	_	_	_	Seg=O
157	incidence	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	which	_	_	_	_	_	_	_	Seg=B-seg
160	could	_	_	_	_	_	_	_	Seg=O
161	be	_	_	_	_	_	_	_	Seg=O
162	higher	_	_	_	_	_	_	_	Seg=O
163	in	_	_	_	_	_	_	_	Seg=O
164	Māori	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=O
166	Pasifik	_	_	_	_	_	_	_	Seg=O
167	as	_	_	_	_	_	_	_	Seg=B-seg
168	a	_	_	_	_	_	_	_	Seg=O
169	result	_	_	_	_	_	_	_	Seg=O
170	of	_	_	_	_	_	_	_	Seg=O
171	crowded	_	_	_	_	_	_	_	Seg=O
172	housing	_	_	_	_	_	_	_	Seg=O
173	and	_	_	_	_	_	_	_	Seg=O
174	higher	_	_	_	_	_	_	_	Seg=O
175	intergenerational	_	_	_	_	_	_	_	Seg=O
176	contact	_	_	_	_	_	_	_	Seg=O
177	rates	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O
179	These	_	_	_	_	_	_	_	Seg=B-seg
180	factors	_	_	_	_	_	_	_	Seg=O
181	should	_	_	_	_	_	_	_	Seg=O
182	be	_	_	_	_	_	_	_	Seg=O
183	included	_	_	_	_	_	_	_	Seg=O
184	in	_	_	_	_	_	_	_	Seg=O
185	future	_	_	_	_	_	_	_	Seg=O
186	disease	_	_	_	_	_	_	_	Seg=O
187	incidence	_	_	_	_	_	_	_	Seg=O
188	modelling	_	_	_	_	_	_	_	Seg=O
189	.	_	_	_	_	_	_	_	Seg=O
190	The	_	_	_	_	_	_	_	Seg=B-seg
191	communities	_	_	_	_	_	_	_	Seg=O
192	at	_	_	_	_	_	_	_	Seg=O
193	the	_	_	_	_	_	_	_	Seg=O
194	highest	_	_	_	_	_	_	_	Seg=O
195	risk	_	_	_	_	_	_	_	Seg=O
196	will	_	_	_	_	_	_	_	Seg=O
197	be	_	_	_	_	_	_	_	Seg=O
198	those	_	_	_	_	_	_	_	Seg=O
199	with	_	_	_	_	_	_	_	Seg=O
200	elderly	_	_	_	_	_	_	_	Seg=O
201	populations	_	_	_	_	_	_	_	Seg=O
202	,	_	_	_	_	_	_	_	Seg=O
203	and	_	_	_	_	_	_	_	Seg=O
204	Māori	_	_	_	_	_	_	_	Seg=O
205	and	_	_	_	_	_	_	_	Seg=O
206	Pasifika	_	_	_	_	_	_	_	Seg=O
207	communities	_	_	_	_	_	_	_	Seg=O
208	,	_	_	_	_	_	_	_	Seg=O
209	where	_	_	_	_	_	_	_	Seg=B-seg
210	the	_	_	_	_	_	_	_	Seg=O
211	compounded	_	_	_	_	_	_	_	Seg=O
212	effects	_	_	_	_	_	_	_	Seg=O
213	of	_	_	_	_	_	_	_	Seg=O
214	underlying	_	_	_	_	_	_	_	Seg=O
215	health	_	_	_	_	_	_	_	Seg=O
216	conditions	_	_	_	_	_	_	_	Seg=O
217	,	_	_	_	_	_	_	_	Seg=O
218	socioeconomic	_	_	_	_	_	_	_	Seg=O
219	disadvantage	_	_	_	_	_	_	_	Seg=O
220	,	_	_	_	_	_	_	_	Seg=O
221	and	_	_	_	_	_	_	_	Seg=O
222	structural	_	_	_	_	_	_	_	Seg=O
223	racism	_	_	_	_	_	_	_	Seg=O
224	result	_	_	_	_	_	_	_	Seg=O
225	in	_	_	_	_	_	_	_	Seg=O
226	imbricated	_	_	_	_	_	_	_	Seg=O
227	risk	_	_	_	_	_	_	_	Seg=O
228	of	_	_	_	_	_	_	_	Seg=B-seg
229	contracting	_	_	_	_	_	_	_	Seg=O
230	COVID-19	_	_	_	_	_	_	_	Seg=O
231	,	_	_	_	_	_	_	_	Seg=O
232	becoming	_	_	_	_	_	_	_	Seg=B-seg
233	unwell	_	_	_	_	_	_	_	Seg=O
234	,	_	_	_	_	_	_	_	Seg=O
235	and	_	_	_	_	_	_	_	Seg=O
236	death	_	_	_	_	_	_	_	Seg=O
237	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = a6ae0b0a1b76a367c6a95d58052c65b2c5feb850
1	Multiple	_	_	_	_	_	_	_	Seg=B-seg
2	sclerosis	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	MS	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	an	_	_	_	_	_	_	_	Seg=O
8	autoimmune	_	_	_	_	_	_	_	Seg=O
9	disease	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	the	_	_	_	_	_	_	_	Seg=O
12	central	_	_	_	_	_	_	_	Seg=O
13	nervous	_	_	_	_	_	_	_	Seg=O
14	system	_	_	_	_	_	_	_	Seg=O
15	(	_	_	_	_	_	_	_	Seg=O
16	CNS	_	_	_	_	_	_	_	Seg=O
17	)	_	_	_	_	_	_	_	Seg=O
18	that	_	_	_	_	_	_	_	Seg=B-seg
19	affects	_	_	_	_	_	_	_	Seg=O
20	about	_	_	_	_	_	_	_	Seg=O
21	0.1	_	_	_	_	_	_	_	Seg=O
22	%	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	worldwide	_	_	_	_	_	_	_	Seg=O
26	population	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	This	_	_	_	_	_	_	_	Seg=B-seg
29	deleterious	_	_	_	_	_	_	_	Seg=O
30	disease	_	_	_	_	_	_	_	Seg=O
31	is	_	_	_	_	_	_	_	Seg=O
32	marked	_	_	_	_	_	_	_	Seg=O
33	by	_	_	_	_	_	_	_	Seg=O
34	infiltration	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	myelinspecific	_	_	_	_	_	_	_	Seg=O
37	T	_	_	_	_	_	_	_	Seg=O
38	cells	_	_	_	_	_	_	_	Seg=O
39	that	_	_	_	_	_	_	_	Seg=B-seg
40	attack	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	protective	_	_	_	_	_	_	_	Seg=O
43	myelin	_	_	_	_	_	_	_	Seg=O
44	sheath	_	_	_	_	_	_	_	Seg=O
45	that	_	_	_	_	_	_	_	Seg=B-seg
46	surrounds	_	_	_	_	_	_	_	Seg=O
47	CNS	_	_	_	_	_	_	_	Seg=O
48	nerve	_	_	_	_	_	_	_	Seg=O
49	axons	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	Upon	_	_	_	_	_	_	_	Seg=B-seg
52	demyelination	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	saltatory	_	_	_	_	_	_	_	Seg=O
55	nerve	_	_	_	_	_	_	_	Seg=O
56	conduction	_	_	_	_	_	_	_	Seg=O
57	is	_	_	_	_	_	_	_	Seg=O
58	disrupted	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=B-seg
61	patients	_	_	_	_	_	_	_	Seg=O
62	experience	_	_	_	_	_	_	_	Seg=O
63	neurologic	_	_	_	_	_	_	_	Seg=O
64	deficiencies	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	The	_	_	_	_	_	_	_	Seg=B-seg
67	exact	_	_	_	_	_	_	_	Seg=O
68	cause	_	_	_	_	_	_	_	Seg=O
69	for	_	_	_	_	_	_	_	Seg=O
70	MS	_	_	_	_	_	_	_	Seg=O
71	remains	_	_	_	_	_	_	_	Seg=O
72	unknown	_	_	_	_	_	_	_	Seg=O
73	,	_	_	_	_	_	_	_	Seg=O
74	although	_	_	_	_	_	_	_	Seg=B-seg
75	most	_	_	_	_	_	_	_	Seg=O
76	evidence	_	_	_	_	_	_	_	Seg=O
77	supports	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	hypothesis	_	_	_	_	_	_	_	Seg=O
80	that	_	_	_	_	_	_	_	Seg=B-seg
81	both	_	_	_	_	_	_	_	Seg=O
82	genetic	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	environmental	_	_	_	_	_	_	_	Seg=O
85	factors	_	_	_	_	_	_	_	Seg=O
86	contribute	_	_	_	_	_	_	_	Seg=O
87	to	_	_	_	_	_	_	_	Seg=O
88	disease	_	_	_	_	_	_	_	Seg=O
89	development	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O
91	Epidemiologic	_	_	_	_	_	_	_	Seg=B-seg
92	evidence	_	_	_	_	_	_	_	Seg=O
93	supports	_	_	_	_	_	_	_	Seg=O
94	a	_	_	_	_	_	_	_	Seg=O
95	role	_	_	_	_	_	_	_	Seg=O
96	for	_	_	_	_	_	_	_	Seg=O
97	environmental	_	_	_	_	_	_	_	Seg=O
98	pathogens	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	such	_	_	_	_	_	_	_	Seg=B-seg
101	as	_	_	_	_	_	_	_	Seg=O
102	viruses	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	as	_	_	_	_	_	_	_	Seg=B-seg
105	potentially	_	_	_	_	_	_	_	Seg=O
106	key	_	_	_	_	_	_	_	Seg=O
107	contributors	_	_	_	_	_	_	_	Seg=O
108	to	_	_	_	_	_	_	_	Seg=O
109	MS	_	_	_	_	_	_	_	Seg=O
110	induction	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	Pathogens	_	_	_	_	_	_	_	Seg=B-seg
113	can	_	_	_	_	_	_	_	Seg=O
114	induce	_	_	_	_	_	_	_	Seg=O
115	autoimmunity	_	_	_	_	_	_	_	Seg=O
116	via	_	_	_	_	_	_	_	Seg=O
117	several	_	_	_	_	_	_	_	Seg=O
118	well	_	_	_	_	_	_	_	Seg=O
119	-	_	_	_	_	_	_	_	Seg=O
120	studied	_	_	_	_	_	_	_	Seg=O
121	mechanisms	_	_	_	_	_	_	_	Seg=O
122	with	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	most	_	_	_	_	_	_	_	Seg=O
125	postulated	_	_	_	_	_	_	_	Seg=O
126	being	_	_	_	_	_	_	_	Seg=O
127	molecular	_	_	_	_	_	_	_	Seg=O
128	mimicry	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	Molecular	_	_	_	_	_	_	_	Seg=B-seg
131	mimicry	_	_	_	_	_	_	_	Seg=O
132	occurs	_	_	_	_	_	_	_	Seg=O
133	when	_	_	_	_	_	_	_	Seg=B-seg
134	T	_	_	_	_	_	_	_	Seg=O
135	cells	_	_	_	_	_	_	_	Seg=O
136	specific	_	_	_	_	_	_	_	Seg=O
137	for	_	_	_	_	_	_	_	Seg=O
138	peptide	_	_	_	_	_	_	_	Seg=O
139	epitopes	_	_	_	_	_	_	_	Seg=O
140	derived	_	_	_	_	_	_	_	Seg=O
141	from	_	_	_	_	_	_	_	Seg=O
142	pathogens	_	_	_	_	_	_	_	Seg=O
143	cross	_	_	_	_	_	_	_	Seg=O
144	-	_	_	_	_	_	_	_	Seg=O
145	react	_	_	_	_	_	_	_	Seg=O
146	with	_	_	_	_	_	_	_	Seg=O
147	selfepitopes	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	leading	_	_	_	_	_	_	_	Seg=B-seg
150	to	_	_	_	_	_	_	_	Seg=O
151	autoimmune	_	_	_	_	_	_	_	Seg=O
152	tissue	_	_	_	_	_	_	_	Seg=O
153	destruction	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O
155	In	_	_	_	_	_	_	_	Seg=B-seg
156	this	_	_	_	_	_	_	_	Seg=O
157	review	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	we	_	_	_	_	_	_	_	Seg=O
160	discuss	_	_	_	_	_	_	_	Seg=O
161	an	_	_	_	_	_	_	_	Seg=O
162	in	_	_	_	_	_	_	_	Seg=O
163	vivo	_	_	_	_	_	_	_	Seg=O
164	virusinduced	_	_	_	_	_	_	_	Seg=O
165	mouse	_	_	_	_	_	_	_	Seg=O
166	model	_	_	_	_	_	_	_	Seg=O
167	of	_	_	_	_	_	_	_	Seg=O
168	MS	_	_	_	_	_	_	_	Seg=O
169	developed	_	_	_	_	_	_	_	Seg=B-seg
170	in	_	_	_	_	_	_	_	Seg=O
171	our	_	_	_	_	_	_	_	Seg=O
172	laboratory	_	_	_	_	_	_	_	Seg=O
173	,	_	_	_	_	_	_	_	Seg=O
174	which	_	_	_	_	_	_	_	Seg=B-seg
175	has	_	_	_	_	_	_	_	Seg=O
176	contributed	_	_	_	_	_	_	_	Seg=O
177	greatly	_	_	_	_	_	_	_	Seg=O
178	to	_	_	_	_	_	_	_	Seg=O
179	our	_	_	_	_	_	_	_	Seg=O
180	understanding	_	_	_	_	_	_	_	Seg=O
181	of	_	_	_	_	_	_	_	Seg=O
182	the	_	_	_	_	_	_	_	Seg=O
183	mechanisms	_	_	_	_	_	_	_	Seg=O
184	underlying	_	_	_	_	_	_	_	Seg=B-seg
185	molecular	_	_	_	_	_	_	_	Seg=O
186	mimicry	_	_	_	_	_	_	_	Seg=O
187	-	_	_	_	_	_	_	_	Seg=O
188	induced	_	_	_	_	_	_	_	Seg=O
189	CNS	_	_	_	_	_	_	_	Seg=O
190	autoimmunity	_	_	_	_	_	_	_	Seg=O
191	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = a6f51bc35967b5ec3948012d00a543a9f51b450f
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	mammalian	_	_	_	_	_	_	_	Seg=O
3	cells	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	Golgi	_	_	_	_	_	_	_	Seg=O
7	complex	_	_	_	_	_	_	_	Seg=O
8	has	_	_	_	_	_	_	_	Seg=O
9	an	_	_	_	_	_	_	_	Seg=O
10	elaborate	_	_	_	_	_	_	_	Seg=O
11	structure	_	_	_	_	_	_	_	Seg=O
12	consisting	_	_	_	_	_	_	_	Seg=B-seg
13	of	_	_	_	_	_	_	_	Seg=O
14	stacked	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	flattened	_	_	_	_	_	_	_	Seg=O
17	cisternal	_	_	_	_	_	_	_	Seg=O
18	membranes	_	_	_	_	_	_	_	Seg=O
19	collected	_	_	_	_	_	_	_	Seg=B-seg
20	into	_	_	_	_	_	_	_	Seg=O
21	a	_	_	_	_	_	_	_	Seg=O
22	ribbon	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	center	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	the	_	_	_	_	_	_	_	Seg=O
28	cell	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Amazingly	_	_	_	_	_	_	_	Seg=B-seg
31	,	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	flattened	_	_	_	_	_	_	_	Seg=O
34	cisternae	_	_	_	_	_	_	_	Seg=O
35	can	_	_	_	_	_	_	_	Seg=O
36	rapidly	_	_	_	_	_	_	_	Seg=O
37	dilate	_	_	_	_	_	_	_	Seg=O
38	to	_	_	_	_	_	_	_	Seg=B-seg
39	accommodate	_	_	_	_	_	_	_	Seg=O
40	large	_	_	_	_	_	_	_	Seg=O
41	cargo	_	_	_	_	_	_	_	Seg=O
42	as	_	_	_	_	_	_	_	Seg=B-seg
43	it	_	_	_	_	_	_	_	Seg=O
44	traffics	_	_	_	_	_	_	_	Seg=O
45	through	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	organelle	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	The	_	_	_	_	_	_	_	Seg=B-seg
50	mechanism	_	_	_	_	_	_	_	Seg=O
51	by	_	_	_	_	_	_	_	Seg=B-seg
52	which	_	_	_	_	_	_	_	Seg=O
53	this	_	_	_	_	_	_	_	Seg=O
54	occurs	_	_	_	_	_	_	_	Seg=O
55	is	_	_	_	_	_	_	_	Seg=B-seg
56	unknown	_	_	_	_	_	_	_	Seg=O
57	.	_	_	_	_	_	_	_	Seg=O
58	Exocytosis	_	_	_	_	_	_	_	Seg=B-seg
59	of	_	_	_	_	_	_	_	Seg=O
60	large	_	_	_	_	_	_	_	Seg=O
61	cargo	_	_	_	_	_	_	_	Seg=O
62	is	_	_	_	_	_	_	_	Seg=O
63	essential	_	_	_	_	_	_	_	Seg=O
64	for	_	_	_	_	_	_	_	Seg=O
65	many	_	_	_	_	_	_	_	Seg=O
66	physiological	_	_	_	_	_	_	_	Seg=O
67	processes	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	including	_	_	_	_	_	_	_	Seg=B-seg
70	collagen	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	lipoprotein	_	_	_	_	_	_	_	Seg=O
73	secretion	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=B-seg
76	defects	_	_	_	_	_	_	_	Seg=O
77	in	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	process	_	_	_	_	_	_	_	Seg=O
80	lead	_	_	_	_	_	_	_	Seg=O
81	to	_	_	_	_	_	_	_	Seg=O
82	disease	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	In	_	_	_	_	_	_	_	Seg=B-seg
85	addition	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	enveloped	_	_	_	_	_	_	_	Seg=O
88	viruses	_	_	_	_	_	_	_	Seg=O
89	that	_	_	_	_	_	_	_	Seg=B-seg
90	bud	_	_	_	_	_	_	_	Seg=O
91	into	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	endoplasmic	_	_	_	_	_	_	_	Seg=O
94	reticulum	_	_	_	_	_	_	_	Seg=O
95	or	_	_	_	_	_	_	_	Seg=O
96	Golgi	_	_	_	_	_	_	_	Seg=O
97	complex	_	_	_	_	_	_	_	Seg=O
98	must	_	_	_	_	_	_	_	Seg=B-seg
99	also	_	_	_	_	_	_	_	Seg=O
100	be	_	_	_	_	_	_	_	Seg=O
101	transported	_	_	_	_	_	_	_	Seg=O
102	through	_	_	_	_	_	_	_	Seg=O
103	Golgi	_	_	_	_	_	_	_	Seg=O
104	cisternae	_	_	_	_	_	_	_	Seg=O
105	for	_	_	_	_	_	_	_	Seg=O
106	secretion	_	_	_	_	_	_	_	Seg=O
107	from	_	_	_	_	_	_	_	Seg=O
108	the	_	_	_	_	_	_	_	Seg=O
109	infected	_	_	_	_	_	_	_	Seg=O
110	cell	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	This	_	_	_	_	_	_	_	Seg=B-seg
113	review	_	_	_	_	_	_	_	Seg=O
114	summarizes	_	_	_	_	_	_	_	Seg=O
115	our	_	_	_	_	_	_	_	Seg=O
116	understanding	_	_	_	_	_	_	_	Seg=O
117	of	_	_	_	_	_	_	_	Seg=O
118	intra	_	_	_	_	_	_	_	Seg=O
119	-	_	_	_	_	_	_	_	Seg=O
120	Golgi	_	_	_	_	_	_	_	Seg=O
121	transport	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	large	_	_	_	_	_	_	_	Seg=O
124	cargo	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	and	_	_	_	_	_	_	_	Seg=B-seg
127	outlines	_	_	_	_	_	_	_	Seg=O
128	current	_	_	_	_	_	_	_	Seg=O
129	questions	_	_	_	_	_	_	_	Seg=O
130	open	_	_	_	_	_	_	_	Seg=B-seg
131	for	_	_	_	_	_	_	_	Seg=O
132	experimentation	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = a7ba852208db4acf89b85705dd9a04d667da521c
1	Norovirus	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	a	_	_	_	_	_	_	_	Seg=O
4	major	_	_	_	_	_	_	_	Seg=O
5	etiologic	_	_	_	_	_	_	_	Seg=O
6	agent	_	_	_	_	_	_	_	Seg=O
7	in	_	_	_	_	_	_	_	Seg=O
8	worldwide	_	_	_	_	_	_	_	Seg=O
9	outbreaks	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	gastroenteritis	_	_	_	_	_	_	_	Seg=O
12	associated	_	_	_	_	_	_	_	Seg=B-seg
13	with	_	_	_	_	_	_	_	Seg=O
14	food	_	_	_	_	_	_	_	Seg=O
15	as	_	_	_	_	_	_	_	Seg=O
16	well	_	_	_	_	_	_	_	Seg=O
17	as	_	_	_	_	_	_	_	Seg=O
18	person	_	_	_	_	_	_	_	Seg=O
19	-	_	_	_	_	_	_	_	Seg=O
20	to	_	_	_	_	_	_	_	Seg=O
21	-	_	_	_	_	_	_	_	Seg=O
22	person	_	_	_	_	_	_	_	Seg=O
23	transmission	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	The	_	_	_	_	_	_	_	Seg=B-seg
26	ubiquitous	_	_	_	_	_	_	_	Seg=O
27	nature	_	_	_	_	_	_	_	Seg=O
28	of	_	_	_	_	_	_	_	Seg=O
29	Norovirus	_	_	_	_	_	_	_	Seg=O
30	necessitates	_	_	_	_	_	_	_	Seg=O
31	simple	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	rapid	_	_	_	_	_	_	_	Seg=O
34	detection	_	_	_	_	_	_	_	Seg=O
35	methods	_	_	_	_	_	_	_	Seg=O
36	with	_	_	_	_	_	_	_	Seg=O
37	high	_	_	_	_	_	_	_	Seg=O
38	accuracy	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	sensitivity	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	To	_	_	_	_	_	_	_	Seg=B-seg
43	this	_	_	_	_	_	_	_	Seg=O
44	end	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	several	_	_	_	_	_	_	_	Seg=O
47	investigators	_	_	_	_	_	_	_	Seg=O
48	have	_	_	_	_	_	_	_	Seg=O
49	evaluated	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	usefulness	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	commercial	_	_	_	_	_	_	_	Seg=O
54	reverse	_	_	_	_	_	_	_	Seg=O
55	-	_	_	_	_	_	_	_	Seg=O
56	transcription	_	_	_	_	_	_	_	Seg=O
57	loop	_	_	_	_	_	_	_	Seg=O
58	-	_	_	_	_	_	_	_	Seg=O
59	mediated	_	_	_	_	_	_	_	Seg=O
60	isothermal	_	_	_	_	_	_	_	Seg=O
61	amplification	_	_	_	_	_	_	_	Seg=O
62	(	_	_	_	_	_	_	_	Seg=O
63	RT	_	_	_	_	_	_	_	Seg=O
64	-	_	_	_	_	_	_	_	Seg=O
65	LAMP	_	_	_	_	_	_	_	Seg=O
66	)	_	_	_	_	_	_	_	Seg=O
67	kits	_	_	_	_	_	_	_	Seg=O
68	for	_	_	_	_	_	_	_	Seg=B-seg
69	detecting	_	_	_	_	_	_	_	Seg=O
70	Norovirus	_	_	_	_	_	_	_	Seg=O
71	genogroups	_	_	_	_	_	_	_	Seg=O
72	I	_	_	_	_	_	_	_	Seg=O
73	(	_	_	_	_	_	_	_	Seg=O
74	GI	_	_	_	_	_	_	_	Seg=O
75	)	_	_	_	_	_	_	_	Seg=O
76	and	_	_	_	_	_	_	_	Seg=O
77	II	_	_	_	_	_	_	_	Seg=O
78	(	_	_	_	_	_	_	_	Seg=O
79	GII	_	_	_	_	_	_	_	Seg=O
80	)	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	In	_	_	_	_	_	_	_	Seg=B-seg
83	previous	_	_	_	_	_	_	_	Seg=O
84	studies	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	conventional	_	_	_	_	_	_	_	Seg=O
88	Loopamp	_	_	_	_	_	_	_	Seg=O
89	kit	_	_	_	_	_	_	_	Seg=O
90	for	_	_	_	_	_	_	_	Seg=O
91	Norovirus	_	_	_	_	_	_	_	Seg=O
92	GII	_	_	_	_	_	_	_	Seg=O
93	showed	_	_	_	_	_	_	_	Seg=O
94	a	_	_	_	_	_	_	_	Seg=O
95	relatively	_	_	_	_	_	_	_	Seg=O
96	high	_	_	_	_	_	_	_	Seg=O
97	detection	_	_	_	_	_	_	_	Seg=O
98	rate	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	while	_	_	_	_	_	_	_	Seg=B-seg
101	that	_	_	_	_	_	_	_	Seg=O
102	for	_	_	_	_	_	_	_	Seg=O
103	Norovirus	_	_	_	_	_	_	_	Seg=O
104	GI	_	_	_	_	_	_	_	Seg=O
105	showed	_	_	_	_	_	_	_	Seg=O
106	a	_	_	_	_	_	_	_	Seg=O
107	relatively	_	_	_	_	_	_	_	Seg=O
108	low	_	_	_	_	_	_	_	Seg=O
109	detection	_	_	_	_	_	_	_	Seg=O
110	rate	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	In	_	_	_	_	_	_	_	Seg=B-seg
113	the	_	_	_	_	_	_	_	Seg=O
114	present	_	_	_	_	_	_	_	Seg=O
115	study	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	clinical	_	_	_	_	_	_	_	Seg=O
118	Norovirus	_	_	_	_	_	_	_	Seg=O
119	specimens	_	_	_	_	_	_	_	Seg=O
120	were	_	_	_	_	_	_	_	Seg=O
121	used	_	_	_	_	_	_	_	Seg=O
122	to	_	_	_	_	_	_	_	Seg=B-seg
123	compare	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	detection	_	_	_	_	_	_	_	Seg=O
126	rate	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	a	_	_	_	_	_	_	_	Seg=O
129	modified	_	_	_	_	_	_	_	Seg=O
130	Loopamp	_	_	_	_	_	_	_	Seg=O
131	kit	_	_	_	_	_	_	_	Seg=O
132	for	_	_	_	_	_	_	_	Seg=O
133	Norovirus	_	_	_	_	_	_	_	Seg=O
134	GI	_	_	_	_	_	_	_	Seg=O
135	with	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	rates	_	_	_	_	_	_	_	Seg=O
138	of	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	conventional	_	_	_	_	_	_	_	Seg=O
141	Loopamp	_	_	_	_	_	_	_	Seg=O
142	kit	_	_	_	_	_	_	_	Seg=O
143	for	_	_	_	_	_	_	_	Seg=O
144	Norovirus	_	_	_	_	_	_	_	Seg=O
145	GI	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	an	_	_	_	_	_	_	_	Seg=O
148	'	_	_	_	_	_	_	_	Seg=O
149	'	_	_	_	_	_	_	_	Seg=O
150	in	_	_	_	_	_	_	_	Seg=O
151	-	_	_	_	_	_	_	_	Seg=O
152	house	_	_	_	_	_	_	_	Seg=O
153	'	_	_	_	_	_	_	_	Seg=O
154	'	_	_	_	_	_	_	_	Seg=O
155	RT	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	LAMP	_	_	_	_	_	_	_	Seg=O
158	GI	_	_	_	_	_	_	_	Seg=O
159	primer	_	_	_	_	_	_	_	Seg=O
160	set	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	methods	_	_	_	_	_	_	_	Seg=O
163	which	_	_	_	_	_	_	_	Seg=B-seg
164	had	_	_	_	_	_	_	_	Seg=O
165	a	_	_	_	_	_	_	_	Seg=O
166	high	_	_	_	_	_	_	_	Seg=O
167	detection	_	_	_	_	_	_	_	Seg=O
168	rate	_	_	_	_	_	_	_	Seg=O
169	.	_	_	_	_	_	_	_	Seg=O
170	Results	_	_	_	_	_	_	_	Seg=B-seg
171	from	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	present	_	_	_	_	_	_	_	Seg=O
174	study	_	_	_	_	_	_	_	Seg=O
175	showed	_	_	_	_	_	_	_	Seg=O
176	that	_	_	_	_	_	_	_	Seg=B-seg
177	the	_	_	_	_	_	_	_	Seg=O
178	modified	_	_	_	_	_	_	_	Seg=O
179	Loopamp	_	_	_	_	_	_	_	Seg=O
180	kit	_	_	_	_	_	_	_	Seg=O
181	for	_	_	_	_	_	_	_	Seg=O
182	Norovirus	_	_	_	_	_	_	_	Seg=O
183	GI	_	_	_	_	_	_	_	Seg=O
184	had	_	_	_	_	_	_	_	Seg=O
185	a	_	_	_	_	_	_	_	Seg=O
186	higher	_	_	_	_	_	_	_	Seg=O
187	detection	_	_	_	_	_	_	_	Seg=O
188	rate	_	_	_	_	_	_	_	Seg=O
189	for	_	_	_	_	_	_	_	Seg=O
190	two	_	_	_	_	_	_	_	Seg=O
191	viral	_	_	_	_	_	_	_	Seg=O
192	genotypes	_	_	_	_	_	_	_	Seg=O
193	(	_	_	_	_	_	_	_	Seg=B-seg
194	GI.3	_	_	_	_	_	_	_	Seg=O
195	,	_	_	_	_	_	_	_	Seg=O
196	GI.11	_	_	_	_	_	_	_	Seg=O
197	)	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	On	_	_	_	_	_	_	_	Seg=B-seg
200	comparison	_	_	_	_	_	_	_	Seg=O
201	with	_	_	_	_	_	_	_	Seg=O
202	an	_	_	_	_	_	_	_	Seg=O
203	'	_	_	_	_	_	_	_	Seg=O
204	'	_	_	_	_	_	_	_	Seg=O
205	in	_	_	_	_	_	_	_	Seg=O
206	-	_	_	_	_	_	_	_	Seg=O
207	house	_	_	_	_	_	_	_	Seg=O
208	'	_	_	_	_	_	_	_	Seg=O
209	'	_	_	_	_	_	_	_	Seg=O
210	GII	_	_	_	_	_	_	_	Seg=O
211	primer	_	_	_	_	_	_	_	Seg=O
212	set	_	_	_	_	_	_	_	Seg=O
213	using	_	_	_	_	_	_	_	Seg=B-seg
214	genotype	_	_	_	_	_	_	_	Seg=O
215	GII.4	_	_	_	_	_	_	_	Seg=O
216	viruses	_	_	_	_	_	_	_	Seg=O
217	circulating	_	_	_	_	_	_	_	Seg=B-seg
218	recently	_	_	_	_	_	_	_	Seg=O
219	,	_	_	_	_	_	_	_	Seg=O
220	the	_	_	_	_	_	_	_	Seg=B-seg
221	detection	_	_	_	_	_	_	_	Seg=O
222	rate	_	_	_	_	_	_	_	Seg=O
223	by	_	_	_	_	_	_	_	Seg=O
224	the	_	_	_	_	_	_	_	Seg=O
225	Loopamp	_	_	_	_	_	_	_	Seg=O
226	kit	_	_	_	_	_	_	_	Seg=O
227	for	_	_	_	_	_	_	_	Seg=O
228	Norovirus	_	_	_	_	_	_	_	Seg=O
229	GII	_	_	_	_	_	_	_	Seg=O
230	was	_	_	_	_	_	_	_	Seg=O
231	found	_	_	_	_	_	_	_	Seg=O
232	to	_	_	_	_	_	_	_	Seg=O
233	be	_	_	_	_	_	_	_	Seg=O
234	higher	_	_	_	_	_	_	_	Seg=O
235	,	_	_	_	_	_	_	_	Seg=O
236	with	_	_	_	_	_	_	_	Seg=O
237	a	_	_	_	_	_	_	_	Seg=O
238	98	_	_	_	_	_	_	_	Seg=O
239	%	_	_	_	_	_	_	_	Seg=O
240	detection	_	_	_	_	_	_	_	Seg=O
241	rate	_	_	_	_	_	_	_	Seg=O
242	.	_	_	_	_	_	_	_	Seg=O
243	These	_	_	_	_	_	_	_	Seg=B-seg
244	results	_	_	_	_	_	_	_	Seg=O
245	indicate	_	_	_	_	_	_	_	Seg=O
246	the	_	_	_	_	_	_	_	Seg=O
247	applicability	_	_	_	_	_	_	_	Seg=O
248	of	_	_	_	_	_	_	_	Seg=O
249	the	_	_	_	_	_	_	_	Seg=O
250	modified	_	_	_	_	_	_	_	Seg=O
251	LAMP	_	_	_	_	_	_	_	Seg=O
252	kit	_	_	_	_	_	_	_	Seg=O
253	for	_	_	_	_	_	_	_	Seg=O
254	GI	_	_	_	_	_	_	_	Seg=O
255	and	_	_	_	_	_	_	_	Seg=O
256	the	_	_	_	_	_	_	_	Seg=O
257	conventional	_	_	_	_	_	_	_	Seg=O
258	LAMP	_	_	_	_	_	_	_	Seg=O
259	kit	_	_	_	_	_	_	_	Seg=O
260	for	_	_	_	_	_	_	_	Seg=O
261	GII	_	_	_	_	_	_	_	Seg=O
262	for	_	_	_	_	_	_	_	Seg=O
263	detection	_	_	_	_	_	_	_	Seg=O
264	of	_	_	_	_	_	_	_	Seg=O
265	Noroviruses	_	_	_	_	_	_	_	Seg=O
266	in	_	_	_	_	_	_	_	Seg=O
267	clinical	_	_	_	_	_	_	_	Seg=O
268	samples	_	_	_	_	_	_	_	Seg=O
269	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = a924e53c9e50e932f6d0b3938b5bdf284e1736a7
1	Apoptosis	_	_	_	_	_	_	_	Seg=B-seg
2	plays	_	_	_	_	_	_	_	Seg=O
3	an	_	_	_	_	_	_	_	Seg=O
4	important	_	_	_	_	_	_	_	Seg=O
5	role	_	_	_	_	_	_	_	Seg=O
6	in	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	pathogenesis	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	viral	_	_	_	_	_	_	_	Seg=O
11	infections	_	_	_	_	_	_	_	Seg=O
12	.	_	_	_	_	_	_	_	Seg=O
13	In	_	_	_	_	_	_	_	Seg=B-seg
14	this	_	_	_	_	_	_	_	Seg=O
15	study	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	we	_	_	_	_	_	_	_	Seg=O
18	investigated	_	_	_	_	_	_	_	Seg=O
19	the	_	_	_	_	_	_	_	Seg=O
20	cell	_	_	_	_	_	_	_	Seg=O
21	death	_	_	_	_	_	_	_	Seg=O
22	processes	_	_	_	_	_	_	_	Seg=O
23	during	_	_	_	_	_	_	_	Seg=O
24	productive	_	_	_	_	_	_	_	Seg=O
25	HHV-6A	_	_	_	_	_	_	_	Seg=O
26	infection	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	underlying	_	_	_	_	_	_	_	Seg=O
30	mechanisms	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	Annexin	_	_	_	_	_	_	_	Seg=B-seg
33	V	_	_	_	_	_	_	_	Seg=O
34	-	_	_	_	_	_	_	_	Seg=O
35	PI	_	_	_	_	_	_	_	Seg=O
36	staining	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	electron	_	_	_	_	_	_	_	Seg=O
39	microscopy	_	_	_	_	_	_	_	Seg=O
40	indicated	_	_	_	_	_	_	_	Seg=O
41	that	_	_	_	_	_	_	_	Seg=B-seg
42	HHV-6A	_	_	_	_	_	_	_	Seg=O
43	is	_	_	_	_	_	_	_	Seg=O
44	a	_	_	_	_	_	_	_	Seg=O
45	strong	_	_	_	_	_	_	_	Seg=O
46	inducer	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	apoptosis	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	HHV-6A	_	_	_	_	_	_	_	Seg=B-seg
51	infection	_	_	_	_	_	_	_	Seg=O
52	decreased	_	_	_	_	_	_	_	Seg=O
53	mitochondrial	_	_	_	_	_	_	_	Seg=O
54	transmembrane	_	_	_	_	_	_	_	Seg=O
55	potential	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=B-seg
57	led	_	_	_	_	_	_	_	Seg=O
58	to	_	_	_	_	_	_	_	Seg=O
59	morphological	_	_	_	_	_	_	_	Seg=O
60	changes	_	_	_	_	_	_	_	Seg=O
61	of	_	_	_	_	_	_	_	Seg=O
62	mitochondria	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	The	_	_	_	_	_	_	_	Seg=B-seg
65	cell	_	_	_	_	_	_	_	Seg=O
66	death	_	_	_	_	_	_	_	Seg=O
67	was	_	_	_	_	_	_	_	Seg=O
68	associated	_	_	_	_	_	_	_	Seg=O
69	with	_	_	_	_	_	_	_	Seg=O
70	activation	_	_	_	_	_	_	_	Seg=O
71	of	_	_	_	_	_	_	_	Seg=O
72	caspase-3	_	_	_	_	_	_	_	Seg=O
73	and	_	_	_	_	_	_	_	Seg=O
74	cleavage	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	DNA	_	_	_	_	_	_	_	Seg=O
77	repair	_	_	_	_	_	_	_	Seg=O
78	enzyme	_	_	_	_	_	_	_	Seg=O
79	poly	_	_	_	_	_	_	_	Seg=O
80	(	_	_	_	_	_	_	_	Seg=O
81	ADP	_	_	_	_	_	_	_	Seg=O
82	-	_	_	_	_	_	_	_	Seg=O
83	ribose	_	_	_	_	_	_	_	Seg=O
84	)	_	_	_	_	_	_	_	Seg=O
85	polymerase	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	which	_	_	_	_	_	_	_	Seg=B-seg
88	is	_	_	_	_	_	_	_	Seg=O
89	known	_	_	_	_	_	_	_	Seg=O
90	to	_	_	_	_	_	_	_	Seg=O
91	be	_	_	_	_	_	_	_	Seg=O
92	an	_	_	_	_	_	_	_	Seg=O
93	important	_	_	_	_	_	_	_	Seg=O
94	substrate	_	_	_	_	_	_	_	Seg=O
95	for	_	_	_	_	_	_	_	Seg=O
96	activated	_	_	_	_	_	_	_	Seg=O
97	caspase-3	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	Caspase-9	_	_	_	_	_	_	_	Seg=B-seg
100	was	_	_	_	_	_	_	_	Seg=O
101	activated	_	_	_	_	_	_	_	Seg=O
102	significantly	_	_	_	_	_	_	_	Seg=O
103	in	_	_	_	_	_	_	_	Seg=O
104	HHV-6Ainfected	_	_	_	_	_	_	_	Seg=O
105	cells	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	whereas	_	_	_	_	_	_	_	Seg=B-seg
108	caspase-8	_	_	_	_	_	_	_	Seg=O
109	was	_	_	_	_	_	_	_	Seg=O
110	not	_	_	_	_	_	_	_	Seg=O
111	activated	_	_	_	_	_	_	_	Seg=O
112	obviously	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Moreover	_	_	_	_	_	_	_	Seg=B-seg
115	,	_	_	_	_	_	_	_	Seg=O
116	HHV-6A	_	_	_	_	_	_	_	Seg=O
117	infection	_	_	_	_	_	_	_	Seg=O
118	upregulated	_	_	_	_	_	_	_	Seg=O
119	Bax	_	_	_	_	_	_	_	Seg=O
120	and	_	_	_	_	_	_	_	Seg=O
121	downregulated	_	_	_	_	_	_	_	Seg=O
122	Bcl-2	_	_	_	_	_	_	_	Seg=O
123	.	_	_	_	_	_	_	_	Seg=O
124	This	_	_	_	_	_	_	_	Seg=B-seg
125	is	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	first	_	_	_	_	_	_	_	Seg=O
128	demonstration	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	mitochondrion	_	_	_	_	_	_	_	Seg=O
131	-	_	_	_	_	_	_	_	Seg=O
132	mediated	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	caspase	_	_	_	_	_	_	_	Seg=O
135	-	_	_	_	_	_	_	_	Seg=O
136	dependent	_	_	_	_	_	_	_	Seg=O
137	apoptosis	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	HHV-6A	_	_	_	_	_	_	_	Seg=O
140	-	_	_	_	_	_	_	_	Seg=O
141	infected	_	_	_	_	_	_	_	Seg=O
142	cells	_	_	_	_	_	_	_	Seg=O
143	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = a987e584291a44e8bbab14f9909629b8bba57853
1	SARS	_	_	_	_	_	_	_	Seg=B-seg
2	-	_	_	_	_	_	_	_	Seg=O
3	CoV-2	_	_	_	_	_	_	_	Seg=O
4	genetic	_	_	_	_	_	_	_	Seg=O
5	identification	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	based	_	_	_	_	_	_	_	Seg=O
8	on	_	_	_	_	_	_	_	Seg=O
9	viral	_	_	_	_	_	_	_	Seg=O
10	RNA	_	_	_	_	_	_	_	Seg=O
11	extraction	_	_	_	_	_	_	_	Seg=O
12	prior	_	_	_	_	_	_	_	Seg=O
13	to	_	_	_	_	_	_	_	Seg=O
14	RT	_	_	_	_	_	_	_	Seg=O
15	-	_	_	_	_	_	_	_	Seg=O
16	qPCR	_	_	_	_	_	_	_	Seg=O
17	assay	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	however	_	_	_	_	_	_	_	Seg=B-seg
20	recent	_	_	_	_	_	_	_	Seg=O
21	studies	_	_	_	_	_	_	_	Seg=O
22	support	_	_	_	_	_	_	_	Seg=O
23	the	_	_	_	_	_	_	_	Seg=O
24	elimination	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	the	_	_	_	_	_	_	_	Seg=O
27	extraction	_	_	_	_	_	_	_	Seg=O
28	step	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Herein	_	_	_	_	_	_	_	Seg=B-seg
31	,	_	_	_	_	_	_	_	Seg=O
32	we	_	_	_	_	_	_	_	Seg=O
33	assessed	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	RNA	_	_	_	_	_	_	_	Seg=O
36	extraction	_	_	_	_	_	_	_	Seg=O
37	necessity	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	by	_	_	_	_	_	_	_	Seg=B-seg
40	comparing	_	_	_	_	_	_	_	Seg=O
41	RT	_	_	_	_	_	_	_	Seg=O
42	-	_	_	_	_	_	_	_	Seg=O
43	qPCR	_	_	_	_	_	_	_	Seg=O
44	efficacy	_	_	_	_	_	_	_	Seg=O
45	in	_	_	_	_	_	_	_	Seg=O
46	several	_	_	_	_	_	_	_	Seg=O
47	direct	_	_	_	_	_	_	_	Seg=O
48	approaches	_	_	_	_	_	_	_	Seg=O
49	vs.	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	gold	_	_	_	_	_	_	_	Seg=O
52	standard	_	_	_	_	_	_	_	Seg=O
53	RNA	_	_	_	_	_	_	_	Seg=O
54	extraction	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=B-seg
57	detection	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	SARS	_	_	_	_	_	_	_	Seg=O
60	-	_	_	_	_	_	_	_	Seg=O
61	CoV-2	_	_	_	_	_	_	_	Seg=O
62	from	_	_	_	_	_	_	_	Seg=O
63	laboratory	_	_	_	_	_	_	_	Seg=O
64	samples	_	_	_	_	_	_	_	Seg=O
65	as	_	_	_	_	_	_	_	Seg=O
66	well	_	_	_	_	_	_	_	Seg=O
67	as	_	_	_	_	_	_	_	Seg=O
68	clinical	_	_	_	_	_	_	_	Seg=O
69	Oro	_	_	_	_	_	_	_	Seg=O
70	-	_	_	_	_	_	_	_	Seg=O
71	nasopharyngeal	_	_	_	_	_	_	_	Seg=O
72	SARS	_	_	_	_	_	_	_	Seg=O
73	-	_	_	_	_	_	_	_	Seg=O
74	CoV-2	_	_	_	_	_	_	_	Seg=O
75	swabs	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	Our	_	_	_	_	_	_	_	Seg=B-seg
78	findings	_	_	_	_	_	_	_	Seg=O
79	show	_	_	_	_	_	_	_	Seg=O
80	advantage	_	_	_	_	_	_	_	Seg=O
81	for	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	extraction	_	_	_	_	_	_	_	Seg=O
84	procedure	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	however	_	_	_	_	_	_	_	Seg=B-seg
87	a	_	_	_	_	_	_	_	Seg=O
88	direct	_	_	_	_	_	_	_	Seg=O
89	no	_	_	_	_	_	_	_	Seg=O
90	-	_	_	_	_	_	_	_	Seg=O
91	buffer	_	_	_	_	_	_	_	Seg=O
92	approach	_	_	_	_	_	_	_	Seg=O
93	might	_	_	_	_	_	_	_	Seg=O
94	be	_	_	_	_	_	_	_	Seg=O
95	an	_	_	_	_	_	_	_	Seg=O
96	alternative	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	since	_	_	_	_	_	_	_	Seg=B-seg
99	it	_	_	_	_	_	_	_	Seg=O
100	identified	_	_	_	_	_	_	_	Seg=O
101	up	_	_	_	_	_	_	_	Seg=O
102	to	_	_	_	_	_	_	_	Seg=O
103	70	_	_	_	_	_	_	_	Seg=O
104	%	_	_	_	_	_	_	_	Seg=O
105	of	_	_	_	_	_	_	_	Seg=O
106	positive	_	_	_	_	_	_	_	Seg=O
107	clinical	_	_	_	_	_	_	_	Seg=O
108	specimens	_	_	_	_	_	_	_	Seg=O
109	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = aa339dc08635486396623300d7ab64d1c8d632f6
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	attention	_	_	_	_	_	_	_	Seg=O
3	mechanism	_	_	_	_	_	_	_	Seg=O
4	has	_	_	_	_	_	_	_	Seg=O
5	demonstrated	_	_	_	_	_	_	_	Seg=O
6	superior	_	_	_	_	_	_	_	Seg=O
7	performance	_	_	_	_	_	_	_	Seg=O
8	for	_	_	_	_	_	_	_	Seg=O
9	inference	_	_	_	_	_	_	_	Seg=O
10	over	_	_	_	_	_	_	_	Seg=O
11	nodes	_	_	_	_	_	_	_	Seg=O
12	in	_	_	_	_	_	_	_	Seg=O
13	graph	_	_	_	_	_	_	_	Seg=O
14	neural	_	_	_	_	_	_	_	Seg=O
15	networks	_	_	_	_	_	_	_	Seg=O
16	(	_	_	_	_	_	_	_	Seg=O
17	GNNs	_	_	_	_	_	_	_	Seg=O
18	)	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	however	_	_	_	_	_	_	_	Seg=B-seg
21	,	_	_	_	_	_	_	_	Seg=O
22	they	_	_	_	_	_	_	_	Seg=O
23	result	_	_	_	_	_	_	_	Seg=O
24	in	_	_	_	_	_	_	_	Seg=O
25	a	_	_	_	_	_	_	_	Seg=O
26	high	_	_	_	_	_	_	_	Seg=O
27	computational	_	_	_	_	_	_	_	Seg=O
28	burden	_	_	_	_	_	_	_	Seg=O
29	during	_	_	_	_	_	_	_	Seg=O
30	both	_	_	_	_	_	_	_	Seg=O
31	training	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	inference	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	We	_	_	_	_	_	_	_	Seg=B-seg
36	propose	_	_	_	_	_	_	_	Seg=O
37	FastGAT	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	a	_	_	_	_	_	_	_	Seg=O
40	method	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=B-seg
42	make	_	_	_	_	_	_	_	Seg=O
43	attention	_	_	_	_	_	_	_	Seg=O
44	based	_	_	_	_	_	_	_	Seg=O
45	GNNs	_	_	_	_	_	_	_	Seg=O
46	lightweight	_	_	_	_	_	_	_	Seg=O
47	by	_	_	_	_	_	_	_	Seg=B-seg
48	using	_	_	_	_	_	_	_	Seg=O
49	spectral	_	_	_	_	_	_	_	Seg=O
50	sparsification	_	_	_	_	_	_	_	Seg=O
51	to	_	_	_	_	_	_	_	Seg=B-seg
52	generate	_	_	_	_	_	_	_	Seg=O
53	an	_	_	_	_	_	_	_	Seg=O
54	optimal	_	_	_	_	_	_	_	Seg=O
55	pruning	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	input	_	_	_	_	_	_	_	Seg=O
59	graph	_	_	_	_	_	_	_	Seg=O
60	.	_	_	_	_	_	_	_	Seg=O
61	This	_	_	_	_	_	_	_	Seg=B-seg
62	results	_	_	_	_	_	_	_	Seg=O
63	in	_	_	_	_	_	_	_	Seg=O
64	a	_	_	_	_	_	_	_	Seg=O
65	per	_	_	_	_	_	_	_	Seg=O
66	-	_	_	_	_	_	_	_	Seg=O
67	epoch	_	_	_	_	_	_	_	Seg=O
68	time	_	_	_	_	_	_	_	Seg=O
69	that	_	_	_	_	_	_	_	Seg=B-seg
70	is	_	_	_	_	_	_	_	Seg=O
71	almost	_	_	_	_	_	_	_	Seg=O
72	linear	_	_	_	_	_	_	_	Seg=O
73	in	_	_	_	_	_	_	_	Seg=O
74	the	_	_	_	_	_	_	_	Seg=O
75	number	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	graph	_	_	_	_	_	_	_	Seg=O
78	nodes	_	_	_	_	_	_	_	Seg=O
79	as	_	_	_	_	_	_	_	Seg=B-seg
80	opposed	_	_	_	_	_	_	_	Seg=O
81	to	_	_	_	_	_	_	_	Seg=O
82	quadratic	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	Further	_	_	_	_	_	_	_	Seg=B-seg
85	,	_	_	_	_	_	_	_	Seg=O
86	we	_	_	_	_	_	_	_	Seg=O
87	provide	_	_	_	_	_	_	_	Seg=O
88	a	_	_	_	_	_	_	_	Seg=O
89	re	_	_	_	_	_	_	_	Seg=O
90	-	_	_	_	_	_	_	_	Seg=O
91	formulation	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	a	_	_	_	_	_	_	_	Seg=O
94	specific	_	_	_	_	_	_	_	Seg=O
95	attention	_	_	_	_	_	_	_	Seg=O
96	based	_	_	_	_	_	_	_	Seg=O
97	GNN	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	Graph	_	_	_	_	_	_	_	Seg=O
100	Attention	_	_	_	_	_	_	_	Seg=O
101	Network	_	_	_	_	_	_	_	Seg=O
102	(	_	_	_	_	_	_	_	Seg=O
103	GAT	_	_	_	_	_	_	_	Seg=O
104	)	_	_	_	_	_	_	_	Seg=O
105	that	_	_	_	_	_	_	_	Seg=B-seg
106	interprets	_	_	_	_	_	_	_	Seg=O
107	it	_	_	_	_	_	_	_	Seg=O
108	as	_	_	_	_	_	_	_	Seg=O
109	a	_	_	_	_	_	_	_	Seg=O
110	graph	_	_	_	_	_	_	_	Seg=O
111	convolution	_	_	_	_	_	_	_	Seg=O
112	method	_	_	_	_	_	_	_	Seg=O
113	using	_	_	_	_	_	_	_	Seg=B-seg
114	the	_	_	_	_	_	_	_	Seg=O
115	random	_	_	_	_	_	_	_	Seg=O
116	walk	_	_	_	_	_	_	_	Seg=O
117	normalized	_	_	_	_	_	_	_	Seg=O
118	graph	_	_	_	_	_	_	_	Seg=O
119	Laplacian	_	_	_	_	_	_	_	Seg=O
120	.	_	_	_	_	_	_	_	Seg=O
121	Using	_	_	_	_	_	_	_	Seg=B-seg
122	this	_	_	_	_	_	_	_	Seg=O
123	framework	_	_	_	_	_	_	_	Seg=O
124	,	_	_	_	_	_	_	_	Seg=O
125	we	_	_	_	_	_	_	_	Seg=B-seg
126	theoretically	_	_	_	_	_	_	_	Seg=O
127	prove	_	_	_	_	_	_	_	Seg=O
128	that	_	_	_	_	_	_	_	Seg=B-seg
129	spectral	_	_	_	_	_	_	_	Seg=O
130	sparsification	_	_	_	_	_	_	_	Seg=O
131	preserves	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	features	_	_	_	_	_	_	_	Seg=O
134	computed	_	_	_	_	_	_	_	Seg=B-seg
135	by	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	GAT	_	_	_	_	_	_	_	Seg=O
138	model	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	thereby	_	_	_	_	_	_	_	Seg=B-seg
141	justifying	_	_	_	_	_	_	_	Seg=O
142	our	_	_	_	_	_	_	_	Seg=O
143	FastGAT	_	_	_	_	_	_	_	Seg=O
144	algorithm	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	We	_	_	_	_	_	_	_	Seg=B-seg
147	experimentally	_	_	_	_	_	_	_	Seg=O
148	evaluate	_	_	_	_	_	_	_	Seg=O
149	FastGAT	_	_	_	_	_	_	_	Seg=O
150	on	_	_	_	_	_	_	_	Seg=O
151	several	_	_	_	_	_	_	_	Seg=O
152	large	_	_	_	_	_	_	_	Seg=O
153	real	_	_	_	_	_	_	_	Seg=O
154	world	_	_	_	_	_	_	_	Seg=O
155	graph	_	_	_	_	_	_	_	Seg=O
156	datasets	_	_	_	_	_	_	_	Seg=O
157	for	_	_	_	_	_	_	_	Seg=O
158	node	_	_	_	_	_	_	_	Seg=O
159	classification	_	_	_	_	_	_	_	Seg=O
160	tasks	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	FastGAT	_	_	_	_	_	_	_	Seg=B-seg
163	can	_	_	_	_	_	_	_	Seg=O
164	dramatically	_	_	_	_	_	_	_	Seg=O
165	reduce	_	_	_	_	_	_	_	Seg=O
166	(	_	_	_	_	_	_	_	Seg=B-seg
167	up	_	_	_	_	_	_	_	Seg=O
168	to	_	_	_	_	_	_	_	Seg=O
169	10x	_	_	_	_	_	_	_	Seg=O
170	)	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=B-seg
172	computational	_	_	_	_	_	_	_	Seg=O
173	time	_	_	_	_	_	_	_	Seg=O
174	and	_	_	_	_	_	_	_	Seg=O
175	memory	_	_	_	_	_	_	_	Seg=O
176	requirements	_	_	_	_	_	_	_	Seg=O
177	,	_	_	_	_	_	_	_	Seg=O
178	allowing	_	_	_	_	_	_	_	Seg=B-seg
179	the	_	_	_	_	_	_	_	Seg=O
180	usage	_	_	_	_	_	_	_	Seg=O
181	of	_	_	_	_	_	_	_	Seg=O
182	attention	_	_	_	_	_	_	_	Seg=O
183	based	_	_	_	_	_	_	_	Seg=O
184	GNNs	_	_	_	_	_	_	_	Seg=O
185	on	_	_	_	_	_	_	_	Seg=O
186	large	_	_	_	_	_	_	_	Seg=O
187	graphs	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ab47b7fee600cd540e17d363002a05a3bdfdd306
1	Current	_	_	_	_	_	_	_	Seg=B-seg
2	research	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	an	_	_	_	_	_	_	_	Seg=O
5	attempt	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=B-seg
7	understand	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	CoVID-19	_	_	_	_	_	_	_	Seg=O
10	pandemic	_	_	_	_	_	_	_	Seg=O
11	curve	_	_	_	_	_	_	_	Seg=O
12	through	_	_	_	_	_	_	_	Seg=O
13	statistical	_	_	_	_	_	_	_	Seg=O
14	approach	_	_	_	_	_	_	_	Seg=O
15	of	_	_	_	_	_	_	_	Seg=O
16	probability	_	_	_	_	_	_	_	Seg=O
17	density	_	_	_	_	_	_	_	Seg=O
18	function	_	_	_	_	_	_	_	Seg=O
19	with	_	_	_	_	_	_	_	Seg=O
20	associated	_	_	_	_	_	_	_	Seg=O
21	skewness	_	_	_	_	_	_	_	Seg=O
22	and	_	_	_	_	_	_	_	Seg=O
23	kurtosis	_	_	_	_	_	_	_	Seg=O
24	measures	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	change	_	_	_	_	_	_	_	Seg=O
27	point	_	_	_	_	_	_	_	Seg=O
28	detection	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	polynomial	_	_	_	_	_	_	_	Seg=O
31	fitting	_	_	_	_	_	_	_	Seg=O
32	to	_	_	_	_	_	_	_	Seg=B-seg
33	estimate	_	_	_	_	_	_	_	Seg=O
34	infected	_	_	_	_	_	_	_	Seg=O
35	population	_	_	_	_	_	_	_	Seg=O
36	along	_	_	_	_	_	_	_	Seg=O
37	with	_	_	_	_	_	_	_	Seg=O
38	30	_	_	_	_	_	_	_	Seg=O
39	days	_	_	_	_	_	_	_	Seg=O
40	projection	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	The	_	_	_	_	_	_	_	Seg=B-seg
43	pandemic	_	_	_	_	_	_	_	Seg=O
44	curve	_	_	_	_	_	_	_	Seg=O
45	has	_	_	_	_	_	_	_	Seg=O
46	been	_	_	_	_	_	_	_	Seg=O
47	explored	_	_	_	_	_	_	_	Seg=O
48	for	_	_	_	_	_	_	_	Seg=O
49	above	_	_	_	_	_	_	_	Seg=O
50	average	_	_	_	_	_	_	_	Seg=O
51	affected	_	_	_	_	_	_	_	Seg=O
52	countries	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	six	_	_	_	_	_	_	_	Seg=O
55	regions	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=O
57	global	_	_	_	_	_	_	_	Seg=O
58	scale	_	_	_	_	_	_	_	Seg=O
59	during	_	_	_	_	_	_	_	Seg=O
60	64	_	_	_	_	_	_	_	Seg=O
61	days	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	22nd	_	_	_	_	_	_	_	Seg=O
64	January	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=O
66	24th	_	_	_	_	_	_	_	Seg=O
67	March	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	2020	_	_	_	_	_	_	_	Seg=O
70	.	_	_	_	_	_	_	_	Seg=O
71	The	_	_	_	_	_	_	_	Seg=B-seg
72	global	_	_	_	_	_	_	_	Seg=O
73	cases	_	_	_	_	_	_	_	Seg=O
74	infection	_	_	_	_	_	_	_	Seg=O
75	as	_	_	_	_	_	_	_	Seg=O
76	well	_	_	_	_	_	_	_	Seg=O
77	as	_	_	_	_	_	_	_	Seg=O
78	recovery	_	_	_	_	_	_	_	Seg=O
79	rate	_	_	_	_	_	_	_	Seg=O
80	curves	_	_	_	_	_	_	_	Seg=O
81	remained	_	_	_	_	_	_	_	Seg=O
82	in	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	ranged	_	_	_	_	_	_	_	Seg=O
85	of	_	_	_	_	_	_	_	Seg=O
86	0	_	_	_	_	_	_	_	Seg=O
87	-9.89	_	_	_	_	_	_	_	Seg=O
88	and	_	_	_	_	_	_	_	Seg=O
89	0	_	_	_	_	_	_	_	Seg=O
90	-8.89	_	_	_	_	_	_	_	Seg=O
91	%	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	respectively	_	_	_	_	_	_	_	Seg=O
94	.	_	_	_	_	_	_	_	Seg=O
95	The	_	_	_	_	_	_	_	Seg=B-seg
96	confirmed	_	_	_	_	_	_	_	Seg=O
97	cases	_	_	_	_	_	_	_	Seg=O
98	probability	_	_	_	_	_	_	_	Seg=O
99	density	_	_	_	_	_	_	_	Seg=O
100	curve	_	_	_	_	_	_	_	Seg=O
101	is	_	_	_	_	_	_	_	Seg=O
102	high	_	_	_	_	_	_	_	Seg=O
103	positive	_	_	_	_	_	_	_	Seg=O
104	skewed	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=O
106	leptokurtic	_	_	_	_	_	_	_	Seg=O
107	with	_	_	_	_	_	_	_	Seg=O
108	mean	_	_	_	_	_	_	_	Seg=O
109	global	_	_	_	_	_	_	_	Seg=O
110	infected	_	_	_	_	_	_	_	Seg=O
111	daily	_	_	_	_	_	_	_	Seg=O
112	population	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	6620	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	The	_	_	_	_	_	_	_	Seg=B-seg
117	recovered	_	_	_	_	_	_	_	Seg=O
118	cases	_	_	_	_	_	_	_	Seg=O
119	showed	_	_	_	_	_	_	_	Seg=O
120	bimodal	_	_	_	_	_	_	_	Seg=O
121	positive	_	_	_	_	_	_	_	Seg=O
122	skewed	_	_	_	_	_	_	_	Seg=O
123	curve	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	leptokurtic	_	_	_	_	_	_	_	Seg=O
126	type	_	_	_	_	_	_	_	Seg=O
127	with	_	_	_	_	_	_	_	Seg=O
128	daily	_	_	_	_	_	_	_	Seg=O
129	recovery	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	1708	_	_	_	_	_	_	_	Seg=O
132	.	_	_	_	_	_	_	_	Seg=O
133	The	_	_	_	_	_	_	_	Seg=B-seg
134	change	_	_	_	_	_	_	_	Seg=O
135	point	_	_	_	_	_	_	_	Seg=O
136	detection	_	_	_	_	_	_	_	Seg=O
137	helped	_	_	_	_	_	_	_	Seg=O
138	to	_	_	_	_	_	_	_	Seg=O
139	understand	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	CoVID-19	_	_	_	_	_	_	_	Seg=O
142	curve	_	_	_	_	_	_	_	Seg=O
143	in	_	_	_	_	_	_	_	Seg=O
144	term	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	sudden	_	_	_	_	_	_	_	Seg=O
147	change	_	_	_	_	_	_	_	Seg=O
148	in	_	_	_	_	_	_	_	Seg=O
149	term	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	mean	_	_	_	_	_	_	_	Seg=O
152	or	_	_	_	_	_	_	_	Seg=O
153	mean	_	_	_	_	_	_	_	Seg=O
154	with	_	_	_	_	_	_	_	Seg=O
155	variance	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	This	_	_	_	_	_	_	_	Seg=B-seg
158	pointed	_	_	_	_	_	_	_	Seg=O
159	out	_	_	_	_	_	_	_	Seg=O
160	disease	_	_	_	_	_	_	_	Seg=B-seg
161	curve	_	_	_	_	_	_	_	Seg=O
162	is	_	_	_	_	_	_	_	Seg=O
163	consist	_	_	_	_	_	_	_	Seg=O
164	of	_	_	_	_	_	_	_	Seg=O
165	three	_	_	_	_	_	_	_	Seg=O
166	phases	_	_	_	_	_	_	_	Seg=O
167	and	_	_	_	_	_	_	_	Seg=O
168	last	_	_	_	_	_	_	_	Seg=O
169	segment	_	_	_	_	_	_	_	Seg=O
170	that	_	_	_	_	_	_	_	Seg=B-seg
171	varies	_	_	_	_	_	_	_	Seg=O
172	in	_	_	_	_	_	_	_	Seg=O
173	term	_	_	_	_	_	_	_	Seg=O
174	of	_	_	_	_	_	_	_	Seg=O
175	day	_	_	_	_	_	_	_	Seg=O
176	lengths	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O
178	The	_	_	_	_	_	_	_	Seg=B-seg
179	mean	_	_	_	_	_	_	_	Seg=O
180	with	_	_	_	_	_	_	_	Seg=O
181	variance	_	_	_	_	_	_	_	Seg=O
182	based	_	_	_	_	_	_	_	Seg=O
183	change	_	_	_	_	_	_	_	Seg=O
184	detection	_	_	_	_	_	_	_	Seg=O
185	is	_	_	_	_	_	_	_	Seg=O
186	better	_	_	_	_	_	_	_	Seg=O
187	in	_	_	_	_	_	_	_	Seg=O
188	differentiating	_	_	_	_	_	_	_	Seg=O
189	phases	_	_	_	_	_	_	_	Seg=O
190	and	_	_	_	_	_	_	_	Seg=O
191	associated	_	_	_	_	_	_	_	Seg=O
192	segment	_	_	_	_	_	_	_	Seg=O
193	length	_	_	_	_	_	_	_	Seg=O
194	as	_	_	_	_	_	_	_	Seg=B-seg
195	compared	_	_	_	_	_	_	_	Seg=O
196	to	_	_	_	_	_	_	_	Seg=O
197	mean	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	Global	_	_	_	_	_	_	_	Seg=B-seg
200	infected	_	_	_	_	_	_	_	Seg=O
201	population	_	_	_	_	_	_	_	Seg=O
202	might	_	_	_	_	_	_	_	Seg=O
203	rise	_	_	_	_	_	_	_	Seg=O
204	in	_	_	_	_	_	_	_	Seg=O
205	the	_	_	_	_	_	_	_	Seg=O
206	range	_	_	_	_	_	_	_	Seg=O
207	of	_	_	_	_	_	_	_	Seg=O
208	0.750	_	_	_	_	_	_	_	Seg=O
209	to	_	_	_	_	_	_	_	Seg=O
210	4.680	_	_	_	_	_	_	_	Seg=O
211	million	_	_	_	_	_	_	_	Seg=O
212	by	_	_	_	_	_	_	_	Seg=O
213	24	_	_	_	_	_	_	_	Seg=O
214	th	_	_	_	_	_	_	_	Seg=O
215	April	_	_	_	_	_	_	_	Seg=O
216	2020	_	_	_	_	_	_	_	Seg=O
217	,	_	_	_	_	_	_	_	Seg=O
218	depending	_	_	_	_	_	_	_	Seg=B-seg
219	upon	_	_	_	_	_	_	_	Seg=O
220	the	_	_	_	_	_	_	_	Seg=O
221	pandemic	_	_	_	_	_	_	_	Seg=O
222	curve	_	_	_	_	_	_	_	Seg=O
223	progress	_	_	_	_	_	_	_	Seg=O
224	beyond	_	_	_	_	_	_	_	Seg=O
225	24th	_	_	_	_	_	_	_	Seg=O
226	March	_	_	_	_	_	_	_	Seg=O
227	,	_	_	_	_	_	_	_	Seg=O
228	2020	_	_	_	_	_	_	_	Seg=O
229	.	_	_	_	_	_	_	_	Seg=O
230	Expected	_	_	_	_	_	_	_	Seg=B-seg
231	most	_	_	_	_	_	_	_	Seg=O
232	affected	_	_	_	_	_	_	_	Seg=O
233	countries	_	_	_	_	_	_	_	Seg=O
234	will	_	_	_	_	_	_	_	Seg=O
235	be	_	_	_	_	_	_	_	Seg=O
236	USA	_	_	_	_	_	_	_	Seg=O
237	,	_	_	_	_	_	_	_	Seg=O
238	and	_	_	_	_	_	_	_	Seg=O
239	UK	_	_	_	_	_	_	_	Seg=O
240	with	_	_	_	_	_	_	_	Seg=O
241	at	_	_	_	_	_	_	_	Seg=O
242	least	_	_	_	_	_	_	_	Seg=O
243	infected	_	_	_	_	_	_	_	Seg=O
244	population	_	_	_	_	_	_	_	Seg=O
245	of	_	_	_	_	_	_	_	Seg=O
246	over	_	_	_	_	_	_	_	Seg=O
247	0.100	_	_	_	_	_	_	_	Seg=O
248	million	_	_	_	_	_	_	_	Seg=O
249	.	_	_	_	_	_	_	_	Seg=O
250	Infected	_	_	_	_	_	_	_	Seg=B-seg
251	population	_	_	_	_	_	_	_	Seg=O
252	polynomial	_	_	_	_	_	_	_	Seg=O
253	projection	_	_	_	_	_	_	_	Seg=O
254	errors	_	_	_	_	_	_	_	Seg=O
255	remained	_	_	_	_	_	_	_	Seg=O
256	in	_	_	_	_	_	_	_	Seg=O
257	the	_	_	_	_	_	_	_	Seg=O
258	range	_	_	_	_	_	_	_	Seg=O
259	of	_	_	_	_	_	_	_	Seg=O
260	-78.8	_	_	_	_	_	_	_	Seg=O
261	to	_	_	_	_	_	_	_	Seg=O
262	49.0	_	_	_	_	_	_	_	Seg=O
263	%	_	_	_	_	_	_	_	Seg=O
264	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ac51af9995edb441f0ce4fdc384908daa6e83675
1	TREM2	_	_	_	_	_	_	_	Seg=B-seg
2	variants	_	_	_	_	_	_	_	Seg=O
3	have	_	_	_	_	_	_	_	Seg=O
4	been	_	_	_	_	_	_	_	Seg=O
5	identified	_	_	_	_	_	_	_	Seg=O
6	as	_	_	_	_	_	_	_	Seg=O
7	risk	_	_	_	_	_	_	_	Seg=O
8	factors	_	_	_	_	_	_	_	Seg=O
9	for	_	_	_	_	_	_	_	Seg=O
10-11	Alzheimer's	_	_	_	_	_	_	_	_
10	Alzheimer	_	_	_	_	_	_	_	Seg=O
11	's	_	_	_	_	_	_	_	Seg=O
12	disease	_	_	_	_	_	_	_	Seg=O
13	(	_	_	_	_	_	_	_	Seg=O
14	AD	_	_	_	_	_	_	_	Seg=O
15	)	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=O
17	other	_	_	_	_	_	_	_	Seg=O
18	neurodegenerative	_	_	_	_	_	_	_	Seg=O
19	diseases	_	_	_	_	_	_	_	Seg=O
20	(	_	_	_	_	_	_	_	Seg=O
21	NDDs	_	_	_	_	_	_	_	Seg=O
22	)	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Because	_	_	_	_	_	_	_	Seg=B-seg
25	TREM2	_	_	_	_	_	_	_	Seg=O
26	encodes	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	receptor	_	_	_	_	_	_	_	Seg=O
29	exclusively	_	_	_	_	_	_	_	Seg=B-seg
30	expressed	_	_	_	_	_	_	_	Seg=O
31	on	_	_	_	_	_	_	_	Seg=O
32	immune	_	_	_	_	_	_	_	Seg=O
33	cells	_	_	_	_	_	_	_	Seg=O
34	,	_	_	_	_	_	_	_	Seg=O
35	identification	_	_	_	_	_	_	_	Seg=B-seg
36	of	_	_	_	_	_	_	_	Seg=O
37	these	_	_	_	_	_	_	_	Seg=O
38	variants	_	_	_	_	_	_	_	Seg=O
39	conclusively	_	_	_	_	_	_	_	Seg=O
40	demonstrates	_	_	_	_	_	_	_	Seg=O
41	that	_	_	_	_	_	_	_	Seg=B-seg
42	the	_	_	_	_	_	_	_	Seg=O
43	immune	_	_	_	_	_	_	_	Seg=O
44	response	_	_	_	_	_	_	_	Seg=O
45	can	_	_	_	_	_	_	_	Seg=O
46	play	_	_	_	_	_	_	_	Seg=O
47	an	_	_	_	_	_	_	_	Seg=O
48	active	_	_	_	_	_	_	_	Seg=O
49	role	_	_	_	_	_	_	_	Seg=O
50	in	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	pathogenesis	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	NDDs	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	These	_	_	_	_	_	_	_	Seg=B-seg
57	TREM2	_	_	_	_	_	_	_	Seg=O
58	variants	_	_	_	_	_	_	_	Seg=O
59	also	_	_	_	_	_	_	_	Seg=O
60	confer	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	highest	_	_	_	_	_	_	_	Seg=O
63	risk	_	_	_	_	_	_	_	Seg=O
64	for	_	_	_	_	_	_	_	Seg=B-seg
65	developing	_	_	_	_	_	_	_	Seg=O
66-67	Alzheimer's	_	_	_	_	_	_	_	_
66	Alzheimer	_	_	_	_	_	_	_	Seg=O
67	's	_	_	_	_	_	_	_	Seg=O
68	disease	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	any	_	_	_	_	_	_	_	Seg=O
71	risk	_	_	_	_	_	_	_	Seg=O
72	factor	_	_	_	_	_	_	_	Seg=O
73	identified	_	_	_	_	_	_	_	Seg=B-seg
74	in	_	_	_	_	_	_	_	Seg=O
75	nearly	_	_	_	_	_	_	_	Seg=O
76	two	_	_	_	_	_	_	_	Seg=O
77	decades	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	suggesting	_	_	_	_	_	_	_	Seg=B-seg
80	that	_	_	_	_	_	_	_	Seg=B-seg
81	understanding	_	_	_	_	_	_	_	Seg=O
82	more	_	_	_	_	_	_	_	Seg=O
83	about	_	_	_	_	_	_	_	Seg=O
84	TREM2	_	_	_	_	_	_	_	Seg=O
85	function	_	_	_	_	_	_	_	Seg=O
86	could	_	_	_	_	_	_	_	Seg=O
87	provide	_	_	_	_	_	_	_	Seg=O
88	key	_	_	_	_	_	_	_	Seg=O
89	insights	_	_	_	_	_	_	_	Seg=O
90	into	_	_	_	_	_	_	_	Seg=O
91	NDD	_	_	_	_	_	_	_	Seg=O
92	pathology	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=B-seg
94	provide	_	_	_	_	_	_	_	Seg=O
95	avenues	_	_	_	_	_	_	_	Seg=O
96	for	_	_	_	_	_	_	_	Seg=O
97	novel	_	_	_	_	_	_	_	Seg=O
98	immune	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	related	_	_	_	_	_	_	_	Seg=O
101	NDD	_	_	_	_	_	_	_	Seg=O
102	biomarkers	_	_	_	_	_	_	_	Seg=O
103	and	_	_	_	_	_	_	_	Seg=O
104	therapeutics	_	_	_	_	_	_	_	Seg=O
105	.	_	_	_	_	_	_	_	Seg=O
106	The	_	_	_	_	_	_	_	Seg=B-seg
107	expression	_	_	_	_	_	_	_	Seg=O
108	,	_	_	_	_	_	_	_	Seg=O
109	signaling	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=O
111	function	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	TREM2	_	_	_	_	_	_	_	Seg=O
114	in	_	_	_	_	_	_	_	Seg=O
115	NDDs	_	_	_	_	_	_	_	Seg=O
116	have	_	_	_	_	_	_	_	Seg=O
117	been	_	_	_	_	_	_	_	Seg=O
118	extensively	_	_	_	_	_	_	_	Seg=O
119	investigated	_	_	_	_	_	_	_	Seg=O
120	in	_	_	_	_	_	_	_	Seg=O
121	an	_	_	_	_	_	_	_	Seg=O
122	effort	_	_	_	_	_	_	_	Seg=O
123	to	_	_	_	_	_	_	_	Seg=B-seg
124	understand	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	role	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	immune	_	_	_	_	_	_	_	Seg=O
129	function	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=O
131	disease	_	_	_	_	_	_	_	Seg=O
132	pathogenesis	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=O
134	progression	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	We	_	_	_	_	_	_	_	Seg=B-seg
137	provide	_	_	_	_	_	_	_	Seg=O
138	a	_	_	_	_	_	_	_	Seg=O
139	comprehensive	_	_	_	_	_	_	_	Seg=O
140	review	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	our	_	_	_	_	_	_	_	Seg=O
143	current	_	_	_	_	_	_	_	Seg=O
144	understanding	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	TREM2	_	_	_	_	_	_	_	Seg=O
147	biology	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	including	_	_	_	_	_	_	_	Seg=B-seg
150	new	_	_	_	_	_	_	_	Seg=O
151	insights	_	_	_	_	_	_	_	Seg=O
152	into	_	_	_	_	_	_	_	Seg=O
153	the	_	_	_	_	_	_	_	Seg=O
154	regulation	_	_	_	_	_	_	_	Seg=O
155	of	_	_	_	_	_	_	_	Seg=O
156	TREM2	_	_	_	_	_	_	_	Seg=O
157	expression	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	TREM2	_	_	_	_	_	_	_	Seg=O
161	signaling	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=O
163	function	_	_	_	_	_	_	_	Seg=O
164	across	_	_	_	_	_	_	_	Seg=O
165	NDDs	_	_	_	_	_	_	_	Seg=O
166	.	_	_	_	_	_	_	_	Seg=O
167	While	_	_	_	_	_	_	_	Seg=B-seg
168	many	_	_	_	_	_	_	_	Seg=O
169	open	_	_	_	_	_	_	_	Seg=O
170	questions	_	_	_	_	_	_	_	Seg=O
171	remain	_	_	_	_	_	_	_	Seg=O
172	,	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=B-seg
174	current	_	_	_	_	_	_	_	Seg=O
175	body	_	_	_	_	_	_	_	Seg=O
176	of	_	_	_	_	_	_	_	Seg=O
177	literature	_	_	_	_	_	_	_	Seg=O
178	provides	_	_	_	_	_	_	_	Seg=O
179	clarity	_	_	_	_	_	_	_	Seg=O
180	on	_	_	_	_	_	_	_	Seg=O
181	several	_	_	_	_	_	_	_	Seg=O
182	issues	_	_	_	_	_	_	_	Seg=O
183	.	_	_	_	_	_	_	_	Seg=O
184	While	_	_	_	_	_	_	_	Seg=B-seg
185	it	_	_	_	_	_	_	_	Seg=O
186	is	_	_	_	_	_	_	_	Seg=O
187	still	_	_	_	_	_	_	_	Seg=O
188	often	_	_	_	_	_	_	_	Seg=O
189	cited	_	_	_	_	_	_	_	Seg=O
190	that	_	_	_	_	_	_	_	Seg=O
191	TREM2	_	_	_	_	_	_	_	Seg=O
192	expression	_	_	_	_	_	_	_	Seg=O
193	is	_	_	_	_	_	_	_	Seg=O
194	decreased	_	_	_	_	_	_	_	Seg=O
195	by	_	_	_	_	_	_	_	Seg=O
196	pro	_	_	_	_	_	_	_	Seg=O
197	-	_	_	_	_	_	_	_	Seg=O
198	inflammatory	_	_	_	_	_	_	_	Seg=O
199	stimuli	_	_	_	_	_	_	_	Seg=O
200	,	_	_	_	_	_	_	_	Seg=O
201	it	_	_	_	_	_	_	_	Seg=B-seg
202	is	_	_	_	_	_	_	_	Seg=O
203	now	_	_	_	_	_	_	_	Seg=O
204	clear	_	_	_	_	_	_	_	Seg=O
205	that	_	_	_	_	_	_	_	Seg=O
206	this	_	_	_	_	_	_	_	Seg=O
207	is	_	_	_	_	_	_	_	Seg=O
208	true	_	_	_	_	_	_	_	Seg=O
209	in	_	_	_	_	_	_	_	Seg=O
210	vitro	_	_	_	_	_	_	_	Seg=O
211	,	_	_	_	_	_	_	_	Seg=O
212	but	_	_	_	_	_	_	_	Seg=B-seg
213	inflammatory	_	_	_	_	_	_	_	Seg=O
214	stimuli	_	_	_	_	_	_	_	Seg=O
215	in	_	_	_	_	_	_	_	Seg=O
216	vivo	_	_	_	_	_	_	_	Seg=O
217	almost	_	_	_	_	_	_	_	Seg=O
218	universally	_	_	_	_	_	_	_	Seg=O
219	increase	_	_	_	_	_	_	_	Seg=O
220	TREM2	_	_	_	_	_	_	_	Seg=O
221	expression	_	_	_	_	_	_	_	Seg=O
222	.	_	_	_	_	_	_	_	Seg=O
223	Likewise	_	_	_	_	_	_	_	Seg=B-seg
224	,	_	_	_	_	_	_	_	Seg=O
225	while	_	_	_	_	_	_	_	Seg=B-seg
226	TREM2	_	_	_	_	_	_	_	Seg=O
227	function	_	_	_	_	_	_	_	Seg=O
228	is	_	_	_	_	_	_	_	Seg=O
229	classically	_	_	_	_	_	_	_	Seg=O
230	described	_	_	_	_	_	_	_	Seg=O
231	as	_	_	_	_	_	_	_	Seg=O
232	promoting	_	_	_	_	_	_	_	Seg=O
233	an	_	_	_	_	_	_	_	Seg=O
234	anti	_	_	_	_	_	_	_	Seg=O
235	-	_	_	_	_	_	_	_	Seg=O
236	inflammatory	_	_	_	_	_	_	_	Seg=O
237	phenotype	_	_	_	_	_	_	_	Seg=O
238	,	_	_	_	_	_	_	_	Seg=O
239	more	_	_	_	_	_	_	_	Seg=B-seg
240	than	_	_	_	_	_	_	_	Seg=O
241	half	_	_	_	_	_	_	_	Seg=O
242	of	_	_	_	_	_	_	_	Seg=O
243	published	_	_	_	_	_	_	_	Seg=O
244	studies	_	_	_	_	_	_	_	Seg=O
245	demonstrate	_	_	_	_	_	_	_	Seg=O
246	a	_	_	_	_	_	_	_	Seg=O
247	pro	_	_	_	_	_	_	_	Seg=O
248	-	_	_	_	_	_	_	_	Seg=O
249	inflammatory	_	_	_	_	_	_	_	Seg=O
250	role	_	_	_	_	_	_	_	Seg=O
251	for	_	_	_	_	_	_	_	Seg=O
252	TREM2	_	_	_	_	_	_	_	Seg=O
253	,	_	_	_	_	_	_	_	Seg=O
254	suggesting	_	_	_	_	_	_	_	Seg=B-seg
255	that	_	_	_	_	_	_	_	Seg=B-seg
256	its	_	_	_	_	_	_	_	Seg=O
257	role	_	_	_	_	_	_	_	Seg=O
258	in	_	_	_	_	_	_	_	Seg=O
259	inflammation	_	_	_	_	_	_	_	Seg=O
260	is	_	_	_	_	_	_	_	Seg=O
261	much	_	_	_	_	_	_	_	Seg=O
262	more	_	_	_	_	_	_	_	Seg=O
263	complex	_	_	_	_	_	_	_	Seg=O
264	.	_	_	_	_	_	_	_	Seg=O
265	Finally	_	_	_	_	_	_	_	Seg=B-seg
266	,	_	_	_	_	_	_	_	Seg=O
267	these	_	_	_	_	_	_	_	Seg=O
268	components	_	_	_	_	_	_	_	Seg=O
269	of	_	_	_	_	_	_	_	Seg=O
270	TREM2	_	_	_	_	_	_	_	Seg=O
271	biology	_	_	_	_	_	_	_	Seg=O
272	are	_	_	_	_	_	_	_	Seg=O
273	applied	_	_	_	_	_	_	_	Seg=O
274	to	_	_	_	_	_	_	_	Seg=O
275	a	_	_	_	_	_	_	_	Seg=O
276	discussion	_	_	_	_	_	_	_	Seg=O
277	of	_	_	_	_	_	_	_	Seg=B-seg
278	how	_	_	_	_	_	_	_	Seg=O
279	TREM2	_	_	_	_	_	_	_	Seg=O
280	impacts	_	_	_	_	_	_	_	Seg=O
281	NDD	_	_	_	_	_	_	_	Seg=O
282	pathologies	_	_	_	_	_	_	_	Seg=O
283	and	_	_	_	_	_	_	_	Seg=B-seg
284	the	_	_	_	_	_	_	_	Seg=O
285	latest	_	_	_	_	_	_	_	Seg=O
286	assessment	_	_	_	_	_	_	_	Seg=O
287	of	_	_	_	_	_	_	_	Seg=B-seg
288	how	_	_	_	_	_	_	_	Seg=O
289	these	_	_	_	_	_	_	_	Seg=O
290	findings	_	_	_	_	_	_	_	Seg=O
291	might	_	_	_	_	_	_	_	Seg=O
292	be	_	_	_	_	_	_	_	Seg=O
293	applied	_	_	_	_	_	_	_	Seg=O
294	to	_	_	_	_	_	_	_	Seg=O
295	immune	_	_	_	_	_	_	_	Seg=O
296	-	_	_	_	_	_	_	_	Seg=O
297	directed	_	_	_	_	_	_	_	Seg=O
298	clinical	_	_	_	_	_	_	_	Seg=O
299	biomarkers	_	_	_	_	_	_	_	Seg=O
300	and	_	_	_	_	_	_	_	Seg=O
301	therapeutics	_	_	_	_	_	_	_	Seg=O
302	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ad147a4279222c5e480a5636fb879540eded760e
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	epidemic	_	_	_	_	_	_	_	Seg=O
3	threshold	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	susceptible	_	_	_	_	_	_	_	Seg=O
7	-	_	_	_	_	_	_	_	Seg=O
8	infected	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	recovered	_	_	_	_	_	_	_	Seg=O
11	model	_	_	_	_	_	_	_	Seg=O
12	is	_	_	_	_	_	_	_	Seg=O
13	a	_	_	_	_	_	_	_	Seg=O
14	boundary	_	_	_	_	_	_	_	Seg=O
15	separating	_	_	_	_	_	_	_	Seg=O
16	parameters	_	_	_	_	_	_	_	Seg=O
17	that	_	_	_	_	_	_	_	Seg=B-seg
18	permit	_	_	_	_	_	_	_	Seg=O
19	epidemics	_	_	_	_	_	_	_	Seg=O
20	from	_	_	_	_	_	_	_	Seg=O
21	those	_	_	_	_	_	_	_	Seg=O
22	that	_	_	_	_	_	_	_	Seg=B-seg
23	do	_	_	_	_	_	_	_	Seg=O
24	not	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	This	_	_	_	_	_	_	_	Seg=B-seg
27	threshold	_	_	_	_	_	_	_	Seg=O
28	corresponds	_	_	_	_	_	_	_	Seg=O
29	to	_	_	_	_	_	_	_	Seg=O
30	parameters	_	_	_	_	_	_	_	Seg=O
31	where	_	_	_	_	_	_	_	Seg=B-seg
32	the	_	_	_	_	_	_	_	Seg=O
33-34	system's	_	_	_	_	_	_	_	_
33	system	_	_	_	_	_	_	_	Seg=O
34	's	_	_	_	_	_	_	_	Seg=O
35	equilibrium	_	_	_	_	_	_	_	Seg=O
36	becomes	_	_	_	_	_	_	_	Seg=O
37	unstable	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	Consequently	_	_	_	_	_	_	_	Seg=B-seg
40	,	_	_	_	_	_	_	_	Seg=O
41	we	_	_	_	_	_	_	_	Seg=O
42	use	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	average	_	_	_	_	_	_	_	Seg=O
45	rate	_	_	_	_	_	_	_	Seg=O
46	at	_	_	_	_	_	_	_	Seg=B-seg
47	which	_	_	_	_	_	_	_	Seg=O
48	deviations	_	_	_	_	_	_	_	Seg=O
49	from	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	equilibrium	_	_	_	_	_	_	_	Seg=O
52	shrink	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=B-seg
54	define	_	_	_	_	_	_	_	Seg=O
55	a	_	_	_	_	_	_	_	Seg=O
56	distance	_	_	_	_	_	_	_	Seg=O
57	to	_	_	_	_	_	_	_	Seg=O
58	this	_	_	_	_	_	_	_	Seg=O
59	threshold	_	_	_	_	_	_	_	Seg=O
60	.	_	_	_	_	_	_	_	Seg=O
61	However	_	_	_	_	_	_	_	Seg=B-seg
62	,	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	vital	_	_	_	_	_	_	_	Seg=O
65	dynamics	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	host	_	_	_	_	_	_	_	Seg=O
69	population	_	_	_	_	_	_	_	Seg=O
70	may	_	_	_	_	_	_	_	Seg=O
71	occur	_	_	_	_	_	_	_	Seg=O
72	slowly	_	_	_	_	_	_	_	Seg=O
73	even	_	_	_	_	_	_	_	Seg=B-seg
74	when	_	_	_	_	_	_	_	Seg=O
75	transmission	_	_	_	_	_	_	_	Seg=O
76	is	_	_	_	_	_	_	_	Seg=O
77	far	_	_	_	_	_	_	_	Seg=O
78	from	_	_	_	_	_	_	_	Seg=O
79	threshold	_	_	_	_	_	_	_	Seg=O
80	levels	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	Here	_	_	_	_	_	_	_	Seg=B-seg
83	,	_	_	_	_	_	_	_	Seg=O
84	we	_	_	_	_	_	_	_	Seg=O
85	show	_	_	_	_	_	_	_	Seg=O
86	analytically	_	_	_	_	_	_	_	Seg=O
87	how	_	_	_	_	_	_	_	Seg=B-seg
88	such	_	_	_	_	_	_	_	Seg=O
89	slow	_	_	_	_	_	_	_	Seg=O
90	dynamics	_	_	_	_	_	_	_	Seg=O
91	can	_	_	_	_	_	_	_	Seg=O
92	prevent	_	_	_	_	_	_	_	Seg=O
93	estimation	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	the	_	_	_	_	_	_	_	Seg=O
96	distance	_	_	_	_	_	_	_	Seg=O
97	to	_	_	_	_	_	_	_	Seg=O
98	the	_	_	_	_	_	_	_	Seg=O
99	threshold	_	_	_	_	_	_	_	Seg=O
100	from	_	_	_	_	_	_	_	Seg=O
101	fluctuations	_	_	_	_	_	_	_	Seg=O
102	in	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	susceptible	_	_	_	_	_	_	_	Seg=O
105	population	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	Although	_	_	_	_	_	_	_	Seg=B-seg
108	these	_	_	_	_	_	_	_	Seg=O
109	results	_	_	_	_	_	_	_	Seg=O
110	are	_	_	_	_	_	_	_	Seg=O
111	exact	_	_	_	_	_	_	_	Seg=O
112	only	_	_	_	_	_	_	_	Seg=O
113	in	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	limit	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	long	_	_	_	_	_	_	_	Seg=O
118	-	_	_	_	_	_	_	_	Seg=O
119	term	_	_	_	_	_	_	_	Seg=O
120	observation	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	a	_	_	_	_	_	_	_	Seg=O
123	large	_	_	_	_	_	_	_	Seg=O
124	system	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	simulations	_	_	_	_	_	_	_	Seg=B-seg
127	show	_	_	_	_	_	_	_	Seg=O
128	that	_	_	_	_	_	_	_	Seg=B-seg
129	they	_	_	_	_	_	_	_	Seg=O
130	still	_	_	_	_	_	_	_	Seg=O
131	provide	_	_	_	_	_	_	_	Seg=O
132	useful	_	_	_	_	_	_	_	Seg=O
133	insight	_	_	_	_	_	_	_	Seg=O
134	into	_	_	_	_	_	_	_	Seg=O
135	systems	_	_	_	_	_	_	_	Seg=O
136	with	_	_	_	_	_	_	_	Seg=O
137	a	_	_	_	_	_	_	_	Seg=O
138	range	_	_	_	_	_	_	_	Seg=O
139	of	_	_	_	_	_	_	_	Seg=O
140	population	_	_	_	_	_	_	_	Seg=O
141	sizes	_	_	_	_	_	_	_	Seg=O
142	,	_	_	_	_	_	_	_	Seg=O
143	environmental	_	_	_	_	_	_	_	Seg=O
144	noise	_	_	_	_	_	_	_	Seg=O
145	and	_	_	_	_	_	_	_	Seg=O
146	observation	_	_	_	_	_	_	_	Seg=O
147	schemes	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	Having	_	_	_	_	_	_	_	Seg=B-seg
150	established	_	_	_	_	_	_	_	Seg=O
151	some	_	_	_	_	_	_	_	Seg=O
152	guidelines	_	_	_	_	_	_	_	Seg=O
153	about	_	_	_	_	_	_	_	Seg=B-seg
154	when	_	_	_	_	_	_	_	Seg=O
155	estimates	_	_	_	_	_	_	_	Seg=O
156	are	_	_	_	_	_	_	_	Seg=O
157	accurate	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	we	_	_	_	_	_	_	_	Seg=B-seg
160	then	_	_	_	_	_	_	_	Seg=O
161	illustrate	_	_	_	_	_	_	_	Seg=O
162	how	_	_	_	_	_	_	_	Seg=B-seg
163	multiple	_	_	_	_	_	_	_	Seg=O
164	distance	_	_	_	_	_	_	_	Seg=O
165	estimates	_	_	_	_	_	_	_	Seg=O
166	can	_	_	_	_	_	_	_	Seg=O
167	be	_	_	_	_	_	_	_	Seg=O
168	used	_	_	_	_	_	_	_	Seg=O
169	to	_	_	_	_	_	_	_	Seg=B-seg
170	estimate	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	rate	_	_	_	_	_	_	_	Seg=O
173	of	_	_	_	_	_	_	_	Seg=O
174	approach	_	_	_	_	_	_	_	Seg=O
175	to	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	threshold	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O
179	The	_	_	_	_	_	_	_	Seg=B-seg
180	estimation	_	_	_	_	_	_	_	Seg=O
181	approach	_	_	_	_	_	_	_	Seg=O
182	is	_	_	_	_	_	_	_	Seg=O
183	general	_	_	_	_	_	_	_	Seg=O
184	and	_	_	_	_	_	_	_	Seg=B-seg
185	may	_	_	_	_	_	_	_	Seg=O
186	be	_	_	_	_	_	_	_	Seg=O
187	applicable	_	_	_	_	_	_	_	Seg=O
188	to	_	_	_	_	_	_	_	Seg=O
189	zoonotic	_	_	_	_	_	_	_	Seg=O
190	pathogens	_	_	_	_	_	_	_	Seg=O
191	such	_	_	_	_	_	_	_	Seg=B-seg
192	as	_	_	_	_	_	_	_	Seg=O
193	Middle	_	_	_	_	_	_	_	Seg=O
194	East	_	_	_	_	_	_	_	Seg=O
195	respiratory	_	_	_	_	_	_	_	Seg=O
196	syndrome	_	_	_	_	_	_	_	Seg=O
197	-	_	_	_	_	_	_	_	Seg=O
198	related	_	_	_	_	_	_	_	Seg=O
199	coronavirus	_	_	_	_	_	_	_	Seg=O
200	(	_	_	_	_	_	_	_	Seg=O
201	MERS	_	_	_	_	_	_	_	Seg=O
202	-	_	_	_	_	_	_	_	Seg=O
203	CoV	_	_	_	_	_	_	_	Seg=O
204	)	_	_	_	_	_	_	_	Seg=O
205	as	_	_	_	_	_	_	_	Seg=O
206	well	_	_	_	_	_	_	_	Seg=O
207	as	_	_	_	_	_	_	_	Seg=O
208	vaccine	_	_	_	_	_	_	_	Seg=O
209	-	_	_	_	_	_	_	_	Seg=O
210	preventable	_	_	_	_	_	_	_	Seg=O
211	diseases	_	_	_	_	_	_	_	Seg=O
212	like	_	_	_	_	_	_	_	Seg=O
213	measles	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = aedcbf29dcf8ecc0cf24cccd05124571f06fe258
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	entry	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	two	_	_	_	_	_	_	_	Seg=O
5	dengue	_	_	_	_	_	_	_	Seg=O
6	virus	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	DENV	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	serotypes	_	_	_	_	_	_	_	Seg=O
11	into	_	_	_	_	_	_	_	Seg=O
12	Vero	_	_	_	_	_	_	_	Seg=O
13	cells	_	_	_	_	_	_	_	Seg=O
14	was	_	_	_	_	_	_	_	Seg=O
15	analysed	_	_	_	_	_	_	_	Seg=O
16	using	_	_	_	_	_	_	_	Seg=B-seg
17	biochemical	_	_	_	_	_	_	_	Seg=O
18	inhibitors	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	dominant	_	_	_	_	_	_	_	Seg=O
21	negative	_	_	_	_	_	_	_	Seg=O
22	mutants	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	cellular	_	_	_	_	_	_	_	Seg=O
25	proteins	_	_	_	_	_	_	_	Seg=O
26	involved	_	_	_	_	_	_	_	Seg=B-seg
27	in	_	_	_	_	_	_	_	Seg=O
28	endocytic	_	_	_	_	_	_	_	Seg=O
29	pathways	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	fluorescence	_	_	_	_	_	_	_	Seg=B-seg
32	microscopy	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	infectivity	_	_	_	_	_	_	_	Seg=O
35	determinations	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	By	_	_	_	_	_	_	_	Seg=B-seg
38	treatment	_	_	_	_	_	_	_	Seg=O
39	with	_	_	_	_	_	_	_	Seg=O
40	dansylcadaverine	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	chlorpromazine	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	overexpression	_	_	_	_	_	_	_	Seg=O
45	of	_	_	_	_	_	_	_	Seg=O
46	a	_	_	_	_	_	_	_	Seg=O
47	dominant	_	_	_	_	_	_	_	Seg=O
48	negative	_	_	_	_	_	_	_	Seg=O
49	form	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	Eps15	_	_	_	_	_	_	_	Seg=O
53	protein	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	a	_	_	_	_	_	_	_	Seg=O
56	clathrin	_	_	_	_	_	_	_	Seg=O
57	-	_	_	_	_	_	_	_	Seg=O
58	mediated	_	_	_	_	_	_	_	Seg=O
59	endocytosis	_	_	_	_	_	_	_	Seg=O
60	for	_	_	_	_	_	_	_	Seg=O
61	productive	_	_	_	_	_	_	_	Seg=O
62	DENV-1	_	_	_	_	_	_	_	Seg=O
63	internalization	_	_	_	_	_	_	_	Seg=O
64	into	_	_	_	_	_	_	_	Seg=O
65	Vero	_	_	_	_	_	_	_	Seg=O
66	cells	_	_	_	_	_	_	_	Seg=O
67	was	_	_	_	_	_	_	_	Seg=O
68	demonstrated	_	_	_	_	_	_	_	Seg=O
69	whereas	_	_	_	_	_	_	_	Seg=B-seg
70	the	_	_	_	_	_	_	_	Seg=O
71	infectious	_	_	_	_	_	_	_	Seg=O
72	entry	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	DENV-2	_	_	_	_	_	_	_	Seg=O
75	in	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77	same	_	_	_	_	_	_	_	Seg=O
78	cell	_	_	_	_	_	_	_	Seg=O
79	system	_	_	_	_	_	_	_	Seg=O
80	was	_	_	_	_	_	_	_	Seg=O
81	independent	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	clathrin	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	Treatment	_	_	_	_	_	_	_	Seg=B-seg
86	with	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	inhibitors	_	_	_	_	_	_	_	Seg=O
89	nystatin	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=O
91	methyl	_	_	_	_	_	_	_	Seg=O
92	-	_	_	_	_	_	_	_	Seg=O
93	b	_	_	_	_	_	_	_	Seg=O
94	-	_	_	_	_	_	_	_	Seg=O
95	cyclodextrin	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	as	_	_	_	_	_	_	_	Seg=O
98	well	_	_	_	_	_	_	_	Seg=O
99	as	_	_	_	_	_	_	_	Seg=O
100	transfection	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	Vero	_	_	_	_	_	_	_	Seg=O
103	cells	_	_	_	_	_	_	_	Seg=O
104	with	_	_	_	_	_	_	_	Seg=O
105	dominant	_	_	_	_	_	_	_	Seg=O
106	negative	_	_	_	_	_	_	_	Seg=O
107	caveolin-1	_	_	_	_	_	_	_	Seg=O
108	,	_	_	_	_	_	_	_	Seg=O
109	had	_	_	_	_	_	_	_	Seg=O
110	no	_	_	_	_	_	_	_	Seg=O
111	effect	_	_	_	_	_	_	_	Seg=O
112	on	_	_	_	_	_	_	_	Seg=O
113	DENV-2	_	_	_	_	_	_	_	Seg=O
114	virus	_	_	_	_	_	_	_	Seg=O
115	infection	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	It	_	_	_	_	_	_	_	Seg=B-seg
118	was	_	_	_	_	_	_	_	Seg=O
119	also	_	_	_	_	_	_	_	Seg=O
120	shown	_	_	_	_	_	_	_	Seg=O
121	,	_	_	_	_	_	_	_	Seg=O
122	by	_	_	_	_	_	_	_	Seg=B-seg
123	using	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	K44A	_	_	_	_	_	_	_	Seg=O
126	mutant	_	_	_	_	_	_	_	Seg=O
127	and	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	inhibitor	_	_	_	_	_	_	_	Seg=O
130	dynasore	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	that	_	_	_	_	_	_	_	Seg=B-seg
133	dynamin	_	_	_	_	_	_	_	Seg=O
134	was	_	_	_	_	_	_	_	Seg=O
135	required	_	_	_	_	_	_	_	Seg=O
136	for	_	_	_	_	_	_	_	Seg=O
137	DENV-2	_	_	_	_	_	_	_	Seg=O
138	entry	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	Consequently	_	_	_	_	_	_	_	Seg=B-seg
141	,	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	infectious	_	_	_	_	_	_	_	Seg=O
144	entry	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	DENV-2	_	_	_	_	_	_	_	Seg=O
147	into	_	_	_	_	_	_	_	Seg=O
148	Vero	_	_	_	_	_	_	_	Seg=O
149	cells	_	_	_	_	_	_	_	Seg=O
150	occurs	_	_	_	_	_	_	_	Seg=O
151	by	_	_	_	_	_	_	_	Seg=O
152	a	_	_	_	_	_	_	_	Seg=O
153	non	_	_	_	_	_	_	_	Seg=O
154	-	_	_	_	_	_	_	_	Seg=O
155	classical	_	_	_	_	_	_	_	Seg=O
156	endocytic	_	_	_	_	_	_	_	Seg=O
157	pathway	_	_	_	_	_	_	_	Seg=O
158	independent	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	clathrin	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	caveolae	_	_	_	_	_	_	_	Seg=O
163	and	_	_	_	_	_	_	_	Seg=O
164	lipid	_	_	_	_	_	_	_	Seg=O
165	rafts	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	but	_	_	_	_	_	_	_	Seg=O
168	dependent	_	_	_	_	_	_	_	Seg=O
169	on	_	_	_	_	_	_	_	Seg=O
170	dynamin	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	By	_	_	_	_	_	_	_	Seg=B-seg
173	contrast	_	_	_	_	_	_	_	Seg=O
174	,	_	_	_	_	_	_	_	Seg=O
175	DENV-2	_	_	_	_	_	_	_	Seg=O
176	entry	_	_	_	_	_	_	_	Seg=O
177	into	_	_	_	_	_	_	_	Seg=O
178	A549	_	_	_	_	_	_	_	Seg=O
179	cells	_	_	_	_	_	_	_	Seg=O
180	was	_	_	_	_	_	_	_	Seg=O
181	clathrin	_	_	_	_	_	_	_	Seg=O
182	-	_	_	_	_	_	_	_	Seg=O
183	dependent	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	as	_	_	_	_	_	_	_	Seg=B-seg
186	previously	_	_	_	_	_	_	_	Seg=O
187	reported	_	_	_	_	_	_	_	Seg=O
188	in	_	_	_	_	_	_	_	Seg=O
189	HeLa	_	_	_	_	_	_	_	Seg=O
190	,	_	_	_	_	_	_	_	Seg=O
191	C6/36	_	_	_	_	_	_	_	Seg=O
192	and	_	_	_	_	_	_	_	Seg=O
193	BS	_	_	_	_	_	_	_	Seg=O
194	-	_	_	_	_	_	_	_	Seg=O
195	C-1	_	_	_	_	_	_	_	Seg=O
196	cells	_	_	_	_	_	_	_	Seg=O
197	.	_	_	_	_	_	_	_	Seg=O
198	Our	_	_	_	_	_	_	_	Seg=B-seg
199	results	_	_	_	_	_	_	_	Seg=O
200	conclusively	_	_	_	_	_	_	_	Seg=O
201	show	_	_	_	_	_	_	_	Seg=O
202	,	_	_	_	_	_	_	_	Seg=O
203	for	_	_	_	_	_	_	_	Seg=O
204	the	_	_	_	_	_	_	_	Seg=O
205	first	_	_	_	_	_	_	_	Seg=O
206	time	_	_	_	_	_	_	_	Seg=O
207	,	_	_	_	_	_	_	_	Seg=O
208	a	_	_	_	_	_	_	_	Seg=O
209	differential	_	_	_	_	_	_	_	Seg=O
210	mode	_	_	_	_	_	_	_	Seg=O
211	of	_	_	_	_	_	_	_	Seg=O
212	infective	_	_	_	_	_	_	_	Seg=O
213	entry	_	_	_	_	_	_	_	Seg=O
214	for	_	_	_	_	_	_	_	Seg=O
215	DENV-1	_	_	_	_	_	_	_	Seg=O
216	and	_	_	_	_	_	_	_	Seg=O
217	DENV-2	_	_	_	_	_	_	_	Seg=O
218	into	_	_	_	_	_	_	_	Seg=O
219	a	_	_	_	_	_	_	_	Seg=O
220	common	_	_	_	_	_	_	_	Seg=O
221	host	_	_	_	_	_	_	_	Seg=O
222	cell	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	Vero	_	_	_	_	_	_	_	Seg=O
225	cells	_	_	_	_	_	_	_	Seg=O
226	,	_	_	_	_	_	_	_	Seg=O
227	as	_	_	_	_	_	_	_	Seg=O
228	well	_	_	_	_	_	_	_	Seg=O
229	as	_	_	_	_	_	_	_	Seg=O
230	alternative	_	_	_	_	_	_	_	Seg=O
231	entry	_	_	_	_	_	_	_	Seg=O
232	pathways	_	_	_	_	_	_	_	Seg=O
233	for	_	_	_	_	_	_	_	Seg=O
234	a	_	_	_	_	_	_	_	Seg=O
235	given	_	_	_	_	_	_	_	Seg=O
236	serotype	_	_	_	_	_	_	_	Seg=O
237	,	_	_	_	_	_	_	_	Seg=O
238	DENV-2	_	_	_	_	_	_	_	Seg=O
239	,	_	_	_	_	_	_	_	Seg=O
240	into	_	_	_	_	_	_	_	Seg=O
241	different	_	_	_	_	_	_	_	Seg=O
242	types	_	_	_	_	_	_	_	Seg=O
243	of	_	_	_	_	_	_	_	Seg=O
244	cells	_	_	_	_	_	_	_	Seg=O
245	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = b25406fedda8c98e076135cef12df228ca6fd4f1
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	coronavirus	_	_	_	_	_	_	_	Seg=O
3	disease	_	_	_	_	_	_	_	Seg=O
4	2019	_	_	_	_	_	_	_	Seg=O
5	pandemic	_	_	_	_	_	_	_	Seg=O
6	has	_	_	_	_	_	_	_	Seg=O
7	led	_	_	_	_	_	_	_	Seg=O
8	to	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	manufacturing	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	novel	_	_	_	_	_	_	_	Seg=O
13	devices	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=B-seg
15	protect	_	_	_	_	_	_	_	Seg=O
16	clinicians	_	_	_	_	_	_	_	Seg=O
17	from	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	risk	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	transmission	_	_	_	_	_	_	_	Seg=O
22	,	_	_	_	_	_	_	_	Seg=O
23	including	_	_	_	_	_	_	_	Seg=B-seg
24	the	_	_	_	_	_	_	_	Seg=O
25	aerosol	_	_	_	_	_	_	_	Seg=O
26	box	_	_	_	_	_	_	_	Seg=O
27	for	_	_	_	_	_	_	_	Seg=O
28	use	_	_	_	_	_	_	_	Seg=O
29	during	_	_	_	_	_	_	_	Seg=O
30	tracheal	_	_	_	_	_	_	_	Seg=O
31	intubation	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	We	_	_	_	_	_	_	_	Seg=B-seg
34	evaluated	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	impact	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	two	_	_	_	_	_	_	_	Seg=O
39	aerosol	_	_	_	_	_	_	_	Seg=O
40	boxes	_	_	_	_	_	_	_	Seg=O
41	(	_	_	_	_	_	_	_	Seg=B-seg
42	an	_	_	_	_	_	_	_	Seg=O
43	early	_	_	_	_	_	_	_	Seg=O
44	-	_	_	_	_	_	_	_	Seg=O
45	generation	_	_	_	_	_	_	_	Seg=O
46	box	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=O
48	a	_	_	_	_	_	_	_	Seg=O
49	latest	_	_	_	_	_	_	_	Seg=O
50	-	_	_	_	_	_	_	_	Seg=O
51	generation	_	_	_	_	_	_	_	Seg=O
52	box	_	_	_	_	_	_	_	Seg=O
53	)	_	_	_	_	_	_	_	Seg=O
54	on	_	_	_	_	_	_	_	Seg=B-seg
55	intubations	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=O
57	patients	_	_	_	_	_	_	_	Seg=O
58	with	_	_	_	_	_	_	_	Seg=O
59	severe	_	_	_	_	_	_	_	Seg=O
60	coronavirus	_	_	_	_	_	_	_	Seg=O
61	disease	_	_	_	_	_	_	_	Seg=O
62	2019	_	_	_	_	_	_	_	Seg=O
63	with	_	_	_	_	_	_	_	Seg=O
64	an	_	_	_	_	_	_	_	Seg=O
65	in	_	_	_	_	_	_	_	Seg=O
66	-	_	_	_	_	_	_	_	Seg=O
67	situ	_	_	_	_	_	_	_	Seg=O
68	simulation	_	_	_	_	_	_	_	Seg=O
69	crossover	_	_	_	_	_	_	_	Seg=O
70	study	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	The	_	_	_	_	_	_	_	Seg=B-seg
73	simulated	_	_	_	_	_	_	_	Seg=O
74	process	_	_	_	_	_	_	_	Seg=O
75	complied	_	_	_	_	_	_	_	Seg=O
76	with	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	Safe	_	_	_	_	_	_	_	Seg=O
79	Airway	_	_	_	_	_	_	_	Seg=O
80	Society	_	_	_	_	_	_	_	Seg=O
81	coronavirus	_	_	_	_	_	_	_	Seg=O
82	disease	_	_	_	_	_	_	_	Seg=O
83	2019	_	_	_	_	_	_	_	Seg=O
84	airway	_	_	_	_	_	_	_	Seg=O
85	management	_	_	_	_	_	_	_	Seg=O
86	guidelines	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	The	_	_	_	_	_	_	_	Seg=B-seg
89	primary	_	_	_	_	_	_	_	Seg=O
90	outcome	_	_	_	_	_	_	_	Seg=O
91	was	_	_	_	_	_	_	_	Seg=O
92	intubation	_	_	_	_	_	_	_	Seg=O
93	time	_	_	_	_	_	_	_	Seg=O
94	;	_	_	_	_	_	_	_	Seg=O
95	secondary	_	_	_	_	_	_	_	Seg=B-seg
96	outcomes	_	_	_	_	_	_	_	Seg=O
97	included	_	_	_	_	_	_	_	Seg=O
98	first	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	pass	_	_	_	_	_	_	_	Seg=O
101	success	_	_	_	_	_	_	_	Seg=O
102	and	_	_	_	_	_	_	_	Seg=O
103	breaches	_	_	_	_	_	_	_	Seg=O
104	to	_	_	_	_	_	_	_	Seg=O
105	personal	_	_	_	_	_	_	_	Seg=O
106	protective	_	_	_	_	_	_	_	Seg=O
107	equipment	_	_	_	_	_	_	_	Seg=O
108	.	_	_	_	_	_	_	_	Seg=O
109	All	_	_	_	_	_	_	_	Seg=B-seg
110	intubations	_	_	_	_	_	_	_	Seg=O
111	were	_	_	_	_	_	_	_	Seg=O
112	performed	_	_	_	_	_	_	_	Seg=O
113	by	_	_	_	_	_	_	_	Seg=O
114	specialist	_	_	_	_	_	_	_	Seg=O
115	(	_	_	_	_	_	_	_	Seg=O
116	consultant	_	_	_	_	_	_	_	Seg=O
117	)	_	_	_	_	_	_	_	Seg=O
118	anaesthetists	_	_	_	_	_	_	_	Seg=O
119	and	_	_	_	_	_	_	_	Seg=O
120	video	_	_	_	_	_	_	_	Seg=O
121	recorded	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	Twelve	_	_	_	_	_	_	_	Seg=B-seg
124	anaesthetists	_	_	_	_	_	_	_	Seg=O
125	performed	_	_	_	_	_	_	_	Seg=O
126	36	_	_	_	_	_	_	_	Seg=O
127	intubations	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	Intubation	_	_	_	_	_	_	_	Seg=B-seg
130	time	_	_	_	_	_	_	_	Seg=O
131	with	_	_	_	_	_	_	_	Seg=O
132	no	_	_	_	_	_	_	_	Seg=O
133	aerosol	_	_	_	_	_	_	_	Seg=O
134	box	_	_	_	_	_	_	_	Seg=O
135	was	_	_	_	_	_	_	_	Seg=O
136	significantly	_	_	_	_	_	_	_	Seg=O
137	shorter	_	_	_	_	_	_	_	Seg=O
138	than	_	_	_	_	_	_	_	Seg=O
139	with	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	early	_	_	_	_	_	_	_	Seg=O
142	-	_	_	_	_	_	_	_	Seg=O
143	generation	_	_	_	_	_	_	_	Seg=O
144	box	_	_	_	_	_	_	_	Seg=O
145	(	_	_	_	_	_	_	_	Seg=B-seg
146	median	_	_	_	_	_	_	_	Seg=O
147	(	_	_	_	_	_	_	_	Seg=O
148	IQR	_	_	_	_	_	_	_	Seg=O
149	[	_	_	_	_	_	_	_	Seg=O
150	range	_	_	_	_	_	_	_	Seg=O
151	]	_	_	_	_	_	_	_	Seg=O
152	)	_	_	_	_	_	_	_	Seg=O
153	42.9	_	_	_	_	_	_	_	Seg=O
154	(	_	_	_	_	_	_	_	Seg=O
155	32.9	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	46.9	_	_	_	_	_	_	_	Seg=O
158	[	_	_	_	_	_	_	_	Seg=O
159	30.9	_	_	_	_	_	_	_	Seg=O
160	-	_	_	_	_	_	_	_	Seg=O
161	57.6])s	_	_	_	_	_	_	_	Seg=O
162	vs.	_	_	_	_	_	_	_	Seg=O
163	82.1	_	_	_	_	_	_	_	Seg=O
164	(	_	_	_	_	_	_	_	Seg=O
165	45.1	_	_	_	_	_	_	_	Seg=O
166	-	_	_	_	_	_	_	_	Seg=O
167	98.3	_	_	_	_	_	_	_	Seg=O
168	[	_	_	_	_	_	_	_	Seg=O
169	30.8	_	_	_	_	_	_	_	Seg=O
170	-	_	_	_	_	_	_	_	Seg=O
171	180.0])s	_	_	_	_	_	_	_	Seg=O
172	p	_	_	_	_	_	_	_	Seg=O
173	=	_	_	_	_	_	_	_	Seg=O
174	0.002	_	_	_	_	_	_	_	Seg=O
175	)	_	_	_	_	_	_	_	Seg=O
176	and	_	_	_	_	_	_	_	Seg=B-seg
177	the	_	_	_	_	_	_	_	Seg=O
178	latest	_	_	_	_	_	_	_	Seg=O
179	-	_	_	_	_	_	_	_	Seg=O
180	generation	_	_	_	_	_	_	_	Seg=O
181	box	_	_	_	_	_	_	_	Seg=O
182	(	_	_	_	_	_	_	_	Seg=B-seg
183	52.4	_	_	_	_	_	_	_	Seg=O
184	(	_	_	_	_	_	_	_	Seg=O
185	43.1	_	_	_	_	_	_	_	Seg=O
186	-	_	_	_	_	_	_	_	Seg=O
187	70.3	_	_	_	_	_	_	_	Seg=O
188	[	_	_	_	_	_	_	_	Seg=O
189	35.7	_	_	_	_	_	_	_	Seg=O
190	-	_	_	_	_	_	_	_	Seg=O
191	169.2])s	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	p	_	_	_	_	_	_	_	Seg=O
194	=	_	_	_	_	_	_	_	Seg=O
195	0.008	_	_	_	_	_	_	_	Seg=O
196	)	_	_	_	_	_	_	_	Seg=O
197	.	_	_	_	_	_	_	_	Seg=O
198	No	_	_	_	_	_	_	_	Seg=B-seg
199	intubations	_	_	_	_	_	_	_	Seg=O
200	without	_	_	_	_	_	_	_	Seg=O
201	a	_	_	_	_	_	_	_	Seg=O
202	box	_	_	_	_	_	_	_	Seg=O
203	took	_	_	_	_	_	_	_	Seg=O
204	more	_	_	_	_	_	_	_	Seg=O
205	than	_	_	_	_	_	_	_	Seg=O
206	1	_	_	_	_	_	_	_	Seg=O
207	min	_	_	_	_	_	_	_	Seg=O
208	,	_	_	_	_	_	_	_	Seg=O
209	whereas	_	_	_	_	_	_	_	Seg=B-seg
210	14	_	_	_	_	_	_	_	Seg=O
211	(	_	_	_	_	_	_	_	Seg=B-seg
212	58	_	_	_	_	_	_	_	Seg=O
213	%	_	_	_	_	_	_	_	Seg=O
214	)	_	_	_	_	_	_	_	Seg=O
215	intubations	_	_	_	_	_	_	_	Seg=B-seg
216	with	_	_	_	_	_	_	_	Seg=O
217	a	_	_	_	_	_	_	_	Seg=O
218	box	_	_	_	_	_	_	_	Seg=O
219	took	_	_	_	_	_	_	_	Seg=O
220	over	_	_	_	_	_	_	_	Seg=O
221	1	_	_	_	_	_	_	_	Seg=O
222	min	_	_	_	_	_	_	_	Seg=O
223	and	_	_	_	_	_	_	_	Seg=B-seg
224	4	_	_	_	_	_	_	_	Seg=O
225	(	_	_	_	_	_	_	_	Seg=B-seg
226	17	_	_	_	_	_	_	_	Seg=O
227	%	_	_	_	_	_	_	_	Seg=O
228	)	_	_	_	_	_	_	_	Seg=O
229	took	_	_	_	_	_	_	_	Seg=B-seg
230	over	_	_	_	_	_	_	_	Seg=O
231	2	_	_	_	_	_	_	_	Seg=O
232	min	_	_	_	_	_	_	_	Seg=O
233	(	_	_	_	_	_	_	_	Seg=B-seg
234	including	_	_	_	_	_	_	_	Seg=O
235	one	_	_	_	_	_	_	_	Seg=O
236	failure	_	_	_	_	_	_	_	Seg=O
237	)	_	_	_	_	_	_	_	Seg=O
238	.	_	_	_	_	_	_	_	Seg=O
239	Without	_	_	_	_	_	_	_	Seg=B-seg
240	an	_	_	_	_	_	_	_	Seg=O
241	aerosol	_	_	_	_	_	_	_	Seg=O
242	box	_	_	_	_	_	_	_	Seg=O
243	,	_	_	_	_	_	_	_	Seg=O
244	all	_	_	_	_	_	_	_	Seg=O
245	anaesthetists	_	_	_	_	_	_	_	Seg=O
246	obtained	_	_	_	_	_	_	_	Seg=O
247	first	_	_	_	_	_	_	_	Seg=O
248	-	_	_	_	_	_	_	_	Seg=O
249	pass	_	_	_	_	_	_	_	Seg=O
250	success	_	_	_	_	_	_	_	Seg=O
251	.	_	_	_	_	_	_	_	Seg=O
252	With	_	_	_	_	_	_	_	Seg=B-seg
253	the	_	_	_	_	_	_	_	Seg=O
254	early	_	_	_	_	_	_	_	Seg=O
255	-	_	_	_	_	_	_	_	Seg=O
256	generation	_	_	_	_	_	_	_	Seg=O
257	and	_	_	_	_	_	_	_	Seg=O
258	latest	_	_	_	_	_	_	_	Seg=O
259	-	_	_	_	_	_	_	_	Seg=O
260	generation	_	_	_	_	_	_	_	Seg=O
261	boxes	_	_	_	_	_	_	_	Seg=O
262	,	_	_	_	_	_	_	_	Seg=O
263	9	_	_	_	_	_	_	_	Seg=O
264	(	_	_	_	_	_	_	_	Seg=B-seg
265	75	_	_	_	_	_	_	_	Seg=O
266	%	_	_	_	_	_	_	_	Seg=O
267	)	_	_	_	_	_	_	_	Seg=O
268	and	_	_	_	_	_	_	_	Seg=B-seg
269	10	_	_	_	_	_	_	_	Seg=O
270	(	_	_	_	_	_	_	_	Seg=B-seg
271	83	_	_	_	_	_	_	_	Seg=O
272	%	_	_	_	_	_	_	_	Seg=O
273	)	_	_	_	_	_	_	_	Seg=O
274	participants	_	_	_	_	_	_	_	Seg=B-seg
275	obtained	_	_	_	_	_	_	_	Seg=O
276	first	_	_	_	_	_	_	_	Seg=O
277	-	_	_	_	_	_	_	_	Seg=O
278	pass	_	_	_	_	_	_	_	Seg=O
279	success	_	_	_	_	_	_	_	Seg=O
280	,	_	_	_	_	_	_	_	Seg=O
281	respectively	_	_	_	_	_	_	_	Seg=O
282	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = b61d4d87ea3b4fa2ff058ee867bdac4f15c0cf11
1	As	_	_	_	_	_	_	_	Seg=B-seg
2	intracellular	_	_	_	_	_	_	_	Seg=O
3	parasites	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	viruses	_	_	_	_	_	_	_	Seg=O
6	require	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	host	_	_	_	_	_	_	_	Seg=O
9	cell	_	_	_	_	_	_	_	Seg=O
10	in	_	_	_	_	_	_	_	Seg=B-seg
11	order	_	_	_	_	_	_	_	Seg=O
12	to	_	_	_	_	_	_	_	Seg=O
13	replicate	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	However	_	_	_	_	_	_	_	Seg=B-seg
16	,	_	_	_	_	_	_	_	Seg=O
17	they	_	_	_	_	_	_	_	Seg=O
18	face	_	_	_	_	_	_	_	Seg=O
19	a	_	_	_	_	_	_	_	Seg=O
20	series	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	cellular	_	_	_	_	_	_	_	Seg=O
23	responses	_	_	_	_	_	_	_	Seg=O
24	against	_	_	_	_	_	_	_	Seg=O
25	infection	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	One	_	_	_	_	_	_	_	Seg=B-seg
28	of	_	_	_	_	_	_	_	Seg=O
29	these	_	_	_	_	_	_	_	Seg=O
30	responses	_	_	_	_	_	_	_	Seg=O
31	is	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	activation	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	double	_	_	_	_	_	_	_	Seg=O
37	-	_	_	_	_	_	_	_	Seg=O
38	stranded	_	_	_	_	_	_	_	Seg=O
39	RNA	_	_	_	_	_	_	_	Seg=O
40	(	_	_	_	_	_	_	_	Seg=O
41	dsRNA)-activated	_	_	_	_	_	_	_	Seg=O
42	protein	_	_	_	_	_	_	_	Seg=O
43	kinase	_	_	_	_	_	_	_	Seg=O
44	R	_	_	_	_	_	_	_	Seg=O
45	(	_	_	_	_	_	_	_	Seg=O
46	PKR	_	_	_	_	_	_	_	Seg=O
47	)	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	PKR	_	_	_	_	_	_	_	Seg=B-seg
50	phosphorylates	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	α	_	_	_	_	_	_	_	Seg=O
53	subunit	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	eukaryotic	_	_	_	_	_	_	_	Seg=O
56	translation	_	_	_	_	_	_	_	Seg=O
57	initiation	_	_	_	_	_	_	_	Seg=O
58	factor	_	_	_	_	_	_	_	Seg=O
59	2	_	_	_	_	_	_	_	Seg=O
60	(	_	_	_	_	_	_	_	Seg=O
61	eIF2α	_	_	_	_	_	_	_	Seg=O
62	)	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	which	_	_	_	_	_	_	_	Seg=B-seg
65	in	_	_	_	_	_	_	_	Seg=O
66	turn	_	_	_	_	_	_	_	Seg=O
67	results	_	_	_	_	_	_	_	Seg=O
68	in	_	_	_	_	_	_	_	Seg=O
69	global	_	_	_	_	_	_	_	Seg=O
70	protein	_	_	_	_	_	_	_	Seg=O
71	synthesis	_	_	_	_	_	_	_	Seg=O
72	inhibition	_	_	_	_	_	_	_	Seg=O
73	and	_	_	_	_	_	_	_	Seg=O
74	formation	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	stress	_	_	_	_	_	_	_	Seg=O
77	granules	_	_	_	_	_	_	_	Seg=O
78	(	_	_	_	_	_	_	_	Seg=O
79	SGs	_	_	_	_	_	_	_	Seg=O
80	)	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	Recent	_	_	_	_	_	_	_	Seg=B-seg
83	studies	_	_	_	_	_	_	_	Seg=O
84	have	_	_	_	_	_	_	_	Seg=O
85	shown	_	_	_	_	_	_	_	Seg=O
86	that	_	_	_	_	_	_	_	Seg=B-seg
87	SGs	_	_	_	_	_	_	_	Seg=O
88	can	_	_	_	_	_	_	_	Seg=O
89	interfere	_	_	_	_	_	_	_	Seg=O
90	with	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	replicative	_	_	_	_	_	_	_	Seg=O
93	cycle	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	certain	_	_	_	_	_	_	_	Seg=O
96	viruses	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	This	_	_	_	_	_	_	_	Seg=B-seg
99	review	_	_	_	_	_	_	_	Seg=O
100	addresses	_	_	_	_	_	_	_	Seg=O
101	how	_	_	_	_	_	_	_	Seg=B-seg
102	viruses	_	_	_	_	_	_	_	Seg=O
103	have	_	_	_	_	_	_	_	Seg=O
104	evolved	_	_	_	_	_	_	_	Seg=O
105	different	_	_	_	_	_	_	_	Seg=O
106	control	_	_	_	_	_	_	_	Seg=O
107	strategies	_	_	_	_	_	_	_	Seg=O
108	at	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	SG	_	_	_	_	_	_	_	Seg=O
111	level	_	_	_	_	_	_	_	Seg=O
112	to	_	_	_	_	_	_	_	Seg=B-seg
113	ensure	_	_	_	_	_	_	_	Seg=O
114	an	_	_	_	_	_	_	_	Seg=O
115	efficient	_	_	_	_	_	_	_	Seg=O
116	replication	_	_	_	_	_	_	_	Seg=O
117	cycle	_	_	_	_	_	_	_	Seg=O
118	during	_	_	_	_	_	_	_	Seg=O
119	the	_	_	_	_	_	_	_	Seg=O
120	cellular	_	_	_	_	_	_	_	Seg=O
121	stress	_	_	_	_	_	_	_	Seg=O
122	response	_	_	_	_	_	_	_	Seg=O
123	triggered	_	_	_	_	_	_	_	Seg=B-seg
124	by	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	viral	_	_	_	_	_	_	_	Seg=O
127	infection	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = b663a1cc707cf69d2f90bda78f077b45b4f4daa5
1	Monadic	_	_	_	_	_	_	_	Seg=B-seg
2	decomposability	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	a	_	_	_	_	_	_	_	Seg=O
5	notion	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	variable	_	_	_	_	_	_	_	Seg=O
8	independence	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	which	_	_	_	_	_	_	_	Seg=B-seg
11	asks	_	_	_	_	_	_	_	Seg=O
12	whether	_	_	_	_	_	_	_	Seg=O
13	a	_	_	_	_	_	_	_	Seg=O
14	given	_	_	_	_	_	_	_	Seg=O
15	formula	_	_	_	_	_	_	_	Seg=O
16	in	_	_	_	_	_	_	_	Seg=O
17	a	_	_	_	_	_	_	_	Seg=O
18	first	_	_	_	_	_	_	_	Seg=O
19	-	_	_	_	_	_	_	_	Seg=O
20	order	_	_	_	_	_	_	_	Seg=O
21	theory	_	_	_	_	_	_	_	Seg=O
22	is	_	_	_	_	_	_	_	Seg=O
23	expressible	_	_	_	_	_	_	_	Seg=O
24	as	_	_	_	_	_	_	_	Seg=O
25	a	_	_	_	_	_	_	_	Seg=O
26	Boolean	_	_	_	_	_	_	_	Seg=O
27	combination	_	_	_	_	_	_	_	Seg=O
28	of	_	_	_	_	_	_	_	Seg=O
29	monadic	_	_	_	_	_	_	_	Seg=O
30	predicates	_	_	_	_	_	_	_	Seg=O
31	in	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	theory	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	Recently	_	_	_	_	_	_	_	Seg=B-seg
36	,	_	_	_	_	_	_	_	Seg=O
37	Veanes	_	_	_	_	_	_	_	Seg=O
38	et	_	_	_	_	_	_	_	Seg=O
39	al	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	showed	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	usefulness	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	monadic	_	_	_	_	_	_	_	Seg=O
46	decomposability	_	_	_	_	_	_	_	Seg=O
47	in	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	context	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	SMT	_	_	_	_	_	_	_	Seg=O
52	(	_	_	_	_	_	_	_	Seg=B-seg
53	i.e.	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	input	_	_	_	_	_	_	_	Seg=O
56	formula	_	_	_	_	_	_	_	Seg=O
57	is	_	_	_	_	_	_	_	Seg=O
58	quantifier	_	_	_	_	_	_	_	Seg=O
59	-	_	_	_	_	_	_	_	Seg=O
60	free	_	_	_	_	_	_	_	Seg=O
61	)	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=B-seg
64	found	_	_	_	_	_	_	_	Seg=O
65	various	_	_	_	_	_	_	_	Seg=O
66	interesting	_	_	_	_	_	_	_	Seg=O
67	applications	_	_	_	_	_	_	_	Seg=O
68	including	_	_	_	_	_	_	_	Seg=B-seg
69	string	_	_	_	_	_	_	_	Seg=O
70	analysis	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	However	_	_	_	_	_	_	_	Seg=B-seg
73	,	_	_	_	_	_	_	_	Seg=O
74	checking	_	_	_	_	_	_	_	Seg=O
75	monadic	_	_	_	_	_	_	_	Seg=O
76	decomposability	_	_	_	_	_	_	_	Seg=O
77	is	_	_	_	_	_	_	_	Seg=O
78	undecidable	_	_	_	_	_	_	_	Seg=O
79	in	_	_	_	_	_	_	_	Seg=O
80	general	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	Decidability	_	_	_	_	_	_	_	Seg=B-seg
83	for	_	_	_	_	_	_	_	Seg=O
84	certain	_	_	_	_	_	_	_	Seg=O
85	theories	_	_	_	_	_	_	_	Seg=O
86	is	_	_	_	_	_	_	_	Seg=O
87	known	_	_	_	_	_	_	_	Seg=O
88	(	_	_	_	_	_	_	_	Seg=B-seg
89	e.g.	_	_	_	_	_	_	_	Seg=O
90	Presburger	_	_	_	_	_	_	_	Seg=O
91	Arithmetic	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93-94	Tarski's	_	_	_	_	_	_	_	_
93	Tarski	_	_	_	_	_	_	_	Seg=O
94	's	_	_	_	_	_	_	_	Seg=O
95	Real	_	_	_	_	_	_	_	Seg=O
96	-	_	_	_	_	_	_	_	Seg=O
97	Closed	_	_	_	_	_	_	_	Seg=O
98	Field	_	_	_	_	_	_	_	Seg=O
99	)	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	but	_	_	_	_	_	_	_	Seg=B-seg
102	there	_	_	_	_	_	_	_	Seg=O
103	are	_	_	_	_	_	_	_	Seg=O
104	very	_	_	_	_	_	_	_	Seg=O
105	few	_	_	_	_	_	_	_	Seg=O
106	results	_	_	_	_	_	_	_	Seg=O
107	regarding	_	_	_	_	_	_	_	Seg=B-seg
108	their	_	_	_	_	_	_	_	Seg=O
109	computational	_	_	_	_	_	_	_	Seg=O
110	complexity	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	In	_	_	_	_	_	_	_	Seg=B-seg
113	this	_	_	_	_	_	_	_	Seg=O
114	paper	_	_	_	_	_	_	_	Seg=O
115	,	_	_	_	_	_	_	_	Seg=O
116	we	_	_	_	_	_	_	_	Seg=O
117	study	_	_	_	_	_	_	_	Seg=O
118	monadic	_	_	_	_	_	_	_	Seg=O
119	decomposability	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	integer	_	_	_	_	_	_	_	Seg=O
122	linear	_	_	_	_	_	_	_	Seg=O
123	arithmetic	_	_	_	_	_	_	_	Seg=O
124	in	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	setting	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	SMT	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	We	_	_	_	_	_	_	_	Seg=B-seg
131	show	_	_	_	_	_	_	_	Seg=O
132	that	_	_	_	_	_	_	_	Seg=O
133	this	_	_	_	_	_	_	_	Seg=O
134	decision	_	_	_	_	_	_	_	Seg=O
135	problem	_	_	_	_	_	_	_	Seg=O
136	is	_	_	_	_	_	_	_	Seg=O
137	coNP	_	_	_	_	_	_	_	Seg=O
138	-	_	_	_	_	_	_	_	Seg=O
139	complete	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=B-seg
141	,	_	_	_	_	_	_	_	Seg=O
142	when	_	_	_	_	_	_	_	Seg=B-seg
143	monadically	_	_	_	_	_	_	_	Seg=O
144	decomposable	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	a	_	_	_	_	_	_	_	Seg=B-seg
147	formula	_	_	_	_	_	_	_	Seg=O
148	admits	_	_	_	_	_	_	_	Seg=O
149	a	_	_	_	_	_	_	_	Seg=O
150	decomposition	_	_	_	_	_	_	_	Seg=O
151	of	_	_	_	_	_	_	_	Seg=O
152	exponential	_	_	_	_	_	_	_	Seg=O
153	size	_	_	_	_	_	_	_	Seg=O
154	in	_	_	_	_	_	_	_	Seg=O
155	the	_	_	_	_	_	_	_	Seg=O
156	worst	_	_	_	_	_	_	_	Seg=O
157	case	_	_	_	_	_	_	_	Seg=O
158	.	_	_	_	_	_	_	_	Seg=O
159	We	_	_	_	_	_	_	_	Seg=B-seg
160	provide	_	_	_	_	_	_	_	Seg=O
161	a	_	_	_	_	_	_	_	Seg=O
162	new	_	_	_	_	_	_	_	Seg=O
163	application	_	_	_	_	_	_	_	Seg=O
164	of	_	_	_	_	_	_	_	Seg=O
165	our	_	_	_	_	_	_	_	Seg=O
166	results	_	_	_	_	_	_	_	Seg=O
167	to	_	_	_	_	_	_	_	Seg=O
168	string	_	_	_	_	_	_	_	Seg=O
169	constraint	_	_	_	_	_	_	_	Seg=O
170	solving	_	_	_	_	_	_	_	Seg=O
171	with	_	_	_	_	_	_	_	Seg=O
172	length	_	_	_	_	_	_	_	Seg=O
173	constraints	_	_	_	_	_	_	_	Seg=O
174	.	_	_	_	_	_	_	_	Seg=O
175	We	_	_	_	_	_	_	_	Seg=B-seg
176	then	_	_	_	_	_	_	_	Seg=O
177	extend	_	_	_	_	_	_	_	Seg=O
178	our	_	_	_	_	_	_	_	Seg=O
179	results	_	_	_	_	_	_	_	Seg=O
180	to	_	_	_	_	_	_	_	Seg=O
181	variadic	_	_	_	_	_	_	_	Seg=O
182	decomposability	_	_	_	_	_	_	_	Seg=O
183	,	_	_	_	_	_	_	_	Seg=O
184	where	_	_	_	_	_	_	_	Seg=B-seg
185	predicates	_	_	_	_	_	_	_	Seg=O
186	could	_	_	_	_	_	_	_	Seg=O
187	admit	_	_	_	_	_	_	_	Seg=O
188	multiple	_	_	_	_	_	_	_	Seg=O
189	free	_	_	_	_	_	_	_	Seg=O
190	variables	_	_	_	_	_	_	_	Seg=O
191	(	_	_	_	_	_	_	_	Seg=B-seg
192	in	_	_	_	_	_	_	_	Seg=O
193	contrast	_	_	_	_	_	_	_	Seg=O
194	to	_	_	_	_	_	_	_	Seg=O
195	monadic	_	_	_	_	_	_	_	Seg=O
196	decomposability	_	_	_	_	_	_	_	Seg=O
197	)	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	Finally	_	_	_	_	_	_	_	Seg=B-seg
200	,	_	_	_	_	_	_	_	Seg=O
201	we	_	_	_	_	_	_	_	Seg=O
202	give	_	_	_	_	_	_	_	Seg=O
203	an	_	_	_	_	_	_	_	Seg=O
204	application	_	_	_	_	_	_	_	Seg=O
205	to	_	_	_	_	_	_	_	Seg=O
206	quantifier	_	_	_	_	_	_	_	Seg=O
207	elimination	_	_	_	_	_	_	_	Seg=O
208	in	_	_	_	_	_	_	_	Seg=O
209	integer	_	_	_	_	_	_	_	Seg=O
210	linear	_	_	_	_	_	_	_	Seg=O
211	arithmetic	_	_	_	_	_	_	_	Seg=O
212	where	_	_	_	_	_	_	_	Seg=B-seg
213	the	_	_	_	_	_	_	_	Seg=O
214	variables	_	_	_	_	_	_	_	Seg=O
215	in	_	_	_	_	_	_	_	Seg=O
216	a	_	_	_	_	_	_	_	Seg=O
217	block	_	_	_	_	_	_	_	Seg=O
218	of	_	_	_	_	_	_	_	Seg=O
219	quantifiers	_	_	_	_	_	_	_	Seg=O
220	,	_	_	_	_	_	_	_	Seg=O
221	if	_	_	_	_	_	_	_	Seg=B-seg
222	independent	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	could	_	_	_	_	_	_	_	Seg=B-seg
225	be	_	_	_	_	_	_	_	Seg=O
226	eliminated	_	_	_	_	_	_	_	Seg=O
227	with	_	_	_	_	_	_	_	Seg=O
228	an	_	_	_	_	_	_	_	Seg=O
229	exponential	_	_	_	_	_	_	_	Seg=O
230	(	_	_	_	_	_	_	_	Seg=B-seg
231	instead	_	_	_	_	_	_	_	Seg=O
232	of	_	_	_	_	_	_	_	Seg=O
233	the	_	_	_	_	_	_	_	Seg=O
234	standard	_	_	_	_	_	_	_	Seg=O
235	doubly	_	_	_	_	_	_	_	Seg=O
236	exponential	_	_	_	_	_	_	_	Seg=O
237	)	_	_	_	_	_	_	_	Seg=O
238	blow	_	_	_	_	_	_	_	Seg=B-seg
239	-	_	_	_	_	_	_	_	Seg=O
240	up	_	_	_	_	_	_	_	Seg=O
241	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ba3522d00ecebd159c5b5dc90119df8642993c49
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	type	_	_	_	_	_	_	_	Seg=O
3	II	_	_	_	_	_	_	_	Seg=O
4	transmembrane	_	_	_	_	_	_	_	Seg=O
5	serine	_	_	_	_	_	_	_	Seg=O
6	proteases	_	_	_	_	_	_	_	Seg=O
7	TMPRSS2	_	_	_	_	_	_	_	Seg=O
8	and	_	_	_	_	_	_	_	Seg=O
9	HAT	_	_	_	_	_	_	_	Seg=O
10	activate	_	_	_	_	_	_	_	Seg=O
11	influenza	_	_	_	_	_	_	_	Seg=O
12	viruses	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=O
14	the	_	_	_	_	_	_	_	Seg=O
15	SARS	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	coronavirus	_	_	_	_	_	_	_	Seg=O
18	(	_	_	_	_	_	_	_	Seg=O
19	TMPRSS2	_	_	_	_	_	_	_	Seg=O
20	)	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	cell	_	_	_	_	_	_	_	Seg=O
23	culture	_	_	_	_	_	_	_	Seg=O
24	and	_	_	_	_	_	_	_	Seg=B-seg
25	may	_	_	_	_	_	_	_	Seg=O
26	play	_	_	_	_	_	_	_	Seg=O
27	an	_	_	_	_	_	_	_	Seg=O
28	important	_	_	_	_	_	_	_	Seg=O
29	role	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	viral	_	_	_	_	_	_	_	Seg=O
32	spread	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	pathogenesis	_	_	_	_	_	_	_	Seg=O
35	in	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	infected	_	_	_	_	_	_	_	Seg=O
38	host	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	However	_	_	_	_	_	_	_	Seg=B-seg
41	,	_	_	_	_	_	_	_	Seg=O
42	it	_	_	_	_	_	_	_	Seg=O
43	is	_	_	_	_	_	_	_	Seg=O
44	at	_	_	_	_	_	_	_	Seg=O
45	present	_	_	_	_	_	_	_	Seg=O
46	largely	_	_	_	_	_	_	_	Seg=O
47	unclear	_	_	_	_	_	_	_	Seg=O
48	to	_	_	_	_	_	_	_	Seg=O
49	what	_	_	_	_	_	_	_	Seg=O
50	extent	_	_	_	_	_	_	_	Seg=O
51	these	_	_	_	_	_	_	_	Seg=O
52	proteases	_	_	_	_	_	_	_	Seg=O
53	are	_	_	_	_	_	_	_	Seg=O
54	expressed	_	_	_	_	_	_	_	Seg=O
55	in	_	_	_	_	_	_	_	Seg=O
56	viral	_	_	_	_	_	_	_	Seg=O
57	target	_	_	_	_	_	_	_	Seg=O
58	cells	_	_	_	_	_	_	_	Seg=O
59	in	_	_	_	_	_	_	_	Seg=O
60	human	_	_	_	_	_	_	_	Seg=O
61	tissues	_	_	_	_	_	_	_	Seg=O
62	.	_	_	_	_	_	_	_	Seg=O
63	Here	_	_	_	_	_	_	_	Seg=B-seg
64	,	_	_	_	_	_	_	_	Seg=O
65	we	_	_	_	_	_	_	_	Seg=O
66	show	_	_	_	_	_	_	_	Seg=O
67	that	_	_	_	_	_	_	_	Seg=B-seg
68	both	_	_	_	_	_	_	_	Seg=O
69	HAT	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	TMPRSS2	_	_	_	_	_	_	_	Seg=O
72	are	_	_	_	_	_	_	_	Seg=O
73	coexpressed	_	_	_	_	_	_	_	Seg=O
74	with	_	_	_	_	_	_	_	Seg=O
75	2,6-linked	_	_	_	_	_	_	_	Seg=O
76	sialic	_	_	_	_	_	_	_	Seg=O
77	acids	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	major	_	_	_	_	_	_	_	Seg=O
81	receptor	_	_	_	_	_	_	_	Seg=O
82	determinant	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	human	_	_	_	_	_	_	_	Seg=O
85	influenza	_	_	_	_	_	_	_	Seg=O
86	viruses	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	throughout	_	_	_	_	_	_	_	Seg=O
89	the	_	_	_	_	_	_	_	Seg=O
90	human	_	_	_	_	_	_	_	Seg=O
91	respiratory	_	_	_	_	_	_	_	Seg=O
92	tract	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	Similarly	_	_	_	_	_	_	_	Seg=B-seg
95	,	_	_	_	_	_	_	_	Seg=O
96	coexpression	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	ACE2	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	the	_	_	_	_	_	_	_	Seg=O
101	SARS	_	_	_	_	_	_	_	Seg=O
102	-	_	_	_	_	_	_	_	Seg=O
103	coronavirus	_	_	_	_	_	_	_	Seg=O
104	receptor	_	_	_	_	_	_	_	Seg=O
105	,	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=O
107	TMPRSS2	_	_	_	_	_	_	_	Seg=O
108	was	_	_	_	_	_	_	_	Seg=O
109	frequently	_	_	_	_	_	_	_	Seg=O
110	found	_	_	_	_	_	_	_	Seg=O
111	in	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	upper	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	lower	_	_	_	_	_	_	_	Seg=O
116	aerodigestive	_	_	_	_	_	_	_	Seg=O
117	tract	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	with	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	exception	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	vocal	_	_	_	_	_	_	_	Seg=O
125	folds	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	epiglottis	_	_	_	_	_	_	_	Seg=O
128	and	_	_	_	_	_	_	_	Seg=O
129	trachea	_	_	_	_	_	_	_	Seg=O
130	.	_	_	_	_	_	_	_	Seg=O
131	Finally	_	_	_	_	_	_	_	Seg=B-seg
132	,	_	_	_	_	_	_	_	Seg=O
133	activation	_	_	_	_	_	_	_	Seg=O
134	of	_	_	_	_	_	_	_	Seg=O
135	influenza	_	_	_	_	_	_	_	Seg=O
136	virus	_	_	_	_	_	_	_	Seg=O
137	was	_	_	_	_	_	_	_	Seg=O
138	conserved	_	_	_	_	_	_	_	Seg=O
139	between	_	_	_	_	_	_	_	Seg=O
140	human	_	_	_	_	_	_	_	Seg=O
141	,	_	_	_	_	_	_	_	Seg=O
142	avian	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=O
144	porcine	_	_	_	_	_	_	_	Seg=O
145	TMPRSS2	_	_	_	_	_	_	_	Seg=O
146	,	_	_	_	_	_	_	_	Seg=O
147	suggesting	_	_	_	_	_	_	_	Seg=B-seg
148	that	_	_	_	_	_	_	_	Seg=B-seg
149	this	_	_	_	_	_	_	_	Seg=O
150	protease	_	_	_	_	_	_	_	Seg=O
151	might	_	_	_	_	_	_	_	Seg=O
152	activate	_	_	_	_	_	_	_	Seg=O
153	influenza	_	_	_	_	_	_	_	Seg=O
154	virus	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	reservoir-	_	_	_	_	_	_	_	Seg=O
157	,	_	_	_	_	_	_	_	Seg=O
158	intermediate	_	_	_	_	_	_	_	Seg=O
159	-	_	_	_	_	_	_	_	Seg=O
160	and	_	_	_	_	_	_	_	Seg=O
161	human	_	_	_	_	_	_	_	Seg=O
162	hosts	_	_	_	_	_	_	_	Seg=O
163	.	_	_	_	_	_	_	_	Seg=O
164	In	_	_	_	_	_	_	_	Seg=B-seg
165	sum	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	our	_	_	_	_	_	_	_	Seg=O
168	results	_	_	_	_	_	_	_	Seg=O
169	show	_	_	_	_	_	_	_	Seg=O
170	that	_	_	_	_	_	_	_	Seg=B-seg
171	TMPRSS2	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=O
173	HAT	_	_	_	_	_	_	_	Seg=O
174	are	_	_	_	_	_	_	_	Seg=O
175	expressed	_	_	_	_	_	_	_	Seg=O
176	by	_	_	_	_	_	_	_	Seg=O
177	important	_	_	_	_	_	_	_	Seg=O
178	influenza	_	_	_	_	_	_	_	Seg=O
179	and	_	_	_	_	_	_	_	Seg=O
180	SARS	_	_	_	_	_	_	_	Seg=O
181	-	_	_	_	_	_	_	_	Seg=O
182	coronavirus	_	_	_	_	_	_	_	Seg=O
183	target	_	_	_	_	_	_	_	Seg=O
184	cells	_	_	_	_	_	_	_	Seg=O
185	and	_	_	_	_	_	_	_	Seg=B-seg
186	could	_	_	_	_	_	_	_	Seg=O
187	thus	_	_	_	_	_	_	_	Seg=O
188	support	_	_	_	_	_	_	_	Seg=O
189	viral	_	_	_	_	_	_	_	Seg=O
190	spread	_	_	_	_	_	_	_	Seg=O
191	in	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	human	_	_	_	_	_	_	_	Seg=O
194	host	_	_	_	_	_	_	_	Seg=O
195	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ba755009e5f7330a8344f1b2dd8e65d54b8488e8
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	In	_	_	_	_	_	_	_	Seg=B-seg
4	China	_	_	_	_	_	_	_	Seg=O
5	,	_	_	_	_	_	_	_	Seg=O
6	large	_	_	_	_	_	_	_	Seg=O
7	-	_	_	_	_	_	_	_	Seg=O
8	scale	_	_	_	_	_	_	_	Seg=O
9	outbreaks	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	severe	_	_	_	_	_	_	_	Seg=O
12	diarrhea	_	_	_	_	_	_	_	Seg=O
13	caused	_	_	_	_	_	_	_	Seg=B-seg
14	by	_	_	_	_	_	_	_	Seg=O
15	viruses	_	_	_	_	_	_	_	Seg=O
16	have	_	_	_	_	_	_	_	Seg=B-seg
17	occurred	_	_	_	_	_	_	_	Seg=O
18	in	_	_	_	_	_	_	_	Seg=O
19	pigs	_	_	_	_	_	_	_	Seg=O
20	since	_	_	_	_	_	_	_	Seg=O
21	late	_	_	_	_	_	_	_	Seg=O
22	2010	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	To	_	_	_	_	_	_	_	Seg=B-seg
25	investigate	_	_	_	_	_	_	_	Seg=O
26	the	_	_	_	_	_	_	_	Seg=O
27	prevalence	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	genetic	_	_	_	_	_	_	_	Seg=O
30	evolution	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	diarrhea	_	_	_	_	_	_	_	Seg=O
33	-	_	_	_	_	_	_	_	Seg=O
34	associated	_	_	_	_	_	_	_	Seg=O
35	viruses	_	_	_	_	_	_	_	Seg=O
36	responsible	_	_	_	_	_	_	_	Seg=B-seg
37	for	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	outbreaks	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	a	_	_	_	_	_	_	_	Seg=B-seg
42	total	_	_	_	_	_	_	_	Seg=O
43	of	_	_	_	_	_	_	_	Seg=O
44	2987	_	_	_	_	_	_	_	Seg=O
45	field	_	_	_	_	_	_	_	Seg=O
46	diarrheal	_	_	_	_	_	_	_	Seg=O
47	samples	_	_	_	_	_	_	_	Seg=O
48	collected	_	_	_	_	_	_	_	Seg=B-seg
49	from	_	_	_	_	_	_	_	Seg=O
50	168	_	_	_	_	_	_	_	Seg=O
51	pig	_	_	_	_	_	_	_	Seg=O
52	farms	_	_	_	_	_	_	_	Seg=O
53	in	_	_	_	_	_	_	_	Seg=O
54	five	_	_	_	_	_	_	_	Seg=O
55	provinces	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=O
57	Southern	_	_	_	_	_	_	_	Seg=O
58	China	_	_	_	_	_	_	_	Seg=O
59	during	_	_	_	_	_	_	_	Seg=O
60	2012	_	_	_	_	_	_	_	Seg=O
61	-	_	_	_	_	_	_	_	Seg=O
62	2018	_	_	_	_	_	_	_	Seg=O
63	were	_	_	_	_	_	_	_	Seg=B-seg
64	tested	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Results	_	_	_	_	_	_	_	Seg=B-seg
67	:	_	_	_	_	_	_	_	Seg=O
68	Porcine	_	_	_	_	_	_	_	Seg=B-seg
69	epidemic	_	_	_	_	_	_	_	Seg=O
70	diarrhea	_	_	_	_	_	_	_	Seg=O
71	virus	_	_	_	_	_	_	_	Seg=O
72	(	_	_	_	_	_	_	_	Seg=O
73	PEDV	_	_	_	_	_	_	_	Seg=O
74	)	_	_	_	_	_	_	_	Seg=O
75	was	_	_	_	_	_	_	_	Seg=O
76	most	_	_	_	_	_	_	_	Seg=O
77	frequently	_	_	_	_	_	_	_	Seg=O
78	detected	_	_	_	_	_	_	_	Seg=O
79	virus	_	_	_	_	_	_	_	Seg=O
80	with	_	_	_	_	_	_	_	Seg=O
81	prevalence	_	_	_	_	_	_	_	Seg=O
82	rates	_	_	_	_	_	_	_	Seg=O
83	between	_	_	_	_	_	_	_	Seg=O
84	50.21	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	62.10	_	_	_	_	_	_	_	Seg=O
87	%	_	_	_	_	_	_	_	Seg=O
88	in	_	_	_	_	_	_	_	Seg=O
89	samples	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	96.43	_	_	_	_	_	_	_	Seg=O
93	%	_	_	_	_	_	_	_	Seg=O
94	(	_	_	_	_	_	_	_	Seg=O
95	162/168	_	_	_	_	_	_	_	Seg=O
96	)	_	_	_	_	_	_	_	Seg=O
97	in	_	_	_	_	_	_	_	Seg=O
98	premises	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	respectively	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	Porcine	_	_	_	_	_	_	_	Seg=B-seg
103	deltacoronavirus	_	_	_	_	_	_	_	Seg=O
104	(	_	_	_	_	_	_	_	Seg=O
105	PDCoV	_	_	_	_	_	_	_	Seg=O
106	)	_	_	_	_	_	_	_	Seg=O
107	was	_	_	_	_	_	_	_	Seg=O
108	the	_	_	_	_	_	_	_	Seg=O
109	second	_	_	_	_	_	_	_	Seg=O
110	prevalent	_	_	_	_	_	_	_	Seg=O
111	virus	_	_	_	_	_	_	_	Seg=O
112	with	_	_	_	_	_	_	_	Seg=O
113	prevalence	_	_	_	_	_	_	_	Seg=O
114	rates	_	_	_	_	_	_	_	Seg=O
115	ranging	_	_	_	_	_	_	_	Seg=B-seg
116	from	_	_	_	_	_	_	_	Seg=O
117	19.62	_	_	_	_	_	_	_	Seg=O
118	to	_	_	_	_	_	_	_	Seg=O
119	29.19	_	_	_	_	_	_	_	Seg=O
120	%	_	_	_	_	_	_	_	Seg=O
121	in	_	_	_	_	_	_	_	Seg=O
122	samples	_	_	_	_	_	_	_	Seg=O
123	,	_	_	_	_	_	_	_	Seg=O
124	and	_	_	_	_	_	_	_	Seg=O
125	70.24	_	_	_	_	_	_	_	Seg=O
126	%	_	_	_	_	_	_	_	Seg=O
127	(	_	_	_	_	_	_	_	Seg=B-seg
128	118/168	_	_	_	_	_	_	_	Seg=O
129	)	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=B-seg
131	premises	_	_	_	_	_	_	_	Seg=O
132	,	_	_	_	_	_	_	_	Seg=O
133	respectively	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O
135	Both	_	_	_	_	_	_	_	Seg=B-seg
136	transmissible	_	_	_	_	_	_	_	Seg=O
137	gastroenteritis	_	_	_	_	_	_	_	Seg=O
138	virus	_	_	_	_	_	_	_	Seg=O
139	(	_	_	_	_	_	_	_	Seg=O
140	TGEV	_	_	_	_	_	_	_	Seg=O
141	)	_	_	_	_	_	_	_	Seg=O
142	and	_	_	_	_	_	_	_	Seg=O
143	porcine	_	_	_	_	_	_	_	Seg=O
144	rotavirus	_	_	_	_	_	_	_	Seg=O
145	(	_	_	_	_	_	_	_	Seg=O
146	PoRV	_	_	_	_	_	_	_	Seg=O
147	)	_	_	_	_	_	_	_	Seg=O
148	were	_	_	_	_	_	_	_	Seg=O
149	detected	_	_	_	_	_	_	_	Seg=O
150	at	_	_	_	_	_	_	_	Seg=O
151	low	_	_	_	_	_	_	_	Seg=O
152	prevalence	_	_	_	_	_	_	_	Seg=O
153	rates	_	_	_	_	_	_	_	Seg=O
154	of	_	_	_	_	_	_	_	Seg=O
155	<	_	_	_	_	_	_	_	Seg=O
156	3	_	_	_	_	_	_	_	Seg=O
157	%	_	_	_	_	_	_	_	Seg=O
158	in	_	_	_	_	_	_	_	Seg=O
159	samples	_	_	_	_	_	_	_	Seg=O
160	and	_	_	_	_	_	_	_	Seg=O
161	10.12	_	_	_	_	_	_	_	Seg=O
162	%	_	_	_	_	_	_	_	Seg=O
163	in	_	_	_	_	_	_	_	Seg=O
164	premises	_	_	_	_	_	_	_	Seg=O
165	.	_	_	_	_	_	_	_	Seg=O
166	In	_	_	_	_	_	_	_	Seg=B-seg
167	this	_	_	_	_	_	_	_	Seg=O
168	study	_	_	_	_	_	_	_	Seg=O
169	,	_	_	_	_	_	_	_	Seg=O
170	we	_	_	_	_	_	_	_	Seg=O
171	identified	_	_	_	_	_	_	_	Seg=O
172	a	_	_	_	_	_	_	_	Seg=O
173	newly	_	_	_	_	_	_	_	Seg=O
174	emerged	_	_	_	_	_	_	_	Seg=O
175	swine	_	_	_	_	_	_	_	Seg=O
176	acute	_	_	_	_	_	_	_	Seg=O
177	diarrhea	_	_	_	_	_	_	_	Seg=O
178	syndrome	_	_	_	_	_	_	_	Seg=O
179	coronavirus	_	_	_	_	_	_	_	Seg=O
180	(	_	_	_	_	_	_	_	Seg=O
181	SADS	_	_	_	_	_	_	_	Seg=O
182	-	_	_	_	_	_	_	_	Seg=O
183	CoV	_	_	_	_	_	_	_	Seg=O
184	)	_	_	_	_	_	_	_	Seg=O
185	in	_	_	_	_	_	_	_	Seg=O
186	diarrheal	_	_	_	_	_	_	_	Seg=O
187	samples	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	piglets	_	_	_	_	_	_	_	Seg=O
190	from	_	_	_	_	_	_	_	Seg=O
191	Fujian	_	_	_	_	_	_	_	Seg=O
192	province	_	_	_	_	_	_	_	Seg=O
193	in	_	_	_	_	_	_	_	Seg=O
194	Southern	_	_	_	_	_	_	_	Seg=O
195	China	_	_	_	_	_	_	_	Seg=O
196	,	_	_	_	_	_	_	_	Seg=O
197	and	_	_	_	_	_	_	_	Seg=B-seg
198	the	_	_	_	_	_	_	_	Seg=O
199	prevalence	_	_	_	_	_	_	_	Seg=O
200	rate	_	_	_	_	_	_	_	Seg=O
201	of	_	_	_	_	_	_	_	Seg=O
202	SADS	_	_	_	_	_	_	_	Seg=O
203	-	_	_	_	_	_	_	_	Seg=O
204	CoV	_	_	_	_	_	_	_	Seg=O
205	was	_	_	_	_	_	_	_	Seg=O
206	10.29	_	_	_	_	_	_	_	Seg=O
207	%	_	_	_	_	_	_	_	Seg=O
208	(	_	_	_	_	_	_	_	Seg=B-seg
209	7/68	_	_	_	_	_	_	_	Seg=O
210	)	_	_	_	_	_	_	_	Seg=O
211	.	_	_	_	_	_	_	_	Seg=O
212	Co	_	_	_	_	_	_	_	Seg=B-seg
213	-	_	_	_	_	_	_	_	Seg=O
214	infections	_	_	_	_	_	_	_	Seg=O
215	of	_	_	_	_	_	_	_	Seg=O
216	these	_	_	_	_	_	_	_	Seg=O
217	diarrhea	_	_	_	_	_	_	_	Seg=O
218	-	_	_	_	_	_	_	_	Seg=O
219	associated	_	_	_	_	_	_	_	Seg=O
220	viruses	_	_	_	_	_	_	_	Seg=O
221	were	_	_	_	_	_	_	_	Seg=O
222	common	_	_	_	_	_	_	_	Seg=O
223	.	_	_	_	_	_	_	_	Seg=O
224	The	_	_	_	_	_	_	_	Seg=B-seg
225	most	_	_	_	_	_	_	_	Seg=O
226	frequent	_	_	_	_	_	_	_	Seg=O
227	co	_	_	_	_	_	_	_	Seg=O
228	-	_	_	_	_	_	_	_	Seg=O
229	infection	_	_	_	_	_	_	_	Seg=O
230	was	_	_	_	_	_	_	_	Seg=O
231	PEDV	_	_	_	_	_	_	_	Seg=O
232	with	_	_	_	_	_	_	_	Seg=O
233	PDCoV	_	_	_	_	_	_	_	Seg=O
234	,	_	_	_	_	_	_	_	Seg=O
235	with	_	_	_	_	_	_	_	Seg=O
236	an	_	_	_	_	_	_	_	Seg=O
237	average	_	_	_	_	_	_	_	Seg=O
238	detection	_	_	_	_	_	_	_	Seg=O
239	rate	_	_	_	_	_	_	_	Seg=O
240	of	_	_	_	_	_	_	_	Seg=O
241	12.72	_	_	_	_	_	_	_	Seg=O
242	%	_	_	_	_	_	_	_	Seg=O
243	(	_	_	_	_	_	_	_	Seg=B-seg
244	380/2987	_	_	_	_	_	_	_	Seg=O
245	,	_	_	_	_	_	_	_	Seg=O
246	ranging	_	_	_	_	_	_	_	Seg=O
247	from	_	_	_	_	_	_	_	Seg=O
248	8.26	_	_	_	_	_	_	_	Seg=O
249	-	_	_	_	_	_	_	_	Seg=O
250	17.33	_	_	_	_	_	_	_	Seg=O
251	%	_	_	_	_	_	_	_	Seg=O
252	)	_	_	_	_	_	_	_	Seg=O
253	.	_	_	_	_	_	_	_	Seg=O
254	Phylogenetic	_	_	_	_	_	_	_	Seg=B-seg
255	analysis	_	_	_	_	_	_	_	Seg=O
256	revealed	_	_	_	_	_	_	_	Seg=O
257	that	_	_	_	_	_	_	_	Seg=B-seg
258	PEDVs	_	_	_	_	_	_	_	Seg=O
259	circulating	_	_	_	_	_	_	_	Seg=B-seg
260	in	_	_	_	_	_	_	_	Seg=O
261	Southern	_	_	_	_	_	_	_	Seg=O
262	China	_	_	_	_	_	_	_	Seg=O
263	during	_	_	_	_	_	_	_	Seg=O
264	the	_	_	_	_	_	_	_	Seg=O
265	last	_	_	_	_	_	_	_	Seg=O
266	7	_	_	_	_	_	_	_	Seg=O
267	years	_	_	_	_	_	_	_	Seg=O
268	were	_	_	_	_	_	_	_	Seg=B-seg
269	clustered	_	_	_	_	_	_	_	Seg=O
270	with	_	_	_	_	_	_	_	Seg=O
271	the	_	_	_	_	_	_	_	Seg=O
272	variant	_	_	_	_	_	_	_	Seg=O
273	strains	_	_	_	_	_	_	_	Seg=O
274	of	_	_	_	_	_	_	_	Seg=O
275	PEDV	_	_	_	_	_	_	_	Seg=O
276	in	_	_	_	_	_	_	_	Seg=O
277	genotype	_	_	_	_	_	_	_	Seg=O
278	IIa	_	_	_	_	_	_	_	Seg=O
279	.	_	_	_	_	_	_	_	Seg=O
280	The	_	_	_	_	_	_	_	Seg=B-seg
281	most	_	_	_	_	_	_	_	Seg=O
282	frequent	_	_	_	_	_	_	_	Seg=O
283	mutations	_	_	_	_	_	_	_	Seg=O
284	were	_	_	_	_	_	_	_	Seg=O
285	present	_	_	_	_	_	_	_	Seg=O
286	in	_	_	_	_	_	_	_	Seg=O
287	the	_	_	_	_	_	_	_	Seg=O
288	collagenase	_	_	_	_	_	_	_	Seg=O
289	equivalent	_	_	_	_	_	_	_	Seg=O
290	(	_	_	_	_	_	_	_	Seg=O
291	COE	_	_	_	_	_	_	_	Seg=O
292	)	_	_	_	_	_	_	_	Seg=O
293	and	_	_	_	_	_	_	_	Seg=O
294	epitope	_	_	_	_	_	_	_	Seg=O
295	regions	_	_	_	_	_	_	_	Seg=O
296	of	_	_	_	_	_	_	_	Seg=O
297	the	_	_	_	_	_	_	_	Seg=O
298	spike	_	_	_	_	_	_	_	Seg=O
299	gene	_	_	_	_	_	_	_	Seg=O
300	of	_	_	_	_	_	_	_	Seg=O
301	the	_	_	_	_	_	_	_	Seg=O
302	PEDVs	_	_	_	_	_	_	_	Seg=O
303	currently	_	_	_	_	_	_	_	Seg=B-seg
304	circulating	_	_	_	_	_	_	_	Seg=O
305	in	_	_	_	_	_	_	_	Seg=O
306	the	_	_	_	_	_	_	_	Seg=O
307	field	_	_	_	_	_	_	_	Seg=O
308	.	_	_	_	_	_	_	_	Seg=O
309	Genetic	_	_	_	_	_	_	_	Seg=B-seg
310	relationships	_	_	_	_	_	_	_	Seg=O
311	of	_	_	_	_	_	_	_	Seg=O
312	PDCoVs	_	_	_	_	_	_	_	Seg=O
313	were	_	_	_	_	_	_	_	Seg=O
314	closely	_	_	_	_	_	_	_	Seg=O
315	related	_	_	_	_	_	_	_	Seg=O
316	with	_	_	_	_	_	_	_	Seg=O
317	Chinese	_	_	_	_	_	_	_	Seg=O
318	strains	_	_	_	_	_	_	_	Seg=O
319	,	_	_	_	_	_	_	_	Seg=O
320	other	_	_	_	_	_	_	_	Seg=O
321	than	_	_	_	_	_	_	_	Seg=O
322	those	_	_	_	_	_	_	_	Seg=O
323	present	_	_	_	_	_	_	_	Seg=O
324	in	_	_	_	_	_	_	_	Seg=O
325	the	_	_	_	_	_	_	_	Seg=O
326	USA	_	_	_	_	_	_	_	Seg=O
327	,	_	_	_	_	_	_	_	Seg=O
328	South	_	_	_	_	_	_	_	Seg=O
329	Korea	_	_	_	_	_	_	_	Seg=O
330	,	_	_	_	_	_	_	_	Seg=O
331	Thailand	_	_	_	_	_	_	_	Seg=O
332	and	_	_	_	_	_	_	_	Seg=O
333-334	Lao's	_	_	_	_	_	_	_	_
333	Lao	_	_	_	_	_	_	_	Seg=O
334	's	_	_	_	_	_	_	_	Seg=O
335	public	_	_	_	_	_	_	_	Seg=O
336	.	_	_	_	_	_	_	_	Seg=O
337	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
338	:	_	_	_	_	_	_	_	Seg=O
339	The	_	_	_	_	_	_	_	Seg=B-seg
340	findings	_	_	_	_	_	_	_	Seg=O
341	of	_	_	_	_	_	_	_	Seg=O
342	this	_	_	_	_	_	_	_	Seg=O
343	study	_	_	_	_	_	_	_	Seg=O
344	indicated	_	_	_	_	_	_	_	Seg=O
345	that	_	_	_	_	_	_	_	Seg=B-seg
346	variant	_	_	_	_	_	_	_	Seg=O
347	PEDV	_	_	_	_	_	_	_	Seg=O
348	,	_	_	_	_	_	_	_	Seg=O
349	PDCoV	_	_	_	_	_	_	_	Seg=O
350	,	_	_	_	_	_	_	_	Seg=O
351	and	_	_	_	_	_	_	_	Seg=O
352	SADS	_	_	_	_	_	_	_	Seg=O
353	-	_	_	_	_	_	_	_	Seg=O
354	CoV	_	_	_	_	_	_	_	Seg=O
355	were	_	_	_	_	_	_	_	Seg=O
356	leading	_	_	_	_	_	_	_	Seg=O
357	etiologic	_	_	_	_	_	_	_	Seg=O
358	agents	_	_	_	_	_	_	_	Seg=O
359	of	_	_	_	_	_	_	_	Seg=O
360	porcine	_	_	_	_	_	_	_	Seg=O
361	diarrhea	_	_	_	_	_	_	_	Seg=O
362	,	_	_	_	_	_	_	_	Seg=O
363	and	_	_	_	_	_	_	_	Seg=B-seg
364	either	_	_	_	_	_	_	_	Seg=O
365	mono	_	_	_	_	_	_	_	Seg=O
366	-	_	_	_	_	_	_	_	Seg=O
367	infections	_	_	_	_	_	_	_	Seg=O
368	or	_	_	_	_	_	_	_	Seg=O
369	co	_	_	_	_	_	_	_	Seg=O
370	-	_	_	_	_	_	_	_	Seg=O
371	infections	_	_	_	_	_	_	_	Seg=O
372	of	_	_	_	_	_	_	_	Seg=O
373	pathogenic	_	_	_	_	_	_	_	Seg=O
374	enteric	_	_	_	_	_	_	_	Seg=O
375	CoVs	_	_	_	_	_	_	_	Seg=O
376	were	_	_	_	_	_	_	_	Seg=O
377	common	_	_	_	_	_	_	_	Seg=O
378	in	_	_	_	_	_	_	_	Seg=O
379	pigs	_	_	_	_	_	_	_	Seg=O
380	in	_	_	_	_	_	_	_	Seg=O
381	Southern	_	_	_	_	_	_	_	Seg=O
382	China	_	_	_	_	_	_	_	Seg=O
383	during	_	_	_	_	_	_	_	Seg=O
384	2012	_	_	_	_	_	_	_	Seg=O
385	-	_	_	_	_	_	_	_	Seg=O
386	2018	_	_	_	_	_	_	_	Seg=O
387	.	_	_	_	_	_	_	_	Seg=O
388	Thus	_	_	_	_	_	_	_	Seg=B-seg
389	,	_	_	_	_	_	_	_	Seg=O
390	significant	_	_	_	_	_	_	_	Seg=O
391	attention	_	_	_	_	_	_	_	Seg=O
392	should	_	_	_	_	_	_	_	Seg=O
393	be	_	_	_	_	_	_	_	Seg=O
394	paid	_	_	_	_	_	_	_	Seg=O
395	in	_	_	_	_	_	_	_	Seg=B-seg
396	order	_	_	_	_	_	_	_	Seg=O
397	to	_	_	_	_	_	_	_	Seg=O
398	effectively	_	_	_	_	_	_	_	Seg=O
399	prevent	_	_	_	_	_	_	_	Seg=O
400	and	_	_	_	_	_	_	_	Seg=O
401	control	_	_	_	_	_	_	_	Seg=O
402	porcine	_	_	_	_	_	_	_	Seg=O
403	viral	_	_	_	_	_	_	_	Seg=O
404	diarrhea	_	_	_	_	_	_	_	Seg=O
405	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = bab3d2a212eaf7740a45ee8efeec3db99bf94589
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	classical	_	_	_	_	_	_	_	Seg=O
3	symptoms	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	porcine	_	_	_	_	_	_	_	Seg=O
6	epidemic	_	_	_	_	_	_	_	Seg=O
7	diarrhea	_	_	_	_	_	_	_	Seg=O
8	(	_	_	_	_	_	_	_	Seg=O
9	PED	_	_	_	_	_	_	_	Seg=O
10	)	_	_	_	_	_	_	_	Seg=O
11	are	_	_	_	_	_	_	_	Seg=O
12	acute	_	_	_	_	_	_	_	Seg=O
13	diarrhea	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=O
15	dehydration	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	The	_	_	_	_	_	_	_	Seg=B-seg
18	isolated	_	_	_	_	_	_	_	Seg=O
19	porcine	_	_	_	_	_	_	_	Seg=O
20	epidemic	_	_	_	_	_	_	_	Seg=O
21	diarrhea	_	_	_	_	_	_	_	Seg=O
22	virus	_	_	_	_	_	_	_	Seg=O
23	(	_	_	_	_	_	_	_	Seg=O
24	PEDV	_	_	_	_	_	_	_	Seg=O
25	)	_	_	_	_	_	_	_	Seg=O
26	CH	_	_	_	_	_	_	_	Seg=O
27	/	_	_	_	_	_	_	_	Seg=O
28	GDGZ/2012	_	_	_	_	_	_	_	Seg=O
29	strain	_	_	_	_	_	_	_	Seg=O
30	was	_	_	_	_	_	_	_	Seg=O
31	obtained	_	_	_	_	_	_	_	Seg=O
32	from	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	feces	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	diseased	_	_	_	_	_	_	_	Seg=O
37	pigs	_	_	_	_	_	_	_	Seg=O
38	in	_	_	_	_	_	_	_	Seg=O
39	2012	_	_	_	_	_	_	_	Seg=O
40	in	_	_	_	_	_	_	_	Seg=O
41	southern	_	_	_	_	_	_	_	Seg=O
42	China	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	We	_	_	_	_	_	_	_	Seg=B-seg
45	report	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	complete	_	_	_	_	_	_	_	Seg=O
48	genome	_	_	_	_	_	_	_	Seg=O
49	sequence	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	strain	_	_	_	_	_	_	_	Seg=O
52	CH	_	_	_	_	_	_	_	Seg=O
53	/	_	_	_	_	_	_	_	Seg=O
54	GDGZ/2012	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	which	_	_	_	_	_	_	_	Seg=B-seg
57	might	_	_	_	_	_	_	_	Seg=O
58	be	_	_	_	_	_	_	_	Seg=O
59	useful	_	_	_	_	_	_	_	Seg=O
60	for	_	_	_	_	_	_	_	Seg=O
61	better	_	_	_	_	_	_	_	Seg=O
62	understanding	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	molecular	_	_	_	_	_	_	_	Seg=O
65	characteristics	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	this	_	_	_	_	_	_	_	Seg=O
68	virus	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = bcbee2c092b43738b2504034db8246acb059d4c5
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	Tanzania	_	_	_	_	_	_	_	Seg=O
3	,	_	_	_	_	_	_	_	Seg=O
4	Unprecedented	_	_	_	_	_	_	_	Seg=O
5	measures	_	_	_	_	_	_	_	Seg=O
6	have	_	_	_	_	_	_	_	Seg=O
7	been	_	_	_	_	_	_	_	Seg=O
8	adopted	_	_	_	_	_	_	_	Seg=O
9	to	_	_	_	_	_	_	_	Seg=B-seg
10	control	_	_	_	_	_	_	_	Seg=O
11	the	_	_	_	_	_	_	_	Seg=O
12	rapid	_	_	_	_	_	_	_	Seg=O
13	spread	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	ongoing	_	_	_	_	_	_	_	Seg=O
17	COVID-19	_	_	_	_	_	_	_	Seg=O
18	epidemic	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	Residents	_	_	_	_	_	_	_	Seg=B-seg
21	adherence	_	_	_	_	_	_	_	Seg=O
22	to	_	_	_	_	_	_	_	Seg=O
23	control	_	_	_	_	_	_	_	Seg=O
24	measures	_	_	_	_	_	_	_	Seg=O
25	is	_	_	_	_	_	_	_	Seg=O
26	affected	_	_	_	_	_	_	_	Seg=O
27	by	_	_	_	_	_	_	_	Seg=O
28	their	_	_	_	_	_	_	_	Seg=O
29	knowledge	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	attitudes	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	practices	_	_	_	_	_	_	_	Seg=O
35	(	_	_	_	_	_	_	_	Seg=O
36	KAP	_	_	_	_	_	_	_	Seg=O
37	)	_	_	_	_	_	_	_	Seg=O
38	towards	_	_	_	_	_	_	_	Seg=O
39	COVID-19	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	In	_	_	_	_	_	_	_	Seg=B-seg
42	this	_	_	_	_	_	_	_	Seg=O
43	study	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	we	_	_	_	_	_	_	_	Seg=O
46	investigated	_	_	_	_	_	_	_	Seg=O
47	Tanzanian	_	_	_	_	_	_	_	Seg=O
48-49	residents'	_	_	_	_	_	_	_	_
48	residents	_	_	_	_	_	_	_	Seg=O
49	'	_	_	_	_	_	_	_	Seg=O
50	KAP	_	_	_	_	_	_	_	Seg=O
51	towards	_	_	_	_	_	_	_	Seg=O
52	COVID-19	_	_	_	_	_	_	_	Seg=O
53	during	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	rapid	_	_	_	_	_	_	_	Seg=O
56	rise	_	_	_	_	_	_	_	Seg=O
57	period	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	the	_	_	_	_	_	_	_	Seg=O
60	outbreak	_	_	_	_	_	_	_	Seg=O
61	.	_	_	_	_	_	_	_	Seg=O
62	This	_	_	_	_	_	_	_	Seg=B-seg
63	was	_	_	_	_	_	_	_	Seg=O
64	a	_	_	_	_	_	_	_	Seg=O
65	cross	_	_	_	_	_	_	_	Seg=O
66	sectional	_	_	_	_	_	_	_	Seg=O
67	study	_	_	_	_	_	_	_	Seg=O
68	that	_	_	_	_	_	_	_	Seg=B-seg
69	involved	_	_	_	_	_	_	_	Seg=O
70	sample	_	_	_	_	_	_	_	Seg=O
71	of	_	_	_	_	_	_	_	Seg=O
72	online	_	_	_	_	_	_	_	Seg=O
73	Tanzanian	_	_	_	_	_	_	_	Seg=O
74	residents	_	_	_	_	_	_	_	Seg=O
75	who	_	_	_	_	_	_	_	Seg=B-seg
76	was	_	_	_	_	_	_	_	Seg=O
77	recruited	_	_	_	_	_	_	_	Seg=O
78	via	_	_	_	_	_	_	_	Seg=O
79	authors	_	_	_	_	_	_	_	Seg=O
80	networks	_	_	_	_	_	_	_	Seg=O
81	with	_	_	_	_	_	_	_	Seg=O
82	residents	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	social	_	_	_	_	_	_	_	Seg=O
85	media	_	_	_	_	_	_	_	Seg=O
86	.	_	_	_	_	_	_	_	Seg=O
87	A	_	_	_	_	_	_	_	Seg=B-seg
88	self	_	_	_	_	_	_	_	Seg=O
89	-	_	_	_	_	_	_	_	Seg=O
90	developed	_	_	_	_	_	_	_	Seg=O
91	online	_	_	_	_	_	_	_	Seg=O
92	KAP	_	_	_	_	_	_	_	Seg=O
93	questionnaire	_	_	_	_	_	_	_	Seg=O
94	using	_	_	_	_	_	_	_	Seg=B-seg
95	Survey	_	_	_	_	_	_	_	Seg=O
96	Monkey	_	_	_	_	_	_	_	Seg=O
97	tool	_	_	_	_	_	_	_	Seg=O
98	was	_	_	_	_	_	_	_	Seg=B-seg
99	used	_	_	_	_	_	_	_	Seg=O
100	to	_	_	_	_	_	_	_	Seg=B-seg
101	collect	_	_	_	_	_	_	_	Seg=O
102	data	_	_	_	_	_	_	_	Seg=O
103	from	_	_	_	_	_	_	_	Seg=O
104	participants	_	_	_	_	_	_	_	Seg=O
105	.	_	_	_	_	_	_	_	Seg=O
106	The	_	_	_	_	_	_	_	Seg=B-seg
107	questionnaire	_	_	_	_	_	_	_	Seg=O
108	assessed	_	_	_	_	_	_	_	Seg=O
109	demographic	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=B-seg
111	had	_	_	_	_	_	_	_	Seg=O
112	12	_	_	_	_	_	_	_	Seg=O
113	questions	_	_	_	_	_	_	_	Seg=O
114	on	_	_	_	_	_	_	_	Seg=O
115	COVID	_	_	_	_	_	_	_	Seg=O
116	Knowledge	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	5	_	_	_	_	_	_	_	Seg=O
119	questions	_	_	_	_	_	_	_	Seg=O
120	on	_	_	_	_	_	_	_	Seg=O
121	attitude	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	practice	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	Descriptive	_	_	_	_	_	_	_	Seg=B-seg
126	and	_	_	_	_	_	_	_	Seg=O
127	inferential	_	_	_	_	_	_	_	Seg=O
128	analysis	_	_	_	_	_	_	_	Seg=O
129	was	_	_	_	_	_	_	_	Seg=O
130	carried	_	_	_	_	_	_	_	Seg=O
131	out	_	_	_	_	_	_	_	Seg=O
132	using	_	_	_	_	_	_	_	Seg=B-seg
133	SPSS	_	_	_	_	_	_	_	Seg=O
134	17	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	Four	_	_	_	_	_	_	_	Seg=B-seg
137	hundred	_	_	_	_	_	_	_	Seg=O
138	residents	_	_	_	_	_	_	_	Seg=O
139	completed	_	_	_	_	_	_	_	Seg=O
140	a	_	_	_	_	_	_	_	Seg=O
141	survey	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	The	_	_	_	_	_	_	_	Seg=B-seg
144	mean	_	_	_	_	_	_	_	Seg=O
145	age	_	_	_	_	_	_	_	Seg=O
146	of	_	_	_	_	_	_	_	Seg=O
147	study	_	_	_	_	_	_	_	Seg=O
148	participants	_	_	_	_	_	_	_	Seg=O
149	was	_	_	_	_	_	_	_	Seg=O
150	28	_	_	_	_	_	_	_	Seg=O
151	years	_	_	_	_	_	_	_	Seg=O
152	,	_	_	_	_	_	_	_	Seg=O
153	and	_	_	_	_	_	_	_	Seg=B-seg
154	majorities	_	_	_	_	_	_	_	Seg=O
155	were	_	_	_	_	_	_	_	Seg=O
156	females	_	_	_	_	_	_	_	Seg=O
157	216	_	_	_	_	_	_	_	Seg=O
158	(	_	_	_	_	_	_	_	Seg=B-seg
159	54.0	_	_	_	_	_	_	_	Seg=O
160	%	_	_	_	_	_	_	_	Seg=O
161	)	_	_	_	_	_	_	_	Seg=O
162	.	_	_	_	_	_	_	_	Seg=O
163	There	_	_	_	_	_	_	_	Seg=B-seg
164	were	_	_	_	_	_	_	_	Seg=O
165	no	_	_	_	_	_	_	_	Seg=O
166	significant	_	_	_	_	_	_	_	Seg=O
167	different	_	_	_	_	_	_	_	Seg=O
168	in	_	_	_	_	_	_	_	Seg=O
169	relation	_	_	_	_	_	_	_	Seg=O
170	to	_	_	_	_	_	_	_	Seg=O
171	demographic	_	_	_	_	_	_	_	Seg=O
172	variables	_	_	_	_	_	_	_	Seg=O
173	(	_	_	_	_	_	_	_	Seg=B-seg
174	p>0.3	_	_	_	_	_	_	_	Seg=O
175	)	_	_	_	_	_	_	_	Seg=O
176	.	_	_	_	_	_	_	_	Seg=O
177	Those	_	_	_	_	_	_	_	Seg=B-seg
178	who	_	_	_	_	_	_	_	Seg=O
179	held	_	_	_	_	_	_	_	Seg=O
180	a	_	_	_	_	_	_	_	Seg=O
181	bachelor	_	_	_	_	_	_	_	Seg=O
182	degree	_	_	_	_	_	_	_	Seg=O
183	or	_	_	_	_	_	_	_	Seg=O
184	above	_	_	_	_	_	_	_	Seg=O
185	(	_	_	_	_	_	_	_	Seg=B-seg
186	60.3	_	_	_	_	_	_	_	Seg=O
187	%	_	_	_	_	_	_	_	Seg=O
188	)	_	_	_	_	_	_	_	Seg=O
189	had	_	_	_	_	_	_	_	Seg=B-seg
190	more	_	_	_	_	_	_	_	Seg=O
191	correct	_	_	_	_	_	_	_	Seg=O
192	score	_	_	_	_	_	_	_	Seg=O
193	.	_	_	_	_	_	_	_	Seg=O
194	The	_	_	_	_	_	_	_	Seg=B-seg
195	overall	_	_	_	_	_	_	_	Seg=O
196	,	_	_	_	_	_	_	_	Seg=O
197	(	_	_	_	_	_	_	_	Seg=O
198	84.4	_	_	_	_	_	_	_	Seg=O
199	%	_	_	_	_	_	_	_	Seg=O
200	)	_	_	_	_	_	_	_	Seg=O
201	of	_	_	_	_	_	_	_	Seg=O
202	participants	_	_	_	_	_	_	_	Seg=O
203	had	_	_	_	_	_	_	_	Seg=O
204	good	_	_	_	_	_	_	_	Seg=O
205	knowledge	_	_	_	_	_	_	_	Seg=O
206	level	_	_	_	_	_	_	_	Seg=O
207	and	_	_	_	_	_	_	_	Seg=B-seg
208	the	_	_	_	_	_	_	_	Seg=O
209	good	_	_	_	_	_	_	_	Seg=O
210	knowledge	_	_	_	_	_	_	_	Seg=O
211	was	_	_	_	_	_	_	_	Seg=O
212	associated	_	_	_	_	_	_	_	Seg=O
213	with	_	_	_	_	_	_	_	Seg=O
214	education	_	_	_	_	_	_	_	Seg=O
215	level	_	_	_	_	_	_	_	Seg=O
216	(	_	_	_	_	_	_	_	Seg=B-seg
217	p=0.001	_	_	_	_	_	_	_	Seg=O
218	)	_	_	_	_	_	_	_	Seg=O
219	.	_	_	_	_	_	_	_	Seg=O
220	Nearly	_	_	_	_	_	_	_	Seg=B-seg
221	all	_	_	_	_	_	_	_	Seg=O
222	of	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	participants	_	_	_	_	_	_	_	Seg=O
225	(	_	_	_	_	_	_	_	Seg=B-seg
226	96.0	_	_	_	_	_	_	_	Seg=O
227	%	_	_	_	_	_	_	_	Seg=O
228	)	_	_	_	_	_	_	_	Seg=O
229	had	_	_	_	_	_	_	_	Seg=B-seg
230	confidence	_	_	_	_	_	_	_	Seg=O
231	that	_	_	_	_	_	_	_	Seg=B-seg
232	Tanzania	_	_	_	_	_	_	_	Seg=O
233	can	_	_	_	_	_	_	_	Seg=O
234	win	_	_	_	_	_	_	_	Seg=O
235	the	_	_	_	_	_	_	_	Seg=O
236	battle	_	_	_	_	_	_	_	Seg=O
237	against	_	_	_	_	_	_	_	Seg=O
238	COVID-19	_	_	_	_	_	_	_	Seg=O
239	.	_	_	_	_	_	_	_	Seg=O
240	:	_	_	_	_	_	_	_	Seg=B-seg
241	medRxiv	_	_	_	_	_	_	_	Seg=O
242	preprint	_	_	_	_	_	_	_	Seg=O
243	2	_	_	_	_	_	_	_	Seg=O
244	The	_	_	_	_	_	_	_	Seg=B-seg
245	majority	_	_	_	_	_	_	_	Seg=O
246	of	_	_	_	_	_	_	_	Seg=O
247	the	_	_	_	_	_	_	_	Seg=O
248	respondents	_	_	_	_	_	_	_	Seg=O
249	(	_	_	_	_	_	_	_	Seg=B-seg
250	77	_	_	_	_	_	_	_	Seg=O
251	%	_	_	_	_	_	_	_	Seg=O
252	)	_	_	_	_	_	_	_	Seg=O
253	did	_	_	_	_	_	_	_	Seg=B-seg
254	not	_	_	_	_	_	_	_	Seg=O
255	do	_	_	_	_	_	_	_	Seg=O
256	to	_	_	_	_	_	_	_	Seg=O
257	the	_	_	_	_	_	_	_	Seg=O
258	crowded	_	_	_	_	_	_	_	Seg=O
259	place	_	_	_	_	_	_	_	Seg=O
260	in	_	_	_	_	_	_	_	Seg=O
261	recent	_	_	_	_	_	_	_	Seg=O
262	says	_	_	_	_	_	_	_	Seg=O
263	.	_	_	_	_	_	_	_	Seg=O
264	Multiple	_	_	_	_	_	_	_	Seg=B-seg
265	linear	_	_	_	_	_	_	_	Seg=O
266	regression	_	_	_	_	_	_	_	Seg=O
267	analysis	_	_	_	_	_	_	_	Seg=O
268	showed	_	_	_	_	_	_	_	Seg=O
269	that	_	_	_	_	_	_	_	Seg=B-seg
270	male	_	_	_	_	_	_	_	Seg=O
271	gender	_	_	_	_	_	_	_	Seg=O
272	,	_	_	_	_	_	_	_	Seg=O
273	age	_	_	_	_	_	_	_	Seg=O
274	-	_	_	_	_	_	_	_	Seg=O
275	group	_	_	_	_	_	_	_	Seg=O
276	of	_	_	_	_	_	_	_	Seg=O
277	16	_	_	_	_	_	_	_	Seg=O
278	-	_	_	_	_	_	_	_	Seg=O
279	29	_	_	_	_	_	_	_	Seg=O
280	years	_	_	_	_	_	_	_	Seg=O
281	and	_	_	_	_	_	_	_	Seg=O
282	education	_	_	_	_	_	_	_	Seg=O
283	of	_	_	_	_	_	_	_	Seg=O
284	secondary	_	_	_	_	_	_	_	Seg=O
285	or	_	_	_	_	_	_	_	Seg=O
286	lower	_	_	_	_	_	_	_	Seg=O
287	were	_	_	_	_	_	_	_	Seg=O
288	significantly	_	_	_	_	_	_	_	Seg=O
289	associated	_	_	_	_	_	_	_	Seg=O
290	with	_	_	_	_	_	_	_	Seg=O
291	lower	_	_	_	_	_	_	_	Seg=O
292	knowledge	_	_	_	_	_	_	_	Seg=O
293	score	_	_	_	_	_	_	_	Seg=O
294	.	_	_	_	_	_	_	_	Seg=O
295	Our	_	_	_	_	_	_	_	Seg=B-seg
296	findings	_	_	_	_	_	_	_	Seg=O
297	suggest	_	_	_	_	_	_	_	Seg=O
298	that	_	_	_	_	_	_	_	Seg=B-seg
299	residents	_	_	_	_	_	_	_	Seg=O
300	of	_	_	_	_	_	_	_	Seg=O
301	a	_	_	_	_	_	_	_	Seg=O
302	relatively	_	_	_	_	_	_	_	Seg=O
303	high	_	_	_	_	_	_	_	Seg=O
304	level	_	_	_	_	_	_	_	Seg=O
305	of	_	_	_	_	_	_	_	Seg=O
306	socioeconomic	_	_	_	_	_	_	_	Seg=O
307	status	_	_	_	_	_	_	_	Seg=O
308	,	_	_	_	_	_	_	_	Seg=O
309	have	_	_	_	_	_	_	_	Seg=O
310	had	_	_	_	_	_	_	_	Seg=O
311	good	_	_	_	_	_	_	_	Seg=O
312	knowledge	_	_	_	_	_	_	_	Seg=O
313	,	_	_	_	_	_	_	_	Seg=O
314	optimistic	_	_	_	_	_	_	_	Seg=O
315	attitudes	_	_	_	_	_	_	_	Seg=O
316	,	_	_	_	_	_	_	_	Seg=O
317	and	_	_	_	_	_	_	_	Seg=O
318	appropriate	_	_	_	_	_	_	_	Seg=O
319	practices	_	_	_	_	_	_	_	Seg=O
320	towards	_	_	_	_	_	_	_	Seg=O
321	COVID-19	_	_	_	_	_	_	_	Seg=O
322	during	_	_	_	_	_	_	_	Seg=O
323	the	_	_	_	_	_	_	_	Seg=O
324	rapid	_	_	_	_	_	_	_	Seg=O
325	rise	_	_	_	_	_	_	_	Seg=O
326	period	_	_	_	_	_	_	_	Seg=O
327	of	_	_	_	_	_	_	_	Seg=O
328	the	_	_	_	_	_	_	_	Seg=O
329	COVID-19	_	_	_	_	_	_	_	Seg=O
330	outbreak	_	_	_	_	_	_	_	Seg=O
331	.	_	_	_	_	_	_	_	Seg=O
332	Suggesting	_	_	_	_	_	_	_	Seg=B-seg
333	that	_	_	_	_	_	_	_	Seg=B-seg
334	health	_	_	_	_	_	_	_	Seg=O
335	education	_	_	_	_	_	_	_	Seg=O
336	programs	_	_	_	_	_	_	_	Seg=O
337	aimed	_	_	_	_	_	_	_	Seg=B-seg
338	at	_	_	_	_	_	_	_	Seg=O
339	improving	_	_	_	_	_	_	_	Seg=O
340	COVID-19	_	_	_	_	_	_	_	Seg=O
341	knowledge	_	_	_	_	_	_	_	Seg=O
342	are	_	_	_	_	_	_	_	Seg=B-seg
343	helpful	_	_	_	_	_	_	_	Seg=O
344	for	_	_	_	_	_	_	_	Seg=O
345	encouraging	_	_	_	_	_	_	_	Seg=O
346	an	_	_	_	_	_	_	_	Seg=O
347	optimistic	_	_	_	_	_	_	_	Seg=O
348	attitudes	_	_	_	_	_	_	_	Seg=O
349	and	_	_	_	_	_	_	_	Seg=O
350	maintaining	_	_	_	_	_	_	_	Seg=O
351	safe	_	_	_	_	_	_	_	Seg=O
352	practices	_	_	_	_	_	_	_	Seg=O
353	.	_	_	_	_	_	_	_	Seg=O
354	Due	_	_	_	_	_	_	_	Seg=B-seg
355	to	_	_	_	_	_	_	_	Seg=O
356	the	_	_	_	_	_	_	_	Seg=O
357	limitation	_	_	_	_	_	_	_	Seg=O
358	in	_	_	_	_	_	_	_	Seg=O
359	representativeness	_	_	_	_	_	_	_	Seg=O
360	of	_	_	_	_	_	_	_	Seg=O
361	the	_	_	_	_	_	_	_	Seg=O
362	sample	_	_	_	_	_	_	_	Seg=O
363	,	_	_	_	_	_	_	_	Seg=O
364	more	_	_	_	_	_	_	_	Seg=B-seg
365	studies	_	_	_	_	_	_	_	Seg=O
366	are	_	_	_	_	_	_	_	Seg=O
367	warranted	_	_	_	_	_	_	_	Seg=O
368	to	_	_	_	_	_	_	_	Seg=B-seg
369	investigate	_	_	_	_	_	_	_	Seg=O
370	the	_	_	_	_	_	_	_	Seg=O
371	KAP	_	_	_	_	_	_	_	Seg=O
372	towards	_	_	_	_	_	_	_	Seg=O
373	COVID-19	_	_	_	_	_	_	_	Seg=O
374	among	_	_	_	_	_	_	_	Seg=O
375	Tanzania	_	_	_	_	_	_	_	Seg=O
376	residents	_	_	_	_	_	_	_	Seg=O
377	of	_	_	_	_	_	_	_	Seg=O
378	a	_	_	_	_	_	_	_	Seg=O
379	low	_	_	_	_	_	_	_	Seg=O
380	socioeconomic	_	_	_	_	_	_	_	Seg=O
381	status	_	_	_	_	_	_	_	Seg=O
382	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = be7c8e5eb861bc4ef5334a348c6741638ffef108
1	Coronavirus	_	_	_	_	_	_	_	Seg=B-seg
2	Disease	_	_	_	_	_	_	_	Seg=O
3	2019	_	_	_	_	_	_	_	Seg=O
4	(	_	_	_	_	_	_	_	Seg=O
5	COVID-19	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	spread	_	_	_	_	_	_	_	Seg=O
8	globally	_	_	_	_	_	_	_	Seg=O
9	in	_	_	_	_	_	_	_	Seg=O
10	early	_	_	_	_	_	_	_	Seg=O
11	2020	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	causing	_	_	_	_	_	_	_	Seg=B-seg
14	the	_	_	_	_	_	_	_	Seg=O
15	world	_	_	_	_	_	_	_	Seg=O
16	to	_	_	_	_	_	_	_	Seg=O
17	face	_	_	_	_	_	_	_	Seg=O
18	an	_	_	_	_	_	_	_	Seg=O
19	existential	_	_	_	_	_	_	_	Seg=O
20	health	_	_	_	_	_	_	_	Seg=O
21	crisis	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	Automated	_	_	_	_	_	_	_	Seg=B-seg
24	detection	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	lung	_	_	_	_	_	_	_	Seg=O
27	infections	_	_	_	_	_	_	_	Seg=O
28	from	_	_	_	_	_	_	_	Seg=O
29	computed	_	_	_	_	_	_	_	Seg=O
30	tomography	_	_	_	_	_	_	_	Seg=O
31	(	_	_	_	_	_	_	_	Seg=O
32	CT	_	_	_	_	_	_	_	Seg=O
33	)	_	_	_	_	_	_	_	Seg=O
34	images	_	_	_	_	_	_	_	Seg=O
35	offers	_	_	_	_	_	_	_	Seg=O
36	a	_	_	_	_	_	_	_	Seg=O
37	great	_	_	_	_	_	_	_	Seg=O
38	potential	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=B-seg
40	augment	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	traditional	_	_	_	_	_	_	_	Seg=O
43	healthcare	_	_	_	_	_	_	_	Seg=O
44	strategy	_	_	_	_	_	_	_	Seg=O
45	for	_	_	_	_	_	_	_	Seg=B-seg
46	tackling	_	_	_	_	_	_	_	Seg=O
47	COVID-19	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	However	_	_	_	_	_	_	_	Seg=B-seg
50	,	_	_	_	_	_	_	_	Seg=O
51	segmenting	_	_	_	_	_	_	_	Seg=O
52	infected	_	_	_	_	_	_	_	Seg=O
53	regions	_	_	_	_	_	_	_	Seg=O
54	from	_	_	_	_	_	_	_	Seg=O
55	CT	_	_	_	_	_	_	_	Seg=O
56	scans	_	_	_	_	_	_	_	Seg=O
57	faces	_	_	_	_	_	_	_	Seg=O
58	several	_	_	_	_	_	_	_	Seg=O
59	challenges	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	including	_	_	_	_	_	_	_	Seg=B-seg
62	high	_	_	_	_	_	_	_	Seg=O
63	variation	_	_	_	_	_	_	_	Seg=O
64	in	_	_	_	_	_	_	_	Seg=O
65	infection	_	_	_	_	_	_	_	Seg=O
66	characteristics	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	and	_	_	_	_	_	_	_	Seg=O
69	low	_	_	_	_	_	_	_	Seg=O
70	intensity	_	_	_	_	_	_	_	Seg=O
71	contrast	_	_	_	_	_	_	_	Seg=O
72	between	_	_	_	_	_	_	_	Seg=O
73	infections	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=O
75	normal	_	_	_	_	_	_	_	Seg=O
76	tissues	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O
78	Further	_	_	_	_	_	_	_	Seg=B-seg
79	,	_	_	_	_	_	_	_	Seg=O
80	collecting	_	_	_	_	_	_	_	Seg=O
81	a	_	_	_	_	_	_	_	Seg=O
82	large	_	_	_	_	_	_	_	Seg=O
83	amount	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	data	_	_	_	_	_	_	_	Seg=O
86	is	_	_	_	_	_	_	_	Seg=O
87	impractical	_	_	_	_	_	_	_	Seg=O
88	within	_	_	_	_	_	_	_	Seg=O
89	a	_	_	_	_	_	_	_	Seg=O
90	short	_	_	_	_	_	_	_	Seg=O
91	time	_	_	_	_	_	_	_	Seg=O
92	period	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	inhibiting	_	_	_	_	_	_	_	Seg=B-seg
95	the	_	_	_	_	_	_	_	Seg=O
96	training	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	a	_	_	_	_	_	_	_	Seg=O
99	deep	_	_	_	_	_	_	_	Seg=O
100	model	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	To	_	_	_	_	_	_	_	Seg=B-seg
103	address	_	_	_	_	_	_	_	Seg=O
104	these	_	_	_	_	_	_	_	Seg=O
105	challenges	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	a	_	_	_	_	_	_	_	Seg=B-seg
108	novel	_	_	_	_	_	_	_	Seg=O
109	COVID-19	_	_	_	_	_	_	_	Seg=O
110	Lung	_	_	_	_	_	_	_	Seg=O
111	Infection	_	_	_	_	_	_	_	Seg=O
112	Segmentation	_	_	_	_	_	_	_	Seg=O
113	Deep	_	_	_	_	_	_	_	Seg=O
114	Network	_	_	_	_	_	_	_	Seg=O
115	(	_	_	_	_	_	_	_	Seg=O
116	Inf	_	_	_	_	_	_	_	Seg=O
117	-	_	_	_	_	_	_	_	Seg=O
118	Net	_	_	_	_	_	_	_	Seg=O
119	)	_	_	_	_	_	_	_	Seg=O
120	is	_	_	_	_	_	_	_	Seg=O
121	proposed	_	_	_	_	_	_	_	Seg=O
122	to	_	_	_	_	_	_	_	Seg=B-seg
123	automatically	_	_	_	_	_	_	_	Seg=O
124	identify	_	_	_	_	_	_	_	Seg=O
125	infected	_	_	_	_	_	_	_	Seg=O
126	regions	_	_	_	_	_	_	_	Seg=O
127	from	_	_	_	_	_	_	_	Seg=O
128	chest	_	_	_	_	_	_	_	Seg=O
129	CT	_	_	_	_	_	_	_	Seg=O
130	scans	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O
132	In	_	_	_	_	_	_	_	Seg=B-seg
133	our	_	_	_	_	_	_	_	Seg=O
134	Inf	_	_	_	_	_	_	_	Seg=O
135	-	_	_	_	_	_	_	_	Seg=O
136	Net	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	a	_	_	_	_	_	_	_	Seg=O
139	parallel	_	_	_	_	_	_	_	Seg=O
140	partial	_	_	_	_	_	_	_	Seg=O
141	decoder	_	_	_	_	_	_	_	Seg=O
142	is	_	_	_	_	_	_	_	Seg=O
143	used	_	_	_	_	_	_	_	Seg=O
144	to	_	_	_	_	_	_	_	Seg=B-seg
145	aggregate	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	high	_	_	_	_	_	_	_	Seg=O
148	-	_	_	_	_	_	_	_	Seg=O
149	level	_	_	_	_	_	_	_	Seg=O
150	features	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=B-seg
152	generate	_	_	_	_	_	_	_	Seg=O
153	a	_	_	_	_	_	_	_	Seg=O
154	global	_	_	_	_	_	_	_	Seg=O
155	map	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	Then	_	_	_	_	_	_	_	Seg=B-seg
158	,	_	_	_	_	_	_	_	Seg=O
159	the	_	_	_	_	_	_	_	Seg=O
160	implicit	_	_	_	_	_	_	_	Seg=O
161	reverse	_	_	_	_	_	_	_	Seg=O
162	attention	_	_	_	_	_	_	_	Seg=O
163	and	_	_	_	_	_	_	_	Seg=O
164	explicit	_	_	_	_	_	_	_	Seg=O
165	edge	_	_	_	_	_	_	_	Seg=O
166	-	_	_	_	_	_	_	_	Seg=O
167	attention	_	_	_	_	_	_	_	Seg=O
168	are	_	_	_	_	_	_	_	Seg=O
169	utilized	_	_	_	_	_	_	_	Seg=O
170	to	_	_	_	_	_	_	_	Seg=B-seg
171	model	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	boundaries	_	_	_	_	_	_	_	Seg=O
174	and	_	_	_	_	_	_	_	Seg=B-seg
175	enhance	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	representations	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O
179	Moreover	_	_	_	_	_	_	_	Seg=B-seg
180	,	_	_	_	_	_	_	_	Seg=O
181	to	_	_	_	_	_	_	_	Seg=B-seg
182	alleviate	_	_	_	_	_	_	_	Seg=O
183	the	_	_	_	_	_	_	_	Seg=O
184	shortage	_	_	_	_	_	_	_	Seg=O
185	of	_	_	_	_	_	_	_	Seg=O
186	labeled	_	_	_	_	_	_	_	Seg=O
187	data	_	_	_	_	_	_	_	Seg=O
188	,	_	_	_	_	_	_	_	Seg=O
189	we	_	_	_	_	_	_	_	Seg=B-seg
190	present	_	_	_	_	_	_	_	Seg=O
191	a	_	_	_	_	_	_	_	Seg=O
192	semi	_	_	_	_	_	_	_	Seg=O
193	-	_	_	_	_	_	_	_	Seg=O
194	supervised	_	_	_	_	_	_	_	Seg=O
195	segmentation	_	_	_	_	_	_	_	Seg=O
196	framework	_	_	_	_	_	_	_	Seg=O
197	based	_	_	_	_	_	_	_	Seg=B-seg
198	on	_	_	_	_	_	_	_	Seg=O
199	a	_	_	_	_	_	_	_	Seg=O
200	randomly	_	_	_	_	_	_	_	Seg=O
201	selected	_	_	_	_	_	_	_	Seg=O
202	propagation	_	_	_	_	_	_	_	Seg=O
203	strategy	_	_	_	_	_	_	_	Seg=O
204	,	_	_	_	_	_	_	_	Seg=O
205	which	_	_	_	_	_	_	_	Seg=B-seg
206	only	_	_	_	_	_	_	_	Seg=O
207	requires	_	_	_	_	_	_	_	Seg=O
208	a	_	_	_	_	_	_	_	Seg=O
209	few	_	_	_	_	_	_	_	Seg=O
210	labeled	_	_	_	_	_	_	_	Seg=O
211	images	_	_	_	_	_	_	_	Seg=O
212	and	_	_	_	_	_	_	_	Seg=B-seg
213	leverages	_	_	_	_	_	_	_	Seg=O
214	primarily	_	_	_	_	_	_	_	Seg=O
215	unlabeled	_	_	_	_	_	_	_	Seg=O
216	data	_	_	_	_	_	_	_	Seg=O
217	.	_	_	_	_	_	_	_	Seg=O
218	Our	_	_	_	_	_	_	_	Seg=B-seg
219	semi	_	_	_	_	_	_	_	Seg=O
220	-	_	_	_	_	_	_	_	Seg=O
221	supervised	_	_	_	_	_	_	_	Seg=O
222	framework	_	_	_	_	_	_	_	Seg=O
223	can	_	_	_	_	_	_	_	Seg=O
224	improve	_	_	_	_	_	_	_	Seg=O
225	the	_	_	_	_	_	_	_	Seg=O
226	learning	_	_	_	_	_	_	_	Seg=O
227	ability	_	_	_	_	_	_	_	Seg=O
228	and	_	_	_	_	_	_	_	Seg=B-seg
229	achieve	_	_	_	_	_	_	_	Seg=O
230	a	_	_	_	_	_	_	_	Seg=O
231	higher	_	_	_	_	_	_	_	Seg=O
232	performance	_	_	_	_	_	_	_	Seg=O
233	.	_	_	_	_	_	_	_	Seg=O
234	Extensive	_	_	_	_	_	_	_	Seg=B-seg
235	experiments	_	_	_	_	_	_	_	Seg=O
236	on	_	_	_	_	_	_	_	Seg=O
237	our	_	_	_	_	_	_	_	Seg=O
238	COVID	_	_	_	_	_	_	_	Seg=O
239	-	_	_	_	_	_	_	_	Seg=O
240	SemiSeg	_	_	_	_	_	_	_	Seg=O
241	and	_	_	_	_	_	_	_	Seg=O
242	and	_	_	_	_	_	_	_	Seg=O
243	real	_	_	_	_	_	_	_	Seg=O
244	CT	_	_	_	_	_	_	_	Seg=O
245	volumes	_	_	_	_	_	_	_	Seg=O
246	demonstrate	_	_	_	_	_	_	_	Seg=O
247	that	_	_	_	_	_	_	_	Seg=B-seg
248	the	_	_	_	_	_	_	_	Seg=O
249	proposed	_	_	_	_	_	_	_	Seg=O
250	Inf	_	_	_	_	_	_	_	Seg=O
251	-	_	_	_	_	_	_	_	Seg=O
252	Net	_	_	_	_	_	_	_	Seg=O
253	outperforms	_	_	_	_	_	_	_	Seg=O
254	most	_	_	_	_	_	_	_	Seg=O
255	cutting	_	_	_	_	_	_	_	Seg=O
256	-	_	_	_	_	_	_	_	Seg=O
257	edge	_	_	_	_	_	_	_	Seg=O
258	segmentation	_	_	_	_	_	_	_	Seg=O
259	models	_	_	_	_	_	_	_	Seg=O
260	and	_	_	_	_	_	_	_	Seg=B-seg
261	advances	_	_	_	_	_	_	_	Seg=O
262	the	_	_	_	_	_	_	_	Seg=O
263	state	_	_	_	_	_	_	_	Seg=O
264	-	_	_	_	_	_	_	_	Seg=O
265	of	_	_	_	_	_	_	_	Seg=O
266	-	_	_	_	_	_	_	_	Seg=O
267	theart	_	_	_	_	_	_	_	Seg=O
268	performance	_	_	_	_	_	_	_	Seg=O
269	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = bfab901132bb4f31381dd086e6c45472fa9b4e44
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	simulation	_	_	_	_	_	_	_	Seg=O
3	tool	_	_	_	_	_	_	_	Seg=O
4	that	_	_	_	_	_	_	_	Seg=B-seg
5	supports	_	_	_	_	_	_	_	Seg=O
6	developers	_	_	_	_	_	_	_	Seg=O
7	to	_	_	_	_	_	_	_	Seg=O
8	build	_	_	_	_	_	_	_	Seg=O
9	scenarios	_	_	_	_	_	_	_	Seg=O
10	automatically	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	multiple	_	_	_	_	_	_	_	Seg=O
13	simulation	_	_	_	_	_	_	_	Seg=O
14	platforms	_	_	_	_	_	_	_	Seg=O
15	is	_	_	_	_	_	_	_	Seg=B-seg
16	proposed	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	As	_	_	_	_	_	_	_	Seg=B-seg
19	an	_	_	_	_	_	_	_	Seg=O
20	essential	_	_	_	_	_	_	_	Seg=O
21	part	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	this	_	_	_	_	_	_	_	Seg=O
24	simulator	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	this	_	_	_	_	_	_	_	Seg=O
27	study	_	_	_	_	_	_	_	Seg=O
28	proposed	_	_	_	_	_	_	_	Seg=O
29	an	_	_	_	_	_	_	_	Seg=O
30	activity	_	_	_	_	_	_	_	Seg=O
31	schedule	_	_	_	_	_	_	_	Seg=O
32	generator	_	_	_	_	_	_	_	Seg=O
33	to	_	_	_	_	_	_	_	Seg=B-seg
34	mimic	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	daily	_	_	_	_	_	_	_	Seg=O
37	life	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	elderly	_	_	_	_	_	_	_	Seg=O
40	people	_	_	_	_	_	_	_	Seg=O
41	living	_	_	_	_	_	_	_	Seg=B-seg
42	alone	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	This	_	_	_	_	_	_	_	Seg=B-seg
45	generator	_	_	_	_	_	_	_	Seg=O
46	outperforms	_	_	_	_	_	_	_	Seg=O
47	existing	_	_	_	_	_	_	_	Seg=O
48	methods	_	_	_	_	_	_	_	Seg=O
49	of	_	_	_	_	_	_	_	Seg=O
50	activity	_	_	_	_	_	_	_	Seg=O
51	schedule	_	_	_	_	_	_	_	Seg=O
52	planning	_	_	_	_	_	_	_	Seg=O
53	in	_	_	_	_	_	_	_	Seg=O
54	three	_	_	_	_	_	_	_	Seg=O
55	aspects	_	_	_	_	_	_	_	Seg=O
56	:	_	_	_	_	_	_	_	Seg=O
57	1	_	_	_	_	_	_	_	Seg=B-seg
58	)	_	_	_	_	_	_	_	Seg=O
59	it	_	_	_	_	_	_	_	Seg=O
60	is	_	_	_	_	_	_	_	Seg=O
61	adaptive	_	_	_	_	_	_	_	Seg=O
62	to	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	layout	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=O
66	a	_	_	_	_	_	_	_	Seg=O
67	simulated	_	_	_	_	_	_	_	Seg=O
68	smart	_	_	_	_	_	_	_	Seg=O
69	house	_	_	_	_	_	_	_	Seg=O
70	;	_	_	_	_	_	_	_	Seg=O
71	2	_	_	_	_	_	_	_	Seg=B-seg
72	)	_	_	_	_	_	_	_	Seg=O
73	there	_	_	_	_	_	_	_	Seg=O
74	is	_	_	_	_	_	_	_	Seg=O
75	no	_	_	_	_	_	_	_	Seg=O
76	unspecified	_	_	_	_	_	_	_	Seg=O
77	time	_	_	_	_	_	_	_	Seg=O
78	in	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	timeline	_	_	_	_	_	_	_	Seg=O
81	of	_	_	_	_	_	_	_	Seg=O
82	generated	_	_	_	_	_	_	_	Seg=O
83	schedules	_	_	_	_	_	_	_	Seg=O
84	;	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=B-seg
86	3	_	_	_	_	_	_	_	Seg=O
87	)	_	_	_	_	_	_	_	Seg=O
88	it	_	_	_	_	_	_	_	Seg=O
89	generates	_	_	_	_	_	_	_	Seg=O
90	stable	_	_	_	_	_	_	_	Seg=O
91	,	_	_	_	_	_	_	_	Seg=O
92	but	_	_	_	_	_	_	_	Seg=O
93	not	_	_	_	_	_	_	_	Seg=O
94	tedious	_	_	_	_	_	_	_	Seg=O
95	schedules	_	_	_	_	_	_	_	Seg=O
96	for	_	_	_	_	_	_	_	Seg=O
97	a	_	_	_	_	_	_	_	Seg=O
98	number	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	days	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	A	_	_	_	_	_	_	_	Seg=B-seg
103	real	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	time	_	_	_	_	_	_	_	Seg=O
106	location	_	_	_	_	_	_	_	Seg=O
107	data	_	_	_	_	_	_	_	Seg=O
108	generator	_	_	_	_	_	_	_	Seg=O
109	is	_	_	_	_	_	_	_	Seg=O
110	proposed	_	_	_	_	_	_	_	Seg=O
111	to	_	_	_	_	_	_	_	Seg=B-seg
112	convert	_	_	_	_	_	_	_	Seg=O
113	generated	_	_	_	_	_	_	_	Seg=O
114	schedules	_	_	_	_	_	_	_	Seg=O
115	to	_	_	_	_	_	_	_	Seg=O
116	simulated	_	_	_	_	_	_	_	Seg=O
117	real	_	_	_	_	_	_	_	Seg=O
118	-	_	_	_	_	_	_	_	Seg=O
119	time	_	_	_	_	_	_	_	Seg=O
120	location	_	_	_	_	_	_	_	Seg=O
121	data	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	resident	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	and	_	_	_	_	_	_	_	Seg=B-seg
127	a	_	_	_	_	_	_	_	Seg=O
128	proposed	_	_	_	_	_	_	_	Seg=O
129	interface	_	_	_	_	_	_	_	Seg=O
130	converts	_	_	_	_	_	_	_	Seg=O
131	these	_	_	_	_	_	_	_	Seg=O
132	simulated	_	_	_	_	_	_	_	Seg=O
133	location	_	_	_	_	_	_	_	Seg=O
134	data	_	_	_	_	_	_	_	Seg=O
135	to	_	_	_	_	_	_	_	Seg=O
136	simulated	_	_	_	_	_	_	_	Seg=O
137	records	_	_	_	_	_	_	_	Seg=O
138	of	_	_	_	_	_	_	_	Seg=O
139	virtual	_	_	_	_	_	_	_	Seg=O
140	passive	_	_	_	_	_	_	_	Seg=O
141	infrared	_	_	_	_	_	_	_	Seg=O
142	(	_	_	_	_	_	_	_	Seg=O
143	PIR	_	_	_	_	_	_	_	Seg=O
144	)	_	_	_	_	_	_	_	Seg=O
145	sensors	_	_	_	_	_	_	_	Seg=O
146	,	_	_	_	_	_	_	_	Seg=O
147	which	_	_	_	_	_	_	_	Seg=B-seg
148	can	_	_	_	_	_	_	_	Seg=O
149	be	_	_	_	_	_	_	_	Seg=O
150	used	_	_	_	_	_	_	_	Seg=O
151	to	_	_	_	_	_	_	_	Seg=B-seg
152	optimize	_	_	_	_	_	_	_	Seg=O
153	placement	_	_	_	_	_	_	_	Seg=O
154	of	_	_	_	_	_	_	_	Seg=O
155	PIR	_	_	_	_	_	_	_	Seg=O
156	sensors	_	_	_	_	_	_	_	Seg=O
157	in	_	_	_	_	_	_	_	Seg=O
158	a	_	_	_	_	_	_	_	Seg=O
159	smart	_	_	_	_	_	_	_	Seg=O
160	house	_	_	_	_	_	_	_	Seg=O
161	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c0e6a4d852babb843d63198cc1e16146efc108b1
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	Severe	_	_	_	_	_	_	_	Seg=O
3	Acute	_	_	_	_	_	_	_	Seg=O
4	Respiratory	_	_	_	_	_	_	_	Seg=O
5	Syndrome	_	_	_	_	_	_	_	Seg=O
6	-	_	_	_	_	_	_	_	Seg=O
7	Coronavirus	_	_	_	_	_	_	_	Seg=O
8	(	_	_	_	_	_	_	_	Seg=O
9	SARS	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	CoV	_	_	_	_	_	_	_	Seg=O
12	)	_	_	_	_	_	_	_	Seg=O
13	3a	_	_	_	_	_	_	_	Seg=O
14	locus	_	_	_	_	_	_	_	Seg=O
15	encodes	_	_	_	_	_	_	_	Seg=O
16	a	_	_	_	_	_	_	_	Seg=O
17	274	_	_	_	_	_	_	_	Seg=O
18	a.a	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	novel	_	_	_	_	_	_	_	Seg=O
21	protein	_	_	_	_	_	_	_	Seg=O
22	,	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=B-seg
24	its	_	_	_	_	_	_	_	Seg=O
25	expression	_	_	_	_	_	_	_	Seg=O
26	has	_	_	_	_	_	_	_	Seg=O
27	been	_	_	_	_	_	_	_	Seg=O
28	confirmed	_	_	_	_	_	_	_	Seg=O
29	in	_	_	_	_	_	_	_	Seg=O
30	SARS	_	_	_	_	_	_	_	Seg=O
31	patients	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	To	_	_	_	_	_	_	_	Seg=B-seg
34	study	_	_	_	_	_	_	_	Seg=O
35	functional	_	_	_	_	_	_	_	Seg=O
36	roles	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	3a	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	we	_	_	_	_	_	_	_	Seg=B-seg
41	established	_	_	_	_	_	_	_	Seg=O
42	a	_	_	_	_	_	_	_	Seg=O
43	transgenic	_	_	_	_	_	_	_	Seg=O
44	fly	_	_	_	_	_	_	_	Seg=O
45	model	_	_	_	_	_	_	_	Seg=O
46	for	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	SARS	_	_	_	_	_	_	_	Seg=O
49	-	_	_	_	_	_	_	_	Seg=O
50	CoV	_	_	_	_	_	_	_	Seg=O
51	3a	_	_	_	_	_	_	_	Seg=O
52	gene	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	Misexpression	_	_	_	_	_	_	_	Seg=B-seg
55	of	_	_	_	_	_	_	_	Seg=O
56	3a	_	_	_	_	_	_	_	Seg=O
57	in	_	_	_	_	_	_	_	Seg=O
58	Drosophila	_	_	_	_	_	_	_	Seg=O
59	caused	_	_	_	_	_	_	_	Seg=O
60	a	_	_	_	_	_	_	_	Seg=O
61	dominant	_	_	_	_	_	_	_	Seg=O
62	rough	_	_	_	_	_	_	_	Seg=O
63	eye	_	_	_	_	_	_	_	Seg=O
64	phenotype	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Using	_	_	_	_	_	_	_	Seg=B-seg
67	a	_	_	_	_	_	_	_	Seg=O
68	specific	_	_	_	_	_	_	_	Seg=O
69	monoclonal	_	_	_	_	_	_	_	Seg=O
70	antibody	_	_	_	_	_	_	_	Seg=O
71	,	_	_	_	_	_	_	_	Seg=O
72	we	_	_	_	_	_	_	_	Seg=B-seg
73	demonstrated	_	_	_	_	_	_	_	Seg=O
74	that	_	_	_	_	_	_	_	Seg=B-seg
75	the	_	_	_	_	_	_	_	Seg=O
76	3a	_	_	_	_	_	_	_	Seg=O
77	protein	_	_	_	_	_	_	_	Seg=O
78	displayed	_	_	_	_	_	_	_	Seg=O
79	a	_	_	_	_	_	_	_	Seg=O
80	punctate	_	_	_	_	_	_	_	Seg=O
81	cytoplasmic	_	_	_	_	_	_	_	Seg=O
82	localization	_	_	_	_	_	_	_	Seg=O
83	in	_	_	_	_	_	_	_	Seg=O
84	Drosophila	_	_	_	_	_	_	_	Seg=O
85	as	_	_	_	_	_	_	_	Seg=O
86	in	_	_	_	_	_	_	_	Seg=O
87	SARS	_	_	_	_	_	_	_	Seg=O
88	-	_	_	_	_	_	_	_	Seg=O
89	CoV	_	_	_	_	_	_	_	Seg=O
90	-	_	_	_	_	_	_	_	Seg=O
91	infected	_	_	_	_	_	_	_	Seg=O
92	cells	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	We	_	_	_	_	_	_	_	Seg=B-seg
95	provide	_	_	_	_	_	_	_	Seg=O
96	genetic	_	_	_	_	_	_	_	Seg=O
97	evidence	_	_	_	_	_	_	_	Seg=O
98	to	_	_	_	_	_	_	_	Seg=B-seg
99	support	_	_	_	_	_	_	_	Seg=O
100	that	_	_	_	_	_	_	_	Seg=B-seg
101	3a	_	_	_	_	_	_	_	Seg=O
102	is	_	_	_	_	_	_	_	Seg=O
103	functionally	_	_	_	_	_	_	_	Seg=O
104	related	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=O
106	clathrin	_	_	_	_	_	_	_	Seg=O
107	-	_	_	_	_	_	_	_	Seg=O
108	mediated	_	_	_	_	_	_	_	Seg=O
109	endocytosis	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	We	_	_	_	_	_	_	_	Seg=B-seg
112	further	_	_	_	_	_	_	_	Seg=O
113	found	_	_	_	_	_	_	_	Seg=O
114	that	_	_	_	_	_	_	_	Seg=B-seg
115	3a	_	_	_	_	_	_	_	Seg=O
116	misexpression	_	_	_	_	_	_	_	Seg=O
117	induces	_	_	_	_	_	_	_	Seg=O
118	apoptosis	_	_	_	_	_	_	_	Seg=O
119	,	_	_	_	_	_	_	_	Seg=O
120	which	_	_	_	_	_	_	_	Seg=B-seg
121	could	_	_	_	_	_	_	_	Seg=O
122	be	_	_	_	_	_	_	_	Seg=O
123	modulated	_	_	_	_	_	_	_	Seg=O
124	by	_	_	_	_	_	_	_	Seg=O
125	cellular	_	_	_	_	_	_	_	Seg=O
126	cytochrome	_	_	_	_	_	_	_	Seg=O
127	c	_	_	_	_	_	_	_	Seg=O
128	levels	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	caspase	_	_	_	_	_	_	_	Seg=O
131	activity	_	_	_	_	_	_	_	Seg=O
132	.	_	_	_	_	_	_	_	Seg=O
133	From	_	_	_	_	_	_	_	Seg=B-seg
134	a	_	_	_	_	_	_	_	Seg=O
135	forward	_	_	_	_	_	_	_	Seg=O
136	genetic	_	_	_	_	_	_	_	Seg=O
137	screen	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	78	_	_	_	_	_	_	_	Seg=O
140	dominant	_	_	_	_	_	_	_	Seg=O
141	3a	_	_	_	_	_	_	_	Seg=O
142	modifying	_	_	_	_	_	_	_	Seg=O
143	loci	_	_	_	_	_	_	_	Seg=O
144	were	_	_	_	_	_	_	_	Seg=O
145	recovered	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=B-seg
147	the	_	_	_	_	_	_	_	Seg=O
148	identity	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	these	_	_	_	_	_	_	_	Seg=O
151	modifiers	_	_	_	_	_	_	_	Seg=O
152	revealed	_	_	_	_	_	_	_	Seg=O
153	that	_	_	_	_	_	_	_	Seg=B-seg
154	the	_	_	_	_	_	_	_	Seg=O
155	severity	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	3a	_	_	_	_	_	_	_	Seg=O
159	-	_	_	_	_	_	_	_	Seg=O
160	induced	_	_	_	_	_	_	_	Seg=O
161	rough	_	_	_	_	_	_	_	Seg=O
162	eye	_	_	_	_	_	_	_	Seg=O
163	phenotype	_	_	_	_	_	_	_	Seg=O
164	depends	_	_	_	_	_	_	_	Seg=O
165	on	_	_	_	_	_	_	_	Seg=O
166	multiple	_	_	_	_	_	_	_	Seg=O
167	cellular	_	_	_	_	_	_	_	Seg=O
168	processes	_	_	_	_	_	_	_	Seg=O
169	including	_	_	_	_	_	_	_	Seg=B-seg
170	gene	_	_	_	_	_	_	_	Seg=O
171	transcriptional	_	_	_	_	_	_	_	Seg=O
172	regulation	_	_	_	_	_	_	_	Seg=O
173	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c280d46d6fa7e2c2938a5c09bd6b092e1058a9b0
1	Mucosal	_	_	_	_	_	_	_	Seg=B-seg
2	vaccination	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	an	_	_	_	_	_	_	_	Seg=O
5	effective	_	_	_	_	_	_	_	Seg=O
6	strategy	_	_	_	_	_	_	_	Seg=O
7	for	_	_	_	_	_	_	_	Seg=B-seg
8	generating	_	_	_	_	_	_	_	Seg=O
9	antigen	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	specific	_	_	_	_	_	_	_	Seg=O
12	immune	_	_	_	_	_	_	_	Seg=O
13	responses	_	_	_	_	_	_	_	Seg=O
14	against	_	_	_	_	_	_	_	Seg=O
15	mucosal	_	_	_	_	_	_	_	Seg=O
16	infections	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	foot	_	_	_	_	_	_	_	Seg=O
19	-	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=O
21	-	_	_	_	_	_	_	_	Seg=O
22	mouth	_	_	_	_	_	_	_	Seg=O
23	disease	_	_	_	_	_	_	_	Seg=O
24	virus	_	_	_	_	_	_	_	Seg=O
25	(	_	_	_	_	_	_	_	Seg=O
26	FMDV	_	_	_	_	_	_	_	Seg=O
27	)	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	In	_	_	_	_	_	_	_	Seg=B-seg
30	this	_	_	_	_	_	_	_	Seg=O
31	study	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	Lactobacillus	_	_	_	_	_	_	_	Seg=O
34	plantarum	_	_	_	_	_	_	_	Seg=O
35	strains	_	_	_	_	_	_	_	Seg=O
36	NC8	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	WCFS1	_	_	_	_	_	_	_	Seg=O
39	were	_	_	_	_	_	_	_	Seg=O
40	used	_	_	_	_	_	_	_	Seg=O
41	as	_	_	_	_	_	_	_	Seg=O
42	oral	_	_	_	_	_	_	_	Seg=O
43	delivery	_	_	_	_	_	_	_	Seg=O
44	vehicles	_	_	_	_	_	_	_	Seg=O
45	containing	_	_	_	_	_	_	_	Seg=B-seg
46	a	_	_	_	_	_	_	_	Seg=O
47	pSIP411-VP1	_	_	_	_	_	_	_	Seg=O
48	recombinant	_	_	_	_	_	_	_	Seg=O
49	plasmid	_	_	_	_	_	_	_	Seg=O
50	to	_	_	_	_	_	_	_	Seg=B-seg
51	initiate	_	_	_	_	_	_	_	Seg=O
52	mucosal	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=O
54	systemic	_	_	_	_	_	_	_	Seg=O
55	immune	_	_	_	_	_	_	_	Seg=O
56	responses	_	_	_	_	_	_	_	Seg=O
57	in	_	_	_	_	_	_	_	Seg=O
58	guinea	_	_	_	_	_	_	_	Seg=O
59	pigs	_	_	_	_	_	_	_	Seg=O
60	.	_	_	_	_	_	_	_	Seg=O
61	Guinea	_	_	_	_	_	_	_	Seg=B-seg
62	pigs	_	_	_	_	_	_	_	Seg=O
63	were	_	_	_	_	_	_	_	Seg=O
64	orally	_	_	_	_	_	_	_	Seg=O
65	vaccinated	_	_	_	_	_	_	_	Seg=O
66	(	_	_	_	_	_	_	_	Seg=B-seg
67	three	_	_	_	_	_	_	_	Seg=O
68	doses	_	_	_	_	_	_	_	Seg=O
69	)	_	_	_	_	_	_	_	Seg=O
70	with	_	_	_	_	_	_	_	Seg=B-seg
71	NC8-pSIP411	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	NC8-pSIP411-VP1	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	WCFS1-pSIP411	_	_	_	_	_	_	_	Seg=O
76	,	_	_	_	_	_	_	_	Seg=O
77	WCFS1-pSIP411-VP1	_	_	_	_	_	_	_	Seg=O
78	or	_	_	_	_	_	_	_	Seg=O
79	milk	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	Animals	_	_	_	_	_	_	_	Seg=B-seg
82	immunized	_	_	_	_	_	_	_	Seg=B-seg
83	with	_	_	_	_	_	_	_	Seg=O
84	NC8-pSIP411-VP1	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	WCFS1-pSIP411-VP1	_	_	_	_	_	_	_	Seg=O
87	developed	_	_	_	_	_	_	_	Seg=B-seg
88	high	_	_	_	_	_	_	_	Seg=O
89	levels	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	antigen	_	_	_	_	_	_	_	Seg=O
92	-	_	_	_	_	_	_	_	Seg=O
93	specific	_	_	_	_	_	_	_	Seg=O
94	serum	_	_	_	_	_	_	_	Seg=O
95	IgG	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	IgA	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	IgM	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	mucosal	_	_	_	_	_	_	_	Seg=O
102	secretory	_	_	_	_	_	_	_	Seg=O
103	IgA	_	_	_	_	_	_	_	Seg=O
104	(	_	_	_	_	_	_	_	Seg=O
105	sIgA	_	_	_	_	_	_	_	Seg=O
106	)	_	_	_	_	_	_	_	Seg=O
107	and	_	_	_	_	_	_	_	Seg=O
108	neutralizing	_	_	_	_	_	_	_	Seg=O
109	antibodies	_	_	_	_	_	_	_	Seg=O
110	,	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=B-seg
112	revealed	_	_	_	_	_	_	_	Seg=O
113	stronger	_	_	_	_	_	_	_	Seg=O
114	cell	_	_	_	_	_	_	_	Seg=O
115	-	_	_	_	_	_	_	_	Seg=O
116	mediated	_	_	_	_	_	_	_	Seg=O
117	immune	_	_	_	_	_	_	_	Seg=O
118	responses	_	_	_	_	_	_	_	Seg=O
119	and	_	_	_	_	_	_	_	Seg=B-seg
120	enhanced	_	_	_	_	_	_	_	Seg=O
121	protection	_	_	_	_	_	_	_	Seg=O
122	against	_	_	_	_	_	_	_	Seg=O
123	FMDV	_	_	_	_	_	_	_	Seg=O
124	challenge	_	_	_	_	_	_	_	Seg=O
125	compared	_	_	_	_	_	_	_	Seg=B-seg
126	with	_	_	_	_	_	_	_	Seg=O
127	control	_	_	_	_	_	_	_	Seg=O
128	groups	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	The	_	_	_	_	_	_	_	Seg=B-seg
131	recombinant	_	_	_	_	_	_	_	Seg=O
132	pSIP411-VP1	_	_	_	_	_	_	_	Seg=O
133	effectively	_	_	_	_	_	_	_	Seg=O
134	improved	_	_	_	_	_	_	_	Seg=O
135	immunoprotection	_	_	_	_	_	_	_	Seg=O
136	against	_	_	_	_	_	_	_	Seg=O
137	FMDV	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	guinea	_	_	_	_	_	_	_	Seg=O
140	pigs	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c4aa9bb066a64db00b8bdd44d5c021c5603a09a2
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	.	_	_	_	_	_	_	_	Seg=O
3	Influenza	_	_	_	_	_	_	_	Seg=B-seg
4	A(H7N9	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	viruses	_	_	_	_	_	_	_	Seg=O
7	isolated	_	_	_	_	_	_	_	Seg=B-seg
8	from	_	_	_	_	_	_	_	Seg=O
9	humans	_	_	_	_	_	_	_	Seg=O
10	show	_	_	_	_	_	_	_	Seg=B-seg
11	features	_	_	_	_	_	_	_	Seg=O
12	suggesting	_	_	_	_	_	_	_	Seg=B-seg
13	partial	_	_	_	_	_	_	_	Seg=O
14	adaptation	_	_	_	_	_	_	_	Seg=O
15	to	_	_	_	_	_	_	_	Seg=O
16	mammals	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	To	_	_	_	_	_	_	_	Seg=B-seg
19	provide	_	_	_	_	_	_	_	Seg=O
20	insights	_	_	_	_	_	_	_	Seg=O
21	into	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	pathogenesis	_	_	_	_	_	_	_	Seg=O
24	of	_	_	_	_	_	_	_	Seg=O
25	H7N9	_	_	_	_	_	_	_	Seg=O
26	virus	_	_	_	_	_	_	_	Seg=O
27	infection	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	we	_	_	_	_	_	_	_	Seg=B-seg
30	compared	_	_	_	_	_	_	_	Seg=O
31	risk	_	_	_	_	_	_	_	Seg=O
32	factors	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	clinical	_	_	_	_	_	_	_	Seg=O
35	presentation	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	progression	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	patients	_	_	_	_	_	_	_	Seg=O
41	hospitalized	_	_	_	_	_	_	_	Seg=B-seg
42	with	_	_	_	_	_	_	_	Seg=O
43	H7N9	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	H5N1	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=O
48	2009	_	_	_	_	_	_	_	Seg=O
49	pandemic	_	_	_	_	_	_	_	Seg=O
50	H1N1	_	_	_	_	_	_	_	Seg=O
51	(	_	_	_	_	_	_	_	Seg=O
52	pH1N1	_	_	_	_	_	_	_	Seg=O
53	)	_	_	_	_	_	_	_	Seg=O
54	virus	_	_	_	_	_	_	_	Seg=O
55	infections	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	Methods	_	_	_	_	_	_	_	Seg=B-seg
58	.	_	_	_	_	_	_	_	Seg=O
59	We	_	_	_	_	_	_	_	Seg=B-seg
60	compared	_	_	_	_	_	_	_	Seg=O
61	individual	_	_	_	_	_	_	_	Seg=O
62	-	_	_	_	_	_	_	_	Seg=O
63	level	_	_	_	_	_	_	_	Seg=O
64	data	_	_	_	_	_	_	_	Seg=O
65	from	_	_	_	_	_	_	_	Seg=O
66	patients	_	_	_	_	_	_	_	Seg=O
67	hospitalized	_	_	_	_	_	_	_	Seg=B-seg
68	with	_	_	_	_	_	_	_	Seg=O
69	infection	_	_	_	_	_	_	_	Seg=O
70	by	_	_	_	_	_	_	_	Seg=O
71	H7N9	_	_	_	_	_	_	_	Seg=O
72	(	_	_	_	_	_	_	_	Seg=B-seg
73	n	_	_	_	_	_	_	_	Seg=O
74	=	_	_	_	_	_	_	_	Seg=O
75	123	_	_	_	_	_	_	_	Seg=O
76	)	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	H5N1	_	_	_	_	_	_	_	Seg=B-seg
79	(	_	_	_	_	_	_	_	Seg=B-seg
80	n	_	_	_	_	_	_	_	Seg=O
81	=	_	_	_	_	_	_	_	Seg=O
82	119	_	_	_	_	_	_	_	Seg=O
83	;	_	_	_	_	_	_	_	Seg=O
84	43	_	_	_	_	_	_	_	Seg=O
85	China	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	76	_	_	_	_	_	_	_	Seg=O
88	Vietnam	_	_	_	_	_	_	_	Seg=O
89	)	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=B-seg
91	and	_	_	_	_	_	_	_	Seg=O
92	pH1N1	_	_	_	_	_	_	_	Seg=O
93	(	_	_	_	_	_	_	_	Seg=B-seg
94	n	_	_	_	_	_	_	_	Seg=O
95	=	_	_	_	_	_	_	_	Seg=O
96	3486	_	_	_	_	_	_	_	Seg=O
97	)	_	_	_	_	_	_	_	Seg=O
98	viruses	_	_	_	_	_	_	_	Seg=B-seg
99	.	_	_	_	_	_	_	_	Seg=O
100	We	_	_	_	_	_	_	_	Seg=B-seg
101	assessed	_	_	_	_	_	_	_	Seg=O
102	risk	_	_	_	_	_	_	_	Seg=O
103	factors	_	_	_	_	_	_	_	Seg=O
104	for	_	_	_	_	_	_	_	Seg=O
105	hospitalization	_	_	_	_	_	_	_	Seg=O
106	after	_	_	_	_	_	_	_	Seg=O
107	adjustment	_	_	_	_	_	_	_	Seg=O
108	for	_	_	_	_	_	_	_	Seg=O
109	age	_	_	_	_	_	_	_	Seg=O
110	-	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=O
112	sex	_	_	_	_	_	_	_	Seg=O
113	-	_	_	_	_	_	_	_	Seg=O
114	specific	_	_	_	_	_	_	_	Seg=O
115	prevalence	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	risk	_	_	_	_	_	_	_	Seg=O
118	factors	_	_	_	_	_	_	_	Seg=O
119	in	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	general	_	_	_	_	_	_	_	Seg=O
122	Chinese	_	_	_	_	_	_	_	Seg=O
123	population	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	Results	_	_	_	_	_	_	_	Seg=B-seg
126	.	_	_	_	_	_	_	_	Seg=O
127	The	_	_	_	_	_	_	_	Seg=B-seg
128	median	_	_	_	_	_	_	_	Seg=O
129	age	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	patients	_	_	_	_	_	_	_	Seg=O
132	with	_	_	_	_	_	_	_	Seg=O
133	H7N9	_	_	_	_	_	_	_	Seg=O
134	virus	_	_	_	_	_	_	_	Seg=O
135	infection	_	_	_	_	_	_	_	Seg=O
136	was	_	_	_	_	_	_	_	Seg=O
137	older	_	_	_	_	_	_	_	Seg=O
138	than	_	_	_	_	_	_	_	Seg=O
139	other	_	_	_	_	_	_	_	Seg=O
140	patient	_	_	_	_	_	_	_	Seg=O
141	groups	_	_	_	_	_	_	_	Seg=O
142	(	_	_	_	_	_	_	_	Seg=B-seg
143	63	_	_	_	_	_	_	_	Seg=O
144	years	_	_	_	_	_	_	_	Seg=O
145	;	_	_	_	_	_	_	_	Seg=O
146	P	_	_	_	_	_	_	_	Seg=O
147	<	_	_	_	_	_	_	_	Seg=O
148	.001	_	_	_	_	_	_	_	Seg=O
149	)	_	_	_	_	_	_	_	Seg=O
150	and	_	_	_	_	_	_	_	Seg=B-seg
151	a	_	_	_	_	_	_	_	Seg=O
152	higher	_	_	_	_	_	_	_	Seg=O
153	proportion	_	_	_	_	_	_	_	Seg=O
154	was	_	_	_	_	_	_	_	Seg=O
155	male	_	_	_	_	_	_	_	Seg=O
156	(	_	_	_	_	_	_	_	Seg=B-seg
157	71	_	_	_	_	_	_	_	Seg=O
158	%	_	_	_	_	_	_	_	Seg=O
159	;	_	_	_	_	_	_	_	Seg=O
160	P	_	_	_	_	_	_	_	Seg=O
161	<	_	_	_	_	_	_	_	Seg=O
162	.02	_	_	_	_	_	_	_	Seg=O
163	)	_	_	_	_	_	_	_	Seg=O
164	.	_	_	_	_	_	_	_	Seg=O
165	After	_	_	_	_	_	_	_	Seg=B-seg
166	adjustment	_	_	_	_	_	_	_	Seg=O
167	for	_	_	_	_	_	_	_	Seg=O
168	age	_	_	_	_	_	_	_	Seg=O
169	and	_	_	_	_	_	_	_	Seg=O
170	sex	_	_	_	_	_	_	_	Seg=O
171	,	_	_	_	_	_	_	_	Seg=O
172	chronic	_	_	_	_	_	_	_	Seg=O
173	heart	_	_	_	_	_	_	_	Seg=O
174	disease	_	_	_	_	_	_	_	Seg=O
175	was	_	_	_	_	_	_	_	Seg=O
176	associated	_	_	_	_	_	_	_	Seg=O
177	with	_	_	_	_	_	_	_	Seg=O
178	an	_	_	_	_	_	_	_	Seg=O
179	increased	_	_	_	_	_	_	_	Seg=O
180	risk	_	_	_	_	_	_	_	Seg=O
181	of	_	_	_	_	_	_	_	Seg=O
182	hospitalization	_	_	_	_	_	_	_	Seg=O
183	with	_	_	_	_	_	_	_	Seg=O
184	H7N9	_	_	_	_	_	_	_	Seg=O
185	(	_	_	_	_	_	_	_	Seg=B-seg
186	relative	_	_	_	_	_	_	_	Seg=O
187	risk	_	_	_	_	_	_	_	Seg=O
188	,	_	_	_	_	_	_	_	Seg=O
189	9.68	_	_	_	_	_	_	_	Seg=O
190	;	_	_	_	_	_	_	_	Seg=O
191	95	_	_	_	_	_	_	_	Seg=O
192	%	_	_	_	_	_	_	_	Seg=O
193	confidence	_	_	_	_	_	_	_	Seg=O
194	interval	_	_	_	_	_	_	_	Seg=O
195	,	_	_	_	_	_	_	_	Seg=O
196	5.24	_	_	_	_	_	_	_	Seg=O
197	-	_	_	_	_	_	_	_	Seg=O
198	17.9	_	_	_	_	_	_	_	Seg=O
199	)	_	_	_	_	_	_	_	Seg=O
200	.	_	_	_	_	_	_	_	Seg=O
201	H7N9	_	_	_	_	_	_	_	Seg=B-seg
202	patients	_	_	_	_	_	_	_	Seg=O
203	had	_	_	_	_	_	_	_	Seg=O
204	similar	_	_	_	_	_	_	_	Seg=O
205	patterns	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	leukopenia	_	_	_	_	_	_	_	Seg=O
208	,	_	_	_	_	_	_	_	Seg=O
209	thrombocytopenia	_	_	_	_	_	_	_	Seg=O
210	,	_	_	_	_	_	_	_	Seg=O
211	and	_	_	_	_	_	_	_	Seg=O
212	elevated	_	_	_	_	_	_	_	Seg=O
213	alanine	_	_	_	_	_	_	_	Seg=O
214	aminotransferase	_	_	_	_	_	_	_	Seg=O
215	,	_	_	_	_	_	_	_	Seg=O
216	creatinine	_	_	_	_	_	_	_	Seg=O
217	kinase	_	_	_	_	_	_	_	Seg=O
218	,	_	_	_	_	_	_	_	Seg=O
219	C	_	_	_	_	_	_	_	Seg=O
220	-	_	_	_	_	_	_	_	Seg=O
221	reactive	_	_	_	_	_	_	_	Seg=O
222	protein	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	and	_	_	_	_	_	_	_	Seg=O
225	lactate	_	_	_	_	_	_	_	Seg=O
226	dehydrogenase	_	_	_	_	_	_	_	Seg=O
227	to	_	_	_	_	_	_	_	Seg=O
228	those	_	_	_	_	_	_	_	Seg=O
229	seen	_	_	_	_	_	_	_	Seg=B-seg
230	in	_	_	_	_	_	_	_	Seg=O
231	H5N1	_	_	_	_	_	_	_	Seg=O
232	patients	_	_	_	_	_	_	_	Seg=O
233	,	_	_	_	_	_	_	_	Seg=O
234	which	_	_	_	_	_	_	_	Seg=B-seg
235	were	_	_	_	_	_	_	_	Seg=O
236	all	_	_	_	_	_	_	_	Seg=O
237	significantly	_	_	_	_	_	_	_	Seg=O
238	different	_	_	_	_	_	_	_	Seg=O
239	from	_	_	_	_	_	_	_	Seg=O
240	pH1N1	_	_	_	_	_	_	_	Seg=O
241	patients	_	_	_	_	_	_	_	Seg=O
242	(	_	_	_	_	_	_	_	Seg=B-seg
243	P	_	_	_	_	_	_	_	Seg=O
244	<	_	_	_	_	_	_	_	Seg=O
245	.005	_	_	_	_	_	_	_	Seg=O
246	)	_	_	_	_	_	_	_	Seg=O
247	.	_	_	_	_	_	_	_	Seg=O
248	H7N9	_	_	_	_	_	_	_	Seg=B-seg
249	patients	_	_	_	_	_	_	_	Seg=O
250	had	_	_	_	_	_	_	_	Seg=O
251	a	_	_	_	_	_	_	_	Seg=O
252	longer	_	_	_	_	_	_	_	Seg=O
253	duration	_	_	_	_	_	_	_	Seg=O
254	of	_	_	_	_	_	_	_	Seg=O
255	hospitalization	_	_	_	_	_	_	_	Seg=O
256	than	_	_	_	_	_	_	_	Seg=O
257	either	_	_	_	_	_	_	_	Seg=O
258	H5N1	_	_	_	_	_	_	_	Seg=O
259	or	_	_	_	_	_	_	_	Seg=O
260	pH1N1	_	_	_	_	_	_	_	Seg=O
261	patients	_	_	_	_	_	_	_	Seg=O
262	(	_	_	_	_	_	_	_	Seg=B-seg
263	P	_	_	_	_	_	_	_	Seg=O
264	<	_	_	_	_	_	_	_	Seg=O
265	.001	_	_	_	_	_	_	_	Seg=O
266	)	_	_	_	_	_	_	_	Seg=O
267	,	_	_	_	_	_	_	_	Seg=O
268	and	_	_	_	_	_	_	_	Seg=B-seg
269	the	_	_	_	_	_	_	_	Seg=O
270	median	_	_	_	_	_	_	_	Seg=O
271	time	_	_	_	_	_	_	_	Seg=O
272	from	_	_	_	_	_	_	_	Seg=O
273	onset	_	_	_	_	_	_	_	Seg=O
274	to	_	_	_	_	_	_	_	Seg=O
275	death	_	_	_	_	_	_	_	Seg=O
276	was	_	_	_	_	_	_	_	Seg=O
277	18	_	_	_	_	_	_	_	Seg=O
278	days	_	_	_	_	_	_	_	Seg=O
279	for	_	_	_	_	_	_	_	Seg=O
280	H7N9	_	_	_	_	_	_	_	Seg=O
281	(	_	_	_	_	_	_	_	Seg=B-seg
282	P	_	_	_	_	_	_	_	Seg=O
283	=	_	_	_	_	_	_	_	Seg=O
284	.002	_	_	_	_	_	_	_	Seg=O
285	)	_	_	_	_	_	_	_	Seg=O
286	vs	_	_	_	_	_	_	_	Seg=B-seg
287	11	_	_	_	_	_	_	_	Seg=O
288	days	_	_	_	_	_	_	_	Seg=O
289	for	_	_	_	_	_	_	_	Seg=O
290	H5N1	_	_	_	_	_	_	_	Seg=O
291	and	_	_	_	_	_	_	_	Seg=O
292	15	_	_	_	_	_	_	_	Seg=O
293	days	_	_	_	_	_	_	_	Seg=O
294	for	_	_	_	_	_	_	_	Seg=O
295	pH1N1	_	_	_	_	_	_	_	Seg=O
296	(	_	_	_	_	_	_	_	Seg=B-seg
297	P	_	_	_	_	_	_	_	Seg=O
298	=	_	_	_	_	_	_	_	Seg=O
299	.154	_	_	_	_	_	_	_	Seg=O
300	)	_	_	_	_	_	_	_	Seg=O
301	.	_	_	_	_	_	_	_	Seg=O
302	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
303	.	_	_	_	_	_	_	_	Seg=O
304	The	_	_	_	_	_	_	_	Seg=B-seg
305	identification	_	_	_	_	_	_	_	Seg=O
306	of	_	_	_	_	_	_	_	Seg=O
307	known	_	_	_	_	_	_	_	Seg=O
308	risk	_	_	_	_	_	_	_	Seg=O
309	factors	_	_	_	_	_	_	_	Seg=O
310	for	_	_	_	_	_	_	_	Seg=O
311	severe	_	_	_	_	_	_	_	Seg=O
312	seasonal	_	_	_	_	_	_	_	Seg=O
313	influenza	_	_	_	_	_	_	_	Seg=O
314	and	_	_	_	_	_	_	_	Seg=O
315	the	_	_	_	_	_	_	_	Seg=O
316	more	_	_	_	_	_	_	_	Seg=O
317	protracted	_	_	_	_	_	_	_	Seg=O
318	clinical	_	_	_	_	_	_	_	Seg=O
319	course	_	_	_	_	_	_	_	Seg=O
320	compared	_	_	_	_	_	_	_	Seg=B-seg
321	with	_	_	_	_	_	_	_	Seg=O
322	that	_	_	_	_	_	_	_	Seg=O
323	of	_	_	_	_	_	_	_	Seg=O
324	H5N1	_	_	_	_	_	_	_	Seg=O
325	suggests	_	_	_	_	_	_	_	Seg=B-seg
326	that	_	_	_	_	_	_	_	Seg=B-seg
327	host	_	_	_	_	_	_	_	Seg=O
328	factors	_	_	_	_	_	_	_	Seg=O
329	are	_	_	_	_	_	_	_	Seg=O
330	an	_	_	_	_	_	_	_	Seg=O
331	important	_	_	_	_	_	_	_	Seg=O
332	contributor	_	_	_	_	_	_	_	Seg=O
333	to	_	_	_	_	_	_	_	Seg=O
334	H7N9	_	_	_	_	_	_	_	Seg=O
335	severity	_	_	_	_	_	_	_	Seg=O
336	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c526fbee33eed355a7c7437950603c4835418b0e
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	general	_	_	_	_	_	_	_	Seg=O
3	,	_	_	_	_	_	_	_	Seg=O
4	a	_	_	_	_	_	_	_	Seg=O
5	whole	_	_	_	_	_	_	_	Seg=O
6	virion	_	_	_	_	_	_	_	Seg=O
7	serves	_	_	_	_	_	_	_	Seg=O
8	as	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	simple	_	_	_	_	_	_	_	Seg=O
11	vaccine	_	_	_	_	_	_	_	Seg=O
12	antigen	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=O
14	often	_	_	_	_	_	_	_	Seg=O
15	essential	_	_	_	_	_	_	_	Seg=O
16	material	_	_	_	_	_	_	_	Seg=O
17	for	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	analysis	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	immune	_	_	_	_	_	_	_	Seg=O
22	responses	_	_	_	_	_	_	_	Seg=O
23	against	_	_	_	_	_	_	_	Seg=O
24	virus	_	_	_	_	_	_	_	Seg=O
25	infection	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	However	_	_	_	_	_	_	_	Seg=B-seg
28	,	_	_	_	_	_	_	_	Seg=O
29	to	_	_	_	_	_	_	_	Seg=B-seg
30	work	_	_	_	_	_	_	_	Seg=O
31	with	_	_	_	_	_	_	_	Seg=O
32	highly	_	_	_	_	_	_	_	Seg=O
33	contagious	_	_	_	_	_	_	_	Seg=O
34	pathogens	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	it	_	_	_	_	_	_	_	Seg=B-seg
37	is	_	_	_	_	_	_	_	Seg=O
38	necessary	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=O
40	take	_	_	_	_	_	_	_	Seg=O
41	precautions	_	_	_	_	_	_	_	Seg=O
42	against	_	_	_	_	_	_	_	Seg=O
43	laboratory	_	_	_	_	_	_	_	Seg=O
44	-	_	_	_	_	_	_	_	Seg=O
45	acquired	_	_	_	_	_	_	_	Seg=O
46	infection	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	We	_	_	_	_	_	_	_	Seg=B-seg
49	have	_	_	_	_	_	_	_	Seg=O
50	learned	_	_	_	_	_	_	_	Seg=O
51	many	_	_	_	_	_	_	_	Seg=O
52	lessons	_	_	_	_	_	_	_	Seg=O
53	from	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	recent	_	_	_	_	_	_	_	Seg=O
56	outbreak	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	severe	_	_	_	_	_	_	_	Seg=O
59	acute	_	_	_	_	_	_	_	Seg=O
60	respiratory	_	_	_	_	_	_	_	Seg=O
61	syndrome	_	_	_	_	_	_	_	Seg=O
62	(	_	_	_	_	_	_	_	Seg=O
63	SARS	_	_	_	_	_	_	_	Seg=O
64	)	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	In	_	_	_	_	_	_	_	Seg=B-seg
67	order	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=O
69	develop	_	_	_	_	_	_	_	Seg=O
70	an	_	_	_	_	_	_	_	Seg=O
71	effective	_	_	_	_	_	_	_	Seg=O
72	vaccine	_	_	_	_	_	_	_	Seg=O
73	and	_	_	_	_	_	_	_	Seg=O
74	diagnostic	_	_	_	_	_	_	_	Seg=O
75	tools	_	_	_	_	_	_	_	Seg=O
76	,	_	_	_	_	_	_	_	Seg=O
77	we	_	_	_	_	_	_	_	Seg=B-seg
78	prepared	_	_	_	_	_	_	_	Seg=O
79	UV	_	_	_	_	_	_	_	Seg=O
80	-	_	_	_	_	_	_	_	Seg=O
81	inactivated	_	_	_	_	_	_	_	Seg=O
82	SARS	_	_	_	_	_	_	_	Seg=O
83	coronavirus	_	_	_	_	_	_	_	Seg=O
84	on	_	_	_	_	_	_	_	Seg=O
85	a	_	_	_	_	_	_	_	Seg=O
86	large	_	_	_	_	_	_	_	Seg=O
87	scale	_	_	_	_	_	_	_	Seg=O
88	under	_	_	_	_	_	_	_	Seg=O
89	the	_	_	_	_	_	_	_	Seg=O
90	strict	_	_	_	_	_	_	_	Seg=O
91	Biosafety	_	_	_	_	_	_	_	Seg=O
92	Level	_	_	_	_	_	_	_	Seg=O
93	3	_	_	_	_	_	_	_	Seg=O
94	(	_	_	_	_	_	_	_	Seg=O
95	BSL3	_	_	_	_	_	_	_	Seg=O
96	)	_	_	_	_	_	_	_	Seg=O
97	regulation	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	Our	_	_	_	_	_	_	_	Seg=B-seg
100	protocol	_	_	_	_	_	_	_	Seg=O
101	for	_	_	_	_	_	_	_	Seg=O
102	large	_	_	_	_	_	_	_	Seg=O
103	-	_	_	_	_	_	_	_	Seg=O
104	scale	_	_	_	_	_	_	_	Seg=O
105	preparation	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	UV	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	inactivated	_	_	_	_	_	_	_	Seg=O
110	SARS	_	_	_	_	_	_	_	Seg=O
111	-	_	_	_	_	_	_	_	Seg=O
112	CoV	_	_	_	_	_	_	_	Seg=O
113	including	_	_	_	_	_	_	_	Seg=B-seg
114	virus	_	_	_	_	_	_	_	Seg=O
115	expansion	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	titration	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	inactivation	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	ultracentrifugation	_	_	_	_	_	_	_	Seg=O
123	is	_	_	_	_	_	_	_	Seg=B-seg
124	applicable	_	_	_	_	_	_	_	Seg=O
125	to	_	_	_	_	_	_	_	Seg=O
126	any	_	_	_	_	_	_	_	Seg=O
127	newly	_	_	_	_	_	_	_	Seg=O
128	emerging	_	_	_	_	_	_	_	Seg=O
129	virus	_	_	_	_	_	_	_	Seg=O
130	we	_	_	_	_	_	_	_	Seg=B-seg
131	might	_	_	_	_	_	_	_	Seg=O
132	encounter	_	_	_	_	_	_	_	Seg=O
133	in	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	future	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c635d21a8dd780ebae0bfe87fd7ef1d7d717c4ec
1	To	_	_	_	_	_	_	_	Seg=B-seg
2	assess	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	economic	_	_	_	_	_	_	_	Seg=O
5	impact	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	bovine	_	_	_	_	_	_	_	Seg=O
8	coronavirus	_	_	_	_	_	_	_	Seg=O
9	(	_	_	_	_	_	_	_	Seg=O
10	BCV	_	_	_	_	_	_	_	Seg=O
11	)	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	bovine	_	_	_	_	_	_	_	Seg=O
14	respiratory	_	_	_	_	_	_	_	Seg=O
15	syncytial	_	_	_	_	_	_	_	Seg=O
16	virus	_	_	_	_	_	_	_	Seg=O
17	(	_	_	_	_	_	_	_	Seg=O
18	BRSV	_	_	_	_	_	_	_	Seg=O
19	)	_	_	_	_	_	_	_	Seg=O
20	infections	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	accurate	_	_	_	_	_	_	_	Seg=B-seg
23	estimates	_	_	_	_	_	_	_	Seg=O
24	of	_	_	_	_	_	_	_	Seg=O
25	their	_	_	_	_	_	_	_	Seg=O
26	associated	_	_	_	_	_	_	_	Seg=O
27	effects	_	_	_	_	_	_	_	Seg=O
28	on	_	_	_	_	_	_	_	Seg=O
29	animal	_	_	_	_	_	_	_	Seg=O
30	performance	_	_	_	_	_	_	_	Seg=O
31	are	_	_	_	_	_	_	_	Seg=O
32	needed	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	This	_	_	_	_	_	_	_	Seg=B-seg
35	study	_	_	_	_	_	_	_	Seg=O
36	aimed	_	_	_	_	_	_	_	Seg=O
37	to	_	_	_	_	_	_	_	Seg=O
38	quantify	_	_	_	_	_	_	_	Seg=O
39	the	_	_	_	_	_	_	_	Seg=O
40	variation	_	_	_	_	_	_	_	Seg=O
41	in	_	_	_	_	_	_	_	Seg=O
42	individual	_	_	_	_	_	_	_	Seg=O
43	test	_	_	_	_	_	_	_	Seg=O
44	-	_	_	_	_	_	_	_	Seg=O
45	day	_	_	_	_	_	_	_	Seg=O
46	milk	_	_	_	_	_	_	_	Seg=O
47	yield	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	somatic	_	_	_	_	_	_	_	Seg=O
50	cell	_	_	_	_	_	_	_	Seg=O
51	count	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	risk	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	reproductive	_	_	_	_	_	_	_	Seg=O
56	failure	_	_	_	_	_	_	_	Seg=O
57	after	_	_	_	_	_	_	_	Seg=O
58	first	_	_	_	_	_	_	_	Seg=O
59	service	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	dairy	_	_	_	_	_	_	_	Seg=O
62	cows	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	risk	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	death	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	calves	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	heifers	_	_	_	_	_	_	_	Seg=O
72	according	_	_	_	_	_	_	_	Seg=O
73	to	_	_	_	_	_	_	_	Seg=O
74	the	_	_	_	_	_	_	_	Seg=O
75	BCV	_	_	_	_	_	_	_	Seg=O
76	and	_	_	_	_	_	_	_	Seg=O
77	BRSV	_	_	_	_	_	_	_	Seg=O
78	status	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	herd	_	_	_	_	_	_	_	Seg=O
82	.	_	_	_	_	_	_	_	Seg=O
83	Three	_	_	_	_	_	_	_	Seg=B-seg
84	types	_	_	_	_	_	_	_	Seg=O
85	of	_	_	_	_	_	_	_	Seg=O
86	status	_	_	_	_	_	_	_	Seg=O
87	were	_	_	_	_	_	_	_	Seg=O
88	defined	_	_	_	_	_	_	_	Seg=O
89	for	_	_	_	_	_	_	_	Seg=O
90	BCV	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	BRSV	_	_	_	_	_	_	_	Seg=O
93	infections	_	_	_	_	_	_	_	Seg=O
94	,	_	_	_	_	_	_	_	Seg=O
95	based	_	_	_	_	_	_	_	Seg=B-seg
96	on	_	_	_	_	_	_	_	Seg=O
97	1	_	_	_	_	_	_	_	Seg=O
98	)	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	dynamics	_	_	_	_	_	_	_	Seg=O
101	over	_	_	_	_	_	_	_	Seg=O
102	a	_	_	_	_	_	_	_	Seg=O
103	7-mo	_	_	_	_	_	_	_	Seg=O
104	period	_	_	_	_	_	_	_	Seg=O
105	of	_	_	_	_	_	_	_	Seg=O
106	BCV	_	_	_	_	_	_	_	Seg=O
107	-	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=O
109	BRSV	_	_	_	_	_	_	_	Seg=O
110	-	_	_	_	_	_	_	_	Seg=O
111	specific	_	_	_	_	_	_	_	Seg=O
112	antibody	_	_	_	_	_	_	_	Seg=O
113	levels	_	_	_	_	_	_	_	Seg=O
114	in	_	_	_	_	_	_	_	Seg=O
115	pooled	_	_	_	_	_	_	_	Seg=O
116	milk	_	_	_	_	_	_	_	Seg=O
117	of	_	_	_	_	_	_	_	Seg=O
118	primiparous	_	_	_	_	_	_	_	Seg=O
119	cows	_	_	_	_	_	_	_	Seg=O
120	;	_	_	_	_	_	_	_	Seg=O
121	2	_	_	_	_	_	_	_	Seg=B-seg
122	)	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	possible	_	_	_	_	_	_	_	Seg=O
125	occurrence	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	presumably	_	_	_	_	_	_	_	Seg=O
128	BCV	_	_	_	_	_	_	_	Seg=O
129	-	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	BRSV	_	_	_	_	_	_	_	Seg=O
132	-	_	_	_	_	_	_	_	Seg=O
133	related	_	_	_	_	_	_	_	Seg=O
134	clinical	_	_	_	_	_	_	_	Seg=O
135	outbreaks	_	_	_	_	_	_	_	Seg=O
136	;	_	_	_	_	_	_	_	Seg=O
137	and	_	_	_	_	_	_	_	Seg=B-seg
138	3	_	_	_	_	_	_	_	Seg=O
139	)	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	combination	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	both	_	_	_	_	_	_	_	Seg=O
144	pieces	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	information	_	_	_	_	_	_	_	Seg=O
147	.	_	_	_	_	_	_	_	Seg=O
148	A	_	_	_	_	_	_	_	Seg=B-seg
149	total	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	36,184	_	_	_	_	_	_	_	Seg=O
152	test	_	_	_	_	_	_	_	Seg=O
153	days	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	2,716	_	_	_	_	_	_	_	Seg=O
156	cows	_	_	_	_	_	_	_	Seg=O
157	with	_	_	_	_	_	_	_	Seg=O
158	a	_	_	_	_	_	_	_	Seg=O
159	first	_	_	_	_	_	_	_	Seg=O
160	service	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=O
163	4,104	_	_	_	_	_	_	_	Seg=O
164	calves	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=O
166	heifers	_	_	_	_	_	_	_	Seg=O
167	in	_	_	_	_	_	_	_	Seg=O
168	65	_	_	_	_	_	_	_	Seg=O
169	Swedish	_	_	_	_	_	_	_	Seg=O
170	herds	_	_	_	_	_	_	_	Seg=O
171	were	_	_	_	_	_	_	_	Seg=O
172	included	_	_	_	_	_	_	_	Seg=O
173	in	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	analyses	_	_	_	_	_	_	_	Seg=O
176	.	_	_	_	_	_	_	_	Seg=O
177	Animal	_	_	_	_	_	_	_	Seg=B-seg
178	performance	_	_	_	_	_	_	_	Seg=O
179	associated	_	_	_	_	_	_	_	Seg=O
180	with	_	_	_	_	_	_	_	Seg=O
181	BCV	_	_	_	_	_	_	_	Seg=O
182	and	_	_	_	_	_	_	_	Seg=O
183	BRSV	_	_	_	_	_	_	_	Seg=O
184	infections	_	_	_	_	_	_	_	Seg=O
185	was	_	_	_	_	_	_	_	Seg=O
186	quantified	_	_	_	_	_	_	_	Seg=O
187	using	_	_	_	_	_	_	_	Seg=B-seg
188	hierarchical	_	_	_	_	_	_	_	Seg=O
189	mixed	_	_	_	_	_	_	_	Seg=O
190	generalized	_	_	_	_	_	_	_	Seg=O
191	and	_	_	_	_	_	_	_	Seg=O
192	survival	_	_	_	_	_	_	_	Seg=O
193	models	_	_	_	_	_	_	_	Seg=O
194	,	_	_	_	_	_	_	_	Seg=O
195	after	_	_	_	_	_	_	_	Seg=O
196	adjustment	_	_	_	_	_	_	_	Seg=O
197	for	_	_	_	_	_	_	_	Seg=O
198	covariates	_	_	_	_	_	_	_	Seg=O
199	known	_	_	_	_	_	_	_	Seg=B-seg
200	to	_	_	_	_	_	_	_	Seg=O
201	influence	_	_	_	_	_	_	_	Seg=O
202	the	_	_	_	_	_	_	_	Seg=O
203	performance	_	_	_	_	_	_	_	Seg=O
204	under	_	_	_	_	_	_	_	Seg=O
205	study	_	_	_	_	_	_	_	Seg=O
206	.	_	_	_	_	_	_	_	Seg=O
207	A	_	_	_	_	_	_	_	Seg=B-seg
208	significant	_	_	_	_	_	_	_	Seg=O
209	reduction	_	_	_	_	_	_	_	Seg=O
210	in	_	_	_	_	_	_	_	Seg=O
211	milk	_	_	_	_	_	_	_	Seg=O
212	yield	_	_	_	_	_	_	_	Seg=O
213	was	_	_	_	_	_	_	_	Seg=O
214	observed	_	_	_	_	_	_	_	Seg=O
215	for	_	_	_	_	_	_	_	Seg=O
216	cows	_	_	_	_	_	_	_	Seg=O
217	in	_	_	_	_	_	_	_	Seg=O
218	presumably	_	_	_	_	_	_	_	Seg=O
219	BRSV	_	_	_	_	_	_	_	Seg=O
220	recently	_	_	_	_	_	_	_	Seg=O
221	infected	_	_	_	_	_	_	_	Seg=O
222	herds	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	as	_	_	_	_	_	_	_	Seg=O
225	well	_	_	_	_	_	_	_	Seg=O
226	as	_	_	_	_	_	_	_	Seg=O
227	in	_	_	_	_	_	_	_	Seg=O
228	herds	_	_	_	_	_	_	_	Seg=O
229	having	_	_	_	_	_	_	_	Seg=O
230	a	_	_	_	_	_	_	_	Seg=O
231	presumably	_	_	_	_	_	_	_	Seg=O
232	BRSV	_	_	_	_	_	_	_	Seg=O
233	-	_	_	_	_	_	_	_	Seg=O
234	related	_	_	_	_	_	_	_	Seg=O
235	clinical	_	_	_	_	_	_	_	Seg=O
236	outbreak	_	_	_	_	_	_	_	Seg=O
237	(	_	_	_	_	_	_	_	Seg=B-seg
238	of	_	_	_	_	_	_	_	Seg=O
239	0.57	_	_	_	_	_	_	_	Seg=O
240	and	_	_	_	_	_	_	_	Seg=O
241	0.91	_	_	_	_	_	_	_	Seg=O
242	kg	_	_	_	_	_	_	_	Seg=O
243	/	_	_	_	_	_	_	_	Seg=O
244	d	_	_	_	_	_	_	_	Seg=O
245	,	_	_	_	_	_	_	_	Seg=O
246	respectively	_	_	_	_	_	_	_	Seg=O
247	)	_	_	_	_	_	_	_	Seg=O
248	,	_	_	_	_	_	_	_	Seg=O
249	compared	_	_	_	_	_	_	_	Seg=B-seg
250	with	_	_	_	_	_	_	_	Seg=O
251	cows	_	_	_	_	_	_	_	Seg=O
252	in	_	_	_	_	_	_	_	Seg=O
253	presumably	_	_	_	_	_	_	_	Seg=O
254	infection	_	_	_	_	_	_	_	Seg=O
255	-	_	_	_	_	_	_	_	Seg=O
256	free	_	_	_	_	_	_	_	Seg=O
257	herds	_	_	_	_	_	_	_	Seg=O
258	.	_	_	_	_	_	_	_	Seg=O
259	There	_	_	_	_	_	_	_	Seg=B-seg
260	was	_	_	_	_	_	_	_	Seg=O
261	also	_	_	_	_	_	_	_	Seg=O
262	a	_	_	_	_	_	_	_	Seg=O
263	significant	_	_	_	_	_	_	_	Seg=O
264	increase	_	_	_	_	_	_	_	Seg=O
265	in	_	_	_	_	_	_	_	Seg=O
266	somatic	_	_	_	_	_	_	_	Seg=O
267	cell	_	_	_	_	_	_	_	Seg=O
268	count	_	_	_	_	_	_	_	Seg=O
269	(	_	_	_	_	_	_	_	Seg=B-seg
270	of	_	_	_	_	_	_	_	Seg=O
271	12,000	_	_	_	_	_	_	_	Seg=O
272	cells	_	_	_	_	_	_	_	Seg=O
273	/	_	_	_	_	_	_	_	Seg=O
274	mL	_	_	_	_	_	_	_	Seg=O
275	)	_	_	_	_	_	_	_	Seg=O
276	for	_	_	_	_	_	_	_	Seg=B-seg
277	cows	_	_	_	_	_	_	_	Seg=O
278	located	_	_	_	_	_	_	_	Seg=O
279	in	_	_	_	_	_	_	_	Seg=O
280	herds	_	_	_	_	_	_	_	Seg=O
281	with	_	_	_	_	_	_	_	Seg=O
282	a	_	_	_	_	_	_	_	Seg=O
283	BRSV	_	_	_	_	_	_	_	Seg=O
284	outbreak	_	_	_	_	_	_	_	Seg=O
285	.	_	_	_	_	_	_	_	Seg=O
286	The	_	_	_	_	_	_	_	Seg=B-seg
287	risk	_	_	_	_	_	_	_	Seg=O
288	of	_	_	_	_	_	_	_	Seg=O
289	failure	_	_	_	_	_	_	_	Seg=O
290	after	_	_	_	_	_	_	_	Seg=O
291	first	_	_	_	_	_	_	_	Seg=O
292	service	_	_	_	_	_	_	_	Seg=O
293	,	_	_	_	_	_	_	_	Seg=O
294	as	_	_	_	_	_	_	_	Seg=O
295	well	_	_	_	_	_	_	_	Seg=O
296	as	_	_	_	_	_	_	_	Seg=O
297	the	_	_	_	_	_	_	_	Seg=O
298	risk	_	_	_	_	_	_	_	Seg=O
299	of	_	_	_	_	_	_	_	Seg=O
300	death	_	_	_	_	_	_	_	Seg=O
301	in	_	_	_	_	_	_	_	Seg=O
302	calf	_	_	_	_	_	_	_	Seg=O
303	and	_	_	_	_	_	_	_	Seg=O
304	heifer	_	_	_	_	_	_	_	Seg=O
305	,	_	_	_	_	_	_	_	Seg=O
306	was	_	_	_	_	_	_	_	Seg=O
307	numerically	_	_	_	_	_	_	_	Seg=O
308	higher	_	_	_	_	_	_	_	Seg=O
309	in	_	_	_	_	_	_	_	Seg=O
310	BRSV	_	_	_	_	_	_	_	Seg=O
311	-	_	_	_	_	_	_	_	Seg=O
312	infected	_	_	_	_	_	_	_	Seg=O
313	herds	_	_	_	_	_	_	_	Seg=O
314	,	_	_	_	_	_	_	_	Seg=O
315	although	_	_	_	_	_	_	_	Seg=B-seg
316	this	_	_	_	_	_	_	_	Seg=O
317	was	_	_	_	_	_	_	_	Seg=O
318	not	_	_	_	_	_	_	_	Seg=O
319	statistically	_	_	_	_	_	_	_	Seg=O
320	significant	_	_	_	_	_	_	_	Seg=O
321	.	_	_	_	_	_	_	_	Seg=O
322	In	_	_	_	_	_	_	_	Seg=B-seg
323	contrast	_	_	_	_	_	_	_	Seg=O
324	,	_	_	_	_	_	_	_	Seg=O
325	BCV	_	_	_	_	_	_	_	Seg=O
326	infection	_	_	_	_	_	_	_	Seg=O
327	herd	_	_	_	_	_	_	_	Seg=O
328	status	_	_	_	_	_	_	_	Seg=O
329	,	_	_	_	_	_	_	_	Seg=O
330	as	_	_	_	_	_	_	_	Seg=B-seg
331	defined	_	_	_	_	_	_	_	Seg=O
332	in	_	_	_	_	_	_	_	Seg=O
333	the	_	_	_	_	_	_	_	Seg=O
334	present	_	_	_	_	_	_	_	Seg=O
335	study	_	_	_	_	_	_	_	Seg=O
336	,	_	_	_	_	_	_	_	Seg=O
337	was	_	_	_	_	_	_	_	Seg=B-seg
338	not	_	_	_	_	_	_	_	Seg=O
339	significantly	_	_	_	_	_	_	_	Seg=O
340	associated	_	_	_	_	_	_	_	Seg=O
341	with	_	_	_	_	_	_	_	Seg=O
342	any	_	_	_	_	_	_	_	Seg=O
343	production	_	_	_	_	_	_	_	Seg=O
344	losses	_	_	_	_	_	_	_	Seg=O
345	in	_	_	_	_	_	_	_	Seg=O
346	animals	_	_	_	_	_	_	_	Seg=O
347	from	_	_	_	_	_	_	_	Seg=O
348	infected	_	_	_	_	_	_	_	Seg=O
349	herds	_	_	_	_	_	_	_	Seg=O
350	compared	_	_	_	_	_	_	_	Seg=B-seg
351	with	_	_	_	_	_	_	_	Seg=O
352	those	_	_	_	_	_	_	_	Seg=O
353	in	_	_	_	_	_	_	_	Seg=O
354	infection	_	_	_	_	_	_	_	Seg=O
355	-	_	_	_	_	_	_	_	Seg=O
356	free	_	_	_	_	_	_	_	Seg=O
357	herds	_	_	_	_	_	_	_	Seg=O
358	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c74427793f554edd3e181603dfdf53f4c89ad129
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	treatment	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	surgical	_	_	_	_	_	_	_	Seg=O
5	patients	_	_	_	_	_	_	_	Seg=O
6	who	_	_	_	_	_	_	_	Seg=B-seg
7	are	_	_	_	_	_	_	_	Seg=O
8	confirmed	_	_	_	_	_	_	_	Seg=O
9	or	_	_	_	_	_	_	_	Seg=O
10	suspected	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	coronavirus	_	_	_	_	_	_	_	Seg=O
13	disease	_	_	_	_	_	_	_	Seg=O
14	2019	_	_	_	_	_	_	_	Seg=O
15	(	_	_	_	_	_	_	_	Seg=O
16	COVID-19	_	_	_	_	_	_	_	Seg=O
17	)	_	_	_	_	_	_	_	Seg=O
18	is	_	_	_	_	_	_	_	Seg=B-seg
19	a	_	_	_	_	_	_	_	Seg=O
20	challenge	_	_	_	_	_	_	_	Seg=O
21	for	_	_	_	_	_	_	_	Seg=O
22	all	_	_	_	_	_	_	_	Seg=O
23	anesthesiologists	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	The	_	_	_	_	_	_	_	Seg=B-seg
26	safety	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	both	_	_	_	_	_	_	_	Seg=O
29	patients	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	healthcare	_	_	_	_	_	_	_	Seg=O
32	workers	_	_	_	_	_	_	_	Seg=O
33	should	_	_	_	_	_	_	_	Seg=O
34	be	_	_	_	_	_	_	_	Seg=O
35	taken	_	_	_	_	_	_	_	Seg=O
36	into	_	_	_	_	_	_	_	Seg=O
37	consideration	_	_	_	_	_	_	_	Seg=O
38	when	_	_	_	_	_	_	_	Seg=B-seg
39	performing	_	_	_	_	_	_	_	Seg=O
40	anesthesia	_	_	_	_	_	_	_	Seg=O
41	management	_	_	_	_	_	_	_	Seg=O
42	for	_	_	_	_	_	_	_	Seg=O
43	patients	_	_	_	_	_	_	_	Seg=O
44	with	_	_	_	_	_	_	_	Seg=O
45	COVID-19	_	_	_	_	_	_	_	Seg=O
46	.	_	_	_	_	_	_	_	Seg=O
47	General	_	_	_	_	_	_	_	Seg=B-seg
48	anesthesia	_	_	_	_	_	_	_	Seg=O
49	requiring	_	_	_	_	_	_	_	Seg=B-seg
50	airway	_	_	_	_	_	_	_	Seg=O
51	intervention	_	_	_	_	_	_	_	Seg=O
52	may	_	_	_	_	_	_	_	Seg=B-seg
53	exacerbate	_	_	_	_	_	_	_	Seg=O
54	COVID-19	_	_	_	_	_	_	_	Seg=O
55	pneumonia	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=B-seg
58	aerosol	_	_	_	_	_	_	_	Seg=O
59	generation	_	_	_	_	_	_	_	Seg=O
60	during	_	_	_	_	_	_	_	Seg=O
61	airway	_	_	_	_	_	_	_	Seg=O
62	intervention	_	_	_	_	_	_	_	Seg=O
63	risks	_	_	_	_	_	_	_	Seg=O
64	COVID-19	_	_	_	_	_	_	_	Seg=O
65	transmission	_	_	_	_	_	_	_	Seg=O
66	to	_	_	_	_	_	_	_	Seg=O
67	medical	_	_	_	_	_	_	_	Seg=O
68	staff	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	However	_	_	_	_	_	_	_	Seg=B-seg
71	,	_	_	_	_	_	_	_	Seg=O
72	regional	_	_	_	_	_	_	_	Seg=O
73	anesthesia	_	_	_	_	_	_	_	Seg=O
74	is	_	_	_	_	_	_	_	Seg=O
75	not	_	_	_	_	_	_	_	Seg=O
76	an	_	_	_	_	_	_	_	Seg=O
77	aerosol	_	_	_	_	_	_	_	Seg=O
78	-	_	_	_	_	_	_	_	Seg=O
79	generating	_	_	_	_	_	_	_	Seg=O
80	procedure	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	The	_	_	_	_	_	_	_	Seg=B-seg
83	neuraxial	_	_	_	_	_	_	_	Seg=O
84	anesthesia	_	_	_	_	_	_	_	Seg=O
85	may	_	_	_	_	_	_	_	Seg=O
86	have	_	_	_	_	_	_	_	Seg=O
87	little	_	_	_	_	_	_	_	Seg=O
88	adverse	_	_	_	_	_	_	_	Seg=O
89	influence	_	_	_	_	_	_	_	Seg=O
90	on	_	_	_	_	_	_	_	Seg=O
91	clinical	_	_	_	_	_	_	_	Seg=O
92	outcomes	_	_	_	_	_	_	_	Seg=O
93	in	_	_	_	_	_	_	_	Seg=O
94	patients	_	_	_	_	_	_	_	Seg=O
95	with	_	_	_	_	_	_	_	Seg=O
96	COVID-19	_	_	_	_	_	_	_	Seg=O
97	after	_	_	_	_	_	_	_	Seg=B-seg
98	reviewing	_	_	_	_	_	_	_	Seg=O
99	previous	_	_	_	_	_	_	_	Seg=O
100	case	_	_	_	_	_	_	_	Seg=O
101	reports	_	_	_	_	_	_	_	Seg=O
102	.	_	_	_	_	_	_	_	Seg=O
103	Regional	_	_	_	_	_	_	_	Seg=B-seg
104	anesthesia	_	_	_	_	_	_	_	Seg=O
105	may	_	_	_	_	_	_	_	Seg=O
106	have	_	_	_	_	_	_	_	Seg=O
107	some	_	_	_	_	_	_	_	Seg=O
108	advantages	_	_	_	_	_	_	_	Seg=O
109	over	_	_	_	_	_	_	_	Seg=O
110	general	_	_	_	_	_	_	_	Seg=O
111	anesthesia	_	_	_	_	_	_	_	Seg=O
112	for	_	_	_	_	_	_	_	Seg=O
113	this	_	_	_	_	_	_	_	Seg=O
114	group	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	patients	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	but	_	_	_	_	_	_	_	Seg=B-seg
119	unplanned	_	_	_	_	_	_	_	Seg=O
120	conversion	_	_	_	_	_	_	_	Seg=O
121	to	_	_	_	_	_	_	_	Seg=O
122	general	_	_	_	_	_	_	_	Seg=O
123	anesthesia	_	_	_	_	_	_	_	Seg=O
124	during	_	_	_	_	_	_	_	Seg=O
125	surgery	_	_	_	_	_	_	_	Seg=O
126	is	_	_	_	_	_	_	_	Seg=O
127	not	_	_	_	_	_	_	_	Seg=O
128	preferred	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	Thus	_	_	_	_	_	_	_	Seg=B-seg
131	,	_	_	_	_	_	_	_	Seg=O
132	careful	_	_	_	_	_	_	_	Seg=O
133	consideration	_	_	_	_	_	_	_	Seg=O
134	should	_	_	_	_	_	_	_	Seg=O
135	be	_	_	_	_	_	_	_	Seg=O
136	given	_	_	_	_	_	_	_	Seg=O
137	to	_	_	_	_	_	_	_	Seg=B-seg
138	ensure	_	_	_	_	_	_	_	Seg=O
139	that	_	_	_	_	_	_	_	Seg=B-seg
140	the	_	_	_	_	_	_	_	Seg=O
141	surgery	_	_	_	_	_	_	_	Seg=O
142	is	_	_	_	_	_	_	_	Seg=O
143	performed	_	_	_	_	_	_	_	Seg=O
144	entirely	_	_	_	_	_	_	_	Seg=O
145	under	_	_	_	_	_	_	_	Seg=O
146	regional	_	_	_	_	_	_	_	Seg=O
147	anesthesia	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	The	_	_	_	_	_	_	_	Seg=B-seg
150	use	_	_	_	_	_	_	_	Seg=O
151	of	_	_	_	_	_	_	_	Seg=O
152	ultrasound	_	_	_	_	_	_	_	Seg=O
153	guidance	_	_	_	_	_	_	_	Seg=O
154	and	_	_	_	_	_	_	_	Seg=O
155	the	_	_	_	_	_	_	_	Seg=O
156	performance	_	_	_	_	_	_	_	Seg=O
157	by	_	_	_	_	_	_	_	Seg=O
158	an	_	_	_	_	_	_	_	Seg=O
159	experienced	_	_	_	_	_	_	_	Seg=O
160	physician	_	_	_	_	_	_	_	Seg=O
161	may	_	_	_	_	_	_	_	Seg=O
162	reduce	_	_	_	_	_	_	_	Seg=O
163	the	_	_	_	_	_	_	_	Seg=O
164	incidence	_	_	_	_	_	_	_	Seg=O
165	of	_	_	_	_	_	_	_	Seg=O
166	failed	_	_	_	_	_	_	_	Seg=O
167	block	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=O
169	complications	_	_	_	_	_	_	_	Seg=O
170	.	_	_	_	_	_	_	_	Seg=O
171	The	_	_	_	_	_	_	_	Seg=B-seg
172	use	_	_	_	_	_	_	_	Seg=O
173	of	_	_	_	_	_	_	_	Seg=O
174	long	_	_	_	_	_	_	_	Seg=O
175	-	_	_	_	_	_	_	_	Seg=O
176	acting	_	_	_	_	_	_	_	Seg=O
177	local	_	_	_	_	_	_	_	Seg=O
178	anesthetic	_	_	_	_	_	_	_	Seg=O
179	prolongs	_	_	_	_	_	_	_	Seg=O
180	the	_	_	_	_	_	_	_	Seg=O
181	anesthetic	_	_	_	_	_	_	_	Seg=O
182	effect	_	_	_	_	_	_	_	Seg=O
183	of	_	_	_	_	_	_	_	Seg=O
184	regional	_	_	_	_	_	_	_	Seg=O
185	anesthesia	_	_	_	_	_	_	_	Seg=O
186	.	_	_	_	_	_	_	_	Seg=O
187	Besides	_	_	_	_	_	_	_	Seg=B-seg
188	,	_	_	_	_	_	_	_	Seg=O
189	a	_	_	_	_	_	_	_	Seg=O
190	safe	_	_	_	_	_	_	_	Seg=O
191	and	_	_	_	_	_	_	_	Seg=O
192	sufficient	_	_	_	_	_	_	_	Seg=O
193	dose	_	_	_	_	_	_	_	Seg=O
194	of	_	_	_	_	_	_	_	Seg=O
195	local	_	_	_	_	_	_	_	Seg=O
196	anesthetic	_	_	_	_	_	_	_	Seg=O
197	should	_	_	_	_	_	_	_	Seg=O
198	be	_	_	_	_	_	_	_	Seg=O
199	used	_	_	_	_	_	_	_	Seg=O
200	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c90121a3f539b59d4b528f3a1dd172b75533c0cc
1	Bird	_	_	_	_	_	_	_	Seg=B-seg
2	to	_	_	_	_	_	_	_	Seg=O
3	human	_	_	_	_	_	_	_	Seg=O
4	transmission	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	high	_	_	_	_	_	_	_	Seg=O
7	pathogenicity	_	_	_	_	_	_	_	Seg=O
8	avian	_	_	_	_	_	_	_	Seg=O
9	influenza	_	_	_	_	_	_	_	Seg=O
10	virus	_	_	_	_	_	_	_	Seg=O
11	(	_	_	_	_	_	_	_	Seg=O
12	HPAIV	_	_	_	_	_	_	_	Seg=O
13	)	_	_	_	_	_	_	_	Seg=O
14	poses	_	_	_	_	_	_	_	Seg=O
15	a	_	_	_	_	_	_	_	Seg=O
16	significant	_	_	_	_	_	_	_	Seg=O
17	risk	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=B-seg
19	triggering	_	_	_	_	_	_	_	Seg=O
20	a	_	_	_	_	_	_	_	Seg=O
21	flu	_	_	_	_	_	_	_	Seg=O
22	pandemic	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	human	_	_	_	_	_	_	_	Seg=O
26	population	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	Therefore	_	_	_	_	_	_	_	Seg=B-seg
29	,	_	_	_	_	_	_	_	Seg=O
30	vaccination	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	susceptible	_	_	_	_	_	_	_	Seg=O
33	poultry	_	_	_	_	_	_	_	Seg=O
34	during	_	_	_	_	_	_	_	Seg=O
35	an	_	_	_	_	_	_	_	Seg=O
36	HPAIV	_	_	_	_	_	_	_	Seg=O
37	outbreak	_	_	_	_	_	_	_	Seg=O
38	might	_	_	_	_	_	_	_	Seg=O
39	be	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	best	_	_	_	_	_	_	_	Seg=O
42	remedy	_	_	_	_	_	_	_	Seg=O
43	to	_	_	_	_	_	_	_	Seg=B-seg
44	prevent	_	_	_	_	_	_	_	Seg=O
45	such	_	_	_	_	_	_	_	Seg=O
46	transmissions	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	To	_	_	_	_	_	_	_	Seg=B-seg
49	this	_	_	_	_	_	_	_	Seg=O
50	end	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	suitable	_	_	_	_	_	_	_	Seg=O
53	formulations	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=O
55	an	_	_	_	_	_	_	_	Seg=O
56	effective	_	_	_	_	_	_	_	Seg=O
57	mass	_	_	_	_	_	_	_	Seg=O
58	vaccination	_	_	_	_	_	_	_	Seg=O
59	method	_	_	_	_	_	_	_	Seg=O
60	that	_	_	_	_	_	_	_	Seg=B-seg
61	can	_	_	_	_	_	_	_	Seg=O
62	be	_	_	_	_	_	_	_	Seg=O
63	translated	_	_	_	_	_	_	_	Seg=O
64	to	_	_	_	_	_	_	_	Seg=O
65	field	_	_	_	_	_	_	_	Seg=O
66	settings	_	_	_	_	_	_	_	Seg=O
67	needs	_	_	_	_	_	_	_	Seg=B-seg
68	to	_	_	_	_	_	_	_	Seg=O
69	be	_	_	_	_	_	_	_	Seg=O
70	developed	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	Our	_	_	_	_	_	_	_	Seg=B-seg
73	previous	_	_	_	_	_	_	_	Seg=O
74	study	_	_	_	_	_	_	_	Seg=O
75	in	_	_	_	_	_	_	_	Seg=O
76	chickens	_	_	_	_	_	_	_	Seg=O
77	has	_	_	_	_	_	_	_	Seg=O
78	shown	_	_	_	_	_	_	_	Seg=O
79	that	_	_	_	_	_	_	_	Seg=B-seg
80	inhalation	_	_	_	_	_	_	_	Seg=O
81	of	_	_	_	_	_	_	_	Seg=O
82	a	_	_	_	_	_	_	_	Seg=O
83	non	_	_	_	_	_	_	_	Seg=O
84	-	_	_	_	_	_	_	_	Seg=O
85	adjuvanted	_	_	_	_	_	_	_	Seg=O
86	dry	_	_	_	_	_	_	_	Seg=O
87	powder	_	_	_	_	_	_	_	Seg=O
88	influenza	_	_	_	_	_	_	_	Seg=O
89	vaccine	_	_	_	_	_	_	_	Seg=O
90	formulation	_	_	_	_	_	_	_	Seg=O
91	during	_	_	_	_	_	_	_	Seg=O
92	normal	_	_	_	_	_	_	_	Seg=O
93	breathing	_	_	_	_	_	_	_	Seg=O
94	results	_	_	_	_	_	_	_	Seg=O
95	in	_	_	_	_	_	_	_	Seg=O
96	partial	_	_	_	_	_	_	_	Seg=O
97	protection	_	_	_	_	_	_	_	Seg=O
98	against	_	_	_	_	_	_	_	Seg=O
99	lethal	_	_	_	_	_	_	_	Seg=O
100	influenza	_	_	_	_	_	_	_	Seg=O
101	challenge	_	_	_	_	_	_	_	Seg=O
102	.	_	_	_	_	_	_	_	Seg=O
103	The	_	_	_	_	_	_	_	Seg=B-seg
104	aim	_	_	_	_	_	_	_	Seg=O
105	of	_	_	_	_	_	_	_	Seg=O
106	the	_	_	_	_	_	_	_	Seg=O
107	present	_	_	_	_	_	_	_	Seg=O
108	study	_	_	_	_	_	_	_	Seg=O
109	was	_	_	_	_	_	_	_	Seg=O
110	to	_	_	_	_	_	_	_	Seg=O
111	improve	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	effectiveness	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	pulmonary	_	_	_	_	_	_	_	Seg=O
116	vaccination	_	_	_	_	_	_	_	Seg=O
117	by	_	_	_	_	_	_	_	Seg=B-seg
118	increasing	_	_	_	_	_	_	_	Seg=O
119	the	_	_	_	_	_	_	_	Seg=O
120	vaccine	_	_	_	_	_	_	_	Seg=O
121	dose	_	_	_	_	_	_	_	Seg=O
122	deposited	_	_	_	_	_	_	_	Seg=B-seg
123	in	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	lungs	_	_	_	_	_	_	_	Seg=O
126	and	_	_	_	_	_	_	_	Seg=B-seg
127	by	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	use	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	suitable	_	_	_	_	_	_	_	Seg=O
132	adjuvants	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O
134	Two	_	_	_	_	_	_	_	Seg=B-seg
135	adjuvants	_	_	_	_	_	_	_	Seg=O
136	,	_	_	_	_	_	_	_	Seg=O
137	namely	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	Bacterium	_	_	_	_	_	_	_	Seg=O
140	-	_	_	_	_	_	_	_	Seg=O
141	like	_	_	_	_	_	_	_	Seg=O
142	Particles	_	_	_	_	_	_	_	Seg=O
143	(	_	_	_	_	_	_	_	Seg=O
144	BLP	_	_	_	_	_	_	_	Seg=O
145	)	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	Advax	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	were	_	_	_	_	_	_	_	Seg=O
150	spray	_	_	_	_	_	_	_	Seg=O
151	freeze	_	_	_	_	_	_	_	Seg=O
152	dried	_	_	_	_	_	_	_	Seg=O
153	with	_	_	_	_	_	_	_	Seg=O
154	influenza	_	_	_	_	_	_	_	Seg=O
155	vaccine	_	_	_	_	_	_	_	Seg=O
156	into	_	_	_	_	_	_	_	Seg=O
157	dry	_	_	_	_	_	_	_	Seg=O
158	powder	_	_	_	_	_	_	_	Seg=O
159	formulations	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O
161	Delivery	_	_	_	_	_	_	_	Seg=B-seg
162	of	_	_	_	_	_	_	_	Seg=O
163	dry	_	_	_	_	_	_	_	Seg=O
164	formulations	_	_	_	_	_	_	_	Seg=O
165	directly	_	_	_	_	_	_	_	Seg=O
166	at	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	syrinx	_	_	_	_	_	_	_	Seg=O
169	revealed	_	_	_	_	_	_	_	Seg=O
170	that	_	_	_	_	_	_	_	Seg=B-seg
171	BLP	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=O
173	Advax	_	_	_	_	_	_	_	Seg=O
174	had	_	_	_	_	_	_	_	Seg=O
175	the	_	_	_	_	_	_	_	Seg=O
176	potential	_	_	_	_	_	_	_	Seg=O
177	to	_	_	_	_	_	_	_	Seg=B-seg
178	boost	_	_	_	_	_	_	_	Seg=O
179	either	_	_	_	_	_	_	_	Seg=O
180	systemic	_	_	_	_	_	_	_	Seg=O
181	or	_	_	_	_	_	_	_	Seg=O
182	mucosal	_	_	_	_	_	_	_	Seg=O
183	immune	_	_	_	_	_	_	_	Seg=O
184	responses	_	_	_	_	_	_	_	Seg=O
185	or	_	_	_	_	_	_	_	Seg=O
186	both	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	Upon	_	_	_	_	_	_	_	Seg=B-seg
189	passive	_	_	_	_	_	_	_	Seg=O
190	inhalation	_	_	_	_	_	_	_	Seg=O
191	of	_	_	_	_	_	_	_	Seg=O
192	dry	_	_	_	_	_	_	_	Seg=O
193	influenza	_	_	_	_	_	_	_	Seg=O
194	vaccine	_	_	_	_	_	_	_	Seg=O
195	formulations	_	_	_	_	_	_	_	Seg=O
196	in	_	_	_	_	_	_	_	Seg=O
197	an	_	_	_	_	_	_	_	Seg=O
198	optimized	_	_	_	_	_	_	_	Seg=O
199	set	_	_	_	_	_	_	_	Seg=O
200	-	_	_	_	_	_	_	_	Seg=O
201	up	_	_	_	_	_	_	_	Seg=O
202	,	_	_	_	_	_	_	_	Seg=O
203	BLP	_	_	_	_	_	_	_	Seg=O
204	and	_	_	_	_	_	_	_	Seg=O
205	Advax	_	_	_	_	_	_	_	Seg=O
206	/	_	_	_	_	_	_	_	Seg=O
207	BLP	_	_	_	_	_	_	_	Seg=O
208	adjuvanted	_	_	_	_	_	_	_	Seg=O
209	formulations	_	_	_	_	_	_	_	Seg=O
210	induced	_	_	_	_	_	_	_	Seg=O
211	significantly	_	_	_	_	_	_	_	Seg=O
212	higher	_	_	_	_	_	_	_	Seg=O
213	systemic	_	_	_	_	_	_	_	Seg=O
214	immune	_	_	_	_	_	_	_	Seg=O
215	responses	_	_	_	_	_	_	_	Seg=O
216	than	_	_	_	_	_	_	_	Seg=O
217	the	_	_	_	_	_	_	_	Seg=O
218	nonadjuvanted	_	_	_	_	_	_	_	Seg=O
219	formulation	_	_	_	_	_	_	_	Seg=O
220	.	_	_	_	_	_	_	_	Seg=O
221	Remarkably	_	_	_	_	_	_	_	Seg=B-seg
222	,	_	_	_	_	_	_	_	Seg=O
223	all	_	_	_	_	_	_	_	Seg=O
224	vaccinated	_	_	_	_	_	_	_	Seg=O
225	animals	_	_	_	_	_	_	_	Seg=O
226	not	_	_	_	_	_	_	_	Seg=O
227	only	_	_	_	_	_	_	_	Seg=O
228	survived	_	_	_	_	_	_	_	Seg=O
229	a	_	_	_	_	_	_	_	Seg=O
230	lethal	_	_	_	_	_	_	_	Seg=O
231	influenza	_	_	_	_	_	_	_	Seg=O
232	challenge	_	_	_	_	_	_	_	Seg=O
233	,	_	_	_	_	_	_	_	Seg=O
234	but	_	_	_	_	_	_	_	Seg=B-seg
235	also	_	_	_	_	_	_	_	Seg=O
236	did	_	_	_	_	_	_	_	Seg=O
237	not	_	_	_	_	_	_	_	Seg=O
238	show	_	_	_	_	_	_	_	Seg=O
239	any	_	_	_	_	_	_	_	Seg=O
240	shedding	_	_	_	_	_	_	_	Seg=O
241	of	_	_	_	_	_	_	_	Seg=O
242	challenge	_	_	_	_	_	_	_	Seg=O
243	virus	_	_	_	_	_	_	_	Seg=O
244	except	_	_	_	_	_	_	_	Seg=O
245	for	_	_	_	_	_	_	_	Seg=O
246	two	_	_	_	_	_	_	_	Seg=O
247	out	_	_	_	_	_	_	_	Seg=O
248	of	_	_	_	_	_	_	_	Seg=O
249	six	_	_	_	_	_	_	_	Seg=O
250	animals	_	_	_	_	_	_	_	Seg=O
251	in	_	_	_	_	_	_	_	Seg=O
252	the	_	_	_	_	_	_	_	Seg=O
253	Advax	_	_	_	_	_	_	_	Seg=O
254	group	_	_	_	_	_	_	_	Seg=O
255	.	_	_	_	_	_	_	_	Seg=O
256	Overall	_	_	_	_	_	_	_	Seg=B-seg
257	,	_	_	_	_	_	_	_	Seg=O
258	our	_	_	_	_	_	_	_	Seg=O
259	results	_	_	_	_	_	_	_	Seg=O
260	indicate	_	_	_	_	_	_	_	Seg=O
261	that	_	_	_	_	_	_	_	Seg=B-seg
262	passive	_	_	_	_	_	_	_	Seg=O
263	inhalation	_	_	_	_	_	_	_	Seg=O
264	is	_	_	_	_	_	_	_	Seg=O
265	feasible	_	_	_	_	_	_	_	Seg=O
266	,	_	_	_	_	_	_	_	Seg=O
267	effective	_	_	_	_	_	_	_	Seg=O
268	and	_	_	_	_	_	_	_	Seg=O
269	suitable	_	_	_	_	_	_	_	Seg=O
270	for	_	_	_	_	_	_	_	Seg=O
271	mass	_	_	_	_	_	_	_	Seg=O
272	vaccination	_	_	_	_	_	_	_	Seg=O
273	of	_	_	_	_	_	_	_	Seg=O
274	chickens	_	_	_	_	_	_	_	Seg=O
275	if	_	_	_	_	_	_	_	Seg=B-seg
276	it	_	_	_	_	_	_	_	Seg=O
277	can	_	_	_	_	_	_	_	Seg=O
278	be	_	_	_	_	_	_	_	Seg=O
279	adapted	_	_	_	_	_	_	_	Seg=O
280	to	_	_	_	_	_	_	_	Seg=O
281	field	_	_	_	_	_	_	_	Seg=O
282	settings	_	_	_	_	_	_	_	Seg=O
283	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ca2a4dbdc3d133ac018b4427e143e1a5ca45d1eb
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	pandemic	_	_	_	_	_	_	_	Seg=O
3	spread	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	COVID-19	_	_	_	_	_	_	_	Seg=O
7	virus	_	_	_	_	_	_	_	Seg=O
8	has	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	as	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	20	_	_	_	_	_	_	_	Seg=O
13	th	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	April	_	_	_	_	_	_	_	Seg=O
16	2020	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	reached	_	_	_	_	_	_	_	Seg=O
19	most	_	_	_	_	_	_	_	Seg=O
20	countries	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	world	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	In	_	_	_	_	_	_	_	Seg=B-seg
26	an	_	_	_	_	_	_	_	Seg=O
27	effort	_	_	_	_	_	_	_	Seg=O
28	to	_	_	_	_	_	_	_	Seg=B-seg
29	design	_	_	_	_	_	_	_	Seg=O
30	informed	_	_	_	_	_	_	_	Seg=O
31	public	_	_	_	_	_	_	_	Seg=O
32	health	_	_	_	_	_	_	_	Seg=O
33	policies	_	_	_	_	_	_	_	Seg=O
34	,	_	_	_	_	_	_	_	Seg=O
35	many	_	_	_	_	_	_	_	Seg=B-seg
36	modelling	_	_	_	_	_	_	_	Seg=O
37	studies	_	_	_	_	_	_	_	Seg=O
38	have	_	_	_	_	_	_	_	Seg=O
39	been	_	_	_	_	_	_	_	Seg=O
40	performed	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=B-seg
42	predict	_	_	_	_	_	_	_	Seg=O
43	crucial	_	_	_	_	_	_	_	Seg=O
44	outcomes	_	_	_	_	_	_	_	Seg=O
45	of	_	_	_	_	_	_	_	Seg=O
46	interest	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	including	_	_	_	_	_	_	_	Seg=B-seg
49	ICU	_	_	_	_	_	_	_	Seg=O
50	solicitation	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	cumulated	_	_	_	_	_	_	_	Seg=O
53	death	_	_	_	_	_	_	_	Seg=O
54	counts	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	etc	_	_	_	_	_	_	_	Seg=O
57	…	_	_	_	_	_	_	_	Seg=O
58	The	_	_	_	_	_	_	_	Seg=B-seg
59	corresponding	_	_	_	_	_	_	_	Seg=O
60	data	_	_	_	_	_	_	_	Seg=O
61	analyses	_	_	_	_	_	_	_	Seg=O
62	however	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	mostly	_	_	_	_	_	_	_	Seg=O
65	rely	_	_	_	_	_	_	_	Seg=O
66	on	_	_	_	_	_	_	_	Seg=O
67	restricted	_	_	_	_	_	_	_	Seg=O
68	(	_	_	_	_	_	_	_	Seg=O
69	openly	_	_	_	_	_	_	_	Seg=O
70	available	_	_	_	_	_	_	_	Seg=O
71	)	_	_	_	_	_	_	_	Seg=O
72	data	_	_	_	_	_	_	_	Seg=O
73	sources	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	which	_	_	_	_	_	_	_	Seg=B-seg
76	typically	_	_	_	_	_	_	_	Seg=O
77	include	_	_	_	_	_	_	_	Seg=O
78	daily	_	_	_	_	_	_	_	Seg=O
79	death	_	_	_	_	_	_	_	Seg=O
80	rates	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	confirmed	_	_	_	_	_	_	_	Seg=O
83	COVID	_	_	_	_	_	_	_	Seg=O
84	cases	_	_	_	_	_	_	_	Seg=O
85	time	_	_	_	_	_	_	_	Seg=O
86	series	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	In	_	_	_	_	_	_	_	Seg=B-seg
89	addition	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	many	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	these	_	_	_	_	_	_	_	Seg=O
94	predictions	_	_	_	_	_	_	_	Seg=O
95	are	_	_	_	_	_	_	_	Seg=O
96	derived	_	_	_	_	_	_	_	Seg=O
97	before	_	_	_	_	_	_	_	Seg=B-seg
98	the	_	_	_	_	_	_	_	Seg=O
99	peak	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	outbreak	_	_	_	_	_	_	_	Seg=O
103	has	_	_	_	_	_	_	_	Seg=O
104	been	_	_	_	_	_	_	_	Seg=O
105	observed	_	_	_	_	_	_	_	Seg=O
106	yet	_	_	_	_	_	_	_	Seg=O
107	(	_	_	_	_	_	_	_	Seg=B-seg
108	as	_	_	_	_	_	_	_	Seg=O
109	is	_	_	_	_	_	_	_	Seg=O
110	still	_	_	_	_	_	_	_	Seg=O
111	currently	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	case	_	_	_	_	_	_	_	Seg=O
114	for	_	_	_	_	_	_	_	Seg=O
115	many	_	_	_	_	_	_	_	Seg=O
116	countries	_	_	_	_	_	_	_	Seg=O
117	)	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	In	_	_	_	_	_	_	_	Seg=B-seg
120	this	_	_	_	_	_	_	_	Seg=O
121	work	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	we	_	_	_	_	_	_	_	Seg=O
124	show	_	_	_	_	_	_	_	Seg=O
125	that	_	_	_	_	_	_	_	Seg=B-seg
126	peak	_	_	_	_	_	_	_	Seg=O
127	phase	_	_	_	_	_	_	_	Seg=O
128	and	_	_	_	_	_	_	_	Seg=O
129	data	_	_	_	_	_	_	_	Seg=O
130	paucity	_	_	_	_	_	_	_	Seg=O
131	have	_	_	_	_	_	_	_	Seg=O
132	a	_	_	_	_	_	_	_	Seg=O
133	substantial	_	_	_	_	_	_	_	Seg=O
134	impact	_	_	_	_	_	_	_	Seg=O
135	on	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	reliability	_	_	_	_	_	_	_	Seg=O
138	of	_	_	_	_	_	_	_	Seg=O
139	model	_	_	_	_	_	_	_	Seg=O
140	predictions	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O
142	Although	_	_	_	_	_	_	_	Seg=B-seg
143	we	_	_	_	_	_	_	_	Seg=O
144	focus	_	_	_	_	_	_	_	Seg=O
145	on	_	_	_	_	_	_	_	Seg=O
146	a	_	_	_	_	_	_	_	Seg=O
147	recent	_	_	_	_	_	_	_	Seg=O
148	model	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=O
151	COVID	_	_	_	_	_	_	_	Seg=O
152	pandemics	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	our	_	_	_	_	_	_	_	Seg=B-seg
155	conclusions	_	_	_	_	_	_	_	Seg=O
156	most	_	_	_	_	_	_	_	Seg=O
157	likely	_	_	_	_	_	_	_	Seg=O
158	apply	_	_	_	_	_	_	_	Seg=O
159	to	_	_	_	_	_	_	_	Seg=O
160	most	_	_	_	_	_	_	_	Seg=O
161	existing	_	_	_	_	_	_	_	Seg=O
162	models	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	which	_	_	_	_	_	_	_	Seg=B-seg
165	are	_	_	_	_	_	_	_	Seg=O
166	variants	_	_	_	_	_	_	_	Seg=O
167	of	_	_	_	_	_	_	_	Seg=O
168	the	_	_	_	_	_	_	_	Seg=O
169	socalled	_	_	_	_	_	_	_	Seg=O
170	"	_	_	_	_	_	_	_	Seg=O
171	Susceptible	_	_	_	_	_	_	_	Seg=O
172	-	_	_	_	_	_	_	_	Seg=O
173	Infected	_	_	_	_	_	_	_	Seg=O
174	-	_	_	_	_	_	_	_	Seg=O
175	Removed	_	_	_	_	_	_	_	Seg=O
176	"	_	_	_	_	_	_	_	Seg=O
177	or	_	_	_	_	_	_	_	Seg=O
178	SIR	_	_	_	_	_	_	_	Seg=O
179	framework	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O
181	Our	_	_	_	_	_	_	_	Seg=B-seg
182	results	_	_	_	_	_	_	_	Seg=O
183	highlight	_	_	_	_	_	_	_	Seg=O
184	the	_	_	_	_	_	_	_	Seg=O
185	need	_	_	_	_	_	_	_	Seg=O
186	for	_	_	_	_	_	_	_	Seg=B-seg
187	performing	_	_	_	_	_	_	_	Seg=O
188	systematic	_	_	_	_	_	_	_	Seg=O
189	reliability	_	_	_	_	_	_	_	Seg=O
190	evaluations	_	_	_	_	_	_	_	Seg=O
191	for	_	_	_	_	_	_	_	Seg=O
192	all	_	_	_	_	_	_	_	Seg=O
193	models	_	_	_	_	_	_	_	Seg=O
194	that	_	_	_	_	_	_	_	Seg=B-seg
195	currently	_	_	_	_	_	_	_	Seg=O
196	inform	_	_	_	_	_	_	_	Seg=O
197	public	_	_	_	_	_	_	_	Seg=O
198	health	_	_	_	_	_	_	_	Seg=O
199	policies	_	_	_	_	_	_	_	Seg=O
200	.	_	_	_	_	_	_	_	Seg=O
201	They	_	_	_	_	_	_	_	Seg=B-seg
202	also	_	_	_	_	_	_	_	Seg=O
203	motivate	_	_	_	_	_	_	_	Seg=O
204	a	_	_	_	_	_	_	_	Seg=O
205	plea	_	_	_	_	_	_	_	Seg=O
206	for	_	_	_	_	_	_	_	Seg=B-seg
207	gathering	_	_	_	_	_	_	_	Seg=O
208	and	_	_	_	_	_	_	_	Seg=O
209	opening	_	_	_	_	_	_	_	Seg=O
210	richer	_	_	_	_	_	_	_	Seg=O
211	and	_	_	_	_	_	_	_	Seg=O
212	more	_	_	_	_	_	_	_	Seg=O
213	reliable	_	_	_	_	_	_	_	Seg=O
214	data	_	_	_	_	_	_	_	Seg=O
215	time	_	_	_	_	_	_	_	Seg=O
216	series	_	_	_	_	_	_	_	Seg=O
217	(	_	_	_	_	_	_	_	Seg=B-seg
218	e.g.	_	_	_	_	_	_	_	Seg=O
219	,	_	_	_	_	_	_	_	Seg=O
220	ICU	_	_	_	_	_	_	_	Seg=O
221	occupancy	_	_	_	_	_	_	_	Seg=O
222	,	_	_	_	_	_	_	_	Seg=O
223	negative	_	_	_	_	_	_	_	Seg=O
224	test	_	_	_	_	_	_	_	Seg=O
225	rates	_	_	_	_	_	_	_	Seg=O
226	,	_	_	_	_	_	_	_	Seg=O
227	social	_	_	_	_	_	_	_	Seg=O
228	distancing	_	_	_	_	_	_	_	Seg=O
229	commitment	_	_	_	_	_	_	_	Seg=O
230	reports	_	_	_	_	_	_	_	Seg=O
231	,	_	_	_	_	_	_	_	Seg=O
232	etc	_	_	_	_	_	_	_	Seg=O
233	)	_	_	_	_	_	_	_	Seg=O
234	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = cb6074cfc9898c507ee6f98f9888fb652b409069
1	On	_	_	_	_	_	_	_	Seg=B-seg
2	30	_	_	_	_	_	_	_	Seg=O
3	January	_	_	_	_	_	_	_	Seg=O
4	2020	_	_	_	_	_	_	_	Seg=O
5	,	_	_	_	_	_	_	_	Seg=O
6	the	_	_	_	_	_	_	_	Seg=O
7	WHO	_	_	_	_	_	_	_	Seg=O
8	declared	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	coronavirus	_	_	_	_	_	_	_	Seg=O
11	disease	_	_	_	_	_	_	_	Seg=O
12	2019	_	_	_	_	_	_	_	Seg=O
13	(	_	_	_	_	_	_	_	Seg=O
14	COVID-19	_	_	_	_	_	_	_	Seg=O
15	)	_	_	_	_	_	_	_	Seg=O
16	a	_	_	_	_	_	_	_	Seg=O
17	public	_	_	_	_	_	_	_	Seg=O
18	health	_	_	_	_	_	_	_	Seg=O
19	emergency	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	international	_	_	_	_	_	_	_	Seg=O
22	concern	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	By	_	_	_	_	_	_	_	Seg=B-seg
25	11	_	_	_	_	_	_	_	Seg=O
26	March	_	_	_	_	_	_	_	Seg=O
27	2020	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	it	_	_	_	_	_	_	_	Seg=O
30	was	_	_	_	_	_	_	_	Seg=O
31	designated	_	_	_	_	_	_	_	Seg=O
32	a	_	_	_	_	_	_	_	Seg=O
33	pandemic	_	_	_	_	_	_	_	Seg=O
34	owing	_	_	_	_	_	_	_	Seg=B-seg
35	to	_	_	_	_	_	_	_	Seg=O
36	its	_	_	_	_	_	_	_	Seg=O
37	rapid	_	_	_	_	_	_	_	Seg=O
38	worldwide	_	_	_	_	_	_	_	Seg=O
39	spread	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	In	_	_	_	_	_	_	_	Seg=B-seg
42	this	_	_	_	_	_	_	_	Seg=O
43	short	_	_	_	_	_	_	_	Seg=O
44	article	_	_	_	_	_	_	_	Seg=O
45	we	_	_	_	_	_	_	_	Seg=O
46	provide	_	_	_	_	_	_	_	Seg=O
47	some	_	_	_	_	_	_	_	Seg=O
48	information	_	_	_	_	_	_	_	Seg=O
49	that	_	_	_	_	_	_	_	Seg=B-seg
50	might	_	_	_	_	_	_	_	Seg=O
51	be	_	_	_	_	_	_	_	Seg=O
52	useful	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=B-seg
54	help	_	_	_	_	_	_	_	Seg=O
55	equip	_	_	_	_	_	_	_	Seg=O
56	colleagues	_	_	_	_	_	_	_	Seg=O
57	to	_	_	_	_	_	_	_	Seg=B-seg
58	reduce	_	_	_	_	_	_	_	Seg=O
59	medical	_	_	_	_	_	_	_	Seg=O
60	error	_	_	_	_	_	_	_	Seg=O
61	during	_	_	_	_	_	_	_	Seg=O
62	a	_	_	_	_	_	_	_	Seg=O
63	pandemic	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	We	_	_	_	_	_	_	_	Seg=B-seg
66	advocate	_	_	_	_	_	_	_	Seg=O
67	a	_	_	_	_	_	_	_	Seg=O
68	systems	_	_	_	_	_	_	_	Seg=O
69	-	_	_	_	_	_	_	_	Seg=O
70	based	_	_	_	_	_	_	_	Seg=O
71	approach	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	rather	_	_	_	_	_	_	_	Seg=O
74	than	_	_	_	_	_	_	_	Seg=O
75	an	_	_	_	_	_	_	_	Seg=O
76-77	individual's	_	_	_	_	_	_	_	_
76	individual	_	_	_	_	_	_	_	Seg=O
77	's	_	_	_	_	_	_	_	Seg=O
78	sole	_	_	_	_	_	_	_	Seg=O
79	responsibility	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=B-seg
82	,	_	_	_	_	_	_	_	Seg=O
83	look	_	_	_	_	_	_	_	Seg=O
84	at	_	_	_	_	_	_	_	Seg=O
85	ways	_	_	_	_	_	_	_	Seg=O
86	to	_	_	_	_	_	_	_	Seg=B-seg
87	provide	_	_	_	_	_	_	_	Seg=O
88	safer	_	_	_	_	_	_	_	Seg=O
89	healthcare	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ceda3aacfcc249a8bdff8eb316c13638860e560b
1	I	_	_	_	_	_	_	_	Seg=B-seg
2	use	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	COVID-19	_	_	_	_	_	_	_	Seg=O
5	death	_	_	_	_	_	_	_	Seg=O
6	rate	_	_	_	_	_	_	_	Seg=O
7	in	_	_	_	_	_	_	_	Seg=O
8	South	_	_	_	_	_	_	_	Seg=O
9	Korea	_	_	_	_	_	_	_	Seg=O
10	and	_	_	_	_	_	_	_	Seg=O
11	a	_	_	_	_	_	_	_	Seg=O
12	method	_	_	_	_	_	_	_	Seg=O
13	relating	_	_	_	_	_	_	_	Seg=B-seg
14	the	_	_	_	_	_	_	_	Seg=O
15	ratio	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	death	_	_	_	_	_	_	_	Seg=O
18	rates	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	a	_	_	_	_	_	_	_	Seg=O
21	U.S.	_	_	_	_	_	_	_	Seg=O
22	state	_	_	_	_	_	_	_	Seg=O
23	to	_	_	_	_	_	_	_	Seg=O
24	its	_	_	_	_	_	_	_	Seg=O
25	share	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	cumulative	_	_	_	_	_	_	_	Seg=O
28	positive	_	_	_	_	_	_	_	Seg=O
29	tests	_	_	_	_	_	_	_	Seg=O
30	to	_	_	_	_	_	_	_	Seg=B-seg
31	estimate	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	total	_	_	_	_	_	_	_	Seg=O
34	cases	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	COVID-19	_	_	_	_	_	_	_	Seg=O
37	in	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	U.S.	_	_	_	_	_	_	_	Seg=O
40	and	_	_	_	_	_	_	_	Seg=B-seg
41	to	_	_	_	_	_	_	_	Seg=O
42	estimate	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	extent	_	_	_	_	_	_	_	Seg=O
45	of	_	_	_	_	_	_	_	Seg=O
46	infection	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	unidentified	_	_	_	_	_	_	_	Seg=O
50	share	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	infected	_	_	_	_	_	_	_	Seg=O
54	population	_	_	_	_	_	_	_	Seg=O
55	in	_	_	_	_	_	_	_	Seg=O
56	each	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	lower-48	_	_	_	_	_	_	_	Seg=O
60	states	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	in	_	_	_	_	_	_	_	Seg=O
63	New	_	_	_	_	_	_	_	Seg=O
64	York	_	_	_	_	_	_	_	Seg=O
65	City	_	_	_	_	_	_	_	Seg=O
66	in	_	_	_	_	_	_	_	Seg=O
67	mid	_	_	_	_	_	_	_	Seg=O
68	-	_	_	_	_	_	_	_	Seg=O
69	April	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	2020	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	I	_	_	_	_	_	_	_	Seg=B-seg
74	identify	_	_	_	_	_	_	_	Seg=O
75	a	_	_	_	_	_	_	_	Seg=O
76	logarithmic	_	_	_	_	_	_	_	Seg=O
77	relationship	_	_	_	_	_	_	_	Seg=O
78	between	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	cumulative	_	_	_	_	_	_	_	Seg=O
81	death	_	_	_	_	_	_	_	Seg=O
82	rate	_	_	_	_	_	_	_	Seg=O
83	in	_	_	_	_	_	_	_	Seg=O
84	a	_	_	_	_	_	_	_	Seg=O
85	state	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	its	_	_	_	_	_	_	_	Seg=O
88	cumulative	_	_	_	_	_	_	_	Seg=O
89	positive	_	_	_	_	_	_	_	Seg=O
90	share	_	_	_	_	_	_	_	Seg=O
91	of	_	_	_	_	_	_	_	Seg=O
92	tests	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	Using	_	_	_	_	_	_	_	Seg=B-seg
95	this	_	_	_	_	_	_	_	Seg=O
96	relationship	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	I	_	_	_	_	_	_	_	Seg=B-seg
99	find	_	_	_	_	_	_	_	Seg=O
100	that	_	_	_	_	_	_	_	Seg=B-seg
101	4.3	_	_	_	_	_	_	_	Seg=O
102	-	_	_	_	_	_	_	_	Seg=O
103	5.4	_	_	_	_	_	_	_	Seg=O
104	million	_	_	_	_	_	_	_	Seg=O
105	people	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	1.4	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	1.7	_	_	_	_	_	_	_	Seg=O
110	%	_	_	_	_	_	_	_	Seg=O
111	of	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	U.S.	_	_	_	_	_	_	_	Seg=O
114	population	_	_	_	_	_	_	_	Seg=O
115	,	_	_	_	_	_	_	_	Seg=O
116	were	_	_	_	_	_	_	_	Seg=O
117	infected	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	with	_	_	_	_	_	_	_	Seg=O
120	rates	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	infection	_	_	_	_	_	_	_	Seg=O
123	that	_	_	_	_	_	_	_	Seg=B-seg
124	ranged	_	_	_	_	_	_	_	Seg=O
125	from	_	_	_	_	_	_	_	Seg=O
126	0.1	_	_	_	_	_	_	_	Seg=O
127	%	_	_	_	_	_	_	_	Seg=O
128	in	_	_	_	_	_	_	_	Seg=O
129	more	_	_	_	_	_	_	_	Seg=O
130	rural	_	_	_	_	_	_	_	Seg=O
131	states	_	_	_	_	_	_	_	Seg=O
132	to	_	_	_	_	_	_	_	Seg=O
133	8	_	_	_	_	_	_	_	Seg=O
134	-	_	_	_	_	_	_	_	Seg=O
135	10	_	_	_	_	_	_	_	Seg=O
136	%	_	_	_	_	_	_	_	Seg=O
137	in	_	_	_	_	_	_	_	Seg=O
138	New	_	_	_	_	_	_	_	Seg=O
139	York	_	_	_	_	_	_	_	Seg=O
140	state	_	_	_	_	_	_	_	Seg=O
141	and	_	_	_	_	_	_	_	Seg=O
142	11	_	_	_	_	_	_	_	Seg=O
143	-	_	_	_	_	_	_	_	Seg=O
144	13	_	_	_	_	_	_	_	Seg=O
145	%	_	_	_	_	_	_	_	Seg=O
146	in	_	_	_	_	_	_	_	Seg=O
147	New	_	_	_	_	_	_	_	Seg=O
148	York	_	_	_	_	_	_	_	Seg=O
149	City	_	_	_	_	_	_	_	Seg=O
150	.	_	_	_	_	_	_	_	Seg=O
151	Only	_	_	_	_	_	_	_	Seg=B-seg
152	16	_	_	_	_	_	_	_	Seg=O
153	-	_	_	_	_	_	_	_	Seg=O
154	20	_	_	_	_	_	_	_	Seg=O
155	%	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	these	_	_	_	_	_	_	_	Seg=O
158	infected	_	_	_	_	_	_	_	Seg=O
159	individuals	_	_	_	_	_	_	_	Seg=O
160	were	_	_	_	_	_	_	_	Seg=O
161	identified	_	_	_	_	_	_	_	Seg=O
162	later	_	_	_	_	_	_	_	Seg=O
163	through	_	_	_	_	_	_	_	Seg=O
164	testing	_	_	_	_	_	_	_	Seg=O
165	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = d125abb6f1e1cb460e9dd29bf71df2895151761d
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Intimate	_	_	_	_	_	_	_	Seg=B-seg
4	partner	_	_	_	_	_	_	_	Seg=O
5	violence	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	IPV	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	is	_	_	_	_	_	_	_	Seg=O
10	defined	_	_	_	_	_	_	_	Seg=O
11	as	_	_	_	_	_	_	_	Seg=O
12	physical	_	_	_	_	_	_	_	Seg=O
13	or	_	_	_	_	_	_	_	Seg=O
14	sexual	_	_	_	_	_	_	_	Seg=O
15	violence	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	emotional	_	_	_	_	_	_	_	Seg=O
18	abuse	_	_	_	_	_	_	_	Seg=O
19	and	_	_	_	_	_	_	_	Seg=O
20	stalking	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	It	_	_	_	_	_	_	_	Seg=B-seg
23	is	_	_	_	_	_	_	_	Seg=O
24	typically	_	_	_	_	_	_	_	Seg=O
25	experienced	_	_	_	_	_	_	_	Seg=O
26	by	_	_	_	_	_	_	_	Seg=O
27	women	_	_	_	_	_	_	_	Seg=O
28	but	_	_	_	_	_	_	_	Seg=B-seg
29	can	_	_	_	_	_	_	_	Seg=O
30	also	_	_	_	_	_	_	_	Seg=O
31	be	_	_	_	_	_	_	_	Seg=O
32	experienced	_	_	_	_	_	_	_	Seg=O
33	by	_	_	_	_	_	_	_	Seg=O
34	men	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	During	_	_	_	_	_	_	_	Seg=B-seg
37	quarantine	_	_	_	_	_	_	_	Seg=O
38	due	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	COVID-19	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	home	_	_	_	_	_	_	_	Seg=O
44	risks	_	_	_	_	_	_	_	Seg=O
45	to	_	_	_	_	_	_	_	Seg=O
46	become	_	_	_	_	_	_	_	Seg=O
47	a	_	_	_	_	_	_	_	Seg=O
48	very	_	_	_	_	_	_	_	Seg=O
49	dangerous	_	_	_	_	_	_	_	Seg=O
50	place	_	_	_	_	_	_	_	Seg=O
51	for	_	_	_	_	_	_	_	Seg=O
52	victims	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	domestic	_	_	_	_	_	_	_	Seg=O
55	violence	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	Method	_	_	_	_	_	_	_	Seg=B-seg
58	:	_	_	_	_	_	_	_	Seg=O
59	Very	_	_	_	_	_	_	_	Seg=B-seg
60	recent	_	_	_	_	_	_	_	Seg=O
61	studies	_	_	_	_	_	_	_	Seg=O
62	focusing	_	_	_	_	_	_	_	Seg=B-seg
63	on	_	_	_	_	_	_	_	Seg=O
64	abusive	_	_	_	_	_	_	_	Seg=O
65	situations	_	_	_	_	_	_	_	Seg=O
66	during	_	_	_	_	_	_	_	Seg=O
67	COVID	_	_	_	_	_	_	_	Seg=O
68	emergence	_	_	_	_	_	_	_	Seg=O
69	were	_	_	_	_	_	_	_	Seg=B-seg
70	identified	_	_	_	_	_	_	_	Seg=O
71	in	_	_	_	_	_	_	_	Seg=O
72	PubMed	_	_	_	_	_	_	_	Seg=O
73	/	_	_	_	_	_	_	_	Seg=O
74	Medline	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	Scopus	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	Embase	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
81	:	_	_	_	_	_	_	_	Seg=O
82	Especially	_	_	_	_	_	_	_	Seg=B-seg
83	during	_	_	_	_	_	_	_	Seg=O
84	quarantine	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	COVID	_	_	_	_	_	_	_	Seg=O
87	emergence	_	_	_	_	_	_	_	Seg=O
88	around	_	_	_	_	_	_	_	Seg=O
89	the	_	_	_	_	_	_	_	Seg=O
90	world	_	_	_	_	_	_	_	Seg=O
91	there	_	_	_	_	_	_	_	Seg=O
92	is	_	_	_	_	_	_	_	Seg=O
93	a	_	_	_	_	_	_	_	Seg=O
94	need	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	programs	_	_	_	_	_	_	_	Seg=O
97	aimed	_	_	_	_	_	_	_	Seg=B-seg
98	to	_	_	_	_	_	_	_	Seg=O
99	prevent	_	_	_	_	_	_	_	Seg=O
100	acts	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	domestic	_	_	_	_	_	_	_	Seg=O
103	violence	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=O
106	achieve	_	_	_	_	_	_	_	Seg=O
107	accurate	_	_	_	_	_	_	_	Seg=O
108	assessment	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=O
110	multiple	_	_	_	_	_	_	_	Seg=O
111	domains	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	abuse	_	_	_	_	_	_	_	Seg=O
114	(	_	_	_	_	_	_	_	Seg=B-seg
115	psychological	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	physical	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	sexual	_	_	_	_	_	_	_	Seg=O
120	)	_	_	_	_	_	_	_	Seg=O
121	provided	_	_	_	_	_	_	_	Seg=B-seg
122	by	_	_	_	_	_	_	_	Seg=O
123	trained	_	_	_	_	_	_	_	Seg=O
124	multidisciplinary	_	_	_	_	_	_	_	Seg=O
125	staffs	_	_	_	_	_	_	_	Seg=O
126	(	_	_	_	_	_	_	_	Seg=B-seg
127	including	_	_	_	_	_	_	_	Seg=O
128	psychiatrists	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	psychologists	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	social	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=O
134	legal	_	_	_	_	_	_	_	Seg=O
135	services	_	_	_	_	_	_	_	Seg=O
136	)	_	_	_	_	_	_	_	Seg=O
137	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = d1bc51c207da125a38e3ab23f94966c37bf6bf8f
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	paper	_	_	_	_	_	_	_	Seg=O
3	employs	_	_	_	_	_	_	_	Seg=O
4	syndemics	_	_	_	_	_	_	_	Seg=O
5	theory	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=B-seg
7	explain	_	_	_	_	_	_	_	Seg=O
8	high	_	_	_	_	_	_	_	Seg=O
9	rates	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	sexually	_	_	_	_	_	_	_	Seg=O
12	transmitted	_	_	_	_	_	_	_	Seg=O
13	disease	_	_	_	_	_	_	_	Seg=O
14	among	_	_	_	_	_	_	_	Seg=O
15	inner	_	_	_	_	_	_	_	Seg=O
16	city	_	_	_	_	_	_	_	Seg=O
17	African	_	_	_	_	_	_	_	Seg=O
18	American	_	_	_	_	_	_	_	Seg=O
19	and	_	_	_	_	_	_	_	Seg=O
20	Puerto	_	_	_	_	_	_	_	Seg=O
21	Rican	_	_	_	_	_	_	_	Seg=O
22	heterosexual	_	_	_	_	_	_	_	Seg=O
23	young	_	_	_	_	_	_	_	Seg=O
24	adults	_	_	_	_	_	_	_	Seg=O
25	in	_	_	_	_	_	_	_	Seg=O
26	Hartford	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	CT	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	USA	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	Syndemic	_	_	_	_	_	_	_	Seg=B-seg
33	theory	_	_	_	_	_	_	_	Seg=O
34	helps	_	_	_	_	_	_	_	Seg=O
35	to	_	_	_	_	_	_	_	Seg=O
36	elucidate	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	tendency	_	_	_	_	_	_	_	Seg=O
39	for	_	_	_	_	_	_	_	Seg=O
40	multiple	_	_	_	_	_	_	_	Seg=O
41	co	_	_	_	_	_	_	_	Seg=O
42	-	_	_	_	_	_	_	_	Seg=O
43	terminus	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=O
45	interacting	_	_	_	_	_	_	_	Seg=O
46	epidemics	_	_	_	_	_	_	_	Seg=O
47	to	_	_	_	_	_	_	_	Seg=B-seg
48	develop	_	_	_	_	_	_	_	Seg=O
49	under	_	_	_	_	_	_	_	Seg=O
50	conditions	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	health	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=O
54	social	_	_	_	_	_	_	_	Seg=O
55	disparity	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	Based	_	_	_	_	_	_	_	Seg=B-seg
58	on	_	_	_	_	_	_	_	Seg=O
59	enhanced	_	_	_	_	_	_	_	Seg=O
60	focus	_	_	_	_	_	_	_	Seg=O
61	group	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	in	_	_	_	_	_	_	_	Seg=O
64	-	_	_	_	_	_	_	_	Seg=O
65	depth	_	_	_	_	_	_	_	Seg=O
66	interview	_	_	_	_	_	_	_	Seg=O
67	data	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=B-seg
70	paper	_	_	_	_	_	_	_	Seg=O
71	argues	_	_	_	_	_	_	_	Seg=O
72	that	_	_	_	_	_	_	_	Seg=B-seg
73	respondents	_	_	_	_	_	_	_	Seg=O
74	employed	_	_	_	_	_	_	_	Seg=O
75	a	_	_	_	_	_	_	_	Seg=O
76	cultural	_	_	_	_	_	_	_	Seg=O
77	logic	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	risk	_	_	_	_	_	_	_	Seg=O
80	assessment	_	_	_	_	_	_	_	Seg=O
81	which	_	_	_	_	_	_	_	Seg=B-seg
82	put	_	_	_	_	_	_	_	Seg=O
83	them	_	_	_	_	_	_	_	Seg=O
84	at	_	_	_	_	_	_	_	Seg=O
85	high	_	_	_	_	_	_	_	Seg=O
86	risk	_	_	_	_	_	_	_	Seg=O
87	for	_	_	_	_	_	_	_	Seg=O
88	STD	_	_	_	_	_	_	_	Seg=O
89	infection	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O
91	This	_	_	_	_	_	_	_	Seg=B-seg
92	cultural	_	_	_	_	_	_	_	Seg=O
93	logic	_	_	_	_	_	_	_	Seg=O
94	was	_	_	_	_	_	_	_	Seg=O
95	shaped	_	_	_	_	_	_	_	Seg=O
96	by	_	_	_	_	_	_	_	Seg=O
97	their	_	_	_	_	_	_	_	Seg=O
98	experiences	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=B-seg
100	growing	_	_	_	_	_	_	_	Seg=O
101	up	_	_	_	_	_	_	_	Seg=O
102	in	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	inner	_	_	_	_	_	_	_	Seg=O
105	city	_	_	_	_	_	_	_	Seg=O
106	which	_	_	_	_	_	_	_	Seg=B-seg
107	included	_	_	_	_	_	_	_	Seg=O
108	:	_	_	_	_	_	_	_	Seg=O
109	coming	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	age	_	_	_	_	_	_	_	Seg=O
112	in	_	_	_	_	_	_	_	Seg=O
113	an	_	_	_	_	_	_	_	Seg=O
114	impoverished	_	_	_	_	_	_	_	Seg=O
115	family	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	living	_	_	_	_	_	_	_	Seg=O
118	in	_	_	_	_	_	_	_	Seg=O
119	a	_	_	_	_	_	_	_	Seg=O
120	broken	_	_	_	_	_	_	_	Seg=O
121	home	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	experiencing	_	_	_	_	_	_	_	Seg=O
124	domestic	_	_	_	_	_	_	_	Seg=O
125	violence	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	limited	_	_	_	_	_	_	_	Seg=O
128	expectations	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	future	_	_	_	_	_	_	_	Seg=O
132	,	_	_	_	_	_	_	_	Seg=O
133	limited	_	_	_	_	_	_	_	Seg=O
134	exposure	_	_	_	_	_	_	_	Seg=O
135	to	_	_	_	_	_	_	_	Seg=O
136	positive	_	_	_	_	_	_	_	Seg=O
137	role	_	_	_	_	_	_	_	Seg=O
138	models	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	lack	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	expectation	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	the	_	_	_	_	_	_	_	Seg=O
145	dependency	_	_	_	_	_	_	_	Seg=O
146	of	_	_	_	_	_	_	_	Seg=O
147	others	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	and	_	_	_	_	_	_	_	Seg=O
150	fear	_	_	_	_	_	_	_	Seg=O
151	of	_	_	_	_	_	_	_	Seg=O
152	intimacy	_	_	_	_	_	_	_	Seg=O
153	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = d1ce2321a8a67ec9c9823cb9c15543fce565ed85
1	Typical	_	_	_	_	_	_	_	Seg=B-seg
2	enteropathogenic	_	_	_	_	_	_	_	Seg=O
3	E.	_	_	_	_	_	_	_	Seg=O
4	coli	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	tEPEC	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	carries	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	highest	_	_	_	_	_	_	_	Seg=O
11	hazard	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	death	_	_	_	_	_	_	_	Seg=O
14	in	_	_	_	_	_	_	_	Seg=O
15	children	_	_	_	_	_	_	_	Seg=O
16	with	_	_	_	_	_	_	_	Seg=O
17	diarrhea	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=B-seg
19	atypical	_	_	_	_	_	_	_	Seg=O
20	EPEC	_	_	_	_	_	_	_	Seg=O
21	(	_	_	_	_	_	_	_	Seg=O
22	aEPEC	_	_	_	_	_	_	_	Seg=O
23	)	_	_	_	_	_	_	_	Seg=O
24	was	_	_	_	_	_	_	_	Seg=O
25	recently	_	_	_	_	_	_	_	Seg=O
26	identified	_	_	_	_	_	_	_	Seg=O
27	as	_	_	_	_	_	_	_	Seg=O
28	significantly	_	_	_	_	_	_	_	Seg=O
29	associated	_	_	_	_	_	_	_	Seg=O
30	with	_	_	_	_	_	_	_	Seg=O
31	diarrheal	_	_	_	_	_	_	_	Seg=O
32	mortality	_	_	_	_	_	_	_	Seg=O
33	in	_	_	_	_	_	_	_	Seg=O
34	kittens	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	In	_	_	_	_	_	_	_	Seg=B-seg
37	both	_	_	_	_	_	_	_	Seg=O
38	children	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	kittens	_	_	_	_	_	_	_	Seg=O
41	there	_	_	_	_	_	_	_	Seg=O
42	is	_	_	_	_	_	_	_	Seg=O
43	a	_	_	_	_	_	_	_	Seg=O
44	significant	_	_	_	_	_	_	_	Seg=O
45	association	_	_	_	_	_	_	_	Seg=O
46	between	_	_	_	_	_	_	_	Seg=O
47	aEPEC	_	_	_	_	_	_	_	Seg=O
48	burden	_	_	_	_	_	_	_	Seg=O
49	and	_	_	_	_	_	_	_	Seg=O
50	diarrheal	_	_	_	_	_	_	_	Seg=O
51	disease	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	however	_	_	_	_	_	_	_	Seg=B-seg
54	the	_	_	_	_	_	_	_	Seg=O
55	infection	_	_	_	_	_	_	_	Seg=O
56	can	_	_	_	_	_	_	_	Seg=O
57	be	_	_	_	_	_	_	_	Seg=O
58	found	_	_	_	_	_	_	_	Seg=O
59	in	_	_	_	_	_	_	_	Seg=O
60	individuals	_	_	_	_	_	_	_	Seg=O
61	with	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	without	_	_	_	_	_	_	_	Seg=O
64	diarrhea	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	It	_	_	_	_	_	_	_	Seg=B-seg
67	remains	_	_	_	_	_	_	_	Seg=O
68	unclear	_	_	_	_	_	_	_	Seg=O
69	to	_	_	_	_	_	_	_	Seg=O
70	what	_	_	_	_	_	_	_	Seg=O
71	extent	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	under	_	_	_	_	_	_	_	Seg=O
74	what	_	_	_	_	_	_	_	Seg=O
75	conditions	_	_	_	_	_	_	_	Seg=O
76	,	_	_	_	_	_	_	_	Seg=O
77	or	_	_	_	_	_	_	_	Seg=O
78	by	_	_	_	_	_	_	_	Seg=O
79	what	_	_	_	_	_	_	_	Seg=O
80	mechanisms	_	_	_	_	_	_	_	Seg=O
81	aEPEC	_	_	_	_	_	_	_	Seg=O
82	serves	_	_	_	_	_	_	_	Seg=O
83	as	_	_	_	_	_	_	_	Seg=O
84	a	_	_	_	_	_	_	_	Seg=O
85	primary	_	_	_	_	_	_	_	Seg=O
86	pathogen	_	_	_	_	_	_	_	Seg=O
87	in	_	_	_	_	_	_	_	Seg=O
88	individuals	_	_	_	_	_	_	_	Seg=O
89	with	_	_	_	_	_	_	_	Seg=O
90	diarrhea	_	_	_	_	_	_	_	Seg=O
91	.	_	_	_	_	_	_	_	Seg=O
92	It	_	_	_	_	_	_	_	Seg=B-seg
93	seems	_	_	_	_	_	_	_	Seg=O
94	likely	_	_	_	_	_	_	_	Seg=O
95	that	_	_	_	_	_	_	_	Seg=O
96	a	_	_	_	_	_	_	_	Seg=O
97	combination	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	host	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=O
101	bacterial	_	_	_	_	_	_	_	Seg=O
102	factors	_	_	_	_	_	_	_	Seg=O
103	enable	_	_	_	_	_	_	_	Seg=O
104	aEPEC	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=O
106	cause	_	_	_	_	_	_	_	Seg=O
107	disease	_	_	_	_	_	_	_	Seg=O
108	in	_	_	_	_	_	_	_	Seg=O
109	some	_	_	_	_	_	_	_	Seg=O
110	individuals	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=O
112	not	_	_	_	_	_	_	_	Seg=O
113	in	_	_	_	_	_	_	_	Seg=O
114	others	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	The	_	_	_	_	_	_	_	Seg=B-seg
117	purpose	_	_	_	_	_	_	_	Seg=O
118	of	_	_	_	_	_	_	_	Seg=O
119	this	_	_	_	_	_	_	_	Seg=O
120	study	_	_	_	_	_	_	_	Seg=O
121	was	_	_	_	_	_	_	_	Seg=O
122	to	_	_	_	_	_	_	_	Seg=O
123	determine	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	impact	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	aEPEC	_	_	_	_	_	_	_	Seg=O
128	on	_	_	_	_	_	_	_	Seg=O
129	intestinal	_	_	_	_	_	_	_	Seg=O
130	function	_	_	_	_	_	_	_	Seg=O
131	and	_	_	_	_	_	_	_	Seg=O
132	diarrhea	_	_	_	_	_	_	_	Seg=O
133	in	_	_	_	_	_	_	_	Seg=O
134	kittens	_	_	_	_	_	_	_	Seg=O
135	following	_	_	_	_	_	_	_	Seg=B-seg
136	experimentally	_	_	_	_	_	_	_	Seg=O
137	-	_	_	_	_	_	_	_	Seg=O
138	induced	_	_	_	_	_	_	_	Seg=O
139	carriage	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=B-seg
141	the	_	_	_	_	_	_	_	Seg=O
142	influence	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	a	_	_	_	_	_	_	_	Seg=O
145	disrupted	_	_	_	_	_	_	_	Seg=O
146	intestinal	_	_	_	_	_	_	_	Seg=O
147	microbiota	_	_	_	_	_	_	_	Seg=O
148	on	_	_	_	_	_	_	_	Seg=O
149	disease	_	_	_	_	_	_	_	Seg=O
150	susceptibility	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	Results	_	_	_	_	_	_	_	Seg=B-seg
153	of	_	_	_	_	_	_	_	Seg=O
154	this	_	_	_	_	_	_	_	Seg=O
155	study	_	_	_	_	_	_	_	Seg=O
156	identify	_	_	_	_	_	_	_	Seg=O
157	aEPEC	_	_	_	_	_	_	_	Seg=O
158	as	_	_	_	_	_	_	_	Seg=O
159	a	_	_	_	_	_	_	_	Seg=O
160	potential	_	_	_	_	_	_	_	Seg=O
161	pathogen	_	_	_	_	_	_	_	Seg=O
162	in	_	_	_	_	_	_	_	Seg=O
163	kittens	_	_	_	_	_	_	_	Seg=O
164	.	_	_	_	_	_	_	_	Seg=O
165	In	_	_	_	_	_	_	_	Seg=B-seg
166	the	_	_	_	_	_	_	_	Seg=O
167	absence	_	_	_	_	_	_	_	Seg=O
168	of	_	_	_	_	_	_	_	Seg=O
169	disruption	_	_	_	_	_	_	_	Seg=O
170	to	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	intestinal	_	_	_	_	_	_	_	Seg=O
173	microbiota	_	_	_	_	_	_	_	Seg=O
174	,	_	_	_	_	_	_	_	Seg=O
175	kittens	_	_	_	_	_	_	_	Seg=B-seg
176	are	_	_	_	_	_	_	_	Seg=O
177	resistant	_	_	_	_	_	_	_	Seg=O
178	to	_	_	_	_	_	_	_	Seg=O
179	clinical	_	_	_	_	_	_	_	Seg=O
180	signs	_	_	_	_	_	_	_	Seg=O
181	of	_	_	_	_	_	_	_	Seg=O
182	aEPEC	_	_	_	_	_	_	_	Seg=O
183	carriage	_	_	_	_	_	_	_	Seg=O
184	but	_	_	_	_	_	_	_	Seg=B-seg
185	demonstrate	_	_	_	_	_	_	_	Seg=O
186	significant	_	_	_	_	_	_	_	Seg=O
187	occult	_	_	_	_	_	_	_	Seg=O
188	changes	_	_	_	_	_	_	_	Seg=O
189	in	_	_	_	_	_	_	_	Seg=O
190	intestinal	_	_	_	_	_	_	_	Seg=O
191	absorption	_	_	_	_	_	_	_	Seg=O
192	and	_	_	_	_	_	_	_	Seg=O
193	permeability	_	_	_	_	_	_	_	Seg=O
194	.	_	_	_	_	_	_	_	Seg=O
195	Antibiotic	_	_	_	_	_	_	_	Seg=B-seg
196	-	_	_	_	_	_	_	_	Seg=O
197	induced	_	_	_	_	_	_	_	Seg=O
198	disruption	_	_	_	_	_	_	_	Seg=O
199	of	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	intestinal	_	_	_	_	_	_	_	Seg=O
202	microbiota	_	_	_	_	_	_	_	Seg=O
203	prior	_	_	_	_	_	_	_	Seg=O
204	to	_	_	_	_	_	_	_	Seg=O
205	infection	_	_	_	_	_	_	_	Seg=O
206	increases	_	_	_	_	_	_	_	Seg=O
207	subsequent	_	_	_	_	_	_	_	Seg=O
208	intestinal	_	_	_	_	_	_	_	Seg=O
209	water	_	_	_	_	_	_	_	Seg=O
210	loss	_	_	_	_	_	_	_	Seg=O
211	as	_	_	_	_	_	_	_	Seg=B-seg
212	determined	_	_	_	_	_	_	_	Seg=O
213	by	_	_	_	_	_	_	_	Seg=O
214	%	_	_	_	_	_	_	_	Seg=O
215	fecal	_	_	_	_	_	_	_	Seg=O
216	wet	_	_	_	_	_	_	_	Seg=O
217	weight	_	_	_	_	_	_	_	Seg=O
218	.	_	_	_	_	_	_	_	Seg=O
219	Enrichment	_	_	_	_	_	_	_	Seg=B-seg
220	of	_	_	_	_	_	_	_	Seg=O
221	the	_	_	_	_	_	_	_	Seg=O
222	intestinal	_	_	_	_	_	_	_	Seg=O
223	microbiota	_	_	_	_	_	_	_	Seg=O
224	with	_	_	_	_	_	_	_	Seg=O
225	a	_	_	_	_	_	_	_	Seg=O
226	commensal	_	_	_	_	_	_	_	Seg=O
227	member	_	_	_	_	_	_	_	Seg=O
228	of	_	_	_	_	_	_	_	Seg=O
229	the	_	_	_	_	_	_	_	Seg=O
230	feline	_	_	_	_	_	_	_	Seg=O
231	mucosa	_	_	_	_	_	_	_	Seg=O
232	-	_	_	_	_	_	_	_	Seg=O
233	associated	_	_	_	_	_	_	_	Seg=O
234	microbiota	_	_	_	_	_	_	_	Seg=O
235	,	_	_	_	_	_	_	_	Seg=O
236	Enterococcus	_	_	_	_	_	_	_	Seg=O
237	hirae	_	_	_	_	_	_	_	Seg=O
238	,	_	_	_	_	_	_	_	Seg=O
239	ameliorated	_	_	_	_	_	_	_	Seg=O
240	the	_	_	_	_	_	_	_	Seg=O
241	effects	_	_	_	_	_	_	_	Seg=O
242	of	_	_	_	_	_	_	_	Seg=O
243	aEPEC	_	_	_	_	_	_	_	Seg=O
244	experimental	_	_	_	_	_	_	_	Seg=O
245	infection	_	_	_	_	_	_	_	Seg=O
246	on	_	_	_	_	_	_	_	Seg=O
247	intestinal	_	_	_	_	_	_	_	Seg=O
248	function	_	_	_	_	_	_	_	Seg=O
249	and	_	_	_	_	_	_	_	Seg=O
250	water	_	_	_	_	_	_	_	Seg=O
251	loss	_	_	_	_	_	_	_	Seg=O
252	.	_	_	_	_	_	_	_	Seg=O
253	These	_	_	_	_	_	_	_	Seg=B-seg
254	observations	_	_	_	_	_	_	_	Seg=O
255	begin	_	_	_	_	_	_	_	Seg=O
256	to	_	_	_	_	_	_	_	Seg=O
257	unravel	_	_	_	_	_	_	_	Seg=O
258	the	_	_	_	_	_	_	_	Seg=O
259	mechanisms	_	_	_	_	_	_	_	Seg=O
260	by	_	_	_	_	_	_	_	Seg=B-seg
261	which	_	_	_	_	_	_	_	Seg=O
262	aEPEC	_	_	_	_	_	_	_	Seg=O
263	infection	_	_	_	_	_	_	_	Seg=O
264	may	_	_	_	_	_	_	_	Seg=O
265	be	_	_	_	_	_	_	_	Seg=O
266	able	_	_	_	_	_	_	_	Seg=O
267	to	_	_	_	_	_	_	_	Seg=O
268	exploit	_	_	_	_	_	_	_	Seg=O
269	susceptible	_	_	_	_	_	_	_	Seg=O
270	hosts	_	_	_	_	_	_	_	Seg=O
271	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = d2bf31d4a63b71e7b5bb16f4375134d4ef881d25
1	Studies	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	SARS	_	_	_	_	_	_	_	Seg=O
4	coronavirus	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	SARS	_	_	_	_	_	_	_	Seg=O
7	-	_	_	_	_	_	_	_	Seg=O
8	CoV)	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=B-seg
10	the	_	_	_	_	_	_	_	Seg=O
11	causative	_	_	_	_	_	_	_	Seg=O
12	agent	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	severe	_	_	_	_	_	_	_	Seg=O
15	acute	_	_	_	_	_	_	_	Seg=O
16	respiratory	_	_	_	_	_	_	_	Seg=O
17	syndrome	_	_	_	_	_	_	_	Seg=O
18	(	_	_	_	_	_	_	_	Seg=O
19	SARS)	_	_	_	_	_	_	_	Seg=O
20	-	_	_	_	_	_	_	_	Seg=O
21	have	_	_	_	_	_	_	_	Seg=B-seg
22	been	_	_	_	_	_	_	_	Seg=O
23	hampered	_	_	_	_	_	_	_	Seg=O
24	by	_	_	_	_	_	_	_	Seg=O
25	its	_	_	_	_	_	_	_	Seg=O
26	high	_	_	_	_	_	_	_	Seg=O
27	transmission	_	_	_	_	_	_	_	Seg=O
28	rate	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	the	_	_	_	_	_	_	_	Seg=O
31	pathogenicity	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	this	_	_	_	_	_	_	_	Seg=O
34	virus	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	To	_	_	_	_	_	_	_	Seg=B-seg
37	permit	_	_	_	_	_	_	_	Seg=O
38	analysis	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	host	_	_	_	_	_	_	_	Seg=O
42	range	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	entry	_	_	_	_	_	_	_	Seg=O
45	mechanism	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	SARS	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=O
49	CoV	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	we	_	_	_	_	_	_	_	Seg=B-seg
52	incorporated	_	_	_	_	_	_	_	Seg=O
53	the	_	_	_	_	_	_	_	Seg=O
54	humanized	_	_	_	_	_	_	_	Seg=O
55	SARS	_	_	_	_	_	_	_	Seg=O
56	-	_	_	_	_	_	_	_	Seg=O
57	CoV	_	_	_	_	_	_	_	Seg=O
58	spike	_	_	_	_	_	_	_	Seg=O
59	(	_	_	_	_	_	_	_	Seg=O
60	S	_	_	_	_	_	_	_	Seg=O
61	)	_	_	_	_	_	_	_	Seg=O
62	glycoprotein	_	_	_	_	_	_	_	Seg=O
63	into	_	_	_	_	_	_	_	Seg=O
64	HIV	_	_	_	_	_	_	_	Seg=O
65	particles	_	_	_	_	_	_	_	Seg=O
66	to	_	_	_	_	_	_	_	Seg=B-seg
67	generate	_	_	_	_	_	_	_	Seg=O
68	a	_	_	_	_	_	_	_	Seg=O
69	highly	_	_	_	_	_	_	_	Seg=O
70	infectious	_	_	_	_	_	_	_	Seg=O
71	SARS	_	_	_	_	_	_	_	Seg=O
72	-	_	_	_	_	_	_	_	Seg=O
73	CoV	_	_	_	_	_	_	_	Seg=O
74	pseudotyped	_	_	_	_	_	_	_	Seg=O
75	virus	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	The	_	_	_	_	_	_	_	Seg=B-seg
78	infection	_	_	_	_	_	_	_	Seg=O
79	on	_	_	_	_	_	_	_	Seg=O
80	Vero	_	_	_	_	_	_	_	Seg=O
81	E6	_	_	_	_	_	_	_	Seg=O
82	-	_	_	_	_	_	_	_	Seg=B-seg
83	a	_	_	_	_	_	_	_	Seg=O
84	permissive	_	_	_	_	_	_	_	Seg=O
85	cell	_	_	_	_	_	_	_	Seg=O
86	line	_	_	_	_	_	_	_	Seg=O
87	to	_	_	_	_	_	_	_	Seg=O
88	SARS	_	_	_	_	_	_	_	Seg=O
89	-	_	_	_	_	_	_	_	Seg=O
90	CoV	_	_	_	_	_	_	_	Seg=O
91	-	_	_	_	_	_	_	_	Seg=O
92	could	_	_	_	_	_	_	_	Seg=B-seg
93	be	_	_	_	_	_	_	_	Seg=O
94	neutralized	_	_	_	_	_	_	_	Seg=O
95	by	_	_	_	_	_	_	_	Seg=O
96	sera	_	_	_	_	_	_	_	Seg=O
97	from	_	_	_	_	_	_	_	Seg=O
98	convalescent	_	_	_	_	_	_	_	Seg=O
99	SARS	_	_	_	_	_	_	_	Seg=O
100	patients	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	and	_	_	_	_	_	_	_	Seg=B-seg
103	the	_	_	_	_	_	_	_	Seg=O
104	entry	_	_	_	_	_	_	_	Seg=O
105	was	_	_	_	_	_	_	_	Seg=O
106	a	_	_	_	_	_	_	_	Seg=O
107	pH	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	dependent	_	_	_	_	_	_	_	Seg=O
110	process	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	With	_	_	_	_	_	_	_	Seg=B-seg
113	these	_	_	_	_	_	_	_	Seg=O
114	highly	_	_	_	_	_	_	_	Seg=O
115	infectious	_	_	_	_	_	_	_	Seg=O
116	SARS	_	_	_	_	_	_	_	Seg=O
117	-	_	_	_	_	_	_	_	Seg=O
118	CoV	_	_	_	_	_	_	_	Seg=O
119	pseudotypes	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	several	_	_	_	_	_	_	_	Seg=O
122	cell	_	_	_	_	_	_	_	Seg=O
123	lines	_	_	_	_	_	_	_	Seg=O
124	derived	_	_	_	_	_	_	_	Seg=B-seg
125	from	_	_	_	_	_	_	_	Seg=O
126	various	_	_	_	_	_	_	_	Seg=O
127	tissues	_	_	_	_	_	_	_	Seg=O
128	were	_	_	_	_	_	_	_	Seg=B-seg
129	revealed	_	_	_	_	_	_	_	Seg=O
130	as	_	_	_	_	_	_	_	Seg=O
131	susceptible	_	_	_	_	_	_	_	Seg=O
132	to	_	_	_	_	_	_	_	Seg=O
133	SARS	_	_	_	_	_	_	_	Seg=O
134	-	_	_	_	_	_	_	_	Seg=O
135	CoV	_	_	_	_	_	_	_	Seg=O
136	,	_	_	_	_	_	_	_	Seg=O
137	which	_	_	_	_	_	_	_	Seg=B-seg
138	were	_	_	_	_	_	_	_	Seg=O
139	highly	_	_	_	_	_	_	_	Seg=O
140	corresponding	_	_	_	_	_	_	_	Seg=O
141	to	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	expression	_	_	_	_	_	_	_	Seg=O
144	pattern	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	virusÕs	_	_	_	_	_	_	_	Seg=O
147	receptor	_	_	_	_	_	_	_	Seg=O
148	angiotensin	_	_	_	_	_	_	_	Seg=O
149	-	_	_	_	_	_	_	_	Seg=O
150	converting	_	_	_	_	_	_	_	Seg=O
151	enzyme	_	_	_	_	_	_	_	Seg=O
152	2	_	_	_	_	_	_	_	Seg=O
153	(	_	_	_	_	_	_	_	Seg=O
154	ACE2	_	_	_	_	_	_	_	Seg=O
155	)	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	In	_	_	_	_	_	_	_	Seg=B-seg
158	addition	_	_	_	_	_	_	_	Seg=O
159	,	_	_	_	_	_	_	_	Seg=O
160	we	_	_	_	_	_	_	_	Seg=O
161	also	_	_	_	_	_	_	_	Seg=O
162	demonstrated	_	_	_	_	_	_	_	Seg=O
163	angiotensin	_	_	_	_	_	_	_	Seg=B-seg
164	1	_	_	_	_	_	_	_	Seg=O
165	converting	_	_	_	_	_	_	_	Seg=O
166	enzyme	_	_	_	_	_	_	_	Seg=O
167	(	_	_	_	_	_	_	_	Seg=O
168	ACE)	_	_	_	_	_	_	_	Seg=O
169	-	_	_	_	_	_	_	_	Seg=B-seg
170	the	_	_	_	_	_	_	_	Seg=O
171	homologue	_	_	_	_	_	_	_	Seg=O
172	of	_	_	_	_	_	_	_	Seg=O
173	ACE2	_	_	_	_	_	_	_	Seg=O
174	could	_	_	_	_	_	_	_	Seg=B-seg
175	not	_	_	_	_	_	_	_	Seg=O
176	function	_	_	_	_	_	_	_	Seg=O
177	as	_	_	_	_	_	_	_	Seg=O
178	a	_	_	_	_	_	_	_	Seg=O
179	receptor	_	_	_	_	_	_	_	Seg=O
180	for	_	_	_	_	_	_	_	Seg=O
181	SARS	_	_	_	_	_	_	_	Seg=O
182	-	_	_	_	_	_	_	_	Seg=O
183	CoV.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = d7e5ba009aed400fac0a223f7fe364b16ac84ae6
1	Next	_	_	_	_	_	_	_	Seg=B-seg
2	-	_	_	_	_	_	_	_	Seg=O
3	Generation	_	_	_	_	_	_	_	Seg=O
4	Sequencing	_	_	_	_	_	_	_	Seg=O
5	has	_	_	_	_	_	_	_	Seg=O
6	been	_	_	_	_	_	_	_	Seg=O
7	used	_	_	_	_	_	_	_	Seg=O
8	in	_	_	_	_	_	_	_	Seg=O
9	numerous	_	_	_	_	_	_	_	Seg=O
10	investigations	_	_	_	_	_	_	_	Seg=O
11	to	_	_	_	_	_	_	_	Seg=B-seg
12	characterize	_	_	_	_	_	_	_	Seg=O
13	andquantifythe	_	_	_	_	_	_	_	Seg=O
14	genetic	_	_	_	_	_	_	_	Seg=O
15	diversity	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	a	_	_	_	_	_	_	_	Seg=O
18	virus	_	_	_	_	_	_	_	Seg=O
19	sample	_	_	_	_	_	_	_	Seg=O
20	through	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	mapping	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	polymorphisms	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	measurement	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	mutation	_	_	_	_	_	_	_	Seg=O
29	frequencies	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	Next	_	_	_	_	_	_	_	Seg=B-seg
32	-	_	_	_	_	_	_	_	Seg=O
33	Generation	_	_	_	_	_	_	_	Seg=O
34	Sequencing	_	_	_	_	_	_	_	Seg=O
35	has	_	_	_	_	_	_	_	Seg=O
36	also	_	_	_	_	_	_	_	Seg=O
37	been	_	_	_	_	_	_	_	Seg=O
38	employed	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=B-seg
40	identify	_	_	_	_	_	_	_	Seg=O
41	recombination	_	_	_	_	_	_	_	Seg=O
42	events	_	_	_	_	_	_	_	Seg=O
43	occurring	_	_	_	_	_	_	_	Seg=B-seg
44	within	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	genomes	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	higher	_	_	_	_	_	_	_	Seg=O
49	organisms	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	for	_	_	_	_	_	_	_	Seg=B-seg
52	example	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	detecting	_	_	_	_	_	_	_	Seg=O
55	alternative	_	_	_	_	_	_	_	Seg=O
56	RNA	_	_	_	_	_	_	_	Seg=O
57	splicing	_	_	_	_	_	_	_	Seg=O
58	events	_	_	_	_	_	_	_	Seg=O
59	and	_	_	_	_	_	_	_	Seg=O
60	oncogenic	_	_	_	_	_	_	_	Seg=O
61	chromosomal	_	_	_	_	_	_	_	Seg=O
62	rearrangements	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	Here	_	_	_	_	_	_	_	Seg=B-seg
65	,	_	_	_	_	_	_	_	Seg=O
66	we	_	_	_	_	_	_	_	Seg=O
67	combine	_	_	_	_	_	_	_	Seg=O
68	these	_	_	_	_	_	_	_	Seg=O
69	two	_	_	_	_	_	_	_	Seg=O
70	approaches	_	_	_	_	_	_	_	Seg=O
71	to	_	_	_	_	_	_	_	Seg=B-seg
72	profile	_	_	_	_	_	_	_	Seg=O
73	RNA	_	_	_	_	_	_	_	Seg=O
74	recombination	_	_	_	_	_	_	_	Seg=O
75	within	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77	encapsidated	_	_	_	_	_	_	_	Seg=O
78	genome	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	a	_	_	_	_	_	_	_	Seg=O
81	eukaryotic	_	_	_	_	_	_	_	Seg=O
82	RNA	_	_	_	_	_	_	_	Seg=O
83	virus	_	_	_	_	_	_	_	Seg=O
84	,	_	_	_	_	_	_	_	Seg=O
85	Flock	_	_	_	_	_	_	_	Seg=O
86	House	_	_	_	_	_	_	_	Seg=O
87	Virus	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	We	_	_	_	_	_	_	_	Seg=B-seg
90	detect	_	_	_	_	_	_	_	Seg=O
91	hundreds	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	thousands	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	recombination	_	_	_	_	_	_	_	Seg=O
96	events	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	with	_	_	_	_	_	_	_	Seg=O
99	single	_	_	_	_	_	_	_	Seg=O
100	-	_	_	_	_	_	_	_	Seg=O
101	nucleotide	_	_	_	_	_	_	_	Seg=O
102	resolution	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	which	_	_	_	_	_	_	_	Seg=B-seg
105	result	_	_	_	_	_	_	_	Seg=O
106	in	_	_	_	_	_	_	_	Seg=O
107	diversity	_	_	_	_	_	_	_	Seg=O
108	in	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	encapsidated	_	_	_	_	_	_	_	Seg=O
111	genome	_	_	_	_	_	_	_	Seg=O
112	rivaling	_	_	_	_	_	_	_	Seg=B-seg
113	that	_	_	_	_	_	_	_	Seg=O
114	due	_	_	_	_	_	_	_	Seg=O
115	to	_	_	_	_	_	_	_	Seg=O
116	mismatch	_	_	_	_	_	_	_	Seg=O
117	mutation	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	We	_	_	_	_	_	_	_	Seg=B-seg
120	detect	_	_	_	_	_	_	_	Seg=O
121	previously	_	_	_	_	_	_	_	Seg=O
122	identified	_	_	_	_	_	_	_	Seg=O
123	Defective	_	_	_	_	_	_	_	Seg=O
124	-	_	_	_	_	_	_	_	Seg=O
125	RNAs	_	_	_	_	_	_	_	Seg=O
126	as	_	_	_	_	_	_	_	Seg=O
127	well	_	_	_	_	_	_	_	Seg=O
128	as	_	_	_	_	_	_	_	Seg=O
129	many	_	_	_	_	_	_	_	Seg=O
130	other	_	_	_	_	_	_	_	Seg=O
131	abundant	_	_	_	_	_	_	_	Seg=O
132	and	_	_	_	_	_	_	_	Seg=O
133	novel	_	_	_	_	_	_	_	Seg=O
134	Defective	_	_	_	_	_	_	_	Seg=O
135	-	_	_	_	_	_	_	_	Seg=O
136	RNAs	_	_	_	_	_	_	_	Seg=O
137	.	_	_	_	_	_	_	_	Seg=O
138	Our	_	_	_	_	_	_	_	Seg=B-seg
139	approach	_	_	_	_	_	_	_	Seg=O
140	is	_	_	_	_	_	_	_	Seg=O
141	exceptionally	_	_	_	_	_	_	_	Seg=O
142	sensitive	_	_	_	_	_	_	_	Seg=O
143	,	_	_	_	_	_	_	_	Seg=O
144	unbiased	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=B-seg
147	requires	_	_	_	_	_	_	_	Seg=O
148	no	_	_	_	_	_	_	_	Seg=O
149	prior	_	_	_	_	_	_	_	Seg=O
150	knowledge	_	_	_	_	_	_	_	Seg=O
151	beyond	_	_	_	_	_	_	_	Seg=O
152	the	_	_	_	_	_	_	_	Seg=O
153	virus	_	_	_	_	_	_	_	Seg=O
154	genome	_	_	_	_	_	_	_	Seg=O
155	sequence	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	RNA	_	_	_	_	_	_	_	Seg=B-seg
158	recombination	_	_	_	_	_	_	_	Seg=O
159	is	_	_	_	_	_	_	_	Seg=O
160	a	_	_	_	_	_	_	_	Seg=O
161	powerful	_	_	_	_	_	_	_	Seg=O
162	driving	_	_	_	_	_	_	_	Seg=O
163	force	_	_	_	_	_	_	_	Seg=O
164	behind	_	_	_	_	_	_	_	Seg=O
165	the	_	_	_	_	_	_	_	Seg=O
166	evolution	_	_	_	_	_	_	_	Seg=O
167	and	_	_	_	_	_	_	_	Seg=O
168	adaptation	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	RNA	_	_	_	_	_	_	_	Seg=O
171	viruses	_	_	_	_	_	_	_	Seg=O
172	.	_	_	_	_	_	_	_	Seg=O
173	The	_	_	_	_	_	_	_	Seg=B-seg
174	strategy	_	_	_	_	_	_	_	Seg=O
175	implemented	_	_	_	_	_	_	_	Seg=B-seg
176	here	_	_	_	_	_	_	_	Seg=O
177	is	_	_	_	_	_	_	_	Seg=B-seg
178	widely	_	_	_	_	_	_	_	Seg=O
179	applicable	_	_	_	_	_	_	_	Seg=O
180	and	_	_	_	_	_	_	_	Seg=B-seg
181	provides	_	_	_	_	_	_	_	Seg=O
182	a	_	_	_	_	_	_	_	Seg=O
183	highly	_	_	_	_	_	_	_	Seg=O
184	detailed	_	_	_	_	_	_	_	Seg=O
185	description	_	_	_	_	_	_	_	Seg=O
186	of	_	_	_	_	_	_	_	Seg=O
187	the	_	_	_	_	_	_	_	Seg=O
188	complex	_	_	_	_	_	_	_	Seg=O
189	mutational	_	_	_	_	_	_	_	Seg=O
190	landscape	_	_	_	_	_	_	_	Seg=O
191	of	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	transmissible	_	_	_	_	_	_	_	Seg=O
194	viral	_	_	_	_	_	_	_	Seg=O
195	genome	_	_	_	_	_	_	_	Seg=O
196	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = d87f44c7d76e4c51ed8e72103669c275e2db3e71
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	major	_	_	_	_	_	_	_	Seg=O
3	physiological	_	_	_	_	_	_	_	Seg=O
4	function	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	milk	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	transport	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	amino	_	_	_	_	_	_	_	Seg=O
12	acids	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	carbohydrates	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	lipids	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=O
18	minerals	_	_	_	_	_	_	_	Seg=O
19	to	_	_	_	_	_	_	_	Seg=O
20	mammalian	_	_	_	_	_	_	_	Seg=O
21	offspring	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	Caseins	_	_	_	_	_	_	_	Seg=B-seg
24	,	_	_	_	_	_	_	_	Seg=O
25	the	_	_	_	_	_	_	_	Seg=O
26	major	_	_	_	_	_	_	_	Seg=O
27	milk	_	_	_	_	_	_	_	Seg=O
28	proteins	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	are	_	_	_	_	_	_	_	Seg=O
31	secreted	_	_	_	_	_	_	_	Seg=O
32	in	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	form	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	a	_	_	_	_	_	_	_	Seg=O
37	micelle	_	_	_	_	_	_	_	Seg=O
38	consisting	_	_	_	_	_	_	_	Seg=B-seg
39	of	_	_	_	_	_	_	_	Seg=O
40	protein	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	calciumphosphate	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	We	_	_	_	_	_	_	_	Seg=B-seg
45	have	_	_	_	_	_	_	_	Seg=O
46	analysed	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	role	_	_	_	_	_	_	_	Seg=O
49	of	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	milk	_	_	_	_	_	_	_	Seg=O
52	protein	_	_	_	_	_	_	_	Seg=O
53	a	_	_	_	_	_	_	_	Seg=O
54	-	_	_	_	_	_	_	_	Seg=O
55	casein	_	_	_	_	_	_	_	Seg=O
56	by	_	_	_	_	_	_	_	Seg=B-seg
57	inactivating	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	corresponding	_	_	_	_	_	_	_	Seg=O
60	gene	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	mice	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	Absence	_	_	_	_	_	_	_	Seg=B-seg
65	of	_	_	_	_	_	_	_	Seg=O
66	a	_	_	_	_	_	_	_	Seg=O
67	-	_	_	_	_	_	_	_	Seg=O
68	casein	_	_	_	_	_	_	_	Seg=O
69	protein	_	_	_	_	_	_	_	Seg=O
70	significantly	_	_	_	_	_	_	_	Seg=O
71	curtails	_	_	_	_	_	_	_	Seg=O
72	secretion	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	other	_	_	_	_	_	_	_	Seg=O
75	milk	_	_	_	_	_	_	_	Seg=O
76	proteins	_	_	_	_	_	_	_	Seg=O
77	and	_	_	_	_	_	_	_	Seg=O
78	calcium	_	_	_	_	_	_	_	Seg=O
79	-	_	_	_	_	_	_	_	Seg=O
80	phosphate	_	_	_	_	_	_	_	Seg=O
81	,	_	_	_	_	_	_	_	Seg=O
82	suggesting	_	_	_	_	_	_	_	Seg=B-seg
83	a	_	_	_	_	_	_	_	Seg=O
84	role	_	_	_	_	_	_	_	Seg=O
85	for	_	_	_	_	_	_	_	Seg=O
86	a	_	_	_	_	_	_	_	Seg=O
87	-	_	_	_	_	_	_	_	Seg=O
88	casein	_	_	_	_	_	_	_	Seg=O
89	in	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	establishment	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	casein	_	_	_	_	_	_	_	Seg=O
94	micelles	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	In	_	_	_	_	_	_	_	Seg=B-seg
97	contrast	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	secretion	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	albumin	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	which	_	_	_	_	_	_	_	Seg=B-seg
104	is	_	_	_	_	_	_	_	Seg=O
105	not	_	_	_	_	_	_	_	Seg=O
106	synthesized	_	_	_	_	_	_	_	Seg=O
107	in	_	_	_	_	_	_	_	Seg=O
108	the	_	_	_	_	_	_	_	Seg=O
109	mammary	_	_	_	_	_	_	_	Seg=O
110	epithelium	_	_	_	_	_	_	_	Seg=O
111	,	_	_	_	_	_	_	_	Seg=O
112	into	_	_	_	_	_	_	_	Seg=B-seg
113	milk	_	_	_	_	_	_	_	Seg=O
114	is	_	_	_	_	_	_	_	Seg=O
115	not	_	_	_	_	_	_	_	Seg=O
116	reduced	_	_	_	_	_	_	_	Seg=O
117	.	_	_	_	_	_	_	_	Seg=O
118	The	_	_	_	_	_	_	_	Seg=B-seg
119	absence	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	a	_	_	_	_	_	_	_	Seg=O
122	-	_	_	_	_	_	_	_	Seg=O
123	casein	_	_	_	_	_	_	_	Seg=O
124	also	_	_	_	_	_	_	_	Seg=O
125	significantly	_	_	_	_	_	_	_	Seg=O
126	inhibits	_	_	_	_	_	_	_	Seg=O
127	transcription	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	other	_	_	_	_	_	_	_	Seg=O
131	casein	_	_	_	_	_	_	_	Seg=O
132	genes	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O
134	a	_	_	_	_	_	_	_	Seg=B-seg
135	-	_	_	_	_	_	_	_	Seg=O
136	Casein	_	_	_	_	_	_	_	Seg=O
137	deficiency	_	_	_	_	_	_	_	Seg=O
138	severely	_	_	_	_	_	_	_	Seg=O
139	delays	_	_	_	_	_	_	_	Seg=O
140	pup	_	_	_	_	_	_	_	Seg=O
141	growth	_	_	_	_	_	_	_	Seg=O
142	during	_	_	_	_	_	_	_	Seg=O
143	lactation	_	_	_	_	_	_	_	Seg=O
144	and	_	_	_	_	_	_	_	Seg=B-seg
145	results	_	_	_	_	_	_	_	Seg=O
146	in	_	_	_	_	_	_	_	Seg=O
147	a	_	_	_	_	_	_	_	Seg=O
148	life	_	_	_	_	_	_	_	Seg=O
149	-	_	_	_	_	_	_	_	Seg=O
150	long	_	_	_	_	_	_	_	Seg=O
151	body	_	_	_	_	_	_	_	Seg=O
152	size	_	_	_	_	_	_	_	Seg=O
153	reduction	_	_	_	_	_	_	_	Seg=O
154	compared	_	_	_	_	_	_	_	Seg=B-seg
155	to	_	_	_	_	_	_	_	Seg=O
156	control	_	_	_	_	_	_	_	Seg=O
157	animals	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	but	_	_	_	_	_	_	_	Seg=B-seg
160	has	_	_	_	_	_	_	_	Seg=O
161	only	_	_	_	_	_	_	_	Seg=O
162	transient	_	_	_	_	_	_	_	Seg=O
163	effects	_	_	_	_	_	_	_	Seg=O
164	on	_	_	_	_	_	_	_	Seg=O
165	physical	_	_	_	_	_	_	_	Seg=O
166	and	_	_	_	_	_	_	_	Seg=O
167	behavioural	_	_	_	_	_	_	_	Seg=O
168	development	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	the	_	_	_	_	_	_	_	Seg=O
171	pups	_	_	_	_	_	_	_	Seg=O
172	.	_	_	_	_	_	_	_	Seg=O
173	The	_	_	_	_	_	_	_	Seg=B-seg
174	data	_	_	_	_	_	_	_	Seg=O
175	support	_	_	_	_	_	_	_	Seg=O
176	a	_	_	_	_	_	_	_	Seg=O
177	critical	_	_	_	_	_	_	_	Seg=O
178	role	_	_	_	_	_	_	_	Seg=O
179	for	_	_	_	_	_	_	_	Seg=O
180	a	_	_	_	_	_	_	_	Seg=O
181	-	_	_	_	_	_	_	_	Seg=O
182	casein	_	_	_	_	_	_	_	Seg=O
183	in	_	_	_	_	_	_	_	Seg=O
184	casein	_	_	_	_	_	_	_	Seg=O
185	micelle	_	_	_	_	_	_	_	Seg=O
186	assembly	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	The	_	_	_	_	_	_	_	Seg=B-seg
189	results	_	_	_	_	_	_	_	Seg=O
190	also	_	_	_	_	_	_	_	Seg=O
191	confirm	_	_	_	_	_	_	_	Seg=O
192	lactation	_	_	_	_	_	_	_	Seg=O
193	as	_	_	_	_	_	_	_	Seg=O
194	a	_	_	_	_	_	_	_	Seg=O
195	critical	_	_	_	_	_	_	_	Seg=O
196	window	_	_	_	_	_	_	_	Seg=O
197	of	_	_	_	_	_	_	_	Seg=O
198	metabolic	_	_	_	_	_	_	_	Seg=O
199	programming	_	_	_	_	_	_	_	Seg=O
200	and	_	_	_	_	_	_	_	Seg=B-seg
201	suggest	_	_	_	_	_	_	_	Seg=O
202	milk	_	_	_	_	_	_	_	Seg=O
203	protein	_	_	_	_	_	_	_	Seg=O
204	concentration	_	_	_	_	_	_	_	Seg=O
205	as	_	_	_	_	_	_	_	Seg=O
206	a	_	_	_	_	_	_	_	Seg=O
207	decisive	_	_	_	_	_	_	_	Seg=O
208	factor	_	_	_	_	_	_	_	Seg=O
209	in	_	_	_	_	_	_	_	Seg=B-seg
210	determining	_	_	_	_	_	_	_	Seg=O
211	adult	_	_	_	_	_	_	_	Seg=O
212	body	_	_	_	_	_	_	_	Seg=O
213	weight	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = db9cea6a24f86d7bc1250050693fd459e3de6e2b
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	detection	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	scintillation	_	_	_	_	_	_	_	Seg=O
5	light	_	_	_	_	_	_	_	Seg=O
6	from	_	_	_	_	_	_	_	Seg=O
7	liquid	_	_	_	_	_	_	_	Seg=O
8	argon	_	_	_	_	_	_	_	Seg=O
9	is	_	_	_	_	_	_	_	Seg=O
10	an	_	_	_	_	_	_	_	Seg=O
11	experimental	_	_	_	_	_	_	_	Seg=O
12	technique	_	_	_	_	_	_	_	Seg=O
13	key	_	_	_	_	_	_	_	Seg=B-seg
14	to	_	_	_	_	_	_	_	Seg=O
15	a	_	_	_	_	_	_	_	Seg=O
16	number	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	current	_	_	_	_	_	_	_	Seg=O
19	and	_	_	_	_	_	_	_	Seg=O
20	future	_	_	_	_	_	_	_	Seg=O
21	nuclear	_	_	_	_	_	_	_	Seg=O
22	/	_	_	_	_	_	_	_	Seg=O
23	particle	_	_	_	_	_	_	_	Seg=O
24	physics	_	_	_	_	_	_	_	Seg=O
25	experiments	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	such	_	_	_	_	_	_	_	Seg=B-seg
28	as	_	_	_	_	_	_	_	Seg=O
29	neutrino	_	_	_	_	_	_	_	Seg=O
30	physics	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	neutrinoless	_	_	_	_	_	_	_	Seg=O
33	double	_	_	_	_	_	_	_	Seg=O
34	beta	_	_	_	_	_	_	_	Seg=O
35	decay	_	_	_	_	_	_	_	Seg=O
36	and	_	_	_	_	_	_	_	Seg=O
37	dark	_	_	_	_	_	_	_	Seg=O
38	matter	_	_	_	_	_	_	_	Seg=O
39	searches	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	Although	_	_	_	_	_	_	_	Seg=B-seg
42	the	_	_	_	_	_	_	_	Seg=O
43	idea	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=B-seg
45	adding	_	_	_	_	_	_	_	Seg=O
46	small	_	_	_	_	_	_	_	Seg=O
47	quantities	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	xenon	_	_	_	_	_	_	_	Seg=O
50	(	_	_	_	_	_	_	_	Seg=O
51	doping	_	_	_	_	_	_	_	Seg=O
52	)	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=B-seg
54	enhance	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	light	_	_	_	_	_	_	_	Seg=O
57	yield	_	_	_	_	_	_	_	Seg=O
58	has	_	_	_	_	_	_	_	Seg=B-seg
59	attracted	_	_	_	_	_	_	_	Seg=O
60	considerable	_	_	_	_	_	_	_	Seg=O
61	interest	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	this	_	_	_	_	_	_	_	Seg=B-seg
64	technique	_	_	_	_	_	_	_	Seg=O
65	has	_	_	_	_	_	_	_	Seg=O
66	never	_	_	_	_	_	_	_	Seg=O
67	been	_	_	_	_	_	_	_	Seg=O
68	demonstrated	_	_	_	_	_	_	_	Seg=O
69	at	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	necessary	_	_	_	_	_	_	_	Seg=O
72	scale	_	_	_	_	_	_	_	Seg=O
73	.	_	_	_	_	_	_	_	Seg=O
74	Here	_	_	_	_	_	_	_	Seg=B-seg
75	we	_	_	_	_	_	_	_	Seg=O
76	report	_	_	_	_	_	_	_	Seg=O
77	on	_	_	_	_	_	_	_	Seg=O
78	xenon	_	_	_	_	_	_	_	Seg=O
79	doping	_	_	_	_	_	_	_	Seg=O
80	in	_	_	_	_	_	_	_	Seg=O
81	a	_	_	_	_	_	_	_	Seg=O
82	100	_	_	_	_	_	_	_	Seg=O
83	l	_	_	_	_	_	_	_	Seg=O
84	crogenic	_	_	_	_	_	_	_	Seg=O
85	vessel	_	_	_	_	_	_	_	Seg=O
86	.	_	_	_	_	_	_	_	Seg=O
87	We	_	_	_	_	_	_	_	Seg=B-seg
88	observed	_	_	_	_	_	_	_	Seg=O
89	an	_	_	_	_	_	_	_	Seg=O
90	increase	_	_	_	_	_	_	_	Seg=O
91	in	_	_	_	_	_	_	_	Seg=O
92	light	_	_	_	_	_	_	_	Seg=O
93	yield	_	_	_	_	_	_	_	Seg=O
94	by	_	_	_	_	_	_	_	Seg=O
95	a	_	_	_	_	_	_	_	Seg=O
96	factor	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	1.81±0.04	_	_	_	_	_	_	_	Seg=O
99	at	_	_	_	_	_	_	_	Seg=O
100	a	_	_	_	_	_	_	_	Seg=O
101	dopant	_	_	_	_	_	_	_	Seg=O
102	concentration	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	10	_	_	_	_	_	_	_	Seg=O
105	ppm	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	consistent	_	_	_	_	_	_	_	Seg=B-seg
108	with	_	_	_	_	_	_	_	Seg=O
109	a	_	_	_	_	_	_	_	Seg=O
110	Geant4	_	_	_	_	_	_	_	Seg=O
111	prediction	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	1.83±0.02	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	We	_	_	_	_	_	_	_	Seg=B-seg
116	determine	_	_	_	_	_	_	_	Seg=O
117	a	_	_	_	_	_	_	_	Seg=O
118	lower	_	_	_	_	_	_	_	Seg=O
119	limit	_	_	_	_	_	_	_	Seg=O
120	on	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	attenuation	_	_	_	_	_	_	_	Seg=O
123	length	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	3	_	_	_	_	_	_	_	Seg=O
126	m	_	_	_	_	_	_	_	Seg=O
127	at	_	_	_	_	_	_	_	Seg=O
128	a	_	_	_	_	_	_	_	Seg=O
129	concentration	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	10	_	_	_	_	_	_	_	Seg=O
132	ppm	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e296fa71274bad6cabcf683a2ba47e58b1326877
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	paper	_	_	_	_	_	_	_	Seg=O
3	offers	_	_	_	_	_	_	_	Seg=O
4	a	_	_	_	_	_	_	_	Seg=O
5	state	_	_	_	_	_	_	_	Seg=O
6	-	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	-	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	art	_	_	_	_	_	_	_	Seg=O
12	overview	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	the	_	_	_	_	_	_	_	Seg=O
15	intertwined	_	_	_	_	_	_	_	Seg=O
16	privacy	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	confidentiality	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=O
21	security	_	_	_	_	_	_	_	Seg=O
22	issues	_	_	_	_	_	_	_	Seg=O
23	that	_	_	_	_	_	_	_	Seg=B-seg
24	are	_	_	_	_	_	_	_	Seg=O
25	commonly	_	_	_	_	_	_	_	Seg=O
26	encountered	_	_	_	_	_	_	_	Seg=O
27	in	_	_	_	_	_	_	_	Seg=O
28	health	_	_	_	_	_	_	_	Seg=O
29	research	_	_	_	_	_	_	_	Seg=O
30	involving	_	_	_	_	_	_	_	Seg=B-seg
31	disaggregate	_	_	_	_	_	_	_	Seg=O
32	geographic	_	_	_	_	_	_	_	Seg=O
33	data	_	_	_	_	_	_	_	Seg=O
34	about	_	_	_	_	_	_	_	Seg=O
35	individuals	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	Key	_	_	_	_	_	_	_	Seg=B-seg
38	definitions	_	_	_	_	_	_	_	Seg=O
39	are	_	_	_	_	_	_	_	Seg=O
40	provided	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	along	_	_	_	_	_	_	_	Seg=O
43	with	_	_	_	_	_	_	_	Seg=O
44	some	_	_	_	_	_	_	_	Seg=O
45	examples	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	actual	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	potential	_	_	_	_	_	_	_	Seg=O
50	security	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=O
52	confidentiality	_	_	_	_	_	_	_	Seg=O
53	breaches	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=O
55	related	_	_	_	_	_	_	_	Seg=O
56	incidents	_	_	_	_	_	_	_	Seg=O
57	that	_	_	_	_	_	_	_	Seg=B-seg
58	captured	_	_	_	_	_	_	_	Seg=O
59	mainstream	_	_	_	_	_	_	_	Seg=O
60	media	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	public	_	_	_	_	_	_	_	Seg=O
63	interest	_	_	_	_	_	_	_	Seg=O
64	in	_	_	_	_	_	_	_	Seg=O
65	recent	_	_	_	_	_	_	_	Seg=O
66	months	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=O
68	years	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	The	_	_	_	_	_	_	_	Seg=B-seg
71	paper	_	_	_	_	_	_	_	Seg=O
72	then	_	_	_	_	_	_	_	Seg=O
73	goes	_	_	_	_	_	_	_	Seg=O
74	on	_	_	_	_	_	_	_	Seg=O
75	to	_	_	_	_	_	_	_	Seg=O
76	present	_	_	_	_	_	_	_	Seg=O
77	a	_	_	_	_	_	_	_	Seg=O
78	brief	_	_	_	_	_	_	_	Seg=O
79	survey	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	research	_	_	_	_	_	_	_	Seg=O
83	literature	_	_	_	_	_	_	_	Seg=O
84	on	_	_	_	_	_	_	_	Seg=O
85	location	_	_	_	_	_	_	_	Seg=O
86	privacy	_	_	_	_	_	_	_	Seg=O
87	/	_	_	_	_	_	_	_	Seg=O
88	confidentiality	_	_	_	_	_	_	_	Seg=O
89	concerns	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=O
91	on	_	_	_	_	_	_	_	Seg=O
92	privacy	_	_	_	_	_	_	_	Seg=O
93	-	_	_	_	_	_	_	_	Seg=O
94	preserving	_	_	_	_	_	_	_	Seg=O
95	solutions	_	_	_	_	_	_	_	Seg=O
96	in	_	_	_	_	_	_	_	Seg=O
97	conventional	_	_	_	_	_	_	_	Seg=O
98	health	_	_	_	_	_	_	_	Seg=O
99	research	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=O
101	beyond	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	touching	_	_	_	_	_	_	_	Seg=B-seg
104	on	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	emerging	_	_	_	_	_	_	_	Seg=O
107	privacy	_	_	_	_	_	_	_	Seg=O
108	issues	_	_	_	_	_	_	_	Seg=O
109	associated	_	_	_	_	_	_	_	Seg=B-seg
110	with	_	_	_	_	_	_	_	Seg=O
111	online	_	_	_	_	_	_	_	Seg=O
112	consumer	_	_	_	_	_	_	_	Seg=O
113	geoinformatics	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	location	_	_	_	_	_	_	_	Seg=O
116	-	_	_	_	_	_	_	_	Seg=O
117	based	_	_	_	_	_	_	_	Seg=O
118	services	_	_	_	_	_	_	_	Seg=O
119	.	_	_	_	_	_	_	_	Seg=O
120	The	_	_	_	_	_	_	_	Seg=B-seg
121	'	_	_	_	_	_	_	_	Seg=O
122	missing	_	_	_	_	_	_	_	Seg=O
123	ring	_	_	_	_	_	_	_	Seg=O
124	'	_	_	_	_	_	_	_	Seg=O
125	(	_	_	_	_	_	_	_	Seg=O
126	in	_	_	_	_	_	_	_	Seg=O
127	many	_	_	_	_	_	_	_	Seg=O
128	treatments	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	topic	_	_	_	_	_	_	_	Seg=O
132	)	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	data	_	_	_	_	_	_	_	Seg=O
135	security	_	_	_	_	_	_	_	Seg=O
136	is	_	_	_	_	_	_	_	Seg=O
137	also	_	_	_	_	_	_	_	Seg=O
138	discussed	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	Personal	_	_	_	_	_	_	_	Seg=B-seg
141	information	_	_	_	_	_	_	_	Seg=O
142	and	_	_	_	_	_	_	_	Seg=O
143	privacy	_	_	_	_	_	_	_	Seg=O
144	legislations	_	_	_	_	_	_	_	Seg=O
145	in	_	_	_	_	_	_	_	Seg=O
146	two	_	_	_	_	_	_	_	Seg=O
147	countries	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	Canada	_	_	_	_	_	_	_	Seg=O
150	and	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	UK	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	are	_	_	_	_	_	_	_	Seg=O
155	covered	_	_	_	_	_	_	_	Seg=O
156	,	_	_	_	_	_	_	_	Seg=O
157	as	_	_	_	_	_	_	_	Seg=O
158	well	_	_	_	_	_	_	_	Seg=O
159	as	_	_	_	_	_	_	_	Seg=O
160	some	_	_	_	_	_	_	_	Seg=O
161	examples	_	_	_	_	_	_	_	Seg=O
162	of	_	_	_	_	_	_	_	Seg=O
163	recent	_	_	_	_	_	_	_	Seg=O
164	research	_	_	_	_	_	_	_	Seg=O
165	projects	_	_	_	_	_	_	_	Seg=O
166	and	_	_	_	_	_	_	_	Seg=O
167	events	_	_	_	_	_	_	_	Seg=O
168	about	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	subject	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	Select	_	_	_	_	_	_	_	Seg=B-seg
173	highlights	_	_	_	_	_	_	_	Seg=O
174	from	_	_	_	_	_	_	_	Seg=O
175	a	_	_	_	_	_	_	_	Seg=O
176	June	_	_	_	_	_	_	_	Seg=O
177	2009	_	_	_	_	_	_	_	Seg=O
178	URISA	_	_	_	_	_	_	_	Seg=O
179	(	_	_	_	_	_	_	_	Seg=O
180	Urban	_	_	_	_	_	_	_	Seg=O
181	and	_	_	_	_	_	_	_	Seg=O
182	Regional	_	_	_	_	_	_	_	Seg=O
183	Information	_	_	_	_	_	_	_	Seg=O
184	Systems	_	_	_	_	_	_	_	Seg=O
185	Association	_	_	_	_	_	_	_	Seg=O
186	)	_	_	_	_	_	_	_	Seg=O
187	workshop	_	_	_	_	_	_	_	Seg=O
188	entitled	_	_	_	_	_	_	_	Seg=O
189	'	_	_	_	_	_	_	_	Seg=O
190	Protecting	_	_	_	_	_	_	_	Seg=O
191	Privacy	_	_	_	_	_	_	_	Seg=O
192	and	_	_	_	_	_	_	_	Seg=O
193	Confidentiality	_	_	_	_	_	_	_	Seg=O
194	of	_	_	_	_	_	_	_	Seg=O
195	Geographic	_	_	_	_	_	_	_	Seg=O
196	Data	_	_	_	_	_	_	_	Seg=O
197	in	_	_	_	_	_	_	_	Seg=O
198	Health	_	_	_	_	_	_	_	Seg=O
199	Research	_	_	_	_	_	_	_	Seg=O
200	'	_	_	_	_	_	_	_	Seg=O
201	are	_	_	_	_	_	_	_	Seg=O
202	then	_	_	_	_	_	_	_	Seg=O
203	presented	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O
205	The	_	_	_	_	_	_	_	Seg=B-seg
206	paper	_	_	_	_	_	_	_	Seg=O
207	concludes	_	_	_	_	_	_	_	Seg=O
208	by	_	_	_	_	_	_	_	Seg=B-seg
209	briefly	_	_	_	_	_	_	_	Seg=O
210	charting	_	_	_	_	_	_	_	Seg=O
211	the	_	_	_	_	_	_	_	Seg=O
212	complexity	_	_	_	_	_	_	_	Seg=O
213	of	_	_	_	_	_	_	_	Seg=O
214	the	_	_	_	_	_	_	_	Seg=O
215	domain	_	_	_	_	_	_	_	Seg=O
216	and	_	_	_	_	_	_	_	Seg=O
217	the	_	_	_	_	_	_	_	Seg=O
218	many	_	_	_	_	_	_	_	Seg=O
219	challenges	_	_	_	_	_	_	_	Seg=O
220	associated	_	_	_	_	_	_	_	Seg=B-seg
221	with	_	_	_	_	_	_	_	Seg=O
222	it	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	and	_	_	_	_	_	_	_	Seg=B-seg
225	proposing	_	_	_	_	_	_	_	Seg=O
226	a	_	_	_	_	_	_	_	Seg=O
227	novel	_	_	_	_	_	_	_	Seg=O
228	,	_	_	_	_	_	_	_	Seg=O
229	'	_	_	_	_	_	_	_	Seg=O
230	one	_	_	_	_	_	_	_	Seg=O
231	stop	_	_	_	_	_	_	_	Seg=O
232	shop	_	_	_	_	_	_	_	Seg=O
233	'	_	_	_	_	_	_	_	Seg=O
234	case	_	_	_	_	_	_	_	Seg=O
235	-	_	_	_	_	_	_	_	Seg=O
236	based	_	_	_	_	_	_	_	Seg=O
237	reasoning	_	_	_	_	_	_	_	Seg=O
238	framework	_	_	_	_	_	_	_	Seg=O
239	to	_	_	_	_	_	_	_	Seg=B-seg
240	streamline	_	_	_	_	_	_	_	Seg=O
241	the	_	_	_	_	_	_	_	Seg=O
242	provision	_	_	_	_	_	_	_	Seg=O
243	of	_	_	_	_	_	_	_	Seg=O
244	clear	_	_	_	_	_	_	_	Seg=O
245	and	_	_	_	_	_	_	_	Seg=O
246	individualised	_	_	_	_	_	_	_	Seg=O
247	guidance	_	_	_	_	_	_	_	Seg=O
248	for	_	_	_	_	_	_	_	Seg=O
249	the	_	_	_	_	_	_	_	Seg=O
250	design	_	_	_	_	_	_	_	Seg=O
251	and	_	_	_	_	_	_	_	Seg=O
252	approval	_	_	_	_	_	_	_	Seg=O
253	of	_	_	_	_	_	_	_	Seg=O
254	new	_	_	_	_	_	_	_	Seg=O
255	research	_	_	_	_	_	_	_	Seg=O
256	projects	_	_	_	_	_	_	_	Seg=O
257	(	_	_	_	_	_	_	_	Seg=B-seg
258	involving	_	_	_	_	_	_	_	Seg=O
259	geographical	_	_	_	_	_	_	_	Seg=O
260	identifiers	_	_	_	_	_	_	_	Seg=O
261	about	_	_	_	_	_	_	_	Seg=O
262	individuals	_	_	_	_	_	_	_	Seg=O
263	)	_	_	_	_	_	_	_	Seg=O
264	,	_	_	_	_	_	_	_	Seg=O
265	including	_	_	_	_	_	_	_	Seg=B-seg
266	crisp	_	_	_	_	_	_	_	Seg=O
267	recommendations	_	_	_	_	_	_	_	Seg=O
268	on	_	_	_	_	_	_	_	Seg=B-seg
269	which	_	_	_	_	_	_	_	Seg=O
270	specific	_	_	_	_	_	_	_	Seg=O
271	privacy	_	_	_	_	_	_	_	Seg=O
272	-	_	_	_	_	_	_	_	Seg=O
273	preserving	_	_	_	_	_	_	_	Seg=O
274	solutions	_	_	_	_	_	_	_	Seg=O
275	and	_	_	_	_	_	_	_	Seg=O
276	approaches	_	_	_	_	_	_	_	Seg=O
277	would	_	_	_	_	_	_	_	Seg=O
278	be	_	_	_	_	_	_	_	Seg=O
279	suitable	_	_	_	_	_	_	_	Seg=O
280	in	_	_	_	_	_	_	_	Seg=O
281	each	_	_	_	_	_	_	_	Seg=O
282	case	_	_	_	_	_	_	_	Seg=O
283	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e29e17f37924d1d14edf56276a5dcca87851e62f
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	HIV-1	_	_	_	_	_	_	_	Seg=O
3	frameshift	_	_	_	_	_	_	_	Seg=O
4	-	_	_	_	_	_	_	_	Seg=O
5	stimulating	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	FSS	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	RNA	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	a	_	_	_	_	_	_	_	Seg=O
12	regulatory	_	_	_	_	_	_	_	Seg=O
13	RNA	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	critical	_	_	_	_	_	_	_	Seg=O
16	importance	_	_	_	_	_	_	_	Seg=O
17	in	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19-20	virus'	_	_	_	_	_	_	_	_
19	virus	_	_	_	_	_	_	_	Seg=O
20	'	_	_	_	_	_	_	_	Seg=O
21	life	_	_	_	_	_	_	_	Seg=O
22	cycle	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	has	_	_	_	_	_	_	_	Seg=O
25	been	_	_	_	_	_	_	_	Seg=O
26	posited	_	_	_	_	_	_	_	Seg=O
27	as	_	_	_	_	_	_	_	Seg=O
28	a	_	_	_	_	_	_	_	Seg=O
29	novel	_	_	_	_	_	_	_	Seg=O
30	target	_	_	_	_	_	_	_	Seg=O
31	for	_	_	_	_	_	_	_	Seg=O
32	anti	_	_	_	_	_	_	_	Seg=O
33	-	_	_	_	_	_	_	_	Seg=O
34	HIV	_	_	_	_	_	_	_	Seg=O
35	drug	_	_	_	_	_	_	_	Seg=O
36	development	_	_	_	_	_	_	_	Seg=O
37	.	_	_	_	_	_	_	_	Seg=O
38	We	_	_	_	_	_	_	_	Seg=B-seg
39	report	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	synthesis	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=O
43	evaluation	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	triazole	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	containing	_	_	_	_	_	_	_	Seg=O
48	compounds	_	_	_	_	_	_	_	Seg=O
49	able	_	_	_	_	_	_	_	Seg=B-seg
50	to	_	_	_	_	_	_	_	Seg=O
51	bind	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	FSS	_	_	_	_	_	_	_	Seg=O
54	with	_	_	_	_	_	_	_	Seg=O
55	high	_	_	_	_	_	_	_	Seg=O
56	affinity	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=O
58	selectivity	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	Readily	_	_	_	_	_	_	_	Seg=B-seg
61	accessible	_	_	_	_	_	_	_	Seg=O
62	synthetically	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	these	_	_	_	_	_	_	_	Seg=O
65	compounds	_	_	_	_	_	_	_	Seg=O
66	are	_	_	_	_	_	_	_	Seg=O
67	less	_	_	_	_	_	_	_	Seg=O
68	toxic	_	_	_	_	_	_	_	Seg=O
69	than	_	_	_	_	_	_	_	Seg=O
70	previously	_	_	_	_	_	_	_	Seg=O
71	reported	_	_	_	_	_	_	_	Seg=O
72	olefin	_	_	_	_	_	_	_	Seg=O
73	congeners	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	We	_	_	_	_	_	_	_	Seg=B-seg
76	show	_	_	_	_	_	_	_	Seg=O
77	for	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	first	_	_	_	_	_	_	_	Seg=O
80	time	_	_	_	_	_	_	_	Seg=O
81	that	_	_	_	_	_	_	_	Seg=B-seg
82	FSS	_	_	_	_	_	_	_	Seg=O
83	-	_	_	_	_	_	_	_	Seg=O
84	targeting	_	_	_	_	_	_	_	Seg=O
85	compounds	_	_	_	_	_	_	_	Seg=O
86	have	_	_	_	_	_	_	_	Seg=O
87	antiviral	_	_	_	_	_	_	_	Seg=O
88	activity	_	_	_	_	_	_	_	Seg=O
89	against	_	_	_	_	_	_	_	Seg=O
90	replication	_	_	_	_	_	_	_	Seg=O
91	-	_	_	_	_	_	_	_	Seg=O
92	competent	_	_	_	_	_	_	_	Seg=O
93	HIV	_	_	_	_	_	_	_	Seg=O
94	in	_	_	_	_	_	_	_	Seg=O
95	human	_	_	_	_	_	_	_	Seg=O
96	cells	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	including	_	_	_	_	_	_	_	Seg=B-seg
99	a	_	_	_	_	_	_	_	Seg=O
100	highly	_	_	_	_	_	_	_	Seg=O
101	cytopathic	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	multidrug	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	resistant	_	_	_	_	_	_	_	Seg=O
106	strain	_	_	_	_	_	_	_	Seg=O
107	.	_	_	_	_	_	_	_	Seg=O
108	These	_	_	_	_	_	_	_	Seg=B-seg
109	results	_	_	_	_	_	_	_	Seg=O
110	support	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	viability	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	HIV-1	_	_	_	_	_	_	_	Seg=O
116	FSS	_	_	_	_	_	_	_	Seg=O
117	RNA	_	_	_	_	_	_	_	Seg=O
118	as	_	_	_	_	_	_	_	Seg=O
119	a	_	_	_	_	_	_	_	Seg=O
120	therapeutic	_	_	_	_	_	_	_	Seg=O
121	target	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=B-seg
123	more	_	_	_	_	_	_	_	Seg=O
124	generally	_	_	_	_	_	_	_	Seg=O
125	highlight	_	_	_	_	_	_	_	Seg=O
126	opportunities	_	_	_	_	_	_	_	Seg=O
127	for	_	_	_	_	_	_	_	Seg=O
128	synthetic	_	_	_	_	_	_	_	Seg=O
129	molecule	_	_	_	_	_	_	_	Seg=O
130	-	_	_	_	_	_	_	_	Seg=O
131	mediated	_	_	_	_	_	_	_	Seg=O
132	interference	_	_	_	_	_	_	_	Seg=O
133	with	_	_	_	_	_	_	_	Seg=O
134	protein	_	_	_	_	_	_	_	Seg=O
135	recoding	_	_	_	_	_	_	_	Seg=O
136	in	_	_	_	_	_	_	_	Seg=O
137	a	_	_	_	_	_	_	_	Seg=O
138	wide	_	_	_	_	_	_	_	Seg=O
139	range	_	_	_	_	_	_	_	Seg=O
140	of	_	_	_	_	_	_	_	Seg=O
141	organisms	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e2c49130523a4232721c16791431632d09810a38
1	COVID-19	_	_	_	_	_	_	_	Seg=B-seg
2	has	_	_	_	_	_	_	_	Seg=O
3	massively	_	_	_	_	_	_	_	Seg=O
4	changed	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	health	_	_	_	_	_	_	_	Seg=O
7	landscape	_	_	_	_	_	_	_	Seg=O
8	around	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	world	_	_	_	_	_	_	_	Seg=O
11	.	_	_	_	_	_	_	_	Seg=O
12	Wide	_	_	_	_	_	_	_	Seg=B-seg
13	-	_	_	_	_	_	_	_	Seg=O
14	ranging	_	_	_	_	_	_	_	Seg=O
15	changes	_	_	_	_	_	_	_	Seg=O
16	to	_	_	_	_	_	_	_	Seg=O
17	healthcare	_	_	_	_	_	_	_	Seg=O
18	delivery	_	_	_	_	_	_	_	Seg=O
19	have	_	_	_	_	_	_	_	Seg=O
20	occurred	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	especially	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	hospitals	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	EDs	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	Health	_	_	_	_	_	_	_	Seg=B-seg
29	services	_	_	_	_	_	_	_	Seg=O
30	have	_	_	_	_	_	_	_	Seg=O
31	made	_	_	_	_	_	_	_	Seg=O
32	local	_	_	_	_	_	_	_	Seg=O
33	decisions	_	_	_	_	_	_	_	Seg=O
34	about	_	_	_	_	_	_	_	Seg=O
35	care	_	_	_	_	_	_	_	Seg=O
36	pathways	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	in	_	_	_	_	_	_	_	Seg=O
39	some	_	_	_	_	_	_	_	Seg=O
40	cases	_	_	_	_	_	_	_	Seg=O
41	deviating	_	_	_	_	_	_	_	Seg=B-seg
42	from	_	_	_	_	_	_	_	Seg=O
43	what	_	_	_	_	_	_	_	Seg=O
44	would	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	until	_	_	_	_	_	_	_	Seg=O
47	recently	_	_	_	_	_	_	_	Seg=O
48	,	_	_	_	_	_	_	_	Seg=O
49	have	_	_	_	_	_	_	_	Seg=O
50	been	_	_	_	_	_	_	_	Seg=O
51	considered	_	_	_	_	_	_	_	Seg=O
52	widely	_	_	_	_	_	_	_	Seg=O
53	accepted	_	_	_	_	_	_	_	Seg=O
54	care	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	These	_	_	_	_	_	_	_	Seg=B-seg
57	changes	_	_	_	_	_	_	_	Seg=O
58	bring	_	_	_	_	_	_	_	Seg=O
59	with	_	_	_	_	_	_	_	Seg=O
60	them	_	_	_	_	_	_	_	Seg=O
61	new	_	_	_	_	_	_	_	Seg=O
62	medicolegal	_	_	_	_	_	_	_	Seg=O
63	risk	_	_	_	_	_	_	_	Seg=O
64	for	_	_	_	_	_	_	_	Seg=O
65	clinicians	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	In	_	_	_	_	_	_	_	Seg=B-seg
68	Australia	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	civil	_	_	_	_	_	_	_	Seg=O
71	liability	_	_	_	_	_	_	_	Seg=O
72	Acts	_	_	_	_	_	_	_	Seg=O
73	provide	_	_	_	_	_	_	_	Seg=O
74	protection	_	_	_	_	_	_	_	Seg=O
75	for	_	_	_	_	_	_	_	Seg=O
76	professionals	_	_	_	_	_	_	_	Seg=O
77	when	_	_	_	_	_	_	_	Seg=B-seg
78	the	_	_	_	_	_	_	_	Seg=O
79	criterion	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=B-seg
81	having	_	_	_	_	_	_	_	Seg=O
82	undertaken	_	_	_	_	_	_	_	Seg=O
83	'	_	_	_	_	_	_	_	Seg=O
84	competent	_	_	_	_	_	_	_	Seg=O
85	'	_	_	_	_	_	_	_	Seg=O
86	practice	_	_	_	_	_	_	_	Seg=O
87	that	_	_	_	_	_	_	_	Seg=B-seg
88	would	_	_	_	_	_	_	_	Seg=O
89	be	_	_	_	_	_	_	_	Seg=O
90	'	_	_	_	_	_	_	_	Seg=O
91	widely	_	_	_	_	_	_	_	Seg=O
92	accepted	_	_	_	_	_	_	_	Seg=O
93	'	_	_	_	_	_	_	_	Seg=O
94	'	_	_	_	_	_	_	_	Seg=O
95	in	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	circumstances	_	_	_	_	_	_	_	Seg=O
98	'	_	_	_	_	_	_	_	Seg=O
99	is	_	_	_	_	_	_	_	Seg=B-seg
100	met	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	There	_	_	_	_	_	_	_	Seg=B-seg
103	is	_	_	_	_	_	_	_	Seg=O
104	doubt	_	_	_	_	_	_	_	Seg=O
105	how	_	_	_	_	_	_	_	Seg=O
106	courts	_	_	_	_	_	_	_	Seg=O
107	,	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	medical	_	_	_	_	_	_	_	Seg=O
111	experts	_	_	_	_	_	_	_	Seg=O
112	who	_	_	_	_	_	_	_	Seg=B-seg
113	advise	_	_	_	_	_	_	_	Seg=O
114	them	_	_	_	_	_	_	_	Seg=O
115	,	_	_	_	_	_	_	_	Seg=O
116	will	_	_	_	_	_	_	_	Seg=B-seg
117	evaluate	_	_	_	_	_	_	_	Seg=O
118	clinical	_	_	_	_	_	_	_	Seg=O
119	care	_	_	_	_	_	_	_	Seg=O
120	provided	_	_	_	_	_	_	_	Seg=B-seg
121	during	_	_	_	_	_	_	_	Seg=O
122	the	_	_	_	_	_	_	_	Seg=O
123	pandemic	_	_	_	_	_	_	_	Seg=O
124	when	_	_	_	_	_	_	_	Seg=B-seg
125	health	_	_	_	_	_	_	_	Seg=O
126	services	_	_	_	_	_	_	_	Seg=O
127	have	_	_	_	_	_	_	_	Seg=O
128	developed	_	_	_	_	_	_	_	Seg=O
129	local	_	_	_	_	_	_	_	Seg=O
130	care	_	_	_	_	_	_	_	Seg=O
131	pathways	_	_	_	_	_	_	_	Seg=O
132	and	_	_	_	_	_	_	_	Seg=B-seg
133	there	_	_	_	_	_	_	_	Seg=O
134	is	_	_	_	_	_	_	_	Seg=O
135	no	_	_	_	_	_	_	_	Seg=O
136	nationally	_	_	_	_	_	_	_	Seg=O
137	accepted	_	_	_	_	_	_	_	Seg=O
138	standard	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e6aaada1af8e6361fefb6307231035a4da1c6141
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	Severe	_	_	_	_	_	_	_	Seg=O
3	Acute	_	_	_	_	_	_	_	Seg=O
4	Respiratory	_	_	_	_	_	_	_	Seg=O
5	Syndrome	_	_	_	_	_	_	_	Seg=O
6	Coronavirus	_	_	_	_	_	_	_	Seg=O
7	2	_	_	_	_	_	_	_	Seg=O
8	(	_	_	_	_	_	_	_	Seg=O
9	SARS	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	CoV-2	_	_	_	_	_	_	_	Seg=O
12	)	_	_	_	_	_	_	_	Seg=O
13	is	_	_	_	_	_	_	_	Seg=O
14	a	_	_	_	_	_	_	_	Seg=O
15	novel	_	_	_	_	_	_	_	Seg=O
16	coronavirus	_	_	_	_	_	_	_	Seg=O
17	first	_	_	_	_	_	_	_	Seg=B-seg
18	identified	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	Wuhan	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	China	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	and	_	_	_	_	_	_	_	Seg=B-seg
25	the	_	_	_	_	_	_	_	Seg=O
26	etiological	_	_	_	_	_	_	_	Seg=O
27	agent	_	_	_	_	_	_	_	Seg=O
28	of	_	_	_	_	_	_	_	Seg=O
29	Coronavirus	_	_	_	_	_	_	_	Seg=O
30	Disease-2019	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	This	_	_	_	_	_	_	_	Seg=B-seg
33	infection	_	_	_	_	_	_	_	Seg=O
34	spreads	_	_	_	_	_	_	_	Seg=O
35	mainly	_	_	_	_	_	_	_	Seg=O
36	through	_	_	_	_	_	_	_	Seg=O
37	direct	_	_	_	_	_	_	_	Seg=O
38	contact	_	_	_	_	_	_	_	Seg=O
39	with	_	_	_	_	_	_	_	Seg=O
40	Flügge	_	_	_	_	_	_	_	Seg=O
41	micro	_	_	_	_	_	_	_	Seg=O
42	droplets	_	_	_	_	_	_	_	Seg=O
43	or	_	_	_	_	_	_	_	Seg=O
44	core	_	_	_	_	_	_	_	Seg=O
45	droplets	_	_	_	_	_	_	_	Seg=O
46	that	_	_	_	_	_	_	_	Seg=B-seg
47	remain	_	_	_	_	_	_	_	Seg=O
48	suspended	_	_	_	_	_	_	_	Seg=O
49	as	_	_	_	_	_	_	_	Seg=O
50	aerosol	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	Moreover	_	_	_	_	_	_	_	Seg=B-seg
53	,	_	_	_	_	_	_	_	Seg=O
54	it	_	_	_	_	_	_	_	Seg=O
55	has	_	_	_	_	_	_	_	Seg=O
56	been	_	_	_	_	_	_	_	Seg=O
57	reported	_	_	_	_	_	_	_	Seg=O
58	that	_	_	_	_	_	_	_	Seg=O
59	infected	_	_	_	_	_	_	_	Seg=O
60	subjects	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	both	_	_	_	_	_	_	_	Seg=O
63	with	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	without	_	_	_	_	_	_	_	Seg=O
66	clinical	_	_	_	_	_	_	_	Seg=O
67	signs	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	COVID-19	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	can	_	_	_	_	_	_	_	Seg=O
72	transmit	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	virus	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Since	_	_	_	_	_	_	_	Seg=B-seg
77	the	_	_	_	_	_	_	_	Seg=O
78	infection	_	_	_	_	_	_	_	Seg=O
79	typically	_	_	_	_	_	_	_	Seg=O
80	enters	_	_	_	_	_	_	_	Seg=O
81	through	_	_	_	_	_	_	_	Seg=O
82	mouth	_	_	_	_	_	_	_	Seg=O
83	,	_	_	_	_	_	_	_	Seg=O
84	nose	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	eyes	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	dentistry	_	_	_	_	_	_	_	Seg=B-seg
90	is	_	_	_	_	_	_	_	Seg=O
91	one	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	medical	_	_	_	_	_	_	_	Seg=O
95	practices	_	_	_	_	_	_	_	Seg=O
96	at	_	_	_	_	_	_	_	Seg=O
97	highest	_	_	_	_	_	_	_	Seg=O
98	risk	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	infection	_	_	_	_	_	_	_	Seg=O
101	due	_	_	_	_	_	_	_	Seg=B-seg
102	to	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	frequent	_	_	_	_	_	_	_	Seg=O
105	production	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	aerosol	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	constant	_	_	_	_	_	_	_	Seg=O
111	presence	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	saliva	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	The	_	_	_	_	_	_	_	Seg=B-seg
116	World	_	_	_	_	_	_	_	Seg=O
117	Health	_	_	_	_	_	_	_	Seg=O
118	Organization	_	_	_	_	_	_	_	Seg=O
119	(	_	_	_	_	_	_	_	Seg=O
120	WHO	_	_	_	_	_	_	_	Seg=O
121	)	_	_	_	_	_	_	_	Seg=O
122	has	_	_	_	_	_	_	_	Seg=O
123	suggested	_	_	_	_	_	_	_	Seg=O
124	that	_	_	_	_	_	_	_	Seg=B-seg
125	only	_	_	_	_	_	_	_	Seg=O
126	emergency	_	_	_	_	_	_	_	Seg=O
127	/	_	_	_	_	_	_	_	Seg=O
128	urgent	_	_	_	_	_	_	_	Seg=O
129	procedures	_	_	_	_	_	_	_	Seg=O
130	should	_	_	_	_	_	_	_	Seg=O
131	be	_	_	_	_	_	_	_	Seg=O
132	performed	_	_	_	_	_	_	_	Seg=O
133	during	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	coronavirus	_	_	_	_	_	_	_	Seg=O
136	outbreak	_	_	_	_	_	_	_	Seg=O
137	.	_	_	_	_	_	_	_	Seg=O
138	Considering	_	_	_	_	_	_	_	Seg=B-seg
139	the	_	_	_	_	_	_	_	Seg=O
140-141	virus'	_	_	_	_	_	_	_	_
140	virus	_	_	_	_	_	_	_	Seg=O
141	'	_	_	_	_	_	_	_	Seg=O
142	route	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	transmission	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	a	_	_	_	_	_	_	_	Seg=B-seg
147	specific	_	_	_	_	_	_	_	Seg=O
148	protocol	_	_	_	_	_	_	_	Seg=O
149	should	_	_	_	_	_	_	_	Seg=O
150	be	_	_	_	_	_	_	_	Seg=O
151	applied	_	_	_	_	_	_	_	Seg=O
152	to	_	_	_	_	_	_	_	Seg=B-seg
153	reduce	_	_	_	_	_	_	_	Seg=O
154	the	_	_	_	_	_	_	_	Seg=O
155	risk	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	infection	_	_	_	_	_	_	_	Seg=O
158	in	_	_	_	_	_	_	_	Seg=B-seg
159	addition	_	_	_	_	_	_	_	Seg=O
160	to	_	_	_	_	_	_	_	Seg=O
161	measures	_	_	_	_	_	_	_	Seg=O
162	that	_	_	_	_	_	_	_	Seg=B-seg
163	prevent	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	spread	_	_	_	_	_	_	_	Seg=O
166	of	_	_	_	_	_	_	_	Seg=O
167	infection	_	_	_	_	_	_	_	Seg=O
168	from	_	_	_	_	_	_	_	Seg=O
169	a	_	_	_	_	_	_	_	Seg=O
170	patient	_	_	_	_	_	_	_	Seg=O
171	to	_	_	_	_	_	_	_	Seg=O
172	another	_	_	_	_	_	_	_	Seg=O
173	person	_	_	_	_	_	_	_	Seg=O
174	or	_	_	_	_	_	_	_	Seg=O
175	medical	_	_	_	_	_	_	_	Seg=O
176	tools	_	_	_	_	_	_	_	Seg=O
177	and	_	_	_	_	_	_	_	Seg=O
178	equipment	_	_	_	_	_	_	_	Seg=O
179	(	_	_	_	_	_	_	_	Seg=O
180	cross	_	_	_	_	_	_	_	Seg=O
181	-	_	_	_	_	_	_	_	Seg=O
182	infection	_	_	_	_	_	_	_	Seg=O
183	)	_	_	_	_	_	_	_	Seg=O
184	.	_	_	_	_	_	_	_	Seg=O
185	This	_	_	_	_	_	_	_	Seg=B-seg
186	protocol	_	_	_	_	_	_	_	Seg=O
187	should	_	_	_	_	_	_	_	Seg=O
188	be	_	_	_	_	_	_	_	Seg=O
189	implemented	_	_	_	_	_	_	_	Seg=O
190	by	_	_	_	_	_	_	_	Seg=B-seg
191	modifying	_	_	_	_	_	_	_	Seg=O
192	both	_	_	_	_	_	_	_	Seg=O
193	patient	_	_	_	_	_	_	_	Seg=O
194	management	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=O
196	clinical	_	_	_	_	_	_	_	Seg=O
197	practice	_	_	_	_	_	_	_	Seg=O
198	,	_	_	_	_	_	_	_	Seg=O
199	introducing	_	_	_	_	_	_	_	Seg=B-seg
200	particular	_	_	_	_	_	_	_	Seg=O
201	devices	_	_	_	_	_	_	_	Seg=O
202	and	_	_	_	_	_	_	_	Seg=O
203	organizational	_	_	_	_	_	_	_	Seg=O
204	practices	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O
206	This	_	_	_	_	_	_	_	Seg=B-seg
207	paper	_	_	_	_	_	_	_	Seg=O
208	aims	_	_	_	_	_	_	_	Seg=O
209	to	_	_	_	_	_	_	_	Seg=O
210	discuss	_	_	_	_	_	_	_	Seg=O
211	and	_	_	_	_	_	_	_	Seg=O
212	suggest	_	_	_	_	_	_	_	Seg=O
213	the	_	_	_	_	_	_	_	Seg=O
214	most	_	_	_	_	_	_	_	Seg=O
215	appropriate	_	_	_	_	_	_	_	Seg=O
216	procedures	_	_	_	_	_	_	_	Seg=O
217	in	_	_	_	_	_	_	_	Seg=O
218	every	_	_	_	_	_	_	_	Seg=O
219	aspect	_	_	_	_	_	_	_	Seg=O
220	of	_	_	_	_	_	_	_	Seg=O
221	dental	_	_	_	_	_	_	_	Seg=O
222	practice	_	_	_	_	_	_	_	Seg=O
223	to	_	_	_	_	_	_	_	Seg=B-seg
224	reduce	_	_	_	_	_	_	_	Seg=O
225	infection	_	_	_	_	_	_	_	Seg=O
226	risk	_	_	_	_	_	_	_	Seg=O
227	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e767d7dc7a215fc7e1eed093425089a179eba77a
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	combination	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	federal	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	state	_	_	_	_	_	_	_	Seg=O
7	-	_	_	_	_	_	_	_	Seg=O
8	level	_	_	_	_	_	_	_	Seg=O
9	decision	_	_	_	_	_	_	_	Seg=O
10	making	_	_	_	_	_	_	_	Seg=O
11	has	_	_	_	_	_	_	_	Seg=O
12	shaped	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	response	_	_	_	_	_	_	_	Seg=O
15	to	_	_	_	_	_	_	_	Seg=O
16	COVID-19	_	_	_	_	_	_	_	Seg=O
17	in	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	United	_	_	_	_	_	_	_	Seg=O
20	States	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	In	_	_	_	_	_	_	_	Seg=B-seg
23	this	_	_	_	_	_	_	_	Seg=O
24	paper	_	_	_	_	_	_	_	Seg=O
25	we	_	_	_	_	_	_	_	Seg=O
26	analyze	_	_	_	_	_	_	_	Seg=O
27	the	_	_	_	_	_	_	_	Seg=O
28	Twitter	_	_	_	_	_	_	_	Seg=O
29	narratives	_	_	_	_	_	_	_	Seg=O
30	around	_	_	_	_	_	_	_	Seg=O
31	this	_	_	_	_	_	_	_	Seg=O
32	decision	_	_	_	_	_	_	_	Seg=O
33	making	_	_	_	_	_	_	_	Seg=O
34	by	_	_	_	_	_	_	_	Seg=B-seg
35	applying	_	_	_	_	_	_	_	Seg=O
36	a	_	_	_	_	_	_	_	Seg=O
37	dynamic	_	_	_	_	_	_	_	Seg=O
38	topic	_	_	_	_	_	_	_	Seg=O
39	model	_	_	_	_	_	_	_	Seg=O
40	to	_	_	_	_	_	_	_	Seg=O
41	COVID-19	_	_	_	_	_	_	_	Seg=O
42	related	_	_	_	_	_	_	_	Seg=O
43	tweets	_	_	_	_	_	_	_	Seg=O
44	by	_	_	_	_	_	_	_	Seg=O
45	U.S.	_	_	_	_	_	_	_	Seg=O
46	Governors	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=O
48	Presidential	_	_	_	_	_	_	_	Seg=O
49	cabinet	_	_	_	_	_	_	_	Seg=O
50	members	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	We	_	_	_	_	_	_	_	Seg=B-seg
53	use	_	_	_	_	_	_	_	Seg=O
54	a	_	_	_	_	_	_	_	Seg=O
55	network	_	_	_	_	_	_	_	Seg=O
56	Hawkes	_	_	_	_	_	_	_	Seg=O
57	binomial	_	_	_	_	_	_	_	Seg=O
58	topic	_	_	_	_	_	_	_	Seg=O
59	model	_	_	_	_	_	_	_	Seg=O
60	to	_	_	_	_	_	_	_	Seg=B-seg
61	track	_	_	_	_	_	_	_	Seg=O
62	evolving	_	_	_	_	_	_	_	Seg=O
63	sub	_	_	_	_	_	_	_	Seg=O
64	-	_	_	_	_	_	_	_	Seg=O
65	topics	_	_	_	_	_	_	_	Seg=O
66	around	_	_	_	_	_	_	_	Seg=O
67	risk	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	testing	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	treatment	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	We	_	_	_	_	_	_	_	Seg=B-seg
74	also	_	_	_	_	_	_	_	Seg=O
75	construct	_	_	_	_	_	_	_	Seg=O
76	influence	_	_	_	_	_	_	_	Seg=O
77	networks	_	_	_	_	_	_	_	Seg=O
78	amongst	_	_	_	_	_	_	_	Seg=O
79	government	_	_	_	_	_	_	_	Seg=O
80	officials	_	_	_	_	_	_	_	Seg=O
81	using	_	_	_	_	_	_	_	Seg=B-seg
82	Granger	_	_	_	_	_	_	_	Seg=O
83	causality	_	_	_	_	_	_	_	Seg=O
84	inferred	_	_	_	_	_	_	_	Seg=B-seg
85	from	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	network	_	_	_	_	_	_	_	Seg=O
88	Hawkes	_	_	_	_	_	_	_	Seg=O
89	process	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e8a03d8f27e9d7b3716997e27ae897e802221339
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	hologram	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	an	_	_	_	_	_	_	_	Seg=O
5	ideal	_	_	_	_	_	_	_	Seg=O
6	method	_	_	_	_	_	_	_	Seg=O
7	for	_	_	_	_	_	_	_	Seg=B-seg
8	displaying	_	_	_	_	_	_	_	Seg=O
9	three	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	dimensional	_	_	_	_	_	_	_	Seg=O
12	images	_	_	_	_	_	_	_	Seg=O
13	visible	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	naked	_	_	_	_	_	_	_	Seg=O
17	eye	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	Metasurfaces	_	_	_	_	_	_	_	Seg=B-seg
20	consisting	_	_	_	_	_	_	_	Seg=B-seg
21	of	_	_	_	_	_	_	_	Seg=O
22	subwavelength	_	_	_	_	_	_	_	Seg=O
23	structures	_	_	_	_	_	_	_	Seg=O
24	show	_	_	_	_	_	_	_	Seg=B-seg
25	great	_	_	_	_	_	_	_	Seg=O
26	potential	_	_	_	_	_	_	_	Seg=O
27	in	_	_	_	_	_	_	_	Seg=O
28	light	_	_	_	_	_	_	_	Seg=O
29	field	_	_	_	_	_	_	_	Seg=O
30	manipulation	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	which	_	_	_	_	_	_	_	Seg=B-seg
33	is	_	_	_	_	_	_	_	Seg=O
34	useful	_	_	_	_	_	_	_	Seg=O
35	for	_	_	_	_	_	_	_	Seg=O
36	overcoming	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	drawbacks	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	common	_	_	_	_	_	_	_	Seg=O
41	computer	_	_	_	_	_	_	_	Seg=O
42	-	_	_	_	_	_	_	_	Seg=O
43	generated	_	_	_	_	_	_	_	Seg=O
44	holography	_	_	_	_	_	_	_	Seg=O
45	.	_	_	_	_	_	_	_	Seg=O
46	However	_	_	_	_	_	_	_	Seg=B-seg
47	,	_	_	_	_	_	_	_	Seg=O
48	there	_	_	_	_	_	_	_	Seg=O
49	are	_	_	_	_	_	_	_	Seg=O
50	long	_	_	_	_	_	_	_	Seg=O
51	-	_	_	_	_	_	_	_	Seg=O
52	existing	_	_	_	_	_	_	_	Seg=O
53	challenges	_	_	_	_	_	_	_	Seg=O
54	to	_	_	_	_	_	_	_	Seg=O
55	achieving	_	_	_	_	_	_	_	Seg=O
56	dynamic	_	_	_	_	_	_	_	Seg=O
57	meta	_	_	_	_	_	_	_	Seg=O
58	-	_	_	_	_	_	_	_	Seg=O
59	holography	_	_	_	_	_	_	_	Seg=O
60	in	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	visible	_	_	_	_	_	_	_	Seg=O
63	range	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	such	_	_	_	_	_	_	_	Seg=B-seg
66	as	_	_	_	_	_	_	_	Seg=O
67	low	_	_	_	_	_	_	_	Seg=O
68	frame	_	_	_	_	_	_	_	Seg=O
69	rate	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	low	_	_	_	_	_	_	_	Seg=O
72	frame	_	_	_	_	_	_	_	Seg=O
73	number	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	In	_	_	_	_	_	_	_	Seg=B-seg
76	this	_	_	_	_	_	_	_	Seg=O
77	work	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	we	_	_	_	_	_	_	_	Seg=O
80	demonstrate	_	_	_	_	_	_	_	Seg=O
81	a	_	_	_	_	_	_	_	Seg=O
82	design	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	meta	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	holography	_	_	_	_	_	_	_	Seg=O
87	that	_	_	_	_	_	_	_	Seg=B-seg
88	can	_	_	_	_	_	_	_	Seg=O
89	achieve	_	_	_	_	_	_	_	Seg=O
90	2	_	_	_	_	_	_	_	Seg=O
91	28	_	_	_	_	_	_	_	Seg=O
92	different	_	_	_	_	_	_	_	Seg=O
93	holographic	_	_	_	_	_	_	_	Seg=O
94	frames	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=O
96	an	_	_	_	_	_	_	_	Seg=O
97	extremely	_	_	_	_	_	_	_	Seg=O
98	high	_	_	_	_	_	_	_	Seg=O
99	frame	_	_	_	_	_	_	_	Seg=O
100	rate	_	_	_	_	_	_	_	Seg=O
101	(	_	_	_	_	_	_	_	Seg=B-seg
102	9523	_	_	_	_	_	_	_	Seg=O
103	frames	_	_	_	_	_	_	_	Seg=O
104	per	_	_	_	_	_	_	_	Seg=O
105	second	_	_	_	_	_	_	_	Seg=O
106	)	_	_	_	_	_	_	_	Seg=O
107	in	_	_	_	_	_	_	_	Seg=B-seg
108	the	_	_	_	_	_	_	_	Seg=O
109	visible	_	_	_	_	_	_	_	Seg=O
110	range	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	The	_	_	_	_	_	_	_	Seg=B-seg
113	design	_	_	_	_	_	_	_	Seg=O
114	is	_	_	_	_	_	_	_	Seg=O
115	based	_	_	_	_	_	_	_	Seg=O
116	on	_	_	_	_	_	_	_	Seg=O
117	a	_	_	_	_	_	_	_	Seg=O
118	space	_	_	_	_	_	_	_	Seg=O
119	channel	_	_	_	_	_	_	_	Seg=O
120	metasurface	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	a	_	_	_	_	_	_	_	Seg=O
123	high	_	_	_	_	_	_	_	Seg=O
124	-	_	_	_	_	_	_	_	Seg=O
125	speed	_	_	_	_	_	_	_	Seg=O
126	dynamic	_	_	_	_	_	_	_	Seg=O
127	structured	_	_	_	_	_	_	_	Seg=O
128	laser	_	_	_	_	_	_	_	Seg=O
129	beam	_	_	_	_	_	_	_	Seg=O
130	modulation	_	_	_	_	_	_	_	Seg=O
131	module	_	_	_	_	_	_	_	Seg=O
132	.	_	_	_	_	_	_	_	Seg=O
133	The	_	_	_	_	_	_	_	Seg=B-seg
134	space	_	_	_	_	_	_	_	Seg=O
135	channel	_	_	_	_	_	_	_	Seg=O
136	consists	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	silicon	_	_	_	_	_	_	_	Seg=O
139	nitride	_	_	_	_	_	_	_	Seg=O
140	nanopillars	_	_	_	_	_	_	_	Seg=O
141	with	_	_	_	_	_	_	_	Seg=O
142	a	_	_	_	_	_	_	_	Seg=O
143	high	_	_	_	_	_	_	_	Seg=O
144	modulation	_	_	_	_	_	_	_	Seg=O
145	efficiency	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
147	This	_	_	_	_	_	_	_	Seg=B-seg
148	method	_	_	_	_	_	_	_	Seg=O
149	can	_	_	_	_	_	_	_	Seg=O
150	satisfy	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	needs	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	a	_	_	_	_	_	_	_	Seg=O
155	holographic	_	_	_	_	_	_	_	Seg=O
156	display	_	_	_	_	_	_	_	Seg=O
157	and	_	_	_	_	_	_	_	Seg=B-seg
158	be	_	_	_	_	_	_	_	Seg=O
159	useful	_	_	_	_	_	_	_	Seg=O
160	in	_	_	_	_	_	_	_	Seg=O
161	other	_	_	_	_	_	_	_	Seg=O
162	applications	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	such	_	_	_	_	_	_	_	Seg=B-seg
165	as	_	_	_	_	_	_	_	Seg=O
166	laser	_	_	_	_	_	_	_	Seg=O
167	fabrication	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	optical	_	_	_	_	_	_	_	Seg=O
170	storage	_	_	_	_	_	_	_	Seg=O
171	,	_	_	_	_	_	_	_	Seg=O
172	optics	_	_	_	_	_	_	_	Seg=O
173	communications	_	_	_	_	_	_	_	Seg=O
174	,	_	_	_	_	_	_	_	Seg=O
175	and	_	_	_	_	_	_	_	Seg=O
176	information	_	_	_	_	_	_	_	Seg=O
177	processing	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O
179	Dynamic	_	_	_	_	_	_	_	Seg=B-seg
180	3D	_	_	_	_	_	_	_	Seg=O
181	meta	_	_	_	_	_	_	_	Seg=O
182	-	_	_	_	_	_	_	_	Seg=O
183	holography	_	_	_	_	_	_	_	Seg=O
184	in	_	_	_	_	_	_	_	Seg=O
185	visible	_	_	_	_	_	_	_	Seg=O
186	range	_	_	_	_	_	_	_	Seg=O
187	with	_	_	_	_	_	_	_	Seg=O
188	large	_	_	_	_	_	_	_	Seg=O
189	frame	_	_	_	_	_	_	_	Seg=O
190	number	_	_	_	_	_	_	_	Seg=O
191	and	_	_	_	_	_	_	_	Seg=O
192	high	_	_	_	_	_	_	_	Seg=O
193	frame	_	_	_	_	_	_	_	Seg=O
194	rate	_	_	_	_	_	_	_	Seg=O
195	.	_	_	_	_	_	_	_	Seg=O
196	Sci	_	_	_	_	_	_	_	Seg=B-seg
197	.	_	_	_	_	_	_	_	Seg=O
198	Adv	_	_	_	_	_	_	_	Seg=O
199	.	_	_	_	_	_	_	_	Seg=O
200	6	_	_	_	_	_	_	_	Seg=O
201	,	_	_	_	_	_	_	_	Seg=O
202	eaba8595	_	_	_	_	_	_	_	Seg=O
203	(	_	_	_	_	_	_	_	Seg=O
204	2020	_	_	_	_	_	_	_	Seg=O
205	)	_	_	_	_	_	_	_	Seg=O
206	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e8c619b901c3fd4c2e830df5c471e7b7d204be6b
1	An	_	_	_	_	_	_	_	Seg=B-seg
2	increasing	_	_	_	_	_	_	_	Seg=O
3	body	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	evidence	_	_	_	_	_	_	_	Seg=O
6	highlights	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	role	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	host	_	_	_	_	_	_	_	Seg=O
11	genetic	_	_	_	_	_	_	_	Seg=O
12	variation	_	_	_	_	_	_	_	Seg=O
13	in	_	_	_	_	_	_	_	Seg=B-seg
14	driving	_	_	_	_	_	_	_	Seg=O
15	susceptibility	_	_	_	_	_	_	_	Seg=O
16	to	_	_	_	_	_	_	_	Seg=O
17	severe	_	_	_	_	_	_	_	Seg=O
18	disease	_	_	_	_	_	_	_	Seg=O
19	following	_	_	_	_	_	_	_	Seg=B-seg
20	pathogen	_	_	_	_	_	_	_	Seg=O
21	infection	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	In	_	_	_	_	_	_	_	Seg=B-seg
24	order	_	_	_	_	_	_	_	Seg=O
25	to	_	_	_	_	_	_	_	Seg=O
26	fully	_	_	_	_	_	_	_	Seg=O
27	appreciate	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	importance	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=O
31	host	_	_	_	_	_	_	_	Seg=O
32	genetics	_	_	_	_	_	_	_	Seg=O
33	on	_	_	_	_	_	_	_	Seg=O
34	infection	_	_	_	_	_	_	_	Seg=O
35	susceptibility	_	_	_	_	_	_	_	Seg=O
36	and	_	_	_	_	_	_	_	Seg=O
37	resulting	_	_	_	_	_	_	_	Seg=O
38	disease	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	genetically	_	_	_	_	_	_	_	Seg=B-seg
41	variable	_	_	_	_	_	_	_	Seg=O
42	experimental	_	_	_	_	_	_	_	Seg=O
43	model	_	_	_	_	_	_	_	Seg=O
44	systems	_	_	_	_	_	_	_	Seg=O
45	should	_	_	_	_	_	_	_	Seg=O
46	be	_	_	_	_	_	_	_	Seg=O
47	employed	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	These	_	_	_	_	_	_	_	Seg=B-seg
50	systems	_	_	_	_	_	_	_	Seg=O
51	allow	_	_	_	_	_	_	_	Seg=O
52	for	_	_	_	_	_	_	_	Seg=O
53	the	_	_	_	_	_	_	_	Seg=O
54	identification	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	characterization	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	and	_	_	_	_	_	_	_	Seg=O
59	mechanistic	_	_	_	_	_	_	_	Seg=O
60	dissection	_	_	_	_	_	_	_	Seg=O
61	of	_	_	_	_	_	_	_	Seg=O
62	genetic	_	_	_	_	_	_	_	Seg=O
63	variants	_	_	_	_	_	_	_	Seg=O
64	that	_	_	_	_	_	_	_	Seg=B-seg
65	cause	_	_	_	_	_	_	_	Seg=O
66	differential	_	_	_	_	_	_	_	Seg=O
67	disease	_	_	_	_	_	_	_	Seg=O
68	responses	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	Herein	_	_	_	_	_	_	_	Seg=B-seg
71	we	_	_	_	_	_	_	_	Seg=O
72	discuss	_	_	_	_	_	_	_	Seg=O
73	application	_	_	_	_	_	_	_	Seg=O
74	of	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	Collaborative	_	_	_	_	_	_	_	Seg=O
77	Cross	_	_	_	_	_	_	_	Seg=O
78	(	_	_	_	_	_	_	_	Seg=O
79	CC	_	_	_	_	_	_	_	Seg=O
80	)	_	_	_	_	_	_	_	Seg=O
81	panel	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	recombinant	_	_	_	_	_	_	_	Seg=O
84	inbred	_	_	_	_	_	_	_	Seg=O
85	strains	_	_	_	_	_	_	_	Seg=O
86	to	_	_	_	_	_	_	_	Seg=B-seg
87	study	_	_	_	_	_	_	_	Seg=O
88	viral	_	_	_	_	_	_	_	Seg=O
89	pathogenesis	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	focusing	_	_	_	_	_	_	_	Seg=B-seg
92	on	_	_	_	_	_	_	_	Seg=O
93	practical	_	_	_	_	_	_	_	Seg=O
94	considerations	_	_	_	_	_	_	_	Seg=O
95	for	_	_	_	_	_	_	_	Seg=O
96	experimental	_	_	_	_	_	_	_	Seg=O
97	design	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	assessment	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=O
101	analysis	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	disease	_	_	_	_	_	_	_	Seg=O
104	responses	_	_	_	_	_	_	_	Seg=O
105	within	_	_	_	_	_	_	_	Seg=O
106	the	_	_	_	_	_	_	_	Seg=O
107	CC	_	_	_	_	_	_	_	Seg=O
108	,	_	_	_	_	_	_	_	Seg=O
109	as	_	_	_	_	_	_	_	Seg=O
110	well	_	_	_	_	_	_	_	Seg=O
111	as	_	_	_	_	_	_	_	Seg=O
112	some	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	resources	_	_	_	_	_	_	_	Seg=O
116	developed	_	_	_	_	_	_	_	Seg=B-seg
117	for	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	CC	_	_	_	_	_	_	_	Seg=O
120	.	_	_	_	_	_	_	_	Seg=O
121	Although	_	_	_	_	_	_	_	Seg=B-seg
122	the	_	_	_	_	_	_	_	Seg=O
123	focus	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	this	_	_	_	_	_	_	_	Seg=O
126	chapter	_	_	_	_	_	_	_	Seg=O
127	is	_	_	_	_	_	_	_	Seg=O
128	on	_	_	_	_	_	_	_	Seg=O
129	viral	_	_	_	_	_	_	_	Seg=O
130	pathogenesis	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	many	_	_	_	_	_	_	_	Seg=B-seg
133	of	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	methods	_	_	_	_	_	_	_	Seg=O
136	presented	_	_	_	_	_	_	_	Seg=B-seg
137	within	_	_	_	_	_	_	_	Seg=O
138	are	_	_	_	_	_	_	_	Seg=B-seg
139	applicable	_	_	_	_	_	_	_	Seg=O
140	to	_	_	_	_	_	_	_	Seg=O
141	studies	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	other	_	_	_	_	_	_	_	Seg=O
144	pathogens	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	as	_	_	_	_	_	_	_	Seg=O
147	well	_	_	_	_	_	_	_	Seg=O
148	as	_	_	_	_	_	_	_	Seg=O
149	to	_	_	_	_	_	_	_	Seg=O
150	case	_	_	_	_	_	_	_	Seg=O
151	-	_	_	_	_	_	_	_	Seg=O
152	control	_	_	_	_	_	_	_	Seg=O
153	designs	_	_	_	_	_	_	_	Seg=O
154	in	_	_	_	_	_	_	_	Seg=O
155	genetically	_	_	_	_	_	_	_	Seg=O
156	diverse	_	_	_	_	_	_	_	Seg=O
157	populations	_	_	_	_	_	_	_	Seg=O
158	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e8fa052071eb975ce74b51e1927e26803deea863
1	Alanyl	_	_	_	_	_	_	_	Seg=B-seg
2	aminopeptidase	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	APN	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	surface	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	bound	_	_	_	_	_	_	_	Seg=O
11	metallopeptidase	_	_	_	_	_	_	_	Seg=O
12	that	_	_	_	_	_	_	_	Seg=B-seg
13	processes	_	_	_	_	_	_	_	Seg=O
14	the	_	_	_	_	_	_	_	Seg=O
15	N	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	terminals	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	biologically	_	_	_	_	_	_	_	Seg=O
20	active	_	_	_	_	_	_	_	Seg=O
21	peptides	_	_	_	_	_	_	_	Seg=O
22	such	_	_	_	_	_	_	_	Seg=B-seg
23	as	_	_	_	_	_	_	_	Seg=O
24	enkephalins	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	angiotensins	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	neurokinins	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	cytokines	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	It	_	_	_	_	_	_	_	Seg=B-seg
34	exerts	_	_	_	_	_	_	_	Seg=O
35	profound	_	_	_	_	_	_	_	Seg=O
36	activity	_	_	_	_	_	_	_	Seg=O
37	on	_	_	_	_	_	_	_	Seg=O
38	vital	_	_	_	_	_	_	_	Seg=O
39	processes	_	_	_	_	_	_	_	Seg=O
40	such	_	_	_	_	_	_	_	Seg=B-seg
41	as	_	_	_	_	_	_	_	Seg=O
42	immune	_	_	_	_	_	_	_	Seg=O
43	response	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	cellular	_	_	_	_	_	_	_	Seg=O
46	growth	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	blood	_	_	_	_	_	_	_	Seg=O
50	pressure	_	_	_	_	_	_	_	Seg=O
51	control	_	_	_	_	_	_	_	Seg=O
52	.	_	_	_	_	_	_	_	Seg=O
53	Inhibition	_	_	_	_	_	_	_	Seg=B-seg
54	of	_	_	_	_	_	_	_	Seg=O
55	either	_	_	_	_	_	_	_	Seg=O
56	APN	_	_	_	_	_	_	_	Seg=O
57	gene	_	_	_	_	_	_	_	Seg=O
58	expression	_	_	_	_	_	_	_	Seg=O
59	or	_	_	_	_	_	_	_	Seg=O
60	its	_	_	_	_	_	_	_	Seg=O
61	enzymatic	_	_	_	_	_	_	_	Seg=O
62	activity	_	_	_	_	_	_	_	Seg=O
63	severely	_	_	_	_	_	_	_	Seg=O
64	affects	_	_	_	_	_	_	_	Seg=O
65	leukocyte	_	_	_	_	_	_	_	Seg=O
66	growth	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=O
68	function	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	We	_	_	_	_	_	_	_	Seg=B-seg
71	show	_	_	_	_	_	_	_	Seg=O
72	here	_	_	_	_	_	_	_	Seg=O
73	that	_	_	_	_	_	_	_	Seg=B-seg
74	oxidoreductasemediated	_	_	_	_	_	_	_	Seg=O
75	modulations	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	cell	_	_	_	_	_	_	_	Seg=O
79	surface	_	_	_	_	_	_	_	Seg=O
80	thiol	_	_	_	_	_	_	_	Seg=O
81	status	_	_	_	_	_	_	_	Seg=O
82	affect	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	enzymatic	_	_	_	_	_	_	_	Seg=O
85	activity	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=O
87	APN	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	Additional	_	_	_	_	_	_	_	Seg=B-seg
90	evidence	_	_	_	_	_	_	_	Seg=O
91	for	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	pivotal	_	_	_	_	_	_	_	Seg=O
94	role	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	extracellular	_	_	_	_	_	_	_	Seg=O
97	cysteines	_	_	_	_	_	_	_	Seg=O
98	in	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	APN	_	_	_	_	_	_	_	Seg=O
101	molecule	_	_	_	_	_	_	_	Seg=O
102	was	_	_	_	_	_	_	_	Seg=O
103	obtained	_	_	_	_	_	_	_	Seg=O
104	when	_	_	_	_	_	_	_	Seg=B-seg
105	substitution	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	any	_	_	_	_	_	_	_	Seg=O
108	of	_	_	_	_	_	_	_	Seg=O
109	these	_	_	_	_	_	_	_	Seg=O
110	six	_	_	_	_	_	_	_	Seg=O
111	cysteines	_	_	_	_	_	_	_	Seg=O
112	caused	_	_	_	_	_	_	_	Seg=O
113	complete	_	_	_	_	_	_	_	Seg=O
114	loss	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	surface	_	_	_	_	_	_	_	Seg=O
117	expression	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	enzymatic	_	_	_	_	_	_	_	Seg=O
120	activity	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	In	_	_	_	_	_	_	_	Seg=B-seg
123	contrast	_	_	_	_	_	_	_	Seg=O
124	,	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	transmembrane	_	_	_	_	_	_	_	Seg=O
127	Cys24	_	_	_	_	_	_	_	Seg=O
128	appears	_	_	_	_	_	_	_	Seg=O
129	to	_	_	_	_	_	_	_	Seg=O
130	have	_	_	_	_	_	_	_	Seg=O
131	no	_	_	_	_	_	_	_	Seg=O
132	similar	_	_	_	_	_	_	_	Seg=O
133	function	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O
135	Enzymatically	_	_	_	_	_	_	_	Seg=B-seg
136	inactive	_	_	_	_	_	_	_	Seg=O
137	cysteine	_	_	_	_	_	_	_	Seg=O
138	mutants	_	_	_	_	_	_	_	Seg=O
139	were	_	_	_	_	_	_	_	Seg=O
140	retained	_	_	_	_	_	_	_	Seg=O
141	in	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	endoplasmic	_	_	_	_	_	_	_	Seg=O
144	reticulum	_	_	_	_	_	_	_	Seg=O
145	as	_	_	_	_	_	_	_	Seg=B-seg
146	shown	_	_	_	_	_	_	_	Seg=O
147	by	_	_	_	_	_	_	_	Seg=O
148	high	_	_	_	_	_	_	_	Seg=O
149	-	_	_	_	_	_	_	_	Seg=O
150	resolution	_	_	_	_	_	_	_	Seg=O
151	imaging	_	_	_	_	_	_	_	Seg=O
152	and	_	_	_	_	_	_	_	Seg=O
153	Endoglycosidase	_	_	_	_	_	_	_	Seg=O
154	H	_	_	_	_	_	_	_	Seg=O
155	digestion	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	In	_	_	_	_	_	_	_	Seg=B-seg
158	the	_	_	_	_	_	_	_	Seg=O
159	absence	_	_	_	_	_	_	_	Seg=O
160	of	_	_	_	_	_	_	_	Seg=O
161	any	_	_	_	_	_	_	_	Seg=O
162	crystal	_	_	_	_	_	_	_	Seg=O
163	-	_	_	_	_	_	_	_	Seg=O
164	structure	_	_	_	_	_	_	_	Seg=O
165	data	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	demonstration	_	_	_	_	_	_	_	Seg=O
169	that	_	_	_	_	_	_	_	Seg=B-seg
170	individual	_	_	_	_	_	_	_	Seg=O
171	extracellular	_	_	_	_	_	_	_	Seg=O
172	cysteines	_	_	_	_	_	_	_	Seg=O
173	contribute	_	_	_	_	_	_	_	Seg=O
174	to	_	_	_	_	_	_	_	Seg=O
175	APN	_	_	_	_	_	_	_	Seg=O
176	expression	_	_	_	_	_	_	_	Seg=O
177	and	_	_	_	_	_	_	_	Seg=O
178	function	_	_	_	_	_	_	_	Seg=O
179	appears	_	_	_	_	_	_	_	Seg=B-seg
180	to	_	_	_	_	_	_	_	Seg=O
181	be	_	_	_	_	_	_	_	Seg=O
182	of	_	_	_	_	_	_	_	Seg=O
183	particular	_	_	_	_	_	_	_	Seg=O
184	importance	_	_	_	_	_	_	_	Seg=O
185	.	_	_	_	_	_	_	_	Seg=O
186	The	_	_	_	_	_	_	_	Seg=B-seg
187	data	_	_	_	_	_	_	_	Seg=O
188	are	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	first	_	_	_	_	_	_	_	Seg=O
191	to	_	_	_	_	_	_	_	Seg=B-seg
192	show	_	_	_	_	_	_	_	Seg=O
193	thiol	_	_	_	_	_	_	_	Seg=O
194	-	_	_	_	_	_	_	_	Seg=O
195	dependent	_	_	_	_	_	_	_	Seg=O
196	modulation	_	_	_	_	_	_	_	Seg=O
197	of	_	_	_	_	_	_	_	Seg=O
198	the	_	_	_	_	_	_	_	Seg=O
199	activity	_	_	_	_	_	_	_	Seg=O
200	of	_	_	_	_	_	_	_	Seg=O
201	a	_	_	_	_	_	_	_	Seg=O
202	typical	_	_	_	_	_	_	_	Seg=O
203	surfacebound	_	_	_	_	_	_	_	Seg=O
204	peptidase	_	_	_	_	_	_	_	Seg=O
205	at	_	_	_	_	_	_	_	Seg=O
206	the	_	_	_	_	_	_	_	Seg=O
207	cell	_	_	_	_	_	_	_	Seg=O
208	surface	_	_	_	_	_	_	_	Seg=O
209	,	_	_	_	_	_	_	_	Seg=O
210	probably	_	_	_	_	_	_	_	Seg=B-seg
211	reflecting	_	_	_	_	_	_	_	Seg=O
212	a	_	_	_	_	_	_	_	Seg=O
213	general	_	_	_	_	_	_	_	Seg=O
214	regulating	_	_	_	_	_	_	_	Seg=O
215	mechanism	_	_	_	_	_	_	_	Seg=O
216	.	_	_	_	_	_	_	_	Seg=O
217	This	_	_	_	_	_	_	_	Seg=B-seg
218	may	_	_	_	_	_	_	_	Seg=O
219	relate	_	_	_	_	_	_	_	Seg=O
220	to	_	_	_	_	_	_	_	Seg=O
221	various	_	_	_	_	_	_	_	Seg=O
222	disease	_	_	_	_	_	_	_	Seg=O
223	processes	_	_	_	_	_	_	_	Seg=O
224	such	_	_	_	_	_	_	_	Seg=B-seg
225	as	_	_	_	_	_	_	_	Seg=O
226	inflammation	_	_	_	_	_	_	_	Seg=O
227	or	_	_	_	_	_	_	_	Seg=O
228	malignant	_	_	_	_	_	_	_	Seg=O
229	transformation	_	_	_	_	_	_	_	Seg=O
230	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = eafd17ebcaf051ac6cdf146a974e4cd0a8f528ea
1	Although	_	_	_	_	_	_	_	Seg=B-seg
2	information	_	_	_	_	_	_	_	Seg=O
3	on	_	_	_	_	_	_	_	Seg=O
4	efficacy	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	adverse	_	_	_	_	_	_	_	Seg=O
7	drug	_	_	_	_	_	_	_	Seg=O
8	reactions	_	_	_	_	_	_	_	Seg=O
9	is	_	_	_	_	_	_	_	Seg=O
10	lacking	_	_	_	_	_	_	_	Seg=O
11	,	_	_	_	_	_	_	_	Seg=O
12	ribavirin	_	_	_	_	_	_	_	Seg=B-seg
13	has	_	_	_	_	_	_	_	Seg=O
14	been	_	_	_	_	_	_	_	Seg=O
15	used	_	_	_	_	_	_	_	Seg=O
16	empirically	_	_	_	_	_	_	_	Seg=O
17	for	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	treatment	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	severe	_	_	_	_	_	_	_	Seg=O
22	acute	_	_	_	_	_	_	_	Seg=O
23	respiratory	_	_	_	_	_	_	_	Seg=O
24	syndrome	_	_	_	_	_	_	_	Seg=O
25	(	_	_	_	_	_	_	_	Seg=O
26	SARS	_	_	_	_	_	_	_	Seg=O
27	)	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	We	_	_	_	_	_	_	_	Seg=B-seg
30	report	_	_	_	_	_	_	_	Seg=O
31	common	_	_	_	_	_	_	_	Seg=O
32	adverse	_	_	_	_	_	_	_	Seg=O
33	events	_	_	_	_	_	_	_	Seg=O
34	in	_	_	_	_	_	_	_	Seg=O
35	110	_	_	_	_	_	_	_	Seg=O
36	patients	_	_	_	_	_	_	_	Seg=O
37	with	_	_	_	_	_	_	_	Seg=O
38	suspected	_	_	_	_	_	_	_	Seg=O
39	or	_	_	_	_	_	_	_	Seg=O
40	probable	_	_	_	_	_	_	_	Seg=O
41	SARS	_	_	_	_	_	_	_	Seg=O
42	who	_	_	_	_	_	_	_	Seg=B-seg
43	were	_	_	_	_	_	_	_	Seg=O
44	treated	_	_	_	_	_	_	_	Seg=O
45	with	_	_	_	_	_	_	_	Seg=O
46	ribavirin	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	Sixty	_	_	_	_	_	_	_	Seg=B-seg
49	-	_	_	_	_	_	_	_	Seg=O
50	one	_	_	_	_	_	_	_	Seg=O
51	percent	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	the	_	_	_	_	_	_	_	Seg=O
54	patients	_	_	_	_	_	_	_	Seg=O
55	had	_	_	_	_	_	_	_	Seg=O
56	evidence	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	hemolytic	_	_	_	_	_	_	_	Seg=O
59	anemia	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=B-seg
62	hypocalcemia	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	hypomagnesmia	_	_	_	_	_	_	_	Seg=O
65	were	_	_	_	_	_	_	_	Seg=O
66	reported	_	_	_	_	_	_	_	Seg=O
67	in	_	_	_	_	_	_	_	Seg=O
68	58	_	_	_	_	_	_	_	Seg=O
69	%	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	46	_	_	_	_	_	_	_	Seg=O
72	%	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	patients	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	respectively	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = eb68173ed9ade0c27573673e9a45ef1be8191edc
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	optimization	_	_	_	_	_	_	_	Seg=O
3	problem	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	fishing	_	_	_	_	_	_	_	Seg=O
6	for	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	stochastic	_	_	_	_	_	_	_	Seg=O
9	logistic	_	_	_	_	_	_	_	Seg=O
10	model	_	_	_	_	_	_	_	Seg=O
11	is	_	_	_	_	_	_	_	Seg=O
12	studied	_	_	_	_	_	_	_	Seg=O
13	in	_	_	_	_	_	_	_	Seg=O
14	this	_	_	_	_	_	_	_	Seg=O
15	paper	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	Besides	_	_	_	_	_	_	_	Seg=B-seg
18	a	_	_	_	_	_	_	_	Seg=O
19	standard	_	_	_	_	_	_	_	Seg=O
20	geometric	_	_	_	_	_	_	_	Seg=O
21	Brownian	_	_	_	_	_	_	_	Seg=O
22	motion	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	another	_	_	_	_	_	_	_	Seg=O
25	two	_	_	_	_	_	_	_	Seg=O
26	driving	_	_	_	_	_	_	_	Seg=O
27	processes	_	_	_	_	_	_	_	Seg=O
28	are	_	_	_	_	_	_	_	Seg=O
29	taken	_	_	_	_	_	_	_	Seg=O
30	into	_	_	_	_	_	_	_	Seg=O
31	account	_	_	_	_	_	_	_	Seg=O
32	:	_	_	_	_	_	_	_	Seg=O
33	a	_	_	_	_	_	_	_	Seg=B-seg
34	stationary	_	_	_	_	_	_	_	Seg=O
35	Poisson	_	_	_	_	_	_	_	Seg=O
36	point	_	_	_	_	_	_	_	Seg=O
37	process	_	_	_	_	_	_	_	Seg=O
38	and	_	_	_	_	_	_	_	Seg=O
39	a	_	_	_	_	_	_	_	Seg=O
40	continuous	_	_	_	_	_	_	_	Seg=O
41	-	_	_	_	_	_	_	_	Seg=O
42	time	_	_	_	_	_	_	_	Seg=O
43	finite	_	_	_	_	_	_	_	Seg=O
44	-	_	_	_	_	_	_	_	Seg=O
45	state	_	_	_	_	_	_	_	Seg=O
46	Markov	_	_	_	_	_	_	_	Seg=O
47	chain	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	The	_	_	_	_	_	_	_	Seg=B-seg
50	classical	_	_	_	_	_	_	_	Seg=O
51	harvesting	_	_	_	_	_	_	_	Seg=O
52	problem	_	_	_	_	_	_	_	Seg=O
53	for	_	_	_	_	_	_	_	Seg=O
54	this	_	_	_	_	_	_	_	Seg=O
55	model	_	_	_	_	_	_	_	Seg=O
56	is	_	_	_	_	_	_	_	Seg=O
57	a	_	_	_	_	_	_	_	Seg=O
58	big	_	_	_	_	_	_	_	Seg=O
59	difficult	_	_	_	_	_	_	_	Seg=O
60	puzzle	_	_	_	_	_	_	_	Seg=O
61	since	_	_	_	_	_	_	_	Seg=B-seg
62	the	_	_	_	_	_	_	_	Seg=O
63	corresponding	_	_	_	_	_	_	_	Seg=O
64	Fokker	_	_	_	_	_	_	_	Seg=O
65	-	_	_	_	_	_	_	_	Seg=O
66	Planck	_	_	_	_	_	_	_	Seg=O
67	equations	_	_	_	_	_	_	_	Seg=O
68	with	_	_	_	_	_	_	_	Seg=O
69	three	_	_	_	_	_	_	_	Seg=O
70	types	_	_	_	_	_	_	_	Seg=O
71	of	_	_	_	_	_	_	_	Seg=O
72	noise	_	_	_	_	_	_	_	Seg=O
73	are	_	_	_	_	_	_	_	Seg=O
74	very	_	_	_	_	_	_	_	Seg=O
75	difficult	_	_	_	_	_	_	_	Seg=O
76	to	_	_	_	_	_	_	_	Seg=O
77	solve	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	Our	_	_	_	_	_	_	_	Seg=B-seg
80	main	_	_	_	_	_	_	_	Seg=O
81	goal	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	this	_	_	_	_	_	_	_	Seg=O
84	paper	_	_	_	_	_	_	_	Seg=O
85	is	_	_	_	_	_	_	_	Seg=O
86	to	_	_	_	_	_	_	_	Seg=O
87	work	_	_	_	_	_	_	_	Seg=O
88	out	_	_	_	_	_	_	_	Seg=O
89	the	_	_	_	_	_	_	_	Seg=O
90	optimization	_	_	_	_	_	_	_	Seg=O
91	problem	_	_	_	_	_	_	_	Seg=O
92	with	_	_	_	_	_	_	_	Seg=O
93	respect	_	_	_	_	_	_	_	Seg=O
94	to	_	_	_	_	_	_	_	Seg=O
95	stationary	_	_	_	_	_	_	_	Seg=O
96	probability	_	_	_	_	_	_	_	Seg=O
97	density	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	One	_	_	_	_	_	_	_	Seg=B-seg
100	of	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	main	_	_	_	_	_	_	_	Seg=O
103	contributions	_	_	_	_	_	_	_	Seg=O
104	is	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=O
106	provide	_	_	_	_	_	_	_	Seg=O
107	a	_	_	_	_	_	_	_	Seg=O
108	new	_	_	_	_	_	_	_	Seg=O
109	equivalent	_	_	_	_	_	_	_	Seg=O
110	approach	_	_	_	_	_	_	_	Seg=O
111	to	_	_	_	_	_	_	_	Seg=B-seg
112	overcome	_	_	_	_	_	_	_	Seg=O
113	this	_	_	_	_	_	_	_	Seg=O
114	problem	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	More	_	_	_	_	_	_	_	Seg=B-seg
117	precisely	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	an	_	_	_	_	_	_	_	Seg=O
120	ergodic	_	_	_	_	_	_	_	Seg=O
121	method	_	_	_	_	_	_	_	Seg=O
122	is	_	_	_	_	_	_	_	Seg=O
123	used	_	_	_	_	_	_	_	Seg=O
124	to	_	_	_	_	_	_	_	Seg=B-seg
125	show	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	almost	_	_	_	_	_	_	_	Seg=O
128	surely	_	_	_	_	_	_	_	Seg=O
129	equivalency	_	_	_	_	_	_	_	Seg=O
130	between	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	time	_	_	_	_	_	_	_	Seg=O
133	averaging	_	_	_	_	_	_	_	Seg=O
134	yield	_	_	_	_	_	_	_	Seg=O
135	and	_	_	_	_	_	_	_	Seg=O
136	sustainable	_	_	_	_	_	_	_	Seg=O
137	yield	_	_	_	_	_	_	_	Seg=O
138	.	_	_	_	_	_	_	_	Seg=O
139	Results	_	_	_	_	_	_	_	Seg=B-seg
140	show	_	_	_	_	_	_	_	Seg=O
141	that	_	_	_	_	_	_	_	Seg=B-seg
142	the	_	_	_	_	_	_	_	Seg=O
143	optimal	_	_	_	_	_	_	_	Seg=O
144	strategy	_	_	_	_	_	_	_	Seg=O
145	changes	_	_	_	_	_	_	_	Seg=O
146	with	_	_	_	_	_	_	_	Seg=O
147	environment	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	An	_	_	_	_	_	_	_	Seg=B-seg
150	interesting	_	_	_	_	_	_	_	Seg=O
151	thing	_	_	_	_	_	_	_	Seg=O
152	is	_	_	_	_	_	_	_	Seg=O
153	that	_	_	_	_	_	_	_	Seg=O
154	the	_	_	_	_	_	_	_	Seg=O
155	optimal	_	_	_	_	_	_	_	Seg=O
156	strategy	_	_	_	_	_	_	_	Seg=O
157	for	_	_	_	_	_	_	_	Seg=O
158	each	_	_	_	_	_	_	_	Seg=O
159	state	_	_	_	_	_	_	_	Seg=O
160	is	_	_	_	_	_	_	_	Seg=O
161	equivalent	_	_	_	_	_	_	_	Seg=O
162	to	_	_	_	_	_	_	_	Seg=O
163	the	_	_	_	_	_	_	_	Seg=O
164	global	_	_	_	_	_	_	_	Seg=O
165	optimality	_	_	_	_	_	_	_	Seg=O
166	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ed43a39e585d77f1fecd662508f8042ed4ad3396
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	As	_	_	_	_	_	_	_	Seg=B-seg
4	the	_	_	_	_	_	_	_	Seg=O
5	outbreak	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	Coronavirus	_	_	_	_	_	_	_	Seg=O
8	disease	_	_	_	_	_	_	_	Seg=O
9	2019	_	_	_	_	_	_	_	Seg=O
10	(	_	_	_	_	_	_	_	Seg=O
11	COVID-19	_	_	_	_	_	_	_	Seg=O
12	)	_	_	_	_	_	_	_	Seg=O
13	is	_	_	_	_	_	_	_	Seg=O
14	a	_	_	_	_	_	_	_	Seg=O
15	worldwide	_	_	_	_	_	_	_	Seg=O
16	pandemic	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=B-seg
19	it	_	_	_	_	_	_	_	Seg=O
20	is	_	_	_	_	_	_	_	Seg=O
21	rapidly	_	_	_	_	_	_	_	Seg=O
22	expanding	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	Iran	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	real	_	_	_	_	_	_	_	Seg=B-seg
27	-	_	_	_	_	_	_	_	Seg=O
28	time	_	_	_	_	_	_	_	Seg=O
29	analyses	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=O
31	epidemiological	_	_	_	_	_	_	_	Seg=O
32	data	_	_	_	_	_	_	_	Seg=O
33	are	_	_	_	_	_	_	_	Seg=O
34	needed	_	_	_	_	_	_	_	Seg=O
35	to	_	_	_	_	_	_	_	Seg=O
36	increase	_	_	_	_	_	_	_	Seg=O
37	situational	_	_	_	_	_	_	_	Seg=O
38	awareness	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	inform	_	_	_	_	_	_	_	Seg=O
41	interventions	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	In	_	_	_	_	_	_	_	Seg=B-seg
44	this	_	_	_	_	_	_	_	Seg=O
45	study	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	we	_	_	_	_	_	_	_	Seg=O
48	built	_	_	_	_	_	_	_	Seg=O
49	a	_	_	_	_	_	_	_	Seg=O
50	predictive	_	_	_	_	_	_	_	Seg=O
51	model	_	_	_	_	_	_	_	Seg=O
52	based	_	_	_	_	_	_	_	Seg=B-seg
53	on	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	cumulative	_	_	_	_	_	_	_	Seg=O
56	trend	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	new	_	_	_	_	_	_	_	Seg=O
59	cases	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=O
61	deaths	_	_	_	_	_	_	_	Seg=O
62	for	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	top	_	_	_	_	_	_	_	Seg=O
65	five	_	_	_	_	_	_	_	Seg=O
66	provinces	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	We	_	_	_	_	_	_	_	Seg=B-seg
69	will	_	_	_	_	_	_	_	Seg=O
70	also	_	_	_	_	_	_	_	Seg=O
71	look	_	_	_	_	_	_	_	Seg=O
72	at	_	_	_	_	_	_	_	Seg=O
73	modeling	_	_	_	_	_	_	_	Seg=O
74	the	_	_	_	_	_	_	_	Seg=O
75	trends	_	_	_	_	_	_	_	Seg=O
76	for	_	_	_	_	_	_	_	Seg=O
77	confirmed	_	_	_	_	_	_	_	Seg=O
78	cases	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	deaths	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	recovered	_	_	_	_	_	_	_	Seg=O
83	for	_	_	_	_	_	_	_	Seg=O
84	the	_	_	_	_	_	_	_	Seg=O
85	whole	_	_	_	_	_	_	_	Seg=O
86	country	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	Method	_	_	_	_	_	_	_	Seg=B-seg
89	:	_	_	_	_	_	_	_	Seg=O
90	In	_	_	_	_	_	_	_	Seg=B-seg
91	this	_	_	_	_	_	_	_	Seg=O
92	study	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	we	_	_	_	_	_	_	_	Seg=O
95	have	_	_	_	_	_	_	_	Seg=O
96	chosen	_	_	_	_	_	_	_	Seg=O
97	to	_	_	_	_	_	_	_	Seg=O
98	apply	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	exponential	_	_	_	_	_	_	_	Seg=O
101	smoothing	_	_	_	_	_	_	_	Seg=O
102	model	_	_	_	_	_	_	_	Seg=O
103	to	_	_	_	_	_	_	_	Seg=B-seg
104	iteratively	_	_	_	_	_	_	_	Seg=O
105	forecast	_	_	_	_	_	_	_	Seg=O
106	future	_	_	_	_	_	_	_	Seg=O
107	values	_	_	_	_	_	_	_	Seg=O
108	of	_	_	_	_	_	_	_	Seg=O
109	a	_	_	_	_	_	_	_	Seg=O
110	regular	_	_	_	_	_	_	_	Seg=O
111	time	_	_	_	_	_	_	_	Seg=O
112	series	_	_	_	_	_	_	_	Seg=O
113	from	_	_	_	_	_	_	_	Seg=O
114	weighted	_	_	_	_	_	_	_	Seg=O
115	averages	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	past	_	_	_	_	_	_	_	Seg=O
118	daily	_	_	_	_	_	_	_	Seg=O
119	values	_	_	_	_	_	_	_	Seg=O
120	.	_	_	_	_	_	_	_	Seg=O
121	This	_	_	_	_	_	_	_	Seg=B-seg
122	method	_	_	_	_	_	_	_	Seg=O
123	is	_	_	_	_	_	_	_	Seg=O
124	exponential	_	_	_	_	_	_	_	Seg=O
125	because	_	_	_	_	_	_	_	Seg=B-seg
126	the	_	_	_	_	_	_	_	Seg=O
127	value	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	each	_	_	_	_	_	_	_	Seg=O
130	level	_	_	_	_	_	_	_	Seg=O
131	is	_	_	_	_	_	_	_	Seg=O
132	influenced	_	_	_	_	_	_	_	Seg=O
133	by	_	_	_	_	_	_	_	Seg=O
134	every	_	_	_	_	_	_	_	Seg=O
135	preceding	_	_	_	_	_	_	_	Seg=O
136	actual	_	_	_	_	_	_	_	Seg=O
137	value	_	_	_	_	_	_	_	Seg=O
138	to	_	_	_	_	_	_	_	Seg=O
139	an	_	_	_	_	_	_	_	Seg=O
140	exponentially	_	_	_	_	_	_	_	Seg=O
141	decreasing	_	_	_	_	_	_	_	Seg=O
142	degree	_	_	_	_	_	_	_	Seg=O
143	-	_	_	_	_	_	_	_	Seg=B-seg
144	more	_	_	_	_	_	_	_	Seg=O
145	recent	_	_	_	_	_	_	_	Seg=O
146	values	_	_	_	_	_	_	_	Seg=O
147	are	_	_	_	_	_	_	_	Seg=O
148	given	_	_	_	_	_	_	_	Seg=O
149	greater	_	_	_	_	_	_	_	Seg=O
150	weight	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	The	_	_	_	_	_	_	_	Seg=B-seg
153	available	_	_	_	_	_	_	_	Seg=O
154	data	_	_	_	_	_	_	_	Seg=O
155	is	_	_	_	_	_	_	_	Seg=O
156	too	_	_	_	_	_	_	_	Seg=O
157	small	_	_	_	_	_	_	_	Seg=O
158	to	_	_	_	_	_	_	_	Seg=B-seg
159	identify	_	_	_	_	_	_	_	Seg=O
160	seasonal	_	_	_	_	_	_	_	Seg=O
161	patterns	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=B-seg
163	make	_	_	_	_	_	_	_	Seg=O
164	a	_	_	_	_	_	_	_	Seg=O
165	predictable	_	_	_	_	_	_	_	Seg=O
166	variation	_	_	_	_	_	_	_	Seg=O
167	in	_	_	_	_	_	_	_	Seg=O
168	value	_	_	_	_	_	_	_	Seg=O
169	,	_	_	_	_	_	_	_	Seg=O
170	such	_	_	_	_	_	_	_	Seg=B-seg
171	as	_	_	_	_	_	_	_	Seg=O
172	annual	_	_	_	_	_	_	_	Seg=O
173	fluctuation	_	_	_	_	_	_	_	Seg=O
174	in	_	_	_	_	_	_	_	Seg=O
175	temperature	_	_	_	_	_	_	_	Seg=O
176	related	_	_	_	_	_	_	_	Seg=B-seg
177	to	_	_	_	_	_	_	_	Seg=O
178	the	_	_	_	_	_	_	_	Seg=O
179	season	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O
181	The	_	_	_	_	_	_	_	Seg=B-seg
182	trend	_	_	_	_	_	_	_	Seg=O
183	is	_	_	_	_	_	_	_	Seg=O
184	a	_	_	_	_	_	_	_	Seg=O
185	tendency	_	_	_	_	_	_	_	Seg=O
186	of	_	_	_	_	_	_	_	Seg=O
187	the	_	_	_	_	_	_	_	Seg=O
188	data	_	_	_	_	_	_	_	Seg=O
189	to	_	_	_	_	_	_	_	Seg=B-seg
190	increase	_	_	_	_	_	_	_	Seg=O
191	or	_	_	_	_	_	_	_	Seg=O
192	decrease	_	_	_	_	_	_	_	Seg=O
193	over	_	_	_	_	_	_	_	Seg=O
194	time	_	_	_	_	_	_	_	Seg=O
195	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ee370aa6a34ccb5c96e1a213dbed64a2fe4af89f
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	recent	_	_	_	_	_	_	_	Seg=O
3	outbreak	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	severe	_	_	_	_	_	_	_	Seg=O
6	acute	_	_	_	_	_	_	_	Seg=O
7	respiratory	_	_	_	_	_	_	_	Seg=O
8	syndrome	_	_	_	_	_	_	_	Seg=O
9	(	_	_	_	_	_	_	_	Seg=O
10	SARS	_	_	_	_	_	_	_	Seg=O
11	)	_	_	_	_	_	_	_	Seg=O
12	caused	_	_	_	_	_	_	_	Seg=B-seg
13	by	_	_	_	_	_	_	_	Seg=O
14	SARS	_	_	_	_	_	_	_	Seg=O
15	coronavirus	_	_	_	_	_	_	_	Seg=O
16	(	_	_	_	_	_	_	_	Seg=O
17	SARS	_	_	_	_	_	_	_	Seg=O
18	-	_	_	_	_	_	_	_	Seg=O
19	CoV	_	_	_	_	_	_	_	Seg=O
20	)	_	_	_	_	_	_	_	Seg=O
21	has	_	_	_	_	_	_	_	Seg=B-seg
22	necessitated	_	_	_	_	_	_	_	Seg=O
23	an	_	_	_	_	_	_	_	Seg=O
24	in	_	_	_	_	_	_	_	Seg=O
25	-	_	_	_	_	_	_	_	Seg=O
26	depth	_	_	_	_	_	_	_	Seg=O
27	molecular	_	_	_	_	_	_	_	Seg=O
28	understanding	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	the	_	_	_	_	_	_	_	Seg=O
31	virus	_	_	_	_	_	_	_	Seg=O
32	to	_	_	_	_	_	_	_	Seg=B-seg
33	identify	_	_	_	_	_	_	_	Seg=O
34	new	_	_	_	_	_	_	_	Seg=O
35	drug	_	_	_	_	_	_	_	Seg=O
36	targets	_	_	_	_	_	_	_	Seg=O
37	.	_	_	_	_	_	_	_	Seg=O
38	The	_	_	_	_	_	_	_	Seg=B-seg
39	availability	_	_	_	_	_	_	_	Seg=O
40	of	_	_	_	_	_	_	_	Seg=O
41	complete	_	_	_	_	_	_	_	Seg=O
42	genome	_	_	_	_	_	_	_	Seg=O
43	sequence	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	several	_	_	_	_	_	_	_	Seg=O
46	strains	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	SARS	_	_	_	_	_	_	_	Seg=O
49	virus	_	_	_	_	_	_	_	Seg=O
50	provides	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	possibility	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	identification	_	_	_	_	_	_	_	Seg=O
55	of	_	_	_	_	_	_	_	Seg=O
56	protein	_	_	_	_	_	_	_	Seg=O
57	-	_	_	_	_	_	_	_	Seg=O
58	coding	_	_	_	_	_	_	_	Seg=O
59	genes	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=O
61	defining	_	_	_	_	_	_	_	Seg=O
62	their	_	_	_	_	_	_	_	Seg=O
63	functions	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	Computational	_	_	_	_	_	_	_	Seg=B-seg
66	approach	_	_	_	_	_	_	_	Seg=O
67	to	_	_	_	_	_	_	_	Seg=B-seg
68	identify	_	_	_	_	_	_	_	Seg=O
69	protein	_	_	_	_	_	_	_	Seg=O
70	-	_	_	_	_	_	_	_	Seg=O
71	coding	_	_	_	_	_	_	_	Seg=O
72	genes	_	_	_	_	_	_	_	Seg=O
73	and	_	_	_	_	_	_	_	Seg=O
74	their	_	_	_	_	_	_	_	Seg=O
75	putative	_	_	_	_	_	_	_	Seg=O
76	functions	_	_	_	_	_	_	_	Seg=O
77	will	_	_	_	_	_	_	_	Seg=B-seg
78	help	_	_	_	_	_	_	_	Seg=O
79	in	_	_	_	_	_	_	_	Seg=O
80	designing	_	_	_	_	_	_	_	Seg=O
81	experimental	_	_	_	_	_	_	_	Seg=O
82	protocols	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	Results	_	_	_	_	_	_	_	Seg=B-seg
85	:	_	_	_	_	_	_	_	Seg=O
86	In	_	_	_	_	_	_	_	Seg=B-seg
87	this	_	_	_	_	_	_	_	Seg=O
88	paper	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	a	_	_	_	_	_	_	_	Seg=O
91	novel	_	_	_	_	_	_	_	Seg=O
92	analysis	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=O
94	SARS	_	_	_	_	_	_	_	Seg=O
95	genome	_	_	_	_	_	_	_	Seg=O
96	using	_	_	_	_	_	_	_	Seg=B-seg
97	gene	_	_	_	_	_	_	_	Seg=O
98	prediction	_	_	_	_	_	_	_	Seg=O
99	method	_	_	_	_	_	_	_	Seg=O
100	GeneDecipher	_	_	_	_	_	_	_	Seg=O
101	developed	_	_	_	_	_	_	_	Seg=B-seg
102	in	_	_	_	_	_	_	_	Seg=O
103	our	_	_	_	_	_	_	_	Seg=O
104	laboratory	_	_	_	_	_	_	_	Seg=O
105	has	_	_	_	_	_	_	_	Seg=B-seg
106	been	_	_	_	_	_	_	_	Seg=O
107	presented	_	_	_	_	_	_	_	Seg=O
108	.	_	_	_	_	_	_	_	Seg=O
109	Each	_	_	_	_	_	_	_	Seg=B-seg
110	of	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	18	_	_	_	_	_	_	_	Seg=O
113	newly	_	_	_	_	_	_	_	Seg=O
114	sequenced	_	_	_	_	_	_	_	Seg=O
115	SARS	_	_	_	_	_	_	_	Seg=O
116	-	_	_	_	_	_	_	_	Seg=O
117	CoV	_	_	_	_	_	_	_	Seg=O
118	genomes	_	_	_	_	_	_	_	Seg=O
119	has	_	_	_	_	_	_	_	Seg=O
120	been	_	_	_	_	_	_	_	Seg=O
121	analyzed	_	_	_	_	_	_	_	Seg=O
122	using	_	_	_	_	_	_	_	Seg=B-seg
123	GeneDecipher	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	In	_	_	_	_	_	_	_	Seg=B-seg
126	addition	_	_	_	_	_	_	_	Seg=O
127	to	_	_	_	_	_	_	_	Seg=O
128	polyprotein	_	_	_	_	_	_	_	Seg=O
129	1ab	_	_	_	_	_	_	_	Seg=O
130	1	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	polyprotein	_	_	_	_	_	_	_	Seg=O
133	1a	_	_	_	_	_	_	_	Seg=O
134	and	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	four	_	_	_	_	_	_	_	Seg=O
137	genes	_	_	_	_	_	_	_	Seg=O
138	coding	_	_	_	_	_	_	_	Seg=O
139	for	_	_	_	_	_	_	_	Seg=O
140	major	_	_	_	_	_	_	_	Seg=O
141	structural	_	_	_	_	_	_	_	Seg=O
142	proteins	_	_	_	_	_	_	_	Seg=O
143	spike	_	_	_	_	_	_	_	Seg=O
144	(	_	_	_	_	_	_	_	Seg=O
145	S	_	_	_	_	_	_	_	Seg=O
146	)	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	small	_	_	_	_	_	_	_	Seg=O
149	envelope	_	_	_	_	_	_	_	Seg=O
150	(	_	_	_	_	_	_	_	Seg=O
151	E	_	_	_	_	_	_	_	Seg=O
152	)	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	membrane	_	_	_	_	_	_	_	Seg=O
155	(	_	_	_	_	_	_	_	Seg=O
156	M	_	_	_	_	_	_	_	Seg=O
157	)	_	_	_	_	_	_	_	Seg=O
158	and	_	_	_	_	_	_	_	Seg=O
159	nucleocapsid	_	_	_	_	_	_	_	Seg=O
160	(	_	_	_	_	_	_	_	Seg=O
161	N	_	_	_	_	_	_	_	Seg=O
162	)	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	six	_	_	_	_	_	_	_	Seg=O
165	to	_	_	_	_	_	_	_	Seg=O
166	eight	_	_	_	_	_	_	_	Seg=O
167	additional	_	_	_	_	_	_	_	Seg=O
168	proteins	_	_	_	_	_	_	_	Seg=O
169	have	_	_	_	_	_	_	_	Seg=O
170	been	_	_	_	_	_	_	_	Seg=O
171	predicted	_	_	_	_	_	_	_	Seg=O
172	depending	_	_	_	_	_	_	_	Seg=B-seg
173	upon	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	strain	_	_	_	_	_	_	_	Seg=O
176	analyzed	_	_	_	_	_	_	_	Seg=B-seg
177	.	_	_	_	_	_	_	_	Seg=O
178	Their	_	_	_	_	_	_	_	Seg=B-seg
179	lengths	_	_	_	_	_	_	_	Seg=O
180	range	_	_	_	_	_	_	_	Seg=O
181	between	_	_	_	_	_	_	_	Seg=O
182	61	_	_	_	_	_	_	_	Seg=O
183	and	_	_	_	_	_	_	_	Seg=O
184	274	_	_	_	_	_	_	_	Seg=O
185	amino	_	_	_	_	_	_	_	Seg=O
186	acids	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	Our	_	_	_	_	_	_	_	Seg=B-seg
189	method	_	_	_	_	_	_	_	Seg=O
190	also	_	_	_	_	_	_	_	Seg=O
191	suggests	_	_	_	_	_	_	_	Seg=O
192	that	_	_	_	_	_	_	_	Seg=B-seg
193	polyprotein	_	_	_	_	_	_	_	Seg=O
194	1ab	_	_	_	_	_	_	_	Seg=O
195	,	_	_	_	_	_	_	_	Seg=O
196	polyprotein	_	_	_	_	_	_	_	Seg=O
197	1a	_	_	_	_	_	_	_	Seg=O
198	,	_	_	_	_	_	_	_	Seg=O
199	S	_	_	_	_	_	_	_	Seg=O
200	,	_	_	_	_	_	_	_	Seg=O
201	M	_	_	_	_	_	_	_	Seg=O
202	and	_	_	_	_	_	_	_	Seg=O
203	N	_	_	_	_	_	_	_	Seg=O
204	are	_	_	_	_	_	_	_	Seg=O
205	proteins	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	viral	_	_	_	_	_	_	_	Seg=O
208	origin	_	_	_	_	_	_	_	Seg=O
209	and	_	_	_	_	_	_	_	Seg=B-seg
210	others	_	_	_	_	_	_	_	Seg=O
211	are	_	_	_	_	_	_	_	Seg=O
212	of	_	_	_	_	_	_	_	Seg=O
213	prokaryotic	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O
215	Putative	_	_	_	_	_	_	_	Seg=B-seg
216	functions	_	_	_	_	_	_	_	Seg=O
217	of	_	_	_	_	_	_	_	Seg=O
218	all	_	_	_	_	_	_	_	Seg=O
219	predicted	_	_	_	_	_	_	_	Seg=O
220	protein	_	_	_	_	_	_	_	Seg=O
221	-	_	_	_	_	_	_	_	Seg=O
222	coding	_	_	_	_	_	_	_	Seg=O
223	genes	_	_	_	_	_	_	_	Seg=O
224	have	_	_	_	_	_	_	_	Seg=O
225	been	_	_	_	_	_	_	_	Seg=O
226	suggested	_	_	_	_	_	_	_	Seg=O
227	using	_	_	_	_	_	_	_	Seg=B-seg
228	conserved	_	_	_	_	_	_	_	Seg=O
229	peptides	_	_	_	_	_	_	_	Seg=O
230	present	_	_	_	_	_	_	_	Seg=O
231	in	_	_	_	_	_	_	_	Seg=O
232	their	_	_	_	_	_	_	_	Seg=O
233	open	_	_	_	_	_	_	_	Seg=O
234	reading	_	_	_	_	_	_	_	Seg=O
235	frames	_	_	_	_	_	_	_	Seg=O
236	.	_	_	_	_	_	_	_	Seg=O
237	Availability	_	_	_	_	_	_	_	Seg=B-seg
238	:	_	_	_	_	_	_	_	Seg=O
239	Detailed	_	_	_	_	_	_	_	Seg=B-seg
240	results	_	_	_	_	_	_	_	Seg=O
241	of	_	_	_	_	_	_	_	Seg=O
242	GeneDecipher	_	_	_	_	_	_	_	Seg=O
243	analysis	_	_	_	_	_	_	_	Seg=O
244	of	_	_	_	_	_	_	_	Seg=O
245	all	_	_	_	_	_	_	_	Seg=O
246	the	_	_	_	_	_	_	_	Seg=O
247	18	_	_	_	_	_	_	_	Seg=O
248	strains	_	_	_	_	_	_	_	Seg=O
249	of	_	_	_	_	_	_	_	Seg=O
250	SARS	_	_	_	_	_	_	_	Seg=O
251	-	_	_	_	_	_	_	_	Seg=O
252	CoV	_	_	_	_	_	_	_	Seg=O
253	genomes	_	_	_	_	_	_	_	Seg=O
254	are	_	_	_	_	_	_	_	Seg=O
255	available	_	_	_	_	_	_	_	Seg=O
256	at	_	_	_	_	_	_	_	Seg=O

# newdoc_id = eeb7b153d2cd9b4aa3ce620bb2f1e538596a9309
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	number	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	methods	_	_	_	_	_	_	_	Seg=O
5	based	_	_	_	_	_	_	_	Seg=B-seg
6	on	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	deep	_	_	_	_	_	_	_	Seg=O
9	learning	_	_	_	_	_	_	_	Seg=O
10	have	_	_	_	_	_	_	_	Seg=B-seg
11	been	_	_	_	_	_	_	_	Seg=O
12	applied	_	_	_	_	_	_	_	Seg=O
13	to	_	_	_	_	_	_	_	Seg=O
14	medical	_	_	_	_	_	_	_	Seg=O
15	image	_	_	_	_	_	_	_	Seg=O
16	segmentation	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=B-seg
18	have	_	_	_	_	_	_	_	Seg=O
19	achieved	_	_	_	_	_	_	_	Seg=O
20	state	_	_	_	_	_	_	_	Seg=O
21	-	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	-	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	-	_	_	_	_	_	_	_	Seg=O
26	art	_	_	_	_	_	_	_	Seg=O
27	performance	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	Due	_	_	_	_	_	_	_	Seg=B-seg
30	to	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	importance	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	chest	_	_	_	_	_	_	_	Seg=O
35	x	_	_	_	_	_	_	_	Seg=O
36	-	_	_	_	_	_	_	_	Seg=O
37	ray	_	_	_	_	_	_	_	Seg=O
38	data	_	_	_	_	_	_	_	Seg=O
39	in	_	_	_	_	_	_	_	Seg=B-seg
40	studying	_	_	_	_	_	_	_	Seg=O
41	COVID-19	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	there	_	_	_	_	_	_	_	Seg=B-seg
44	is	_	_	_	_	_	_	_	Seg=O
45	a	_	_	_	_	_	_	_	Seg=O
46	demand	_	_	_	_	_	_	_	Seg=O
47	for	_	_	_	_	_	_	_	Seg=O
48	state	_	_	_	_	_	_	_	Seg=O
49	-	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	-	_	_	_	_	_	_	_	Seg=O
52	art	_	_	_	_	_	_	_	Seg=O
53	models	_	_	_	_	_	_	_	Seg=O
54	capable	_	_	_	_	_	_	_	Seg=O
55	of	_	_	_	_	_	_	_	Seg=O
56	precisely	_	_	_	_	_	_	_	Seg=O
57	segmenting	_	_	_	_	_	_	_	Seg=O
58	chest	_	_	_	_	_	_	_	Seg=O
59	x	_	_	_	_	_	_	_	Seg=O
60	-	_	_	_	_	_	_	_	Seg=O
61	rays	_	_	_	_	_	_	_	Seg=O
62	before	_	_	_	_	_	_	_	Seg=B-seg
63	obtaining	_	_	_	_	_	_	_	Seg=O
64	mask	_	_	_	_	_	_	_	Seg=O
65	annotations	_	_	_	_	_	_	_	Seg=O
66	about	_	_	_	_	_	_	_	Seg=O
67	this	_	_	_	_	_	_	_	Seg=O
68	sort	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	dataset	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	The	_	_	_	_	_	_	_	Seg=B-seg
73	dataset	_	_	_	_	_	_	_	Seg=O
74	for	_	_	_	_	_	_	_	Seg=B-seg
75	exploring	_	_	_	_	_	_	_	Seg=O
76	best	_	_	_	_	_	_	_	Seg=O
77	pre	_	_	_	_	_	_	_	Seg=O
78	-	_	_	_	_	_	_	_	Seg=O
79	trained	_	_	_	_	_	_	_	Seg=O
80	model	_	_	_	_	_	_	_	Seg=O
81	is	_	_	_	_	_	_	_	Seg=B-seg
82	from	_	_	_	_	_	_	_	Seg=O
83	Montgomery	_	_	_	_	_	_	_	Seg=O
84	and	_	_	_	_	_	_	_	Seg=O
85	Shenzhen	_	_	_	_	_	_	_	Seg=O
86	hospital	_	_	_	_	_	_	_	Seg=O
87	which	_	_	_	_	_	_	_	Seg=B-seg
88	had	_	_	_	_	_	_	_	Seg=O
89	opened	_	_	_	_	_	_	_	Seg=O
90	in	_	_	_	_	_	_	_	Seg=O
91	2014	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	The	_	_	_	_	_	_	_	Seg=B-seg
94	most	_	_	_	_	_	_	_	Seg=O
95	famous	_	_	_	_	_	_	_	Seg=O
96	technique	_	_	_	_	_	_	_	Seg=O
97	is	_	_	_	_	_	_	_	Seg=O
98	U	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	Net	_	_	_	_	_	_	_	Seg=O
101	which	_	_	_	_	_	_	_	Seg=B-seg
102	has	_	_	_	_	_	_	_	Seg=O
103	been	_	_	_	_	_	_	_	Seg=O
104	used	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=O
106	many	_	_	_	_	_	_	_	Seg=O
107	medical	_	_	_	_	_	_	_	Seg=O
108	datasets	_	_	_	_	_	_	_	Seg=O
109	including	_	_	_	_	_	_	_	Seg=B-seg
110	the	_	_	_	_	_	_	_	Seg=O
111	Chest	_	_	_	_	_	_	_	Seg=O
112	X	_	_	_	_	_	_	_	Seg=O
113	-	_	_	_	_	_	_	_	Seg=O
114	ray	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	However	_	_	_	_	_	_	_	Seg=B-seg
117	,	_	_	_	_	_	_	_	Seg=O
118	most	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	variant	_	_	_	_	_	_	_	Seg=O
121	U	_	_	_	_	_	_	_	Seg=O
122	-	_	_	_	_	_	_	_	Seg=O
123	Net	_	_	_	_	_	_	_	Seg=O
124	mainly	_	_	_	_	_	_	_	Seg=O
125	focus	_	_	_	_	_	_	_	Seg=O
126	on	_	_	_	_	_	_	_	Seg=O
127	extraction	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	contextual	_	_	_	_	_	_	_	Seg=O
130	information	_	_	_	_	_	_	_	Seg=O
131	and	_	_	_	_	_	_	_	Seg=O
132	dense	_	_	_	_	_	_	_	Seg=O
133	skip	_	_	_	_	_	_	_	Seg=O
134	connection	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	There	_	_	_	_	_	_	_	Seg=B-seg
137	is	_	_	_	_	_	_	_	Seg=O
138	still	_	_	_	_	_	_	_	Seg=O
139	a	_	_	_	_	_	_	_	Seg=O
140	large	_	_	_	_	_	_	_	Seg=O
141	space	_	_	_	_	_	_	_	Seg=O
142	for	_	_	_	_	_	_	_	Seg=B-seg
143	improving	_	_	_	_	_	_	_	Seg=O
144	extraction	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	spatial	_	_	_	_	_	_	_	Seg=O
147	feature	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	In	_	_	_	_	_	_	_	Seg=B-seg
150	this	_	_	_	_	_	_	_	Seg=O
151	paper	_	_	_	_	_	_	_	Seg=O
152	,	_	_	_	_	_	_	_	Seg=O
153	we	_	_	_	_	_	_	_	Seg=O
154	propose	_	_	_	_	_	_	_	Seg=O
155	a	_	_	_	_	_	_	_	Seg=O
156	dual	_	_	_	_	_	_	_	Seg=O
157	encoder	_	_	_	_	_	_	_	Seg=O
158	fusion	_	_	_	_	_	_	_	Seg=O
159	U	_	_	_	_	_	_	_	Seg=O
160	-	_	_	_	_	_	_	_	Seg=O
161	Net	_	_	_	_	_	_	_	Seg=O
162	framework	_	_	_	_	_	_	_	Seg=O
163	for	_	_	_	_	_	_	_	Seg=O
164	Chest	_	_	_	_	_	_	_	Seg=O
165	X	_	_	_	_	_	_	_	Seg=O
166	-	_	_	_	_	_	_	_	Seg=O
167	rays	_	_	_	_	_	_	_	Seg=O
168	based	_	_	_	_	_	_	_	Seg=B-seg
169	on	_	_	_	_	_	_	_	Seg=O
170	Inception	_	_	_	_	_	_	_	Seg=O
171	Convolutional	_	_	_	_	_	_	_	Seg=O
172	Neural	_	_	_	_	_	_	_	Seg=O
173	Network	_	_	_	_	_	_	_	Seg=O
174	with	_	_	_	_	_	_	_	Seg=O
175	dilation	_	_	_	_	_	_	_	Seg=O
176	,	_	_	_	_	_	_	_	Seg=O
177	Densely	_	_	_	_	_	_	_	Seg=O
178	Connected	_	_	_	_	_	_	_	Seg=O
179	Recurrent	_	_	_	_	_	_	_	Seg=O
180	Convolutional	_	_	_	_	_	_	_	Seg=O
181	Neural	_	_	_	_	_	_	_	Seg=O
182	Network	_	_	_	_	_	_	_	Seg=O
183	,	_	_	_	_	_	_	_	Seg=O
184	which	_	_	_	_	_	_	_	Seg=B-seg
185	is	_	_	_	_	_	_	_	Seg=O
186	named	_	_	_	_	_	_	_	Seg=O
187	DEFU	_	_	_	_	_	_	_	Seg=O
188	-	_	_	_	_	_	_	_	Seg=O
189	Net	_	_	_	_	_	_	_	Seg=O
190	.	_	_	_	_	_	_	_	Seg=O
191	The	_	_	_	_	_	_	_	Seg=B-seg
192	densely	_	_	_	_	_	_	_	Seg=O
193	connected	_	_	_	_	_	_	_	Seg=O
194	recurrent	_	_	_	_	_	_	_	Seg=O
195	path	_	_	_	_	_	_	_	Seg=O
196	extends	_	_	_	_	_	_	_	Seg=O
197	the	_	_	_	_	_	_	_	Seg=O
198	network	_	_	_	_	_	_	_	Seg=O
199	deeper	_	_	_	_	_	_	_	Seg=O
200	for	_	_	_	_	_	_	_	Seg=B-seg
201	facilitating	_	_	_	_	_	_	_	Seg=O
202	context	_	_	_	_	_	_	_	Seg=O
203	feature	_	_	_	_	_	_	_	Seg=O
204	extraction	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O
206	In	_	_	_	_	_	_	_	Seg=B-seg
207	order	_	_	_	_	_	_	_	Seg=O
208	to	_	_	_	_	_	_	_	Seg=O
209	increase	_	_	_	_	_	_	_	Seg=O
210	the	_	_	_	_	_	_	_	Seg=O
211	width	_	_	_	_	_	_	_	Seg=O
212	of	_	_	_	_	_	_	_	Seg=O
213	network	_	_	_	_	_	_	_	Seg=O
214	and	_	_	_	_	_	_	_	Seg=B-seg
215	enrich	_	_	_	_	_	_	_	Seg=O
216	representation	_	_	_	_	_	_	_	Seg=O
217	of	_	_	_	_	_	_	_	Seg=O
218	features	_	_	_	_	_	_	_	Seg=O
219	,	_	_	_	_	_	_	_	Seg=O
220	the	_	_	_	_	_	_	_	Seg=B-seg
221	inception	_	_	_	_	_	_	_	Seg=O
222	blocks	_	_	_	_	_	_	_	Seg=O
223	with	_	_	_	_	_	_	_	Seg=O
224	dilation	_	_	_	_	_	_	_	Seg=O
225	have	_	_	_	_	_	_	_	Seg=O
226	been	_	_	_	_	_	_	_	Seg=O
227	used	_	_	_	_	_	_	_	Seg=O
228	.	_	_	_	_	_	_	_	Seg=O
229	The	_	_	_	_	_	_	_	Seg=B-seg
230	inception	_	_	_	_	_	_	_	Seg=O
231	blocks	_	_	_	_	_	_	_	Seg=O
232	can	_	_	_	_	_	_	_	Seg=O
233	capture	_	_	_	_	_	_	_	Seg=O
234	globally	_	_	_	_	_	_	_	Seg=O
235	and	_	_	_	_	_	_	_	Seg=O
236	locally	_	_	_	_	_	_	_	Seg=O
237	spatial	_	_	_	_	_	_	_	Seg=O
238	information	_	_	_	_	_	_	_	Seg=O
239	by	_	_	_	_	_	_	_	Seg=O
240	various	_	_	_	_	_	_	_	Seg=O
241	receptive	_	_	_	_	_	_	_	Seg=O
242	fields	_	_	_	_	_	_	_	Seg=O
243	.	_	_	_	_	_	_	_	Seg=O
244	Meanwhile	_	_	_	_	_	_	_	Seg=B-seg
245	,	_	_	_	_	_	_	_	Seg=O
246	the	_	_	_	_	_	_	_	Seg=O
247	features	_	_	_	_	_	_	_	Seg=O
248	fusion	_	_	_	_	_	_	_	Seg=O
249	of	_	_	_	_	_	_	_	Seg=O
250	two	_	_	_	_	_	_	_	Seg=O
251	path	_	_	_	_	_	_	_	Seg=O
252	by	_	_	_	_	_	_	_	Seg=O
253	summation	_	_	_	_	_	_	_	Seg=O
254	preserve	_	_	_	_	_	_	_	Seg=O
255	the	_	_	_	_	_	_	_	Seg=O
256	context	_	_	_	_	_	_	_	Seg=O
257	and	_	_	_	_	_	_	_	Seg=O
258	the	_	_	_	_	_	_	_	Seg=O
259	spatial	_	_	_	_	_	_	_	Seg=O
260	information	_	_	_	_	_	_	_	Seg=O
261	for	_	_	_	_	_	_	_	Seg=O
262	decoding	_	_	_	_	_	_	_	Seg=O
263	part	_	_	_	_	_	_	_	Seg=O
264	.	_	_	_	_	_	_	_	Seg=O
265	This	_	_	_	_	_	_	_	Seg=B-seg
266	multi	_	_	_	_	_	_	_	Seg=O
267	-	_	_	_	_	_	_	_	Seg=O
268	learning	_	_	_	_	_	_	_	Seg=O
269	-	_	_	_	_	_	_	_	Seg=O
270	scale	_	_	_	_	_	_	_	Seg=O
271	model	_	_	_	_	_	_	_	Seg=O
272	are	_	_	_	_	_	_	_	Seg=O
273	benefiting	_	_	_	_	_	_	_	Seg=O
274	in	_	_	_	_	_	_	_	Seg=O
275	Chest	_	_	_	_	_	_	_	Seg=O
276	X	_	_	_	_	_	_	_	Seg=O
277	-	_	_	_	_	_	_	_	Seg=O
278	ray	_	_	_	_	_	_	_	Seg=O
279	dataset	_	_	_	_	_	_	_	Seg=O
280	from	_	_	_	_	_	_	_	Seg=O
281	two	_	_	_	_	_	_	_	Seg=O
282	different	_	_	_	_	_	_	_	Seg=O
283	manufacturers	_	_	_	_	_	_	_	Seg=O
284	(	_	_	_	_	_	_	_	Seg=B-seg
285	Montgomery	_	_	_	_	_	_	_	Seg=O
286	and	_	_	_	_	_	_	_	Seg=O
287	Shenzhen	_	_	_	_	_	_	_	Seg=O
288	hospital	_	_	_	_	_	_	_	Seg=O
289	)	_	_	_	_	_	_	_	Seg=O
290	.	_	_	_	_	_	_	_	Seg=O
291	The	_	_	_	_	_	_	_	Seg=B-seg
292	DEFU	_	_	_	_	_	_	_	Seg=O
293	-	_	_	_	_	_	_	_	Seg=O
294	Net	_	_	_	_	_	_	_	Seg=O
295	achieves	_	_	_	_	_	_	_	Seg=O
296	the	_	_	_	_	_	_	_	Seg=O
297	better	_	_	_	_	_	_	_	Seg=O
298	performance	_	_	_	_	_	_	_	Seg=O
299	than	_	_	_	_	_	_	_	Seg=O
300	basic	_	_	_	_	_	_	_	Seg=O
301	U	_	_	_	_	_	_	_	Seg=O
302	-	_	_	_	_	_	_	_	Seg=O
303	Net	_	_	_	_	_	_	_	Seg=O
304	,	_	_	_	_	_	_	_	Seg=O
305	residual	_	_	_	_	_	_	_	Seg=O
306	U	_	_	_	_	_	_	_	Seg=O
307	-	_	_	_	_	_	_	_	Seg=O
308	Net	_	_	_	_	_	_	_	Seg=O
309	,	_	_	_	_	_	_	_	Seg=O
310	BCDU	_	_	_	_	_	_	_	Seg=O
311	-	_	_	_	_	_	_	_	Seg=O
312	Net	_	_	_	_	_	_	_	Seg=O
313	,	_	_	_	_	_	_	_	Seg=O
314	modified	_	_	_	_	_	_	_	Seg=O
315	R2U	_	_	_	_	_	_	_	Seg=O
316	-	_	_	_	_	_	_	_	Seg=O
317	Net	_	_	_	_	_	_	_	Seg=O
318	and	_	_	_	_	_	_	_	Seg=O
319	modified	_	_	_	_	_	_	_	Seg=O
320	attention	_	_	_	_	_	_	_	Seg=O
321	R2U	_	_	_	_	_	_	_	Seg=O
322	-	_	_	_	_	_	_	_	Seg=O
323	Net	_	_	_	_	_	_	_	Seg=O
324	.	_	_	_	_	_	_	_	Seg=O
325	This	_	_	_	_	_	_	_	Seg=B-seg
326	model	_	_	_	_	_	_	_	Seg=O
327	is	_	_	_	_	_	_	_	Seg=O
328	proved	_	_	_	_	_	_	_	Seg=O
329	the	_	_	_	_	_	_	_	Seg=O
330	feasibility	_	_	_	_	_	_	_	Seg=O
331	for	_	_	_	_	_	_	_	Seg=O
332	mixed	_	_	_	_	_	_	_	Seg=O
333	dataset	_	_	_	_	_	_	_	Seg=O
334	.	_	_	_	_	_	_	_	Seg=O
335	The	_	_	_	_	_	_	_	Seg=B-seg
336	open	_	_	_	_	_	_	_	Seg=O
337	source	_	_	_	_	_	_	_	Seg=O
338	code	_	_	_	_	_	_	_	Seg=O
339	for	_	_	_	_	_	_	_	Seg=O
340	this	_	_	_	_	_	_	_	Seg=O
341	proposed	_	_	_	_	_	_	_	Seg=O
342	framework	_	_	_	_	_	_	_	Seg=O
343	will	_	_	_	_	_	_	_	Seg=O
344	be	_	_	_	_	_	_	_	Seg=O
345	public	_	_	_	_	_	_	_	Seg=O
346	soon	_	_	_	_	_	_	_	Seg=O
347	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = f26b4d2b79d661c896a22c4050ae0818effafe8f
1	Porcine	_	_	_	_	_	_	_	Seg=B-seg
2	reproductive	_	_	_	_	_	_	_	Seg=O
3	and	_	_	_	_	_	_	_	Seg=O
4	respiratory	_	_	_	_	_	_	_	Seg=O
5	syndrome	_	_	_	_	_	_	_	Seg=O
6	virus	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	PRRSV	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	is	_	_	_	_	_	_	_	Seg=O
11	an	_	_	_	_	_	_	_	Seg=O
12	economically	_	_	_	_	_	_	_	Seg=O
13	important	_	_	_	_	_	_	_	Seg=O
14	swine	_	_	_	_	_	_	_	Seg=O
15	pathogen	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	Since	_	_	_	_	_	_	_	Seg=B-seg
18	its	_	_	_	_	_	_	_	Seg=O
19	discovery	_	_	_	_	_	_	_	Seg=O
20	in	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	early	_	_	_	_	_	_	_	Seg=O
23	1990s	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	tremendous	_	_	_	_	_	_	_	Seg=O
26	progresses	_	_	_	_	_	_	_	Seg=O
27	have	_	_	_	_	_	_	_	Seg=O
28	been	_	_	_	_	_	_	_	Seg=O
29	made	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	understanding	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	molecular	_	_	_	_	_	_	_	Seg=O
34	biology	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	pathogenesis	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	PRRSV	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	Although	_	_	_	_	_	_	_	Seg=B-seg
41	modified	_	_	_	_	_	_	_	Seg=O
42	live	_	_	_	_	_	_	_	Seg=O
43	-	_	_	_	_	_	_	_	Seg=O
44	attenuated	_	_	_	_	_	_	_	Seg=O
45	vaccines	_	_	_	_	_	_	_	Seg=O
46	(	_	_	_	_	_	_	_	Seg=O
47	MLVs	_	_	_	_	_	_	_	Seg=O
48	)	_	_	_	_	_	_	_	Seg=O
49	and	_	_	_	_	_	_	_	Seg=O
50	inactivated	_	_	_	_	_	_	_	Seg=O
51	vaccines	_	_	_	_	_	_	_	Seg=O
52	against	_	_	_	_	_	_	_	Seg=O
53	PRRSV	_	_	_	_	_	_	_	Seg=O
54	have	_	_	_	_	_	_	_	Seg=O
55	been	_	_	_	_	_	_	_	Seg=O
56	available	_	_	_	_	_	_	_	Seg=O
57	for	_	_	_	_	_	_	_	Seg=O
58	more	_	_	_	_	_	_	_	Seg=O
59	than	_	_	_	_	_	_	_	Seg=O
60	a	_	_	_	_	_	_	_	Seg=O
61	decade	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=B-seg
64	disease	_	_	_	_	_	_	_	Seg=O
65	remains	_	_	_	_	_	_	_	Seg=O
66	difficult	_	_	_	_	_	_	_	Seg=O
67	to	_	_	_	_	_	_	_	Seg=O
68	control	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	The	_	_	_	_	_	_	_	Seg=B-seg
71	efficacies	_	_	_	_	_	_	_	Seg=O
72	of	_	_	_	_	_	_	_	Seg=O
73	these	_	_	_	_	_	_	_	Seg=O
74	vaccines	_	_	_	_	_	_	_	Seg=O
75	especially	_	_	_	_	_	_	_	Seg=O
76	against	_	_	_	_	_	_	_	Seg=O
77	heterologous	_	_	_	_	_	_	_	Seg=O
78	strains	_	_	_	_	_	_	_	Seg=O
79	remain	_	_	_	_	_	_	_	Seg=O
80	questionable	_	_	_	_	_	_	_	Seg=O
81	:	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=B-seg
83	MLVs	_	_	_	_	_	_	_	Seg=O
84	were	_	_	_	_	_	_	_	Seg=O
85	generally	_	_	_	_	_	_	_	Seg=O
86	effective	_	_	_	_	_	_	_	Seg=O
87	against	_	_	_	_	_	_	_	Seg=O
88	homologous	_	_	_	_	_	_	_	Seg=O
89	strains	_	_	_	_	_	_	_	Seg=O
90	but	_	_	_	_	_	_	_	Seg=O
91	variable	_	_	_	_	_	_	_	Seg=O
92	in	_	_	_	_	_	_	_	Seg=O
93	success	_	_	_	_	_	_	_	Seg=O
94	against	_	_	_	_	_	_	_	Seg=O
95	heterologous	_	_	_	_	_	_	_	Seg=O
96	strains	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	and	_	_	_	_	_	_	_	Seg=B-seg
99	the	_	_	_	_	_	_	_	Seg=O
100	outcomes	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	inactivated	_	_	_	_	_	_	_	Seg=O
103	vaccines	_	_	_	_	_	_	_	Seg=O
104	in	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	field	_	_	_	_	_	_	_	Seg=O
107	are	_	_	_	_	_	_	_	Seg=O
108	not	_	_	_	_	_	_	_	Seg=O
109	very	_	_	_	_	_	_	_	Seg=O
110	promising	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	With	_	_	_	_	_	_	_	Seg=B-seg
113	the	_	_	_	_	_	_	_	Seg=O
114	development	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	PRRSV	_	_	_	_	_	_	_	Seg=O
117	reverse	_	_	_	_	_	_	_	Seg=O
118	genetics	_	_	_	_	_	_	_	Seg=O
119	systems	_	_	_	_	_	_	_	Seg=O
120	and	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	acquisition	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	new	_	_	_	_	_	_	_	Seg=O
125	understanding	_	_	_	_	_	_	_	Seg=O
126	on	_	_	_	_	_	_	_	Seg=O
127	anti	_	_	_	_	_	_	_	Seg=O
128	-	_	_	_	_	_	_	_	Seg=O
129	PRRSV	_	_	_	_	_	_	_	Seg=O
130	immunity	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	rational	_	_	_	_	_	_	_	Seg=O
133	design	_	_	_	_	_	_	_	Seg=O
134	of	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	next	_	_	_	_	_	_	_	Seg=O
137	generation	_	_	_	_	_	_	_	Seg=O
138	of	_	_	_	_	_	_	_	Seg=O
139	PRRSV	_	_	_	_	_	_	_	Seg=O
140	vaccines	_	_	_	_	_	_	_	Seg=O
141	can	_	_	_	_	_	_	_	Seg=O
142	now	_	_	_	_	_	_	_	Seg=O
143	be	_	_	_	_	_	_	_	Seg=O
144	explored	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	In	_	_	_	_	_	_	_	Seg=B-seg
147	this	_	_	_	_	_	_	_	Seg=O
148	review	_	_	_	_	_	_	_	Seg=O
149	,	_	_	_	_	_	_	_	Seg=O
150	we	_	_	_	_	_	_	_	Seg=O
151	discussed	_	_	_	_	_	_	_	Seg=O
152	the	_	_	_	_	_	_	_	Seg=O
153	recent	_	_	_	_	_	_	_	Seg=O
154	advances	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	anti	_	_	_	_	_	_	_	Seg=O
157	-	_	_	_	_	_	_	_	Seg=O
158	PRRSV	_	_	_	_	_	_	_	Seg=O
159	immunity	_	_	_	_	_	_	_	Seg=O
160	and	_	_	_	_	_	_	_	Seg=O
161	vaccinology	_	_	_	_	_	_	_	Seg=O
162	,	_	_	_	_	_	_	_	Seg=O
163	the	_	_	_	_	_	_	_	Seg=O
164	recent	_	_	_	_	_	_	_	Seg=O
165	progresses	_	_	_	_	_	_	_	Seg=O
166	in	_	_	_	_	_	_	_	Seg=O
167	PRRSV	_	_	_	_	_	_	_	Seg=O
168	vaccine	_	_	_	_	_	_	_	Seg=O
169	development	_	_	_	_	_	_	_	Seg=O
170	particularly	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	reverse	_	_	_	_	_	_	_	Seg=O
173	genetics	_	_	_	_	_	_	_	Seg=O
174	system	_	_	_	_	_	_	_	Seg=O
175	-	_	_	_	_	_	_	_	Seg=O
176	based	_	_	_	_	_	_	_	Seg=O
177	vaccine	_	_	_	_	_	_	_	Seg=O
178	development	_	_	_	_	_	_	_	Seg=O
179	,	_	_	_	_	_	_	_	Seg=O
180	and	_	_	_	_	_	_	_	Seg=B-seg
181	provided	_	_	_	_	_	_	_	Seg=O
182	a	_	_	_	_	_	_	_	Seg=O
183	perspective	_	_	_	_	_	_	_	Seg=O
184	on	_	_	_	_	_	_	_	Seg=O
185	potential	_	_	_	_	_	_	_	Seg=O
186	novel	_	_	_	_	_	_	_	Seg=O
187	strategies	_	_	_	_	_	_	_	Seg=O
188	and	_	_	_	_	_	_	_	Seg=O
189	approaches	_	_	_	_	_	_	_	Seg=O
190	that	_	_	_	_	_	_	_	Seg=B-seg
191	may	_	_	_	_	_	_	_	Seg=O
192	be	_	_	_	_	_	_	_	Seg=O
193	applicable	_	_	_	_	_	_	_	Seg=O
194	to	_	_	_	_	_	_	_	Seg=O
195	the	_	_	_	_	_	_	_	Seg=O
196	development	_	_	_	_	_	_	_	Seg=O
197	of	_	_	_	_	_	_	_	Seg=O
198	the	_	_	_	_	_	_	_	Seg=O
199	next	_	_	_	_	_	_	_	Seg=O
200	generation	_	_	_	_	_	_	_	Seg=O
201	of	_	_	_	_	_	_	_	Seg=O
202	PRRSV	_	_	_	_	_	_	_	Seg=O
203	vaccines	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = f7185938312bfa794681998fe0bff4e2697c053d
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	development	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	synthetic	_	_	_	_	_	_	_	Seg=O
5	peptide	_	_	_	_	_	_	_	Seg=O
6	-	_	_	_	_	_	_	_	Seg=O
7	based	_	_	_	_	_	_	_	Seg=O
8	vaccines	_	_	_	_	_	_	_	Seg=O
9	has	_	_	_	_	_	_	_	Seg=O
10	many	_	_	_	_	_	_	_	Seg=O
11	advantages	_	_	_	_	_	_	_	Seg=O
12	in	_	_	_	_	_	_	_	Seg=B-seg
13	comparison	_	_	_	_	_	_	_	Seg=O
14	with	_	_	_	_	_	_	_	Seg=O
15	vaccines	_	_	_	_	_	_	_	Seg=O
16	based	_	_	_	_	_	_	_	Seg=B-seg
17	on	_	_	_	_	_	_	_	Seg=O
18	live	_	_	_	_	_	_	_	Seg=O
19	attenuated	_	_	_	_	_	_	_	Seg=O
20	organisms	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	inactivated	_	_	_	_	_	_	_	Seg=O
23	or	_	_	_	_	_	_	_	Seg=O
24	killed	_	_	_	_	_	_	_	Seg=O
25	organism	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	or	_	_	_	_	_	_	_	Seg=O
28	toxins	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Peptide	_	_	_	_	_	_	_	Seg=B-seg
31	-	_	_	_	_	_	_	_	Seg=O
32	based	_	_	_	_	_	_	_	Seg=O
33	vaccines	_	_	_	_	_	_	_	Seg=O
34	can	_	_	_	_	_	_	_	Seg=O
35	not	_	_	_	_	_	_	_	Seg=O
36	revert	_	_	_	_	_	_	_	Seg=O
37	to	_	_	_	_	_	_	_	Seg=O
38	a	_	_	_	_	_	_	_	Seg=O
39	virulent	_	_	_	_	_	_	_	Seg=O
40	form	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	allow	_	_	_	_	_	_	_	Seg=B-seg
43	a	_	_	_	_	_	_	_	Seg=O
44	better	_	_	_	_	_	_	_	Seg=O
45	conservation	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=B-seg
48	are	_	_	_	_	_	_	_	Seg=O
49	produced	_	_	_	_	_	_	_	Seg=O
50	more	_	_	_	_	_	_	_	Seg=O
51	easily	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	safely	_	_	_	_	_	_	_	Seg=O
54	.	_	_	_	_	_	_	_	Seg=O
55	However	_	_	_	_	_	_	_	Seg=B-seg
56	,	_	_	_	_	_	_	_	Seg=O
57	they	_	_	_	_	_	_	_	Seg=O
58	generate	_	_	_	_	_	_	_	Seg=O
59	a	_	_	_	_	_	_	_	Seg=O
60	weaker	_	_	_	_	_	_	_	Seg=O
61	immune	_	_	_	_	_	_	_	Seg=O
62	response	_	_	_	_	_	_	_	Seg=O
63	than	_	_	_	_	_	_	_	Seg=O
64	other	_	_	_	_	_	_	_	Seg=O
65	vaccines	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=B-seg
68	the	_	_	_	_	_	_	_	Seg=O
69	inclusion	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	adjuvants	_	_	_	_	_	_	_	Seg=O
72	and/or	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	use	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	vaccine	_	_	_	_	_	_	_	Seg=O
77	delivery	_	_	_	_	_	_	_	Seg=O
78	systems	_	_	_	_	_	_	_	Seg=O
79	is	_	_	_	_	_	_	_	Seg=O
80	almost	_	_	_	_	_	_	_	Seg=O
81	always	_	_	_	_	_	_	_	Seg=O
82	needed	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	Among	_	_	_	_	_	_	_	Seg=B-seg
85	vaccine	_	_	_	_	_	_	_	Seg=O
86	delivery	_	_	_	_	_	_	_	Seg=O
87	systems	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	micro	_	_	_	_	_	_	_	Seg=O
90	-	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	nanoparticulated	_	_	_	_	_	_	_	Seg=O
93	ones	_	_	_	_	_	_	_	Seg=O
94	are	_	_	_	_	_	_	_	Seg=O
95	attractive	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	because	_	_	_	_	_	_	_	Seg=B-seg
98	their	_	_	_	_	_	_	_	Seg=O
99	particulate	_	_	_	_	_	_	_	Seg=O
100	nature	_	_	_	_	_	_	_	Seg=O
101	can	_	_	_	_	_	_	_	Seg=O
102	increase	_	_	_	_	_	_	_	Seg=O
103	cross	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	presentation	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	peptide	_	_	_	_	_	_	_	Seg=O
109	.	_	_	_	_	_	_	_	Seg=O
110	In	_	_	_	_	_	_	_	Seg=B-seg
111	addition	_	_	_	_	_	_	_	Seg=O
112	,	_	_	_	_	_	_	_	Seg=O
113	they	_	_	_	_	_	_	_	Seg=O
114	can	_	_	_	_	_	_	_	Seg=O
115	be	_	_	_	_	_	_	_	Seg=O
116	passively	_	_	_	_	_	_	_	Seg=O
117	or	_	_	_	_	_	_	_	Seg=O
118	actively	_	_	_	_	_	_	_	Seg=O
119	targeted	_	_	_	_	_	_	_	Seg=O
120	to	_	_	_	_	_	_	_	Seg=O
121	antigen	_	_	_	_	_	_	_	Seg=O
122	presenting	_	_	_	_	_	_	_	Seg=O
123	cells	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
126	,	_	_	_	_	_	_	_	Seg=O
127	particulate	_	_	_	_	_	_	_	Seg=O
128	adjuvants	_	_	_	_	_	_	_	Seg=O
129	are	_	_	_	_	_	_	_	Seg=O
130	able	_	_	_	_	_	_	_	Seg=O
131	to	_	_	_	_	_	_	_	Seg=O
132	directly	_	_	_	_	_	_	_	Seg=O
133	activate	_	_	_	_	_	_	_	Seg=O
134	innate	_	_	_	_	_	_	_	Seg=O
135	immune	_	_	_	_	_	_	_	Seg=O
136	system	_	_	_	_	_	_	_	Seg=O
137	in	_	_	_	_	_	_	_	Seg=O
138	vivo	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	Here	_	_	_	_	_	_	_	Seg=B-seg
141	,	_	_	_	_	_	_	_	Seg=O
142	we	_	_	_	_	_	_	_	Seg=O
143	summarize	_	_	_	_	_	_	_	Seg=O
144	micro	_	_	_	_	_	_	_	Seg=O
145	-	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	nanoparticulated	_	_	_	_	_	_	_	Seg=O
148	vaccine	_	_	_	_	_	_	_	Seg=O
149	delivery	_	_	_	_	_	_	_	Seg=O
150	systems	_	_	_	_	_	_	_	Seg=O
151	used	_	_	_	_	_	_	_	Seg=B-seg
152	in	_	_	_	_	_	_	_	Seg=O
153	the	_	_	_	_	_	_	_	Seg=O
154	field	_	_	_	_	_	_	_	Seg=O
155	of	_	_	_	_	_	_	_	Seg=O
156	synthetic	_	_	_	_	_	_	_	Seg=O
157	peptide	_	_	_	_	_	_	_	Seg=O
158	-	_	_	_	_	_	_	_	Seg=O
159	based	_	_	_	_	_	_	_	Seg=O
160	vaccines	_	_	_	_	_	_	_	Seg=O
161	as	_	_	_	_	_	_	_	Seg=B-seg
162	well	_	_	_	_	_	_	_	Seg=O
163	as	_	_	_	_	_	_	_	Seg=O
164	strategies	_	_	_	_	_	_	_	Seg=O
165	to	_	_	_	_	_	_	_	Seg=B-seg
166	increase	_	_	_	_	_	_	_	Seg=O
167	their	_	_	_	_	_	_	_	Seg=O
168	immunogenicity	_	_	_	_	_	_	_	Seg=O
169	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = f729e0e5f3472840a5f1be47d12b29c83d1c4879
1	Infection	_	_	_	_	_	_	_	Seg=B-seg
2	with	_	_	_	_	_	_	_	Seg=O
3	Mycobacterium	_	_	_	_	_	_	_	Seg=O
4	tuberculosis	_	_	_	_	_	_	_	Seg=O
5	remains	_	_	_	_	_	_	_	Seg=O
6	a	_	_	_	_	_	_	_	Seg=O
7	major	_	_	_	_	_	_	_	Seg=O
8	cause	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	morbidity	_	_	_	_	_	_	_	Seg=O
11	and	_	_	_	_	_	_	_	Seg=O
12	mortality	_	_	_	_	_	_	_	Seg=O
13	all	_	_	_	_	_	_	_	Seg=O
14	over	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	world	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	Since	_	_	_	_	_	_	_	Seg=B-seg
19	the	_	_	_	_	_	_	_	Seg=O
20	effectiveness	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	only	_	_	_	_	_	_	_	Seg=O
24	available	_	_	_	_	_	_	_	Seg=O
25	tuberculosis	_	_	_	_	_	_	_	Seg=O
26	vaccine	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	Mycobacterium	_	_	_	_	_	_	_	Seg=O
29	bovis	_	_	_	_	_	_	_	Seg=O
30	bacillus	_	_	_	_	_	_	_	Seg=O
31	Calmette	_	_	_	_	_	_	_	Seg=O
32	-	_	_	_	_	_	_	_	Seg=O
33	Guérin	_	_	_	_	_	_	_	Seg=O
34	(	_	_	_	_	_	_	_	Seg=O
35	BCG	_	_	_	_	_	_	_	Seg=O
36	)	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	is	_	_	_	_	_	_	_	Seg=O
39	suboptimal	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	there	_	_	_	_	_	_	_	Seg=B-seg
42	is	_	_	_	_	_	_	_	Seg=O
43	a	_	_	_	_	_	_	_	Seg=O
44	strong	_	_	_	_	_	_	_	Seg=O
45	demand	_	_	_	_	_	_	_	Seg=O
46	to	_	_	_	_	_	_	_	Seg=B-seg
47	develop	_	_	_	_	_	_	_	Seg=O
48	new	_	_	_	_	_	_	_	Seg=O
49	tuberculosis	_	_	_	_	_	_	_	Seg=O
50	vaccines	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	As	_	_	_	_	_	_	_	Seg=B-seg
53	tuberculosis	_	_	_	_	_	_	_	Seg=O
54	is	_	_	_	_	_	_	_	Seg=O
55	an	_	_	_	_	_	_	_	Seg=O
56	airborne	_	_	_	_	_	_	_	Seg=O
57	disease	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	the	_	_	_	_	_	_	_	Seg=B-seg
60	intranasal	_	_	_	_	_	_	_	Seg=O
61	route	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	vaccination	_	_	_	_	_	_	_	Seg=O
64	might	_	_	_	_	_	_	_	Seg=O
65	be	_	_	_	_	_	_	_	Seg=O
66	preferable	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	Live	_	_	_	_	_	_	_	Seg=B-seg
69	influenza	_	_	_	_	_	_	_	Seg=O
70	virus	_	_	_	_	_	_	_	Seg=O
71	vaccines	_	_	_	_	_	_	_	Seg=O
72	might	_	_	_	_	_	_	_	Seg=O
73	be	_	_	_	_	_	_	_	Seg=O
74	considered	_	_	_	_	_	_	_	Seg=O
75	as	_	_	_	_	_	_	_	Seg=O
76	potential	_	_	_	_	_	_	_	Seg=O
77	vectors	_	_	_	_	_	_	_	Seg=O
78	for	_	_	_	_	_	_	_	Seg=O
79	mucosal	_	_	_	_	_	_	_	Seg=O
80	immunization	_	_	_	_	_	_	_	Seg=O
81	against	_	_	_	_	_	_	_	Seg=O
82	various	_	_	_	_	_	_	_	Seg=O
83	viral	_	_	_	_	_	_	_	Seg=O
84	or	_	_	_	_	_	_	_	Seg=O
85	bacterial	_	_	_	_	_	_	_	Seg=O
86	pathogens	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	including	_	_	_	_	_	_	_	Seg=B-seg
89	M.	_	_	_	_	_	_	_	Seg=O
90	tuberculosis	_	_	_	_	_	_	_	Seg=O
91	.	_	_	_	_	_	_	_	Seg=O
92	We	_	_	_	_	_	_	_	Seg=B-seg
93	generated	_	_	_	_	_	_	_	Seg=O
94	several	_	_	_	_	_	_	_	Seg=O
95	subtypes	_	_	_	_	_	_	_	Seg=O
96	of	_	_	_	_	_	_	_	Seg=O
97	attenuated	_	_	_	_	_	_	_	Seg=O
98	recombinant	_	_	_	_	_	_	_	Seg=O
99	influenza	_	_	_	_	_	_	_	Seg=O
100	A	_	_	_	_	_	_	_	Seg=O
101	viruses	_	_	_	_	_	_	_	Seg=O
102	expressing	_	_	_	_	_	_	_	Seg=B-seg
103	the	_	_	_	_	_	_	_	Seg=O
104	6-kDa	_	_	_	_	_	_	_	Seg=O
105	early	_	_	_	_	_	_	_	Seg=O
106	secretory	_	_	_	_	_	_	_	Seg=O
107	antigenic	_	_	_	_	_	_	_	Seg=O
108	target	_	_	_	_	_	_	_	Seg=O
109	protein	_	_	_	_	_	_	_	Seg=O
110	(	_	_	_	_	_	_	_	Seg=O
111	ESAT-6	_	_	_	_	_	_	_	Seg=O
112	)	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	M.	_	_	_	_	_	_	_	Seg=O
115	tuberculosis	_	_	_	_	_	_	_	Seg=O
116	from	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	NS1	_	_	_	_	_	_	_	Seg=O
119	reading	_	_	_	_	_	_	_	Seg=O
120	frame	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	We	_	_	_	_	_	_	_	Seg=B-seg
123	were	_	_	_	_	_	_	_	Seg=O
124	able	_	_	_	_	_	_	_	Seg=O
125	to	_	_	_	_	_	_	_	Seg=O
126	demonstrate	_	_	_	_	_	_	_	Seg=O
127	the	_	_	_	_	_	_	_	Seg=O
128	potency	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	influenza	_	_	_	_	_	_	_	Seg=O
131	virus	_	_	_	_	_	_	_	Seg=O
132	NS	_	_	_	_	_	_	_	Seg=O
133	vectors	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=B-seg
135	induce	_	_	_	_	_	_	_	Seg=O
136	an	_	_	_	_	_	_	_	Seg=O
137	M.	_	_	_	_	_	_	_	Seg=O
138	tuberculosisspecific	_	_	_	_	_	_	_	Seg=O
139	Th1	_	_	_	_	_	_	_	Seg=O
140	immune	_	_	_	_	_	_	_	Seg=O
141	response	_	_	_	_	_	_	_	Seg=O
142	in	_	_	_	_	_	_	_	Seg=O
143	mice	_	_	_	_	_	_	_	Seg=O
144	.	_	_	_	_	_	_	_	Seg=O
145	Moreover	_	_	_	_	_	_	_	Seg=B-seg
146	,	_	_	_	_	_	_	_	Seg=O
147	intranasal	_	_	_	_	_	_	_	Seg=O
148	immunization	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	mice	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=O
152	guinea	_	_	_	_	_	_	_	Seg=O
153	pigs	_	_	_	_	_	_	_	Seg=O
154	with	_	_	_	_	_	_	_	Seg=O
155	such	_	_	_	_	_	_	_	Seg=O
156	vectors	_	_	_	_	_	_	_	Seg=O
157	induced	_	_	_	_	_	_	_	Seg=O
158	protection	_	_	_	_	_	_	_	Seg=O
159	against	_	_	_	_	_	_	_	Seg=O
160	mycobacterial	_	_	_	_	_	_	_	Seg=O
161	challenge	_	_	_	_	_	_	_	Seg=O
162	,	_	_	_	_	_	_	_	Seg=O
163	similar	_	_	_	_	_	_	_	Seg=O
164	to	_	_	_	_	_	_	_	Seg=O
165	that	_	_	_	_	_	_	_	Seg=O
166	induced	_	_	_	_	_	_	_	Seg=B-seg
167	by	_	_	_	_	_	_	_	Seg=O
168	BCG	_	_	_	_	_	_	_	Seg=O
169	vaccination	_	_	_	_	_	_	_	Seg=O
170	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = f72abb1b0683ec97335167e3e3b8c2790531654e
1	With	_	_	_	_	_	_	_	Seg=B-seg
2	rabbit	_	_	_	_	_	_	_	Seg=O
3	patients	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	as	_	_	_	_	_	_	_	Seg=O
6	in	_	_	_	_	_	_	_	Seg=O
7	other	_	_	_	_	_	_	_	Seg=O
8	species	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	analyzing	_	_	_	_	_	_	_	Seg=O
11	blood	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	urine	_	_	_	_	_	_	_	Seg=O
14	samples	_	_	_	_	_	_	_	Seg=O
15	can	_	_	_	_	_	_	_	Seg=O
16	be	_	_	_	_	_	_	_	Seg=O
17	useful	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	informative	_	_	_	_	_	_	_	Seg=O
20	,	_	_	_	_	_	_	_	Seg=O
21	although	_	_	_	_	_	_	_	Seg=B-seg
22	interpretation	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	results	_	_	_	_	_	_	_	Seg=O
26	is	_	_	_	_	_	_	_	Seg=O
27	sometimes	_	_	_	_	_	_	_	Seg=O
28	challenging	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	This	_	_	_	_	_	_	_	Seg=B-seg
31	article	_	_	_	_	_	_	_	Seg=O
32	summarizes	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	interpretation	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	laboratory	_	_	_	_	_	_	_	Seg=O
37	results	_	_	_	_	_	_	_	Seg=O
38	from	_	_	_	_	_	_	_	Seg=O
39	rabbits	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	Hematological	_	_	_	_	_	_	_	Seg=B-seg
42	parameters	_	_	_	_	_	_	_	Seg=O
43	can	_	_	_	_	_	_	_	Seg=O
44	yield	_	_	_	_	_	_	_	Seg=O
45	information	_	_	_	_	_	_	_	Seg=O
46	about	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	red	_	_	_	_	_	_	_	Seg=O
49	blood	_	_	_	_	_	_	_	Seg=O
50	cell	_	_	_	_	_	_	_	Seg=O
51	population	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	leukocyte	_	_	_	_	_	_	_	Seg=O
54	response	_	_	_	_	_	_	_	Seg=O
55	to	_	_	_	_	_	_	_	Seg=O
56	stress	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=O
58	pathogens	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	Biochemistry	_	_	_	_	_	_	_	Seg=B-seg
61	evaluation	_	_	_	_	_	_	_	Seg=O
62	can	_	_	_	_	_	_	_	Seg=O
63	be	_	_	_	_	_	_	_	Seg=O
64	used	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=B-seg
66	investigate	_	_	_	_	_	_	_	Seg=O
67	liver	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	kidney	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	other	_	_	_	_	_	_	_	Seg=O
73	organ	_	_	_	_	_	_	_	Seg=O
74	function	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	and	_	_	_	_	_	_	_	Seg=B-seg
77	urinalysis	_	_	_	_	_	_	_	Seg=O
78	results	_	_	_	_	_	_	_	Seg=O
79	may	_	_	_	_	_	_	_	Seg=O
80	yield	_	_	_	_	_	_	_	Seg=O
81	additional	_	_	_	_	_	_	_	Seg=O
82	information	_	_	_	_	_	_	_	Seg=O
83	about	_	_	_	_	_	_	_	Seg=O
84	kidney	_	_	_	_	_	_	_	Seg=O
85	function	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	electrolyte	_	_	_	_	_	_	_	Seg=O
88	imbalances	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O
90	Serological	_	_	_	_	_	_	_	Seg=B-seg
91	tests	_	_	_	_	_	_	_	Seg=O
92	are	_	_	_	_	_	_	_	Seg=O
93	available	_	_	_	_	_	_	_	Seg=O
94	for	_	_	_	_	_	_	_	Seg=O
95	several	_	_	_	_	_	_	_	Seg=O
96	pathogens	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	rabbits	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	including	_	_	_	_	_	_	_	Seg=B-seg
101	Encephalitozoon	_	_	_	_	_	_	_	Seg=O
102	cuniculi	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	although	_	_	_	_	_	_	_	Seg=B-seg
105	the	_	_	_	_	_	_	_	Seg=O
106	significance	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	positive	_	_	_	_	_	_	_	Seg=O
109	results	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=O
111	antibody	_	_	_	_	_	_	_	Seg=O
112	titers	_	_	_	_	_	_	_	Seg=O
113	is	_	_	_	_	_	_	_	Seg=O
114	not	_	_	_	_	_	_	_	Seg=O
115	clear	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	Serum	_	_	_	_	_	_	_	Seg=B-seg
118	protein	_	_	_	_	_	_	_	Seg=O
119	electrophoresis	_	_	_	_	_	_	_	Seg=O
120	aids	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	understanding	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	protein	_	_	_	_	_	_	_	Seg=O
125	disorders	_	_	_	_	_	_	_	Seg=O
126	and	_	_	_	_	_	_	_	Seg=O
127	the	_	_	_	_	_	_	_	Seg=O
128	immune	_	_	_	_	_	_	_	Seg=O
129	response	_	_	_	_	_	_	_	Seg=O
130	to	_	_	_	_	_	_	_	Seg=O
131	acute	_	_	_	_	_	_	_	Seg=O
132	and	_	_	_	_	_	_	_	Seg=O
133	chronic	_	_	_	_	_	_	_	Seg=O
134	inflammation	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = f849d3e71f4d2eae8a1e39802195bc9c06fc30ae
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Viral	_	_	_	_	_	_	_	Seg=B-seg
4	respiratory	_	_	_	_	_	_	_	Seg=O
5	infection	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	VRI	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	is	_	_	_	_	_	_	_	Seg=O
10	a	_	_	_	_	_	_	_	Seg=O
11	common	_	_	_	_	_	_	_	Seg=O
12	contraindication	_	_	_	_	_	_	_	Seg=O
13	to	_	_	_	_	_	_	_	Seg=O
14	elective	_	_	_	_	_	_	_	Seg=O
15	surgery	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	Asymptomatic	_	_	_	_	_	_	_	Seg=B-seg
18	shedding	_	_	_	_	_	_	_	Seg=O
19	among	_	_	_	_	_	_	_	Seg=O
20	pediatric	_	_	_	_	_	_	_	Seg=O
21	surgery	_	_	_	_	_	_	_	Seg=O
22	patients	_	_	_	_	_	_	_	Seg=O
23	(	_	_	_	_	_	_	_	Seg=O
24	PSPs	_	_	_	_	_	_	_	Seg=O
25	)	_	_	_	_	_	_	_	Seg=O
26	could	_	_	_	_	_	_	_	Seg=O
27	potentially	_	_	_	_	_	_	_	Seg=O
28	lead	_	_	_	_	_	_	_	Seg=O
29	to	_	_	_	_	_	_	_	Seg=O
30	progression	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	symptomatic	_	_	_	_	_	_	_	Seg=O
33	diseases	_	_	_	_	_	_	_	Seg=O
34	and	_	_	_	_	_	_	_	Seg=B-seg
35	cause	_	_	_	_	_	_	_	Seg=O
36	outbreaks	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	respiratory	_	_	_	_	_	_	_	Seg=O
39	diseases	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	The	_	_	_	_	_	_	_	Seg=B-seg
42	aim	_	_	_	_	_	_	_	Seg=O
43	of	_	_	_	_	_	_	_	Seg=O
44	this	_	_	_	_	_	_	_	Seg=O
45	study	_	_	_	_	_	_	_	Seg=O
46	is	_	_	_	_	_	_	_	Seg=O
47	to	_	_	_	_	_	_	_	Seg=O
48	investigate	_	_	_	_	_	_	_	Seg=O
49	the	_	_	_	_	_	_	_	Seg=O
50	incidence	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	infection	_	_	_	_	_	_	_	Seg=O
53	among	_	_	_	_	_	_	_	Seg=O
54	mild	_	_	_	_	_	_	_	Seg=O
55	symptomatic	_	_	_	_	_	_	_	Seg=O
56	PSP	_	_	_	_	_	_	_	Seg=O
57	group	_	_	_	_	_	_	_	Seg=O
58	and	_	_	_	_	_	_	_	Seg=O
59	asymptomatic	_	_	_	_	_	_	_	Seg=O
60	PSP	_	_	_	_	_	_	_	Seg=O
61	group	_	_	_	_	_	_	_	Seg=O
62	after	_	_	_	_	_	_	_	Seg=O
63	surgical	_	_	_	_	_	_	_	Seg=O
64	procedure	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Methods	_	_	_	_	_	_	_	Seg=B-seg
67	:	_	_	_	_	_	_	_	Seg=O
68	We	_	_	_	_	_	_	_	Seg=B-seg
69	collected	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	induced	_	_	_	_	_	_	_	Seg=O
72	sputum	_	_	_	_	_	_	_	Seg=O
73	from	_	_	_	_	_	_	_	Seg=O
74	enrolled	_	_	_	_	_	_	_	Seg=O
75	1629	_	_	_	_	_	_	_	Seg=O
76	children	_	_	_	_	_	_	_	Seg=O
77	(	_	_	_	_	_	_	_	Seg=B-seg
78	under	_	_	_	_	_	_	_	Seg=O
79	18	_	_	_	_	_	_	_	Seg=O
80	years	_	_	_	_	_	_	_	Seg=O
81	of	_	_	_	_	_	_	_	Seg=O
82	age	_	_	_	_	_	_	_	Seg=O
83	)	_	_	_	_	_	_	_	Seg=O
84	with	_	_	_	_	_	_	_	Seg=B-seg
85	no	_	_	_	_	_	_	_	Seg=O
86	respiratory	_	_	_	_	_	_	_	Seg=O
87	symptom	_	_	_	_	_	_	_	Seg=O
88	prior	_	_	_	_	_	_	_	Seg=O
89	to	_	_	_	_	_	_	_	Seg=O
90	pediatric	_	_	_	_	_	_	_	Seg=O
91	surgery	_	_	_	_	_	_	_	Seg=O
92	between	_	_	_	_	_	_	_	Seg=O
93	March	_	_	_	_	_	_	_	Seg=O
94	2017	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=O
96	February	_	_	_	_	_	_	_	Seg=O
97	2019	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	We	_	_	_	_	_	_	_	Seg=B-seg
100	tested	_	_	_	_	_	_	_	Seg=O
101	16	_	_	_	_	_	_	_	Seg=O
102	different	_	_	_	_	_	_	_	Seg=O
103	respiratory	_	_	_	_	_	_	_	Seg=O
104	virus	_	_	_	_	_	_	_	Seg=O
105	infections	_	_	_	_	_	_	_	Seg=O
106	in	_	_	_	_	_	_	_	Seg=O
107	post	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	surgery	_	_	_	_	_	_	_	Seg=O
110	mild	_	_	_	_	_	_	_	Seg=O
111	symptomatic	_	_	_	_	_	_	_	Seg=O
112	PSP	_	_	_	_	_	_	_	Seg=O
113	group	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	asymptomatic	_	_	_	_	_	_	_	Seg=O
116	PSP	_	_	_	_	_	_	_	Seg=O
117	group	_	_	_	_	_	_	_	Seg=O
118	using	_	_	_	_	_	_	_	Seg=B-seg
119	a	_	_	_	_	_	_	_	Seg=O
120	quantitative	_	_	_	_	_	_	_	Seg=O
121	real	_	_	_	_	_	_	_	Seg=O
122	-	_	_	_	_	_	_	_	Seg=O
123	time	_	_	_	_	_	_	_	Seg=O
124	reverse	_	_	_	_	_	_	_	Seg=O
125	transcriptase	_	_	_	_	_	_	_	Seg=O
126	polymerase	_	_	_	_	_	_	_	Seg=O
127	chain	_	_	_	_	_	_	_	Seg=O
128	reaction	_	_	_	_	_	_	_	Seg=O
129	(	_	_	_	_	_	_	_	Seg=O
130	qRT	_	_	_	_	_	_	_	Seg=O
131	-	_	_	_	_	_	_	_	Seg=O
132	PCR	_	_	_	_	_	_	_	Seg=O
133	)	_	_	_	_	_	_	_	Seg=O
134	assay	_	_	_	_	_	_	_	Seg=O
135	panel	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	We	_	_	_	_	_	_	_	Seg=B-seg
138	analyzed	_	_	_	_	_	_	_	Seg=O
139	symptom	_	_	_	_	_	_	_	Seg=O
140	data	_	_	_	_	_	_	_	Seg=O
141	and	_	_	_	_	_	_	_	Seg=O
142	quantitative	_	_	_	_	_	_	_	Seg=O
143	viral	_	_	_	_	_	_	_	Seg=O
144	load	_	_	_	_	_	_	_	Seg=O
145	to	_	_	_	_	_	_	_	Seg=B-seg
146	investigate	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	association	_	_	_	_	_	_	_	Seg=O
149	between	_	_	_	_	_	_	_	Seg=O
150	viruses	_	_	_	_	_	_	_	Seg=O
151	,	_	_	_	_	_	_	_	Seg=O
152	symptoms	_	_	_	_	_	_	_	Seg=O
153	and	_	_	_	_	_	_	_	Seg=O
154	viral	_	_	_	_	_	_	_	Seg=O
155	quantity	_	_	_	_	_	_	_	Seg=O
156	in	_	_	_	_	_	_	_	Seg=O
157	qRT	_	_	_	_	_	_	_	Seg=O
158	-	_	_	_	_	_	_	_	Seg=O
159	PCR	_	_	_	_	_	_	_	Seg=O
160	-	_	_	_	_	_	_	_	Seg=O
161	positive	_	_	_	_	_	_	_	Seg=O
162	PSPs	_	_	_	_	_	_	_	Seg=O
163	.	_	_	_	_	_	_	_	Seg=O
164	Results	_	_	_	_	_	_	_	Seg=B-seg
165	:	_	_	_	_	_	_	_	Seg=O
166	Out	_	_	_	_	_	_	_	Seg=B-seg
167	of	_	_	_	_	_	_	_	Seg=O
168	1629	_	_	_	_	_	_	_	Seg=O
169	children	_	_	_	_	_	_	_	Seg=O
170	enrolled	_	_	_	_	_	_	_	Seg=O
171	,	_	_	_	_	_	_	_	Seg=O
172	a	_	_	_	_	_	_	_	Seg=O
173	total	_	_	_	_	_	_	_	Seg=O
174	of	_	_	_	_	_	_	_	Seg=O
175	204	_	_	_	_	_	_	_	Seg=O
176	respiratory	_	_	_	_	_	_	_	Seg=O
177	viruses	_	_	_	_	_	_	_	Seg=O
178	were	_	_	_	_	_	_	_	Seg=O
179	present	_	_	_	_	_	_	_	Seg=O
180	in	_	_	_	_	_	_	_	Seg=O
181	171	_	_	_	_	_	_	_	Seg=O
182	(	_	_	_	_	_	_	_	Seg=B-seg
183	10.50	_	_	_	_	_	_	_	Seg=O
184	%	_	_	_	_	_	_	_	Seg=O
185	)	_	_	_	_	_	_	_	Seg=O
186	PSPs	_	_	_	_	_	_	_	Seg=B-seg
187	including	_	_	_	_	_	_	_	Seg=B-seg
188	47	_	_	_	_	_	_	_	Seg=O
189	patients	_	_	_	_	_	_	_	Seg=O
190	with	_	_	_	_	_	_	_	Seg=O
191	mild	_	_	_	_	_	_	_	Seg=O
192	symptoms	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=O
194	124	_	_	_	_	_	_	_	Seg=O
195	with	_	_	_	_	_	_	_	Seg=O
196	no	_	_	_	_	_	_	_	Seg=O
197	symptoms	_	_	_	_	_	_	_	Seg=O
198	after	_	_	_	_	_	_	_	Seg=O
199	surgery	_	_	_	_	_	_	_	Seg=O
200	.	_	_	_	_	_	_	_	Seg=O
201	Commonly	_	_	_	_	_	_	_	Seg=B-seg
202	detected	_	_	_	_	_	_	_	Seg=O
203	viruses	_	_	_	_	_	_	_	Seg=O
204	were	_	_	_	_	_	_	_	Seg=O
205	human	_	_	_	_	_	_	_	Seg=O
206	rhino	_	_	_	_	_	_	_	Seg=O
207	/	_	_	_	_	_	_	_	Seg=O
208	enterovirus	_	_	_	_	_	_	_	Seg=O
209	(	_	_	_	_	_	_	_	Seg=B-seg
210	HRV	_	_	_	_	_	_	_	Seg=O
211	/	_	_	_	_	_	_	_	Seg=O
212	EV	_	_	_	_	_	_	_	Seg=O
213	,	_	_	_	_	_	_	_	Seg=O
214	42.19	_	_	_	_	_	_	_	Seg=O
215	%	_	_	_	_	_	_	_	Seg=O
216	)	_	_	_	_	_	_	_	Seg=O
217	,	_	_	_	_	_	_	_	Seg=O
218	parainfluenza	_	_	_	_	_	_	_	Seg=B-seg
219	virus	_	_	_	_	_	_	_	Seg=O
220	3	_	_	_	_	_	_	_	Seg=O
221	(	_	_	_	_	_	_	_	Seg=B-seg
222	PIV3	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	24.48	_	_	_	_	_	_	_	Seg=O
225	%	_	_	_	_	_	_	_	Seg=O
226	)	_	_	_	_	_	_	_	Seg=O
227	,	_	_	_	_	_	_	_	Seg=O
228	coronavirus	_	_	_	_	_	_	_	Seg=B-seg
229	(	_	_	_	_	_	_	_	Seg=B-seg
230	CoV	_	_	_	_	_	_	_	Seg=O
231	NL63	_	_	_	_	_	_	_	Seg=O
232	,	_	_	_	_	_	_	_	Seg=O
233	OC43	_	_	_	_	_	_	_	Seg=O
234	,	_	_	_	_	_	_	_	Seg=O
235	HKU1	_	_	_	_	_	_	_	Seg=O
236	,	_	_	_	_	_	_	_	Seg=O
237	11.46	_	_	_	_	_	_	_	Seg=O
238	%	_	_	_	_	_	_	_	Seg=O
239	)	_	_	_	_	_	_	_	Seg=O
240	,	_	_	_	_	_	_	_	Seg=O
241	and	_	_	_	_	_	_	_	Seg=B-seg
242	respiratory	_	_	_	_	_	_	_	Seg=O
243	syncytial	_	_	_	_	_	_	_	Seg=O
244	virus	_	_	_	_	_	_	_	Seg=O
245	(	_	_	_	_	_	_	_	Seg=B-seg
246	RSV	_	_	_	_	_	_	_	Seg=O
247	,	_	_	_	_	_	_	_	Seg=O
248	9.9	_	_	_	_	_	_	_	Seg=O
249	%	_	_	_	_	_	_	_	Seg=O
250	)	_	_	_	_	_	_	_	Seg=O
251	.	_	_	_	_	_	_	_	Seg=O
252	PIV3	_	_	_	_	_	_	_	Seg=B-seg
253	infection	_	_	_	_	_	_	_	Seg=O
254	with	_	_	_	_	_	_	_	Seg=O
255	a	_	_	_	_	_	_	_	Seg=O
256	higher	_	_	_	_	_	_	_	Seg=O
257	viral	_	_	_	_	_	_	_	Seg=O
258	load	_	_	_	_	_	_	_	Seg=O
259	was	_	_	_	_	_	_	_	Seg=O
260	frequently	_	_	_	_	_	_	_	Seg=O
261	found	_	_	_	_	_	_	_	Seg=O
262	in	_	_	_	_	_	_	_	Seg=O
263	PSPs	_	_	_	_	_	_	_	Seg=O
264	presenting	_	_	_	_	_	_	_	Seg=B-seg
265	with	_	_	_	_	_	_	_	Seg=O
266	mild	_	_	_	_	_	_	_	Seg=O
267	symptoms	_	_	_	_	_	_	_	Seg=O
268	,	_	_	_	_	_	_	_	Seg=O
269	progressing	_	_	_	_	_	_	_	Seg=B-seg
270	to	_	_	_	_	_	_	_	Seg=O
271	pneumonia	_	_	_	_	_	_	_	Seg=O
272	with	_	_	_	_	_	_	_	Seg=O
273	radiographic	_	_	_	_	_	_	_	Seg=O
274	evidence	_	_	_	_	_	_	_	Seg=O
275	after	_	_	_	_	_	_	_	Seg=O
276	surgery	_	_	_	_	_	_	_	Seg=O
277	.	_	_	_	_	_	_	_	Seg=O
278	HRV	_	_	_	_	_	_	_	Seg=B-seg
279	/	_	_	_	_	_	_	_	Seg=O
280	EV	_	_	_	_	_	_	_	Seg=O
281	were	_	_	_	_	_	_	_	Seg=O
282	the	_	_	_	_	_	_	_	Seg=O
283	most	_	_	_	_	_	_	_	Seg=O
284	commonly	_	_	_	_	_	_	_	Seg=O
285	detected	_	_	_	_	_	_	_	Seg=O
286	pathogens	_	_	_	_	_	_	_	Seg=O
287	in	_	_	_	_	_	_	_	Seg=O
288	both	_	_	_	_	_	_	_	Seg=O
289	asymptomatic	_	_	_	_	_	_	_	Seg=O
290	and	_	_	_	_	_	_	_	Seg=O
291	mild	_	_	_	_	_	_	_	Seg=O
292	symptomatic	_	_	_	_	_	_	_	Seg=O
293	PSPs	_	_	_	_	_	_	_	Seg=O
294	.	_	_	_	_	_	_	_	Seg=O
295	CoV	_	_	_	_	_	_	_	Seg=B-seg
296	(	_	_	_	_	_	_	_	Seg=O
297	OC43	_	_	_	_	_	_	_	Seg=O
298	,	_	_	_	_	_	_	_	Seg=O
299	HKU1	_	_	_	_	_	_	_	Seg=O
300	)	_	_	_	_	_	_	_	Seg=O
301	infections	_	_	_	_	_	_	_	Seg=O
302	with	_	_	_	_	_	_	_	Seg=O
303	a	_	_	_	_	_	_	_	Seg=O
304	higher	_	_	_	_	_	_	_	Seg=O
305	viral	_	_	_	_	_	_	_	Seg=O
306	load	_	_	_	_	_	_	_	Seg=O
307	were	_	_	_	_	_	_	_	Seg=O
308	mostly	_	_	_	_	_	_	_	Seg=O
309	observed	_	_	_	_	_	_	_	Seg=O
310	in	_	_	_	_	_	_	_	Seg=O
311	asymptomatic	_	_	_	_	_	_	_	Seg=O
312	PSPs	_	_	_	_	_	_	_	Seg=O
313	progressing	_	_	_	_	_	_	_	Seg=O
314	to	_	_	_	_	_	_	_	Seg=O
315	alveolar	_	_	_	_	_	_	_	Seg=O
316	or	_	_	_	_	_	_	_	Seg=O
317	interstitial	_	_	_	_	_	_	_	Seg=O
318	infiltration	_	_	_	_	_	_	_	Seg=O
319	.	_	_	_	_	_	_	_	Seg=O
320	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
321	:	_	_	_	_	_	_	_	Seg=O
322	Our	_	_	_	_	_	_	_	Seg=B-seg
323	study	_	_	_	_	_	_	_	Seg=O
324	suggested	_	_	_	_	_	_	_	Seg=O
325	that	_	_	_	_	_	_	_	Seg=B-seg
326	PIV3	_	_	_	_	_	_	_	Seg=O
327	is	_	_	_	_	_	_	_	Seg=O
328	a	_	_	_	_	_	_	_	Seg=O
329	new	_	_	_	_	_	_	_	Seg=O
330	risk	_	_	_	_	_	_	_	Seg=O
331	factor	_	_	_	_	_	_	_	Seg=O
332	for	_	_	_	_	_	_	_	Seg=O
333	VRI	_	_	_	_	_	_	_	Seg=O
334	in	_	_	_	_	_	_	_	Seg=O
335	PSPs	_	_	_	_	_	_	_	Seg=O
336	.	_	_	_	_	_	_	_	Seg=O
337	Employing	_	_	_	_	_	_	_	Seg=B-seg
338	a	_	_	_	_	_	_	_	Seg=O
339	more	_	_	_	_	_	_	_	Seg=O
340	comprehensive	_	_	_	_	_	_	_	Seg=O
341	,	_	_	_	_	_	_	_	Seg=O
342	sensitive	_	_	_	_	_	_	_	Seg=O
343	and	_	_	_	_	_	_	_	Seg=O
344	quantitative	_	_	_	_	_	_	_	Seg=O
345	method	_	_	_	_	_	_	_	Seg=O
346	should	_	_	_	_	_	_	_	Seg=O
347	be	_	_	_	_	_	_	_	Seg=O
348	considered	_	_	_	_	_	_	_	Seg=O
349	for	_	_	_	_	_	_	_	Seg=O
350	preoperative	_	_	_	_	_	_	_	Seg=O
351	testing	_	_	_	_	_	_	_	Seg=O
352	of	_	_	_	_	_	_	_	Seg=O
353	respiratory	_	_	_	_	_	_	_	Seg=O
354	viruses	_	_	_	_	_	_	_	Seg=O
355	in	_	_	_	_	_	_	_	Seg=B-seg
356	order	_	_	_	_	_	_	_	Seg=O
357	to	_	_	_	_	_	_	_	Seg=O
358	guide	_	_	_	_	_	_	_	Seg=O
359	optimal	_	_	_	_	_	_	_	Seg=O
360	surgical	_	_	_	_	_	_	_	Seg=O
361	timing	_	_	_	_	_	_	_	Seg=O
362	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = faffbac0e2a22d215556feec30516c1a6ccdb283
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	computational	_	_	_	_	_	_	_	Seg=O
3	search	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	chemical	_	_	_	_	_	_	_	Seg=O
6	libraries	_	_	_	_	_	_	_	Seg=O
7	has	_	_	_	_	_	_	_	Seg=O
8	been	_	_	_	_	_	_	_	Seg=O
9	used	_	_	_	_	_	_	_	Seg=O
10	as	_	_	_	_	_	_	_	Seg=O
11	a	_	_	_	_	_	_	_	Seg=O
12	powerful	_	_	_	_	_	_	_	Seg=O
13	tool	_	_	_	_	_	_	_	Seg=O
14	for	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	rapid	_	_	_	_	_	_	_	Seg=O
17	discovery	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	candidate	_	_	_	_	_	_	_	Seg=O
20	compounds	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	To	_	_	_	_	_	_	_	Seg=B-seg
23	find	_	_	_	_	_	_	_	Seg=O
24	small	_	_	_	_	_	_	_	Seg=O
25	molecules	_	_	_	_	_	_	_	Seg=O
26	with	_	_	_	_	_	_	_	Seg=O
27	anti	_	_	_	_	_	_	_	Seg=O
28	-	_	_	_	_	_	_	_	Seg=O
29	feline	_	_	_	_	_	_	_	Seg=O
30	infectious	_	_	_	_	_	_	_	Seg=O
31	peritonitis	_	_	_	_	_	_	_	Seg=O
32	virus	_	_	_	_	_	_	_	Seg=O
33	(	_	_	_	_	_	_	_	Seg=O
34	FIPV	_	_	_	_	_	_	_	Seg=O
35	)	_	_	_	_	_	_	_	Seg=O
36	properties	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	we	_	_	_	_	_	_	_	Seg=B-seg
39	utilized	_	_	_	_	_	_	_	Seg=O
40	a	_	_	_	_	_	_	_	Seg=O
41	virtual	_	_	_	_	_	_	_	Seg=O
42	screening	_	_	_	_	_	_	_	Seg=O
43	technique	_	_	_	_	_	_	_	Seg=O
44	to	_	_	_	_	_	_	_	Seg=B-seg
45	identify	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	active	_	_	_	_	_	_	_	Seg=O
48	site	_	_	_	_	_	_	_	Seg=O
49	on	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	viral	_	_	_	_	_	_	_	Seg=O
52	protease	_	_	_	_	_	_	_	Seg=O
53	for	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	binding	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	available	_	_	_	_	_	_	_	Seg=O
59	natural	_	_	_	_	_	_	_	Seg=O
60	compounds	_	_	_	_	_	_	_	Seg=O
61	.	_	_	_	_	_	_	_	Seg=O
62	The	_	_	_	_	_	_	_	Seg=B-seg
63	protease	_	_	_	_	_	_	_	Seg=O
64	3CL	_	_	_	_	_	_	_	Seg=O
65	(	_	_	_	_	_	_	_	Seg=O
66	3CL	_	_	_	_	_	_	_	Seg=O
67	pro	_	_	_	_	_	_	_	Seg=O
68	)	_	_	_	_	_	_	_	Seg=O
69	plays	_	_	_	_	_	_	_	Seg=O
70	an	_	_	_	_	_	_	_	Seg=O
71	important	_	_	_	_	_	_	_	Seg=O
72	role	_	_	_	_	_	_	_	Seg=O
73	in	_	_	_	_	_	_	_	Seg=O
74	the	_	_	_	_	_	_	_	Seg=O
75	replication	_	_	_	_	_	_	_	Seg=O
76	cycle	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	FIPV	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	other	_	_	_	_	_	_	_	Seg=O
81	viruses	_	_	_	_	_	_	_	Seg=O
82	within	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	family	_	_	_	_	_	_	_	Seg=O
85	Coronaviridae	_	_	_	_	_	_	_	Seg=O
86	.	_	_	_	_	_	_	_	Seg=O
87	The	_	_	_	_	_	_	_	Seg=B-seg
88	15	_	_	_	_	_	_	_	Seg=O
89	best	_	_	_	_	_	_	_	Seg=O
90	-	_	_	_	_	_	_	_	Seg=O
91	ranked	_	_	_	_	_	_	_	Seg=O
92	candidate	_	_	_	_	_	_	_	Seg=O
93	consensus	_	_	_	_	_	_	_	Seg=O
94	compounds	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	based	_	_	_	_	_	_	_	Seg=B-seg
97	on	_	_	_	_	_	_	_	Seg=O
98	three	_	_	_	_	_	_	_	Seg=O
99	docking	_	_	_	_	_	_	_	Seg=O
100	tools	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	were	_	_	_	_	_	_	_	Seg=B-seg
103	evaluated	_	_	_	_	_	_	_	Seg=O
104	for	_	_	_	_	_	_	_	Seg=O
105	further	_	_	_	_	_	_	_	Seg=O
106	assays	_	_	_	_	_	_	_	Seg=O
107	.	_	_	_	_	_	_	_	Seg=O
108	The	_	_	_	_	_	_	_	Seg=B-seg
109	protease	_	_	_	_	_	_	_	Seg=O
110	inhibitor	_	_	_	_	_	_	_	Seg=O
111	assay	_	_	_	_	_	_	_	Seg=O
112	on	_	_	_	_	_	_	_	Seg=O
113	recombinant	_	_	_	_	_	_	_	Seg=O
114	FIPV	_	_	_	_	_	_	_	Seg=O
115	3CL	_	_	_	_	_	_	_	Seg=O
116	pro	_	_	_	_	_	_	_	Seg=O
117	was	_	_	_	_	_	_	_	Seg=O
118	performed	_	_	_	_	_	_	_	Seg=O
119	to	_	_	_	_	_	_	_	Seg=B-seg
120	screen	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	inhibitory	_	_	_	_	_	_	_	Seg=O
123	effect	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	candidate	_	_	_	_	_	_	_	Seg=O
127	compounds	_	_	_	_	_	_	_	Seg=O
128	with	_	_	_	_	_	_	_	Seg=O
129	IC	_	_	_	_	_	_	_	Seg=O
130	50	_	_	_	_	_	_	_	Seg=O
131	ranging	_	_	_	_	_	_	_	Seg=B-seg
132	from	_	_	_	_	_	_	_	Seg=O
133	6.36	_	_	_	_	_	_	_	Seg=O
134	±	_	_	_	_	_	_	_	Seg=O
135	2.15	_	_	_	_	_	_	_	Seg=O
136	to	_	_	_	_	_	_	_	Seg=O
137	78.40	_	_	_	_	_	_	_	Seg=O
138	±	_	_	_	_	_	_	_	Seg=O
139	2.60	_	_	_	_	_	_	_	Seg=O
140	μM.	_	_	_	_	_	_	_	Seg=O
141	As	_	_	_	_	_	_	_	Seg=B-seg
142	determined	_	_	_	_	_	_	_	Seg=O
143	by	_	_	_	_	_	_	_	Seg=O
144	the	_	_	_	_	_	_	_	Seg=O
145	cell	_	_	_	_	_	_	_	Seg=O
146	-	_	_	_	_	_	_	_	Seg=O
147	based	_	_	_	_	_	_	_	Seg=O
148	assay	_	_	_	_	_	_	_	Seg=O
149	,	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=B-seg
151	compounds	_	_	_	_	_	_	_	Seg=O
152	NSC345647	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	NSC87511	_	_	_	_	_	_	_	Seg=O
155	,	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	NSC343256	_	_	_	_	_	_	_	Seg=O
158	showed	_	_	_	_	_	_	_	Seg=O
159	better	_	_	_	_	_	_	_	Seg=O
160	EC	_	_	_	_	_	_	_	Seg=O
161	50	_	_	_	_	_	_	_	Seg=O
162	values	_	_	_	_	_	_	_	Seg=O
163	than	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	broad	_	_	_	_	_	_	_	Seg=O
166	-	_	_	_	_	_	_	_	Seg=O
167	spectrum	_	_	_	_	_	_	_	Seg=O
168	antiviral	_	_	_	_	_	_	_	Seg=O
169	drug	_	_	_	_	_	_	_	Seg=O
170	ribavirin	_	_	_	_	_	_	_	Seg=O
171	and	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	protease	_	_	_	_	_	_	_	Seg=O
174	inhibitor	_	_	_	_	_	_	_	Seg=O
175	lopinavir	_	_	_	_	_	_	_	Seg=O
176	,	_	_	_	_	_	_	_	Seg=O
177	under	_	_	_	_	_	_	_	Seg=O
178	all	_	_	_	_	_	_	_	Seg=O
179	the	_	_	_	_	_	_	_	Seg=O
180	test	_	_	_	_	_	_	_	Seg=O
181	conditions	_	_	_	_	_	_	_	Seg=O
182	including	_	_	_	_	_	_	_	Seg=B-seg
183	pre	_	_	_	_	_	_	_	Seg=O
184	-	_	_	_	_	_	_	_	Seg=O
185	viral	_	_	_	_	_	_	_	Seg=O
186	entry	_	_	_	_	_	_	_	Seg=O
187	,	_	_	_	_	_	_	_	Seg=O
188	post	_	_	_	_	_	_	_	Seg=O
189	-	_	_	_	_	_	_	_	Seg=O
190	viral	_	_	_	_	_	_	_	Seg=O
191	entry	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=O
194	prophylactic	_	_	_	_	_	_	_	Seg=O
195	activity	_	_	_	_	_	_	_	Seg=O
196	.	_	_	_	_	_	_	_	Seg=O
197	The	_	_	_	_	_	_	_	Seg=B-seg
198	NSC87511	_	_	_	_	_	_	_	Seg=O
199	particularly	_	_	_	_	_	_	_	Seg=O
200	yielded	_	_	_	_	_	_	_	Seg=O
201	the	_	_	_	_	_	_	_	Seg=O
202	best	_	_	_	_	_	_	_	Seg=O
203	selective	_	_	_	_	_	_	_	Seg=O
204	index	_	_	_	_	_	_	_	Seg=O
205	(	_	_	_	_	_	_	_	Seg=B-seg
206	>	_	_	_	_	_	_	_	Seg=O
207	4	_	_	_	_	_	_	_	Seg=O
208	;	_	_	_	_	_	_	_	Seg=O
209	range	_	_	_	_	_	_	_	Seg=O
210	of	_	_	_	_	_	_	_	Seg=O
211	SI	_	_	_	_	_	_	_	Seg=O
212	=	_	_	_	_	_	_	_	Seg=O
213	13.80	_	_	_	_	_	_	_	Seg=O
214	-	_	_	_	_	_	_	_	Seg=O
215	22.90	_	_	_	_	_	_	_	Seg=O
216	)	_	_	_	_	_	_	_	Seg=O
217	.	_	_	_	_	_	_	_	Seg=O
218	These	_	_	_	_	_	_	_	Seg=B-seg
219	results	_	_	_	_	_	_	_	Seg=O
220	indicated	_	_	_	_	_	_	_	Seg=O
221	that	_	_	_	_	_	_	_	Seg=B-seg
222	the	_	_	_	_	_	_	_	Seg=O
223	natural	_	_	_	_	_	_	_	Seg=O
224	small	_	_	_	_	_	_	_	Seg=O
225	-	_	_	_	_	_	_	_	Seg=O
226	molecular	_	_	_	_	_	_	_	Seg=O
227	compounds	_	_	_	_	_	_	_	Seg=O
228	specifically	_	_	_	_	_	_	_	Seg=O
229	targeted	_	_	_	_	_	_	_	Seg=O
230	the	_	_	_	_	_	_	_	Seg=O
231	3CL	_	_	_	_	_	_	_	Seg=O
232	pro	_	_	_	_	_	_	_	Seg=O
233	of	_	_	_	_	_	_	_	Seg=O
234	FIPV	_	_	_	_	_	_	_	Seg=O
235	and	_	_	_	_	_	_	_	Seg=B-seg
236	inhibited	_	_	_	_	_	_	_	Seg=O
237	its	_	_	_	_	_	_	_	Seg=O
238	replication	_	_	_	_	_	_	_	Seg=O
239	.	_	_	_	_	_	_	_	Seg=O
240	Structural	_	_	_	_	_	_	_	Seg=B-seg
241	modification	_	_	_	_	_	_	_	Seg=O
242	of	_	_	_	_	_	_	_	Seg=O
243	these	_	_	_	_	_	_	_	Seg=O
244	compounds	_	_	_	_	_	_	_	Seg=O
245	may	_	_	_	_	_	_	_	Seg=O
246	generate	_	_	_	_	_	_	_	Seg=O
247	a	_	_	_	_	_	_	_	Seg=O
248	higher	_	_	_	_	_	_	_	Seg=O
249	anti	_	_	_	_	_	_	_	Seg=O
250	-	_	_	_	_	_	_	_	Seg=O
251	viral	_	_	_	_	_	_	_	Seg=O
252	potency	_	_	_	_	_	_	_	Seg=O
253	for	_	_	_	_	_	_	_	Seg=O
254	the	_	_	_	_	_	_	_	Seg=O
255	further	_	_	_	_	_	_	_	Seg=O
256	development	_	_	_	_	_	_	_	Seg=O
257	of	_	_	_	_	_	_	_	Seg=O
258	a	_	_	_	_	_	_	_	Seg=O
259	novel	_	_	_	_	_	_	_	Seg=O
260	therapy	_	_	_	_	_	_	_	Seg=O
261	against	_	_	_	_	_	_	_	Seg=O
262	FIP	_	_	_	_	_	_	_	Seg=O
263	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = fb824a8c9ca3c15f49dffa5e22fbfdc1b1fec4ac
1	As	_	_	_	_	_	_	_	Seg=B-seg
2	Sun	_	_	_	_	_	_	_	Seg=O
3	Tzu	_	_	_	_	_	_	_	Seg=O
4	wrote	_	_	_	_	_	_	_	Seg=O
5	in	_	_	_	_	_	_	_	Seg=O
6	The	_	_	_	_	_	_	_	Seg=O
7	Art	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	War	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	"	_	_	_	_	_	_	_	Seg=B-seg
12	All	_	_	_	_	_	_	_	Seg=O
13	warfare	_	_	_	_	_	_	_	Seg=O
14	is	_	_	_	_	_	_	_	Seg=O
15	based	_	_	_	_	_	_	_	Seg=O
16	on	_	_	_	_	_	_	_	Seg=O
17	deception	_	_	_	_	_	_	_	Seg=O
18	"	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	He	_	_	_	_	_	_	_	Seg=B-seg
21	could	_	_	_	_	_	_	_	Seg=O
22	have	_	_	_	_	_	_	_	Seg=O
23	easily	_	_	_	_	_	_	_	Seg=O
24	been	_	_	_	_	_	_	_	Seg=O
25	describing	_	_	_	_	_	_	_	Seg=O
26	the	_	_	_	_	_	_	_	Seg=O
27	ancient	_	_	_	_	_	_	_	Seg=O
28	battle	_	_	_	_	_	_	_	Seg=O
29	between	_	_	_	_	_	_	_	Seg=O
30	virus	_	_	_	_	_	_	_	Seg=O
31	and	_	_	_	_	_	_	_	Seg=O
32	host	_	_	_	_	_	_	_	Seg=O
33	rather	_	_	_	_	_	_	_	Seg=O
34	than	_	_	_	_	_	_	_	Seg=O
35	on	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	lore	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	Chinese	_	_	_	_	_	_	_	Seg=O
40	warfare	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	A	_	_	_	_	_	_	_	Seg=B-seg
43	virus	_	_	_	_	_	_	_	Seg=O
44	must	_	_	_	_	_	_	_	Seg=O
45	infect	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	replicate	_	_	_	_	_	_	_	Seg=B-seg
48	and	_	_	_	_	_	_	_	Seg=B-seg
49	spread	_	_	_	_	_	_	_	Seg=O
50	for	_	_	_	_	_	_	_	Seg=B-seg
51	it	_	_	_	_	_	_	_	Seg=O
52	to	_	_	_	_	_	_	_	Seg=O
53	survive	_	_	_	_	_	_	_	Seg=O
54	;	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=B-seg
56	host	_	_	_	_	_	_	_	Seg=O
57	attempting	_	_	_	_	_	_	_	Seg=O
58	to	_	_	_	_	_	_	_	Seg=O
59	thwart	_	_	_	_	_	_	_	Seg=O
60	it	_	_	_	_	_	_	_	Seg=O
61	at	_	_	_	_	_	_	_	Seg=O
62	every	_	_	_	_	_	_	_	Seg=O
63	step	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	way	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	This	_	_	_	_	_	_	_	Seg=B-seg
69	ancient	_	_	_	_	_	_	_	Seg=O
70	battle	_	_	_	_	_	_	_	Seg=O
71	has	_	_	_	_	_	_	_	Seg=O
72	been	_	_	_	_	_	_	_	Seg=O
73	waged	_	_	_	_	_	_	_	Seg=O
74	for	_	_	_	_	_	_	_	Seg=O
75	millions	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	years	_	_	_	_	_	_	_	Seg=O
78	and	_	_	_	_	_	_	_	Seg=B-seg
79	has	_	_	_	_	_	_	_	Seg=O
80	spawned	_	_	_	_	_	_	_	Seg=O
81	an	_	_	_	_	_	_	_	Seg=O
82	innumerable	_	_	_	_	_	_	_	Seg=O
83	number	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	viruses	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	each	_	_	_	_	_	_	_	Seg=O
88	with	_	_	_	_	_	_	_	Seg=O
89	their	_	_	_	_	_	_	_	Seg=O
90	own	_	_	_	_	_	_	_	Seg=O
91	unique	_	_	_	_	_	_	_	Seg=O
92	ways	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=B-seg
94	trying	_	_	_	_	_	_	_	Seg=O
95	to	_	_	_	_	_	_	_	Seg=O
96	outsmart	_	_	_	_	_	_	_	Seg=O
97	the	_	_	_	_	_	_	_	Seg=O
98	host	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	Some	_	_	_	_	_	_	_	Seg=B-seg
101	viruses	_	_	_	_	_	_	_	Seg=O
102	encode	_	_	_	_	_	_	_	Seg=O
103	proteins	_	_	_	_	_	_	_	Seg=O
104	that	_	_	_	_	_	_	_	Seg=B-seg
105	directly	_	_	_	_	_	_	_	Seg=O
106	inhibit	_	_	_	_	_	_	_	Seg=O
107	/	_	_	_	_	_	_	_	Seg=O
108	degrade	_	_	_	_	_	_	_	Seg=O
109	/	_	_	_	_	_	_	_	Seg=O
110	alter	_	_	_	_	_	_	_	Seg=O
111	host	_	_	_	_	_	_	_	Seg=O
112	pathways	_	_	_	_	_	_	_	Seg=O
113	and	_	_	_	_	_	_	_	Seg=B-seg
114	some	_	_	_	_	_	_	_	Seg=O
115	simply	_	_	_	_	_	_	_	Seg=O
116	have	_	_	_	_	_	_	_	Seg=O
117	evolved	_	_	_	_	_	_	_	Seg=O
118	ways	_	_	_	_	_	_	_	Seg=O
119	to	_	_	_	_	_	_	_	Seg=B-seg
120	hide	_	_	_	_	_	_	_	Seg=O
121	from	_	_	_	_	_	_	_	Seg=O
122	the	_	_	_	_	_	_	_	Seg=O
123	hosts	_	_	_	_	_	_	_	Seg=O
124	detection	_	_	_	_	_	_	_	Seg=O
125	system	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O
127	The	_	_	_	_	_	_	_	Seg=B-seg
128	host	_	_	_	_	_	_	_	Seg=O
129	is	_	_	_	_	_	_	_	Seg=O
130	not	_	_	_	_	_	_	_	Seg=O
131	passive	_	_	_	_	_	_	_	Seg=O
132	in	_	_	_	_	_	_	_	Seg=O
133	this	_	_	_	_	_	_	_	Seg=O
134	battle	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	It	_	_	_	_	_	_	_	Seg=B-seg
137	has	_	_	_	_	_	_	_	Seg=O
138	evolved	_	_	_	_	_	_	_	Seg=O
139	complex	_	_	_	_	_	_	_	Seg=O
140	pathways	_	_	_	_	_	_	_	Seg=O
141	and	_	_	_	_	_	_	_	Seg=O
142	redundant	_	_	_	_	_	_	_	Seg=O
143	mechanisms	_	_	_	_	_	_	_	Seg=O
144	to	_	_	_	_	_	_	_	Seg=B-seg
145	respond	_	_	_	_	_	_	_	Seg=O
146	to	_	_	_	_	_	_	_	Seg=O
147	viral	_	_	_	_	_	_	_	Seg=O
148	interlopers	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = fcc503a22ab18a67222842a84aa2ba08e0e4865e
1	It	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	a	_	_	_	_	_	_	_	Seg=O
4	much	_	_	_	_	_	_	_	Seg=O
5	desirable	_	_	_	_	_	_	_	Seg=O
6	skill	_	_	_	_	_	_	_	Seg=O
7	among	_	_	_	_	_	_	_	Seg=O
8	physicians	_	_	_	_	_	_	_	Seg=O
9	that	_	_	_	_	_	_	_	Seg=O
10	clinical	_	_	_	_	_	_	_	Seg=O
11	practice	_	_	_	_	_	_	_	Seg=O
12	should	_	_	_	_	_	_	_	Seg=O
13	be	_	_	_	_	_	_	_	Seg=O
14	guided	_	_	_	_	_	_	_	Seg=O
15	by	_	_	_	_	_	_	_	Seg=O
16	ethical	_	_	_	_	_	_	_	Seg=O
17	norms	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	The	_	_	_	_	_	_	_	Seg=B-seg
20	dissection	_	_	_	_	_	_	_	Seg=O
21	room	_	_	_	_	_	_	_	Seg=O
22	experience	_	_	_	_	_	_	_	Seg=O
23	provides	_	_	_	_	_	_	_	Seg=O
24	an	_	_	_	_	_	_	_	Seg=O
25	opportunity	_	_	_	_	_	_	_	Seg=O
26	for	_	_	_	_	_	_	_	Seg=B-seg
27	nurturing	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	principles	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=O
31	ethical	_	_	_	_	_	_	_	Seg=O
32	practice	_	_	_	_	_	_	_	Seg=O
33	among	_	_	_	_	_	_	_	Seg=O
34	medical	_	_	_	_	_	_	_	Seg=O
35	students	_	_	_	_	_	_	_	Seg=O
36	early	_	_	_	_	_	_	_	Seg=O
37	in	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	curriculum	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	When	_	_	_	_	_	_	_	Seg=B-seg
42	the	_	_	_	_	_	_	_	Seg=O
43	exercise	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	human	_	_	_	_	_	_	_	Seg=O
46	dissection	_	_	_	_	_	_	_	Seg=O
47	is	_	_	_	_	_	_	_	Seg=O
48	followed	_	_	_	_	_	_	_	Seg=O
49	within	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	boundaries	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	ethics	_	_	_	_	_	_	_	Seg=O
54	it	_	_	_	_	_	_	_	Seg=B-seg
55	effectively	_	_	_	_	_	_	_	Seg=O
56	props	_	_	_	_	_	_	_	Seg=O
57	an	_	_	_	_	_	_	_	Seg=O
58	ideal	_	_	_	_	_	_	_	Seg=O
59	example	_	_	_	_	_	_	_	Seg=O
60	for	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	young	_	_	_	_	_	_	_	Seg=O
63	minds	_	_	_	_	_	_	_	Seg=O
64	to	_	_	_	_	_	_	_	Seg=B-seg
65	emulate	_	_	_	_	_	_	_	Seg=O
66	in	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	future	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	Hence	_	_	_	_	_	_	_	Seg=B-seg
71	in	_	_	_	_	_	_	_	Seg=O
72	every	_	_	_	_	_	_	_	Seg=O
73	stage	_	_	_	_	_	_	_	Seg=O
74	of	_	_	_	_	_	_	_	Seg=O
75	dissection	_	_	_	_	_	_	_	Seg=O
76	room	_	_	_	_	_	_	_	Seg=O
77	activity	_	_	_	_	_	_	_	Seg=O
78	precious	_	_	_	_	_	_	_	Seg=O
79	human	_	_	_	_	_	_	_	Seg=O
80	body	_	_	_	_	_	_	_	Seg=O
81	needs	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=O
83	be	_	_	_	_	_	_	_	Seg=O
84	handled	_	_	_	_	_	_	_	Seg=O
85	in	_	_	_	_	_	_	_	Seg=O
86	an	_	_	_	_	_	_	_	Seg=O
87	ethical	_	_	_	_	_	_	_	Seg=O
88	manner	_	_	_	_	_	_	_	Seg=O
89	so	_	_	_	_	_	_	_	Seg=B-seg
90	as	_	_	_	_	_	_	_	Seg=O
91	to	_	_	_	_	_	_	_	Seg=O
92	set	_	_	_	_	_	_	_	Seg=O
93	a	_	_	_	_	_	_	_	Seg=O
94	standard	_	_	_	_	_	_	_	Seg=O
95	for	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	students	_	_	_	_	_	_	_	Seg=O
98	The	_	_	_	_	_	_	_	Seg=B-seg
99	present	_	_	_	_	_	_	_	Seg=O
100	review	_	_	_	_	_	_	_	Seg=O
101	is	_	_	_	_	_	_	_	Seg=O
102	an	_	_	_	_	_	_	_	Seg=O
103	attempt	_	_	_	_	_	_	_	Seg=O
104	to	_	_	_	_	_	_	_	Seg=B-seg
105	collate	_	_	_	_	_	_	_	Seg=O
106	the	_	_	_	_	_	_	_	Seg=O
107	recommendations	_	_	_	_	_	_	_	Seg=O
108	documented	_	_	_	_	_	_	_	Seg=B-seg
109	by	_	_	_	_	_	_	_	Seg=O
110	researchers	_	_	_	_	_	_	_	Seg=O
111	as	_	_	_	_	_	_	_	Seg=O
112	per	_	_	_	_	_	_	_	Seg=O
113	ethical	_	_	_	_	_	_	_	Seg=O
114	guidelines	_	_	_	_	_	_	_	Seg=O
115	in	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	context	_	_	_	_	_	_	_	Seg=O
118	of	_	_	_	_	_	_	_	Seg=O
119	human	_	_	_	_	_	_	_	Seg=O
120	dissection	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	The	_	_	_	_	_	_	_	Seg=B-seg
123	review	_	_	_	_	_	_	_	Seg=O
124	highlights	_	_	_	_	_	_	_	Seg=O
125	on	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	ethical	_	_	_	_	_	_	_	Seg=O
128	norms	_	_	_	_	_	_	_	Seg=O
129	which	_	_	_	_	_	_	_	Seg=B-seg
130	needs	_	_	_	_	_	_	_	Seg=O
131	to	_	_	_	_	_	_	_	Seg=O
132	be	_	_	_	_	_	_	_	Seg=O
133	adhered	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=O
135	while	_	_	_	_	_	_	_	Seg=B-seg
136	receiving	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	human	_	_	_	_	_	_	_	Seg=O
139	body	_	_	_	_	_	_	_	Seg=O
140	of	_	_	_	_	_	_	_	Seg=O
141	a	_	_	_	_	_	_	_	Seg=O
142	donor	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=O
144	during	_	_	_	_	_	_	_	Seg=O
145	preservation	_	_	_	_	_	_	_	Seg=O
146	of	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	same	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	It	_	_	_	_	_	_	_	Seg=B-seg
151	reflects	_	_	_	_	_	_	_	Seg=O
152	on	_	_	_	_	_	_	_	Seg=O
153	ideal	_	_	_	_	_	_	_	Seg=O
154	ethical	_	_	_	_	_	_	_	Seg=O
155	behaviour	_	_	_	_	_	_	_	Seg=O
156	in	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	dissection	_	_	_	_	_	_	_	Seg=O
159	room	_	_	_	_	_	_	_	Seg=O
160	during	_	_	_	_	_	_	_	Seg=O
161	the	_	_	_	_	_	_	_	Seg=O
162	act	_	_	_	_	_	_	_	Seg=O
163	of	_	_	_	_	_	_	_	Seg=O
164	dissection	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=B-seg
166	finally	_	_	_	_	_	_	_	Seg=O
167	emphasize	_	_	_	_	_	_	_	Seg=O
168	on	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	respectful	_	_	_	_	_	_	_	Seg=O
171	disposal	_	_	_	_	_	_	_	Seg=O
172	of	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=O
174	human	_	_	_	_	_	_	_	Seg=O
175	remains	_	_	_	_	_	_	_	Seg=O
176	in	_	_	_	_	_	_	_	Seg=O
177	an	_	_	_	_	_	_	_	Seg=O
178	ethical	_	_	_	_	_	_	_	Seg=O
179	manner	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O
181	The	_	_	_	_	_	_	_	Seg=B-seg
182	intended	_	_	_	_	_	_	_	Seg=O
183	purpose	_	_	_	_	_	_	_	Seg=O
184	of	_	_	_	_	_	_	_	Seg=O
185	this	_	_	_	_	_	_	_	Seg=O
186	article	_	_	_	_	_	_	_	Seg=O
187	is	_	_	_	_	_	_	_	Seg=O
188	to	_	_	_	_	_	_	_	Seg=O
189	support	_	_	_	_	_	_	_	Seg=O
190	uniform	_	_	_	_	_	_	_	Seg=O
191	adoption	_	_	_	_	_	_	_	Seg=O
192	of	_	_	_	_	_	_	_	Seg=O
193	the	_	_	_	_	_	_	_	Seg=O
194	recommendations	_	_	_	_	_	_	_	Seg=O
195	for	_	_	_	_	_	_	_	Seg=O
196	ethical	_	_	_	_	_	_	_	Seg=O
197	handling	_	_	_	_	_	_	_	Seg=O
198	of	_	_	_	_	_	_	_	Seg=O
199	human	_	_	_	_	_	_	_	Seg=O
200	bodies	_	_	_	_	_	_	_	Seg=O
201	used	_	_	_	_	_	_	_	Seg=B-seg
202	in	_	_	_	_	_	_	_	Seg=O
203	anatomical	_	_	_	_	_	_	_	Seg=O
204	dissection	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O
